PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lashuel, HA; Hartley, DM; Balakhaneh, D; Aggarwal, A; Teichberg, S; Callaway, DJE				Lashuel, HA; Hartley, DM; Balakhaneh, D; Aggarwal, A; Teichberg, S; Callaway, DJE			New class of inhibitors of amyloid-beta fibril formation - Implications for the mechanism of pathogenesis in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SELECTIVE-INHIBITION; OXIDATIVE STRESS; PEPTIDE; PROTEIN; NEUROTOXICITY; APOMORPHINE; AGGREGATION; TOXICITY; STATE	The amyloid hypothesis suggests that the process of amyloid-beta protein (Abeta) fibrillogenesis is responsible for triggering a cascade of physiological events that contribute directly to the initiation and progression of Alzheimer's disease. Consequently, preventing this process might provide a viable therapeutic strategy for slowing and/or preventing the progression of this devastating disease. A promising strategy to achieve prevention of this disease is to discover compounds that inhibit Abeta polymerization and deposition. Herein, we describe a new class of small molecules that inhibit Abeta aggregation, which is based on the chemical structure of apomorphine. These molecules were found to interfere with Abeta1-40 fibrillization as determined by transmission electron microscopy, Thioflavin T fluorescence and velocity sedimentation analytical ultracentrifugation studies. Using electron microscopy, time-dependent studies demonstrate that apomorphine and its derivatives promote the oligomerization of Abeta but inhibit its fibrillization. Preliminary structural activity studies demonstrate that the 10,11-dihydroxy substitutions of the D-ring of apomorphine are required for the inhibitory effectiveness of these aporphines, and methylation of these hydroxyl groups reduces their inhibitory potency. The ability of these small molecules to inhibit Abeta amyloid fibril formation appears to be linked to their tendency to undergo rapid autoxidation, suggesting that autoxidation product(s) acts directly or indirectly on Abeta and inhibits its fibrillization. The inhibitory properties of the compounds presented suggest a new class of small molecules that could serve as a scaffold for the design of more efficient inhibitors of Abeta amyloidogenesis in vivo.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA; N Shore Long Isl Jewish Res Inst, Ctr Neurosci, Manhasset, NY 11030 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10010 USA; N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA	Harvard University; Brigham & Women's Hospital; Northwell Health; Icahn School of Medicine at Mount Sinai; Northwell Health; North Shore University Hospital	Lashuel, HA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA.		Lashuel, Hilal/M-3500-2017					Buchet R, 1996, BBA-MOL BASIS DIS, V1315, P40, DOI 10.1016/0925-4439(95)00102-6; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; CASTANO EM, 1988, LAB INVEST, V58, P122; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CORBOY DL, 1995, ANN PHARMACOTHER, V29, P282, DOI 10.1177/106002809502900310; Cutler NR, 2001, PROG NEURO-PSYCHOPH, V25, P27, DOI 10.1016/S0278-5846(00)00147-0; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; El-Bacha RD, 2001, BIOCHEM PHARMACOL, V61, P73, DOI 10.1016/S0006-2952(00)00524-4; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Frenkel D, 2000, J NEUROIMMUNOL, V106, P23, DOI 10.1016/S0165-5728(99)00232-5; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Gassen M, 1996, EUR J PHARMACOL, V308, P219, DOI 10.1016/0014-2999(96)00291-9; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; HOU L, 2002, IN PRESS J BIOL CHEM; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Jacobsen J. Steven, 2002, Current Topics in Medicinal Chemistry, V2, P343, DOI 10.2174/1568026024607481; Janus C, 2001, Curr Neurol Neurosci Rep, V1, P451, DOI 10.1007/s11910-001-0105-8; KAUL PN, 1961, J PHARM SCI, V50, P266, DOI 10.1002/jps.2600500323; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LeVine H, 2002, CURR MED CHEM, V9, P1121, DOI 10.2174/0929867023370167; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; LINDE HHA, 1968, HELV CHIM ACTA, V51, P683, DOI 10.1002/hlca.660510411; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUNDGREN P, 1970, ACTA PHARM SUEC, V7, P133; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; Perkins SJ, 1998, INT J BIOL MACROMOL, V22, P1, DOI 10.1016/S0141-8130(97)00088-3; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poduslo JF, 1999, J NEUROBIOL, V39, P371, DOI 10.1002/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.3.CO;2-5; SAM E, 1994, J CHROMATOGR B, V658, P311, DOI 10.1016/0378-4347(94)00239-8; Schenk D, 2001, J MOL NEUROSCI, V17, P259, DOI 10.1385/JMN:17:2:259; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SMITH RV, 1985, J MED CHEM, V28, P613, DOI 10.1021/jm50001a014; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; UBEDA A, 1993, FREE RADICAL RES COM, V18, P167, DOI 10.3109/10715769309147490; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; WILCOX RE, 1980, J PHARM SCI, V69, P974, DOI 10.1002/jps.2600690830; Wolfe Michael S., 2002, Current Topics in Medicinal Chemistry, V2, P371, DOI 10.2174/1568026024607535; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yang DS, 2001, AMYLOID, V8, P10; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	65	126	147	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42881	42890		10.1074/jbc.M206593200	http://dx.doi.org/10.1074/jbc.M206593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12167652	hybrid			2022-12-25	WOS:000179081200061
J	Wiame, E; Delpierre, G; Collard, F; Van Schaftingen, E				Wiame, E; Delpierre, G; Collard, F; Van Schaftingen, E			Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSAMINE 6-PHOSPHATE SYNTHASE; ANGSTROM CRYSTAL-STRUCTURE; D-TAGATOSE 3-EPIMERASE; AMINO-ACID OXIDASE; SP SOIL STRAIN; DIABETIC COMPLICATIONS; PURIFICATION; FRUCTOSAMINE; EXPRESSION; BINDING	Escherichia coli was found to grow on fructoselysine as an energetic substrate at a rate of about one-third of that observed with glucose. Extracts of cells grown on fructoselysine catalyzed in the presence of ATP the phosphorylation of fructoselysine and a delayed formation of glucose 6-phosphate from this substrate. Data base searches allowed us to identify an operon containing a putative kinase (YhfQ) belonging to the PfkB/ ribokinase family, a putative deglycase (YhfN), homologous to the isomerase domain of glucosamine-6-phosphate synthase, and a putative cationic amino acid transporter (YhfM). The proteins encoded by YhfQ and YhfN were overexpressed in E. coli, purified, and shown to catalyze the ATP-dependent phosphorylation of fructoselysine to a product identified as fructoselysine 6-phosphate by P-31 NMR (YhfQ), and the reversible conversion of fructoselysine 6-phosphate and water to lysine and glucose 6-phosphate (YhfN). The K. of the kinase for fructoselysine amounted to 18 gm, and the K-m of the deglycase for fructoselysine 6-phosphate, to 0.4 mm. A value of 0.15 m was found for the equilibrium constant of the deglycase reaction. The kinase and the deglycase were both induced when E. coli was grown on fructoselysine and then reached activities sufficient to account for the rate of fructoselysine utilization.	Univ Catholique Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian De Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Univ Catholique Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium.		Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMBRUSTER DA, 1987, CLIN CHEM, V33, P2153; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BORK P, 1993, PROTEIN SCI, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627; Delpierre G, 2002, BIOCHEM J, V365, P801, DOI 10.1042/BJ20020325; Delpierre G, 2000, BIOCHEM J, V352, P835, DOI 10.1042/0264-6021:3520835; Erbersdobler HF, 2001, NAHRUNG, V45, P177, DOI 10.1002/1521-3803(20010601)45:3&lt;177::AID-FOOD177&gt;3.0.CO;2-A; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GOLDSTEIN DE, 1986, CLIN CHEM, V32, P64; GOLINELLIPIMPANEAU B, 1991, EUR J BIOCHEM, V201, P175, DOI 10.1111/j.1432-1033.1991.tb16271.x; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; Ishida Y, 1997, J FERMENT BIOENG, V83, P529, DOI 10.1016/S0922-338X(97)81132-4; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; ITOH H, 1995, J FERMENT BIOENG, V80, P101, DOI 10.1016/0922-338X(95)98186-O; JOHNSON RN, 1982, CLIN CHIM ACTA, V127, P87; Kim KS, 1996, J BACTERIOL, V178, P3275, DOI 10.1128/jb.178.11.3275-3284.1996; ORCHARD LMD, 1990, P ROY SOC B-BIOL SCI, V242, P87, DOI 10.1098/rspb.1990.0108; RAVANDI A, 1995, LIPIDS, V30, P885, DOI 10.1007/BF02537478; Saxena AK, 1996, J BIOL CHEM, V271, P32803, DOI 10.1074/jbc.271.51.32803; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139; Takahashi M, 1997, J BIOL CHEM, V272, P12505, DOI 10.1074/jbc.272.19.12505; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; WU LF, 1991, J BACTERIOL, V173, P3117, DOI 10.1128/JB.173.10.3117-3127.1991	31	99	104	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42523	42529		10.1074/jbc.M200863200	http://dx.doi.org/10.1074/jbc.M200863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12147680	hybrid			2022-12-25	WOS:000179081200014
J	Lafont, J; Laurent, M; Thibout, H; Lallemand, F; Le Bouc, Y; Atfi, A; Martinerie, C				Lafont, J; Laurent, M; Thibout, H; Lallemand, F; Le Bouc, Y; Atfi, A; Martinerie, C			The expression of novH in adrenocortical cells is down-regulated by TGF beta 1 through c-Jun in a Smad-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TGF-BETA; PROTEIN-KINASE; IGF-II; TRANSCRIPTIONAL ACTIVITY; ENDOTHELIAL-CELLS; ACTIVATION DOMAIN; PROMOTER ACTIVITY; WILMS-TUMORS	The human NOV secreted glycoprotein (NOVH) is abundant in the fetal and adult adrenal cortex. The amount of NOVH increases in benign adrenocortical tumors and decreases in malignant adrenocortical tumors, suggesting that NOVH plays a role in tumorigenesis in the adrenal cortex. Transforming growth factor beta1 (TGFbeta1), fibroblast growth factor 2 (FGF2), and insulin growth factors (IGFs) play crucial roles in the physiology of the adrenal cortex. We investigated the effects of these factors on the expression of novH in the NCI H295R adrenocortical cell line. The amounts of NOVH protein and novH transcripts were down-regulated by TGFbeta1 and up-regulated by FGF2, whereas IGFs had no effect. Furthermore, the TGFbeta1-dependent inhibition of novH promoter activity was completely abrogated following site-directed mutation of two activating protein (AP-1) sequences (positions -473 and -447), whereas the stimulatory effect of FGF2 was not affected. Co-transfection with dominant negative forms of c-Jun and MEKK1 also abrogated novH-targeted regulation by TGFbeta1, whereas the overproduction of Smad proteins or dominant negative forms of Smad had no effect. Taken together, these results suggest that c-Jun and MEKK1 signaling but not Smad signaling are involved in the TGFbeta1-dependent decrease in NOVH in NCI H295R cells. In conclusion, our data provide evidence that novH is a new target of TGFbeta1; unlike other members of the CCN ((c) under bar yr61, (c) under bar tgf, (n) under bar ov) family, however, its expression is repressed rather than induced.	Hop St Antoine, INSERM U515, F-75571 Paris 12, France; Hop St Antoine, INSERM U482, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Martinerie, C (corresponding author), Hop St Antoine, INSERM U515, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	martiner@st-antoine.inserm.fr	Lafont, Jerome E/AAY-2277-2020	Lafont, Jerome E/0000-0001-8313-9873				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Boulle N, 2000, ENDOCRINOLOGY, V141, P3127, DOI 10.1210/en.141.9.3127; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brand C, 1998, BIOCHEM BIOPH RES CO, V253, P780, DOI 10.1006/bbrc.1998.9829; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Chevalier G, 1998, AM J PATHOL, V152, P1563; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Feige JJ, 1998, J ENDOCRINOL, V158, P7, DOI 10.1677/joe.0.1580007; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GAZDAR AF, 1990, CANCER RES, V50, P5488; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; Gicquel C, 1998, CURR OPIN ENDOCRINOL, V5, P189; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hocevar BA, 2000, METH MOL B, V142, P97; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ILVESMAKI V, 1993, MOL CELL ENDOCRINOL, V91, P59, DOI 10.1016/0303-7207(93)90255-I; ILVESMAKI V, 1993, J CLIN ENDOCR METAB, V77, P852, DOI 10.1210/jc.77.3.852; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latronico AC, 1997, J CLIN ENDOCR METAB, V82, P1317, DOI 10.1210/jc.82.5.1317; LAU L, 1985, P NATL ACAD SCI USA, V84, P1182; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Logie A, 1999, J MOL ENDOCRINOL, V23, P23, DOI 10.1677/jme.0.0230023; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Martinerie C, 1996, ONCOGENE, V12, P1479; MARTINERIE C, 1994, ONCOGENE, V9, P2729; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Messiano S, 1997, ENDOCR REV, V18, P378; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Rich CB, 1999, J BIOL CHEM, V274, P33433, DOI 10.1074/jbc.274.47.33433; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Scholz G, 1996, MOL CELL BIOL, V16, P481; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Snaith MR, 1996, GENOMICS, V38, P425, DOI 10.1006/geno.1996.0647; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; Weber MM, 1997, ENDOCRINOLOGY, V138, P2207, DOI 10.1210/en.138.5.2207; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; WENXIN L, 1996, J CLIN PATHOL-MOL PA, V49, pM91; Zatelli MC, 2000, J CLIN ENDOCR METAB, V85, P847, DOI 10.1210/jc.85.2.847; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	86	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41220	41229		10.1074/jbc.M204405200	http://dx.doi.org/10.1074/jbc.M204405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12149257	hybrid			2022-12-25	WOS:000178791400133
J	Luberto, C; Hassler, DF; Signorelli, P; Okamoto, Y; Sawai, H; Boros, E; Hazen-Martin, DJ; Obeid, LM; Hannun, YA; Smith, GK				Luberto, C; Hassler, DF; Signorelli, P; Okamoto, Y; Sawai, H; Boros, E; Hazen-Martin, DJ; Obeid, LM; Hannun, YA; Smith, GK			Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; NERVE GROWTH-FACTOR; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; LYSOSOMAL SPHINGOMYELINASE; QUANTITATIVE-DETERMINATION; CERAMIDE GENERATION; INVOLVEMENT; GLUTATHIONE; ACTIVATION	A high throughput screen for neutral, magnesium-dependent sphingomyelinase (SMase) was performed. One inhibitor discovered in the screen, GW4869, functioned as a noncompetitive inhibitor of the enzyme in vitro with an IC50 of 1 mum. It did not inhibit acid SMase at up to at least 150 mum. The compound was then evaluated for its ability to inhibit tumor necrosis factor (TNF)-induced activation of neutral SMase (N-SMase) in MCF7 cells. GW4869 (10 mum) partially inhibited TNF-induced sphingomyelin (SM) hydrolysis, and 20 mum of the compound was protected completely from the loss of SM. The addition of 10-20 mum GW4869 completely inhibited the initial accumulation of ceramide, whereas this effect was partially lost at later time points (24 h). These data therefore support the inhibitory action of GW4869 on N-SMase not only in vitro but also in a cellular model. The addition of GW4869 at both 10 and 20 mum did not modify cellular glutathione levels in response to TNF, suggesting that the action of GW4869 occurred downstream of the drop in glutathione, which was shown previously to occur upstream of the activation of N-SMase. Further, whereas TNF treatment also caused a 75% increase of de novo synthesized ceramide after 20 h of incubation, GW4869, at either 10 or 20 mum, had no effect on this pathway of ceramide generation. In addition, GW4869 did not significantly impair TNF-induced NF-kappaB translocation to nuclei. Therefore, GW4869 does not interfere with other key TNF-mediated signaling effects. GW4869 was able, in a dose-dependent manner, to significantly protect from cell death as measured by nuclear condensation, caspase activation, PARP degradation, and trypan blue uptake. These protective effects were accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction. In conclusion, our results indicate that N-SMase activation is a necessary step for the full development of the cytotoxic program induced by TNF.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; GlaxoSmithKline, Div Discovery Chem, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Div Biol, Res Triangle Pk, NC 27709 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; GlaxoSmithKline; GlaxoSmithKline	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@muse.edu		obeid, lina/0000-0002-0734-0847; signorelli, paola/0000-0003-2368-2393	NCI NIH HHS [CA 87584] Funding Source: Medline; NIA NIH HHS [AG 16583] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bezombes C, 2001, FASEB J, V15, P297; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Doman RK, 1999, J INTERF CYTOK RES, V19, P261, DOI 10.1089/107999099314199; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gouaze V, 2001, MOL PHARMACOL, V60, P488; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hassler DF, 2000, METHOD ENZYMOL, V311, P176; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; Keppler-Hafkemeyer A, 1998, BIOCHEMISTRY-US, V37, P16934, DOI 10.1021/bi980995m; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1999, CHEM PHYS LIPIDS, V102, P167, DOI 10.1016/S0009-3084(99)00085-7; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sofic E, 2001, J NEURAL TRANSM, V108, P541, DOI 10.1007/s007020170055; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	59	234	246	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41128	41139		10.1074/jbc.M206747200	http://dx.doi.org/10.1074/jbc.M206747200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154098	hybrid			2022-12-25	WOS:000178791400123
J	Paulucci, AA; Hicks, L; Machado, A; Miranda, MTM; Kay, CM; Farah, CS				Paulucci, AA; Hicks, L; Machado, A; Miranda, MTM; Kay, CM; Farah, CS			Specific sequences determine the stability and cooperativity of folding of the C-terminal half of tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MUSCLE ALPHA-TROPOMYOSIN; SYNTHETIC MODEL PROTEINS; AMINO-ACID SUBSTITUTIONS; COILED-COILS; THERMAL-DENATURATION; CRYSTAL-STRUCTURE; OLIGOMERIZATION STATE; REGULATORY PROPERTIES; SELF-ASSOCIATION	Tropomyosin is a flexible 410 A coiled-coil protein in which the relative stabilities of specific regions may be important for its proper function in the control of muscle contraction. In addition, tropomyosin can be used as a simple model of natural occurrence to understand the inter- and intramolecular interactions that govern the stability of coiled-coils. We have produced eight recombinant tropomyosin fragments (Tm141-284(50HW), Tm189-284(5OHW), Tm189-284, TM220-284(5OHW), TM220-284, Tm143-235, Tm167-260, and Tm143-260) and one synthetic peptide (Ac-TM215-235) to investigate the relative conformational stability of different regions derived from the C-terminal region of the protein, which is known to interact with the troponin complex. Analytical ultracentrifugation experiments show that the fragments that include the last 24 residues of the molecule (Tm143-284(5OHW), Tm189-284(50HW), TM220-284(5OHW), TM220-284) are completely dimerized at 10 mum dimer (50 mm phosphate, 100 mm NaCl, 1.0 mm dithiothreitol, and 0.5 mm EDTA, 10 degreesC), whereas fragments that lack the native C terminus (Tm143-235,Tm167-260, and Tm143-260) are in a monomer-dimer equilibrium under these conditions. The presence of trifluoroethanol resulted in a reduction in the [theta](222)/[theta](208) circular dichroism ratio in all of the fragments and induced stable trimer formation only in those containing residues 261-284. Urea denaturation monitored by circular dichroism and fluorescence revealed that residues 261-284 of tropomyosin are very important for the stability of the C-terminal half of the molecule as a whole. Furthermore, the absence of this region greatly increases the cooperativity of urea-induced unfolding. Temperature and urea denaturation experiments show that Tm143-235 is less stable than other fragments of the same size. We have identified a number of factors that may contribute to this particular instability, including an interhelix repulsion between g and e' positions of the heptad repeat, a charged residue at the hydrophobic coiled-coil interface, and a greater fraction of beta-branched residues located at d positions.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada	Universidade de Sao Paulo; University of Alberta; University of Alberta	Farah, CS (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, 748 Av Prof Lineu Prestes,CP 26-077, BR-05508900 Sao Paulo, Brazil.	chsfarah@iq.usp.br	Lunkes, Alessandra/G-8501-2015; Farah, Chuck Shaker/G-5565-2012; Machini, M. Teresa/D-2009-2012	Lunkes, Alessandra/0000-0002-7258-9905; Farah, Chuck Shaker/0000-0003-3110-6302; Machini, M. Teresa/0000-0001-5772-004X				CLARK ID, 1990, BIOCHEMISTRY-US, V29, P10842, DOI 10.1021/bi00500a018; de Sousa AD, 2001, BIOPHYS J, V80, p91A; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; HOLTZER A, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P177; HOLTZER ME, 1995, BIOPOLYMERS, V35, P125, DOI 10.1002/bip.360350113; HOLTZER ME, 1991, J AM CHEM SOC, V113, P7444, DOI 10.1021/ja00019a064; HOLTZER ME, 1983, MACROMOLECULES, V16, P173, DOI 10.1021/ma00236a004; HOLTZER ME, 1990, BIOPOLYMERS, V30, P985, DOI 10.1002/bip.360300913; Holtzer ME, 2001, BIOPOLYMERS, V59, P257, DOI 10.1002/1097-0282(20011005)59:4<257::AID-BIP1022>3.0.CO;2-7; HOLTZER ME, 1995, BIOPOLYMERS, V36, P365, DOI 10.1002/bip.360360310; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; LAUE TM, 1991, ANAL ULTRACENTRIFUGA, P125; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1978, J MOL BIOL, V118, P209, DOI 10.1016/0022-2836(78)90413-8; Lehrer SS, 1998, J STRUCT BIOL, V122, P176, DOI 10.1006/jsbi.1998.3973; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; MacPhee CE, 1997, FEBS LETT, V416, P265, DOI 10.1016/S0014-5793(97)01224-6; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Maroun RG, 1999, J BIOL CHEM, V274, P34174, DOI 10.1074/jbc.274.48.34174; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MO JM, 1991, P NATL ACAD SCI USA, V88, P916, DOI 10.1073/pnas.88.3.916; MO JM, 1990, BIOPOLYMERS, V30, P921, DOI 10.1002/bip.360300907; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; PACE CN, 1987, PROTEIN STRUCTURE PR, P299; PATO MD, 1981, J BIOL CHEM, V256, P593; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTEKHIN SA, 1982, J MOL BIOL, V159, P519, DOI 10.1016/0022-2836(82)90299-6; QUADRIFO.F, 1968, J AM CHEM SOC, V90, P2755, DOI 10.1021/ja01013a004; STEWART JM, 1984, SOLID PHASE PEPTIDE, P1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Varanda LM, 1997, J PEPT RES, V50, P102; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; WAHL P, 1978, EUR J BIOCHEM, V88, P421, DOI 10.1111/j.1432-1033.1978.tb12464.x; Whitby FG, 2000, PROTEINS, V38, P49; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Yu Y, 1996, J MOL BIOL, V255, P367, DOI 10.1006/jmbi.1996.0030; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	61	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39574	39584		10.1074/jbc.M204749200	http://dx.doi.org/10.1074/jbc.M204749200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167616	hybrid			2022-12-25	WOS:000178662500068
J	Schubert, W; Frank, PG; Woodman, SE; Hyogo, H; Cohen, DE; Chow, CW; Lisanti, MP				Schubert, W; Frank, PG; Woodman, SE; Hyogo, H; Cohen, DE; Chow, CW; Lisanti, MP			Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice - Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PERMEABILITY; PLASMALEMMAL VESICLES; IN-VIVO; PROTEIN; ACTIVATION; PATHWAYS; RAS	Microvascular permeability is mediated by W the caveolar transcytosis of molecules across endothelial cells and (ii) the paracellular movement of ions and nutrients. Recently, we derived Cav-1 (-/-) knock-out mice using standard homologous recombination techniques. These mice are viable but show a loss of endothelial cell caveolae and striking defects in caveolae-mediated endocytosis. Thus, a compensatory mechanism must be operating in these mice. One possible compensatory response would be an increase in the paracellular pathway, resulting in increased microvascular permeability. To test this hypothesis directly, we studied the microvascular permeability of Cav-1 null mice using a variety of complementary in vivo approaches. Radio-iodinated bovine serum albumin was injected into Cav-1-deficient mice, and its rate of clearance from the circulatory system was compared with that of wild type control mice. Our results indicate that iodinated bovine serum albumin is removed from the circulatory system of Cav-1-deficient mice at a substantially faster rate. To determine whether this defect is restricted to the paracellular movement of albumin, lungs from Cav-1-deficient mice were next perfused with the electron dense dye Ruthenium Red. Micrographs of lung endothelial cells from Cav-1-deficient mice demonstrate that the paracellular movement of Ruthenium Red is dramatically increased. In addition, electron micrographs of Cav-1-deficient lung capillaries reveal defects in tight junction morphology and abnormalities in capillary endothelial cell adhesion to the basement membrane. This defect in cell-substrate attachment is consistent with the postulated role of caveolin-1 in positively regulating integrin signaling. Because loss of caveolin-1 expression results in constitutive activation of eNOS activity, we also examined whether these increases in microvascular permeability are NO-dependent. Interestingly, treatment with L-NAME (a well established nitric-oxide synthase inhibitor) successfully reversed the microvascular hyperpermeability phenotype of Cav-1 knock-out mice. Thus, caveolin-1 plays a dual regulatory role in controlling microvascular permeability: (i) as a structural protein that is required for caveolae formation and caveolar transcytosis and (ii) as a tonic inhibitor of eNOS activity to negatively regulate the paracellular pathway.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Frank, Philippe G/A-3463-2011	Lisanti, Michael/0000-0003-2034-1382; Frank, Philippe G/0000-0003-4857-5279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GARCIA JGN, 1995, J INVEST MED, V43, P117; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Haynes J, 1996, J PHARMACOL EXP THER, V276, P752; He P, 1998, AM J PHYSIOL-HEART C, V274, pH1865, DOI 10.1152/ajpheart.1998.274.6.H1865; Hinder F, 1997, J APPL PHYSIOL, V83, P1941, DOI 10.1152/jappl.1997.83.6.1941; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Inoue H, 2001, NITRIC OXIDE-BIOL CH, V5, P334, DOI 10.1006/niox.2001.0350; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; RAMIREZ MM, 1995, MICROVASC RES, V50, P223, DOI 10.1006/mvre.1995.1055; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Suttorp N, 1996, AM J PHYSIOL-CELL PH, V270, pC778, DOI 10.1152/ajpcell.1996.270.3.C778; Takeda N, 2001, DIABETOLOGIA, V44, P1043, DOI 10.1007/s001250100588; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Tsukahara H, 2000, LIFE SCI, V67, P1, DOI 10.1016/S0024-3205(00)00598-1; Vallance P, 2001, HEART, V85, P342, DOI 10.1136/heart.85.3.342; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; YUAN YA, 1993, AM J PHYSIOL, V264, pH1734, DOI 10.1152/ajpheart.1993.264.5.H1734	37	254	262	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40091	40098		10.1074/jbc.M205948200	http://dx.doi.org/10.1074/jbc.M205948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167625	hybrid			2022-12-25	WOS:000178662500130
J	Conus, NM; Hannan, KM; Cristiano, BE; Hemmings, BA; Pearson, RB				Conus, NM; Hannan, KM; Cristiano, BE; Hemmings, BA; Pearson, RB			Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PHOSPHATASE INHIBITORS; ACTIVATION; INSULIN; PATHWAY; DOMAIN; PKB; PHOSPHOTYROSINE	Understanding the regulation of Akt has been of major interest for elucidating the control of normal cellular physiology as well as malignant transformation. The paradigm for activation of Akt involves phosphatidylinositol 3-kinase-dependent membrane localization followed by activating phosphorylation of Thr-308 and Ser-473. Many of the activating signals for Akt involve the stimulation of receptor and non-receptor tyrosine kinases, and the most potent activator known is the tyrosine phosphatase inhibitor pervanadate, highlighting a possible role for tyrosine phosphorylation. in the regulation of the enzyme. In this study we show that activation of Akt by pervanadate or serum is associated with tyrosine phosphorylation of Akt. In addition, in SKOV3 ovarian carcinoma cells that exhibit high basal levels of Akt activity, Akt was tyrosine-phosphorylated in the basal state, and this phosphorylation was further enhanced by both pervanadate and insulin-like growth factor-1. We have used NH2-terminal sequencing and phosphate release analysis to directly identify Tyr-474 as the site of tyrosine phosphorylation. Substitution of Tyr-474 with phenylalanine abolished tyrosine phosphorylation of Akt and resulted in up to 55% inhibition of Akt activation, indicating phosphorylation at Tyr-474 is required for full activation of the kinase. Our data identifies a novel regulatory mechanism for this pleiotropic enzyme that may be applicable to the AGC family of protein kinases given the conserved nature of the COOH-terminal hydrophobic motif containing Tyr-474.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Peter Maccallum Cancer Center; Friedrich Miescher Institute for Biomedical Research	Pearson, RB (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.		Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090; Hannan, Katherine/0000-0003-4186-8167				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; MITCHELHILL KI, 1999, PROTEIN PHOSPHORYLAT, P127; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	39	79	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38021	38028		10.1074/jbc.M203387200	http://dx.doi.org/10.1074/jbc.M203387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149249	hybrid			2022-12-25	WOS:000178529600008
J	Dhanak, D; Duffy, KJ; Johnston, VK; Lin-Goerke, J; Darey, M; Shaw, AN; Gu, BH; Silverman, C; Gates, AT; Nonnemacher, MR; Earnshaw, DL; Casper, DJ; Kaura, A; Baker, A; Greenwood, C; Gutshall, LL; Maley, D; DelVecchio, A; Macarron, R; Hofmann, GA; Alnoah, Z; Cheng, HY; Chan, G; Khandekar, S; Keenan, RM; Sarisky, RT				Dhanak, D; Duffy, KJ; Johnston, VK; Lin-Goerke, J; Darey, M; Shaw, AN; Gu, BH; Silverman, C; Gates, AT; Nonnemacher, MR; Earnshaw, DL; Casper, DJ; Kaura, A; Baker, A; Greenwood, C; Gutshall, LL; Maley, D; DelVecchio, A; Macarron, R; Hofmann, GA; Alnoah, Z; Cheng, HY; Chan, G; Khandekar, S; Keenan, RM; Sarisky, RT			Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DE-NOVO INITIATION; CRYSTAL-STRUCTURE; E2-NS2 REGION; NON-A; NS5B; REPLICATION; TEMPLATE; CLEAVAGE; GENOME	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp), the primary catalytic enzyme of the HCV replicase complex. We established a biochemical RNA synthesis assay, using purified recombinant NS5B lacking the C-terminal 21 amino acid residues, to identify potential polymerase inhibitors from a high throughput screen of the Glaxo-SmithKline proprietary compound collection. The benzo-1,2,4-thiadiazine compound 1 was found to be a potent, highly specific inhibitor of NS5B. This agent interacts directly with the viral polymerase and inhibits RNA synthesis in a manner noncompetitive with respect to GTP. Furthermore, in the absence of an in vitro-reconstituted HCV replicase assay employing viral and host proteins, the ability of compound 1 to inhibit NS5B-directed viral RNA replication was determined using the Huh7 cell-based HCV replicon system. Compound 1 reduced viral RNA in replicon cells with an IC50 of similar to0.5 muM, suggesting that the inhibitor was able to access the perinuclear membrane and inhibit the polymerase activity in the context of a replicase complex. Preliminary structure-activity studies on compound 1 led to the identification of a modified inhibitor, compound 4, showing an improvement in both biochemical and cell-based potency. Lastly, data are presented suggesting that these compounds interfere with the formation of negative and positive strand progeny RNA by a similar mode of action. Investigations are ongoing to assess the potential utility of such agents in the treatment of chronic HCV disease.	GlaxoSmithKline, Dept Virol, Metab & Viral Dis Ctr Excellence Drug Discovery, Collegeville, PA 19426 USA; GlaxoSmithKline, Dept Med Chem, Musculoskeletal Microbial & Proliferat Dis Ctr Ex, Collegeville, PA 19426 USA; GlaxoSmithKline, Discovery Res, Collegeville, PA 19426 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Med Chem, Collegeville, PA 19426 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Sarisky, RT (corresponding author), GlaxoSmithKline, Dept Virol, Metab & Viral Dis Ctr Excellence Drug Discovery, 1250 S Collegeville Rd,UP1450, Collegeville, PA 19426 USA.	robert_t_sarisky@gsk.com		Earnshaw, David/0000-0002-0650-1362; Nonnemacher, Michael/0000-0003-4299-3779; Duffy, Kevin/0000-0002-7184-2059				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Cecchetti V, 2000, J MED CHEM, V43, P3799, DOI 10.1021/jm9903390; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Craggs JK, 2001, J VIROL METHODS, V94, P111, DOI 10.1016/S0166-0934(01)00281-6; DOYLE ML, 1997, ADV MOL CEL A&B, V22, P279; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Ukrainets I.V., 2000, CHEM HETEROCYC COMPO, V36, P346; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998	26	186	214	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38322	38327		10.1074/jbc.M205566200	http://dx.doi.org/10.1074/jbc.M205566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167642	hybrid			2022-12-25	WOS:000178529600043
J	Cassel, TN; Berg, T; Suske, G; Nord, M				Cassel, TN; Berg, T; Suske, G; Nord, M			Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein A and the homeodomain factor Nkx2.1/thyroid transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; ACTIVATION DOMAIN; FACTOR-I; EXPRESSION; PROMOTER; FAMILY; MOUSE; LIVER; PROLIFERATION; MORPHOGENESIS	The basic region-leucine zipper transcription factor CCAAT/enhancer-binding protein alpha (C/EBPalpha) and the homeodomain transcription factor Nkx2.1/thyroid transcription factor-1 are essential for normal lung morphogenesis. Nkx2.1 is expressed from the onset of lung development, whereas C/EBPalpha expression is turned on at later stages. The expression of C/EBPalpha correlates to the appearance of lung-specific proteins with differentiation-dependent expression patterns, such as the Clara cell secretory protein (secretoglobin 1a1 (Scgb1a1), CCSP). In this study, we demonstrate synergistic transactivation by C/EBPalpha and Nkx2.1 in the regulation of the CCSP gene. We show that the synergistic activity of C/EBPalpha and Nkx2.1 originates from cis-acting elements in the proximal promoter of CCSP and that the synergism is dependent on NH2-terminal transactivation domains of C/EBPalpha and Nkx2.1. Our results suggest that the cooperation of C/EBPalpha and N-kx2.1 is a major determinant for the high level, lung epithelial-specific expression of CCSP during the later stages of lung development and in the adult lung.	Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Karolinska Institutet; Philipps University Marburg	Nord, M (corresponding author), Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.		berg, tove/H-9916-2012	Suske, Guntram/0000-0002-4807-0513				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Cassel Tobias N., 2000, Molecular Cell Biology Research Communications, V3, P42, DOI 10.1006/mcbr.2000.0187; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NORD M, 1992, ARCH BIOCHEM BIOPHYS, V296, P302, DOI 10.1016/0003-9861(92)90576-I; Nord M, 1998, DNA CELL BIOL, V17, P481, DOI 10.1089/dna.1998.17.481; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Patrone C, 1998, MOL ENDOCRINOL, V12, P835, DOI 10.1210/me.12.6.835; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH CI, 1995, AM J PHYSIOL-LUNG C, V269, pL603, DOI 10.1152/ajplung.1995.269.5.L603; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Suske G, 2000, Methods Mol Biol, V130, P175; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; TENHAVEOPBROEK AAW, 1993, MICROSC RES TECHNIQ, V26, P400, DOI 10.1002/jemt.1070260508; TENHAVEOPBROEK AAW, 1981, AM J ANAT, V162, P201, DOI 10.1002/aja.1001620303; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Whitsett JA, 1996, AM J RESP CELL MOL, V14, P118, DOI 10.1165/ajrcmb.14.2.8630260; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36970	36977		10.1074/jbc.M201293200	http://dx.doi.org/10.1074/jbc.M201293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161423	hybrid			2022-12-25	WOS:000178447100010
J	Engelhardt, H; Heinz, C; Niederweis, M				Engelhardt, H; Heinz, C; Niederweis, M			A tetrameric porin limits the cell wall permeability of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PORINS; CRYSTAL-STRUCTURE; OUTER-MEMBRANE; PROTEIN; TUBERCULOSIS; CHANNELS; FLUIDITY; CHELONAE; EFFLUX; GENE	Mycobacteria protect themselves with an outer lipid bilayer, which is the thickest biological membrane hitherto known and has an exceptionally low permeability rendering mycobacteria intrinsically resistant against many antibiotics. Pore proteins mediate the diffusion of hydrophilic nutrients across this membrane. Electron microscopy revealed that the outer membrane of Mycobacterium smegmatis contained about 1000 protein pores per mum(2), which are about 50-fold fewer pores per mum(2) than in Gram-negative bacteria. The projection structure of the TV or porin MspA of M. smegmatis was determined at 17 resolution. MspA forms a cone-like tetrameric complex of 10 nm in length with a single central pore. Thus, MspA is drastically different from the trimeric porins of Gram-negative bacteria and represents a new class of channel proteins. The formation of MspA micelles indicated that the ends of MspA have different hydrophobicities. Oriented insertion of MspA into membranes was demonstrated in lipid bilayer experiments, which revealed a strongly asymmetrical voltage gating of MspA channels at -30 mV. The length of MspA is sufficient to span the outer membrane and contributes in combination with the tapering end of the pore and the low number of pores to the low permeability of the cell wall of M. smegmatis for hydrophilic compounds.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Max Planck Inst Biochem, Abt Mol Strukt Biol, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Max Planck Society	Niederweis, M (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.							Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRUNEN M, 1993, EUR J BIOCHEM, V212, P129, DOI 10.1111/j.1432-1033.1993.tb17642.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Fajardo DA, 1998, J BACTERIOL, V180, P4452, DOI 10.1128/JB.180.17.4452-4459.1998; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Gouaux E, 1998, STRUCT FOLD DES, V6, P1221, DOI 10.1016/S0969-2126(98)00122-1; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; HEINZ C, 2003, IN PRESS MEMBRANE PR; Hoiczyk E, 1998, CURR BIOL, V8, P1161, DOI 10.1016/S0960-9822(07)00487-3; Im W, 2002, J MOL BIOL, V319, P1177, DOI 10.1016/S0022-2836(02)00380-7; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Kartmann B, 1999, J BACTERIOL, V181, P6543, DOI 10.1128/JB.181.20.6543-6546.1999; KESSEL M, 1988, J MOL BIOL, V203, P275, DOI 10.1016/0022-2836(88)90108-8; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LIN CM, 1990, BIOCHIM BIOPHYS ACTA, V1038, P382, DOI 10.1016/0167-4838(90)90252-B; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; MAUK MR, 1989, EUR J BIOCHEM, V186, P473, DOI 10.1111/j.1432-1033.1989.tb15231.x; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2001, NANO LETT, V1, P169, DOI 10.1021/nl015503x; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Nikaido H, 2001, SEMIN CELL DEV BIOL, V12, P215, DOI 10.1006/scdb.2000.0247; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; PAUL A, 1992, BIOPHYS J, V61, P172, DOI 10.1016/S0006-3495(92)81825-8; PAUL TR, 1993, ZBL BAKT-INT J MED M, V279, P450; Riess FG, 2001, J MEMBRANE BIOL, V182, P147, DOI 10.1007/s00232-001-0037-x; Saier MH, 2000, J MEMBRANE BIOL, V175, P165, DOI 10.1007/s00232001065; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; SEN K, 1988, J BIOL CHEM, V263, P1182; Senaratne RH, 1998, J BACTERIOL, V180, P3541, DOI 10.1128/JB.180.14.3541-3547.1998; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS JQ, 1993, J BIOL CHEM, V268, P6234	43	58	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37567	37572		10.1074/jbc.M206983200	http://dx.doi.org/10.1074/jbc.M206983200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130659	hybrid			2022-12-25	WOS:000178447100084
J	Figueroa, Y; Wald, FA; Salas, PJI				Figueroa, Y; Wald, FA; Salas, PJI			p34(cdc2)-mediated phosphorylation mobilizes microtubule-organizing centers from the apical intermediate filament scaffold in CACO-2 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CELLS; ORGANIZATION; PROTEINS; POLARITY; GLYCOSYLATION; CYTOSKELETON	We have shown previously that centrosomes and other microtubule-organizing centers (MTOCs) attach to the apical intermediate filament (IF) network in CACO-2 cells. In this cell line, intermediate filaments do not disorganize during mitosis. Therefore, we speculated that the trigger of the G(2)-M boundary may also detach MTOCs from their IF anchor. If that was the case, at least one of the proteins involved in the attachment must be phosphorylated by p34(cdc2) (cdk1). Using confocal microscopy and standard biochemical analysis, we found that p34(cdc2)-mediated phosphorylation indeed released MTOCs from IFs in permeabilized cells. In isolated, immunoprecipitated multiprotein complexes containing both gamma-tubulin and cytokeratin 19, p34(cdc2) phosphorylated only one protein, and phosphorylation released cytokeratin 19 from the complexes. We conclude that this as yet unidentified protein is a part of the molecular mechanism that attaches MTOCs to IFs in interphase.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami	Salas, PJI (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, R-124,POB 016960, Miami, FL 33101 USA.	psalas@miami.edu	Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NIDDK NIH HHS [R01 DK57805] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057805] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BUENDIA B, 1990, J CELL BIOL, V110, P1123, DOI 10.1083/jcb.110.4.1123; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; CHOU CF, 1993, J BIOL CHEM, V268, P4465; Csala M, 2000, BIOCHEM PHARMACOL, V59, P801, DOI 10.1016/S0006-2952(99)00392-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; Goncalves CA, 2000, NEUROCHEM RES, V25, P885, DOI 10.1023/A:1007533927813; HERSEY SJ, 1990, ANNU REV PHYSIOL, V52, P345; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; LEPERS A, 1990, BIOCHIMIE, V72, P1, DOI 10.1016/0300-9084(90)90166-E; Liu JM, 1999, METHODS, V19, P403, DOI 10.1006/meth.1999.0876; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Melan M A, 1994, Methods Mol Biol, V34, P55; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; PINTO M, 1983, BIOL CELL, V47, P323; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RODRIGUEZ ML, 1994, J CELL SCI, V107, P3145; Salas PJI, 1999, J CELL BIOL, V146, P645, DOI 10.1083/jcb.146.3.645; Salas PJI, 1997, J CELL BIOL, V137, P359, DOI 10.1083/jcb.137.2.359; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8	28	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37848	37854		10.1074/jbc.M207037200	http://dx.doi.org/10.1074/jbc.M207037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151413	hybrid			2022-12-25	WOS:000178447100120
J	Flemmer, AW; Gimenez, I; Dowd, BFX; Darman, RB; Forbush, B				Flemmer, AW; Gimenez, I; Dowd, BFX; Darman, RB; Forbush, B			Activation of the Na-K-Cl cotransporter NKM detected with a phospho-specific antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; PAROTID ACINAR-CELLS; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; UP-REGULATION; DIRECT PHOSPHORYLATION; EXPRESSION; SECRETION; PROTEIN; EPITHELIUM	The Na-K-Cl cotransporter NKCC1 is activated by phosphorylation of a regulatory domain in its N terminus. In the accompanying paper (Darman, R. B., and Forbush, B. (2002) J. Biol. Chem. 277, 37542-37550), we identify three phosphothreonines important in this process. Using a phospho-specific antibody (anti-phospho-NKCC1 antibody R5) raised against a diphosphopeptide containing Thr(212) and Thr(217) of human NKCC, we were readily able to monitor the cotransporter activation state. In P-32 phosphorylation experiments with rectal gland tubules, we show that the R5 antibody signal is proportional to the amount of P-32 incorporated into NKCC1; and in experiments with NKCC1-transfected HEK-293 cells, we demonstrate that R5-detected phosphorylation directly mirrors functional activation. Immunofluorescence analysis of shark rectal gland shows activation-dependent R5 antibody staining along the basolateral membrane. In perfused rat parotid glands, isoproterenol induced staining of both acinar and ductal cells along the basolateral membrane. Isoproterenol also induced basolateral staining of the epithelial cells in rat trachea, whereas basal cells in the subepithelial tissue displayed heavy, non-polarized staining of the cell membrane. In rat colon, agonist stimulation induced staining along the basolateral membrane of crypt cells. These data provide direct evidence of NKCC1 regulation in these tissues, and they further link phosphorylation of NKCC1 with its activation in transfected cells and native tissue. The high conservation of the regulatory threonine residues among NKCC1, NKCC2, and NCC family members, together with the fact that tissues from divergent vertebrate species exhibit similar R5-binding profiles, lends further support to the role of this regulatory locus in vivo.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	Forbush, B (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	biff.forbush@yale.edu	Giménez, Ignacio/B-6322-2013; W., Andreas Flemmer/AAQ-5654-2021	Giménez, Ignacio/0000-0002-6043-4869; 	NIDDK NIH HHS [DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000, DOI 10.1164/ajrccm.157.6.9707011; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; Flemmer AW, 1999, FASEB J, V13, pA399; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HALM DR, 1986, AM J PHYSIOL, V251, pC252, DOI 10.1152/ajpcell.1986.251.2.C252; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Kurihara K, 2002, AM J PHYSIOL-CELL PH, V282, pC817, DOI 10.1152/ajpcell.00352.2001; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; McDaniel N, 1999, AM J PHYSIOL-GASTR L, V276, pG1273, DOI 10.1152/ajpgi.1999.276.5.G1273; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schultheiss G, 2000, EUR J PHARMACOL, V403, P251, DOI 10.1016/S0014-2999(00)00487-8; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252	28	154	156	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37551	37558		10.1074/jbc.M206294200	http://dx.doi.org/10.1074/jbc.M206294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145305	hybrid			2022-12-25	WOS:000178447100082
J	Velling, T; Risteli, J; Wennerberg, K; Mosher, DF; Johansson, S				Velling, T; Risteli, J; Wennerberg, K; Mosher, DF; Johansson, S			Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha(11)beta(1) and alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITE; 3-DIMENSIONAL COLLAGEN; FIBRILLAR COLLAGENS; GENE-EXPRESSION; MATRIX PROTEIN; BLOOD-VESSELS; HUMAN-SKIN; DECORIN; CELLS; FIBRILLOGENESIS	Polymerization of the ECM proteins fibronectin and laminin has been shown to take place in close vicinity to the cell surface and be facilitated by beta(1), integrins (Lohikangas, L., Gullberg, D., and Johansson, S. (2001) Exp. Cell Res. 265, 135-144 and Wennerberg, K., Lohikangas, L., Gullberg, D., Pfaff, M., Johansson, S., and Fassler, R. (1996) J. Cell Biol. 132,227-238). We have studied the role of collagen receptors, integrins alpha(11)beta(1) and alpha(2)beta(1), and fibronectin in collagen polymerization using fibronectin-deficient mouse embryonic fibroblast cell lines. In contrast to the earlier belief that collagen polymerization occurs via self-assembly of collagen molecules we show that a preformed fibronectin matrix is essential for collagen network formation and that collagen-binding integrins strongly enhance this process. Thus, collagen deposition is regulated by the cells, both indirectly through integrin alpha(5)beta(1)-dependent polymerization of fibronectin and directly through collagen-binding integrins.	Inst Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Oulu, Dept Clin Chem, FIN-90014 Oulu, Finland; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Oulu; University of Wisconsin System; University of Wisconsin Madison	Velling, T (corresponding author), Inst Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.		Velling, Teet/G-6129-2016; Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANYAI L, 1990, EUR J BIOCHEM, V193, P801, DOI 10.1111/j.1432-1033.1990.tb19403.x; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chernousov MA, 1998, J CELL SCI, V111, P2763; CIDADAO AJ, 1989, EUR J CELL BIOL, V48, P303; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; Gardner H, 1999, J CELL SCI, V112, P263; Graham HK, 2000, J MOL BIOL, V295, P891, DOI 10.1006/jmbi.1999.3384; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEDMAN K, 1982, EMBO J, V1, P47, DOI 10.1002/j.1460-2075.1982.tb01122.x; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Holmes DF, 2001, MICRON, V32, P273, DOI 10.1016/S0968-4328(00)00040-8; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; JOHANSSON S, 1984, J CELL BIOL, V98, P810, DOI 10.1083/jcb.98.3.810; JOHANSSON S, 1980, BIOCHEM J, V187, P521, DOI 10.1042/bj1870521; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; KURKINEN M, 1980, LAB INVEST, V43, P47; Kypreos KE, 2000, J CELL BIOCHEM, V80, P146; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Lafrenie RM, 1998, J CELL PHYSIOL, V175, P163, DOI 10.1002/(SICI)1097-4652(199805)175:2<163::AID-JCP6>3.0.CO;2-M; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LAPIERE JC, 1994, J INVEST DERMATOL, V103, P637, DOI 10.1111/1523-1747.ep12398270; Lohikangas L, 2001, EXP CELL RES, V265, P135, DOI 10.1006/excr.2001.5170; Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; MOSHER DF, 1995, THROMB HAEMOSTASIS, V74, P529; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Obara M, 1997, FEBS LETT, V412, P48, DOI 10.1016/S0014-5793(97)00737-0; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RISTELI J, 1988, CLIN CHEM, V34, P715; RISTELI J, 1993, CLIN CHEM, V39, P635; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; UGAROVA T, 1995, THROMB HAEMOSTASIS, V74, P253; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x	58	276	281	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37377	37381		10.1074/jbc.M206286200	http://dx.doi.org/10.1074/jbc.M206286200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145303	hybrid			2022-12-25	WOS:000178447100060
J	Russelakis-Carneiro, M; Saborio, GP; Anderes, L; Soto, C				Russelakis-Carneiro, M; Saborio, GP; Anderes, L; Soto, C			Changes in the glycosylation pattern of prion protein in murine scrapie - Implications for the mechanism of neurodegeneration in prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE DISTRIBUTION; GLYCOPROTEIN; NEURONS; SPREAD; AGENT; CELLS; PRPC	In prion diseases, the normal prion protein (PrPc) undergoes a conformational change that results in the abnormal form, named scrapie prion protein (PrPsc). The visual system of rodents provides a relatively simple neuronal model in which the cell bodies of neurons are confined to the retina and the axons constitute the optic nerve. We investigated by Western blot the profile of PrPc in the optic nerve and retina of normal hamsters and mice. We found that in the optic nerve the amount of PrPc is significantly higher than in the retina. A less abundant non-glycosylated band was observed in retinas compared with the optic nerve and brain. Similar results were found in the gray and white matter from normal mice and hamsters. After stereotaxic injection of ME7 or 139A in the superior colliculus, a visual target area, the proportion and glycopattern of PrP changed in the retina and optic nerve throughout the course of the disease. Similar results were found in the gray and white matter at terminal stage of scrapie after injection of ME7 and 139A in the dorsal hippocampus. This is the first time that changes in the distribution and glycopattern of PrP have been described in an in vivo model of prion diseases.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		Soto, C (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.							Belichenko PV, 2000, NEUROPATH APPL NEURO, V26, P143, DOI 10.1046/j.1365-2990.2000.026002143.x; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Betmouni S, 1999, NEUROPATH APPL NEURO, V25, P20, DOI 10.1046/j.1365-2990.1999.00153.x; BORCHELT DR, 1994, J BIOL CHEM, V269, P14711; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; FRASER H, 1982, NATURE, V295, P149, DOI 10.1038/295149a0; Gray F, 1999, J NEUROPATH EXP NEUR, V58, P321, DOI 10.1097/00005072-199904000-00002; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; LINDEN R, 1983, BRAIN RES, V272, P145, DOI 10.1016/0006-8993(83)90371-2; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4	20	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36872	36877		10.1074/jbc.M202229200	http://dx.doi.org/10.1074/jbc.M202229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130636	hybrid			2022-12-25	WOS:000178275100140
J	Tinoco, LW; da Silva, A; Leite, A; Valente, AP; Almeida, FCL				Tinoco, LW; da Silva, A; Leite, A; Valente, AP; Almeida, FCL			NMR structure of PW2 bound to SDS micelles - A tryptophan-rich anticoccidial peptide selected from phage display libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; CIRCULAR-DICHROISM; INDOLICIDIN; MEMBRANE; PROTEIN; ANTIBACTERIAL; MECHANISM; MAGAININS; PROGRAM	PW2 (HPLKQYWWRPSI) was selected from phage display libraries through an alternative panning method using living sporozoites of Eimeria acervulina as target. Synthetic PW2 shows anticoccidial activity against E. acervulina and Eimeria tenella with very low hemolytic activity. It also displays antifungal activity but no activity against bacteria. We present the solution structure of the PW2 bound to SDS micelles. In the absence of an interface, PW2 is in random coil conformation. In micelles, structural calculation shows that Trp-7 forms the hydrophobic core that is important for the peptide folding. Lys-4, Tyr-6, Trp-8, and Arg-9 are in the same surface, possibly facing the micelle interface. This possibility was supported by the fact that chemical shift differences for these residues were more pronounced when compared with PW2 in water and in SDS. PW2 gains structure upon binding to SDS micelles. Lys-4, Tyr-6, Trp-8, and Arg-9 were found to bind to the micelle. Trp-7, Trp-8, and Arg-9 composed the WW+ consensus found in the sequence of the peptides selected with the phage display technique against E. acervulina sporozoites. This suggested that Trp-7, Trp-8, and Arg-9 are probably key residues not only for the peptide interaction with SDS micelles but also for the interaction with E. acervulina sporozoites surface.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl, BR-21941590 Rio De Janeiro, RJ, Brazil; Univ Estadual Campinas, Ctr Biol Mol & Engn Genet, BR-23083970 Campinas, SP, Brazil	Universidade Federal do Rio de Janeiro; Universidade Estadual de Campinas	Almeida, FCL (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl, BR-21941590 Rio De Janeiro, RJ, Brazil.	valente@cnrmn.bioqmed.ufrj.br	Valente, Ana Paula/J-3010-2017; Tinoco, Luzineide W/G-3630-2014; Almeida, Fabio/O-4989-2018	Valente, Ana Paula/0000-0001-7219-1123; Tinoco, Luzineide W/0000-0002-1299-6242; Almeida, Fabio/0000-0001-6046-7006				AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BIERBAUM G, 1985, ARCH MICROBIOL, V141, P249, DOI 10.1007/BF00408067; Bihan TL, 1996, BIOCHEMISTRY-US, V35, P12712, DOI 10.1021/bi960869n; BLOCHET JE, 1993, FEBS LETT, V329, P336, DOI 10.1016/0014-5793(93)80249-T; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; da Silva A, 2002, MOL BIOCHEM PARASIT, V120, P53, DOI 10.1016/S0166-6851(01)00439-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Friedrich CL, 2001, J BIOL CHEM, V276, P24015, DOI 10.1074/jbc.M009691200; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lawyer C, 1996, FEBS LETT, V390, P95, DOI 10.1016/0014-5793(96)00637-0; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; Tassin S, 1998, BIOCHEMISTRY-US, V37, P3623, DOI 10.1021/bi9723515; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200; Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3	37	37	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36351	36356		10.1074/jbc.M204225200	http://dx.doi.org/10.1074/jbc.M204225200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130641	hybrid			2022-12-25	WOS:000178275100073
J	Schwientek, T; Keck, B; Levery, SB; Jensen, MA; Pedersen, JW; Wandall, HH; Stroud, M; Cohen, SM; Amado, M; Clausen, H				Schwientek, T; Keck, B; Levery, SB; Jensen, MA; Pedersen, JW; Wandall, HH; Stroud, M; Cohen, SM; Amado, M; Clausen, H			The Drosophila gene brainiac encodes a glycosyltransferase putatively involved in glycosphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; UDP-GALACTOSE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; EXPRESSION CLONING; CALLIPHORA-VICINA; MOLECULAR-CLONING; FRINGE; BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE; IDENTIFICATION; MELANOGASTER	The Drosophila genes fringe and brainiac exhibit sequence similarities to glycosyltransferases. Drosophila and mammalian fringe homologs encode UDP-N-acetylglucosamine:fucose-O-Ser 131,3-N-acetylglucosaminyltransferases that modulate the function of Notch family receptors. The biological function of brainiac is less well understood. brainiac is a member of a large homologous mammalian beta3-glycosyltransferase family with diverse functions. Eleven distinct mammalian homologs have been demonstrated to encode functional enzymes forming beta1-3 glycosidic linkages with different UDP donor sugars and acceptor sugars. The putative mammalian homologs with highest sequence similarity to brainiac encode UDP-N-acetylglucosamine:131,3-N-acetylglucosaminyltransferases (beta3GlcNAc-transferases), and in the present study we show that brainiac also encodes a beta3GlcNAc-transferase that uses beta-linked mannose as well as beta-linked galactose as acceptor sugars. The inner disaccharide core structures of glycosphingolipids in mammals (Galbeta1-4Glcbeta1-Cer) and insects (Manbeta1-4Glcbeta1-Cer) are different. Both disaccharide glycolipids served as substrates for brainiac, but glycolipids of insect cells have so far only been found to be based on the GlcNAcbeta1-3Manbeta1-4Glcbeta1-Cer core structure. Infection of High Five(TM) cells with baculovirus containing full coding brainiac cDNA markedly increased the ratio of GlcNAcbeta1-3Manbeta1-4Glcbeta1-Cer glycolipids compared with Galbeta1-4Manbeta1-4Glcbeta1-Cer found in wild type cells. We suggest that brainiac exerts its biological functions by regulating biosynthesis of glycosphingolipids.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; NW Biotherapeut Inc, Bothell, WA 98021 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Copenhagen; University System Of New Hampshire; University of New Hampshire; European Molecular Biology Laboratory (EMBL)	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	henrik.clausen@odont.ku.dk	clausen, henrik/AAD-8016-2021; Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Wandall, Hans H./0000-0003-0240-9232; Clausen, Henrik/0000-0002-0915-5055	NCRR NIH HHS [P20 RR16459, P41 RR05351] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016459, P41RR005351] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; DENNIS RD, 1985, EUR J BIOCHEM, V146, P51, DOI 10.1111/j.1432-1033.1985.tb08618.x; DENNIS RD, 1993, ADV LIPID RES, V26, P321; Egan S, 2000, GLYCOCONJUGATE J, V17, P867, DOI 10.1023/A:1010921313314; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Gerdt S, 1997, GLYCOBIOLOGY, V7, P265, DOI 10.1093/glycob/7.2.265; Goode S, 1997, COLD SPRING HARB SYM, V62, P177; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; Hakamori S, 1998, ACTA ANAT, V161, P79; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hellberg A, 2002, J BIOL CHEM, V277, P29455, DOI 10.1074/jbc.M203047200; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P1069, DOI 10.1021/bi00119a016; Lopez-Schier H, 2001, GENE DEV, V15, P1393, DOI 10.1101/gad.200901; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; SAITO T, 1971, J LIPID RES, V12, P257; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; WIELS J, 1991, INT IMMUNOL, V3, P1289, DOI 10.1093/intimm/3.12.1289; Wuhrer M, 2000, BIOCHEM J, V348, P417, DOI 10.1042/0264-6021:3480417; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	50	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32421	32429		10.1074/jbc.M206213200	http://dx.doi.org/10.1074/jbc.M206213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12130651	hybrid			2022-12-25	WOS:000177859000005
J	Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL				Daly, RJ; Gu, HH; Parmar, J; Malaney, S; Lyons, RJ; Kairouz, R; Head, DR; Henshall, SM; Neel, BG; Sutherland, RL			The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer	ONCOGENE			English	Article						tyrosine kinase; growth factors; steroid hormones; signal transduction; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; CYCLIN E-CDK2 ACTIVATION; GROWTH-FACTOR; PHOSPHATASE CORKSCREW; SIGNALING PATHWAY; TYROSINE KINASE; MCF-7 CELLS; EXPRESSION; PROGRESSION; ALPHA	Grb2-associated binder 2 (Gab2) is a recently identified member of the Gab/Daughter of sevenless family of docking proteins, which localize, amplify and integrate signaling pathways activated by various receptors including receptor tyrosine kinases (RTKs). To date, Gab2 signaling has been primarily investigated in hematopoietic cells. Here we report marked overexpression of Gab2 in a subset of breast cancer cell lines relative to normal breast epithelial strains and a trend for increased Gab2 expression in estrogen receptor (ER)positive lines. Overexpression relative to normal ductal epithelium was also observed in some primary breast cancers. In MCF-7 breast cancer cells Gab2 was markedly tyrosine phosphorylated in response to heregulin and also following EGF, insulin or bFGF administration, indicating that a variety of RTKs implicated in breast cancer development or progression couple to this docking protein. In hormone-responsive breast cancer cells, GAB2 mRNA and protein expression were induced by estradiol in a manner sensitive to the pure anti-estrogen ICI 182780, indicating that this regulation is mediated via the ER. Gab2 therefore represents a novel link between steroid and growth factor signaling in breast cancer, and when overexpressed, may modulate the sensitivity of breast cancer cells to these important growth regulators.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol & Oncol, Boston, MA 02215 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152, R01CA066600] Funding Source: NIH RePORTER; NCI NIH HHS [CA66600, CA49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Allard JD, 1996, DEVELOPMENT, V122, P1137; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke R, 2000, J MAMMARY GLAND BIOL, V5, P245, DOI 10.1023/A:1009527609611; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; JANES PW, 1994, ONCOGENE, V9, P3601; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa H, 2000, CANCER RES, V60, P5887; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lai A, 2001, J BIOL CHEM, V276, P25823, DOI 10.1074/jbc.M100925200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Rocha RL, 1997, CLIN CANCER RES, V3, P103; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	38	76	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5175	5181		10.1038/sj.onc.1205522	http://dx.doi.org/10.1038/sj.onc.1205522			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140767				2022-12-25	WOS:000176975900015
J	Panyam, J; Zhou, WZ; Prabha, S; Sahoo, SK; Labhasetwar, V				Panyam, J; Zhou, WZ; Prabha, S; Sahoo, SK; Labhasetwar, V			Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery	FASEB JOURNAL			English	Article						intracellular delivery; gene therapy; antiproliferative effect; sustained release; restenosis	BIOLOGICALLY-ACTIVE PROTEINS; SMOOTH-MUSCLE-CELLS; BIODEGRADABLE NANOSPHERES; INTRACELLULAR DELIVERY; MOLECULAR-MECHANISMS; BREFELDIN-A; IN-VIVO; LIPOSOMES; PEPTIDE; CULTURE	The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly( DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endolysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U. S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.	Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Nebraska Med Ctr 986025, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Labhasetwar, V (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Nebraska Med Ctr 986025, 600 S 42nd St, Omaha, NE 68198 USA.	vlabhase@unmc.edu	Labhasetwar, Vinod/J-9660-2016; Sanjeeb, Sahoo/ABF-3419-2020	Labhasetwar, Vinod/0000-0001-7950-1542; Panyam, Jayanth/0000-0002-8656-2244	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 2000, PULM PHARMACOL THER, V13, P115, DOI 10.1006/pupt.2000.0243; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; Belanger AJ, 2001, CARDIOVASC RES, V51, P749, DOI 10.1016/S0008-6363(01)00329-7; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Clark PR, 1999, CURR OPIN MOL THER, V1, P158; Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Guzman LA, 1996, CIRCULATION, V94, P1441, DOI 10.1161/01.CIR.94.6.1441; Labhasetwar V, 1999, COLLOID SURFACE B, V16, P281, DOI 10.1016/S0927-7765(99)00079-X; LABHASETWAR V, 1997, PHARM NEWS, V4, P28; Langer R, 1997, PHARMACEUT RES, V14, P840, DOI 10.1023/A:1012131329148; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Maheshwari A, 2000, MOL THER, V2, P121, DOI 10.1006/mthe.2000.0105; Makino K, 1986, J Microencapsul, V3, P195, DOI 10.3109/02652048609031573; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PANYAM J, 2002, IN PRESS J DRUG TARG; Peters PJ, 2001, TRAFFIC, V2, P885, DOI 10.1034/j.1600-0854.2001.21204.x; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Shitara Y, 1998, J CONTROL RELEASE, V55, P35, DOI 10.1016/S0168-3659(98)00025-X; STOLNIK S, 1995, COLLOID SURFACE A, V97, P235, DOI 10.1016/0927-7757(95)03081-N; Suh H, 1998, PHARMACEUT RES, V15, P1495, DOI 10.1023/A:1011982428413; Tachibana R, 1998, BIOCHEM BIOPH RES CO, V251, P538, DOI 10.1006/bbrc.1998.9460; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; WAGNER M, 1994, J CELL SCI, V107, P933; Wattiaux R, 2000, ADV DRUG DELIVER REV, V41, P201, DOI 10.1016/S0169-409X(99)00066-6	33	827	895	7	198	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1217	10.1096/fj.02-0088com	http://dx.doi.org/10.1096/fj.02-0088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153989				2022-12-25	WOS:000177814000030
J	Caricasole, A; Bruno, V; Cappuccio, I; Melchiorri, D; Copani, A; Nicoletti, F				Caricasole, A; Bruno, V; Cappuccio, I; Melchiorri, D; Copani, A; Nicoletti, F			A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity	FASEB JOURNAL			English	Article						Alzheimer's disease; Rattin; neurodegeneration	METABOTROPIC GLUTAMATE RECEPTORS; FAMILIAL ALZHEIMERS-DISEASE; RESCUE FACTOR HUMANIN; IN-VITRO; BETA; TOXICITY; ACTIVATION; PROTEIN; NEURONS	We report the identification of a novel rat cDNA encoding a peptide homologous to Humanin, a secreted peptide that specifically protects against neuronal cell death induced by beta-amyloid peptide (Abeta) or by mutations causing early-onset familial Alzheimer's disease. The rat gene, which we termed Rattin, encodes a peptide of 38 residues (15 residues longer than Humanin) showing 73% identity in the conserved region to Humanin. The expression profile of the 1.6-kb Rattin transcript is comparable to that displayed by Humanin, with significant expression levels in the central nervous system and in cardiac and skeletal muscle. The full-length Rattin peptide and its 1-25 fragment were equally effective as Humanin in protecting rat- and mouse-cultured cortical neurons against Abeta-induced toxicity. However, Rattin was much more effective than Humanin against excitotoxic neuronal death induced by a toxic pulse with NMDA. Rattin and its short fragment were protective against excitotoxic death not only when coapplied with NMDA, but also when added to the cultures after the NMDA pulse. Neither Rattin not Humanin could affect neuronal apoptosis by trophic deprivation induced in cultured cerebellar granule cells depleted of extracellular potassium. This suggests that Rattin is the prototype of a novel class of peptides, phylogenetically related to Humanin, endowed with protective activity not only against Abeta but also toward excitotoxic neuronal death. The identification of Rattin may be instrumental for the development of novel pharmacological strategies aimed at enhancing the production of endogenous Humanin-like peptides.	Univ Roma La Sapienza, Inst Human Physiol & Pharmacol Vittorio Erspamer, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; Univ Catania, Dept Pharmaceut Sci, I-95124 Catania, Italy; INM Neuromed, Pozzilli, Italy	Sapienza University Rome; University of Catania; IRCCS Neuromed	Caricasole, A (corresponding author), Univ Roma La Sapienza, Inst Human Physiol & Pharmacol Vittorio Erspamer, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	andrea.caricasole@uniroma1.it	Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016; bruno, Valeria/F-3146-2012; Nicoletti, Ferdinando/A-2446-2010	bruno, Valeria/0000-0003-4231-0739; NICOLETTI, Ferdinando/0000-0003-3366-7269; Nicoletti, Ferdinando/0000-0003-0917-443X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; COPANI A, 1995, MOL PHARMACOL, V47, P890; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; Exley C, 1996, BIOCHEM J, V314, P709, DOI 10.1042/bj3140709; Fagarasan MO, 1996, MOL PSYCHIATR, V1, P398; Fassbender K, 2001, NATURWISSENSCHAFTEN, V88, P261; GALLO V, 1987, EUR J PHARMACOL, V138, P293, DOI 10.1016/0014-2999(87)90448-1; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GEORGEHYSLOP PH, 2000, BIOL PSYCHIAT, V47, P183; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Melchiorri D, 2001, EUR J NEUROSCI, V13, P1694, DOI 10.1046/j.1460-9568.2001.01549.x; Nabeshima Toshitaka, 1998, Journal of Toxicological Sciences, V23, P177; Neve RL, 2001, BIOCHEM SOC SYMP, V67, P37; Nicoletti F, 1986, Funct Neurol, V1, P345; OLSHANSKY SJ, 1993, SCI AM, V268, P46, DOI 10.1038/scientificamerican0493-46; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; ROSE KGM, 2001, METHODS TOXICOLOGY, P40; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Zoghbi HY, 2000, CURR OPIN NEUROBIOL, V10, P655, DOI 10.1016/S0959-4388(00)00135-5	31	46	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1331	+		10.1096/fj.02-0018fje	http://dx.doi.org/10.1096/fj.02-0018fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154011				2022-12-25	WOS:000176683900025
J	Kerkhoff, C; Hofmann, HA; Vormoor, J; Melkonyan, H; Roth, J; Sorg, C; Klempt, M				Kerkhoff, C; Hofmann, HA; Vormoor, J; Melkonyan, H; Roth, J; Sorg, C; Klempt, M			Binding of two nuclear complexes to a novel regulatory element within the human S100A9 promoter drives the. S100A9 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-ASSOCIATED BOX; ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REGULATION; ARACHIDONIC-ACID; REPRESSION DOMAIN; C/EBP-ALPHA; CELL-LINES; MRP14; DIFFERENTIATION; COREPRESSOR	S100A9, also referred to as MRP14, is a calcium-binding protein whose expression is tightly regulated during differentiation of myeloid cells. The present study was performed to study the cell type- and differentiation-specific transcriptional regulation of the S100A9 gene. Analysis of the S100A9 promoter in MonoMac-6 cells revealed evidence for a novel regulatory region from position -400 to -374 bp, termed myeloid-related protein regulatory element (MRE). MRE deletion resulted in a 5.2-fold reduction of promoter activity. By electrophoretic mobility shift analysis two nuclear complexes binding to this region were identified and referred to as MRE-binding complex A (MbcA) and MRE-binding complex B (MbcB). By mutagenesis the MRE-binding motif could be narrowed to a 12-bp region. The relevance of MRE is deduced from the observations that the formation of either MRE-binding complex A or MRE-binding complex B strongly correlated with S100A9 gene expression in a cell type-specific, activation- and differentiation-dependent manner. Moreover, DNA affinity chromatography and Western blot studies indicate that a Kruppel-related zinc finger protein and the transcriptional intermediary factor 1beta (TIF1beta) are involved in an MRE-binding complex, thereby regulating the S100A9 gene expression.	Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Pediat Hematol Oncol, D-48149 Munster, Germany	University of Munster; University of Munster	Kerkhoff, C (corresponding author), Inst Expt Dermatol, von Esmarch Str 58, D-48149 Munster, Germany.	kerkhoc@uni-muenster.de	Vormoor, Josef/GPS-7248-2022	Vormoor, Josef/0000-0002-1825-1890				ABRINK M, 1995, DNA CELL BIOL, V14, P125, DOI 10.1089/dna.1995.14.125; Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BRUN JG, 1994, J RHEUMATOL, V21, P733; Cammas F, 2000, DEVELOPMENT, V127, P2955; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Ciotti P, 2001, EUR J BIOCHEM, V268, P225, DOI 10.1046/j.1432-1327.2001.01859.x; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dreier J, 1998, DNA CELL BIOL, V17, P321, DOI 10.1089/dna.1998.17.321; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Klempt M, 1999, J CELL BIOCHEM, V73, P49, DOI 10.1002/(SICI)1097-4644(19990401)73:1<49::AID-JCB6>3.0.CO;2-2; Klempt M, 1998, IMMUNOBIOLOGY, V199, P148, DOI 10.1016/S0171-2985(98)80070-3; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kuruto-Niwa R, 1998, CELL STRUCT FUNCT, V23, P109, DOI 10.1247/csf.23.109; KUWAYAMA A, 1993, BLOOD, V81, P3116; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; LOVERING R, 1991, NUCLEIC ACIDS RES, V19, P2921, DOI 10.1093/nar/19.11.2921; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317; NATSUKA S, 1992, BLOOD, V79, P460; OGAWA M, 1993, BLOOD, V81, P2844; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Poncelet DA, 1998, DNA CELL BIOL, V17, P931, DOI 10.1089/dna.1998.17.931; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROTH J, 1992, IMMUNOBIOLOGY, V186, P304, DOI 10.1016/S0171-2985(11)80259-7; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P1001; TOMMERUP N, 1993, HUM MOL GENET, V2, P1571, DOI 10.1093/hmg/2.10.1571; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; VANROOZENDAAL KEP, 1990, EXP CELL RES, V190, P137, DOI 10.1016/0014-4827(90)90155-4; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	52	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41879	41887		10.1074/jbc.M207990200	http://dx.doi.org/10.1074/jbc.M207990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167632	hybrid			2022-12-25	WOS:000178985300075
J	deSouza, N; Reiken, S; Ondrias, K; Yang, YM; Matkovich, S; Marks, AR				deSouza, N; Reiken, S; Ondrias, K; Yang, YM; Matkovich, S; Marks, AR			Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; RECONSTITUTED LIPID VESICLES; TYROSINE PHOSPHORYLATION; TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; CA2+ RELEASE; CALCIUM; CAMP; FLUX; CALCINEURIN	The inositol 1,4,5-trisphosphate receptor (IP3R) is a ubiquitously expressed intracellular calcium (Ca2+) release channel on the endoplasmic reticulum. IP3Rs play key roles in controlling Ca2+ signals that activate numerous cellular functions including T cell activation, neurotransmitter release, oocyte fertilization and apoptosis. There are three forms of IP3R, all of which are ligand-gated channels activated by the second messenger inositol 1,4,5-trisphosphate. Channel function is modulated via cross-talk with other signaling pathways including those mediated by kinases and phosphatases. In particular IP3Rs are known to be regulated by cAMP-dependent protein kinase (PKA) phosphorylation. In the present study we show that PKA and the protein phosphatases PP1 and PP2A are components of the IP3R1 macromolecular signaling complex. PKA phosphorylation of IP3R1 increases channel activity in planar lipid bilayers. These studies indicate that regulation of IP3R1 function via PKA phosphorylation involves components of a macromolecular signaling complex.	Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Slovak Acad Sci, Inst Mol Physiol, Bratislava 83334, Slovakia	Columbia University; Columbia University; Slovak Academy of Sciences	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, Dept Med, Box 65,Rm 9-401,630 W 168th St, New York, NY 10032 USA.		Matkovich, Scot J/AFP-0908-2022; Matkovich, Scot J/B-9077-2009	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857; Ondrias, Karol/0000-0001-8329-3563	FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00949] Funding Source: Medline; NIAID NIH HHS [R01 AI37994] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Giovannucci DR, 2000, J KOREAN MED SCI, V15, pS55, DOI 10.3346/jkms.2000.15.S.S55; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Miller C., 1986, ION CHANNEL RECONSTI; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299	37	114	116	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39397	39400		10.1074/jbc.M207059200	http://dx.doi.org/10.1074/jbc.M207059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167631	hybrid			2022-12-25	WOS:000178662500044
J	Lee, JY; Urbatsch, IL; Senior, AE; Wilkens, S				Lee, JY; Urbatsch, IL; Senior, AE; Wilkens, S			Projection structure of P-glycoprotein by electron microscopy - Evidence for a closed conformation of the nucleotide binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; PICHIA-PASTORIS CELLS; ABC TRANSPORTER; MULTIDRUG TRANSPORTER; CRYSTAL-STRUCTURE; 2-DIMENSIONAL CRYSTALLIZATION; MEMBRANE-PROTEINS; ACTIVE-SITE; WALKER-A; ATPASE	The structure of P-glycoprotein (Pgp) from mouse has been studied by electron microscopy and image analysis. Two-dimensional crystals of Pgp in a lipid bilayer were generated by reconstituting pure, detergent-solubilized protein containing a C-terminal six-histidine tag using the lipid monolayer technique. The crystals belong to plane group P1 with a = b = 104 +/- 2 Angstrom and gamma = 90 +/- 4degrees. The projection structure of Pgp calculated at a resolution of 22 A shows two closely interacting protein domains that can be interpreted as the N- and C-terminal halves of the protein. The projection structure of Pgp is consistent with the recently published x-ray structure of MsbA, a lipid A flippase from Escherichia coli with high sequence homology to Pgp but only when the two MsbA subunits are rotated to bring their nucleotide binding domains together.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of California System; University of California Riverside; University of Rochester	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.		Lee, Jyh-Yeuan/ACA-2717-2022	Lee, Jyh-Yeuan/0000-0003-1799-2416	NIGMS NIH HHS [GM50156, GM58600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058600, R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; KESSEL M, 1985, J MICROSC-OXFORD, V139, P63, DOI 10.1111/j.1365-2818.1985.tb04662.x; Lebeau L, 2001, J MOL BIOL, V308, P639, DOI 10.1006/jmbi.2001.4629; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sherman MB, 1998, ULTRAMICROSCOPY, V74, P179, DOI 10.1016/S0304-3991(98)00041-2; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2001, ARCH BIOCHEM BIOPHYS, V388, P171, DOI 10.1006/abbi.2001.2299; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	35	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40125	40131		10.1074/jbc.M206871200	http://dx.doi.org/10.1074/jbc.M206871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163504	hybrid			2022-12-25	WOS:000178662500135
J	Allen, MP; Xu, M; Linseman, DA; Pawlowski, JE; Bokoch, GM; Heidenreich, KA; Wierman, ME				Allen, MP; Xu, M; Linseman, DA; Pawlowski, JE; Bokoch, GM; Heidenreich, KA; Wierman, ME			Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires Rac activation of the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; TRANSCRIPTION FACTOR MEF2C; RHO-FAMILY GTPASES; PROTEIN-KINASE; GROWTH-FACTOR; SURVIVAL ACTIVITIES; CELL-PROLIFERATION; MAMMALIAN-CELLS; NUCLEAR FACTOR	Recent studies suggest that adhesion-related kinase (Ark) plays a role in gonadotropin-releasing hormone (GnRH) neuronal physiology. Ark promotes migration of GnRH neurons via Rae GTPase and concomitantly suppresses GnRH gene expression via homeodomain and myocyte enhancer factor-2 (MEF2) transcription factors. Here, we investigated the signaling cascade required for Ark inhibition of the GnRH promoter in GT1-7 GnRH neuronal cells. Ark repression was blocked by the MEK/ERK pathway inhibitor, PD98059, and dominant negative MEK1 but was unaffected by dominant negative Ras. Inhibitors of the Rho family GTPases, Clostridium difficile toxin B (Rho/Rac/Cdc42 inhibitor) and Clostridium sordellii lethal toxin (Rac/Cdc42 inhibitor), blocked Ark inhibition of GnRH transcription. Moreover, dominant negative Rae blunted both Ark activation of ERK and repression of the GnRH promoter, demonstrating an essential role for Rae in coupling Ark to ERK activation. Like Ark, a constitutively active mutant of Rae suppressed GnRH transcription in an ERK-dependent manner. Finally, Ark-mediated repression was significantly attenuated by a dominant negative MEF2C, whereas repression induced by constitutively active Rae was unaffected, indicating that MEF2 proteins are not targets of the Ark --> Rac --> MEK --> ERK cascade. The data suggest that Ark suppresses GnRH gene expression via the coordinated activation of a Rac ---> ERK signaling pathway and a distinct MEF2-dependent mechanism.	Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Scripps Research Institute; Scripps Research Institute	Wierman, ME (corresponding author), Vet Affairs Med Ctr, Res Serv, 1055 Clermont St,Box 111H, Denver, CO 80220 USA.		Linseman, Daniel/L-3846-2019		NICHD NIH HHS [HD31191-04, HD08667-02] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD031191, F32HD008667, R01HD031191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191; Allen MP, 2000, J BIOL CHEM, V275, P39662, DOI 10.1074/jbc.M007097200; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Fang ZQ, 1998, ENDOCRINOLOGY, V139, P3654, DOI 10.1210/en.139.8.3654; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hullinger TG, 2001, J BIOL CHEM, V276, P46807, DOI 10.1074/jbc.M103176200; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Li RH, 1996, J NEUROSCI, V16, P2012; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Linseman DA, 2001, J BIOL CHEM, V276, P39123, DOI 10.1074/jbc.M103959200; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1996, CANCER SURV, V27, P101; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MING CW, 2001, ARTERIOSCLER THROMB, V21, P1592; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Rafty LA, 2000, J BIOL CHEM, V275, P11478, DOI 10.1074/jbc.275.15.11478; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schiavo G, 2001, NAT REV MOL CELL BIO, V2, P530, DOI 10.1038/35080089; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang Y, 1999, MOL CELL BIOL, V19, P1881; VAN AL, 1997, GENE DEV, V11, P2295; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WETSEL WC, 1995, CELL MOL NEUROBIOL, V15, P43, DOI 10.1007/BF02069558; WETSEL WC, 1992, P NATL ACAD SCI USA, V89, P4149, DOI 10.1073/pnas.89.9.4149; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WRAY S, 1994, DEV BIOL, V166, P349, DOI 10.1006/dbio.1994.1320; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Yoshida K, 1995, J NEUROSCI, V15, P7769; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200	75	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38133	38140		10.1074/jbc.M200826200	http://dx.doi.org/10.1074/jbc.M200826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138087	hybrid			2022-12-25	WOS:000178529600022
J	Gotoh, M; Sato, T; Akashima, T; Iwasaki, H; Kameyama, A; Mochizuki, H; Yada, T; Inaba, N; Zhang, Y; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, H; Kimata, K; Narimatsu, H				Gotoh, M; Sato, T; Akashima, T; Iwasaki, H; Kameyama, A; Mochizuki, H; Yada, T; Inaba, N; Zhang, Y; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, H; Kimata, K; Narimatsu, H			Enzymatic synthesis of chondroitin with a novel chondroitin sulfate N-acetylgalactosaminyltransferase that transfers N-acetylgalactosamine to glucuronic acid in initiation and elongation of chondroitin sulfate synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; PROTEIN LINKAGE REGION; HEPARAN-SULFATE; MOLECULAR-CLONING; TUMOR SUPPRESSORS; CDNA CLONING; BIOSYNTHESIS	We found a novel glycosyltransferase gene having a hypothetical beta1,4-galactosyltransferase motif (GenBank(TM) accession number AB081516) by a BLAST search and cloned its full-length open reading frame using the 5'-rapid amplification of cDNA ends method. The truncated form was expressed in insect cells as a soluble enzyme. It transferred N-acetylgalactosamine, not galactose, to para-nitrophenyl-p-glucuronic acid. The N-acetylgalactosamine-glucuronic acid linkage has been identified only in chondroitin sulfate; therefore, we examined its chondroitin elongation and initiation activities. N-Acetylgalactosaminyltransferase activity was observed toward chondroitin poly- and oligosaccharides, chondroitin sulfate oligosaccharides, and linkage tetrasaccharide (GlcA-Gal-Gal-Xyl-O-methoxyphenyl), and the chondroitin polysaccharide and linkage tetrasaccharide were better acceptor substrates than the others. Northern blot analysis and quantitative real-time PCR analysis revealed that its 4-kb transcripts were highly expressed in thyroid and placenta, although they were ubiquitously expressed in various tissues and cells. These results suggest that this enzyme has N-acetylgalactosaminyltransferase activity in both the elongation and initiation of chondroitin sulfate synthesis. Furthermore, we performed enzymatic synthesis of chondroitin pentasaccharide in vitro. In one tube reaction with four enzymes, B1,4-galactosyltransferase-VII, B1,3-galactosyltransferase-VI, glucuronyltransferase-I, and this enzyme, and a synthetic xylose-peptide acceptor, the structure GalNAc-GlcA-Gal-Gal-Xyl-peptide was constructed. This is the first report of a chondroitin pentasaccharide constructed with recombinant glycosyltransferases in vitro.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab C2, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Seikagaku Corp, Tokyo 2070021, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Japan Genome Solut Inc, Tokyo 1920031, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan; Soka Univ, Inst Life Sci, Tokyo 1928577, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Seikagaku Corporation; Aichi Medical University; Soka University	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab C2, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018; Kameyama, Akihiko/A-9641-2008	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Kameyama, Akihiko/0000-0002-8229-4449; Watanabe, Hideto/0000-0001-5291-0696; Nishihara, Shoko/0000-0002-1668-2603				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Gastinel LN, 2001, TRENDS GLYCOSCI GLYC, V13, P131, DOI 10.4052/tigg.13.131; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; IYAMA T, 2002, J BIOL CHEM, V277, P8841; JERONIMO SMB, 1994, BRAZ J MED BIOL RES, V27, P2253; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; SAMPAIO LO, 1977, BIOCHIM BIOPHYS ACTA, V498, P123, DOI 10.1016/0304-4165(77)90093-9; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; WASSERMAN L, 1980, AM J OBSTET GYNECOL, V138, P763, DOI 10.1016/S0002-9378(16)32733-8; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156	43	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38189	38196		10.1074/jbc.M203619200	http://dx.doi.org/10.1074/jbc.M203619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163485	hybrid			2022-12-25	WOS:000178529600028
J	Holmes, VF; Scandellari, F; Benjamin, KR; Cozzarelli, NR				Holmes, VF; Scandellari, F; Benjamin, KR; Cozzarelli, NR			Structure of reaction intermediates formed during Saccharomyces cerevisiae Rad51-catalyzed strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; PROMOTED BRANCH MIGRATION; DUPLEX DNA-MOLECULES; YEAST RAD51 PROTEIN; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; ATP HYDROLYSIS; EXCHANGE-REACTIONS; PAIRING SEQUENCES; BINDING-PROTEINS	The process by which the Saccharomyces cerevisiae strand transfer protein, Rad51, seeks out homologous sequences in vivo can be modeled by an in vitro reaction between a single-stranded DNA circle and a double-stranded linear DNA. In addition to the substrates and products, electrophoresis of reaction mixtures resolves two groups of low mobility bands. Here we show that the low mobility bands formed during strand transfer by Rad51 (or Escherichia coli RecA) represent joint molecules (JM) between the two substrates. One group, which we name JM1, is an obligatory reaction intermediate in which the complementary strand from the duplex substrate has been partially transferred to the single-stranded circle. Our assignment is based on pulse-chase and restriction enzyme digestion experiments and verified by electron microscopy. The slower moving group of bands, designated JM2, is formed by an unexpected reaction between JM1 and a second double-stranded linear substrate. Strand transfer of the second duplex initiates noncanonically from the end where the complementary strand is recessed. Thus JM2 is formed by two strand transfer reactions with the same single-stranded circular substrate but with opposite polarities. Finally, we show that the multiple sharp bands in JM1 and JM2 are the result of substrate sequences that pause strand transfer.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall,3204, Berkeley, CA 94720 USA.	neozzare@socrates.berkeley.edu	Scandellari, Francesca/ABI-6248-2020	Scandellari, Francesca/0000-0002-2242-2656; Benjamin, Kirsten/0000-0003-4267-1972				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HE M, 1988, BIOTECHNIQUES, V6, P728; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Namsaraev EA, 1998, P NATL ACAD SCI USA, V95, P10477, DOI 10.1073/pnas.95.18.10477; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; RADDING CM, 1978, ANNU REV BIOCHEM, V47, P847, DOI 10.1146/annurev.bi.47.070178.004215; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	40	4	4	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38945	38953		10.1074/jbc.M206962200	http://dx.doi.org/10.1074/jbc.M206962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147704	hybrid			2022-12-25	WOS:000178529600118
J	Moller, JV; Lenoir, G; Marchand, C; Montigny, C; le Maire, M; Toyoshima, C; Juul, BS; Champeil, P				Moller, JV; Lenoir, G; Marchand, C; Montigny, C; le Maire, M; Toyoshima, C; Juul, BS; Champeil, P			Calcium transport by sarcoplasmic reticulum Ca2+-ATPase - Role of the A domain and its C-terminal link with the transmembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING; CROSS-LINKING; HIGH-AFFINITY; CA2+ BINDING; CONFORMATIONAL TRANSITIONS; FLUORESCEIN ISOTHIOCYANATE; PHOSPHOENZYME INTERMEDIATE	After treatment of sarcoplasmic reticulum Ca2+-ATPase with proteinase K (PK) in the presence of Ca2+ and a protecting non-phosphorylated ligand (e.g. adenosine 5'-(beta,gamma-methylenetriphosphate), we were able to prepare in high yield an ATPase species that only differs from intact ATPase because of excision of the MAATE(243) sequence from the loop linking the A domain with the third transmembrane segment. The PK-treated ATPase was unable to transport Ca2+ and to catalyze ATP hydrolysis, but it could bind two calcium ions with high affinity and react with ATP to form a classical ADP-sensitive phosphoenzyme, Ca(2)E1P, with occluded Ca2+. The ability of Ca(2)E1P to become converted to the Ca2+-free ADP-insensitive form, E2P, was strongly reduced, as was the ability of PK-treated ATPase to react with orthovanadate or to form an E2P intermediate from inorganic phosphate in the absence of Ca2+. PK-treated ATPase also reacted with thapsigargin to form a complex with altered properties, and the tryptic cleavage "T2' site in the A domain was no longer protected in the absence of Ca2+. It is probable that disrupting the C-terminal link of the A domain with the transmembrane region severely compromises reorientation of A and P domains and the functionally critical cross-talk of these domains with the membrane-bound Ca2+ ions.	Univ Paris Sud, Serv Biophys Fonct Membranaires, DBJC, CEA,URA 2096,CNRS,LRA 17V, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, IFR 46, F-91191 Gif Sur Yvette, France; Univ Aarhus, Dept Biophys, DK-8000 Aarhus C, Denmark; CNRS, Inst Biochim & Biophys Mol & Cellulaire, Equipe Chimie Prot, UMR 8619,CNRS, F-91405 Orsay, France; Univ Paris 11, IFR 46, F-91405 Orsay, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), Univ Paris Sud, Serv Biophys Fonct Membranaires, DBJC, CEA,URA 2096,CNRS,LRA 17V, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Toyoshima, Chikashi/R-4153-2019; MARCHAND, Christophe H/B-5854-2008; Lenoir, Guillaume/I-4002-2019	MARCHAND, Christophe H/0000-0002-0729-3841; Lenoir, Guillaume/0000-0002-8759-5179				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; FORGE V, 1993, J BIOL CHEM, V268, P10953; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; IMAMURA Y, 1986, J BIOCHEM, V100, P133, DOI 10.1093/oxfordjournals.jbchem.a121685; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; Inesi G, 1997, ANN NY ACAD SCI, V834, P207, DOI 10.1111/j.1749-6632.1997.tb52252.x; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; INESI G, 1987, J BIOL CHEM, V262, P16338; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; Ogawa H, 2000, FEBS LETT, V471, P99, DOI 10.1016/S0014-5793(00)01374-0; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1982, J BIOL CHEM, V257, P6120; PORTILLO F, 1995, BIOMEMBRANE, V6, P225; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; Schepens I, 2000, J BIOL CHEM, V275, P35792, DOI 10.1074/jbc.M006526200; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1991, J BIOL CHEM, V266, P18839; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	70	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38647	38659		10.1074/jbc.M204603200	http://dx.doi.org/10.1074/jbc.M204603200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138099	hybrid			2022-12-25	WOS:000178529600082
J	Pesu, M; Aittomaki, S; Takaluoma, K; Lagerstedt, A; Silvennoinen, O				Pesu, M; Aittomaki, S; Takaluoma, K; Lagerstedt, A; Silvennoinen, O			p38 mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTI-CD40 MONOCLONAL-ANTIBODY; GERMLINE EPSILON-PROMOTER; SERINE PHOSPHORYLATION; SIGNALING PATHWAY; MAP KINASE; SYNERGISTIC ACTIVATION; C/EBP-BETA; CD40; STAT6	STAT6 functions as a critical mediator of IL-4-stimulated gene activation, and the function of STAT6 is regulated by both tyrosine and serine kinase activities. Here we analyzed the role of serine phosphorylation in regulation of STAT6-mediated transcription. Optimal transcriptional response of IL-4-inducible promoters requires costimulatory signals through CD40-stimulated intracellular kinases such as p38 MAPK. We found that the p38 MAPK inhibitor SB202190 as well as the dominant negative p38 MAPK inhibited interleukin (IL)-4 regulated expression of CD23 in Ramos B cells. IL-4 stimulation did not stimulate p38 MAPK activity, but inhibition of p38 MAPK activity directly correlated with inhibition of IL-4-induced gene activation. Dissection of individual response elements on IL-4-regulated promoter showed that C/EBPbeta-mediated transcription was insensitive to SB202190 treatment in B cells whereas STAT6-mediated transcription was regulated by p38 MAPK. The IL-4-induced immediate activation events of STAT6 were not affected by p38 MAPK activity. Furthermore, phosphoamino acid analysis and phosphopeptide mapping indicated that STAT6 is not a direct substrate for p38 MAPK. Instead, p38 MAPK was found to directly regulate the activity of the transactivation domain of STAT6. These results show that, in addition to the well established proinflammatory effects, p38 MAPK also provides a costimulatory signal for IL-4-induced gene responses by directly stimulating the transcriptional activation of STAT6.	Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, FIN-33521 Tampere, Finland; Univ Tampere, Dept Pathol, FIN-33014 Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Tampere University	Silvennoinen, O (corresponding author), Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.	olli.silvennoinen@uta.fi	Pesu, Marko/L-6344-2013	Pesu, Marko/0000-0002-7541-3921				BERBERICH I, 1994, J IMMUNOL, V153, P4357; Birrell M, 2000, EUR RESPIR J, V16, P947, DOI 10.1183/09031936.00.16594700; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Craxton A, 1998, J IMMUNOL, V161, P3225; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Iciek LA, 1997, J IMMUNOL, V158, P4769; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Karras JG, 1997, J IMMUNOL, V159, P4350; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Paterson RLK, 1996, EUR J IMMUNOL, V26, P1979, DOI 10.1002/eji.1830260902; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Richards ML, 1997, J IMMUNOL, V158, P263; Saharinen P, 1997, BLOOD, V90, P4341; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; Sutherland CL, 1996, J IMMUNOL, V157, P3381; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	47	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38254	38261		10.1074/jbc.M201427200	http://dx.doi.org/10.1074/jbc.M201427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161424	hybrid			2022-12-25	WOS:000178529600036
J	Maekawa, M; Nishida, E; Tanoue, T				Maekawa, M; Nishida, E; Tanoue, T			Identification of the anti-proliferative protein Tob as a MAPK substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; TOB/BTG1 FAMILY; KINASE CASCADES; MEMBER; ACTIVATION; CELLS; PHOSPHORYLATION; TRANSCRIPTION; COMPONENT; COMPLEX	Mitogen-activated protein kinases (MAPKs) regulate a wide variety of cellular functions by phosphorylating their specific substrates. Here we have identified Tob as a novel substrate of MAPK Tob, a member of the Tob and B-cell translocation gene anti-proliferative protein family, is shown to negatively regulate the proliferation of osteoblasts and T cells. In this study, our two-hybrid screening has identified Tob as an ERK2-interacting protein. Biochemical analyses have then shown that ERK MAPK (ERK2) and JNK/SAPK (JNK2) bind to and phosphorylate Tob in vitro. ERK catalyzes the phosphorylation more efficiently than JNK. When the ERK pathway is activated in cells, phosphorylation of Tob is induced. An ERK-binding or -docking site locates in the N-terminal portion of Tob, and phosphorylation sites reside in the C-terminal stretch region. The docking is crucial for efficient phosphorylation. Mutant forms of Tob, in which serines are replaced by glutamic acids to mimic phosphorylation, show a much reduced ability to inhibit the cell cycle progression to S phase from G(0)/G(1) phase, as compared with wild-type Tob, indicating that ERK phosphorylation negatively regulates the anti-proliferative function of Tob.	Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Badarinarayana V, 2000, GENETICS, V155, P1045; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denis CL, 2001, GENETICS, V158, P627; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Holland ND, 1997, DEV DYNAM, V210, P11, DOI 10.1002/(SICI)1097-0177(199709)210:1<11::AID-AJA2>3.0.CO;2-4; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda S, 1996, ONCOGENE, V12, P705; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	31	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37783	37787		10.1074/jbc.M204506200	http://dx.doi.org/10.1074/jbc.M204506200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151396	hybrid			2022-12-25	WOS:000178447100112
J	Trinel, PA; Maes, E; Zanetta, JP; Delplace, F; Coddeville, B; Jouault, T; Strecker, G; Poulain, D				Trinel, PA; Maes, E; Zanetta, JP; Delplace, F; Coddeville, B; Jouault, T; Strecker, G; Poulain, D			Candida albicans phospholipomannan, a new member of the fungal mannose inositol phosphoceramide family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SABOURAUD LIQUID-MEDIUM; YEAST EXTRACT; HEPTAFLUOROBUTYRATE DERIVATIVES; SPHINGOLIPIDS; SEROTYPE; STRAINS; LIPOARABINOMANNAN; OLIGOMANNOSIDES; CHROMATOGRAPHY; TEMPERATURE	The pathogenic yeast Candida albicans has the ability to synthesize unique sequences of beta-1,2-oligomannosides that act as adhesins, induce cytokine production, and generate protective antibodies. Depending on the growth conditions, beta-1,2-oligomannosides are associated with different carrier molecules in the cell wall. Structural evidence has been obtained for the presence of these residues in the polysaccharide moiety of the glycolipid, phospholipomannan (PLM). In this study, the refinement of purification techniques led to large quantities of PLM being extracted from Candida albicans cells. A combination of methanolysis, gas chromatography, mass spectrometry, and nuclear magnetic resonance analyses allowed the complete structure of PLM to be deduced. The lipid moiety was shown to consist of a phytoceramide associating a C-18/C-20 phytosphingosine and C-25, C-26, or mainly C-24 hydroxy fatty acids. The spacer linking the glycan part was identified as a unique structure: -Man-P-Man-Ins-P-. Therefore, in contrast to the major class of membranous glycosphingolipids represented by mannose diinositol phosphoceramide, which is derived from mannose inositol phosphoceramide by the addition of inositol phosphate, PLM seems to be derived from mannose inositol phosphoceramide by the addition of mannose phosphate. In relation to a previous study of the glycan part of the molecule, the assignment of the second phosphorus position leads to the definition of PLM beta-1,2-oligomannosides as unbranched linear structures that may reach up to 19 residues in length. Therefore, PLM appears to be a new type of glycosphingolipid, which is glycosylated extensively through a unique spacer. The conferred hydrophilic properties allow PLM to diffuse into the cell wall in which together with mannan it presents C. albicans beta-1,2-oligomannosides to host cells.	Fac Med, INSERM, Lab Mycol Fondamentale & Appl, F-59037 Lille, France; Univ Sci & Technol Lille, Chim Biol Lab, UMR 8576, CNRS,Lab Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Poulain, D (corresponding author), Fac Med, INSERM, Lab Mycol Fondamentale & Appl, EPI 9915,Pole Rech, F-59037 Lille, France.	dan_poulain@compuserve.com	Jouault, Thierry/I-1071-2018; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARNES PF, 1992, J IMMUNOL, V149, P541; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Hakomori S, 1996, CANCER RES, V56, P5309; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Jennemann R, 2001, EUR J BIOCHEM, V268, P1190, DOI 10.1046/j.1432-1327.2001.01963.x; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; LI RK, 1993, J BIOL CHEM, V268, P18293; Mandala SM, 1997, J BIOL CHEM, V272, P32709, DOI 10.1074/jbc.272.51.32709; Masuoka J, 1999, GLYCOBIOLOGY, V9, P1281, DOI 10.1093/glycob/9.11.1281; MATSUBARA T, 1987, CHEM PHYS LIPIDS, V43, P1, DOI 10.1016/0009-3084(87)90012-0; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; OKAWA Y, 1994, FEBS LETT, V345, P167, DOI 10.1016/0014-5793(94)00434-X; Okawa Y, 1996, CLIN DIAGN LAB IMMUN, V3, P331, DOI 10.1128/CDLI.3.3.331-336.1996; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P327, DOI 10.1016/S0732-8893(97)00240-X; Pons A, 2000, ANAL BIOCHEM, V284, P201, DOI 10.1006/abio.2000.4686; Pons A, 2002, J LIPID RES, V43, P794; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; SCHNAAR RL, 1994, PROG BRAIN RES, V101, P185; Schofield L, 1996, IMMUNOL CELL BIOL, V74, P555, DOI 10.1038/icb.1996.89; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1999, J BIOL CHEM, V274, P30520, DOI 10.1074/jbc.274.43.30520; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Zhong WY, 2000, ANTIMICROB AGENTS CH, V44, P651, DOI 10.1128/AAC.44.3.651-653.2000	42	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37260	37271		10.1074/jbc.M202295200	http://dx.doi.org/10.1074/jbc.M202295200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138092	hybrid			2022-12-25	WOS:000178447100047
J	Wagner, S; Flood, TA; O'Reilly, P; Hume, K; Sabourin, LA				Wagner, S; Flood, TA; O'Reilly, P; Hume, K; Sabourin, LA			Association of the Ste20-like kinase (SLK) with the microtubule - Role in Rac1-mediated regulation of actin dynamics during cell adhesion and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; STE20-RELATED KINASE; ACTIVATES RAC1; STRESS FIBERS; CYTOSKELETON; MIGRATION; BINDING; RHO; STABILIZATION	Cytoskeletal remodeling events are tightly regulated by signal transduction systems that impinge on adhesion components and modulators of cellular architecture. We have previously shown that the Ste20-like kinase (SLK) can induce apoptosis through the induction of actin disassembly and cellular retraction (Sabourin, L. A., Tamai, K., Seale, P., Wagner, J., and Rudnicki, M. A. (2000) Mol. Cell. Biol. 20, 684-696). Using immunofluorescence studies, we report that SLK is redistributed with adhesion components at large podosome-like adhesion sites in fibronectin-stimulated fibroblasts. However, in vitro kinase assays demonstrate that its activity is not modulated following fibronectin stimulation. Double immunofluorescence studies in exponentially growing or spreading fibroblasts show that SLK is associated with the microtubule network and can be coprecipitated with alpha-tubulin. Furthermore, the stimulation of adhesion site formation by microtubule-disrupting agents induces the relocalization of SLK with unpolymerized alpha-tubulin to large vinculin-containing adhesion complexes. Using microinjection studies, we show that ectopic expression of activated SLK induces the disassembly of actin stress fibers, a process that can be inhibited by dominant negative Rac1. Significantly, endogenous SLK can be colocalized with Rac1 in spreading cells on FN. Finally, the overexpression of SLK by adenoviral infection inhibits cell spreading on fibronectin. These results suggest that SLK is part of a microtubule-associated complex that is targeted to adhesion sites and implicated in the regulation of cytoskeletal dynamics.	Univ Ottawa, Dept Cellular & Mol Med, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Ottawa Hlth Res Inst, Program Neurosci, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	lsab@uottawa.ca		Flood, Trevor/0000-0002-5227-2708				Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Best A, 1996, J BIOL CHEM, V271, P3756; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; DANOWSKI BA, 1989, J CELL SCI, V93, P255; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hollenbeck P, 2001, CURR BIOL, V11, pR820, DOI 10.1016/S0960-9822(01)00494-8; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ilic D, 1997, J CELL SCI, V110, P401; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 2000, CURR BIOL, V10, P739, DOI 10.1016/S0960-9822(00)00544-3; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lezama R, 2001, CELL MOTIL CYTOSKEL, V50, P147, DOI 10.1002/cm.10003; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PARSONS JT, 1994, J CELL SCI, P109; Pytowski B, 1998, ARCH BIOCHEM BIOPHYS, V359, P310, DOI 10.1006/abbi.1998.0907; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Small JV, 1999, FEBS LETT, V452, P96, DOI 10.1016/S0014-5793(99)00530-X; Small JV, 1998, BBA-MOL CELL RES, V1404, P271, DOI 10.1016/S0167-4889(98)00080-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; VAN AL, 1997, GENE DEV, V11, P2295; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	37	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37685	37692		10.1074/jbc.M205899200	http://dx.doi.org/10.1074/jbc.M205899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151406	hybrid			2022-12-25	WOS:000178447100100
J	Xia, GQ; Chen, JH; Tiwari, V; Ju, WJ; Li, JP; Malmstrom, A; Shukla, D; Liu, J				Xia, GQ; Chen, JH; Tiwari, V; Ju, WJ; Li, JP; Malmstrom, A; Shukla, D; Liu, J			Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HUMAN CDNAS; EXPRESSION; SULFOTRANSFERASE; DIVERSITY; DOMAIN; PROTEOGLYCANS; SYNDECAN-1; ISOZYMES; SEQUENCE	Heparan sulfate 3-O-sulfotransferase transfers sulfate to the 3-OH position of a glucosamine residue of heparan sulfate (HS) to form 3-O-sulfated HS. The 3-O-sulfated glucosamine residue contributes to two important biological functions of HS: binding to antithrombin and thereby carrying anticoagulant activity, and binding to herpes simplex viral envelope glycoprotein D to serve as an entry receptor for herpes simplex virus 1. A total of five HS 3-O-sulfotransferase isoforms were reported previously. Here we report the isolation and characterization of a novel HS 3-O-sulfotransferase isoform, designated as HS 3-O-sulfotransferase isoform 5 (3-OST-5). 3-OST-5 cDNA was isolated from a human placenta cDNA library and expressed in COS-7 cells. The disaccharide analysis of 3-OST-5-modified HS revealed that 3-OST-5 generated at least three 3-O-sulfated disaccharides as follows: IdoUA2S-AnMan3S, GlcUA-AnMan3S6S, and IdoUA2S-AnMan3S6S. Transfection of the plasmid expressing 3-OST-5 rendered wild type Chinese hamster ovary cells susceptible to the infection by herpes simplex virus 1, suggesting that 3-OST-5-modified HS serves as an entry receptor for herpes simplex virus 1. In addition, 3-OST-5-modified HS bound to herpes simplex viral envelope protein glycoprotein D. Furthermore, we found that 3-OST-5-modified HS also bound to antithrombin, suggesting that 3-OST-5 also produces anticoagulant HS. In summary, our results indicate that a new member of 3-OST family generates both anticoagulant HS and an entry receptor for herpes simplex virus 1. These results provide a new insight regarding the mechanism for the biosynthesis of biologically active HS.	Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Chapel Hill, NC 27599 USA; Lund Univ, Biomed Ctr C13, S-22184 Lund, Sweden; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of North Carolina; University of North Carolina Chapel Hill; Lund University; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Uppsala University	Liu, J (corresponding author), Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Rm 309,Beard Hall,CB7360, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Xia, Guoqing/C-2365-2015	Xia, Guoqing/0000-0003-4492-9156; Malmstrom, Anders/0000-0002-6691-146X; Shukla, Deepak/0000-0002-3039-6953	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050, K22AI053836] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50050-01, AI053836-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Akkaraju GR, 1999, J GENE MED, V1, P280, DOI 10.1002/(SICI)1521-2254(199907/08)1:4<280::AID-JGM45>3.0.CO;2-L; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BJORNSSON S, 1993, ANAL BIOCHEM, V210, P282, DOI 10.1006/abio.1993.1197; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Liu Jian, 2002, P475; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yabe T, 2001, BIOCHEM J, V359, P235, DOI 10.1042/0264-6021:3590235; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681	40	140	146	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37912	37919		10.1074/jbc.M204209200	http://dx.doi.org/10.1074/jbc.M204209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138164	Green Published, hybrid			2022-12-25	WOS:000178447100128
J	Deming, PB; Flores, KG; Downes, CS; Paules, RS; Kaufmann, WK				Deming, PB; Flores, KG; Downes, CS; Paules, RS; Kaufmann, WK			ATR enforces the topoisomerase II-dependent G(2) checkpoint through inhibition of Plk1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; NUCLEAR EXPORT; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; PROTEIN-KINASE; PHOSPHORYLATION; B1; LOCALIZATION	An ATR-dependent G(2) checkpoint responds to inhibition of topoisomerase 11 and delays entry into mitosis by sustaining nuclear exclusion of cyclin B1-Cdk1 complexes. Here we report that induction of this checkpoint with ICRF-193, a topoisomerase H catalytic inhibitor that does not cause DNA damage, was associated with an ATR-dependent inhibition of polo-like kinase 1 (Plk1) kinase activity and a decrease in cyclin B1 phosphorylation. Expression of constitutively active Plk1 but not wild type Plk1 reversed ICRF-193-induced mitotic delay in HeLa cells, suggesting that Plk1 kinase activity is important for the checkpoint response to ICRF-193. G(2)/M synchronized normal human fibroblasts, when treated with ICRF-193, showed a decrease in cyclin B1 phosphorylation and Plk1 kinase activity despite high cyclin B1-Cdk1 kinase activity. G(2) fibroblasts that were treated with caffeine to override the checkpoint response to ICRF-193 displayed a high incidence of chromosomal aberrations. Taken together, these results suggest that ATR-dependent inhibition of Plk1 kinase activity may be one mechanism to regulate cyclin B1 phosphorylation and sustain nuclear exclusion during the G(2) checkpoint response to topoisomerase 11 inhibition. Moreover, the results demonstrate an important role for the topoisomerase II-dependent G(2) checkpoint in the preservation of human genomic stability.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA; NIEHS, Growth Control & Canc Grp, NIH, Res Triangle Pk, NC 27709 USA; Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Ulster University	Kaufmann, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.			Deming, Paula/0000-0003-3278-1705; Paules, Richard S/0000-0001-9106-7486	NCI NIH HHS [R01 CA081343, CA42765, P30-CA16086] Funding Source: Medline; NIEHS NIH HHS [P30-ES10126, T32-ES07017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016086, P01CA042765, R01CA081343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021157, T32ES007017, P30ES010126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Brown EJ, 2000, GENE DEV, V14, P397; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Gimenez-Abian JF, 2000, CHROMOSOMA, V109, P235, DOI 10.1007/s004120000065; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liu QH, 2000, GENE DEV, V14, P1448; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Takaha N, 2002, CANCER RES, V62, P647; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	46	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36832	36838		10.1074/jbc.M206109200	http://dx.doi.org/10.1074/jbc.M206109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147700	Green Published, hybrid			2022-12-25	WOS:000178275100135
J	Eklund, EA; Goldenberg, I; Lu, YF; Andrejic, J; Kakar, R				Eklund, EA; Goldenberg, I; Lu, YF; Andrejic, J; Kakar, R			SHP1 protein-tyrosine phosphatase regulates HoxA10 DNA binding and transcriptional repression activity in undifferentiated myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH-EATEN MICE; CHRONIC GRANULOMATOUS-DISEASE; HEMATOPOIETIC-CELLS; GP91(PHOX) EXPRESSION; HOMEOBOX GENE; PU.1; MACROPHAGE; P67(PHOX); LEUKEMIA; DIFFERENTIATION	The homeodomain protein HoxA10 interacts with negative cis elements to repress gene transcription in undifferentiated myeloid cells. The CYBB and NCF2 genes, which encode the gp91(PHOX) and p67(PHOX) proteins, are two such HoxA10 target genes. During interferon gamma-induced myeloid differentiation, tyrosine phosphorylation decreases HoxA10 DNA binding affinity and transcriptional repression. Therefore, decreased HoxA10 repression contributes to increased CYBB and NCF2 transcription in differentiating myeloid cells. The current studies investigate modulation of HoxA10 repression activity during myelopoiesis. We determine that phosphorylation of tyrosine residues in the conserved homeodomain decreases HoxA10-DNA binding. We also determine that interaction of the homeodomain phosphotyrosine residues with an adjacent domain in the HoxA10 protein is necessary for decreased DNA binding affinity. Since SHP1 protein-tyrosine phosphatase antagonizes myeloid differentiation and decreases CYBB and NCF2 transcription, we investigated the influence of SHP1-protein-tyrosine phosphatase (PTP) on HoxA10 tyrosine phosphorylation. We find that SHP1-PTP activity increases HoxA10 target gene repression in undifferentiated myeloid cells. Consistent with this, SHP1-PTP interacts with HoxA10 and decreases homeodomain-tyrosine phosphorylation. These investigations suggest that SHP1-PTP activity, in undifferentiated myeloid cells, influences HoxA10 repression of myeloid-specific genes. Therefore, increased HoxA10 repression of myeloid gene transcription is a molecular mechanism for SHP1 inhibition of myeloid differentiation.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Chicago Lakeside Vet Adm Hosp, Chicago, IL 60611 USA; Birmingham Vet Adm Hosp, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Northwestern Univ, Sch Med, Dept Med, Olson Pavil,Rm 8527,710 N Fairbanks Ct, Chicago, IL 60611 USA.				NCI NIH HHS [CA95266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong Q, 1999, J IMMUNOL, V162, P3220; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Kautz B, 2001, J BIOL CHEM, V276, P37868; KENNEY RT, 1993, BLOOD, V82, P3739; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LARRICK JW, 1980, J IMMUNOL, V125, P6; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; MCCOY KL, 1982, J IMMUNOL, V128, P1797; MCCOY KL, 1983, AM J PATHOL, V112, P18; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook H., 1989, MOL CLONING LAB MANU; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tapley P, 1997, EXP HEMATOL, V25, P122; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495	30	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36878	36888		10.1074/jbc.M203917200	http://dx.doi.org/10.1074/jbc.M203917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145285	hybrid			2022-12-25	WOS:000178275100141
J	Siow, NL; Choi, RCY; Cheng, AWM; Jiang, JXS; Wan, DCC; Zhu, SQ; Tsim, KWK				Siow, NL; Choi, RCY; Cheng, AWM; Jiang, JXS; Wan, DCC; Zhu, SQ; Tsim, KWK			A cyclic AMP-dependent pathway regulates the expression of acetylcholinesterase during myogenic differentiation of C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; CULTURED CHICK MYOTUBES; PROTEIN-KINASE-C; NEUROMUSCULAR-JUNCTION; MESSENGER-RNA; MOUSE ACETYLCHOLINESTERASE; TRANSCRIPTIONAL REGULATION; MUSCLE DIFFERENTIATION; PROMOTER ELEMENTS; CAMP	The expression of acetylcholinesterase (AChE) is markedly increased during myogenic differentiation of C2C12 myoblasts to myotubes; the expression is mediated by intrinsic factor(s) during muscle differentiation. In order to analyze the molecular mechanisms regulating AChE expression during myogenic differentiation, a similar to2.2-kb human AChE promoter tagged with a luciferase reporter gene, namely pAChE-Luc, was stably transfected into C2C12 cells. The profile of promoter-driven luciferase activity during myogenic differentiation of C2C12 myotubes was found to be similar to that of endogenous expression of AChE catalytic subunit. The increase of AChE expression was reciprocally regulated by a cAMP-dependent signaling pathway. The level of intracellular cAMP, the activity of cAMP-dependent protein kinase, the phosphorylation of cAMP-responsive element binding protein and the activity of cAMP-responsive element (CRE) were down-regulated during the myotube formation. Mutating the CRE site of human AChE promoter altered the original myogenic profile of the promoter activity and its suppressive response to cAMP. In addition, the suppressive effect of the CRE site is dependent on its location on the promoter. Therefore, our results suggest that a cAMP-dependent signaling pathway serves as a suppressive element in regulating the expression of AChE during early myogenesis.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Kowloon, Hong Kong, Peoples R China.		Wan, David C/H-3335-2014	Tsim, Karl/0000-0003-4808-1674				ANGLISTER L, 1994, NEURON, V12, P783, DOI 10.1016/0896-6273(94)90331-X; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi RCY, 2000, NEUROREPORT, V11, P801, DOI 10.1097/00001756-200003200-00029; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; Choi RCY, 1996, NEUROSCI LETT, V217, P165, DOI 10.1016/0304-3940(96)13102-5; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; Garcia MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; HU JS, 1988, J BIOL CHEM, V263, P19670; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Lagord C, 1996, CELL BIOL TOXICOL, V12, P177, DOI 10.1007/BF00148171; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; TOUTANT JP, 1988, REPROD NUTR DEV, V28, P693, DOI 10.1051/rnd:19880503; Tsim KWK, 1997, J NEUROCHEM, V68, P479; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; Wan DCC, 2000, NEUROSCI LETT, V288, P81, DOI 10.1016/S0304-3940(00)01200-3; WINTER B, 1993, J BIOL CHEM, V268, P9869; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	43	64	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36129	36136		10.1074/jbc.M206498200	http://dx.doi.org/10.1074/jbc.M206498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140295	hybrid			2022-12-25	WOS:000178275100047
J	Yarov-Yarovoy, V; McPhee, JC; Idsvoog, D; Pate, C; Scheuer, T; Catterall, WA				Yarov-Yarovoy, V; McPhee, JC; Idsvoog, D; Pate, C; Scheuer, T; Catterall, WA			Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel alpha subunit in voltage-dependent gating and drug block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; LOCAL-ANESTHETIC AFFINITIES; RAT HIPPOCAMPAL-NEURONS; FAST INACTIVATION; MOLECULAR DETERMINANTS; K+-CHANNEL; DOMAIN-IV; RECEPTOR-SITE; ANTIARRHYTHMIC DRUGS; ACUTE STROKE	Alanine-scanning mutagenesis of transmembrane segments IS6 and IIS6 of the rat brain Na(v)1.2 channel a subunit identified mutations N418A in IS6 and L975A in IIS6 as causing strong positive shifts in the voltage dependence of activation. In contrast, mutations V424A in IS6 and L983A in IIS6 caused strong negative shifts. Most IS6 mutations opposed inactivation from closed states, but most IIS6 mutations favored such inactivation. Mutations L421C and L983A near the intracellular ends of IS6 and IIS6, respectively, exhibited significant sustained Na+ currents at the end of 30-ms depolarizations, indicating a role for these residues in Na+ channel fast inactivation. These residues, in combination with residues at the intracellular end of IVS6, are well situated to form an inactivation gate receptor. Mutation I409A in IS6 reduced the affinity of the local anesthetic etidocaine for the inactivated state by 6-fold, and mutations I409A and N418A reduced use-dependent block by etidocaine. No IS6 or IIS6 mutations studied affected inactivated-state affinity or use-dependent block by the neuroprotective drug sipatrigine (compound 619C89). These results suggest that the local anesthetic receptor site is formed primarily by residues in segments IIIS6 and IVS6 with the contribution of a single amino acid in segment IS6.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, POB 357280, Seattle, WA 98195 USA.		Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	PHS HHS [R-01 N515751] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; Calabresi P, 2000, EXP NEUROL, V162, P171, DOI 10.1006/exnr.2000.7285; Carter AJ, 2000, P NATL ACAD SCI USA, V97, P4944, DOI 10.1073/pnas.040577097; CATTERALL WA, 1986, TRENDS NEUROSCI, V9, P7, DOI 10.1016/0166-2236(86)90004-4; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cohen S A, 1993, Int Rev Cytol, V137C, P55; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Filatov GN, 1998, J GEN PHYSIOL, V111, P703, DOI 10.1085/jgp.111.6.703; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Kontis KJ, 1997, J GEN PHYSIOL, V110, P391, DOI 10.1085/jgp.110.4.391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CC, 1994, MOL PHARMACOL, V46, P716; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; Lerche H, 1997, J PHYSIOL-LONDON, V505, P345, DOI 10.1111/j.1469-7793.1997.345bb.x; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Liu GY, 1998, BIOPHYS J, V74, pA399; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muir K W, 1995, Ann N Y Acad Sci, V765, P328, DOI 10.1111/j.1749-6632.1995.tb16605.x; Muir KW, 1998, CEREBROVASC DIS, V8, P31, DOI 10.1159/000015812; Muir KW, 2000, CEREBROVASC DIS, V10, P431, DOI 10.1159/000016103; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sheets MF, 1999, BIOPHYS J, V77, P747, DOI 10.1016/S0006-3495(99)76929-8; Smith MR, 1997, BIOPHYS J, V73, P1885, DOI 10.1016/S0006-3495(97)78219-5; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Tang LH, 1998, J GEN PHYSIOL, V111, P639, DOI 10.1085/jgp.111.5.639; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 1998, PFLUG ARCH EUR J PHY, V435, P293; Wang SY, 1997, BIOPHYS J, V72, P1633, DOI 10.1016/S0006-3495(97)78809-X; Wang SY, 2000, BIOPHYS J, V79, P1379, DOI 10.1016/S0006-3495(00)76390-9; Weiser T, 1999, MOL PHARMACOL, V56, P1238, DOI 10.1124/mol.56.6.1238; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; Xie XM, 1996, NEUROSCIENCE, V73, P951, DOI 10.1016/0306-4522(96)00092-9; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yarov-Yarovoy V, 2001, J BIOL CHEM, V276, P20, DOI 10.1074/jbc.M006992200; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	71	175	179	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35393	35401		10.1074/jbc.M206126200	http://dx.doi.org/10.1074/jbc.M206126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130650	hybrid			2022-12-25	WOS:000178117000095
J	Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW				Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW			Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1	ONCOGENE			English	Article						prostate cancer; androgen receptor; ErbB receptors; Ebp1	DIFFERENTIATION FACTOR HEREGULIN; LIGAND-INDEPENDENT ACTIVATION; PROSTATE-CANCER CELLS; GROWTH-FACTORS; CYCLIN D1; EXPRESSION; MECHANISM; C-ERBB-2; COMPLEX; BENIGN	Members of the ErbB family of receptors have been implicated in regulation of androgen receptor (AR) activity. Ebp1, an ErbB-3 binding protein recently cloned in our laboratory, possesses an LXXLL motif important in mediating interactions with nuclear hormone receptors. Therefore, we sought to determine if Ebp1 could bind AR and influence AR transcriptional activation potential. We demonstrate in this study that Ebp1 bound to AR in vitro and in vivo, and that this binding was increased by androgen treatment. The C terminal 79 amino acids of Ebp1 were sufficient to bind AR. The N terminal domain of AR was responsible for binding Ebp1. Ligand-mediated transcriptional activation of both artificial and natural AR regulated promoters was inhibited by ectopic expression of ebp1 in transient transfection systems. Ebp1 deletion mutants that either lacked the C terminal AR binding region or had a mutated LXXLL motif failed to inhibit AR activated transcription. PSA expression from its endogenous promoter was also decreased in LNCaP prostate cancer cells overexpressing Ebp1. The growth of AR positive LNCaP cells was inhibited by ectopic expression of ebp1, but mutants that failed to repress transcription did not inhibit cell growth. These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School	Hamburger, AW (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	ahamburg@umaryland.edu	Wang, Qianben/E-4267-2011		NATIONAL CANCER INSTITUTE [R01CA076047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76047] Funding Source: Medline; PHS HHS [R21 088882-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; Barton J, 2001, UROLOGY, V58, P114, DOI 10.1016/S0090-4295(01)01253-5; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jenster G, 2000, J PATHOL, V191, P227; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Knudsen KE, 1999, CANCER RES, V59, P2297; Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Morote J, 1999, INT J CANCER, V84, P421, DOI 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Slagsvold T, 2001, J BIOL CHEM, V276, P31030, DOI 10.1074/jbc.M104310200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; Wen Y, 2000, CANCER RES, V60, P6841; Whitfield GK, 1999, J CELL BIOCHEM, P110; WILSON EM, 1991, ANN NY ACAD SCI, V637, P56, DOI 10.1111/j.1749-6632.1991.tb27300.x; XIA X, 2001, J CELL PHYSL, V187, P809; Xia XM, 1999, BIOCHEM J, V341, P831, DOI 10.1042/0264-6021:3410831; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; YEH S, 1999, NAT MED, V5, P280; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874	46	63	74	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5609	5618		10.1038/sj.onc.1205638	http://dx.doi.org/10.1038/sj.onc.1205638			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165860				2022-12-25	WOS:000177442000011
J	Babiychuk, EB; Monastyrskaya, K; Burkhard, FC; Wray, S; Draeger, A				Babiychuk, EB; Monastyrskaya, K; Burkhard, FC; Wray, S; Draeger, A			Modulating signaling events in smooth muscle: cleavage of annexin 2 abolishes its binding to lipid rafts	FASEB JOURNAL			English	Article						5 '-nucleotidase; microdomains; contraction; protein kinase C; RhoA; compartmentalization; annexins	CONTRACTILE PROPERTIES; MEMBRANE DYNAMICS; LIPOCORTIN-I; G-PROTEINS; CELLS; PROTEOLYSIS; PHOSPHORYLATION; CHROMATOGRAPHY; MICRODOMAINS; TRANSDUCTION	Cell membrane compartmentalization, which is believed to involve association of cholesterol- and glycosphingolipid-enriched membrane rafts, represents an important means of transmitting information across the plasma membrane. We have previously shown that raft association is mediated by the Ca2+ dependent binding of annexin 2 to the plasma membrane. In the present study, we demonstrate that the association of annexins 1 and 2 with the smooth muscle cell membrane can be terminated by their proteolytic cleavage. This proteolysis is thought to be triggered by calpain and occurs at non-raft regions of the plasma membrane. It is critically dependent on the intracellular concentration of free Ca2+ and requires an intact contractile apparatus. Annexins 1 and 2 interact with different membrane microcompartments-the former with non-raft, glycerolipid regions, the latter preferentially with membrane rafts. We demonstrate that PKC and RhoA, major signaling molecules that regulate smooth muscle contraction, are spatially segregated and interact with distinct membrane microcompartments. Proteolysis abolishes annexin binding to the plasma membrane and might result in rearrangement of membrane constituents followed by the interruption of segregation-dependent signaling events.	Univ Bern, Inst Anat, Dept Cell Biol, CH-3012 Bern, Switzerland; Taras Schevchenko Kiev Univ, Inst Physiol, Kiev, Ukraine; Univ Bern, Dept Urol, CH-3012 Bern, Switzerland; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Bern; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev; University of Bern; University of Liverpool	Draeger, A (corresponding author), Univ Bern, Inst Anat, Dept Cell Biol, Buhlstr 26, CH-3012 Bern, Switzerland.	draeger@ana.unibe.ch	Babiychuk, Eduard/AAV-7223-2021; wray, susan/B-1197-2009; Burkhard, Fiona/AAE-4524-2020	Wray, Susan/0000-0002-0086-1359; Monastyrskaya, Katia/0000-0003-2042-1139; Babiychuk, Eduard/0000-0003-1786-0085; Burkhard, Fiona/0000-0002-8271-014X				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHUAH SY, 1989, J BIOL CHEM, V264, P21160; Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Jost M, 1997, J CELL SCI, V110, P221; Jostarndt-Fogen K, 1998, HISTOCHEM CELL BIOL, V110, P273, DOI 10.1007/s004180050289; Kohler A, 1999, ANAT EMBRYOL, V200, P313, DOI 10.1007/s004290050282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu L, 1995, BIOCHEM MOL BIOL INT, V36, P373; MACALA LJ, 1983, J LIPID RES, V24, P1243; Movitz C, 2000, BBA-BIOMEMBRANES, V1468, P231, DOI 10.1016/S0005-2736(00)00261-3; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sjolin C, 1996, BBA-BIOMEMBRANES, V1281, P227, DOI 10.1016/0005-2736(96)00018-1; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080	35	64	64	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1177	10.1096/fj.02-0070com	http://dx.doi.org/10.1096/fj.02-0070com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153985				2022-12-25	WOS:000177814000026
J	Becker, A; Kabsch, W				Becker, A; Kabsch, W			X-ray structure of pyruvate formate-lyase in complex with pyruvate and CoA - How the enzyme uses the Cys-418 thiyl radical for pyruvate cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; DIFFRACTION DATA; MOLSCRIPT; ALIGNMENT; MECHANISM; ROTATION	The glycyl radical enzyme pyruvate formate-lyase (PFL) synthesizes acetyl-CoA and formate from pyruvate and CoA. With the crystal structure of the non-radical form of PFL in complex with its two substrates, we have trapped the moment prior to pyruvate cleavage. The structure reveals how the active site aligns the scissile bond of pyruvate for radical attack, prevents non-radical side reactions of the pyruvate, and confines radical migration. The structure shows CoA in a syn conformation awaiting pyruvate cleavage. By changing to an anti conformation, without affecting the adenine binding mode of CoA, the thiol of CoA could pick up the acetyl group resulting from pyruvate cleavage.	Max Planck Inst Med Res, Biophys Abt, D-69120 Heidelberg, Germany	Max Planck Society	Becker, A (corresponding author), Max Planck Inst Med Res, Biophys Abt, Jahnstr 29, D-69120 Heidelberg, Germany.	abecker@mpimf-heidelberg.mpg.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BECKER A, 1995, THESIS U HEIDELBERG; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Eklund H, 1999, STRUCT FOLD DES, V7, pR257, DOI 10.1016/S0969-2126(00)80019-2; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREY M, 1994, J BIOL CHEM, V269, P12432; Himo F, 1998, J AM CHEM SOC, V120, P11449, DOI 10.1021/ja9820947; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KNAPPE J, 1974, EUR J BIOCHEM, V50, P253, DOI 10.1111/j.1432-1033.1974.tb03894.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1995, METHOD ENZYMOL, V258, P343; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; Knappe J, 2001, ADV PROTEIN CHEM, V58, P277; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leppanen VM, 1999, STRUCT FOLD DES, V7, P733, DOI 10.1016/S0969-2126(99)80098-7; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	30	75	77	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40036	40042		10.1074/jbc.M205821200	http://dx.doi.org/10.1074/jbc.M205821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163496	hybrid			2022-12-25	WOS:000178662500124
J	Bernaudin, M; Tang, Y; Reilly, M; Petit, E; Sharp, FR				Bernaudin, M; Tang, Y; Reilly, M; Petit, E; Sharp, FR			Brain genomic response following hypoxia and re-oxygenation in the neonatal rat - Identification of genes that might contribute to hypoxia-induced ischemic tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; MICROARRAY ANALYSIS; INDUCIBLE FACTOR-1; GLUCOSE-TRANSPORT; FACTOR-I; EXPRESSION; CELLS; TRANSCRIPTION; ACTIVATION	Hypoxic preconditioning (8% O-2, 3 h) produces tolerance 24 h after hypoxic-ischemic brain injury in neonatal rats. To better understand the ischemic tolerance mechanisms induced by hypoxia, we used oligonucleotide microarrays to examine genomic responses in neonatal rat brain following 3 h of hypoxia (8% O-2) and either 0, 6, 18, or 24 h of re-oxygenation. The results showed that hypoxia-inducible factor (HIF)-1- but not HIF-2-mediated gene expression may be involved in brain hypoxia-induced tolerance. Among the genes regulated by hypoxia, 12 genes were confirmed by real time reverse transcriptase-PCR as follows: VEGF, EPO, GLUT-1, adrenomedullin, propyl 4-hydroxylase alpha, MT-1, MKP-1, CELF, 12-lipoxygenase, t-PA, CAR-1, and an expressed sequence tag. Some genes, for example GLUT-1, MT-1, CELF, MKP-1, and t-PA did not show any hypoxic regulation in either astrocytes or neurons, suggesting that other cells are responsible for the up-regulation of these genes in the hypoxic brain. These genes were expressed in normal and hypoxic brain, heart, kidney, liver, and lung, with adrenomedullin, MT-1, and VEGF being prominently induced in brain by hypoxia. These results suggest that a number of endogenous molecular mechanisms may explain how hypoxic preconditioning protects against subsequent ischemia, and may provide novel therapeutic targets for treatment of cerebral ischemia.	Univ Caen, UMR CNRS 6551, F-14074 Caen, France; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Neurosci Program, Cincinnati, OH 45267 USA	Universite de Caen Normandie; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bernaudin, M (corresponding author), Univ Caen, UMR CNRS 6551, Bd Henri Becquerel,BP5229,IFR 47, F-14074 Caen, France.	m_bernaudin@hotmail.com	PETIT, Edwige/C-1896-2008; Bernaudin, Myriam/B-7663-2008	Bernaudin, Myriam/0000-0003-0778-3397	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028167, R01NS038743, R01NS042774, R01NS043252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG019561] Funding Source: NIH RePORTER; NIA NIH HHS [AG19561] Funding Source: Medline; NINDS NIH HHS [NS28167, NS38743, NS42774, NS43252] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beitner-Johnson D, 2001, PARKINSONISM RELAT D, V7, P273, DOI 10.1016/S1353-8020(00)00070-5; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Cau E, 2000, DEVELOPMENT, V127, P2323; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ehleben W, 1997, KIDNEY INT, V51, P483, DOI 10.1038/ki.1997.67; Emerson MR, 2000, CELL MOL BIOL, V46, P619; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gracey AY, 2001, P NATL ACAD SCI USA, V98, P1993, DOI 10.1073/pnas.98.4.1993; Gu ZL, 2001, NEUROREPORT, V12, P3487, DOI 10.1097/00001756-200111160-00023; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hsu L, 2001, J NEUROSCI RES, V64, P193, DOI 10.1002/jnr.1065; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kobayashi S, 2001, J NEUROCHEM, V76, P1935, DOI 10.1046/j.1471-4159.2001.00214.x; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Miller BA, 2001, NEUROREPORT, V12, P1663, DOI 10.1097/00001756-200106130-00030; Murphy BJ, 1999, CANCER RES, V59, P1315; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P1213, DOI 10.1097/00004647-199911000-00005; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Ota A, 1998, AM J OBSTET GYNECOL, V179, P1075, DOI 10.1016/S0002-9378(98)70218-2; Prass K, 2000, BRAIN RES, V871, P146, DOI 10.1016/S0006-8993(00)02264-2; Rumora L, 2001, NEUROCHEM INT, V39, P25, DOI 10.1016/S0197-0186(01)00004-3; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Scandurro AB, 2001, INT J ONCOL, V19, P129; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Shinmura K, 2000, P NATL ACAD SCI USA, V97, P10197, DOI 10.1073/pnas.97.18.10197; Sinor AD, 1998, BRAIN RES, V812, P289, DOI 10.1016/S0006-8993(98)00976-7; Takagi H, 1998, DIABETES, V47, P1480, DOI 10.2337/diabetes.47.9.1480; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; VANNUCCI SJ, 1994, MOL CELL BIOCHEM, V140, P177, DOI 10.1007/BF00926756; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Watanabe K, 2001, ACTA NEUROCHIR, V143, P1157, DOI 10.1007/s007010100007; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yan SF, 2000, J APPL PHYSIOL, V88, P2303, DOI 10.1152/jappl.2000.88.6.2303; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	69	239	263	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39728	39738		10.1074/jbc.M204619200	http://dx.doi.org/10.1074/jbc.M204619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145288	hybrid			2022-12-25	WOS:000178662500087
J	Ishii, J; Adachi, H; Aoki, J; Koizumi, H; Tomita, S; Suzuki, T; Tsujimoto, M; Inoue, K; Arai, H				Ishii, J; Adachi, H; Aoki, J; Koizumi, H; Tomita, S; Suzuki, T; Tsujimoto, M; Inoue, K; Arai, H			SREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREG-I through its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; ADHESION MOLECULE-1; EXPRESSION CLONING; BINDING-SITE; HOST-DEFENSE; ATHEROSCLEROSIS; THROMBOSPONDIN; GROWTH	The scavenger receptor expressed by endothelial cells (SREC) with an extremely large cytoplasmic domain, was originally identified in a human endothelial cell line. In this study, we have cloned a second isoform named SREC-H and shown that there is a heterophilic interaction between SREC-I and -II at their extracellular domains. The cDNA for murine SREC-II encodes an 834-amino acid protein with 35% homology to SREC-I. Similar to SREC-I, SREC-II contains multiple epidermal growth factor-like repeats in its extracellular domain. However, in contrast to SREG-I, SREG-II had little activity to internalize modified low density lipoproteins (LDL). A Northern blot analysis revealed a tissue expression pattern of SREG-II similar to that of SREC-I with predominant expression in human heart, lung, ovary, and placenta. Mouse fibroblast L cells with no tendency to associate showed noticeable aggregation when SREC-I was overexpressed in these cells, whereas overexpression of SREC-II caused only slight aggregation. Remarkably, intense aggregation was observed when SREC-I-expressing cells were mixed with those expressing SREC-II. Deletion of almost all of the cytoplasmic receptor domain had no effect on the receptor expression and cell aggregation, indicating that solely the extracellular domain is involved in cell aggregation. The association of SREC-I and -II was effectively suppressed by the presence of scavenger receptor ligands such as acetylated LDL and oxidized LDL. These findings suggest that SREC-I and -II show weak cell-cell interaction by their extracellular domains (termed homophilic trans-interaction) but display strong heterophilic trans-interaction through the extracellular epidermal growth factor-like repeat domains.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	University of Tokyo; University of Tokyo; RIKEN	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Suzuki, Toshiharu/B-5342-2013	Aoki, Junken/0000-0001-9435-1896				ACTON S, 1997, SCIENCE, V271, P518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROMQUIST MC, 1984, P NATL ACAD SCI USA, V81, P7363; Claise C, 1996, FEBS LETT, V398, P223, DOI 10.1016/S0014-5793(96)01255-0; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GEBUHRER V, 1995, BIOCHEM J, V306, P293, DOI 10.1042/bj3060293; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hayashida K, 2002, FEBS LETT, V511, P133, DOI 10.1016/S0014-5793(01)03297-5; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; Khoury J, 1994, J BIOL CHEM, V269, P10197; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI WX, 1993, J BIOL CHEM, V268, P16179; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MIURA M, 1992, J BIOL CHEM, V90, P55; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; ROHER L, 1990, NATURE, V343, P570; Sakaguchi H, 1998, LAB INVEST, V78, P423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Wahl SM, 1996, J LEUKOCYTE BIOL, V59, P789, DOI 10.1002/jlb.59.6.789; Yokota T, 1998, EXP CELL RES, V239, P16, DOI 10.1006/excr.1997.3876; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	47	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39696	39702		10.1074/jbc.M206140200	http://dx.doi.org/10.1074/jbc.M206140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154095	hybrid			2022-12-25	WOS:000178662500083
J	Kavli, B; Sundheim, O; Akbari, M; Otterlei, M; Nilsen, H; Skorpen, F; Aas, PA; Hagen, L; Krokan, HE; Slupphaug, G				Kavli, B; Sundheim, O; Akbari, M; Otterlei, M; Nilsen, H; Skorpen, F; Aas, PA; Hagen, L; Krokan, HE; Slupphaug, G			HUNG2 is the major repair enzyme for removal of uracil from U : A matches, U : G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; GLYCOSYLASE ACTIVITY; SUBSTRATE-SPECIFICITY; CYTOSINE DEAMINATION; N-GLYCOSYLASE; NUCLEAR; ENDONUCLEASE; EXPRESSION; MECHANISM; THYMINE	hUNG2 and hSMUG1 are the only known glycosylases that may remove uracil from both double- and single-stranded DNA in nuclear chromatin, but their relative contribution to base excision repair remains elusive. The present study demonstrates that both enzymes are strongly stimulated by physiological concentrations of Mg2+ at which the activity of hUNG2 is 2-3 orders of magnitude higher than of hSMUG1. Moreover, Mg2+ increases the preference of hUNG2 toward uracil in ssDNA nearly 40-fold. APE1 has a strong stimulatory effect on hSMUG1 against dsU, apparently because of enhanced dissociation of hSMUG1 from AP sites in dsDNA. hSMUG1 also has a broader substrate specificity than hUNG2, including 5-hydroxymethyluracil and 3,N-4-ethenocytosine. hUNG2 is excluded from, whereas hSMUG1 accumulates in, nucleoli in living cells. In contrast, only hUNG2 accumulates in replication foci in the S-phase. hUNG2 in nuclear extracts initiates base excision repair of plasmids containing either U:A and U:G in vitro. Moreover, an additional but delayed repair of the U:G plasmid is observed that is not inhibited by neutralizing antibodies against hUNG2 or hSMUG1. We propose a model in which hUNG2 is responsible for both prereplicative removal of deaminated cytosine and postreplicative removal of misincorporated uracil at the replication fork. We also provide evidence that hUNG2 is the major enzyme for removal of deaminated cytosine outside of replication foci, with hSMUG1 acting as a broad specificity backup.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Slupphaug, G (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway.	geir.slupphaug@medisin.ntnu.no	Slupphaug, Geir/AAN-3794-2020; Nilsen, Hilde/F-6432-2014	Akbari, Mansour/0000-0002-6490-7766; Slupphaug, Geir/0000-0002-7498-3500; Skorpen, Frank/0000-0001-7093-8000; Otterlei, Marit/0000-0002-5232-1186; Nilsen, Hilde/0000-0003-2115-2663				Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Blatny JM, 1997, PLASMID, V38, P35, DOI 10.1006/plas.1997.1294; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; BOORSTEIN RJ, 1989, NUCLEIC ACIDS RES, V17, P7653, DOI 10.1093/nar/17.19.7653; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dizdaroglu M, 1996, NUCLEIC ACIDS RES, V24, P418, DOI 10.1093/nar/24.3.418; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; EFTEDAL I, 1994, ANN NY ACAD SCI, V726, P312, DOI 10.1111/j.1749-6632.1994.tb52836.x; FONDA L, 2002, SCI WORLD J, V2, P1312; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FROSINA G, 1998, METHOD MOL BIOL, P301; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; Krokan HE, 1997, BIOCHEM J, V325, P1; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Morey NJ, 2000, GENETICS, V154, P109; Muller-Weeks S, 1998, J BIOL CHEM, V273, P21909, DOI 10.1074/jbc.273.34.21909; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Otterlei M, 2000, EMBO J, V19, P5542, DOI 10.1093/emboj/19.20.5542; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Radany EH, 2000, MUTAT RES-DNA REPAIR, V461, P41, DOI 10.1016/S0921-8777(00)00040-9; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; Spek EJ, 2002, J BACTERIOL, V184, P3501, DOI 10.1128/JB.184.13.3501-3507.2002; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WITTWER CU, 1989, BIOCHEMISTRY-US, V28, P780, DOI 10.1021/bi00428a055; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157	48	268	278	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39926	39936		10.1074/jbc.M207107200	http://dx.doi.org/10.1074/jbc.M207107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161446	hybrid			2022-12-25	WOS:000178662500110
J	Lefrere, I; de Coppet, P; Camelin, JC; Le Lay, S; Mercier, N; Elshourbagy, N; Bril, A; Berrebi-Bertrand, I; Feve, B; Krief, S				Lefrere, I; de Coppet, P; Camelin, JC; Le Lay, S; Mercier, N; Elshourbagy, N; Bril, A; Berrebi-Bertrand, I; Feve, B; Krief, S			Neuropeptide AF and FF modulation of adipocyte metabolism - Primary insights from functional genomics and effects on beta-adrenergic responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; 3T3-F442A ADIPOCYTES; BETA(3)-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; ADIPOSE CONVERSION; BETA-2-ADRENERGIC RECEPTORS; MAMMALIAN NEUROPEPTIDE; TRANSCRIPTION FACTORS; DIFFERENTIATION; PROTEIN	The presence of a neuropeptide AF and FF receptor (NPFF-R2) mRNA in human adipose tissue (Elshourbagy, N.A., Ames, R.S., Fitzgerald, L.R, Foley, J.J., Chambers, J.K, Szekeres, P.G., Evans, N.A., Schmidt, D.B., Buckley, P.T., Dytko, G.M, Murdock, P.R, Tan, K.B., Shabon, U., Nuthulaganti, P., Wang, D.Y., Wilson, S., Bergsma, D.J., and Sarau, H.M. (2000) J. Biol. Chem 275, 25965-25971) suggested these peptides, principally recognized for their pain modulating effects, may also impact on adipocyte metabolism, an aspect that has not been explored previously. Our aim was thus to obtain more insights into the actions of these peptides on adipocytes, an approach initially undertaken with a functional genomic assay. First we showed that 3T3-L1 adipocytes express both NPFF-R1 and NPFF-R2 transcripts, and that NPAF binds adipocyte membranes with a nanomolar affinity as assessed by surface plasmon resonance technology. Then, and following a 24-h treatment with NPFF or NPAF (1 mum), we have measured using real-time quantitative reverse transcriptase-PCR the mRNA steady state levels of already well characterized genes involved in key pathways of adipose metabolism. Among the 45 genes tested, few were modulated by NPFF (similar to10%) and a larger number by NPAF (similar to27%). Interestingly, NPAF increased the mRNA levels of beta2- and beta3-adrenergic receptors (AR), and to a lesser extent those of beta1-ARs. These variations in catecholamine receptor mRNAs correlated with a clear induction in the density of beta2- and beta3-AR proteins, and in the potency of beta-AR subtype-selective agonists to stimulate adenylyl cyclase activity. Altogether, these data show that NPFF-R1 and NPFF-R2 are functionally present in adipocytes and suggest that besides their well described pain modulation effects, NPAF and to a lesser extent NPFF, may have a global impact on body energy storage and utilization.	GlaxoSmithKline Labs Pharmaceut, F-35762 St Gregoire, France; GlaxoSmithKline, King Of Prussia, PA 19406 USA; Ctr Rech Biomed Cordeliers, UMR CNRS Paris 6 7079, F-75270 Paris 06, France	GlaxoSmithKline; GlaxoSmithKline	Krief, S (corresponding author), Bioprojet Biotech, 4 Rue Chesnay Beauregard,BP 96205, F-35762 St Gregoire, France.	S.Krief@bioprojet.com	Le Lay, Soazig/N-6862-2018; Le Lay, Soazig/AAI-2442-2021; Mercier, Nathalie/P-6814-2016	Le Lay, Soazig/0000-0003-2456-2422; Mercier, Nathalie/0000-0002-3983-2336; Krief, Stephane/0000-0002-5543-731X; Feve, Bruno/0000-0001-6577-9009				ALLARD M, 1995, J PHARMACOL EXP THER, V274, P577; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Deedwania PC, 1997, AM J HYPERTENS, V10, pS280, DOI 10.1016/S0895-7061(97)00335-X; Desprat C, 1997, PHARMACOL BIOCHEM BE, V58, P559, DOI 10.1016/S0091-3057(97)00249-9; EBBERINK RHM, 1987, PEPTIDES, V8, P515, DOI 10.1016/0196-9781(87)90018-0; ElHadri K, 1997, J BIOL CHEM, V272, P24514, DOI 10.1074/jbc.272.39.24514; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; FEHMANN HC, 1990, NEUROPEPTIDES, V17, P87, DOI 10.1016/0143-4179(90)90054-3; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; FEVE B, 1995, J BIOL CHEM, V270, P10952, DOI 10.1074/jbc.270.18.10952; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kim S, 2000, J NUTR, V130, p3110S; Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; KRIEF S, 1994, J BIOL CHEM, V269, P6664; Labrouche S, 1998, J NEUROENDOCRINOL, V10, P559, DOI 10.1046/j.1365-2826.1998.00241.x; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Laguzzi R, 1996, BRAIN RES, V711, P193, DOI 10.1016/0006-8993(95)01382-2; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Murase T, 1996, PEPTIDES, V17, P353, DOI 10.1016/0196-9781(95)02137-X; Orlicky DJ, 1998, J LIPID RES, V39, P1152; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; PAIRAULT J, 1982, EUR J BIOCHEM, V127, P351, DOI 10.1111/j.1432-1033.1982.tb06879.x; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; *PE APPL BIOS, 1997, US B, V2, P1; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; SORENSON RL, 1984, PEPTIDES, V5, P777, DOI 10.1016/0196-9781(84)90021-4; Sundblom DM, 1998, PEPTIDES, V19, P1165, DOI 10.1016/S0196-9781(98)00060-6; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vilim FS, 1999, MOL PHARMACOL, V55, P804	52	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39169	39178		10.1074/jbc.M205084200	http://dx.doi.org/10.1074/jbc.M205084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149260	hybrid			2022-12-25	WOS:000178662500016
J	Rudra-Ganguly, N; Reddy, ST; Korge, P; Herschman, HR				Rudra-Ganguly, N; Reddy, ST; Korge, P; Herschman, HR			Diesel exhaust particle extracts and associated polycyclic aromatic hydrocarbons inhibit Cox-2-dependent prostaglandin synthesis in murine macrophages and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 GENE; IGE PRODUCTION; ADJUVANT ACTIVITY; SYNTHASE GENE; EXPRESSION; INDUCTION; CELLS; ACTIVATION; CHEMICALS	Diesel exhaust particles (DEP) and their organic constituents modulate the immune system and exacerbate allergic airway inflammation. We investigated the role of DEP extract and associated polycyclic aromatic hydrocarbons (PAHs) on prostaglandin synthesis in endotoxin-activated murine macrophages and in mitogen-stimulated fibroblasts. In both macrophages and fibroblasts, DEP extract, phenanthrene, anthracene, phenanthrenequinone, and beta-napthoflavone inhibit prostaglandin production from endogenous arachidonic acid in response to ligand stimulation. However, DEP extract and PAHs do not block ligand induction of cyclooxygenase-2 (COX-2) protein, either in mitogen-stimulated fibroblasts or endotoxin-treated macrophages. Release of total arachidonic acid and total lipid products is not reduced by DEP or PAHs following ligand stimulation of macrophages or fibroblasts. DEP extract and the PAHs inhibit the activity of purified COX-2 enzyme in vitro but do not inhibit COX-1 activity. Thus, DEP and PAHs do not affect ligand-induced COX-2 gene expression, phospholipase activation, or arachidonic acid release in macrophages and fibroblasts but exert their inhibitory effect on prostaglandin production by preferentially blocking COX-2 enzyme activity.	Univ Calif Los Angeles, Hlth Sci Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Hlth Sci Ctr, Inst Mol Biol, 341 Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	hherschman@mednet.ucla.edu			NIAID NIH HHS [AI50495] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, ALLERGY, V52, P52; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Goldenberg MM, 1999, CLIN THER, V21, P1497, DOI 10.1016/S0149-2918(00)80005-3; Han JY, 2001, FREE RADICAL BIO MED, V30, P516, DOI 10.1016/S0891-5849(00)00501-3; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Kawasaki S, 2001, AM J RESP CELL MOL, V24, P419, DOI 10.1165/ajrcmb.24.4.4085; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Korge P, 2002, P NATL ACAD SCI USA, V99, P3312, DOI 10.1073/pnas.052713199; LEVINE L, 1977, PROSTAGLANDINS, V14, P1, DOI 10.1016/0090-6980(77)90152-6; Li N, 2000, J IMMUNOL, V165, P3393, DOI 10.4049/jimmunol.165.6.3393; Marston CP, 2001, CARCINOGENESIS, V22, P1077, DOI 10.1093/carcin/22.7.1077; Miyamoto T, 1997, ALLERGY, V52, P30, DOI 10.1111/j.1398-9995.1997.tb04867.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ng D, 1998, J IMMUNOL, V161, P942; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reynolds LJ, 2001, TOXICOLOGY, V165, P145, DOI 10.1016/S0300-483X(01)00417-6; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 2000, CLIN EXP IMMUNOL, V120, P356, DOI 10.1046/j.1365-2249.2000.01213.x; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949	47	10	11	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39259	39265		10.1074/jbc.M110215200	http://dx.doi.org/10.1074/jbc.M110215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163478	hybrid			2022-12-25	WOS:000178662500027
J	Zhang, H; Zha, XM; Tan, Y; Hornbeck, PV; Mastrangelo, AJ; Alessi, DR; Polakiewicz, RD; Comb, MJ				Zhang, H; Zha, XM; Tan, Y; Hornbeck, PV; Mastrangelo, AJ; Alessi, DR; Polakiewicz, RD; Comb, MJ			Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; ANTI-PHOSPHOTYROSINE ANTIBODIES; P70 S6 KINASE; MONOCLONAL-ANTIBODIES; MAPKAP KINASE-1; SEQUENCE MOTIFS; C ISOZYMES; PDK1; SUBSTRATE; GENERATION	The substrates of most protein kinases remain unknown because of the difficulty tracing signaling pathways and identifying sites of protein phosphorylation. Here we describe a method useful in detecting subclasses of protein kinase substrates. Although the method is broadly applicable to any protein kinase for which a substrate consensus motif has been identified, we illustrate here the use of antibodies broadly reactive against phosphorylated Ser/Thr-motifs typical of AGC kinase substrates. Phosphopeptide libraries with fixed residues corresponding to consensus motifs RXRXXT-*/S* (Akt motif) and S*XR (protein kinase C motif) were used as antigens to generate antibodies that recognize many different phosphoproteins containing the fixed motif. Because most AGC kinase members are phosphorylated and activated by phosphoinositide-dependent protein kinase-1 (PDK1), we used PDK1-/- ES cells to profile potential AGC kinase substrates downstream of PDK1. To identify phosphoproteins detected using the Akt substrate antibody, we characterized the antibody binding specificity to generate a specificity matrix useful in predicting antibody reactivity. Using this approach we predicted and then identified a 30-kDa phosphoprotein detected by both Akt and protein kinase C substrate antibodies as S6 ribosomal protein. Phosphospecific motif antibodies offer a new approach to protein kinase substrate identification that combines immunoreactivity data with protein data base searches based upon antibody specificity.	Cell Signaling Technol, Beverly, MA 01915 USA; Univ Dundee, Med Res Council Prot Phosphorylat Unit, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee	Comb, MJ (corresponding author), Cell Signaling Technol, 166B Cummings Ctr, Beverly, MA 01915 USA.	mcomb@cellsignal.com	Hornbeck, Peter V/K-2226-2017	Hornbeck, Peter V/0000-0002-1126-5149; Zha, Xiangming/0000-0001-9490-2731; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GALSKI H, 1983, BIOCHIM BIOPHYS ACTA, V761, P284, DOI 10.1016/0304-4165(83)90078-8; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; Hunter T, 1998, Harvey Lect, V94, P81; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PERLMANN H, 1994, CELL BIOL LAB HDB; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 1999, NATURE, V402, P30; Zhou HL, 2002, NAT BIOTECHNOL, V20, P512, DOI 10.1038/nbt0502-512; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 2001, METHOD ENZYMOL, V332, P171	48	217	232	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39379	39387		10.1074/jbc.M206399200	http://dx.doi.org/10.1074/jbc.M206399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151408	hybrid			2022-12-25	WOS:000178662500042
J	Cave, JS; Meng, WM; Pennella, MA; Applehoff, RJ; Giedroc, DP; Robinson, NJ				Cave, JS; Meng, WM; Pennella, MA; Applehoff, RJ; Giedroc, DP; Robinson, NJ			A nickel-cobalt-sensing ArsR-SmtB family repressor - Contributions of cytosol and effector binding sites to metal selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ENCODES; METALLOREGULATORY PROTEIN; STAPHYLOCOCCUS-AUREUS; COORDINATION CHEMISTRY; METALLOTHIONEIN LOCUS; PLASMID PI258; ZNTA GENE; OPERON; IDENTIFICATION; ATPASE	NmtR from Mycobacterium tuberculosis is a new member of the ArsR-SmtB family of metal sensor transcriptional repressors. NmtR binds to the operator-promoter of a gene encoding a P-1 type ATPase (NmtA), repressing transcription in vivo except in medium supplemented with nickel or, to some extent, cobalt. In a cyanobacterial host, Synechococcus PCC 7942 strain R2-PIM8(smt), NmtR-mediated repression is alleviated by cobalt but not nickel or zinc addition, while the related sensor SmtB responds exclusively to zinc. Quantification of the number of atoms of nickel per cell shows that NmtR nickel sensitivity correlates with cytosolic nickel contents. Differential metal discrimination in a common cytosol by SmtB (zinc) and NmtR (cobalt) is not simply explained by affinities at equilibrium; although NmtR does bind nickel substantially more tightly than SmtB, it has a higher affinity for zinc than for cobalt and binds cobalt more weakly than SmtB. SmtB is known to bind and sense zinc at interhelical four-coordinate, tetrahedral sites across the C-terminal alpha5 helices, while absorption spectroscopy of Co(II)- and Ni(II)-substituted NmtR reveals five- and six-coordinate metal complexes. Site-directed mutagenesis identifies six potential cobalt/ nickel ligands that are obligatory for inducer recognition but not repression by NmtR, four of which (Asp(91), His(93), His(104), His(107)) align with alpha5 ligands of SmtB with two additional His provided by a carboxyl-terminal "extension" (designated alpha5C). Gel retardation assays reveal that zinc does not allosterically regulate NmtR-DNA binding at concentrations where lower affinity cobalt does. These data suggest that two additional ligands form hexacoordinate metal complexes and are crucial for driving allosteric regulation of DNA binding by NmtR, thereby allowing NmtR to preferentially sense metals that favor higher coordination numbers relative to SmtB.	Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Texas A&M University System; Texas A&M University College Station; Newcastle University - UK	Robinson, NJ (corresponding author), Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, College Stn, TX 77843 USA.		Robinson, Nigel J/J-6363-2012; Giedroc, David/A-8608-2018	Robinson, Nigel J/0000-0001-5586-1092; Giedroc, David/0000-0002-2342-1620; Cavet, Jennifer/0000-0001-5913-7157				Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P4219, DOI 10.1021/bi00363a008; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; CORWIN DT, 1987, INORG CHEM, V26, P3079, DOI 10.1021/ic00266a001; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; He MM, 2000, BIOCHEMISTRY-US, V39, P8719, DOI 10.1021/bi000856g; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Outten CE, 2001, BIOCHEMISTRY-US, V40, P10417, DOI 10.1021/bi0155448; POSEWITZ MC, 1995, CHEM RES TOXICOL, V8, P1020, DOI 10.1021/tx00050a005; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Robinson NJ, 2001, ADV MICROB PHYSIOL, V44, P183, DOI 10.1016/S0065-2911(01)44014-8; Rosa DT, 2001, INORG CHEM, V40, P1606, DOI 10.1021/ic000971f; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sambrook J., 2002, MOL CLONING LAB MANU; SCANLAN DJ, 1990, GENE, V90, P43, DOI 10.1016/0378-1119(90)90437-V; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; Singh VK, 1999, MOL MICROBIOL, V33, P200, DOI 10.1046/j.1365-2958.1999.01466.x; Sun Y, 2001, J BIOL CHEM, V276, P14955, DOI 10.1074/jbc.M010595200; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; TIMM JL, 1994, J BACTERIOL, V176, P6749, DOI 10.1128/JB.176.21.6749-6753.1994; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; TURNER JS, 1993, J BIOL CHEM, V268, P4494; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9776, DOI 10.1021/bi020178t; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9765, DOI 10.1021/bi0201771; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	41	120	127	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38441	38448		10.1074/jbc.M207677200	http://dx.doi.org/10.1074/jbc.M207677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163508	hybrid			2022-12-25	WOS:000178529600058
J	Chen, TP; Ueda, Y; Xie, SP; Li, E				Chen, TP; Ueda, Y; Xie, SP; Li, E			A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CYTOSINE-5 METHYLTRANSFERASES; EMBRYONIC STEM-CELLS; DE-NOVO; MAMMALIAN DEVELOPMENT; GERM-LINE; GENE; LETHALITY; MUTATION; CLONING; DOMAIN	Previous studies have shown that the Dnmt3b gene encodes multiple variants via alternative splicing. However, only one form of Dnmt3a has been identified to date. We report here the discovery of a small form of Dnmt3a, denoted Dnmt3a2, from both human and mouse. The transcript encoding Dnmt3a2 is initiated from a downstream intronic promoter. As a result, the Dnmt3a2 protein lacks the N-terminal 223 (human) or 219 (mouse) amino acid residues of the full-length Dnmt3a. Recombinant Dnmt3a2 protein displayed similar cytosine methyltransferase activity as Dnmt3a in vitro. However, Dnmt3a and Dnmt3a2 exhibited strikingly different subcellular localization patterns. Unlike Dnmt3a, which was concentrated on heterochromatin, Dnmt3a2 displayed a localization pattern suggestive of euchromatin association. Dnmt3a2 is the predominant form in embryonic stem cells and embryonal carcinoma cells and can also be detected from testis, ovary, thymus, and spleen, whereas Dnmt3a is expressed at low levels ubiquitously. Comparison of human embryonal carcinoma cell lines with breast/ovarian cancer cell lines indicates that DNMT3A2 expression correlates with high de novo methylation activity. These findings suggest that Dnmt3a and Dnmt3a2 may have distinct DNA targets and different functions in development.	Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Li, E (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494	NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER; NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hata K, 2002, DEVELOPMENT, V129, P1983; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	28	263	279	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38746	38754		10.1074/jbc.M205312200	http://dx.doi.org/10.1074/jbc.M205312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138111	hybrid			2022-12-25	WOS:000178529600094
J	Gotoh, M; Yada, T; Sato, T; Akashima, T; Iwasaki, H; Mochizuki, H; Inaba, N; Togayachi, A; Kudo, T; Watanabe, H; Kimata, K; Narimatsu, H				Gotoh, M; Yada, T; Sato, T; Akashima, T; Iwasaki, H; Mochizuki, H; Inaba, N; Togayachi, A; Kudo, T; Watanabe, H; Kimata, K; Narimatsu, H			Molecular cloning and characterization of a novel chondroitin sulfate glucuronyltransferase that transfers glucuronic acid to N-acetylgalactosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; BETA-D-XYLOSYLTRANSFERASE; PROTEIN LINKAGE REGION; UDP-D-XYLOSE; HEPARAN-SULFATE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; TUMOR SUPPRESSORS; BIOSYNTHESIS; EXPRESSION; GALACTOSE	We found a novel human gene (GenBank(TM) accession number AB037823, Kazusa DNA Research Institute KIAA1402) that possesses homology with chondroitin synthase. The full-length open reading frame consists of 772 amino acids and encodes a typical type 11 membrane protein. This enzyme had a domain containing beta3-glycosyltransferase motifs, which might be a beta3-glucuronyltransferase domain, but no domain with beta4-glycosyltransferase motifs, although both are found in chondroitin synthase. The putative catalytic domain was expressed in COS-7 cells as a soluble enzyme. Its glucuronyltransferase activity was observed when chondroitin and chondroitin sulfate polysaccharides and oligosaccharides were used as acceptor substrates. However, it was not detected when dermatan sulfate, hyaluronan, heparan sulfate, heparin, N-acetylheparosan, lactosamine tetrasaccharide, and linkage tri- and tetrasaccharide acceptors were employed. The reaction product, which was speculated to exhibit a GlcAbeta1-3GalNAc linkage structure at its non-reducing terminus, showed the following characteristics. 1) It was catabolized by beta-glucuronidase. 2) It was an acceptor for Escherichia coli K4 chondroitin polymerase (K4 chondroitin polymerase). 3) The product of K4 chondroitin polymerase was cleaved by chondroitinase ACII. On the other hand, no N-acetylgalactosaminyltransferase activity was detected toward any acceptors. Quantitative real time PCR analysis revealed that its transcripts were highly expressed in the placenta, small intestine, and pancreas, although they were ubiquitously expressed in various tissues and cell lines. This enzyme could play a role in the synthesis of chondroitin sulfate as a glucuronyltransferase.	Natl Inst Adv Ind Sci & Technol, Open Space Lab, Res Ctr Glycosci, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Aichi Med Univ, Inst Mol Sci, Aichi 4801195, Japan; Seikagaku Corp, Tokyo 2070021, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Aichi Medical University; Seikagaku Corporation	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Open Space Lab, Res Ctr Glycosci, Glycogene Funct Team, C-2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Yang, Fang/AAF-3024-2019; Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Watanabe, Hideto/0000-0001-5291-0696				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bayliss MT, 1999, J BIOL CHEM, V274, P15892, DOI 10.1074/jbc.274.22.15892; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Shiina T, 2000, IMMUNOGENETICS, V51, P75, DOI 10.1007/s002510050012; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	48	60	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38179	38188		10.1074/jbc.M202601200	http://dx.doi.org/10.1074/jbc.M202601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145278	hybrid			2022-12-25	WOS:000178529600027
J	He, C; Hobert, M; Friend, L; Carlin, C				He, C; Hobert, M; Friend, L; Carlin, C			The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; POLYCYSTIC KIDNEY-DISEASE; GPI-ANCHORED PROTEINS; MDCK CELLS; CYTOPLASMIC DOMAIN; EGF RECEPTOR; APICAL DISTRIBUTION; SORTING SIGNALS; PDZ PROTEIN	The epidermal growth factor (EGF) receptor is located predominantly in the basolateral membrane of polarized epithelia, where it plays a pivotal role during organogenesis and tissue homeostasis. We have shown previously that a 22-amino acid sequence in the EGF receptor juxtamembrane domain contains autonomous sorting information necessary for basolateral localization using the Madin-Darby canine kidney epithelial cell model. The goal of this study was to determine the molecular basis of EGF receptor basolateral membrane expression using site-directed mutagenesis to modify specific residues in this region. We now show that this sequence has two different, functionally redundant basolateral sorting signals with distinct amino acid requirements: one dependent on residues (LL659)-L-658 conforming to well-characterized leucine-based sorting signals, and a second containing a polyproline core comprising residues Pro(667) and Pro(670) ((PXXP670)-P-667). Our data also suggest that Arg(662) contributes to the function of the proline-based signal. (PXXP670)-P-667 was the dominant signal when both motifs were present and was more effective than (LL659)-L-658 at overriding strong apical sorting signals located in the same molecule. Site-directed mutations at Arg(662), Pro(667), and Pro(670) were also associated with increased apical expression of full-length EGF receptors, demonstrating for the first time that the juxtamembrane region is necessary for accurate polarized expression of the native molecule.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07717] Funding Source: Medline; NIDDK NIH HHS [P50 DK54178] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG CP, 1993, J BIOL CHEM, V268, P19312; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keller P, 1997, J CELL SCI, V110, P3001; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419, DOI 10.1152/ajpcell.1998.275.6.C1419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATLIN KS, 1992, KIDNEY PHYSL PATHOPH, P447; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; MULLIN JM, 1988, CANCER RES, V48, P4886; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; ORELLANA SA, 1995, SEMIN NEPHROL, V15, P341; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Sweeney WE, 2000, KIDNEY INT, V57, P33, DOI 10.1046/j.1523-1755.2000.00829.x; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	58	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38284	38293		10.1074/jbc.M104646200	http://dx.doi.org/10.1074/jbc.M104646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161422	hybrid			2022-12-25	WOS:000178529600039
J	Li, CG; Zhu, NL; Tan, RC; Ballard, PL; Derynck, R; Minoo, P				Li, CG; Zhu, NL; Tan, RC; Ballard, PL; Derynck, R; Minoo, P			Transforming growth factor-beta inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG MORPHOGENESIS; FAMILY MEMBERS; FACTOR-I; PROMOTER; EXPRESSION; ACTIVATION; DEFECTS; MICE; DIFFERENTIATION; IDENTIFICATION	Transforming growth factor-beta (TGF-beta) represses surfactant protein B (Sp-B) gene transcription through a mechanism that remains unknown. A homeodomain and a forkhead transcription factor, NKX2.1 and HNF-3, respectively, are known activators of Sp-B transcription. Because SMADs are the effectors of TGF-beta-induced gene activation, we examined the possibility that gene repression by TGF-beta may also occur through interactions of SMADs with NKX2.1 and HNF-3. We found that lung epithelial carcinoma H441 cells contain SMAD2/3 and -4, which localize to the nucleus in response to TGF-beta treatment. The activity of a transfected Sp-B promoter/reporter construct was reduced in a dose-dependent manner by TGF-beta. Cotransfection with a mutant, constitutively activated form of the Tgf-beta type I receptor repressed Sp-B promoter activity in the absence of TGF-beta ligand. Dominant negative mutants of Smads blocked the repressor activity of TGF-beta. SMAD3, but not SMAD2, mediated the repressor activity of TGF-beta on the Sp-B promoter. Mutations within a 70-base pair domain that includes binding sites for NKX2.1, hepatocyte nuclear factor 3 (HNF-3), or cAMP response element-binding protein (CREB) eliminated SMAD3-dependent repression of Sp-B transcription. Electrophoretic mobility shift analysis showed no evidence for direct binding of SMAD3 to the Sp-B promoter, and a DNA binding mutant of SMAD3 also repressed Sp-B, suggesting that direct DNA binding of SMAD3 may not be required. Using a mammalian two hybrid assay, we found physical and functional interactions between SMAD3 and both NKX2.1 and HNF-3. Also, a glutathione S-transferase-fused SMAD3 directly binds to in vitro synthesized NKX2.1 or HNF-3, demonstrating protein-protein interactions between SMAD3 and the two transcriptional factors. The DNA binding of NKX2.1 to Sp-B promoter was reduced in response to TGF-beta treatment, although expression of Nkx2.1 was not affected. We conclude that SMAD3 interactions with the positive regulators NKX2.1 and HNF-3 underlie the molecular basis for TGF-beta-induced repression of Sp-B gene transcription.	Univ So Calif, Sch Med, Womens & Childrens Hosp, Dept Pediat, Los Angeles, CA 90033 USA; Univ Penn, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA	Children's Hospital Los Angeles; University of Southern California; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco	Minoo, P (corresponding author), Univ So Calif, Sch Med, Womens & Childrens Hosp, Dept Pediat, Gen Labs Bldg,1801 E Marengo St,Rm 1G38, Los Angeles, CA 90033 USA.	minoo@hse.usc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, R01HL056590, P01HL060231] Funding Source: NIH RePORTER; NHLBI NIH HHS [PM-HL56590, PM-HL60231, PB-HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Beers MF, 1998, AM J PHYSIOL-LUNG C, V275, pL950, DOI 10.1152/ajplung.1998.275.5.L950; Berhane K, 2001, GENE, V268, P141, DOI 10.1016/S0378-1119(01)00417-6; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chang A, 2000, ANN NY ACAD SCI, V923, P181, DOI 10.1111/j.1749-6632.2000.tb05529.x; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Cole FS, 2001, PEDIATR RES, V50, P157, DOI 10.1203/00006450-200108000-00001; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dunbar AE, 2000, PEDIATR RES, V48, P275, DOI 10.1203/00006450-200009000-00003; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Gonzales LW, 2001, PEDIATR PATHOL MOL M, V20, P387, DOI 10.1080/15513810109168622; Hamdan H, 1998, BBA-GENE STRUCT EXPR, V1396, P336, DOI 10.1016/S0167-4781(97)00210-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kumar AS, 2000, BBA-GENE STRUCT EXPR, V1492, P45, DOI 10.1016/S0167-4781(00)00058-0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lecart C, 2000, BIOL NEONATE, V77, P217, DOI 10.1159/000014219; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Miyazono K, 2000, J CELL SCI, V113, P1101; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Sanford LP, 1997, DEVELOPMENT, V124, P2659; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	43	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38399	38408		10.1074/jbc.M203188200	http://dx.doi.org/10.1074/jbc.M203188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161428	hybrid			2022-12-25	WOS:000178529600053
J	Park, S; Gakh, O; Mooney, SM; Isaya, G				Park, S; Gakh, O; Mooney, SM; Isaya, G			The ferroxidase activity of yeast frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL IRON ACCUMULATION; FRIEDREICH ATAXIA; HEME-SYNTHESIS; HORSE SPLEEN; HOMOLOG; FERRITIN; REQUIREMENT; HOMEOSTASIS; DEFICIENCY; OXIDATION	Frataxin is required for maintenance of normal mitochondrial iron levels and respiration. The mature form of yeast frataxin (mYfh1p) assembles stepwise into a multimer of 840 kDa (alpha(48)) that accumulates iron in a water-soluble form. Here, two distinct iron oxidation reactions are shown to take place during the initial assembly step (alpha --> alpha(3)). A ferroxidase reaction with a stoichiometry of 2 Fe(II)/O-2 is detected at Fe(II)/mYfh1p ratios of less than or equal to0.5. Ferroxidation is progressively overcome by autoxidation at Fe(II)/mYfh1p ratios of >0.5. Gel filtration analysis indicates that an oligomer of mYfh1p, as, is responsible for both reactions. The observed 2 Fe(II)/O-2 stoichiometry implies production of H2O2 during the ferroxidase reaction. However, only a fraction of the expected total H2O2 is detected in solution. Oxidative degradation of mYfh1p during the ferroxidase reaction suggests that most H2O2 reacts with the protein. Accordingly, the addition of mYfh1p to a mixture of Fe(II) and H2O2 results in significant attenuation of Fenton chemistry. Multimer assembly is fully inhibited under anaerobic conditions, indicating that mYfh1p is activated by Fe(II) in the presence of O-2. This combination induces oligomerization and mYfh1p-catalyzed Fe(II) oxidation, starting a process that ultimately leads to the sequestration of as many as 50 Fe(II)/subunit inside the multimer.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Isaya, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW,Stabile 7-52, Rochester, MN 55905 USA.	isaya@mayo.edu			NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG015709, AG15709] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Corsi B, 2002, J BIOL CHEM, V277, P22430, DOI 10.1074/jbc.M105372200; DARNELL J, 1990, MOL CELL BIOL, P583; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Halliwell B., 1999, FREE RADICAL BIO MED, P1, DOI DOI 10.1093/ACPROF:OSO/9780198717478.001.0001; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lindsay S, 2001, BIOCHEMISTRY-US, V40, P3340, DOI 10.1021/bi001981v; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Richards TD, 1996, J INORG BIOCHEM, V61, P1, DOI 10.1016/0162-0134(95)00029-1; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Yang XK, 1999, BIOCHEM J, V338, P615, DOI 10.1042/0264-6021:3380615; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j	33	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38589	38595		10.1074/jbc.M206711200	http://dx.doi.org/10.1074/jbc.M206711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149269	Green Accepted, hybrid			2022-12-25	WOS:000178529600076
J	Sobott, F; Benesch, JLP; Vierling, E; Robinson, CV				Sobott, F; Benesch, JLP; Vierling, E; Robinson, CV			Subunit exchange of multimeric protein complexes - Real-time monitoring of subunit exchange between small heat shock proteins by using electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMOLECULAR EXCHANGE; DENATURED PROTEINS; OLIGOMER FORMATION; CHAPERONE ACTIVITY; CRYSTAL-STRUCTURE; ALPHA-CRYSTALLIN; EVOLUTION; HSP25	The subunit exchange of the small heat shock proteins (sHSPs) PsHSP18.1 from pea and TaHSP16.9 from wheat has been monitored in real-time using nanoelectrospray mass spectrometry. By preserving the noncovalent interactions between subunits in the mass spectrometer, we show that these proteins are dodecameric. After mixing PsHSP18.1 and TaHSP16.9, a distribution of heterododecamers is formed. A comparison with spectra obtained from statistical modeling demonstrates that after equilibration the distribution of these heterocomplexes is governed by the starting ratio of the two components rather than an inherent preference for certain stoichiometries. This finding suggests that the two different sHSP subunits interact in a very similar manner. Following the kinetics of this reaction by mass spectrometry reveals that exchange proceeds via sequential incorporation of subunits with dimeric species being the principal units of exchange. Therefore, we conclude that sHSP complexes are in rapid dissociation/reassociation equilibria with suboligomeric forms. More generally, these experiments illustrate a powerful approach for the real-time analysis of the evolution of transient species and their relative populations during the subunit exchange of multimeric protein complexes.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Cambridge; University of Arizona	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Benesch, Justin/A-4250-2008	Vierling, Elizabeth/0000-0002-0066-4881; Sobott, Frank/0000-0001-9029-1865; Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NIGMS NIH HHS [GM-42762] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO AP, 2002, PROGR MOL SUBCELLULA, P1; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bruce JE, 1998, PROTEIN SCI, V7, P1180, DOI 10.1002/pro.5560070512; Datta SA, 2000, J BIOL CHEM, V275, P41004, DOI 10.1074/jbc.M007686200; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; GAESTEL M, 1997, GUIDEBOOK MOL CHAPER, P269; Garnier C, 2001, EUR J BIOCHEM, V268, P2402, DOI 10.1046/j.1432-1327.2001.02121.x; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; Helm KW, 1997, PLANT PHYSIOL, V114, P1477, DOI 10.1104/pp.114.4.1477; Hernandez H, 2001, J BIOL CHEM, V276, P46685, DOI 10.1074/jbc.R100024200; Kappe Guido, 2002, Prog Mol Subcell Biol, V28, P1; Kebarle P, 2000, J MASS SPECTROM, V35, P804, DOI 10.1002/1096-9888(200007)35:7<804::AID-JMS22>3.3.CO;2-H; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; Loo JA, 2000, INT J MASS SPECTROM, V200, P175, DOI 10.1016/S1387-3806(00)00298-0; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Schneider F, 2001, PROTEIN SCI, V10, P1606, DOI 10.1110/ps.8901; Smith VF, 1996, PROTEIN SCI, V5, P488; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Tito MA, 2000, J AM CHEM SOC, V122, P3550, DOI 10.1021/ja993740k; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; van den IJssel P, 1999, CURR BIOL, V9, pR103, DOI 10.1016/S0960-9822(99)80061-X; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WATERS ER, 1995, GENETICS, V141, P785; Waters ER, 1999, MOL BIOL EVOL, V16, P127, DOI 10.1093/oxfordjournals.molbev.a026033; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325	42	166	169	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38921	38929		10.1074/jbc.M206060200	http://dx.doi.org/10.1074/jbc.M206060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138169	hybrid			2022-12-25	WOS:000178529600115
J	Litowski, JR; Hodges, RS				Litowski, JR; Hodges, RS			Designing heterodimeric two-stranded alpha-helical coiled-coils - Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; DE-NOVO DESIGN; SYNTHETIC MODEL PROTEINS; OLIGOMERIZATION-STATE; ELECTROSTATIC INTERACTIONS; CHAIN-LENGTH; DIMERIZATION SPECIFICITY; THERMODYNAMIC SCALE; HEPTAD POSITIONS; HYBRID HYDROGELS	The E/K coli, a heterodimeric colied-coli, has been designed as a universal peptide capture and delivery system for use in applications such as biosensors and as an expression and affinity purification tag. In this design, heterodimer formation is specified through the placement of charged residues at the e and g positions of the heptad repeat such that the E coli contains all glutamic acid residues at these positions, and the K coli contains all lysine residues at these positions. The affinity and stability of the E/K coli have been modified to allow a greater range of conditions for association and dissociation. Increasing the hydrophobicity of the colied-coli core, by substituting isoleucine for valine, gave increases in stability of 2.81 and 3.73 kcal/mol (0.47 kcal/ mol/substitution). Increasing the alpha-helical propensity of residues outside the core, by substituting alanine for serine, yielded increases in stability of 2.68 and 3.28 kcal/mol (0.41 and 0.45 kcal/mol/substitution). These sequence changes yielded a series of heterodimeric colied-colis whose stabilities varied from 6.8 to 11.2 kcal/mol, greatly expanding their scope for use in protein engineering and biomedical applications.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alberta	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Box B121,4200 E 9th Ave, Denver, CO 80262 USA.	robert.hodges@uchsc.edu						Arndt KM, 2001, J MOL BIOL, V312, P221, DOI 10.1006/jmbi.2001.4915; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Behncken SN, 2000, J BIOL CHEM, V275, P17000, DOI 10.1074/jbc.275.22.17000; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Catimel B, 2001, J PEPT RES, V58, P493, DOI 10.1034/j.1399-3011.2001.10973.x; Cedervall T, 1997, BIOCHEMISTRY-US, V36, P4987, DOI 10.1021/bi962971q; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Chao HM, 1998, J CHROMATOGR B, V715, P307, DOI 10.1016/S0378-4347(98)00172-8; Chao HM, 1996, BIOCHEMISTRY-US, V35, P12175, DOI 10.1021/bi9530604; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; Erickson B. W., 1976, PROTEINS, VII, P255; Fairman R, 1996, BIOCHEMISTRY-US, V35, P2824, DOI 10.1021/bi952784c; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FERSHT AR, 1993, CURR OPIN STRUC BIOL, V3, P75, DOI 10.1016/0959-440X(93)90205-Y; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Holtzer ME, 1997, BIOPHYS J, V73, P1031, DOI 10.1016/S0006-3495(97)78136-0; Houston ME, 1996, J MOL BIOL, V262, P270, DOI 10.1006/jmbi.1996.0512; Jelesarov I, 1996, J MOL BIOL, V263, P344, DOI 10.1006/jmbi.1996.0579; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Kiyokawa T, 2000, BIOPOLYMERS, V55, P407, DOI 10.1002/1097-0282(2000)55:5<407::AID-BIP1015>3.3.CO;2-P; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kohn WD, 1998, TRENDS BIOTECHNOL, V16, P379, DOI 10.1016/S0167-7799(98)01212-8; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; KOHN WD, 1995, PROTEIN SCI, V4, P237; Krittanai C, 2000, PROTEINS, V39, P132, DOI 10.1002/(SICI)1097-0134(20000501)39:2<132::AID-PROT3>3.0.CO;2-2; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; KWOK SC, 1998, P 25 EUR PEPT S, P34; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Litowski JR, 1999, J PEPT RES, V54, P1, DOI 10.1034/j.1399-3011.1999.00066.x; Liu JF, 2001, PROTEIN SCI, V10, P1970, DOI 10.1110/ps.10101; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; Miceli R, 1996, Drug Des Discov, V13, P95; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; Muller KM, 2000, METHOD ENZYMOL, V328, P261; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NAUTIYAL S, 1995, BIOCHEMISTRY-US, V34, P11645, DOI 10.1021/bi00037a001; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Pace C N, 1986, Methods Enzymol, V131, P266; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Padmanabhan S, 1996, J MOL BIOL, V257, P726, DOI 10.1006/jmbi.1996.0197; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; Schnarr NA, 2001, J AM CHEM SOC, V123, P11081, DOI 10.1021/ja015912v; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Tang A, 2001, J CONTROL RELEASE, V72, P57, DOI 10.1016/S0168-3659(01)00262-0; Tripet B, 1996, PROTEIN ENG, V9, P1029, DOI 10.1093/protein/9.11.1029; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Vu C, 2001, PROTEIN SCI, V10, P631, DOI 10.1110/ps.41101; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Walshaw J, 2001, PROTEIN SCI, V10, P668, DOI 10.1110/ps.36901; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; WOLBER V, 1992, BIO-TECHNOL, V10, P900, DOI 10.1038/nbt0892-900; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Wu ZN, 1999, PROTEIN SCI, V8, P482; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	88	232	277	2	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37272	37279		10.1074/jbc.M204257200	http://dx.doi.org/10.1074/jbc.M204257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138097	hybrid			2022-12-25	WOS:000178447100048
J	Takanami-Ohnishi, Y; Amano, S; Kimura, S; Asada, S; Utani, A; Maruyama, M; Osada, H; Tsunoda, H; Irukayama-Tomobe, Y; Goto, K; Karin, M; Sudo, T; Kasuya, Y				Takanami-Ohnishi, Y; Amano, S; Kimura, S; Asada, S; Utani, A; Maruyama, M; Osada, H; Tsunoda, H; Irukayama-Tomobe, Y; Goto, K; Karin, M; Sudo, T; Kasuya, Y			Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MAP KINASE; MESSENGER-RNA; FACTOR-ALPHA; GAMMA PRODUCTION; MURINE MODEL; T-CELLS; EXPRESSION; CYTOKINE; INDUCTION	The present study was designed to elucidate the role of p38 mitogen-activated protein kinase (p38) in the pathogenesis of inflammation, using a mouse contact hypersensitivity (CHS) model induced by 2,4-dinitro-1-fluorobenzene (DNFB). Ear swelling was induced by challenge with DNFB, accompanied by infiltration of mononuclear cells, neutrophils, and eosinophils and a marked increase in mRNA levels of cytokines such as interleukin (IL)-2, interferon (IFN)-gamma, IL-4, IL-5, IL-1beta, IL-18, and tumor necrosis factor-alpha in the challenged ear skin. Both ear swelling and the number of infiltrated cells in DNFB-challenged ear skin were significantly inhibited by treatment with SB202190, a p38 inhibitor. Furthermore, the DNFB-induced expression of all cytokines except IL-4 was significantly inhibited by treatment with SB202190. Ribonuclease protection assay revealed that the mRNA levels of chemokines such as IP-10 and MCP-1 in ear skin were markedly increased at 24 h after challenge with DNFB. The induction of these chemokines was significantly inhibited by treatment with SB202190. In p38alpha +/- mice, both ear swelling and infiltration of cells induced by DNFB were reduced compared with those in wild-type mice. However, induction of cytokines by DNFB was also observed in p38alpha +/- mice, although the induction of IFN-gamma, IL-5, and IL-18 was typically reduced compared with that in wild-type mice. Challenge with DNFB slightly induced IP-10 and MCP-1 mRNA in p38alpha +/- mice, with weaker signals than those in SB202190-treated wild-type mice. These results suggest that p38 plays a key role in CHS and is an important target for the treatment of CHS.	Chiba Univ, Dept Biochem & Mol Pharmacol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Dept Dermatol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Cardiol, Inst Clin Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Pharmacol, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Chiba University; Chiba University; RIKEN; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of California System; University of California San Diego	Kasuya, Y (corresponding author), Chiba Univ, Dept Biochem & Mol Pharmacol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	kasuya@faculty.chiba-u.jp	Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Kasuya, Yoshitoshi/0000-0003-0614-5836; Kimura, Sadao/0000-0001-6768-7474				Abe M, 1996, J INVEST DERMATOL, V107, P360, DOI 10.1111/1523-1747.ep12363337; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Foey AD, 1998, J IMMUNOL, V160, P920; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KONDO S, 1995, J INVEST DERMATOL, V105, P334, DOI 10.1111/1523-1747.ep12320329; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mori A, 1999, J IMMUNOL, V163, P4763; Nagai H, 1999, J PHARMACOL EXP THER, V288, P43; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Rand ML, 1996, AM J PATHOL, V148, P855; Riemann H, 1996, J IMMUNOL, V156, P1799; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schwarz T, 1995, RES IMMUNOL, V146, P494, DOI 10.1016/0923-2494(96)83022-7; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Stoll S, 1997, J IMMUNOL, V159, P298; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tomobe YI, 2000, LIPIDS, V35, P61, DOI 10.1007/s11745-000-0495-0; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; Yamazaki S, 1997, YAKUGAKU ZASSHI, V117, P155, DOI 10.1248/yakushi1947.117.3_155; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	48	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37896	37903		10.1074/jbc.M207326200	http://dx.doi.org/10.1074/jbc.M207326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138127	hybrid			2022-12-25	WOS:000178447100126
J	Hirohawa, G; Kiel, MC; Muto, A; Kawai, G; Igarashi, K; Kaji, H; Kaji, A				Hirohawa, G; Kiel, MC; Muto, A; Kawai, G; Igarashi, K; Kaji, H; Kaji, A			Binding of ribosome recycling factor to ribosomes, comparison with tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; ELONGATION-FACTOR-G; SOLUBLE RIBONUCLEIC-ACID; DEACYLATED TRANSFER-RNA; CRYSTAL-STRUCTURE; MESSENGER-RNA; FACTOR RRF; 70S RIBOSOME; 4TH STEP; E-SITE	The prokaryotic post-termination ribosomal complex is disassembled by ribosome recycling factor (RRF) and elongation factor G. Because of the structural similarity of RRF and tRNA, we compared the biochemical characteristics of RRF binding to ribosomes with that of tRNA. Unesterified tRNA inhibited the disassembly of the post-termination complex in a competitive manner with RRF, suggesting that RRF binds to the A-site. Approximately one molecule of ribosome-bound RRF was detected after isolation of the RRF-ribosome complex. RRF and unesterified tRNA similarly inhibited the binding of N-acetylphenylalanyl-tRNA to the P-site of nonprogrammed but not programmed ribosomes. Under the conditions in which unesterified tRNA binds to both the P- and E-sites of non-programmed ribosomes, RRF inhibited 50% of the tRNA binding, suggesting that RRF does not bind to the E-site. The results are consistent with the notion that a single RRF binds to the A- and P-sites in a somewhat analogous manner to the A/P-site bound peptidyl tRNA. The binding of RRF and tRNA to ribosomes was influenced by Mg2+ and NH4+ ions in a 4 similar manner.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Clin Biochem, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Dept Ind Chem, Narashino, Chiba 2758588, Japan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	University of Pennsylvania; Chiba University; Chiba Institute of Technology; Jefferson University	Kaji, A (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Room 203B,Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	kaji@mail.med.upenn.edu		Igarashi, Kazuei/0000-0003-3751-3187	CGH CDC HHS [1-R01-GH-60429-01A2] Funding Source: Medline	CGH CDC HHS		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BONINCONTRO A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P27, DOI 10.1016/0167-4781(93)90088-U; CANNON M, 1963, J MOL BIOL, V7, P360, DOI 10.1016/S0022-2836(63)80030-3; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CELANO B, 1988, EUR J BIOCHEM, V178, P351, DOI 10.1111/j.1432-1033.1988.tb14457.x; CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; Frank J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P45; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; HIRASHIM.A, 1970, BIOCHEM BIOPH RES CO, V41, P877, DOI 10.1016/0006-291X(70)90165-8; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; IGARASHI K, 1970, EUR J BIOCHEM, V14, P41, DOI 10.1111/j.1432-1033.1970.tb00258.x; IGARASHI K, 1967, P NATL ACAD SCI USA, V58, P1971, DOI 10.1073/pnas.58.5.1971; Inokuchi Y, 2000, EMBO J, V19, P3788, DOI 10.1093/emboj/19.14.3788; Janosi L, 2000, J MOL BIOL, V295, P815, DOI 10.1006/jmbi.1999.3401; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; Kaji A, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P527; Kaji A, 2001, COLD SPRING HARB SYM, V66, P515, DOI 10.1101/sqb.2001.66.515; KAJI A, 1963, BIOCHEM BIOPH RES CO, V13, P186, DOI 10.1016/0006-291X(63)90279-1; KAJI A, 1968, METHODS ENZYMOLOGY B, V12, P692; KAJI H, 1966, J BIOL CHEM, V241, P1251; KAJI H, 1966, J MOL BIOL, V18, P219, DOI 10.1016/S0022-2836(66)80242-5; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Kim KK, 2000, EMBO J, V19, P2362, DOI 10.1093/emboj/19.10.2362; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUNG HF, 1977, P NATL ACAD SCI USA, V74, P3217, DOI 10.1073/pnas.74.8.3217; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; PESTKA S, 1966, J MOL BIOL, V21, P145, DOI 10.1016/0022-2836(66)90085-4; Rao AR, 2001, EMBO J, V20, P2977, DOI 10.1093/emboj/20.11.2977; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1980, BIOCHEM INT, V1, P297; Rodnina PV, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P301; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; Spirin AS, 1999, RIBOSOMES; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUZUKA I, 1966, P NATL ACAD SCI USA, V55, P1483, DOI 10.1073/pnas.55.6.1483; TANAKA S, 1972, J BIOL CHEM, V247, P45; Toyoda T, 2000, RNA, V6, P1432, DOI 10.1017/S1355838200001060; TRAUB P, 1969, J MOL BIOL, V40, P391, DOI 10.1016/0022-2836(69)90161-2; Wilson DN, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P495; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	61	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35847	35852		10.1074/jbc.M206295200	http://dx.doi.org/10.1074/jbc.M206295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138121	hybrid			2022-12-25	WOS:000178275100013
J	Mello, LV; de Groot, BL; Li, SL; Jedrzejas, MJ				Mello, LV; de Groot, BL; Li, SL; Jedrzejas, MJ			Structure and flexibility of Streptococcus agalactiae hyaluronate lyase complex with its substrate - Insights into the mechanism of processive degradation of hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; ESSENTIAL DYNAMICS; DOMAIN MOTIONS; ACTION PATTERN; EXPRESSION; GENE; SITE; MUTAGENESIS	Streptococcus agalactiae hyaluronate lyase degrades primarily hyaluronan, the main polysaccharide component of the host connective tissues, into unsaturated disaccharide units as the end product. Such function of the enzyme destroys the normal connective tissue structure of the host and exposes the tissue cells to various bacterial toxins. The crystal structure of hexasaccharide hyaluronan complex with the S. agalactiae hyaluronate lyase was determined at 2.2 Angstrom resolution; the mechanism of the catalytic process, including the identification of specific residues involved in the degradation of hyaluronan, was clearly identified. The enzyme is composed structurally and functionally from two distinct domains, an alpha-helical alpha-domain and a beta-sheet beta-domain. The flexibility of the protein was investigated by comparing the crystal structures of the S. agalactiae and the Streptococcus pneumoniae enzymes, and by using essential dynamics analyses of CONCOORD computer simulations. These revealed important modes of flexibility, which could be related to the protein function. First, a rotation/twist of the a-domain relative to the beta-domain is potentially related to the mechanism of processivity of the enzyme; this twist motion likely facilitates shifting of the ligand along the catalytic site cleft in order to reposition it to be ready for further cleavage. Second, a movement of the alpha- and beta-domains with respect to each other was found to contribute to a change in electrostatic characteristics of the enzyme and appears to facilitate binding of the negatively charged hyaluronan ligand. Third, an opening/closing of the substrate binding cleft brings a catalytic histidine closer to the cleavable substrate beta1,4,-glycosidic bond. This opening/closing mode also reflects the main conformational difference between the crystal structures of the S. agalactiae and the S. pneumoniae hyaluronate lyases.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; EMBRAPA, Natl Ctr Genet Resources & Biotechnol, Cenargen, BR-70770900 Brasilia, DF, Brazil; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Max Planck Society; University of Alabama System; University of Alabama Birmingham	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COURTISS EH, 1995, PLAST RECONSTR SURG, V95, P876, DOI 10.1097/00006534-199595050-00017; de Groot BL, 1999, J MOL BIOL, V286, P1241, DOI 10.1006/jmbi.1998.2568; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gase K, 1998, BBA-GENE STRUCT EXPR, V1398, P86, DOI 10.1016/S0167-4781(98)00045-1; GREILING H, 1975, CONNECT TISSUE RES, V3, P135, DOI 10.3109/03008207509152171; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 1997, PROTEINS, V27, P425, DOI 10.1002/(SICI)1097-0134(199703)27:3<425::AID-PROT10>3.0.CO;2-N; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2000, ACTA CRYSTALLOGR D, V56, P460, DOI 10.1107/S0907444900000706; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kleinjung J, 2000, FEBS LETT, V470, P257, DOI 10.1016/S0014-5793(00)01295-3; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labrou NE, 2001, BIOCHEM J, V358, P101, DOI 10.1042/0264-6021:3580101; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LIN B, 1994, J BIOL CHEM, V269, P30113; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rolland K, 1999, J CLIN MICROBIOL, V37, P1892, DOI 10.1128/JCM.37.6.1892-1898.1999; Schappach A, 2001, PHARMAZIE, V56, P435; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	53	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36678	36688		10.1074/jbc.M205140200	http://dx.doi.org/10.1074/jbc.M205140200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130645	hybrid, Green Submitted			2022-12-25	WOS:000178275100114
J	Nusser, N; Gosmanova, E; Zheng, Y; Tigyi, G				Nusser, N; Gosmanova, E; Zheng, Y; Tigyi, G			Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURITE RETRACTION; GUANOSINE TRIPHOSPHATASES; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION; FAMILY GTPASES; AXON GUIDANCE; RAS; KINASE; PROTEIN; ACTIVATION	In PC12 rat pheochromocytoma cells, nerve growth factor (NGF)-induced neuronal differentiation is blocked by constitutively active dominant mutants of RhoA but augmented by negative ones, suggesting a not yet elucidated inhibitory signaling link between NGF receptors and RhoA. Here we show that NGF treatment rapidly translocates RhoA from the plasma membrane to the cytosol and simultaneously decreases RhoA affinity to its target Rho-associated kinase (ROK), a key mediator of neurite outgrowth. This effect was transient, because after 2 days of NGF treatment, RhoA relocated from the cytosol to the plasma membrane, and its GTP loading returned to a level found in undifferentiated cells. Inhibition of RhoA is mediated by activation of the TrkA receptor, because NGF failed to induce RhoA translocation and inhibition of ROK binding in nnr5 cells that lack TrkA, whereas the inhibition was reconstituted in receptor add-back B5 cells. In MM17-26 cells, which due to expression of dominant negative Ras do not differentiate, NGF-stimulated transient RhoA inhibition was unaffected. The inhibitory pathway from TrkA to RhoA involves phosphatidylinositol-3-kinase (PI3K), because the inhibitors LY294002 or wortmannin prevented NGF-induced RhoA translocation and increased RhoA association with ROK. Furthermore, inhibition of PI3K significantly - reduced NGF-mediated Rac1 activation, whereas dominant negative Rac1 abolished the inhibitory signaling to RhoA. Taken together, these data indicate that NGF-mediated activation of TrkA receptor stimulates PI3K, which in turn increases Racl activity to induce transient RhoA inactivation during the initial phase of neurite outgrowth.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Pecs, Sch Med, Dept Biol, H-7643 Pecs, Hungary	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Pecs	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boglari G, 2001, EUR J NEUROSCI, V14, P1445, DOI 10.1046/j.0953-816x.2001.01787.x; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P537; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	37	101	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35840	35846		10.1074/jbc.M203617200	http://dx.doi.org/10.1074/jbc.M203617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133829	hybrid			2022-12-25	WOS:000178275100012
J	Tan, SL; Tareen, SU; Melville, MW; Blakely, CM; Katze, MG				Tan, SL; Tareen, SU; Melville, MW; Blakely, CM; Katze, MG			The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA-BINDING; VIRUS NS1 PROTEIN; TRANSLATION INITIATION; REGULATORY SUBUNIT; MALIGNANT-TRANSFORMATION; GAMMA(1)34.5 PROTEIN; INTERFERON; PHOSPHATASE; ACTIVATION; PHOSPHORYLATION	The PKR protein kinase is among the best-studied effectors of the host interferon (IFN)-induced antiviral and antiproliferative response system. In response to stress signals, including virus infection, the normally latent PKR becomes activated through autophosphorylation and dimerization and phosphorylates the eIF2alpha translation initiation factor subunit, leading to an inhibition of mRNA translation initiation. While numerous virally encoded or modulated proteins that bind and inhibit PKR during virus infection have been studied, little is known about the cellular proteins that counteract PKR activity in uninfected cells. Overexpression of PKR in yeast also leads to an inhibition of eIF2alpha-dependent protein synthesis, resulting in severe growth suppression. Screening of a human cDNA library for clones capable of counteracting the PKR-mediated growth defect in yeast led to the identification of the catalytic subunit (PP1(C)) of protein phosphatase 1alpha. PP1(C) reduced double-stranded RNA-mediated auto-activation of PKR and inhibited PKR transphosphorylation activities. A specific and direct interaction between PP1(C) and PKR was detected, with PP1C binding to the N-terminal regulatory region regardless of the double-stranded RNA-binding activity of PKR. Importantly, a consensus motif shared by many PP1(C)-interacting proteins was necessary for PKR binding to PP1(C). The PKR-interactive site was mapped to a C-terminal non-catalytic region that is conserved in the PP1(C)2 isoform. Indeed, co-expression of PP1(C) or PP1(C)2 inhibited PKR dimer formation in Escherichia coli. Interestingly, co-expression of a PP1(C) mutant lacking the catalytic domain, despite retaining its ability to bind PKR, did not prevent PKR dimerization. Our findings suggest that PP1(C) modulates PKR activity via protein dephosphorylation and subsequent disruption of PKR dimers.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tan, SL (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Infect Dis Res, Indianapolis, IN 46285 USA.	tan_seng-lai@lilly.com			NIAID NIH HHS [AI22646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cohen PTW, 2002, J CELL SCI, V115, P241; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERSHEY J, 1996, TRANSLATIONAL CONTRO, P139; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PETRYSHYN R, 1982, P NATL ACAD SCI-BIOL, V79, P6512, DOI 10.1073/pnas.79.21.6512; Ragolia L, 2000, J BIOL CHEM, V275, P26102, DOI 10.1074/jbc.M001955200; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Salzberg S, 2000, EXP CELL RES, V254, P45, DOI 10.1006/excr.1999.4721; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; Tam NWN, 1999, EUR J BIOCHEM, V262, P149, DOI 10.1046/j.1432-1327.1999.00360.x; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1998, J INTERF CYTOK RES, V18, P757, DOI 10.1089/jir.1998.18.757; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tan SL, 1998, METHODS, V15, P207, DOI 10.1006/meth.1998.0625; Taylor DR, 2001, J VIROL, V75, P1265, DOI 10.1128/JVI.75.3.1265-1273.2001; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang J, 2002, J BIOL CHEM, V277, P46035, DOI 10.1074/jbc.M208519200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	63	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36109	36117		10.1074/jbc.M205109200	http://dx.doi.org/10.1074/jbc.M205109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138106	hybrid			2022-12-25	WOS:000178275100045
J	Fang, WZ; Mori, T; Cobrinik, D				Fang, WZ; Mori, T; Cobrinik, D			Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants	ONCOGENE			English	Article						pRB; PML; Mad; transcriptional repression; senescence	ACUTE PROMYELOCYTIC LEUKEMIA; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; RAR-ALPHA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GROWTH-SUPPRESSOR; TUMOR-CELLS; PREMATURE SENESCENCE; ONCOGENIC RAS	The retinoblastoma protein (pRB) is thought to suppress tumorigenesis, in part, through interactions with E2F transcription factors. However, certain low penetrance pRB mutants substantially reduce tumor incidence despite having a minimal ability to bind E2F. These low penetrance mutants retain the ability to induce a senescence-like state, suggesting that they may suppress tumorigenesis through a senescence-associated process. Here, we identify a novel pRB function that is associated with senescence and which is retained by non-EN binding low penetrance pRB mutants. It was found that pRB and these mutants substantially increased the production of PML nuclear bodies (NBs). In keeping with the role of PML in transcriptional repression, pRB also promoted PML-dependent transcriptional repression by the c-Myc antagonist Mad1. In a series of pRB-p130 chimeric proteins, the ability to increase NB production correlated with the ability to induce a senescence-like phenotype. However, neither NB formation nor PML function were required for pRB to induce the senescence-like response. Together, these observations indicate that a pRB-induced increase in PML NB formation is coordinated with, but separable from, the pRB-induced senescence program. The data further suggest that PML may contribute to an E2F-independent tumor suppressor function of pRB.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	dc197@columbia.edu			NCI NIH HHS [P30CA 13696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	55	13	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5557	5565		10.1038/sj.onc.1205666	http://dx.doi.org/10.1038/sj.onc.1205666			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165854				2022-12-25	WOS:000177442000005
J	Pan, YH; Yu, BZ; Singer, AG; Ghomashchi, F; Lambeau, G; Gelb, MH; Jain, MK; Bahnson, BJ				Pan, YH; Yu, BZ; Singer, AG; Ghomashchi, F; Lambeau, G; Gelb, MH; Jain, MK; Bahnson, BJ			Crystal structure of human group X secreted phospholipase A(2) - Electrostatically neutral interfacial binding surface targets zwitterionic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; STRUCTURE-BASED DESIGN; ARACHIDONIC-ACID; KINETIC BASIS; COMPETITIVE INHIBITORS; VENOM PHOSPHOLIPASE-A2; BILAYER INTERFACE; RAY STRUCTURE; CATALYSIS; ACTIVATION	The crystal structure of human group X (hGX) secreted phospholippse A(2) (sPLA(2)) has been solved to a resolution of 1.97 Angstrom. As expected the protein fold is similar to previously reported sPLA(2) structures. The active site architecture, including the positions of the catalytic residues and the first and second shell water around the Ca2+ cofactor, are highly conserved and remarkably similar to the group IB and group IIA enzymes. Differences are seen in the structures following the (1-12)-N-terminal helix and at the C terminus. These regions are proposed to interact with the substrate membrane surface. The opening to the active site slot is considerably larger in hGX than in human group IIA sPLA(2). Furthermore, the electrostatic surface potential of the hGX interfacial-binding surface does not resemble that of the human group IIA sPLA(2); the former is highly neutral, whereas the latter is highly cationic. The cationic residues on this face of group IB and IIA enzymes have been implicated in membrane binding and in k*(cat) allostery. In contrast, hGX does not show activation by the anionic charge at the lipid interface when acting on phospholipid vesicles or short-chain phospholipid micelles. Together, the crystal structure and kinetic results of hGX supports the conclusion that it is as active onzwitterionic as on anionic interfaces, and thus it is predicted to target the zwitterionic membrane surfaces of mammalian cells.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Delaware; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Bahnson, BJ (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.		Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL-36235] Funding Source: Medline; NIGMS NIH HHS [GM-29703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APITZCASTRO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P349, DOI 10.1016/0005-2736(82)90346-7; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 1997, BIOCHEMISTRY-US, V36, P14512, DOI 10.1021/bi970855x; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1992, BIOCHEMISTRY-US, V31, P7841, DOI 10.1021/bi00149a014; JAIN MK, 1995, METHOD ENZYMOL, V249, P567; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Rogers J, 1996, BIOCHEMISTRY-US, V35, P9375, DOI 10.1021/bi960526p; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; Steiner RA, 2001, ACTA CRYSTALLOGR D, V57, P516, DOI 10.1107/S0907444901002530; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VANEIJK JH, 1983, EUR J BIOCHEM, V132, P183; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; Yu BZ, 2000, BIOCHEMISTRY-US, V39, P12312, DOI 10.1021/bi000740k; Yu BZ, 1999, BIOCHEMISTRY-US, V38, P10449, DOI 10.1021/bi990194z	53	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29086	29093		10.1074/jbc.M202531200	http://dx.doi.org/10.1074/jbc.M202531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12161451	hybrid			2022-12-25	WOS:000177342600096
J	Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H				Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H			Identification of MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal carcinomas with microsatellite instability	ONCOGENE			English	Article						DNA mismatch repair; microsatellite instability; coding mononucleotide repeats; frameshift mutation; colorectal carcinoma	SOMATIC FRAMESHIFT MUTATIONS; DNA MISMATCH REPAIR; C-KINASE SUBSTRATE; II RECEPTOR GENE; MUTATOR PHENOTYPE; GROWTH-FACTOR; CANCER-CELLS; GASTROINTESTINAL CANCER; MONONUCLEOTIDE REPEATS; COLON CANCERS	Somatic frameshift mutations in some genes containing coding mononucleotide repeats (cMNRs) are well known characteristics of tumors with high microsatellite instability (MSI-H). We identified 22 novel and 11 known target genes containing cMNRs with a length of 10 or more nucleotides by using a systematic database search. Frameshift mutation analysis was performed with these 33 genes in 39 MSI-H and 24 microsatellite stable (MSS) colorectal carcinomas by assessing the mobility shifts of PCR products in gel electrophoresis and by sequencing. All the 39 MSI-H colorectal carcinomas, except one, showed mutations in more than one gene, while no mutations were found in 24 MSS colorectal carcinomas. Of these MSI-H tumors, 11 genes were mutated in more than 40%. The most frequently mutated novel genes were MARCKS (72%), FLJ11383 (74%) and TAF1B (82%). Bialletic inactivation in MARCKS and FLJ11383 was also frequent in MSI-H tumors. The observed mutation frequency of the 11 known target genes was compatible with that found by previous studies. The very high frequency of mutations, biallelic mutations and the predicted truncation of protein products suggests that mutations of MARCKS, FLJ11383 and TAF1B are selected, and play a role in the tumorigenesis of MSI-H colorectal carcinomas.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea; Yonsei Univ, Dept Canc Metastasis Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Brain Korea 21 Projects Med Sci, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120749, South Korea.	hkyonsei@yumc.yonsei.ac.kr		LEE, JIN-SUNG/0000-0002-1262-8597; Kim, Nam-Kyu/0000-0003-0639-5632				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CHEN JS, 1995, CANCER RES, V55, P174; CHOI SJ, 1998, J KOREAN CANC ASS, V30, P527; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 1999, ONCOGENE, V18, P6806, DOI 10.1038/sj.onc.1203287; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; Kim JJ, 1999, LAB INVEST, V79, P1113; Kim NG, 2001, CANCER RES, V61, P36; Ku JL, 1999, EUR J CANCER, V35, P1724, DOI 10.1016/S0959-8049(99)00206-3; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Manenti S, 1998, CANCER RES, V58, P1429; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori Y, 2001, CANCER RES, V61, P6046; Ohmiya N, 2001, GENE, V272, P301, DOI 10.1016/S0378-1119(01)00517-0; Park J, 2002, CANCER RES, V62, P1284; PARK JG, 1987, CANCER RES, V47, P6710; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, BIOL CHEM, V377, P675; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhang L, 2001, CANCER RES, V61, P3801	33	46	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5081	5087		10.1038/sj.onc.1205703	http://dx.doi.org/10.1038/sj.onc.1205703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140758				2022-12-25	WOS:000176975900006
J	Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE				Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE			DNA binding and 3 '-5 ' exonuclease activity in the murine alternatively-spliced p53 protein	ONCOGENE			English	Article						alternatively-spliced p53; DNA binding; exonuclease activity; phosphorothioate-modified DNA-binding sites	SUBSTRATE-SPECIFICITY; TERMINAL DOMAIN; IN-VITRO; EXONUCLEASE; INVOLVEMENT; EXCISION; SITE; INHIBITION; TARGET; LATENT	In this study we show that the naturally occurring C-terminally alternative spliced p53 (referred to as AS-p53) is active as a sequence-specific DNA binding protein as well as a 3'-5'-exonuclease in the presence of Mg2+ ions. The two activities are positively correlated as the sequence-specific DNA target is more efficiently degraded than a non-specific target. In contrast, a mutated AS-p53 protein that is deficient in DNA binding lacks exonuclease activity. The use of modified p53 binding sites, where the 3'-phosphate is replaced by a phosphorothioate group, enabled the inhibition of DNA degradation under the binding conditions. We demonstrate that AS-p53 interacts with its specific DNA target by two distinct binding modes: a high-affinity mode characterized by a low-mobility protein-DNA complex at the nanomolar range, and a low-affinity mode shown by a high-mobility complex at the micromolar range. Comparison of the data on the natural and the modified p53 binding sites suggests that the high-affinity mode is related to AS-p53 function as a transcription factor and that the low-affinity mode is associated with its exonuclease activity. The implications of these findings to a specific cellular role of AS-p53 are discussed.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Technion Israel Institute of Technology	Shakked, Z (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	zippi.shakked@weizmann.ac.il; bitali@techunix.technion.ac.il	Haran, Tali E./AAF-7816-2021	Haran, Tali E./0000-0002-9700-3392				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Molinari M, 1996, ONCOGENE, V13, P2077; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nichols NM, 2001, BIOCHEMISTRY-US, V40, P3847, DOI 10.1021/bi002088z; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OKOROKOV AL, 1999, ONC RES, V9, P267; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	51	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5117	5126		10.1038/sj.onc.1205667	http://dx.doi.org/10.1038/sj.onc.1205667			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140762				2022-12-25	WOS:000176975900010
J	Kim, HS; Skurk, C; Thomas, SR; Bialik, A; Suhara, T; Kureishi, Y; Birnbaum, M; Keaney, JF; Walsh, K				Kim, HS; Skurk, C; Thomas, SR; Bialik, A; Suhara, T; Kureishi, Y; Birnbaum, M; Keaney, JF; Walsh, K			Regulation of angiogenesis by glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE AKT; TRANSCRIPTION FACTOR; GLUCOSE-METABOLISM; CELLS; EXPRESSION; 3-BETA; MIGRATION; MANNER; GSK3	Glycogen synthase kinase-3beta (GSK3beta) plays important roles in metabolism, embryonic development, and tumorigenesis. Here we investigated the role of GSK3beta signaling in vascular biology by examining its function in endothelial cells (ECs). In EC, the regulatory phosphorylation of GSK3beta,6 was found to be under the control of phosphoinositide 3-kinase-, MAPK-, and protein kinase A-dependent signaling pathways. The transduction of a nonphosphorylatable constitutively active mutant of GSKbeta promoted apoptosis under the conditions of prolonged serum deprivation or the disruption of eel matrix attachments. Conversely, the transduction of catalytically inactive GSK3beta promoted EC survival under the conditions of cellular stress. Under normal cell culture conditions, the activation of GSK3beta signaling inhibited the migration of EC to vascular endothelial growth factor or basic fibroblast growth factor. Angiogenesis was inhibited by GSK3beta activation in an in vivo Matrigel plug assay, whereas the inhibition of GSK3beta signaling enhanced capillary formation. These data suggest that GSK3beta functions at the nodal point of converging signaling pathways in EC to regulate vessel growth through its control of vascular cell migration and survival.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA	Boston University; Howard Hughes Medical Institute; University of Pennsylvania; Seoul National University (SNU); Seoul National University Hospital; St. Elizabeth's Medical Center; Tufts University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.		Kim, Hyo Soo/J-2753-2012; Bando, Yasuko K./M-4831-2014	Bando, Yasuko K./0000-0003-4166-6784; Keaney, John/0000-0002-0866-1837; Birnbaum, Morris/0000-0001-9972-8680	NHLBI NIH HHS [HL-50692] Funding Source: Medline; NIAMS NIH HHS [AR-40197] Funding Source: Medline; NIA NIH HHS [AG-15052, AG-17241] Funding Source: Medline; NICHD NIH HHS [HD-23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Duplaa C, 1999, CIRC RES, V84, P1433; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; PASSANITI A, 1992, LAB INVEST, V67, P519; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251	27	109	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41888	41896		10.1074/jbc.M206657200	http://dx.doi.org/10.1074/jbc.M206657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167628	hybrid			2022-12-25	WOS:000178985300076
J	Stahl, A; Moberg, P; Ytterberg, J; Panfilov, O; von Lowenhielm, HB; Nilsson, F; Glaser, E				Stahl, A; Moberg, P; Ytterberg, J; Panfilov, O; von Lowenhielm, HB; Nilsson, F; Glaser, E			Isolation and identification of a novel mitochondrial metalloprotease (PreP) that degrades targeting presequences in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; OPPOSITE MEMBRANE SURFACES; AAA PROTEASES; IMPORT MACHINERY; CATALYTIC SITES; INNER MEMBRANE; RAT-LIVER; DEGRADATION; COMPLEX; RESPIRATION	Most of the nuclear encoded mitochondrial precursor proteins contain an N-terminal extension called the presequence that carries targeting information and that is cleaved off after import into mitochondria. The presequences are amphiphilic, positively charged, membrane-interacting peptides with a propensity to form a-helices. Here we have investigated the proteolysis of the presequences that have been cleaved off inside mitochondria. A presequence derived from the overexpressed F(1)beta subunit of the ATP synthase and specific synthetic fluorescent peptides (Pep Tag Protease assay) have been shown to undergo rapid degradation catalyzed by a matrix located protease. We have developed a three-step chromatographic procedure including affinity and anion exchange chromatography for isolation of the protease from potato tuber mitochondria. Two-dimensional gel electrophoresis of the isolated proteolytically active fraction followed by electrospray ionization-mass spectrometry/mass spectrometry and data base searches allowed identification of the presequence peptide-degrading protease in Arabidopsis thaliana data base as a novel mitochondrial metalloendoprotease with a molecular mass of 105 kDa. The identified metalloprotease contains an inverted zinc-binding motif and belongs to the pitrilysin family.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; AstraZeneca R & D Molndal, Dept Biochem & Cell Biol, Res Area Cardiovasc Gastrointestinal, S-43183 Molndal, Sweden	Stockholm University; Cornell University; AstraZeneca	Glaser, E (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	e_glaser@dbb.su.se	Ytterberg, Anders/E-1773-2016	Ytterberg, Anders/0000-0002-1485-2314				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; Barakat S, 1998, PLANT MOL BIOL, V37, P141, DOI 10.1023/A:1005912831051; BRANDT U, 1993, J BIOL CHEM, V268, P8387; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; Deng KP, 1998, J BIOL CHEM, V273, P20752, DOI 10.1074/jbc.273.33.20752; Donate F, 2000, J BIOL CHEM, V275, P34147, DOI 10.1074/jbc.M004494200; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; DYCK LV, 1999, CELL MOL LIFE SCI, V30, P825; DYCK LV, 1998, GENE DEV, V15, P1515; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fluckiger S, 2002, J IMMUNOL, V168, P1267, DOI 10.4049/jimmunol.168.3.1267; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; Glaser E, 1999, J BIOENERG BIOMEMBR, V31, P259, DOI 10.1023/A:1005475930477; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; Goodfellow BJ, 2001, FEBS LETT, V505, P325, DOI 10.1016/S0014-5793(01)02818-6; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; HUGOSSON M, 1994, EUR J BIOCHEM, V223, P1027, DOI 10.1111/j.1432-1033.1994.tb19081.x; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kaiser R, 1999, ANAL BIOCHEM, V266, P1, DOI 10.1006/abio.1998.2945; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Klanner C, 2001, MOL BIOL CELL, V12, P2858, DOI 10.1091/mbc.12.9.2858; KUZELA S, 1994, METHOD ENZYMOL, V244, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lanne B, 2001, PROTEOMICS, V1, P819, DOI 10.1002/1615-9861(200107)1:7<819::AID-PROT819>3.3.CO;2-M; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leveque VJP, 2000, BIOCHEMISTRY-US, V39, P7131, DOI 10.1021/bi9929958; Lu Y, 1997, J BIOL CHEM, V272, P13555, DOI 10.1074/jbc.272.21.13555; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Meisinger C, 1999, CELL MOL LIFE SCI, V56, P817, DOI 10.1007/s000180050028; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; NICOLAY K, 1994, J BIOENERG BIOMEMBR, V26, P327, DOI 10.1007/BF00763104; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; ONO H, 1988, J BIOL CHEM, V263, P3188; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; PAVLOV P, 1999, BIOCHEM J, V1, P95; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rassow J, 2000, TRAFFIC, V1, P457, DOI 10.1034/j.1600-0854.2000.010603.x; RAWLINGS N, 1991, BIOCHEM J, V15, P389; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; RYAN CA, 1974, J BIOL CHEM, V249, P5495; SAGARRA MD, 1999, J MOL BIOL, V1, P819; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schneider G, 1998, PROTEINS, V30, P49, DOI 10.1002/(SICI)1097-0134(19980101)30:1<49::AID-PROT5>3.3.CO;2-P; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7; Stahl A, 2000, BIOCHEM J, V349, P703, DOI 10.1042/bj3490703; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Truscott KN, 2001, REV PHYSIOL BIOCH P, V143, P81, DOI 10.1007/BFb0115593; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P15297, DOI 10.1021/bi001774v; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; ZARDENETA G, 1992, J BIOL CHEM, V267, P24193; Zhang XP, 1999, J MOL BIOL, V288, P177, DOI 10.1006/jmbi.1999.2669; Zhang XP, 2002, TRENDS PLANT SCI, V7, P14, DOI 10.1016/S1360-1385(01)02180-X; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	75	99	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41931	41939		10.1074/jbc.M205500200	http://dx.doi.org/10.1074/jbc.M205500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12138166	hybrid			2022-12-25	WOS:000178985300081
J	Jung, H; Buchholz, M; Clausen, J; Nietschke, M; Revermann, A; Schmid, R; Jung, K				Jung, H; Buchholz, M; Clausen, J; Nietschke, M; Revermann, A; Schmid, R; Jung, K			CaiT of Escherichia coli, a new transporter catalyzing L-carnitine/gamma-butyrobetaine exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; GLYCINE BETAINE; CROTONOBETAINE REDUCTASE; MELIBIOSE PERMEASE; METABOLISM; PROTEINS; RECONSTITUTION; PURIFICATION; EXPRESSION; SYSTEM	L-Carnitine is essential for 6-oxidation of fatty acids in mitochondria. Bacterial metabolic pathways are used for the production of this medically important compound. Here, we report the first detailed functional characterization of the caiT gene product, a putative transport protein whose function is required for L-carnitine conversion in Escherichia coli. The caiT gene was overexpressed in E. coli, and the gene product was purified by affinity chromatography and reconstituted into proteoliposomes. Functional analyses with intact cells and proteoliposomes demonstrated that CaiT is able to catalyze the exchange of L-carnitine for gamma-butyrobetaine, the excreted end product of L-carnitine conversion in E. coli, and related betaines. Electrochemical ion gradients did not significantly stimulate L-carnitine uptake. Analysis of L-carnitine counterflow yielded an apparent external K. of 105 mum and a turnover number of 5.5 s(-1). Contrary to related proteins, CaiT activity was not modulated by osmotic stress. L-Carnitine binding to CaiT increased the protein fluorescence and caused a red shift in the emission maximum, an observation explained by ligand-induced conformational alterations. The fluorescence effect was specific for betaine structures, for which the distance between trimethylammonium and carboxyl groups proved to be crucial for affinity. Taken together, the results suggest that CaiT functions as an exchanger (antiporter) for L-carnitine and gamma-butyrobetaine according to the substrate/product antiport principle.	Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, Barbarastr 11, D-49069 Osnabruck, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; Buchet A, 1999, MOL MICROBIOL, V34, P562, DOI 10.1046/j.1365-2958.1999.01622.x; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EICHLER K, 1994, MOL MICROBIOL, V13, P775, DOI 10.1111/j.1365-2958.1994.tb00470.x; EICHLER K, 1994, J BACTERIOL, V176, P2970, DOI 10.1128/JB.176.10.2970-2975.1994; EICHLER K, 1995, J BASIC MICROB, V35, P217, DOI 10.1002/jobm.3620350404; Elssner T, 2000, BIOCHEMISTRY-US, V39, P10761, DOI 10.1021/bi000776c; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P231, DOI 10.1016/0005-2736(91)90235-Z; JUNG H, 1990, J BASIC MICROB, V30, P409, DOI 10.1002/jobm.3620300605; JUNG H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P270, DOI 10.1016/0005-2760(89)90232-4; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; JUNG H, 1990, J BASIC MICROB, V30, P507, DOI 10.1002/jobm.3620300711; Jung H, 1993, Adv Biochem Eng Biotechnol, V50, P21; JUNG K, 1987, J BASIC MICROB, V27, P131, DOI 10.1002/jobm.3620270303; Kappes RM, 1996, J BACTERIOL, V178, P5071, DOI 10.1128/jb.178.17.5071-5079.1996; Kleber HP, 1997, FEMS MICROBIOL LETT, V147, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MILLER JH, 1992, SHORT COURSE BACTERI, P102; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; Obon JM, 1999, APPL MICROBIOL BIOT, V51, P760, DOI 10.1007/s002530051459; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; Preusser A, 1999, BBA-PROTEIN STRUCT M, V1431, P166, DOI 10.1016/S0167-4838(99)00032-1; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROTH S, 1994, ANTON LEEUW INT J G, V65, P63, DOI 10.1007/BF00878280; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; SEIM H, 1980, Z ALLG MIKROBIOL, V20, P591, DOI 10.1002/jobm.3630200909; SEIM H, 1982, ACTA BIOL MED GER, V41, P1009; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Veenstra M, 2002, J MEMBRANE BIOL, V185, P249, DOI 10.1007/s00232-001-0127-9; Verheul A, 1998, J APPL MICROBIOL, V85, P1036, DOI 10.1111/j.1365-2672.1998.tb05269.x; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	43	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39251	39258		10.1074/jbc.M206319200	http://dx.doi.org/10.1074/jbc.M206319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163501	hybrid			2022-12-25	WOS:000178662500026
J	Liu, YQ; Jetton, TL; Leahy, JL				Liu, YQ; Jetton, TL; Leahy, JL			beta-cell adaptation to insulin resistance - Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE DEHYDROGENASE; GLUCOSE-REGULATED ANAPLEROSIS; PANCREATIC-ISLETS; ACID CYCLE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PHOSPHOFRUCTOKINASE ACTIVITY; MITOCHONDRIAL METABOLISM; GK RAT; SECRETION; OBESITY	The beta-cell biochemical mechanisms that account for the compensatory hyperfunction with insulin resistance (so-called beta-cell adaptation) are unknown. We investigated glucose metabolism in isolated islets from 10-12-week-old Zucker fatty (ZF) and Zucker lean (ZL) rats (results expressed per mg/islet of protein). ZF rats were obese, hyperlipidemic, and normoglycemic. They had a 3.8-fold increased beta-cell mass along with 3-10-fold increases in insulin secretion to various stimuli during pancreas perfusion despite insulin content per milligram of beta-cells being only one-third that of ZL rats. Islet glucose metabolism (utilization and oxidation) was 1.5-2-fold increased in the ZF islets despite pyruvate dehydrogenase activity being 30% lowered compared with the ZL islets. The reason was increased flux through pyruvate carboxylase (PC) and the malate-pyruvate and citrate-pyruvate shuttles based on the following observations (% ZL islets): increased V-max of PC (160%), malate dehydrogenase (170%), and malic enzyme (275%); elevated concentrations of oxaloacetate (150%), malate (250%), citrate (140%), and pyruvate (250%); and 2-fold increased release of malate from isolated mitochondria. Inhibition of PC by 5 mm phenylacetic acid markedly lowered glucose-induced insulin secretion in ZF and ZL islets. Thus, our results suggest that PC and the pyruvate shuttles are increased in ZF islets, and this accounts for glucose mitochondrial metabolism being increased when pyruvate dehydrogenase activity is reduced. As the anaplerosis pathways are implicated in glucose-induced insulin secretion and the synthesis of glucose-derived lipid and amino acids, our results highlight the potential importance of PC and the anaplerosis pathways in the enhanced insulin secretion and beta-cell growth that characterize beta-cell adaptation to insulin resistance.	Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Burlington, VT 05405 USA	University of Vermont	Leahy, JL (corresponding author), Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Given C331, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056818, R01DK056818] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56818] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; Brunzell JD, 1999, DIABETES CARE, V22, pC10; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Flamez D, 2002, DIABETES, V51, P2018, DOI 10.2337/diabetes.51.7.2018; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Hosokawa YA, 1997, DIABETES, V46, P808, DOI 10.2337/diabetes.46.5.808; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Laclau M, 2001, MOL CELL BIOCHEM, V225, P151, DOI 10.1023/A:1012238709063; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MacDonald MJ, 2002, METABOLISM, V51, P318, DOI 10.1053/meta.2002.29960; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Nicholls LI, 2002, BIOCHEM BIOPH RES CO, V291, P1081, DOI 10.1006/bbrc.2002.6567; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Ueda K, 1998, DIABETOLOGIA, V41, P649, DOI 10.1007/s001250050963; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; WEIR GC, 1974, J CLIN INVEST, V54, P1403, DOI 10.1172/JCI107887; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394; Zhou YP, 1999, METABOLISM, V48, P857, DOI 10.1016/S0026-0495(99)90219-6	47	125	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39163	39168		10.1074/jbc.M207157200	http://dx.doi.org/10.1074/jbc.M207157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12147706	hybrid			2022-12-25	WOS:000178662500015
J	Munshi, HG; Ghosh, S; Mukhopadhyay, S; Wu, YI; Sen, R; Green, KJ; Stack, MS				Munshi, HG; Ghosh, S; Mukhopadhyay, S; Wu, YI; Sen, R; Green, KJ; Stack, MS			Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; METALLOPROTEINASE EXPRESSION; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; ADHESION; ACTIVATION; CARCINOMA; MIGRATION; PROTEOLYSIS	The expression and activity of epithelial proteinases is under stringent control to prevent aberrant hydrolysis of structural proteins and disruption of tissue architecture. E-cadherin-dependent cell-cell adhesion is also important for maintenance of epithelial structural integrity, and loss of E-cadherin expression has been correlated with enhanced invasive potential in multiple tumor models. To address the hypothesis that there is a functional link between E-cadherin and proteinase expression, we have examined the role of E-cadherin in proteinase regulation. By using a calcium switch protocol to manipulate junction assembly, our data demonstrate that initiation of de novo E-cadherin-mediated adhesive contacts suppresses expression of both relative matrix metalloproteinase-9 levels and net urinary-type plasminogen activator activity. E-cadherin-mediated cell-cell adhesion increases both phosphatidylinositol W-kinase (PI3-kinase)-dependent AKT phosphorylation and epidermal growth factor receptor-dependent MAPK/ERK activation. Pharmacologic inhibition of the PI3-kinase pathway, but not the epidermal growth factor receptor/MAPK pathway, prevents E-cadherin-mediated suppression of proteinases and delays junction assembly. Moreover, inhibition of junction assembly with a function-blocking anti-E-cadherin antibody stimulates proteinase-dependent Matrigel invasion. As matrix metalloproteinase-9 and urinary-type plasminogen activator potentiate the invasive activity of oral squamous cell carcinoma, these data suggest E-cadherin-mediated signaling through PI3-kinase can regulate the invasive behavior of cells by modulating proteinase secretion.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pathol & Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA079447, R01CA085870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85870, T32 CA79447] Funding Source: Medline; NIDCR NIH HHS [DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Angst BD, 2001, J CELL SCI, V114, P629; Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Barker N, 2000, BIOESSAYS, V22, P961; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; FRIXEN UH, 1993, CANCER RES, V53, P3618; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Ghosh S, 2000, FIBRINOLYSIS PROTEOL, V14, P87, DOI 10.1054/fipr.2000.0060; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li G, 2001, CANCER RES, V61, P3819; Llorens A, 1998, LAB INVEST, V78, P1131; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luo J, 1999, CANCER RES, V59, P3552; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mignatti P, 2000, ADV CANCER RES, V78, P103; Miyaki M, 1995, ONCOGENE, V11, P2547; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noe V, 2001, J CELL SCI, V114, P111; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Parks WC, 1998, BIOL EXTRAC, P263; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Shinohara M, 2001, J BIOL CHEM, V276, P18941, DOI 10.1074/jbc.M100909200; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, BIOL EXTRAC, P115; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; YU H, 1990, CANCER RES, V50, P7623	58	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38159	38167		10.1074/jbc.M202384200	http://dx.doi.org/10.1074/jbc.M202384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138162	hybrid			2022-12-25	WOS:000178529600025
J	Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Febbraio, M; Hajjar, DP; Silverstein, RL; Hoff, HF; Salomon, RG; Hazen, SL				Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Febbraio, M; Hajjar, DP; Silverstein, RL; Hoff, HF; Salomon, RG; Hazen, SL			A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; INSULIN-RESISTANCE; FATTY-ACID; PPAR-GAMMA; IN-VITRO; LDL; EXPRESSION; METABOLISM; THROMBOSPONDIN-1	The macrophage scavenger receptor CD36 plays an important role in binding and uptake of oxidized forms of low-density lipoprotein (LDL), foam cell formation, and lesion development during atherosclerosis. The structural basis of CD36-lipoprotein ligand recognition is an area of intense interest. In a companion article we reported the characterization of a structurally conserved family of oxidized choline glycerophospholipids (oxPC(CD36)) that serve as novel high affinity ligands for cells stably transfected with CD36, mediating recognition of multiple oxidized forms of LDL (Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P., Shan, L., Gugiu, B., Fox, P. L., Hoff, H. F., Salomon, R. G., and Hazen, S. L. (July 8, 2002) J. Biol. Chem. 277, 10.1074/ jbc.M203318200). Here we use macrophages from wildtype and CD36 null mice to demonstrate that CD36 is the major receptor on macrophages mediating recognition of oxPC(CD36) species when presented (+/- plasma) in pure form, within PC bilayers in small unilamellar vesicles, and within liposomes generated from lipid extracts of native LDL. We also show that oxPC(CD36) promote CD36-dependent recognition when present at only a few molecules per particle, resulting in macrophage binding, uptake, metabolism, cholesterol accumulation, and foam cell formation. Finally, using high performance liquid chromatography with on-line electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS), we demonstrate that oxPC(CD36) are generated in vivo and are enriched in atherosclerotic lesions. Collectively, our data suggest that formation of this novel family of oxidized phospholipids participates in CD36-mediated recognition of oxidized lipoproteins and foam cell formation in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Prevent Cardiol Sect, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cornell University; Cornell University; University System of Ohio; Cleveland State University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.		Hazen, Stanley L/ABD-5845-2021; Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NHLBI NIH HHS [HL53315, HL62526, HL70621, HL61878] Funding Source: Medline; NIGMS NIH HHS [GM21249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315, R01HL070621, R01HL061878, R01HL062526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Colles SM, 1996, J LIPID RES, V37, P2018; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Hirano K, 1999, CIRC RES, V85, P108; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huh HY, 1996, BLOOD, V87, P2020; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZHANG R, 2002, BLOOD, V85, P950; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	34	303	333	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38517	38523		10.1074/jbc.M205924200	http://dx.doi.org/10.1074/jbc.M205924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145296	hybrid			2022-12-25	WOS:000178529600067
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Importance of Glu(282) in transmembrane segment M3 of the Na+,K+-ATPase for control of cation interaction and conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; TRANSPORT ADENOSINE-TRIPHOSPHATASE; NA,K-ATPASE ALPHA-SUBUNIT; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; COORDINATING RESIDUES; RENAL NA,K-ATPASE; BINDING POCKET; POTASSIUM-IONS	Glu(282) located in the NH2-terminal part of transmembrane helix M3 of the Na+,K+-ATPase was replaced by alanine, glycine, leucine, lysine, aspartate, or glutamine, and the effects of the mutations on the overall and partial reactions of the enzyme were analyzed. The mutations affected at least 3 important functions of the Na+,K+-ATPase: (i) the conformational transitions between E-1 and E-2 forms of dephospho- and phosphoenzyme, (ii) Na+ binding at the cytoplasmically facing sites of E-1, and (iii) long-range interaction controlling dephosphorylation. In mutants Glu(282) --> Lys and Glu(282) --> Asp, the E, form was favored during ATP hydrolysis, whereas the E-2 form was favored in Glu(282) --> Ala and Glu(282) --> Gly. Regardless of the change of conformational. equilibrium, all the mutants displayed a reduced apparent affinity for Na+, at least 3-fold for Glu(282) --> Lys and Glu(282) --> Asp, suggesting a direct effect on the Na+ binding properties of E-1. Glu(282) --> Ala and Glu(282) --> Gly exhibited an extraordinary high rate of ATP hydrolysis in the mere presence of Na+ without K+ ("Na+-ATPase activity"), because of an increased rate of dephosphorylation of E2P. These results are in accordance with the hypothesis that Glu(282) is involved in the communication between the cation binding pocket and the catalytic site and in control of the cytoplasmic entry pathway for Na+.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Toustrup-Jensen, Mads Schak/0000-0003-2064-5861				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HANSEN O, 1984, PHARMACOL REV, V36, P143; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; KUNKEL TA, 1985, P NATL ACAD SCI USA, V85, P3314; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Petrov VV, 2000, J BIOL CHEM, V275, P15709, DOI 10.1074/jbc.M000546200; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; Suzuki K, 1997, J GEN PHYSIOL, V109, P537, DOI 10.1085/jgp.109.5.537; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZHONGSEN Z, 2000, BIOCHEMISTRY-US, V39, P8758	40	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38607	38617		10.1074/jbc.M203665200	http://dx.doi.org/10.1074/jbc.M203665200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149251	hybrid			2022-12-25	WOS:000178529600078
J	Ilari, A; Ceci, P; Ferrari, D; Rossi, GL; Chiancone, E				Ilari, A; Ceci, P; Ferrari, D; Rossi, GL; Chiancone, E			Iron incorporation into Escherichia coli Dps gives rise to a ferritin-like microcrystalline core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; RELEASE	Escherichia coli Dps belongs to a family of bacterial stress-induced proteins to protect DNA from oxidative damage. It shares with Listeria innocua ferritin several structural features, such as the quaternary assemblage and the presence of an unusual ferroxidase center. Indeed, it was recently recognized to be able to oxidize and incorporate iron. Since ferritins are endowed with the unique capacity to direct iron deposition toward formation of a microcrystalline core, the structure of iron deposited in the E. coli Dps cavity was studied. Polarized single crystal absorption microspectrophotometry of iron-loaded Dps shows that iron ions are oriented. The spectral properties in the high spin 3d(5) configuration point to a crystal form with tetrahedral symmetry where the tetrahedron center is occupied by iron ions and the vertices by oxygen. Crystals of iron-loaded Dps also show that, as in mammalian ferritins, iron does not remain bound to the site after oxidation has taken place. The kinetics of the iron reduction/release process induced by dithionite were measured in the crystal and in solution. The reaction appears to have two phases, with t(1/2) of a few seconds and several minutes at neutral pH values, as in canonical ferritins. This behavior is attributed to a similar composition of the iron core.	Univ Roma La Sapienza, CNR, Ctr Studio Biol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Parma	Chiancone, E (corresponding author), Univ Roma La Sapienza, CNR, Ctr Studio Biol Mol, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/T-5501-2017; Ilari, Andrea/AAC-7670-2022	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Ceci, Pierpaolo/0000-0001-7712-8430; ferrari, davide/0000-0001-7084-6800				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; BOTHWELL TH, 1955, BIOCHEM J, V59, P599, DOI 10.1042/bj0590599; BOYD D, 1985, J BIOL CHEM, V260, P1755; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CLEGG GA, 1980, PROG BIOPHYS MOL BIO, V36, P53; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FUNK F, 1985, EUR J BIOCHEM, V152, P167, DOI 10.1111/j.1432-1033.1985.tb09177.x; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; HAGGIS GH, 1965, J MOL BIOL, V14, P598, DOI 10.1016/S0022-2836(65)80210-8; HALLIGAN BD, 1993, NUCLEIC ACIDS RES, V21, P5520, DOI 10.1093/nar/21.23.5520; Harrison P.M., 1989, IRON CARRIERS IRON P, P123; HARRISON PM, 1967, NATURE, V216, P1188, DOI 10.1038/2161188a0; Huang HQ, 1999, J PROTEIN CHEM, V18, P497, DOI 10.1023/A:1020653028685; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; MASSOVER WH, 1973, P NATL ACAD SCI USA, V70, P3847, DOI 10.1073/pnas.70.12.3847; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Richards TD, 1996, J INORG BIOCHEM, V61, P1, DOI 10.1016/0162-0134(95)00029-1; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; STEFANINI S, 1975, PROTEINS IRON STORAG, P295; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; TOWE KM, 1967, J COLLOID INTERF SCI, V24, P384, DOI 10.1016/0021-9797(67)90266-4; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; WEBB J, 1974, BIOCHIM BIOPHYS ACTA, V351, P224, DOI 10.1016/0005-2795(74)90184-6; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	28	111	116	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37619	37623		10.1074/jbc.M206186200	http://dx.doi.org/10.1074/jbc.M206186200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163499	hybrid			2022-12-25	WOS:000178447100091
J	Liu, LP; Pegg, AE; Williams, KM; Guengerich, FP				Liu, LP; Pegg, AE; Williams, KM; Guengerich, FP			Paradoxical enhancement of the toxicity of 1,2-dibromoethane by O-6-alkylguanine-DNA alkyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-ADDUCTS S-<2-(N-7-GUANYL)ETHYL>GLUTATHIONE; MAMMALIAN GLUTATHIONE TRANSFERASES; ESCHERICHIA-COLI; ETHYLENE DIBROMIDE; ALKYLATING-AGENTS; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASES; REPAIR METHYLTRANSFERASES; EXCISION-REPAIR; VINYL-CHLORIDE; CONJUGATION	The presence of the DNA repair protein O-6-alkylguanine-DNA alkyltransferase (AGT) paradoxically increases the mutagenicity and cytotoxicity of 1,2-dibromoethane (DBE) in Escherichia coli. This enhancement of genotoxicity did not occur when the inactive C145A mutant of human AGT (hAGT) was used. Also, hAGT did not enhance the genotoxicity of S-(2-haloethyl)glutathiones that mimic the reactive product of the reaction of DBE with glutathione, which is catalyzed by glutathione S-transferase. These experiments support a mechanism by which hAGT activates DBE. Studies in vitro showed a direct reaction between purified recombinant hAGT and DBE resulting in a loss of AGT repair activity and a formation of an hAGT-DBE conjugate at Cys(145). A 2-hydroxyethyl adduct was found by mass spectrometry to be present in the Gly(136)-Arg(147) peptide from tryptic digests of AGT reacted with DBE. Incubation of AGT with DBE and oligodeoxyribonucleotides led to the formation of covalent AGT-oligonucleotide complexes. These results indicate that DBE reacts at the active site of AGT to generate an S-(2-bromoethyl) intermediate, which forms a highly reactive half-mustard at Cys(145). In the presence of DNA, the DNA-binding function of AGT facilitates formation of DNA adducts. In the absence of DNA, the intermediate undergoes hydrolytic decomposition to form AGT-Cys(145)-SCH2CH2OH.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University; Vanderbilt University	Pegg, AE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, RM C4739B,POB 850,500 Univ Dr, Hershey, PA 17033 USA.		Williams, Kevin/C-3804-2011	Williams, Kevin/0000-0003-4019-8528	NCI NIH HHS [R01-CA18137] Funding Source: Medline; NIEHS NIH HHS [R01-ES10546, P30ES00267, T32-ES07028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010546, T32ES007028, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abril N, 1997, CARCINOGENESIS, V18, P1883, DOI 10.1093/carcin/18.10.1883; Abril N, 2001, MUTAT RES-GEN TOX EN, V497, P111, DOI 10.1016/S1383-5718(01)00235-2; ABRIL N, 1995, MOL CARCINOGEN, V12, P110, DOI 10.1002/mc.2940120208; Abril N, 1999, CARCINOGENESIS, V20, P2089, DOI 10.1093/carcin/20.11.2089; Abril N, 1999, CHEM RES TOXICOL, V12, P544, DOI 10.1021/tx980250h; Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Edara S, 1999, CARCINOGENESIS, V20, P103, DOI 10.1093/carcin/20.1.103; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; GONZAGA PE, 1992, CANCER RES, V52, P6052; GONZAGA PE, 1990, NUCLEIC ACIDS RES, V18, P3961, DOI 10.1093/nar/18.13.3961; Goodtzova K, 1997, J BIOL CHEM, V272, P8332, DOI 10.1074/jbc.272.13.8332; GUENGERICH FP, 1994, CHEM RES TOXICOL, V7, P205, DOI 10.1021/tx00038a014; GUENGERICH FP, 1981, CANCER RES, V41, P4391; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, CHEM RES TOXICOL, V5, P2, DOI 10.1021/tx00025a001; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; Kim MS, 1997, CHEM RES TOXICOL, V10, P1133, DOI 10.1021/tx9701081; LETZ GA, 1984, JAMA-J AM MED ASSOC, V252, P2428, DOI 10.1001/jama.252.17.2428; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu H, 2000, MUTAT RES-FUND MOL M, V452, P1, DOI 10.1016/S0027-5107(00)00062-2; Liu LP, 2002, CANCER RES, V62, P3037; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; Ozaki K, 1998, CANCER RES, V58, P3806; OZAKI K, 1993, JPN J CANCER RES, V84, P1245, DOI 10.1111/j.1349-7006.1993.tb02829.x; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; OZAWA N, 1983, TOXICOLOGIST, V3, P114; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pieper RO, 1997, PHARMACOL THERAPEUT, V74, P285, DOI 10.1016/S0163-7258(97)00003-X; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Sekiguchi M, 1996, J CANCER RES CLIN, V122, P199, DOI 10.1007/BF01209646; Sekiguchi M, 1997, JPN J HUM GENET, V42, P389, DOI 10.1007/BF02766939; VANBLADEREN PJ, 1981, BIOCHEM PHARMACOL, V30, P2499, DOI 10.1016/0006-2952(81)90352-X; VANBLADEREN PJ, 1980, BIOCHEM PHARMACOL, V29, P2975, DOI 10.1016/0006-2952(80)90047-7; Wang LJ, 1997, CHEM RES TOXICOL, V10, P562, DOI 10.1021/tx9602067; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1107, DOI 10.1021/tx0100183; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1118, DOI 10.1021/tx010019v; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Xu-Welliver M, 1998, CANCER RES, V58, P1936; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823	47	43	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37920	37928		10.1074/jbc.M205548200	http://dx.doi.org/10.1074/jbc.M205548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151404	hybrid			2022-12-25	WOS:000178447100129
J	Sato, K; Yomogida, K; Wada, T; Yorihuzi, T; Nishimune, Y; Hosokawa, N; Nagata, K				Sato, K; Yomogida, K; Wada, T; Yorihuzi, T; Nishimune, Y; Hosokawa, N; Nagata, K			Type XXVI collagen, a new member of the collagen family, is specifically expressed in the testis and ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEIN HSP47; MOLECULAR CHAPERONE HSP47; TRIPLE-HELIX; PROCOLLAGEN; DOMAIN; BIOSYNTHESIS; REQUIREMENTS; RECOGNITION; SEQUENCE; DISEASES	HSP47 is a collagen-specific molecular chaperone that specifically recognizes and binds to the triple helical domain of various types of collagens. Here we report the cloning of the entire coding region of a novel collagen-like protein by yeast two-hybrid screening of a 17.5-day whole mouse embryo cDNA library using HSP47 as a bait. The cDNA of this protein and its deduced amino acid sequence are 2,690 bp and 438 amino acids long, respectively. The protein contains two clusters of Gly-X-Y collagenous repeats and three noncollagenous domains. Northern blot analysis showed that its mRNA is specifically expressed in the testis and ovary in adult tissues and that expression in these tissues is highest in the neonate. Biochemical characterization of this protein revealed that its proline residues are hydroxylated, it undergoes N-linked glycosylation, it forms trimers, and it is secreted in vitro. Immunohistochemical studies showed that the myoid cells and the pre-theca cells synthesized it in the testis and ovary, respectively, resulting in the accumulation of this protein in the extracellular spaces of these organs. these observations suggest that this protein is a new member of the collagen protein family. We thus designated this protein as type XXVI collagen.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Osaka Univ, Dept Sci Lab Anim Expt, Microbial Dis Res Inst, Suita, Osaka 565, Japan	Kyoto University; Osaka University	Nagata, K (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan.	nagata@frontier.kyoto-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; Gordon MK, 2000, INVEST OPHTH VIS SCI, V41, pS752; GORDON MK, 2002, IN PRESS INVEST OPHT; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; Kadler KE, 1996, BIOCHEM J, V316, P1; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sumiyoshi H, 1997, J BIOL CHEM, V272, P17104, DOI 10.1074/jbc.272.27.17104; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tuckwell D, 2002, MATRIX BIOL, V21, P63, DOI 10.1016/S0945-053X(01)00176-7	31	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37678	37684		10.1074/jbc.M205347200	http://dx.doi.org/10.1074/jbc.M205347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145293	hybrid			2022-12-25	WOS:000178447100099
J	Smith, TK; Crossman, A; Paterson, MJ; Borissow, CN; Brimacombe, JS; Ferguson, MAJ				Smith, TK; Crossman, A; Paterson, MJ; Borissow, CN; Brimacombe, JS; Ferguson, MAJ			Specificities of enzymes of glycosylphosphatidylinositol biosynthesis in trypanosoma brucei and HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; INOSITOL-ACYLATION; MEMBRANE ANCHOR; PLASMODIUM-FALCIPARUM; SUBSTRATE-ANALOGS; TOXOPLASMA-GONDII; D-GLUCOSAMINYLPHOSPHATIDYLINOSITOL; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; PARASITIC PROTOZOA; GPI BIOSYNTHESIS	A series of synthetic analogues Of D-GlcNalpha1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol, consisting of 22 variants of the D-GlcN or lipid components, were tested in trypanosomal and human (HeLa) cell-free systems. The assays measured the abilities of the analogues to act as substrates or inhibitors of the enzymes of glycosylphosphatidylinositol biosynthesis downstream of GlcNAc-phosphatidylinositol (GlcNAc-PI) de-N-acetylase. One compound, 4-deoxy-D-GlcNalpha1-6-D-myo-inositol-1-HP04-Sn-1,2-dipalmitoylglycerol, proved to be an inhibitor of both the trypanosomal and HeLa pathways, whereas 4-O-methyl-D-GlcNalpha1-6-D-myo-inositol-1-HPO(4)sn-1,2-dipalmitoylglycerol and the 4'-epimer, D-GalN-alpha1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol, were neither substrates nor inhibitors. The results with other analogues showed that the 6-OH of the alpha-D-GlcN residue is not required for substrate recognition in the trypanosomal and human pathways, whereas the 3-OH group is essential for both. Parasite-specific recognition of the P-linked analogue D-GlcNbeta1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol is striking. This suggests that, like the GlcNAc-PI de-N-acetylase, the trypanosomal glycosylphosphatidylinositol alpha-mannosyltransferases, inositol acyltransferse and ethanolamine phosphate transferase, do not recognize the 2-, 3-, 4-, and 5-OH groups of the D-myo-inositol residue, whereas the human inositol acyltransferase and/or first alpha-mannosyltransferase recognizes one or more of these groups. All of the various lipid analogues tested served as substrates in both the trypanosomal and HeLa cell-free systems, suggesting that a precise lipid structure and stereochemistry are not essential for substrate recognition. However, an analogue containing a single C18:0 alkyl chain in place of sn-1,2-dipalmitoylglycerol proved to be a better substrate in the trypanosomal than in the HeLa cell-free system. These findings should have a bearing on the design of future generations of specific inhibitors of the trypanosomal glycosylphosphatidylinositol biosynthetic pathway.	Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dundee DD1 5EH, Scotland.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714				Borissow CN, 2001, TETRAHEDRON LETT, V42, P121, DOI 10.1016/S0040-4039(00)01901-8; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COTTAZ S, 1993, J CHEM SOC P1, P945; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Crossman A, 1999, CARBOHYD RES, V321, P42, DOI 10.1016/S0008-6215(99)00170-6; Dix AP, 2001, TETRAHEDRON LETT, V42, P117, DOI 10.1016/S0040-4039(00)01900-6; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Franzot SP, 1999, BIOCHEM J, V340, P25, DOI 10.1042/0264-6021:3400025; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; Morita Y. S., 2000, OLIGOSACCHARIDES CHE, P417; Morita YS, 2000, J BIOL CHEM, V275, P14147, DOI 10.1074/jbc.275.19.14147; Morita YS, 2001, MOL BIOCHEM PARASIT, V115, P157, DOI 10.1016/S0166-6851(01)00279-1; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; PUOTI A, 1993, J BIOL CHEM, V268, P7215; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SINGH BN, 1994, ARCH BIOCHEM BIOPHYS, V309, P273, DOI 10.1006/abbi.1994.1113; Smith TK, 1997, BIOCHEM J, V326, P393, DOI 10.1042/bj3260393; Smith TK, 2000, BIOCHEMISTRY-US, V39, P11801, DOI 10.1021/bi000854w; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; Smith TK, 1999, EMBO J, V18, P5922, DOI 10.1093/emboj/18.21.5922; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; Striepen B, 1999, BIOCHEMISTRY-US, V38, P1478, DOI 10.1021/bi981884q; Striepen B, 1997, J MOL BIOL, V266, P797, DOI 10.1006/jmbi.1996.0806; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; YE J, 1996, BIOORG MED CHEM LETT, V14, P1715; Zinecker CF, 2001, MOL BIOCHEM PARASIT, V116, P127, DOI 10.1016/S0166-6851(01)00313-9	52	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37147	37153		10.1074/jbc.M203371200	http://dx.doi.org/10.1074/jbc.M203371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147686	hybrid			2022-12-25	WOS:000178447100032
J	Bultel-Brienne, S; Lestavel, S; Pilon, A; Laffont, I; Tailleux, A; Fruchart, JC; Siest, G; Clavey, V				Bultel-Brienne, S; Lestavel, S; Pilon, A; Laffont, I; Tailleux, A; Fruchart, JC; Siest, G; Clavey, V			Lipid free apolipoprotein E binds to the class B type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; HIGH-AFFINITY RECEPTOR; APOE-DEFICIENT MICE; SELECTIVE UPTAKE; CELL-SURFACE; HEPATIC LIPASE; A-I; ADRENOCORTICAL-CELLS; HDL RECEPTOR	The Class B type I scavenger receptor I (SR-BI) is a physiologically relevant high density lipoprotein (HDL) receptor that can mediate selective cholesteryl ester (CE) uptake by cells. Direct interaction of apolipoprotein E (apoE) with this receptor has never been demonstrated, and its implication in CE uptake is still controversial. By using a human adrenal cell line (NCI-H295R), we have addressed the role of apoE in binding to SR-BI and in selective CE uptake from lipoproteins to cells. This dell line does not secrete apoE and SR-BI is its major HDL-binding protein. We can now provide evidence that 1) free apoE is a ligand for SR-BI, 2) apoE associated to lipids or in lipoproteins does not modulate binding or CE-selective uptake by the SR-BI pathway, and 3) the direct interaction of free apoE to SR-BI leads to an increase in CE uptake from lipoproteins of both low and high densities. We propose that this direct interaction could modify SR-BI structure in cell membranes and potentiate CE uptake.	Univ Lille 2, Inst Pasteur, INSERM U545, Fac Pharm, F-59019 Lille, France; Univ Nancy 1, Fac Pharm, Ctr Medicament, INSERM U525,Equipe 4, F-54000 Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Clavey, V (corresponding author), Fac Sci Pharmaceut & Biol, INSERM U545, 3 Rue Prof Laguesse,BP 83, F-59006 Lille, France.		TAILLEUX, Anne/R-5530-2018; Lestavel, Sophie/B-4658-2017	TAILLEUX, Anne/0000-0003-1430-2627; Lestavel, Sophie/0000-0001-7839-4757; SIEST, Gerard/0000-0002-3001-760X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Amar MJA, 1998, J LIPID RES, V39, P2436; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Boisvert WA, 1999, J LIPID RES, V40, P806; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY WA, 1982, BIOCHEM BIOPH RES CO, V109, P1360, DOI 10.1016/0006-291X(82)91927-1; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P524, DOI 10.1021/bi9819778; Calvo D, 1998, J LIPID RES, V39, P777; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; Collet X, 1999, J LIPID RES, V40, P1185; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUM DW, 1993, CLIN CHEM, V39, P333; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jolivalt C, 2000, FREE RADICAL BIO MED, V28, P129, DOI 10.1016/S0891-5849(99)00232-4; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEROY A, 1988, J IMMUNOASSAY, V9, P309, DOI 10.1080/01971528808053219; Li XP, 2002, J BIOL CHEM, V277, P21149, DOI 10.1074/jbc.M200658200; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maurer AM, 1996, J LAB CLIN MED, V127, P382, DOI 10.1016/S0022-2143(96)90186-9; MAZZONE T, 1994, J LIPID RES, V35, P1345; MULDER M, 1993, J BIOL CHEM, V268, P9369; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; RALL SC, 1986, METHOD ENZYMOL, V128, P273; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1990, BIOCHIM BIOPHYS ACTA, V1043, P318, DOI 10.1016/0005-2760(90)90033-T; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; von Eckardstein A, 2000, CURR OPIN CARDIOL, V15, P348, DOI 10.1097/00001573-200009000-00007; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WILLIAMS DL, 1995, J LIPID RES, V36, P745; Xu SZ, 1997, J LIPID RES, V38, P1289	61	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36092	36099		10.1074/jbc.M201943200	http://dx.doi.org/10.1074/jbc.M201943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138091	hybrid			2022-12-25	WOS:000178275100043
J	Derand, R; Bulteau-Pignoux, L; Becq, F				Derand, R; Bulteau-Pignoux, L; Becq, F			The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; ATPASE ACTIVITY; CL CHANNEL; PHOSPHORYLATION; ACTIVATION; PROTEIN; HYDROLYSIS; MECHANISMS; CELLS	Loss of cystic fibrosis transmembrane conductance regulator (CFTR) channel activity explains most of the manifestations of the cystic fibrosis (CF) disease. To understand the consequences of CF mutations on CFTR channel activity, we compared the pharmacological properties of wild-type (wt) and G551D-CFTR. Dose-dependent relationships of wt-CFTR activated by genistein follows a non-Michaelis-Menten behavior consistent with the presence of two binding sites. With phosphorylated CFTR, a high affinity site for genistein is the activator (K-s approximate to 3 muM), whereas a second site of low affinity (K-i approximate to 75 muM) is the inhibitor. With non-phosphorylated CFTR, K-s was increased (K-s approximate to 12 muM), but K, was not affected (K-i approximate to 70 muM). In G551D-CFTR cells, channel activity was recovered by co-application of forskolin and genistein in a dose-dependent manner. A further stimulation of G551D-CFTR channel activity was measured at concentrations from 30 pm to 1 mm. The dose response is described by a classical Michaelis-Menten kinetics with only a single apparent site (K-m approximate to 11 muM). Our results suggest glycine 551 in NBD1 as an important location within the low affinity inhibitory site for genistein and offers new evidence for pharmacological alteration caused by an NBD1 mutation of CFTR. This study also reveals how a mutation of an ion channel converts a non-Michaelis-Menten behavior (two binding sites) into a classical Michaelis-Menten model (one binding site).	Univ Poitiers, LBSC, CNRS, UMR 6558, F-86022 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, LBSC, CNRS, UMR 6558, 40 Ave Recteur Pineau, F-86022 Poitiers, France.		Becq, Frederic/P-9233-2016	Becq, Frederic/0000-0003-3915-0973				BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; Bronnikov GE, 1999, J BIOL CHEM, V274, P37770, DOI 10.1074/jbc.274.53.37770; Bulteau L, 2000, AM J PHYSIOL-CELL PH, V279, pC1925, DOI 10.1152/ajpcell.2000.279.6.C1925; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Derand R, 2001, AM J PHYSIOL-CELL PH, V281, pC1657, DOI 10.1152/ajpcell.2001.281.5.C1657; GABSDY DC, 1999, PHYSIOL REV, V79, pS78; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Illek B, 1999, AM J PHYSIOL-CELL PH, V277, pC833, DOI 10.1152/ajpcell.1999.277.4.C833; Johnen G, 1995, P NATL ACAD SCI USA, V92, P12384, DOI 10.1073/pnas.92.26.12384; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Leung GPH, 2000, BIOL REPROD, V62, P143, DOI 10.1095/biolreprod62.1.143; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; LOGAN J, 1994, J CLIN INVEST, V94, P228, DOI 10.1172/JCI117311; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; McAndrew RS, 1998, BBA-LIPID LIPID MET, V1390, P21, DOI 10.1016/S0005-2760(97)00166-5; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Obayashi K, 1999, PFLUG ARCH EUR J PHY, V438, P269, DOI 10.1007/s004240050909; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Reenstra WW, 1996, AM J PHYSIOL-CELL PH, V271, pC650, DOI 10.1152/ajpcell.1996.271.2.C650; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6; Schultz BD, 1999, PHYSL REV S, V79, P109; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; 1983, BIOCH J, V213, P561	33	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35999	36004		10.1074/jbc.M206121200	http://dx.doi.org/10.1074/jbc.M206121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124395	hybrid			2022-12-25	WOS:000178275100030
J	Yang, BX; Verkman, AS				Yang, BX; Verkman, AS			Analysis of double knockout mice lacking aquaporin-1 and urea transporter UT-B - Evidence for UT-B-facilitated water transport in erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; URINARY CONCENTRATING ABILITY; NULL MICE; REFLECTION COEFFICIENT; SLC14A2 GENE; PERMEABILITY; CLONING; PROTEIN; CHANNEL; MEMBRANE	We reported increased water permeability and a low urea reflection coefficient in Xenopus oocytes expressing urea transporter UT-B (former name UT3), suggesting that water and urea share a common aqueous pathway (Yang, B., and Verkman, A. S. (1998) J. Biol. Chem. 273, 9369-9372). Although increased water permeability was confirmed in the Xenopus oocyte expression system, it has been argued (Sidoux-Walter, F., Lucien, N., Olives, B., Gobin, R., Rousselet, G., Kamsteeg, E. J., Ripoche, P., Deen, P. M., Cartron, J. P., and Bailly, P. (1999) J. Biol. Chem. 274, 30228-30235) that UT-B does not transport water when expressed at normal levels in mammalian cells such as erythrocytes. To quantify UT-B-mediated water transport, we generated double knockout mice lacking UT-B and the major erythrocyte water channel, aquaporin-1 (AQP1). The mice had reduced survival, retarded growth, and defective urinary concentrating ability. However, erythrocyte size and morphology were not affected. Stopped-flow light scattering measurements indicated erythrocyte osmotic water permeabilities (in cm/s x 0.01, 10degreesC): 2.1 +/- 0.2 (wild-type mice), 2.1 +/- 0.05 (UT-B null), 0.19 +/- 0.02 (AQP1 null), and 0.045 +/- 0.009 (AQP1/UT-B null). The low water permeability found in AQP1/UT-B null erythrocytes was also seen after HgCl2 treatment of UT-B null erythrocytes or phloretin treatment of AQP1 null erythrocytes. The apparent activation energy for UT-B-mediated water transport was low, <2 kcal/mol. Estimating 14,000 UT-B molecules per mouse erythrocyte, the UT-B-dependent P-f Of 0.15 X 10(-4) cm/s indicated a substantial single channel water permeability of UT-B of 7.5 x 10(-14) cm(3)/s, similar to that of AQP1. These results provide direct functional evidence for UT-B-facilitated water transport in erythrocytes and suggest that urea traverses an aqueous pore in the UT-B protein.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yang, BX (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL60288, HL58198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CHASAN B, 1985, BIOCHIM BIOPHYS ACTA, V821, P56, DOI 10.1016/0005-2736(85)90152-X; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DIX JA, 1984, BIOCHIM BIOPHYS ACTA, V773, P219, DOI 10.1016/0005-2736(84)90085-3; EDWARDSMOULDS J, 1988, VOX SANG, V55, P181, DOI 10.1111/j.1423-0410.1988.tb05089.x; Fenton RA, 2002, AM J PHYSIOL-RENAL, V282, pF630, DOI 10.1152/ajprenal.00264.2001; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; LEVITT DG, 1983, J GEN PHYSIOL, V81, P239, DOI 10.1085/jgp.81.2.239; Lucien N, 2002, J BIOL CHEM, V277, P34101, DOI 10.1074/jbc.M205073200; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACEY RI, 1984, AM J PHYSIOL, V246, P195; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; Nakayama Y, 2001, BBA-GENE STRUCT EXPR, V1518, P19, DOI 10.1016/S0167-4781(00)00311-0; OLIVES B, 1994, J BIOL CHEM, V269, P31649; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Timmer RT, 2001, AM J PHYSIOL-CELL PH, V281, pC1318, DOI 10.1152/ajpcell.2001.281.4.C1318; Toon MR, 1996, J MEMBRANE BIOL, V153, P137, DOI 10.1007/s002329900117; TRINHTRANGTAN MM, 2002, IN PRESS AM J PHYSL; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF1030, DOI 10.1152/ajprenal.2000.278.6.F1030; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 2002, EXP NEPHROL, V10, P235; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	40	97	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36782	36786		10.1074/jbc.M206948200	http://dx.doi.org/10.1074/jbc.M206948200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133842				2022-12-25	WOS:000178275100128
J	Du, XY; Clemetson, JM; Navdaev, A; Magnenat, EM; Wells, TNC; Clemetson, KJ				Du, XY; Clemetson, JM; Navdaev, A; Magnenat, EM; Wells, TNC; Clemetson, KJ			Ophioluxin, a convulxin-like C-type lectin from Ophiophagus hannah (King cobra) is a powerful platelet activator via glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; VON-WILLEBRAND-FACTOR; AMINO-ACID-SEQUENCE; MALAYAN PIT VIPER; COLLAGEN RECEPTOR; SNAKE-VENOM; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); PHOSPHOLIPASE C-GAMMA-2; BETA-SUBUNIT	Ophioluxin, a potent platelet agonist, was purified from the venom of Ophiophagus hannah (King cobra). Under nonreducing conditions it has a mass of 85 kDa, similar to convulxin, and on reduction gives two subunits with masses of 16 and 17 kDa, slightly larger than those of convulxin. The N-terminal sequences of both subunits are very similar to those of convulxin and other C-type lectins. Ophioluxin induces a pattern of tyrosine-phosphorylated proteins in platelets like that caused by convulxin, when using appropriate concentrations based on aggregation response, because it is about 2-4 times more powerful as agonist than the latter. Ophioluxin and convulxin induce [Ca2+](i) elevation both in platelets and in Dami megakaryocytic cells, and each of these C-type lectins desensitizes responses to the other. Convulxin agglutinates fixed platelets at 2 mug/ml, whereas ophioluxin does not, even at 80 mug/ml. Ophioluxin resembles convulxin more than echicetin or alboaggregin B because polyclonal anti-ophioluxin antibodies recognize both ophioluxin and convulxin, but not echicetin, and platelets adhere to and spread on ophioluxin- or convulxin-precoated surfaces in the same way that is clearly different from their behavior on an alboaggregin B surface. Immobilized ophioluxin was used to isolate the glycoprotein VI-Fcgamma complex from resting platelets, which also contained Fyn, Lyn, Syk, LAT, and SLP76. Ophioluxin is the first multiheterodimeric, convulxin-like snake C-type lectin, as well as the first platelet agonist, to be described from the Elapidae snake family.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Serono Pharmaceut Res Inst SA, CH-1228 Geneva, Switzerland	University of Bern	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.			Wells, Timothy/0000-0001-9796-847X				Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Andrews RK, 2000, TOXICON, V38, P775, DOI 10.1016/S0041-0101(99)00187-7; ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Chiang TM, 1997, J CLIN INVEST, V100, P2079, DOI 10.1172/JCI119741; Chung CH, 2001, BIOCHEM BIOPH RES CO, V285, P689, DOI 10.1006/bbrc.2001.5228; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 1998, PLATELETS, V9, P165, DOI 10.1080/09537109876636; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Clemetson KJ, 2001, HAEMOSTASIS, V31, P148; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Du XY, 2002, THROMB HAEMOSTASIS, V87, P692, DOI 10.1055/s-0037-1613067; Du XY, 2001, THROMB HAEMOSTASIS, V86, P1277, DOI 10.1055/s-0037-1616062; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Hamako J, 1996, BIOCHEM BIOPH RES CO, V226, P273, DOI 10.1006/bbrc.1996.1345; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; KIRBY EP, 1975, J CLIN INVEST, V56, P491, DOI 10.1172/JCI108116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAS G, 1985, BIOCHIMIE, V67, P1231, DOI 10.1016/S0300-9084(85)80132-2; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; PENG ML, 1991, BIOCHEMISTRY-US, V30, P11529, DOI 10.1021/bi00113a007; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; PENG ML, 1993, BLOOD, V81, P2321; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Polgar J, 1997, BIOCHEM J, V323, P533, DOI 10.1042/bj3230533; RUAN CG, 1987, BLOOD, V69, P570; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Tsai IH, 2001, ARCH BIOCHEM BIOPHYS, V394, P236, DOI 10.1006/abbi.2001.2524; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	50	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35124	35132		10.1074/jbc.M204372200	http://dx.doi.org/10.1074/jbc.M204372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130642	hybrid			2022-12-25	WOS:000178117000060
J	Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE				Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE			Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G(1) arrest associated with induction of p16ink4a and activation of RB	ONCOGENE			English	Article						rhabdoid; SWI/SNF; hSNF5/INI1/BAF47; RB; p16ink4a	SENESCENT HUMAN FIBROBLASTS; SWI-SNF COMPLEX; CHROMATIN-REMODELING COMPLEXES; HUMAN-DIPLOID FIBROBLASTS; MALIGNANT RHABDOID TUMOR; RETINOBLASTOMA-PROTEIN; CELLULAR SENESCENCE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; REPLICATIVE SENESCENCE	Truncating mutations and homozygous deletions in the hSNF5/INI1/BAF47 subunit of human SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies. How loss of hSNF5 contributes to tumorigenesis remains unknown. Because the SWI/ SNF subunit BRG1 is required for RB-mediated cell cycle arrest, we hypothesized that hSNF5 deficiency disrupts RB signaling. Here we demonstrate that unlike BRG1, hSNF5 deficient cells retain functional RB since ectopic expression of either p16ink4a or a constitutively active form of RB (PSM - RB) led to cell cycle arrest. To determine how hSNF5 loss might contribute to tumorigenesis, we used a retrovirus to introduce hSNF5 into multiple deficient cell lines. In all cases, re-expression inhibited colony formation and induced cell cycle arrest characterized by a flattened morphology. Flow cytometry revealed that these cells accumulated in G(0)/G(1). Importantly, arrested cells exhibited strong induction of p16ink4a, hypophosphorylated RB, and down-regulation of cyclin A, suggesting that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t abolished hSNF5-induced G(1) arrest and activation of RB. Likewise, HPV-16 E7 was sufficient to partially overcome cell cycle arrest. These results suggest that hSNF5 loss is not equivalent to BRG1/BRM loss in human tumor cell lines. Furthermore, hSNF5-induced cell cycle arrest of deficient cells is mediated in part through activation of p16ink4a expression. These findings provide insight into mechanisms of hSNF5-mediated tumor suppression.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati	Weissman, BE (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA091048, R01CA082525, T32CA071341] Funding Source: NIH RePORTER; NCI NIH HHS [CA82525, CA71341, CA91048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jiang H, 2000, ONCOGENE, V19, P3878, DOI 10.1038/sj.onc.1203722; KARNES PS, 1991, CANCER GENET CYTOGEN, V56, P31, DOI 10.1016/0165-4608(91)90359-3; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; ROBBINS E, 1970, J EXP MED, V131, P1211, DOI 10.1084/jem.131.6.1211; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Suzuki A, 1997, DIAGN MOL PATHOL, V6, P326, DOI 10.1097/00019606-199712000-00004; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	82	155	163	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5193	5203		10.1038/sj.onc.1205706	http://dx.doi.org/10.1038/sj.onc.1205706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149641				2022-12-25	WOS:000177193900001
J	Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G				Tari, AM; Lim, SJ; Hung, MC; Esteva, FJ; Lopez-Berestein, G			Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells	ONCOGENE			English	Article						HER2/neu; ATRA; Grb2; Akt	GROWTH-FACTOR RECEPTOR; TUMOR NECROSIS FACTOR; GRB2 DOWN-REGULATION; PROTEIN-KINASE-B; MCF-7 CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ALPHA GENE; RAR-ALPHA; INHIBITION	We observed that all-trans retinoic acid (ATRA) inhibited the growth of MCF-7 breast cancer cells, but not those transfected with HER2/NEU or its transactivating ligand HEREGULIN. This suggests that Her2/neu causes breast cancer cells to be resistant to the growth inhibitory effects of ATRA. To confirm this observation, MDA-MB-453 and BT-474 cells, which have high levels of Her2/neu and are resistant to ATRA, were incubated with the trastuzumab (Herceptin(TM)) antibody so that we could determine whether inhibition of the expression and function of Her2/neu would resensitize these cells to ATRA. Indeed, we found that MDA-MB-453 and BT-474 cells treated with trastuzumab were growth inhibitory by ATRA. We then determined whether Her2/neu uses Grb2 and Akt proteins to induce ATRA resistance. Liposome-incorporated Grb2 antisense oligonucleotides (L-Grb2) and a dominant negative (DN) AKT mutant were used to down-regulate Grb2 expression and inhibit Akt activity, respectively. When incubated with L-Grb2 or transfected with the DN AKT mutant, ATRA-resistant, Her2/neu-overexpressing cells became sensitive to ATRA. Our results indicate that Her2/neu utilizes Grb2 and Akt proteins to induce ATRA resistance in breast cancer cells. ATRA sensitivity was also correlated with RARalpha protein levels since higher RARalpha protein levels were observed in cells in which the Her2/neu pathway was inhibited.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, 1515 Holcombe Blvd,Box 422, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Esteva, Francisco J./0000-0003-2437-3920	NCI NIH HHS [K23-CA82119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K23CA082119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baselga J, 1998, CANCER RES, V58, P2825; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carter CA, 2000, EXP MOL PATHOL, V68, P170, DOI 10.1006/exmp.2000.2301; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; De Luca LM, 1997, J CELL PHYSIOL, V173, P297, DOI 10.1002/(SICI)1097-4652(199711)173:2<297::AID-JCP39>3.0.CO;2-A; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FRAKER LD, 1984, CANCER RES, V44, P5757; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; Lenferink AEG, 2001, CANCER RES, V61, P6583; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; LOTAN R, 1979, CANCER RES, V39, P1014; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Mangelsdorf David J., 1994, P319; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; Muller A, 1997, CANCER LETT, V113, P95, DOI 10.1016/S0304-3835(97)04601-6; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rishi AK, 1996, CANCER RES, V56, P5246; ROULIER S, 1994, MOL CELL ENDOCRINOL, V105, P165, DOI 10.1016/0303-7207(94)90166-X; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; SANG H, 1995, J NEUROSURG, V82, P841; Schneider SM, 2000, CANCER RES, V60, P5479; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tang CK, 1996, CANCER RES, V56, P3350; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Toma S, 1998, ANTICANCER RES, V18, P935; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang LM, 1997, CANCER RES, V57, P4652; YU DH, 1992, ONCOGENE, V7, P2263; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LF, 2002, LAB INVEST, V82, P71, DOI 10.1038/labinvest.3780396; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	59	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5224	5232		10.1038/sj.onc.1205660	http://dx.doi.org/10.1038/sj.onc.1205660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149644				2022-12-25	WOS:000177193900004
J	Zou, WQ; Cashman, NR				Zou, WQ; Cashman, NR			Acidic pH and detergents enhance in vitro conversion of human brain PrPc to a PrPsc-like form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEINS; CELL-SURFACE; CONFORMATION; ISOFORM; DISEASE; BINDING; INTERMEDIATE; TERMINUS; FEATURES; PATHWAY	In the presence of a low concentration of denaturants or detergents, acidic pH triggers a conformational transition of alpha-helices into beta-sheets in recombinant prion protein (PrP), likely mimicking some aspects of the transformation of host-encoded normal cellular PrP (PrPC) into its pathogenic isoform (PrPSc). Here we observed the effects of acidic pH and guanidine hydrochloride (GdnHCl) on the physicochemical and structural properties of PrPC derived from normal human brain and determined the ability of the acid/GdnHCl-treated PrP to form a proteinase K(PK)-resistant species in the absence and presence of PrPSc template. After treatment with 1.5 M GdnHCl at pH 3.5, PrPC from normal brain homogenates was converted into a detergent-insoluble form similar to PrPSc. Unlike PrPSc, however, the treated brain PrPC was protease-sensitive and retained epitope accessibility to monoclonal antibodies 3F4 and 6H4. Brain PrPC treated with acidic pH/GdnHCl acquired partial PK resistance upon further treatment with low concentrations of sodium dodecyl sulfate (SDS). Formation of this PrPSc-like isoform was greatly enhanced by incubation with trace quantities of PrPSc from Creutzfeldt-Jakob disease brain. Acid/GdnHCl-treated brain PrP may constitute a "recruitable intermediate" in PrPSc formation. Further structural rearrangement seems essential for this species to acquire PK resistance, which can be promoted by the presence of a PrPSc template.	Univ Toronto, CRND, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Cashman, NR (corresponding author), Univ Toronto, CRND, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	neil.cashman@utoronto.ca	Zou, Wenquan/ABF-2875-2020; Zou, Wenquan/GWQ-3489-2022					Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; ARNOLD JE, 1995, J PATHOL, V176, P403, DOI 10.1002/path.1711760412; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; CASHMAN NR, 2001, 31 ANN M NEUR NOV 10; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; Jansen K, 2001, BIOL CHEM, V382, P683, DOI 10.1515/BC.2001.081; Kanyo ZF, 1999, J MOL BIOL, V293, P855, DOI 10.1006/jmbi.1999.3193; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1999, METHOD ENZYMOL, V309, P106; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; LOWE J, 1992, J PATHOL, V168, P169, DOI 10.1002/path.1711680204; MAYER RJ, 1994, BIOMED PHARMACOTHER, V48, P282, DOI 10.1016/0753-3322(94)90173-2; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MCKINLEY MP, 1991, LAB INVEST, V65, P622; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Prusiner SB, 1999, COLD SPRING HARBOR M, V38, P349; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Race R, 1998, NATURE, V392, P770, DOI 10.1038/33834; Race R, 2001, J VIROL, V75, P10106, DOI 10.1128/JVI.75.21.10106-10112.2001; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Saborio GP, 1999, BIOCHEM BIOPH RES CO, V258, P470, DOI 10.1006/bbrc.1999.0660; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395; Zou WQ, 2001, EUR J BIOCHEM, V268, P4885, DOI 10.1046/j.1432-1327.2001.02415.x	44	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43942	43947		10.1074/jbc.M203611200	http://dx.doi.org/10.1074/jbc.M203611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12161431	hybrid			2022-12-25	WOS:000179272000054
J	Schluter, OM; Khvotchev, M; Jahn, R; Sudhof, TC				Schluter, OM; Khvotchev, M; Jahn, R; Sudhof, TC			Localization versus function of Rab3 proteins - Evidence for a common regulatory role in controlling fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLE PROTEIN; PLASMA-MEMBRANE; CA2+-DEPENDENT EXOCYTOSIS; SUBCELLULAR-DISTRIBUTION; SECRETORY GRANULES; CHROMAFFIN; SYNAPTOPHYSIN; ASSOCIATION; INHIBITION	Rab3A, Rab3B, Rab3C, and Rab3D constitute a family of GTP-binding proteins that are implicated in regulated exocytosis. Various localizations and distinct functions have been proposed for different and occasionally even for the same Rab3 protein. This is exemplified by studies demonstrating that deletion of Rab3A in knock-out mice results in dysregulation of the final stages of exocytosis, whereas overexpression of Rab3A in neuroendocrine cells causes nearly complete inhibition of Ca2+-triggered exocytosis. We have now examined the properties of all Rab3 proteins in the same assays, with the long-term goal of identifying a common conceptual framework for their functions. Using quantitative immunoblotting, we found that all four Rab3 proteins were expressed in brain and endocrine tissues, although at widely different levels. Rab3A, Rab3B, and Rab3C co-localized to synaptic and secretory vesicles consistent with potential redundancy, whereas Rab3D was expressed at high levels only in the endocrine pituitary (where it was more abundant than Rab3A, Rab3B, and Rab3C combined), in exocrine glands, and in adipose tissue. In transfected PC12 cells, all four Rab3 proteins strongly inhibited Ca2+-triggered exocytosis. Except for a mutation that fixes Rab3 into a permanently GDP-bound state, all Rab3 mutations tested had no effect on this inhibition, including a mutation in the calmodulin-binding site that was described as inactivating (Coppola, T., Perret-Menoud, V., Luthi, S., Farnsworth, C. C., Glomset, J. A., and Regazzi, R. (1999) EMBO J. 18, 5885-5891).:Unexpectedly, overexpression of wild type Rab3A and permanently GTP-bound mutant Rab3A in PC12 cells caused a loss of secretory vesicles and an increase in constitutive, Ca2+-independent exocytosis that correlated with the inhibition of regulated Ca2+-triggered exocytosis. Our data indicate that overexpression of Rab3 in PC12 cells impairs the normal control of the final step in exocytosis, thereby converting the regulated secretory pathway into a constitutive pathway. These results offer an hypothesis that reconciles Rab3 transfection and knockout studies by suggesting that Rab3 functions as a gatekeeper of a late stage in exocytosis.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, NA4-118,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549; Jahn, Reinhard/0000-0003-1542-3498				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1993, BIOCHEM J, V293, P157, DOI 10.1042/bj2930157; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1994, J BIOL CHEM, V269, P16780; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; FISCHER V, 1991, NATURE, V349, P79; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Lin CG, 1997, BIOCHEM J, V324, P85, DOI 10.1042/bj3240085; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NAGY A, 1976, BRAIN RES, V109, P285, DOI 10.1016/0006-8993(76)90531-X; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Piiper A, 2001, BIOCHEM BIOPH RES CO, V287, P746, DOI 10.1006/bbrc.2001.5651; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Takamori S, 2000, J NEUROSCI, V20, P4904; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Ward CR, 1999, MOL REPROD DEV, V53, P413, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;413::AID-MRD7&gt;3.0.CO;2-W; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	52	126	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40919	40929		10.1074/jbc.M203704200	http://dx.doi.org/10.1074/jbc.M203704200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167638	hybrid			2022-12-25	WOS:000178791400098
J	Ward, BK; Allan, RK; Mok, D; Temple, SE; Taylor, P; Dornan, J; Mark, PJ; Shaw, DJ; Kumar, P; Walkinshaw, MD; Ratajczak, T				Ward, BK; Allan, RK; Mok, D; Temple, SE; Taylor, P; Dornan, J; Mark, PJ; Shaw, DJ; Kumar, P; Walkinshaw, MD; Ratajczak, T			A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROGESTERONE-RECEPTOR COMPLEXES; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; IMMUNOPHILIN FKBP51; ESCHERICHIA-COLI; SQUIRREL-MONKEY; CHAPERONE SITES; HEAT-SHOCK-PROTEIN-90; MUTANTS	Cyclophilin 40 (CyP40) is a tetratricopeptide repeat (TPR)-containing immunophilin and a modulator of steroid receptor function through its binding to heat shock protein 90 (Hsp90). Critical to this binding are the carboxyl-terminal MEEVD motif of Hsp90 and the TPR domain of CyP40. Two different models of the CyP40-MEEVD peptide interaction were used as the basis for a comprehensive mutational analysis of the Hsp90-interacting domain of CyP40. Using a carboxyl-terminal CyP40 construct as template, 24 amino acids from the TPR and flanking acidic and basic domains were individually mutated by site-directed mutagenesis, and the mutants were coexpressed in yeast with a carboxyl-terminal Hsp90beta construct and qualitatively assessed for binding using a beta-galactosidase filter assay. For quantitative assessment, mutants were expressed as glutathione S-transferase fusion proteins and assayed for binding to carboxyl-terminal Hsp90beta using conventional pulldown and enzyme-linked immunosorbent assay microtiter plate assays. Collectively, the models predict that the following TPR residues help define a binding groove for the MEEVD peptide: Lys-227, Asn-231, Phe234, Ser-274, Asn-278, Lys-308, and Arg-312. Mutational analysis identified five of these residues (Lys-227, Asn-231, Asn-278, Lys-308, and Arg-312) as essential for Hsp90 binding. The other two residues (Phe-234 and Ser-274) and another three TPR domain residues not definitively associated with the binding groove (Leu-284, Lys-285, and Asp-329) are required for efficient Hsp90 binding. These data confirm the critical importance of the MEEVD binding groove in CyP40 for Hsp90 recognition and reveal that additional charged and hydrophobic residues within the CyP40 TPR domain are required for Hsp90 binding.	Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Queen Elizabeth Med Ctr 2, Nedlands, WA 6009, Australia; Western Australian Inst Med Res, Perth, WA, Australia; Univ Western Australia, Dept Pharmacol, Nedlands, WA 6009, Australia; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Western Australia; University of Western Australia; University of Western Australia; University of Edinburgh	Ratajczak, T (corresponding author), Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Queen Elizabeth Med Ctr 2, Block C, Nedlands, WA 6009, Australia.		walkinshaw, malcolm/AAB-7497-2019; Mok, Danny/A-5328-2011; Mark, Peter/H-5365-2014	walkinshaw, malcolm/0000-0001-5955-9325				Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BINART N, 1995, BIOCHEM J, V311, P797, DOI 10.1042/bj3110797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Dornan A, 1999, ACTA CRYSTALLOGR D, V55, P1079, DOI 10.1107/S0907444999003017; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; HONORE B, 1992, J BIOL CHEM, V267, P8485; Irmer H, 1997, J BIOL CHEM, V272, P2230; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Meng X, 1996, J CELL SCI, V109, P1677; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WIDMER A, 1997, WITNOTP COMPUTER PRO; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	51	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40799	40809		10.1074/jbc.M207097200	http://dx.doi.org/10.1074/jbc.M207097200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12145316	hybrid			2022-12-25	WOS:000178791400083
J	Han, XB; Patters, AB; Chesney, RW				Han, XB; Patters, AB; Chesney, RW			Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE; PROMOTER; BINDING; ACTIVATION; EXPRESSION; CLONING; CANCER; SITE	Taurine, an intracellular osmolyte whose body pool size is adaptively regulated by the kidney, is required for normal renal development. Overexpression of the p53 tumor suppressor gene in p53 transgenic mice results in renal malformation, suggesting that altered expression of certain p53 target gene(s) involved in renal development may be responsible. This study shows that the taurine transporter gene (TauT is a transcriptional target of p53. Expression of TauT was decreased after activation of p53 by doxorubicin, a DNA-damaging drug, in 293 and NRK-52E renal cells. TauT promoter activity was decreased 5-10-fold by cotransfection of a full-length TauT promoter-reporter construct with p53, which was reversed by cotransfection with a mutant p53 (p53-281). Electrophoretic mobility shift assays using nuclear extracts from p53-expressing (10)1val cells showed a putative p53-binding site in the TauT promoter region, which bound to the p53 in electrophoretic mobility shift assays. Mutation of this p53 consensus sequence abolished binding of p53. These results demonstrate that TauT may represent a downstream target gene of p53 that could link the roles of p53 in renal development and apoptosis.	Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA; Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center	Chesney, RW (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, 50 N Dunlap, Memphis, TN 38103 USA.	rchesney@utmem.edu						Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XC, 1998, ADV EXP MED BIOL, V442, P397; CHESNEY RW, 1985, J CLIN INVEST, V76, P2213, DOI 10.1172/JCI112230; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GEDLEY LA, 1996, GENE DEV, V110, P836; Han XB, 2000, ADV EXP MED BIOL, V483, P535; Han XB, 2000, ADV EXP MED BIOL, V483, P97; Han XB, 1999, J AM SOC NEPHROL, V10, P1874; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heller-Stilb B, 2001, FASEB J, V15, P231, DOI 10.1096/fj.01-0691fje; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMAKI H, 1986, DEV NEUROSCI-BASEL, V8, P160, DOI 10.1159/000112251; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; LEIBBRANDT MEI, 1995, KIDNEY INT, V48, P761, DOI 10.1038/ki.1995.348; Matsell DG, 1997, KIDNEY INT, V52, P748, DOI 10.1038/ki.1997.391; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; Oz E, 1999, GEN PHARMACOL-VASC S, V33, P137, DOI 10.1016/S0306-3623(98)00284-5; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Saad SY, 2002, CHEMOTHERAPY, V48, P42, DOI 10.1159/000048587; Schaffer SW, 1998, AMINO ACIDS, V15, P135, DOI 10.1007/BF01345286; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; SMITH KE, 1992, MOL PHARMACOL, V42, P563; STURMAN JA, 1985, ADV EXP MED BIOL, V179, P43; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191	30	32	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39266	39273		10.1074/jbc.M205939200	http://dx.doi.org/10.1074/jbc.M205939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163498	hybrid			2022-12-25	WOS:000178662500028
J	Peters, MA; Jackson, DC; Crabb, BS; Browning, GF				Peters, MA; Jackson, DC; Crabb, BS; Browning, GF			Chicken anemia virus VP2 is a novel dual specificity protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TT-VIRUS; TYROSINE PHOSPHATASES; VACCINIA VIRUS; HIGH PREVALENCE; DNA; PHOSPHORYLATION; VH1; BACULOVIRUS; EXPRESSION; MECHANISM	The function of viral protein 2 (VP2) of the immunosuppressive circovirus chicken anemia virus (CAV) has not yet been established. We show that the CAV VP2 amino acid sequence has some similarity to a number of eukaryotic, receptor, protein-tyrosine phosphatase (PTPase) alpha proteins as well as to a cluster of human TT viruses within the Sanban group. To investigate if CAV VP2 functions as a PTPase, purified glutathione S-transferase (GST)-VP2 fusion protein was assayed for PTPase activity using the generalized peptide substrates ENDpYINASL and DADEpYLIPQQG (where pY represents phosphotyrosine), with free phosphate detected using the malachite green colorimetric assay. CAV GST-VP2 was shown to catalyze dephosphorylation of both substrates. CAV GST-VP2 PTPase activity for the ENDpYINASL substrate had a V-max of 14,925 units/mg.min and a K-m of 18.88 muM. Optimal activity was observed between pH 6 and 7, and activity was specifically inhibited by 0.01 mm orthovanadate. We also show that the ORF2 sequence of the CAV-related human virus TT-like minivirus (TLMV) possessed PTPase activity and steady state kinetics equivalent to CAV GST-VP2 when expressed as a GST fusion protein. To establish whether these viral proteins were dual specificity protein phosphatases, the CAV GST-VP2 and TLMV GST-ORF2 fusion proteins were also assayed for serine/threonine phosphatase (S/T P'Pase) activity using the generalized peptide substrate RRApTVA, with free phosphate detected using the malachite green colorimetric assay. Both CAV GST-VP2 and TLMV GST-ORF2 fusion proteins possessed S/T PPase activity, which was specifically inhibited by 50 mm sodium fluoride. CAV GST-VP2 exhibited S/T P'Pase activity with a V-max. of 28,600 units/mg.min and a K-m of 76 muM. Mutagenesis of residue Cys(95) to serine in CAV GST-VP2 abrogated both PTPase and S/T PPase activity, identifying it as the catalytic cysteine within the proposed signature motif. These studies thus show that the circoviruses CAV and TLAW encode dual specificity protein phosphatases (DSP) with an unusual signature motif that may play a role in intracellular signaling during viral replication. This is the first DSP gene to be identified in a small viral genome.	Univ Melbourne, Dept Vet Sci, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Browning, GF (corresponding author), Univ Melbourne, Dept Vet Sci, Melbourne, Vic 3010, Australia.	glenfb@unimelb.edu.au	Crabb, Brendan/F-5287-2013; Browning, Glenn Francis/P-4459-2014	Browning, Glenn Francis/0000-0002-0903-2469; Jackson, David/0000-0001-7255-270X				Asabe S, 2001, BIOCHEM BIOPH RES CO, V286, P298, DOI 10.1006/bbrc.2001.5385; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Brown K, 2000, AUST VET J, V78, P637, DOI 10.1111/j.1751-0813.2000.tb11942.x; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Dai Chia-Yen, 2000, Kaohsiung Journal of Medical Sciences, V16, P500; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; Dhenain M, 2000, CLIN INVEST MED, V23, P307; DUTZ JP, 1995, J IMMUNOL, V154, P2588; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; HANCOCK WS, 1976, ANAL BIOCHEM, V71, P260, DOI 10.1016/0003-2697(76)90034-8; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; Huang LY, 2001, J MED VIROL, V64, P381, DOI 10.1002/jmv.1062; Itoh M, 2001, DIGEST DIS SCI, V46, P457, DOI 10.1023/A:1005618308943; Kanda Y, 2001, LEUKEMIA LYMPHOMA, V40, P483, DOI 10.3109/10428190109097647; Kozieradzki I, 1997, J IMMUNOL, V158, P3130; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; LIU K, 1995, J VIROL, V69, P7823, DOI 10.1128/JVI.69.12.7823-7834.1995; MARTH JD, 1994, ADV EXP MED BIOL, V365, P149; MEEHAN BM, 1992, ARCH VIROL, V124, P301, DOI 10.1007/BF01309811; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; ONG CJ, 1994, J IMMUNOL, V152, P3793; Ong CJ, 1997, IMMUNOLOGY, V91, P95, DOI 10.1046/j.1365-2567.1997.00216.x; PHENIX KV, 1994, J GEN VIROL, V75, P905, DOI 10.1099/0022-1317-75-4-905; Poovorawan Y, 2001, HEPATO-GASTROENTEROL, V48, P256; Ragnarsson U, 1995, J Pept Sci, V1, P149, DOI 10.1002/psc.310010302; Safadi R, 2001, BONE MARROW TRANSPL, V27, P183, DOI 10.1038/sj.bmt.1702749; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; Shibayama T, 2001, AIDS, V15, P563, DOI 10.1097/00002030-200103300-00004; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takahashia K, 2000, INTERVIROLOGY, V43, P119, DOI 10.1159/000025034; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Vasconcelos HCF, 2001, MEM I OSWALDO CRUZ, V96, P519, DOI 10.1590/S0074-02762001000400013; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1	42	83	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39566	39573		10.1074/jbc.M201752200	http://dx.doi.org/10.1074/jbc.M201752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151384	hybrid			2022-12-25	WOS:000178662500067
J	Vetcher, AA; Napierala, M; Wells, RD				Vetcher, AA; Napierala, M; Wells, RD			Sticky DNA: Effect of the polypurine center dot polypyrimidine sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAA TRIPLET REPEAT; FRIEDREICHS-ATAXIA; TTC REPEATS; GENE; TRANSCRIPTION; EXPANSION; CLONING; INVIVO	The polypurine-polypyrimidine sequence requirements for the formation of sticky DNA were evaluated in Escherichia coli plasmid systems to determine the potential occurrence of this conformation throughout biological systems. A mirror repeat, dinucleotide tract of (GA.TC)(37), which is ubiquitous in eukaryotes, formed sticky DNA, but shorter sequences of 10 or 20 repeats were inert. (GGA.TCC)(n) inserts (where n = 126,159, and 222 bp) also formed sticky DNA. As shown previously, the control sequence (GAA.TTC)(150) (450 bp) readily adopted the X-shaped sticky structure; however, this structure has never been found for the nonpathogenic (GAAGGA.TCCTTC)(65) of the same approximate length (390 bp). A sequence that is replete with polypurine-polypyrimidine tracts that can form triplexes and slipped structures but lacks long repeating motifs (the 2.5-kbp intron 21 sequence from the polycystic kidney disease gene 1) was also inert. Interestingly, tracts of (GAA.TTC)(n) (where n = 176 or 80) readily formed sticky DNA with (GAAGGA.TCCTTC)(65) cloned into the same plasmid when the pair of inserts was in the direct, but not in the indirect (inverted), orientation. The stabilities of the triple base (Watson-Crick and Hoogsteen) interactions in the DNA/DNA associated triplex region of the sticky conformations account for these observations. Our results have significant chemical and biological implications for the structure and function of this unusual DNA conformation in Friedreich's ataxia.	Texas A&M Univ, Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.			Vetcher, Alexandre/0000-0002-4828-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; GRAY HB, 1968, J MOL BIOL, V35, P111, DOI 10.1016/S0022-2836(68)80041-5; HEARST JE, 1962, J CHEM PHYS, V37, P1425, DOI 10.1063/1.1733300; KLEIN RD, 1982, J BIOL CHEM, V257, P2962; KLEIN RD, 1982, J BIOL CHEM, V257, P2954; LE DT, 1987, NUCLEIC ACIDS RES, V15, P7749; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Montermini L, 1997, NEUROLOGY, V49, P606, DOI 10.1212/WNL.49.2.606; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Toth G, 2000, GENOME RES, V10, P967, DOI 10.1101/gr.10.7.967; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Wells R.D., 1998, GENETIC INSTABILITIE; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	27	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39228	39234		10.1074/jbc.M205210200	http://dx.doi.org/10.1074/jbc.M205210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161438	hybrid			2022-12-25	WOS:000178662500023
J	Yang, FM; Liu, XB; Quinones, M; Melby, PC; Ghio, A; Haile, DJ				Yang, FM; Liu, XB; Quinones, M; Melby, PC; Ghio, A; Haile, DJ			Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; RECOMBINANT HUMAN INTERLEUKIN-6; CANCER-PATIENTS; STORAGE IRON; SERUM IRON; TNF-ALPHA; ANEMIA; MICE; METABOLISM	Acute and chronic inflammation cause many changes in total body iron metabolism including the sequestration of iron in phagocytic cells of the reticuloendothelial system. This change in iron metabolism contributes to the development of the anemia of inflammation. MTP1, the duodenal enterocyte basolateral iron exporter, is also expressed in the cells of the reticuloendothelial system (RES) and is likely to be involved in iron recycling of these cells. In this study, we use a lipopolysaccharide model of the acute inflammation in the mouse and demonstrate that MTP1 expression in RES cells of the spleen, liver, and bone marrow is down-regulated by inflammation. The down-regulation of splenic expression of MTP1 by inflammation was also observed in a Leishmania donovani model of chronic infection. The response of MTP1 to lipopolysaccharide (LPS) requires signaling through the LPS receptor, Toll-like receptor 4 (TLR4). In mice lacking TLR4, MTP1 expression is not altered in response to LPS. In addition, mice lacking tumor necrosis factor-receptor 1a respond appropriately to LPS with down-regulation of MTP1, despite hyporesponsiveness to tumor necrosis factor-alpha signaling, suggesting that this cytokine may not be required for the LPS effect. We hypothesize that the iron sequestration in the RES system that accompanies inflammation is because of down-regulation of MTP1.	S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA; US EPA, Natl Hlth & Environm Effect Res Lab, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; United States Environmental Protection Agency; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Haile, DJ (corresponding author), S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA.	Haile@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053079] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; ALVAREZHERNANDEZ X, 1989, LAB INVEST, V61, P319; BEGUIN Y, 1989, J LAB CLIN MED, V113, P346; Bertero MT, 1997, HAEMATOLOGICA, V82, P375; BERTINI R, 1989, J LEUKOCYTE BIOL, V46, P254, DOI 10.1002/jlb.46.3.254; CORTELL S, 1967, AM J PHYSIOL, V213, P43, DOI 10.1152/ajplegacy.1967.213.1.43; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; ELSHOBAKI F, 1985, BLUT, V50, P95, DOI 10.1007/BF00321172; Feelders RA, 1998, EUR J CLIN INVEST, V28, P520; FELDMAN BF, 1981, AM J VET RES, V42, P1109; FELDMAN BF, 1981, AM J VET RES, V42, P583; FELDMAN BF, 1981, AM J VET RES, V42, P586; FILLET G, 1989, BLOOD, V74, P844; FILLET G, 1974, J CLIN INVEST, V53, P1527, DOI 10.1172/JCI107703; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; GORDEUK VR, 1988, J CLIN INVEST, V82, P1934, DOI 10.1172/JCI113812; GUTTEBERG TJ, 1989, SCAND J INFECT DIS, V21, P709, DOI 10.3109/00365548909021701; HERSHKO C, 1974, BRIT J HAEMATOL, V28, P67, DOI 10.1111/j.1365-2141.1974.tb06640.x; Hill AG, 1997, ANN SURG, V225, P246, DOI 10.1097/00000658-199703000-00002; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; KAMPSCHMIDT RF, 1985, P SOC EXP BIOL MED, V179, P197; KAMPSCHMIDT RF, 1965, AM J PHYSIOL, V208, P68, DOI 10.1152/ajplegacy.1965.208.1.68; KAMPSCHMIDT RF, 1980, J LAB CLIN MED, V95, P616; KAMPSCHMIDT RF, 1963, P SOC EXP BIOL MED, V113, P142; KOBUNE M, 1994, HEPATOLOGY, V19, P1468, DOI 10.1002/hep.1840190623; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; Lauzurica P, 1999, EUR J IMMUNOL, V29, P1890, DOI 10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F; Mabika M, 1999, PFLUG ARCH EUR J PHY, V438, P218, DOI 10.1007/s004240050901; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Means RT, 1999, INT J HEMATOL, V70, P7; Melby PC, 1998, INFECT IMMUN, V66, P18, DOI 10.1128/IAI.66.1.18-27.1998; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; NIEKEN J, 1995, BLOOD, V86, P900, DOI 10.1182/blood.V86.3.900.bloodjournal863900; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Patruta SI, 1999, KIDNEY INT, V55, pS125, DOI 10.1046/j.1523-1755.1999.055Suppl.69125.x; PEKAREK RS, 1969, AM J MED SCI, V258, P14, DOI 10.1097/00000441-196907000-00003; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAJA KB, 1990, INT J EXP PATHOL, V71, P785; TANAKA T, 1987, J BIOL RESP MODIF, V6, P484; UCHIDA T, 1991, EUR J HAEMATOL, V46, P1; UCHIDA T, 1983, TOHOKU J EXP MED, V139, P293, DOI 10.1620/tjem.139.293; VANGAMEREN MM, 1994, BLOOD, V84, P1434; Weiss G, 1999, KIDNEY INT, V55, pS12, DOI 10.1046/j.1523-1755.1999.055Suppl.69012.x	45	168	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39786	39791		10.1074/jbc.M201485200	http://dx.doi.org/10.1074/jbc.M201485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161425	hybrid			2022-12-25	WOS:000178662500093
J	Beranger, F; Mange, A; Goud, B; Lehmann, S				Beranger, F; Mange, A; Goud, B; Lehmann, S			Stimulation of PrPC retrograde transport toward the endoplasmic reticulum increases accumulation of PrPSc in prion-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; NEUROBLASTOMA-CELLS; GOLGI NETWORK; RAB PROTEINS; TRAFFICKING; POPULATIONS; DEGRADATION; CONVERSION; COMPLEXES	Prion diseases are fatal and transmissible neurodegenerative disorders characterized by the accumulation of an abnormally folded isoform. of the cellular prion protein (PrPC) denoted PrPSc. To identify intracellular organelles involved in PrPSc formation, we studied the role of the Ras-related GTP-binding proteins Rab4 and Rab6a in intracellular trafficking of the prion protein and production of PrPSc. When a dominant-negative Rab4 mutant or a constitutively active GTP-bound Rab6a protein was overexpressed in prion-infected neuroblastoma N2a cells, there was a marked increase of PrPSc formation. By immunofluoreseence and cell fractionation studies, we have shown that expression of Rab6a-GTP delocalizes PrP within intracellular compartments, leading to an accumulation in the endoplasmic reticulum. These results suggest that prion protein can be subjected to retrograde transport toward the endoplasmic reticulum and that this compartment may play a significant role in PrPSc conversion.	Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier 5, France; Inst Curie, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Beranger, F (corresponding author), Inst Genet Humaine, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.		Lehmann, Sylvain/P-1301-2017; Goud, Bruno/GWC-4807-2022; Beranger, Florence/R-7581-2019; Mange, Alain/U-1157-2017	Lehmann, Sylvain/0000-0001-6117-562X; Mange, Alain/0000-0002-1566-9407				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lee KS, 2001, J NEUROCHEM, V79, P79, DOI 10.1046/j.1471-4159.2001.00529.x; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; MCKINLEY MP, 1991, LAB INVEST, V65, P622; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; PFEIFER K, 1993, CELL BIOCHEM FUNCT, V11, P1, DOI 10.1002/cbf.290110102; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rybner C, 2002, J CELL BIOCHEM, V84, P408, DOI 10.1002/jcb.10017; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	88	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38972	38977		10.1074/jbc.M205110200	http://dx.doi.org/10.1074/jbc.M205110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163492	hybrid			2022-12-25	WOS:000178529600121
J	Gomez-Gaviro, MV; Gonzalez-Alvaro, I; Dominguez-Jimenez, C; Peschon, J; Black, RA; Sanchez-Madrid, F; Diaz-Gonzalez, F				Gomez-Gaviro, MV; Gonzalez-Alvaro, I; Dominguez-Jimenez, C; Peschon, J; Black, RA; Sanchez-Madrid, F; Diaz-Gonzalez, F			Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATES REPERFUSION INJURY; LEUKOCYTE ADHESION; RAT-KIDNEY; INHIBITION; NEUTROPHILS; EXPRESSION; MAC-1; SALICYLATE; EMIGRATION; MECHANISM	It has been recently described that some non-steroidal anti-inflammatory drugs (NSAIDs) are able to induce the shedding of L-selectin in neutrophils, an adhesion molecule that plays an essential role in the inflammatory response. We have found that, according to this capability, NSAIDs could be grouped into three categories. A high releaser group (flufenamic, meclofenamic, and mefenamic acids, diclofenac and aceclofenac), a group of moderate releasers (aspirin, indomethacin, nimesulide, flurbiprofen, and ketoprofen), and a non-releaser group (phenylbutazone and the oxicams, piroxicam and meloxicam). Only NSAIDs from the high releaser group shared diphenylamine in their chemical structure. The amine group of this chemical agent proved to be essential for the anti-L-selectin activity of diphenylamine-based NSAIDs. The presence of a carboxylic acid group in the diphenylamine (N-phenylanthranilic acid) highly increased its ability to reduce the L-selectin surface expression in neutrophils. Diphenylamine and N-phenylanthranilic acid neither affected COX activity in platelets nor modified the activation state of neutrophils. Diphenylamine-related compounds, which include the diphenylamine-based NSAIDs caused a variable reduction in the neutrophil intracellular ATP concentration, which correlated with the differential ability of such compounds to trigger L-selectin shedding (r = 0.97, p < 0.01). Diphenylamine-related compounds failed to down-regulate L-selectin in a tumor necrosis factor-a-converting enzyme (TACE)deficient murine monocytic cell line. Our data indicate that diphenylamine seems to be the structural core of NSAIDs accounting for their down-regulatory activity of L-selectin leukocyte expression. Diphenylamine and its related compounds exert this action on L-selectin through a prostaglandin-independent, TACE-dependent mechanism that seems to be linked to the capability of these agents to uncouple the mitochondrial oxidative phosphorylation.	Univ La Laguna, Hosp Univ Canarias, Serv Reumatol, San Cristobal la Laguna 38320, St Cruz Tenerif, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Reumatol, Madrid 28006, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; Immunex Corp, Seattle, WA 98101 USA	Universidad de la Laguna; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Immunex Corporation	Diaz-Gonzalez, F (corresponding author), Univ La Laguna, Hosp Univ Canarias, Serv Reumatol, Ofra S-N, San Cristobal la Laguna 38320, St Cruz Tenerif, Spain.	fdiaz@cnb.uam.es	Diaz-Gonzalez, Federico/R-2382-2019; Sanchez-Madrid, Francisco/M-7889-2016	Diaz-Gonzalez, Federico/0000-0002-4139-9295; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Gomez-Gaviro, Maria Victoria/0000-0002-8683-5150				ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; ALTMAN RD, 1990, AM J PHYSIOL, V4, P1; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Bennett TA, 1996, J IMMUNOL, V156, P3093; BERG M, 1990, BLOOD, V76, P2381; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOMBARDIER C, 1995, J RHEUMATOL, V22, P617; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; Diaz-Gonzalez F, 1998, IMMUNOL TODAY, V19, P169, DOI 10.1016/S0167-5699(97)01216-4; DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Featherstone C, 1996, LANCET, V347, P1106, DOI 10.1016/S0140-6736(96)90297-4; FORTENBERRY JD, 1994, BLOOD, V84, P889, DOI 10.1182/blood.V84.3.889.bloodjournal843889; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; GonzalezAlvaro I, 1996, J RHEUMATOL, V23, P723; HUMBRIA A, 1994, ARTHRITIS RHEUM, V37, P342, DOI 10.1002/art.1780370307; JUNG U, 1998, AM J PHYSIOL, V274, P1785; JUTILA MA, 1989, J IMMUNOL, V143, P3318; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LACAL P, 1988, J BIOL CHEM, V263, P9946; Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208; Masubuchi Y, 1999, BIOCHEM PHARMACOL, V58, P861, DOI 10.1016/S0006-2952(99)00163-X; MIHELCIC D, 1994, BLOOD, V84, P2322; Mingatto FE, 1996, ARCH BIOCHEM BIOPHYS, V334, P303, DOI 10.1006/abbi.1996.0459; NISHIHARA KK, 1997, ARTHRITIS ALLIED CON, V1, P611; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ramamoorthy C, 1996, AM J PHYSIOL-HEART C, V271, pH1871, DOI 10.1152/ajpheart.1996.271.5.H1871; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; Simon LS, 1997, ARTHRITIS RHEUM, V40, P1940; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; TRAVIS J, 1993, SCIENCE, V260, P906, DOI 10.1126/science.8493523; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0	43	47	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38212	38221		10.1074/jbc.M205142200	http://dx.doi.org/10.1074/jbc.M205142200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147693	hybrid			2022-12-25	WOS:000178529600031
J	Gorbunova, V; Seluanov, A; Pereira-Smith, OM				Gorbunova, V; Seluanov, A; Pereira-Smith, OM			Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; HUMAN LUNG FIBROBLASTS; DNA-DAMAGE; PREMATURE SENESCENCE; G(1) ARREST; TREATED FIBROBLASTS; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; LIFE-SPAN	Cells subjected to sub-lethal doses of stress such as irradiation or oxidative damage enter a state that closely resembles replicative senescence. What triggers stress-induced premature senescence (SIPS) and how similar this mechanism is to replicative senescence are not well understood. It has been suggested that stress-induced senescence is caused by rapid telomere shortening resulting from DNA damage. In order to test this hypothesis directly, we examined whether overexpression of the catalytic subunit of human telomerase (hTERT) can protect cells from SIPS. We therefore analyzed the response of four different lines of normal human fibroblasts with and without hTERT to stress induced by UV, gamma-irradiation, and H2O2. SIPS was induced with the same efficiency in normal and hTERT-immortalized cells. This suggests that SIPS is not triggered by telomere shortening and that nonspecific DNA damage serves as a signal for induction of SIPS. Although telomerase did not protect cells from SIPS, fibroblasts expressing hTERT were more resistant to stress-induced apoptosis and necrosis. We hypothesize that healing of DNA breaks by telomerase inhibits the induction of cell death, but because healing does not provide legitimate DNA repair, it does not protect cells from SIPS.	Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, Houston, TX 77030 USA	Baylor College of Medicine	Gorbunova, V (corresponding author), Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, 1 Baylor Plaza, Houston, TX 77030 USA.			Gorbunova, Vera/0000-0001-8979-0333; Seluanov, Andrei/0000-0003-3400-538X	NIA NIH HHS [R37AG60533, P01AG620752] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P427; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Frippiat C, 2000, EXP GERONTOL, V35, P733, DOI 10.1016/S0531-5565(00)00167-4; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; GELVAN D, 1995, BIOCHEM BIOPH RES CO, V206, P421, DOI 10.1006/bbrc.1995.1058; Hande MP, 1998, MUTAT RES-FUND MOL M, V404, P205, DOI 10.1016/S0027-5107(98)00115-8; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mattson MP, 2001, MECH AGEING DEV, V122, P659, DOI 10.1016/S0047-6374(01)00221-4; MEDRANO EE, 1995, CANCER RES, V55, P4047; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Oh CW, 2001, RADIAT RES, V156, P232, DOI 10.1667/0033-7587(2001)156[0232:IOASLP]2.0.CO;2; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Samuni AM, 2001, BBA-GEN SUBJECTS, V1525, P70, DOI 10.1016/S0304-4165(00)00172-0; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Slijepcevic P, 1998, INT J RADIAT BIOL, V73, P1; Stein G H, 1979, Methods Enzymol, V58, P279; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wei S, 1999, CANCER RES, V59, P1539; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yeo EJ, 2000, EXP GERONTOL, V35, P553, DOI 10.1016/S0531-5565(00)00108-X; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	191	203	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38540	38549		10.1074/jbc.M202671200	http://dx.doi.org/10.1074/jbc.M202671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140282	hybrid			2022-12-25	WOS:000178529600070
J	Kaup, M; Dassler, K; Weise, C; Fuchs, H				Kaup, M; Dassler, K; Weise, C; Fuchs, H			Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN-CONVERTING ENZYME; LINKED GLYCOSYLATION SITE; DISINTEGRIN-METALLOPROTEASE; SECRETASE CLEAVAGE; INTRACELLULAR MATURATION; IRON-DEFICIENCY; GROWTH-FACTOR; SERUM; CELLS	The transferrin receptor (TfR) is a transmembrane protein that mediates cellular uptake of iron. Although the serum concentration of the soluble TfR (sTfR) is altered in several diseases and used for diagnostic purposes, the identity and regulation of the shedding protease is unknown. In this study we quantified sTfR release from microsomal membranes and leukocytic cell lines in the presence of numerous protease inhibitors and cell activating compounds. We show that sTfR release is mediated by an integral membrane metalloprotease and can be inhibited by matrix metalloproteinase inhibitor 2 and tumor necrosis factor a protease inhibitor-2 (TAPI-2). Cleavage is also inhibited by a specific furin inhibitor, indicating that the protease is activated by a furin-like proprotein convertase. Whereas stimulation of the cells by the ectodomain shedding activator phorbol 12-N-myristate 13-acetate did not alter sTfR release significantly, the phosphatase inhibitor pervanadate led to an increase of TfR shedding in several leukocytic cell lines. Our results suggest that TfR shedding is constitutively mediated by a member of the metalloprotease family known as ADAM (for a disintegrin and metalloprotease).	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Fuchs, H (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, Hindenburgdamm 30, D-12200 Berlin, Germany.		Fuchs, Hendrik/AAE-7379-2019	Fuchs, Hendrik/0000-0001-9153-9594				AHN JH, 1993, BLOOD, V81, P2442; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BAYNES RD, 1994, J LAB CLIN MED, V123, P407; BAYNES RD, 1991, BRIT J HAEMATOL, V78, P450, DOI 10.1111/j.1365-2141.1991.tb04463.x; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHITAMBAR CR, 1989, BLOOD, V74, P602; CHITAMBAR CR, 1991, BLOOD, V78, P2444; Codony-Servat J, 1999, CANCER RES, V59, P1196; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; Fuchs H, 2001, BIOTECHNIQUES, V31, P584, DOI 10.2144/01313rr03; FUCHS H, 1995, BIOCHEMISTRY-US, V34, P6196, DOI 10.1021/bi00018a024; GomezOrtiz M, 1997, FEBS LETT, V400, P336, DOI 10.1016/S0014-5793(96)01412-3; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUEBERS HA, 1990, BLOOD, V75, P102; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Johnstone RM, 1996, J CELL PHYSIOL, V168, P333, DOI 10.1002/(SICI)1097-4652(199608)168:2<333::AID-JCP12>3.0.CO;2-4; KATO J, 1992, INT J HEMATOL, V56, P161; Kaup M, 2002, BIOL CHEM, V383, P1011, DOI 10.1515/BC.2002.108; KOHGO Y, 1988, JPN J MED, V27, P64, DOI 10.2169/internalmedicine1962.27.64; KOHGO Y, 1986, BRIT J HAEMATOL, V64, P277, DOI 10.1111/j.1365-2141.1986.tb04120.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; R'zik S, 2001, EXP HEMATOL, V29, P677, DOI 10.1016/S0301-472X(01)00641-5; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rutledge EA, 1998, J BIOL CHEM, V273, P12169, DOI 10.1074/jbc.273.20.12169; RUTLEDGE EA, 1994, BLOOD, V83, P580; RUTLEDGE EA, 1994, J BIOL CHEM, V269, P31864; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; SKIKNE BS, 1990, BLOOD, V75, P1870; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WOITH W, 1993, CLIN EXP IMMUNOL, V92, P537; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	73	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38494	38502		10.1074/jbc.M203461200	http://dx.doi.org/10.1074/jbc.M203461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163483	hybrid			2022-12-25	WOS:000178529600065
J	Regula, KM; Ens, K; Kirshenbaum, LA				Regula, KM; Ens, K; Kirshenbaum, LA			IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; BCL-X-L; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; MICE LACKING; KINASE-ALPHA; BH4 DOMAIN; PERMEABILITY TRANSITION	The transcription factor nuclear factor kappaB (NF-kappaB) is regulated by cytoplasmic inhibitor IkappaBalpha. An integral step in the activation of NF-kappaB involves the phosphorylation and degradation of IkappaBalpha. We have previously reported that IkappaBalpha activity is diminished in ventricular myocytes expressing Bcl-2 (de Moissac, D., Zheng, H., and Kirshenbaum, L. A. (1999) J. Biol. Chem. 274, 29505-29509). The underlying mechanism by which Bcl-2 activates NF-kappaB is undefined. In view of growing evidence that the IkappaB kinases (IKKs), notably IKKbeta, are involved in signal induced phosphorylation of IkappaBalpha, we ascertained whether IKKbeta is necessary and sufficient for Bcl-2 mediated NF-kappaB activation. Here we demonstrate that expression of Bcl-2 in ventricular myocytes resulted in an increase in NF-kappaB-dependent DNA binding, NF-kappaB gene transcription and reduced IkappaBalpha levels. An increase in the IKKbeta kinase activity was observed in cells expressing full-length Bcl-2 but not in cells expressing the BH4 deletion mutant of Bcl-2 (DeltaBH4; residues 10-30). Catalytically inactive mutants of IKKbeta, but not IKKalpha, suppressed Bcl-2-mediated IkappaBalpha phosphorylation and NF-kappaB activation. Transfection of human embryonic 293 cells with a kinase-defective Raf-1 or a kinase-defective mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEKK-1) suppressed Bcl2-mediated IKKbeta activity and NF-kappaB activation. Further, Bcl-2-mediated NF-kappaB activity was impaired in nullizygous mouse embryonic fibroblasts deficient for IKKbeta. In this report, we provide the first direct evidence that Bcl-2 activates NF-kappaB by a signaling mechanism that involves Raf-1/MEKK-1 mediated activation of IKKbeta.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Kirshenbaum, LA (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Rm 3042,351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	Lorrie@sbrc.ca	Kirshenbaum, Lorrie A./F-5742-2014					ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Marchetti P, 1996, J IMMUNOL, V157, P4830; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAN AD, 1996, SCIENCE, V274, P787; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162	68	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38676	38682		10.1074/jbc.M206175200	http://dx.doi.org/10.1074/jbc.M206175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167626	hybrid			2022-12-25	WOS:000178529600085
J	Yang, KS; Kang, SW; Woo, HA; Hwang, SC; Chae, HZ; Kim, K; Rhee, SG				Yang, KS; Kang, SW; Woo, HA; Hwang, SC; Chae, HZ; Kim, K; Rhee, SG			Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; MAMMALIAN PEROXIREDOXIN; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; NADH PEROXIDASE; SULFENIC ACIDS; SACCHAROMYCES-CEREVISIAE; TRYPAREDOXIN PEROXIDASE	By following peroxiredoxin I (Prx I)-dependent NADPH oxidation spectrophotometrically, we observed that Prx I activity decreased gradually with time. The decay in activity was coincident with the conversion of Prx I to a more acidic species as assessed by two-dimensional gel electrophoresis. Mass spectral analysis and studies with Cys mutants determined that this shift in pI was due to selective oxidation of the catalytic site Cys(51)-SH to Cys(51)-SO2H. Thus, Cys(51)-SOH generated as an intermediate during catalysis appeared to undergo occasional further oxidation to Cys(51)-SO2H, which cannot be reversed by thioredoxin. The presence of H2O2 alone was not sufficient to cause oxidation of Cys(51) to Cys(51)-SO2H. Rather, the presence of complete catalytic components (H2O2, thioredoxin, thioredoxin reductase, and NADPH) was necessary, indicating that such hyperoxidation occurs only when Prx I is engaged in the catalytic cycle. Likewise, hyperoxidation of Cys(172)/Ser(172) mutant Prx I required not only H2O2, but also a catalysis-supporting thiol (dithiothreitol). Kinetic analysis of Prx I inactivation in the presence of a low steady-state level (< 1 &mu;M) of H2O2 indicated that Prx I was hyperoxidized at a rate of 0.072% per turnover at 30 &DEG;C. Hyperoxidation of Prx I was also detected in HeLa cells treated with H2O2.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.		Woo, Hyun Ae/AAT-9586-2021	Hwang, Sung Chul/0000-0003-2401-619X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAE HZ, 1994, BIOFACTORS, V4, P177; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Crane EJ, 2000, BIOCHEMISTRY-US, V39, P10353, DOI 10.1021/bi000553m; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; Gay CA, 2002, ANAL BIOCHEM, V304, P42, DOI 10.1006/abio.2001.5566; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; KIM KW, 1988, J BIOL CHEM, V263, P4704; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shen CL, 2002, MOL MED, V8, P95, DOI 10.1007/BF03402079; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	43	346	358	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38029	38036		10.1074/jbc.M206626200	http://dx.doi.org/10.1074/jbc.M206626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161445	hybrid			2022-12-25	WOS:000178529600009
J	Gendlina, I; Gutman, DM; Thomas, V; Collins, CM				Gendlina, I; Gutman, DM; Thomas, V; Collins, CM			Urea-dependent signal transduction by the virulence regulator UreR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEUS-MIRABILIS UREASE; GENE-CLUSTER; FAMILY ENTEROBACTERIACEAE; CONTROLLING EXPRESSION; KLEBSIELLA-AEROGENES; IDENTIFICATION; INFECTION; TRANSCRIPTION; PROMOTERS; BACTERIA	Identification of the environmental triggers involved in the expression of virulence genes is a fundamental objective in studies of bacterial pathogens. For uropathogens, urea, found in the urinary tract at concentrations of up to 500 mM, functions as an environmental signal. Urea freely diffuses into the bacterium Providencia stuartii and activates UreR, a member of the AraC family of transcriptional activators. Active UreR promotes transcription of virulence-associated urease genes and alerts the organisms of its immediate milieu. Thus, the UreR.urea complex has a dual role, acting as both a transcriptional activator as well as an environmental sensor. Here, we describe the molecular events associated with activation of gene expression by urea-bound UreR. The K-d of the urea-UreR binding reaction was measured as 0.2 mM by fluorescence quenching assays, and the shape of the binding curve indicated a single specific urea-binding site on UreR. Histidine residues are critical for urea binding in urease, and therefore to identify the urea-binding site in UreR, five mutant UreR forms were generated with histidine to alanine substitutions. Two of the mutants (UreR) exhibited a constitutive phenotype by both activating transcription and binding to DNA with an increased affinity in the absence of urea. The UreR(c) bound urea with an affinity similar to that of wild-type UreR. We concluded, therefore, that the mutations resulting in constitutive activity were not involved in the UreR.urea interaction. UreR was activated, then, either by binding urea or by histidine to alanine substitutions at one of two positions. Circular dichroism indicated little change in the structure of UreR when activated, and size-exclusion chromatography demonstrated that both rUreR and rUreR(c) were dimers in both the presence and absence of urea. Thus, the structural changes associated with activation are subtle.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Collins, CM (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.				NIDDK NIH HHS [DK60163, DK50495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050495, R01DK060163] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAUDE AI, 1960, J BACTERIOL, V80, P171, DOI 10.1128/JB.80.2.171-179.1960; Collins Carleen M., 1996, P299; COLLINS CM, 1993, MOL MICROBIOL, V8, P187, DOI 10.1111/j.1365-2958.1993.tb01215.x; COLLINS CM, 1990, J BACTERIOL, V172, P7138, DOI 10.1128/jb.172.12.7138-7144.1990; Donnenberg Michael S., 1996, P135; DOrazio SEF, 1996, MOL MICROBIOL, V21, P643, DOI 10.1111/j.1365-2958.1996.tb02572.x; DORAZIO SEF, 1993, J BACTERIOL, V175, P3459, DOI 10.1128/jb.175.11.3459-3467.1993; DORAZIO SEF, 1993, J BACTERIOL, V175, P1860, DOI 10.1128/JB.175.6.1860-1864.1993; DORAZIO SEF, 1995, MOL MICROBIOL, V16, P145, DOI 10.1111/j.1365-2958.1995.tb02399.x; FOWLER JE, 1984, J UROLOGY, V131, P213, DOI 10.1016/S0022-5347(17)50311-0; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; GRIFFITH DP, 1976, INVEST UROL, V13, P346; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LERNER SP, 1989, J UROLOGY, V141, P753, DOI 10.1016/S0022-5347(17)41002-0; MACLAREN DM, 1986, MICROBIAL DISEASES N, P183; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller J.H., 1972, EXPT MOL GENETICS; Mobley Harry L. T., 1996, P245; MOBLEY HLT, 1985, J CLIN MICROBIOL, V22, P851, DOI 10.1128/JCM.22.5.851-853.1985; MOBLEY HLT, 1987, J CLIN MICROBIOL, V25, P2216, DOI 10.1128/JCM.25.11.2216-2217.1987; NICHOLSON EB, 1993, J BACTERIOL, V175, P465, DOI 10.1128/JB.175.2.465-473.1993; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; Poore CA, 2001, J BACTERIOL, V183, P4526, DOI 10.1128/JB.183.15.4526-4535.2001; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Thomas VJ, 1999, MOL MICROBIOL, V31, P1417, DOI 10.1046/j.1365-2958.1999.01283.x; Warren John W., 1996, P3	30	26	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37349	37358		10.1074/jbc.M203462200	http://dx.doi.org/10.1074/jbc.M203462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147687	hybrid			2022-12-25	WOS:000178447100057
J	Lamorte, L; Rodrigues, S; Naujokas, M; Park, M				Lamorte, L; Rodrigues, S; Naujokas, M; Park, M			Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the Met morphogenic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRB2 BINDING-SITE; PLECKSTRIN HOMOLOGY DOMAIN; KIDNEY-CELLS REQUIRES; DOCKING PROTEIN GAB1; SCATTER FACTOR; ADAPTER PROTEIN; FACTOR-RECEPTOR; C-MET; PHOSPHOINOSITIDE 3-KINASE; SUSTAINED ACTIVATION	Activation of the Met receptor tyrosine kinase through its ligand, hepatocyte growth factor, stimulates cell spreading, cell dispersal, and the inherent morphogenic program of various epithelial cell lines. Although both hepatocyte growth factor and epidermal growth factor (EGF) can activate downstream signaling pathways in Madin-Darby canine kidney epithelial cells, EGF fails to promote the breakdown of cell-cell junctional complexes and initiate an invasive morphogenic program. We have undertaken a strategy to identify signals that synergize with EGF in this process. We provide evidence that the overexpression of the CrkII adapter protein complements EGF-stimulated pathways to induce cell dispersal in two-dimensional cultures and cell invasion and branching morphogenesis in three-dimensional collagen gels. This finding correlates with the ability of CrkII to promote the breakdown of adherens junctions in stable cell lines and the ability of EGF to stimulate enhanced Rac activity in cells overexpressing CrkII. We have previously shown that the Gab1-docking protein is required for branching morphogenesis downstream of the Met receptor. Consistent with a role for CrkII in promoting EGF-dependent branching morphogenesis, the binding of Gab1 to CrkII is required for the branching morphogenic program downstream of Met. Together, our data support a role for the CrkII adapter protein in epithelial invasion and morphogenesis and underscores the importance of considering the synergistic actions of signaling pathways in cancer progression.	McGill Univ, Mol Oncol Grp, Ctr Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Ctr Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Ctr Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Mol Oncol Grp, Ctr Hosp, Dept Oncol, Rm H510,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowes RC, 1999, J CELL PHYSIOL, V180, P81, DOI 10.1002/(SICI)1097-4652(199907)180:1<81::AID-JCP9>3.0.CO;2-J; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; El-Obeid A, 1997, CANCER RES, V57, P5598; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kjelsberg C, 1997, AM J PHYSIOL-RENAL, V272, pF222, DOI 10.1152/ajprenal.1997.272.2.F222; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MATTHAY MA, 1993, J CELL SCI, V106, P869; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Otsuka T, 1998, CANCER RES, V58, P5157; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sakurai H, 1997, AM J PHYSIOL-RENAL, V273, pF463, DOI 10.1152/ajprenal.1997.273.3.F463; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Simian M, 2001, DEVELOPMENT, V128, P3117; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; SORIANO JV, 1995, J CELL SCI, V108, P413; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	72	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37904	37911		10.1074/jbc.M201743200	http://dx.doi.org/10.1074/jbc.M201743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138161	hybrid, Green Published			2022-12-25	WOS:000178447100127
J	Mysorekar, IU; Lorenz, RG; Gordon, JI				Mysorekar, IU; Lorenz, RG; Gordon, JI			A gnotobiotic transgenic mouse model for studying interactions between small intestinal enterocytes and intraepithelial lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; EPITHELIAL-CELL TYPES; C-KIT; GASTROINTESTINAL ECOSYSTEM; GUT CRYPTOPATCHES; FLT3 LIGAND; T-CELLS; GAMMA; DIFFERENTIATION; MICE	The mouse intestinal epithelium undergoes continuous renewal throughout life. Intraepithelial lymphocytes (IELs) represent a significant fraction of this epithelium and play an important role in intestinal mucosal barrier function. We have generated a germfree transgenic mouse model to examine the effects of a genetically engineered proliferative abnormality in the principal epithelial cell lineage (enterocytes) on IEL census and on IEL-enterocytic cross-talk. SV40 large T antigen (TAgWt) or a mutant derivative (TAgK107/8) that does not bind pRB was expressed in small intestinal villus enterocytes under the control of elements from the intestinal fatty acid binding protein gene (Fabpi). Quantitative immunohistochemical and flow cytometric analyses of conventionally raised and germ-free FVB/N Fabpi-TAgWt, Fabpi-TAgK107/8, and nontransgenic mice disclosed that forced reentry of enterocytes into the cell cycle is accompanied by an influx of thymically educated alphabeta T cell receptor (TCR)(+) CD4(+) and alphabeta TCR+ CD8alphabeta(+) IELs and a decrease in intestinally derived gammadelta TCR+ CD8alphaalpha IELs. Real time quantitative reverse transcriptase-PCR studies of jejunal villus epithelium recovered from germ-free transgenic and normal mice by laser capture microdissection and gammadelta TCR+ jejunal IELs purified by flow cytometry disclosed that the proliferative abnormality is accompanied by decreased expression of enterocytic interleukin-7 as well as IEL interleukin-7Ralpha and transforming growth factor beta3. The analysis also revealed that normal villus epithelium expresses Fins-like tyrosine kinase 3 (Flt3), a known regulator of hematopoietic stem cell proliferation and neuronal cell survival, and its ligand (Flt3L). Epithelial expression of this receptor and its ligand is reduced by the proliferative abnormality, whereas IEL expression of Flt3L remains constant. Together, these findings demonstrate that changes in the proliferative status of the intestinal epithelium affects maturation of gammadelta TCR+ IELs and produces an influx of alphabeta TCR+ IELs even in the absence of a microflora.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu	Mysorekar, Indira U./GRS-4574-2022; Lorenz, Robin G/AAJ-1499-2021	Mysorekar, Indira U./0000-0003-3917-8677; Lorenz, Robin G/0000-0002-2514-9819	NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; Brazel CY, 2001, MOL CELL NEUROSCI, V18, P381, DOI 10.1006/mcne.2001.1033; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1969, AM J ANAT, V126, P507, DOI 10.1002/aja.1001260409; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; COHN SM, 1984, J BIOL CHEM, V259, P2456; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; Fahrer AM, 2001, P NATL ACAD SCI USA, V98, P10261, DOI 10.1073/pnas.171320798; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Fujihashi K, 1997, EUR J IMMUNOL, V27, P2133, DOI 10.1002/eji.1830270903; GODFREY DI, 1992, J IMMUNOL, V149, P2281; Gordon JI, 1997, AM J PHYSIOL-GASTR L, V273, pG565, DOI 10.1152/ajpgi.1997.273.3.G565; HERMISTON ML, 1995, AM J PHYSIOL-GASTR L, V268, pG813, DOI 10.1152/ajpgi.1995.268.5.G813; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; HOYNE GF, 1993, IMMUNOLOGY, V80, P204; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; Laky K, 2000, J EXP MED, V191, P1569, DOI 10.1084/jem.191.9.1569; Lambolez F, 2002, J EXP MED, V195, P437, DOI 10.1084/jem.20010798; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; McCracken VJ, 2001, CELL MICROBIOL, V3, P1, DOI 10.1046/j.1462-5822.2001.00090.x; McKaig BC, 1999, AM J PHYSIOL-GASTR L, V276, pG1087, DOI 10.1152/ajpgi.1999.276.5.G1087; Moore TA, 1996, J IMMUNOL, V157, P2366; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; NICHOLS DB, 1974, J HISTOCHEM CYTOCHEM, V22, P929, DOI 10.1177/22.10.929; Ohbo K, 1996, INT IMMUNOL, V8, P951, DOI 10.1093/intimm/8.6.951; Oida T, 2000, J IMMUNOL, V164, P3616, DOI 10.4049/jimmunol.164.7.3616; Omori M, 1997, AM J PATHOL, V150, P1179; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROSNET O, 1991, ONCOGENE, V6, P1641; Shah AJ, 1996, BLOOD, V87, P3563, DOI 10.1182/blood.V87.9.3563.bloodjournal8793563; Shires J, 2001, IMMUNITY, V15, P419, DOI 10.1016/S1074-7613(01)00192-3; STAPPENBECK TS, 2002, METHOD ENZYMOL, V31, P559; Stein S A, 1991, Thyroid, V1, P257, DOI 10.1089/thy.1991.1.257; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; Suzuki K, 2000, IMMUNITY, V13, P691, DOI 10.1016/S1074-7613(00)00068-6; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; Yamamoto M, 1998, J IMMUNOL, V160, P2188; YAMAMOTO M, 1993, J IMMUNOL, V150, P106	57	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37811	37819		10.1074/jbc.M205300200	http://dx.doi.org/10.1074/jbc.M205300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138109	hybrid			2022-12-25	WOS:000178447100116
J	Said, EA; Krust, B; Nisole, S; Svab, J; Briand, JP; Hovanessian, AG				Said, EA; Krust, B; Nisole, S; Svab, J; Briand, JP; Hovanessian, AG			The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOLECULE HB-GAM; GROWTH-FACTOR; WILMS-TUMOR; ACTIN CYTOSKELETON; RICH DOMAIN; V3 LOOP; PROTEIN; IDENTIFICATION; ATTACHMENT	The growth factor midkine (MK) is a cytokine that inhibits the attachment of human immunodeficiency virus particles by a mechanism similar to the nucleolin binding HB-19 pseudopeptide. Here we show that the binding of MK to cells occurs specifically at a high and a low affinity binding site. HB-19 prevents the binding of MK to the low affinity binding site only. Confocal immunofluorescence laser microscopy revealed the colocalization of MK and the cell-surface-expressed nucleolin at distinct spots. The use of various deletion constructs of nucleolin then indicated that the extreme C-terminal end of nucleolin, containing repeats of the amino acid motif RGG, is the domain that binds MK. The specific binding of MK to cells is independent of heparan sulfate and chondroitin sulfate expression. After binding to cells, MK enters cells by an active process. Interestingly, the cross-linking of surface-bound MK with a specific antibody results in the clustering of surface nucleolin along with glycosylphosphatidylinositol-linked proteins CD90 and CD59, thus, pointing out that MK binding induces lateral assemblies of nucleolin with specific membrane components of lipid rafts. Our results suggest that the cell surface-expressed nucleolin serves as a low affinity receptor for MK and could be implicated in its entry process.	Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, F-75724 Paris 15, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-75700 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Hovanessian, AG (corresponding author), Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.		Said, Elias/AAY-5557-2020; Nisole, Sébastien/ABA-2367-2021	Nisole, Sébastien/0000-0001-9793-419X; Said, Elias/0000-0003-4224-6351				Adachi Y, 1996, ONCOGENE, V13, P2197; ARIDOME K, 1995, JAP J CANC RES, V118, P88; BERGER EA, 1997, AIDS SA, V1, P3; Bishop NE, 1997, REV MED VIROL, V7, P199, DOI 10.1002/(SICI)1099-1654(199712)7:4<199::AID-RMV203>3.0.CO;2-F; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Callebaut C, 1996, VIROLOGY, V218, P181, DOI 10.1006/viro.1996.0178; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Callebaut C, 2001, VIROLOGY, V281, P248, DOI 10.1006/viro.2000.0767; Callebaut C, 1997, J BIOL CHEM, V272, P7159, DOI 10.1074/jbc.272.11.7159; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; GUO N, 1989, J BIOL CHEM, V264, P13267; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Holowka D, 2000, J CELL SCI, V113, P1009; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; KRUST B, 1987, ANN INST PASTEUR VIR, V138, P245, DOI 10.1016/S0769-2617(87)80008-4; Kurosawa N, 2000, EUR J BIOCHEM, V267, P344, DOI 10.1046/j.1432-1327.2000.01005.x; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Larrucea S, 1999, BIOCHEM BIOPH RES CO, V266, P51, DOI 10.1006/bbrc.1999.1766; Limal D, 1998, J PEPT RES, V52, P121; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522; Nisole S, 1999, J BIOL CHEM, V274, P27875, DOI 10.1074/jbc.274.39.27875; Nisole S, 2000, AIDS RES HUM RETROV, V16, P237, DOI 10.1089/088922200309331; OBrien WA, 1996, J VIROL, V70, P2825, DOI 10.1128/JVI.70.5.2825-2831.1996; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Ratovitski EA, 1997, CELL MOL BIOL, V43, P425; RAULO E, 1994, J BIOL CHEM, V269, P12999; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; Salama RHM, 2001, EXP CELL RES, V270, P13, DOI 10.1006/excr.2001.5341; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Takahashi A, 2001, J BIOCHEM-TOKYO, V129, P599, DOI 10.1093/oxfordjournals.jbchem.a002896; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TSUTSUI J, 1993, CANCER RES, V53, P1281; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YASUHARA O, 1993, BIOCHEM BIOPH RES CO, V192, P246, DOI 10.1006/bbrc.1993.1406; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	68	115	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37492	37502		10.1074/jbc.M201194200	http://dx.doi.org/10.1074/jbc.M201194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147681	hybrid			2022-12-25	WOS:000178447100075
J	E, XP; Zhang, L; Lu, JY; Tso, P; Blaner, WS; Levin, MS; Li, E				E, XP; Zhang, L; Lu, JY; Tso, P; Blaner, WS; Levin, MS; Li, E			Increased neonatal mortality in mice lacking cellular retinol-binding protein II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; RAT SMALL-INTESTINE; TISSUE-SPECIFIC EXPRESSION; DEVELOPMENTAL REGULATION; EMBRYONIC-DEVELOPMENT; NORMAL-PREGNANCY; ACID RECEPTORS; LUNG; METABOLISM; ABSORPTION	Cellular retinol-binding protein II (CRBP H) is a member of the cellular retinol-binding protein family, which is expressed primarily in the small intestine. To investigate the physiological role of CRBP II, the gene encoding CRBP II was inactivated. The saturable component of intestinal retinol uptake is impaired in CRBP II-/- mice. The knockout mice, while maintained on a vitamin A-enriched diet, have reduced (40%) hepatic vitamin A stores but grow and reproduce normally. However, reducing maternal dietary vitamin A to marginal levels during the latter half of gestation results in 100% mortality/litter within 24 h after birth in the CRBP II-/- line but no mortality in the wild type line. The neonatal mortality in heterozygote offspring of CRBP II-/- dams (79 +/- 21% deaths/litter) was increased as compared with the neonatal mortality in heterozygote offspring of wild type dams (29 +/- 25% deaths per litter, p < 0.05). Maternal CRBP II was localized by immunostaining in the placenta at 18 days postcoitum as well as in the small intestine. These studies suggest that both fetal as well as maternal CRBP II are required to ensure adequate delivery of vitamin A to the developing fetus when dietary vitamin A is limiting.	Washington Univ, Sch Med, Div Gastroenterol, Dept Med, St Louis, MO 63110 USA; St Louis Vet Affairs Adm Med Ctr, St Louis, MO 63106 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati; Columbia University	Li, E (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Med, Campus Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.	eli@im.wustl.edu			NIDDK NIH HHS [DK52444, DK50446, DK40172, DK 56341, DK 52574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK050446, R01DK040172, R29DK040172, P30DK056341, R01DK052444] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antipatis C, 2000, BRIT J NUTR, V84, P125; Antipatis C, 1998, AM J PHYSIOL-LUNG C, V275, pL1184, DOI 10.1152/ajplung.1998.275.6.L1184; Barua AB, 1998, J NUTR BIOCHEM, V9, P8, DOI 10.1016/S0955-2863(97)00133-2; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BRUINSE HW, 1995, EUR J OBSTET GYN R B, V61, P31, DOI 10.1016/0028-2243(95)02150-Q; Chailley-Heu B, 1999, AM J RESP CELL MOL, V21, P89, DOI 10.1165/ajrcmb.21.1.3563; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cikot RJLM, 2001, BRIT J NUTR, V85, P49, DOI 10.1079/BJN2000209; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; Dann WJ, 1932, BIOCHEM J, V26, P1072, DOI 10.1042/bj0261072; DARLOW BA, 2001, COCHRANE DATABASE SY, V2; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEW SE, 1994, BIOCHEMISTRY-US, V33, P12340, DOI 10.1021/bi00206a042; Dickman ED, 1997, DEVELOPMENT, V124, P3111; DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; GARDNER EM, 1993, J NUTR, V123, P1435; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; Harrison EH, 2001, J NUTR, V131, P1405, DOI 10.1093/jn/131.5.1405; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Hind M, 2002, AM J PHYSIOL-LUNG C, V282, pL468, DOI 10.1152/ajplung.00196.2001; HOLLANDER D, 1981, J LAB CLIN MED, V97, P449; HOLLANDER D, 1977, AM J PHYSIOL, V232, pE471, DOI 10.1152/ajpendo.1977.232.5.E471; ISMADI SD, 1982, INT J VITAM NUTR RES, V52, P111; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; Levin Marc Stephen, 1994, P1957; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1993, J BIOL CHEM, V268, P8267; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; Lindberg LA, 1999, RES VET SCI, V66, P259, DOI 10.1053/rvsc.1998.0280; MACDONALD PN, 1988, J BIOL CHEM, V263, P19478; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MOORE T, 1971, INT J VITAM NUTR RES, V41, P301; Napoli JL, 2000, NUTR REV, V58, P230, DOI 10.1111/j.1753-4887.2000.tb01870.x; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P823; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; QUICK TC, 1989, J LIPID RES, V30, P1049; RABINOVITCH M, 1998, COMPREHENSIVE CARDIO, P3001; ROSS AC, 1990, METHOD ENZYMOL, V189, P442; Sapin V, 1997, DEV DYNAM, V208, P199, DOI 10.1002/(SICI)1097-0177(199702)208:2<199::AID-AJA7>3.0.CO;2-D; TAKAHASHI YI, 1977, AM J PHYSIOL, V233, pE263, DOI 10.1152/ajpendo.1977.233.4.E263; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang JL, 1997, J NUTR, V127, P1297, DOI 10.1093/jn/127.7.1297; Wellik DM, 1997, AM J PHYSIOL-ENDOC M, V272, pE25, DOI 10.1152/ajpendo.1997.272.1.E25; White JC, 1998, P NATL ACAD SCI USA, V95, P13459, DOI 10.1073/pnas.95.23.13459; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	55	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36617	36623		10.1074/jbc.M205519200	http://dx.doi.org/10.1074/jbc.M205519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138113	hybrid			2022-12-25	WOS:000178275100106
J	Kaul, S; Murphy, PJM; Chen, J; Brown, L; Pratt, WB; Simons, SS				Kaul, S; Murphy, PJM; Chen, J; Brown, L; Pratt, WB; Simons, SS			Mutations at positions 547-553 of rat glucocorticoid receptors reveal that hsp90 binding requires the presence, but not defined composition, of a seven-amino acid sequence at the amino terminus of the ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NUCLEAR-RECEPTOR; STEROID-BINDING; PROGESTERONE-RECEPTOR; INTERDOMAIN COMMUNICATION; CONFORMATIONAL-CHANGES; RETICULOCYTE LYSATE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DNA-BINDING	Glucocorticoid receptors (GRs) must heterocomplex with hsp90 to have an open steroid binding cleft that can be accessed by steroid. We reported that a seven-amino acid sequence (547-553 of rat GR) overlapping the amino-terminal end of the ligand binding domain is required for hsp90 binding to GR. We have now conducted saturation mutagenesis of this sequence, which appears to be part of the surface where the ligand binding cleft merges with the surface of the ligand binding domain. No single point mutation causes significant changes in any of a variety of biochemical and biological properties in addition to hsp90 binding. A triple mutation (P548A/T549A/V551A) increases by > 100-fold the steroid concentration required for half-maximal induction without affecting the level of maximal induction or coactivator response. Interestingly, this triple mutant displays reduced binding of steroid and hsp90 in whole cells, but it possesses wild type affinity for steroid and normal hsp90 binding capacity under cell-free conditions. This phenotype of a dramatic shift in the dose response for transactivation would be expected from an increase in the rate of disassembly of the triple mutant GR-hsp90 heterocomplex in the cell. Mutation of the entire seven-amino acid region to CAAAAAC maintains the presence of a critical alpha-helical structure and heterocomplex formation with hsp90 but eliminates steroid binding and transcriptional activation, thus disconnecting hsp90 binding from opening of the ligand binding cleft and steroid binding.	NIDDK, LMCB, Steroid Hormones Sect, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormones Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NIDDK NIH HHS [DK31753] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CARSONJURICA MA, 1989, J STEROID BIOCHEM, V34, P1, DOI 10.1016/0022-4731(89)90060-5; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; Mackem S, 2001, J BIOL CHEM, V276, P45501, DOI 10.1074/jbc.C100269200; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1988, J BIOL CHEM, V263, P267; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	56	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36223	36232		10.1074/jbc.M206748200	http://dx.doi.org/10.1074/jbc.M206748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145311	hybrid			2022-12-25	WOS:000178275100058
J	Matsui, T; Kinoshita, T; Hirano, T; Yokota, T; Miyajima, A				Matsui, T; Kinoshita, T; Hirano, T; Yokota, T; Miyajima, A			STAT3 down-regulates the expression of cyclin D during liver development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B VIRUS; EMBRYONIC STEM-CELLS; MOUSE ONCOSTATIN-M; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; MACROPHAGE DIFFERENTIATION; SIGNALING MOLECULES; HEMATOPOIETIC-CELLS; HUMAN INTERLEUKIN-6; BINDING PROTEIN	As the expression of cyclin D1 is induced during liver regeneration and also in hepatic tumor cells, cyclin D1 is likely to play an important role in the proliferation and transformation of hepatocytes. However, the role of cyclin D1 in liver development remains unknown. Here we show that the expression of D-type cyclins including cyclin D1, D2, and D3 is down-regulated along with liver development. In addition, oncostatin M (OSM), an interleukin-6 family cytokine, down-regulated the expression of cyclin D1 and D2 in a primary culture of fetal hepatocytes in which OSM induces hepatic differentiation. Ectopic expression of receptor mutants defective in the activation of either STAT3 or SHP-2/Ras indicated that the down-regulation of D1 and D2 cyclins by OSM was mediated by STAT3 but not by SHP-2/Ras. Consistently, expression of dominant negative STAT3 but not Ras relieved OSM-induced suppression of cyclin D expression. Activation of STAT3 in fetal hepatocytes of transgenic mice expressing the STAT3-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in the suppression of cyclin D1 and D2 expression. These results indicate that STAT3 activation is necessary and sufficient for down-regulation of D1 and D2 cyclins in fetal hepatocytes. Furthermore, STAT3-C, a constitutively active form of STAT3, suppressed transcription of the cyclin D1 promoter in fetal hepatocytes, whereas it activated the transcription in hepatic tumor cells, huH7 and HepG2. Thus, STAT3-mediated down-regulation of cyclin D expression is rather specific to fetal hepatocytes that are undergoing maturation processes including a reduction of their proliferation potential.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1188639, Japan; Teikyo Univ, Biotechnol Res Ctr, Kanagawa Acad Sci & Technol, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	University of Tokyo; Osaka University; Osaka University; University of Tokyo; Kanagawa Academy Science & Technology; Teikyo University	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015; Hirano, Toshio/C-8194-2009					ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GILLETT C, 1994, CANCER RES, V54, P1812; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; Ito Y, 2000, HEPATOLOGY, V32, P1370, DOI 10.1053/jhep.2000.19815; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Matsui T, 2002, EMBO J, V21, P1021, DOI 10.1093/emboj/21.5.1021; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCDONALD VL, 1993, GROWTH FACTORS, V9, P167; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; ORITANI K, 1992, BLOOD, V80, P2298; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Schrump DS, 1996, CANCER GENE THER, V3, P131; SHERR CJ, 1994, STEM CELLS, V12, P47; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; YAGINUMA K, 1985, P NATL ACAD SCI USA, V82, P4458, DOI 10.1073/pnas.82.13.4458; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	50	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36167	36173		10.1074/jbc.M203184200	http://dx.doi.org/10.1074/jbc.M203184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147685	hybrid			2022-12-25	WOS:000178275100052
J	Torigoe, T; Izumi, H; Ishiguchi, H; Uramoto, H; Murakami, T; Ise, T; Yoshida, Y; Tanabe, M; Nomoto, M; Itoh, H; Kohno, K				Torigoe, T; Izumi, H; Ishiguchi, H; Uramoto, H; Murakami, T; Ise, T; Yoshida, Y; Tanabe, M; Nomoto, M; Itoh, H; Kohno, K			Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS SP1; TUMOR-CELLS; CISPLATIN RESISTANCE; DRUG-RESISTANCE; PROTON PUMP; V-ATPASES; IN-VIVO; DNA; PLASMA; PH	We have isolated two overlapping genomic clones that contain the 5'-terminal portion of the human vacuolar H+-ATPase c subunit (ATP6L) gene. The sequence preceding the transcription initiation site, which is GC-rich, contains four GC boxes and one Oct1-binding site, but there is no TATA box or CCAAT box. In vivo footprint analysis in human cancer cells shows that two GC boxes and the Oct1-binding site are occupied by Sp1 and Oct1, respectively. We show here that treatment with anticancer agents enhances ATP6L expression. Although cisplatin did not induce ATP6L promoter activity, it altered ATP6L mRNA stability. On the other hand, the DNA topoisomerase 11 inhibitor, TAS-103, strongly induced promoter activity, and this effect was completely eradicated when a mutation was introduced into the Oct1-binding site. Treatment with TAS-103 increased the levels of both Sp1/Sp3 and Oct1 in nuclear extracts. Cooperative binding of Sp1 and Oct1 to the promoter is required for promoter activation by TAS-103. Incubation of a labeled oligonucleotide probe encompassing the -73/-68 GC box and -64/-57 Oct1-binding site with a nuclear extract from drug-treated KB cells yielded higher levels of the specific DNA-protein complex than an extract of untreated cells. Thus, the two transcription factors, Sp1 and Oct1 interact, in an adaptive response to DNA damage, by up-regulating expression of the vacuolar H+-ATPase genes. Furthermore, combination of the vacuolar H+-ATPase (V-ATPase) inhibitor, bafilomycin A1, with TAS-103 enhanced apoptosis of KB cells with an associated increase in caspase-3 activity. Our data suggest that the induction of V-ATPase expression is an anti-apoptotic defense, and V-ATPase inhibitors in combination with low-dose anticancer agents may provide a new therapeutic approach.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.			Yoshida, Yoichiro/0000-0001-6583-7352				Azuma R, 1997, J CHROMATOGR B, V691, P179, DOI 10.1016/S0378-4347(96)00449-5; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Byl JAW, 1999, BIOCHEMISTRY-US, V38, P15573; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; FURUYA Y, 1994, CANCER LETT, V81, P95, DOI 10.1016/0304-3835(94)90170-8; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Ise T, 1999, CANCER RES, V59, P342; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; Kluza J, 2000, CANCER RES, V60, P4077; Koike K, 1996, JPN J CANCER RES, V87, P765, DOI 10.1111/j.1349-7006.1996.tb00290.x; KONISHI T, 1995, J BIOCHEM-TOKYO, V118, P1021, DOI 10.1093/jb/118.5.1021; LAURENCOT CM, 1995, ONCOL RES, V7, P363; Malone CS, 2000, J IMMUNOL, V164, P2550, DOI 10.4049/jimmunol.164.5.2550; Martinez-Zaguilan R, 1998, J CELL PHYSIOL, V176, P196, DOI 10.1002/(SICI)1097-4652(199807)176:1<196::AID-JCP21>3.0.CO;2-4; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; NAKAGAWA M, 1993, J UROLOGY, V150, P1970, DOI 10.1016/S0022-5347(17)35948-7; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; NOMOTO M, 1995, BBA-GENE STRUCT EXPR, V1264, P35, DOI 10.1016/0167-4781(95)00158-D; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Rundlof AK, 2001, J BIOL CHEM, V276, P30542, DOI 10.1074/jbc.M101452200; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SCHLAPPACK OK, 1991, BRIT J CANCER, V64, P663, DOI 10.1038/bjc.1991.378; SHEN DW, 1995, BRIT J CANCER, V71, P676, DOI 10.1038/bjc.1995.134; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Wang SP, 2002, J BIOL CHEM, V277, P8827, DOI 10.1074/jbc.M111959200; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wieczorek H, 2000, J EXP BIOL, V203, P127; Zhao HC, 2000, CANCER RES, V60, P6276	47	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36534	36543		10.1074/jbc.M202605200	http://dx.doi.org/10.1074/jbc.M202605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133827	hybrid			2022-12-25	WOS:000178275100096
J	Veenendaal, AKJ; van der Does, C; Driessen, AJM				Veenendaal, AKJ; van der Does, C; Driessen, AJM			The core of the bacterial translocase harbors a tilted transmembrane segment 3 of SecE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; MEMBRANE TRANSLOCATION; CATALYTIC CYCLE; CROSS-LINKING; SECYEG; MACHINERY; PRLA; RECONSTITUTION	The bacterial translocase mediates the translocation and membrane integration of proteins. The integral membrane proteins SecY and SecE are conserved core subunits of the translocase. Previous cysteine-scanning studies showed that the transmembrane segment (TMS) 3 of SecE contacts TMS 2 and 7 of SecY, and TMS 3 of another SecE. We now demonstrate that SecE also contacts,TMS 10 of SecY. Combining all available cysteine-scanning mutagenesis data, a three-dimensional model has been built in which the positions of the helices that form the central core of the bacterial translocase are mapped. Remarkably, this model reveals that TMS 3 of SecE is strongly tilted relative to SecY.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	aj.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; HANADA M, 1994, J BIOL CHEM, V269, P23625; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393	30	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36640	36645		10.1074/jbc.M205713200	http://dx.doi.org/10.1074/jbc.M205713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138117	hybrid, Green Published			2022-12-25	WOS:000178275100109
J	Ahel, I; Stathopoulos, C; Ambrogelly, A; Sauerwald, A; Toogood, H; Hartsch, T; Soll, D				Ahel, I; Stathopoulos, C; Ambrogelly, A; Sauerwald, A; Toogood, H; Hartsch, T; Soll, D			Cysteine activation is an inherent in vitro property of Prolyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; GENETIC-CODE; AMINO-ACIDS; METHANOCOCCUS-JANNASCHII; EDITING MECHANISM; PROTEIN-SYNTHESIS; BIOSYNTHESIS; SPECIFICITY	Aminoacyl-tRNA synthetases are well known for their remarkable precision in substrate selection during aminoacyl-tRNA formation. Some synthetases enhance the accuracy of this process by editing mechanisms that lead to hydrolysis of incorrectly activated and/or charged amino acids. Prolyl-tRNA synthetases (ProRSs) can be divided into two structurally divergent groups, archaeal-type and bacterial-type enzymes. A striking difference between these groups is the presence of an insertion domain (similar to180 amino acids) in the bacterial-type ProRS. Because the archaeal-type ProRS enzymes have been shown to recognize cysteine, we tested selected ProRSs from all three domains of life to determine whether cysteine activation is a general property of ProRS. Here we show that cysteine is activated by recombinant ProRS enzymes from the archaea Methanocaldococcus jannaschii and Methanothermobacter thermautotrophicus, from the eukaryote Saccharomyces cerevisiae, and from the bacteria Aquifex aeolicus, Borrelia burgdorferi, Clostridium sticklandii, Cytophaga hutchinsonii, Deinococcus radiodurans, Escherichia coli, Magnetospirillum magnetotacticum, Novosphingobium aromaticivorans, Rhodopseudomonas palustris, and Thermus thermophilus. This non-cognate amino acid was efficiently acylated in vitro onto tRNA Pro, and the misacylated Cys-tRNA(Pro) was not edited by ProRS. Therefore, ProRS exhibits a natural level of mischarging that is to date unequalled among the aminoacyl-tRNA synthetases.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	Yale University; Yale University; University of Gottingen	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Stathopoulos, Constantinos/0000-0002-5699-4118; Ahel, Ivan/0000-0002-9446-3756; Toogood, Helen/0000-0003-4797-0293				Ambrogelly A, 2002, J BIOL CHEM, V277, P34749, DOI 10.1074/jbc.M206929200; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Brooks DJ, 2002, MOL CELL PROTEOMICS, V1, P125, DOI 10.1074/mcp.M100001-MCP200; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; Burke B, 2001, J BIOL CHEM, V276, P20286, DOI 10.1074/jbc.M100456200; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; de Pouplana LR, 2001, J MOL EVOL, V53, P261, DOI 10.1007/s002390010216; Di Giulio M, 1999, J MOL EVOL, V49, P1, DOI 10.1007/PL00006522; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Doring V, 1998, GENETICS, V150, P543; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Feng L, 2002, EXTREMOPHILES, V6, P167, DOI 10.1007/s007920100245; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1245, DOI 10.1021/bi00574a020; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; GILLAM I, 1967, BIOCHEMISTRY-US, V6, P3043, DOI 10.1021/bi00862a011; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Jacquin-Becker C, 2002, FEBS LETT, V514, P34, DOI 10.1016/S0014-5793(02)02331-1; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Kabisch UC, 1999, J BIOL CHEM, V274, P8445, DOI 10.1074/jbc.274.13.8445; LEE ML, 1969, J BIOL CHEM, V244, P223; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Newberry KJ, 2002, EMBO J, V21, P2778, DOI 10.1093/emboj/21.11.2778; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; RIVERA JA, 1984, CAN J BIOCHEM CELL B, V62, P507, DOI 10.1139/o84-068; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, BIOCHEMISTRY-US, V40, P46, DOI 10.1021/bi002108x; Trifonov EN, 2000, GENE, V261, P139, DOI 10.1016/S0378-1119(00)00476-5; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712	45	55	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34743	34748		10.1074/jbc.M206928200	http://dx.doi.org/10.1074/jbc.M206928200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130657	hybrid			2022-12-25	WOS:000178117000013
J	Mao, JH; Maye, P; Kogerman, P; Tejedor, FJ; Toftgard, R; Xie, W; Wu, GQ; Wu, DQ				Mao, JH; Maye, P; Kogerman, P; Tejedor, FJ; Toftgard, R; Xie, W; Wu, GQ; Wu, DQ			Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEDGEHOG SIGNALING PATHWAY; SYNDROME CRITICAL REGION; CUBITUS-INTERRUPTUS; PROTEIN-KINASE; SONIC HEDGEHOG; DUAL-SPECIFICITY; PHOSPHORYLATION SITE; BINDING PROTEIN; HUMAN HOMOLOG; IN-VITRO	To investigate the cellular role of dual specificity Yak1-related kinase (Dyrk) 1, a nuclear localized dual specificity protein kinase, we examined its effect on transcriptional regulation using reporter gene assays. We found that Dyrk1 can substantially enhance Gli1-dependent, but not LEF-1-, c-Jun-, or Elk-dependent, gene transcription. In part, Dyrk1 does this through retaining Gli1 in the nucleus. However, we also demonstrate that Dyrk1 can enhance the transcriptional activity of Gli1-AHA, a nuclear export mutant, suggesting that Dyrk1 may be more directly involved in regulating the transcriptional activity of Gli1. In addition, Dyrk1 acted synergistically with Sonic hedgehog (Shh) to induce gene transcription and differentiation in mouse C3H10T1/2 cells. The failure of Shh to stimulate Dyrk1 kinase activity suggests that Dyrk1 may not be directly regulated by the Shh signaling pathway but functionally interacts with it. Thus, Gli1 transcriptional activity may be subjected to further regulation in the cell nucleus by a pathway distinct from Shh signaling, one mediated by Dyrk1.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Karolinska Inst, Dept Biosci, SE-14157 Huddinge, Sweden; Novum, Ctr Nutr & Toxicol, SE-14157 Huddinge, Sweden; Tallinn Univ Technol, NICPB, EE-200108 Tallinn, Estonia; Tallinn Univ Technol, Ctr Gene Technol, EE-200108 Tallinn, Estonia; Univ Miguel Hernandezy, CSIC, Inst Neurociencias, Unidad Neurobiol Desarrollo, Alicante 03550, Spain; Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; SE Univ, Sch Med, Dept Genet, Nanjing 210018, Peoples R China; Vanderbilt Univ, Dept Med Med Genet, Nashville, TN 37232 USA	University of Connecticut; Karolinska Institutet; Karolinska Institutet; National Institute of Chemical Physics & Biophysics (NICPB); Tallinn University of Technology; Tallinn University of Technology; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); University of Rochester; Southeast University - China; Vanderbilt University	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, MC3301,263 Farmington Ave, Farmington, CT 06030 USA.	dwu@neuron.uchc.edu	Kogerman, Priit/B-6333-2008	Maye, Peter/0000-0003-0098-4399; Tejedor, Francisco J/0000-0003-1942-2580				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 2000, MOL CELL BIOL, V20, P1616, DOI 10.1128/MCB.20.5.1616-1625.2000; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HARTLEY AD, 1994, GENETICS, V136, P465; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Methot N, 2000, DEVELOPMENT, V127, P4001; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Muller B, 2000, DEVELOPMENT, V127, P2999; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shang EY, 2000, MOL REPROD DEV, V55, P372, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;372::AID-MRD3&gt;3.0.CO;2-A; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Stone DM, 1999, J CELL SCI, V112, P4437; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	50	152	155	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35156	35161		10.1074/jbc.M206743200	http://dx.doi.org/10.1074/jbc.M206743200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12138125	hybrid			2022-12-25	WOS:000178117000064
J	Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J				Horton, LE; Bushell, M; Barth-Baus, D; Tilleray, VJ; Clemens, MJ; Hensold, J			p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation	ONCOGENE			English	Article						growth inhibition; mTOR; p53; polypeptide chain initiation; protein synthesis	CAP-DEPENDENT INITIATION; MESSENGER-RNA; MAMMALIAN TARGET; FACTOR 4E; PHAS-I; DIFFERENTIAL REQUIREMENTS; SIGNALING PATHWAYS; BINDING PROTEIN; PHOSPHORYLATION; RAPAMYCIN	p53 is an important regulator of cell cycle progression and apoptosis, and inactivation of p53 is associated with tumorigenesis. Although p53 exerts many of its effects through regulation of transcription, this protein is also found in association with ribosomes and several mRNAs have been identified that are translationally controlled in a p53-dependent manner. We have utilized murine erythroleukemic cells that express a temperature-sensitive p53 protein to determine whether p53 also functions at the level of translation. The data presented here demonstrate that p53 causes a rapid decrease in translation initiation. Analysis of several potential mechanisms for regulating protein synthesis shows that p53 has selective effects on the phosphorylation of the eIF4E-binding protein, 4E-BP1, and the activity of the p70 ribosomal protein S6 kinase. These data provide evidence that modulation of translational activity constitutes a further mechanism by which the growth inhibitory effects of p53 may be mediated.	St George Hosp, Sch Med, Dept Biochem & Immunol, London SW17 0RE, England; Case Western Reserve Univ, Sch Med, Dept Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA	St Georges University London; Case Western Reserve University	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Biochem & Immunol, Cranmer Terrace, London SW17 0RE, England.	M.Clemens@sghms.ac.uk			NIDDK NIH HHS [DK43414] Funding Source: Medline; PHITPO CDC HHS [HK07147-21A1] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHITPO CDC HHS		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hensold JO, 1996, J BIOL CHEM, V271, P23246, DOI 10.1074/jbc.271.38.23246; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MERRICK W, 2000, CURR PROTOCALS CELL, V11; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Morley SJ, 2000, FEBS LETT, V477, P229, DOI 10.1016/S0014-5793(00)01805-6; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SMITH M R, 1990, New Biologist, V2, P648; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1995, J IMMUNOL, V155, P3418; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WANG Y, 2000, P NATL ACAD SCI USA, V97, P5486; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	82	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5325	5334		10.1038/sj.onc.1205662	http://dx.doi.org/10.1038/sj.onc.1205662			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149653				2022-12-25	WOS:000177193900013
J	Ishida, Y; Kondo, T; Ohshima, T; Fujiwara, H; Iwakura, Y; Mukaida, N				Ishida, Y; Kondo, T; Ohshima, T; Fujiwara, H; Iwakura, Y; Mukaida, N			A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury	FASEB JOURNAL			English	Article						interferon; chemokines; adhesion molecules; nitric oxide synthase	INDUCED HEPATIC-NECROSIS; NITRIC-OXIDE SYNTHASE; INDUCED HEPATOTOXICITY; INTERFERON-GAMMA; FACTOR-ALPHA; IN-VITRO; MICE; PARACETAMOL; PRETREATMENT; HEPATOCYTES	In wild-type BALB/c mice, i.p. administration of acetaminophen (APAP; 750 mg/kg) induced intrahepatic IFN-gamma mRNA expression and a marked increase in serum transaminase levels, leading to acute lethality of similar to45%. Histopathological examination showed centrilobular hepatic necrosis with leukocyte infiltration and a large number of apoptotic hepatocytes 10 and 24 h after APAP challenge. mRNA expression of intercellular adhesion molecule 1, vascular cell adhesion molecule 1, interleukin (IL) 1alpha, IL-1beta, IL-6, tumor necrosis factor alpha, monocyte chemoattractant protein 1, macrophage inflammatory protein (MIP) 1alpha, MIP-2, KC, IP-10, Mig, Fas, and inducible nitric oxide synthase was enhanced in the liver of wild-type mice injected with APAP. To clarify the role of IFN-gamma in this process, IFN-gamma-deficient mice were treated in the same manner. All IFN-gamma-deficient mice survived with reduced serum transaminase elevation and attenuated hepatic necrosis, leukocyte infiltration, and hepatocyte apoptosis. The gene expression of all molecules was significantly attenuated in IFN-gamma-deficient mice. Administration of an anti-IFN-gamma neutralizing antibody even 2 or 8 h after APAP challenge to wild-type mice alleviated APAP-induced liver injury, and all mice survived. Thus, IFN-gamma is responsible for APAP-induced liver injury by mediating leukocyte infiltration, hepatocyte apoptosis, and NO production as well as cytokine and chemokine production. Moreover, immunoneutralization of IFN-gamma may be therapeutically effective for developing APAP-induced liver injury.	Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, Kanazawa, Ishikawa 9208640, Japan; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol, Osaka, Japan; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Tokyo 108, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 920, Japan	Kanazawa University; Osaka University; University of Tokyo; Kanazawa University	Ohshima, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ohshimat@med.kanazawa-u.ac.jp	Iwakura, Yoichiro/E-5457-2011; Mukaida, Naofumi/D-7623-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Mukaida, Naofumi/0000-0002-4193-1851; Kondo, Toshikazu/0000-0002-5059-8309				Blazka ME, 1996, TOXICOL PATHOL, V24, P181, DOI 10.1177/019262339602400206; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Boess F, 1998, HEPATOLOGY, V27, P1021, DOI 10.1002/hep.510270418; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DEGROOTE J, 1995, ACTA GASTRO-ENT BELG, V58, P326; Delanty N, 1996, IRISH MED J, V89, P156; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316; Goldin RD, 1996, J PATHOL, V179, P432; Hajri A, 1998, BRIT J CANCER, V78, P841, DOI 10.1038/bjc.1998.591; Hogaboam CM, 2000, AM J PATHOL, V156, P1245, DOI 10.1016/S0002-9440(10)64995-4; Hogaboam CM, 1999, FASEB J, V13, P1565, DOI 10.1096/fasebj.13.12.1565; Hogaboam CM, 1999, GENE THER, V6, P573, DOI 10.1038/sj.gt.3300858; KELLOKUMPULEHTINEN P, 1989, LANCET, V1, P1143; KUO PC, 1994, J SURG RES, V56, P594, DOI 10.1006/jsre.1994.1094; Luster MI, 2001, TOXICOL LETT, V120, P317, DOI 10.1016/S0378-4274(01)00284-3; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Maeda M, 1998, NEUROSCI LETT, V240, P69, DOI 10.1016/S0304-3940(97)00901-4; Makin AJ, 1997, ADV INTERNAL MED, V42, P453; Michael SL, 1999, HEPATOLOGY, V30, P186, DOI 10.1002/hep.510300104; Mihm S, 1996, MED MICROBIOL IMMUN, V185, P95, DOI 10.1007/s004300050020; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; Mizuhara H, 1996, HEPATOLOGY, V23, P1608, DOI 10.1002/hep.510230643; NAKAE D, 1990, AM J PATHOL, V136, P787; Neumann B, 1996, J IMMUNOL, V156, P1587; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Robson RL, 2001, J IMMUNOL, V167, P1028, DOI 10.4049/jimmunol.167.2.1028; Sass G, 2001, J CLIN INVEST, V107, P439, DOI 10.1172/JCI10613; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; Simpson KJ, 2000, J PATHOL, V190, P489; Smith GS, 1998, J SURG RES, V80, P252, DOI 10.1006/jsre.1998.5441; Tagawa Y, 1997, J IMMUNOL, V159, P1418; TAKADA H, 1995, DIGEST DIS SCI, V40, P1831, DOI 10.1007/BF02212709; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Tsuji H, 1999, J IMMUNOL, V162, P1049; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WHITCOMB DC, 1994, NEW ENGL J MED, V331, P1311	38	169	176	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1227	10.1096/fj.02-0046com	http://dx.doi.org/10.1096/fj.02-0046com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153990				2022-12-25	WOS:000177814000031
J	Shamri, R; Grabovsky, V; Feigelson, SW; Dwir, O; van Kooyk, Y; Alon, R				Shamri, R; Grabovsky, V; Feigelson, SW; Dwir, O; van Kooyk, Y; Alon, R			Chemokine stimulation of lymphocyte alpha(4) integrin avidity but not of leukocyte function-associated antigen-1 avidity to endothelial ligands under shear flow requires cholesterol membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; LIPID RAFTS; VASCULAR ENDOTHELIUM; T-LYMPHOCYTES; RECEPTOR; ARREST; ACTIVATION; AFFINITY; BINDING; KINASE	VLA-4 and LFA-1 are the major vascular integrins expressed on circulating lymphocytes. Previous studies suggested that intact cholesterol rafts are required for integrin adhesiveness in different leukocytes. We found the alpha(4) integrins VLA-4 and alpha(4)beta(7), as well as the LFA-1 integrin to be excluded from rafts of human peripheral blood lymphocytes. Disruption of cholesterol rafts with the chelator methyl-beta-cyclodextrin did not affect the ability of these lymphocyte integrins to generate high avidity to their respective endothelial ligands and to promote lymphocyte rolling and arrest on inflamed endothelium. under shear flow. In contrast, cholesterol extraction abrogated rapid chemokine triggering of alpha(4)-integrin-dependent peripheral blood lymphocytes adhesion, a process tightly regulated by G(i)-protein activation of G protein-coupled chemokine receptors (GPCR). Strikingly, stimulation of LFA-1 avidity to intercellular adhesion molecule 1 (ICAM-1) by the same chemokines, although G(i)-dependent, was insensitive to raft disruption. Our results suggest that alpha(4) but not LFA-1 integrin avidity stimulation by chemokines involves rapid chemokine-induced GPCR rearrangement that takes place at cholesterol raft platforms upstream to G(i) signaling. Our results provide the first evidence that a particular chemokine/GPCR pair can activate different integrins on the same cell using distinct G(i) protein-associated machineries segregated within defined membrane compartments.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; VU Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands	Weizmann Institute of Science; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Alonso MA, 2001, J CELL SCI, V114, P3957; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Leitinger B, 2002, J CELL SCI, V115, P963; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Manes S, 1999, MOL CELL BIOL, V19, P3125; Manes S, 2001, SEMIN IMMUNOL, V13, P147, DOI 10.1006/smim.2000.0306; Mitchell JS, 2002, J IMMUNOL, V168, P2737, DOI 10.4049/jimmunol.168.6.2737; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; Sorice M, 2001, FEBS LETT, V506, P55, DOI 10.1016/S0014-5793(01)02830-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001	42	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40027	40035		10.1074/jbc.M206806200	http://dx.doi.org/10.1074/jbc.M206806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163503	hybrid			2022-12-25	WOS:000178662500123
J	Tulik, GR; Chodavarapu, S; Edgar, R; Giannunzio, L; Langland, A; Schultz, B; Beckman, JD				Tulik, GR; Chodavarapu, S; Edgar, R; Giannunzio, L; Langland, A; Schultz, B; Beckman, JD			Inhibition of bovine phenol sulfotransferase (bSULT1A1) by CoA thioesters - Evidence for positive cooperativity and inhibition by interaction with both the nucleotide and phenol binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE SULFOTRANSFERASE; ARYL SULFOTRANSFERASE; COENZYME-A; KINETIC CHARACTERIZATION; POTENT INHIBITORS; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; SULFATING FORM; HUMAN-BRAIN; MECHANISM	Previous work with the bovine phenol sulfotransferase (bSULT1A1, EC 2.8.2.1) demonstrated inhibition by CoA that was competitive with respect to the sulfuryl donor substrate, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) (Leach, M., Cameron, E., Fite, N., Stassinopoulos, J., Palmreuter, N., and Beckmann, J. D. (1999) Biochem. Biophys. Res. Commun. 261, 815-819). Here we report that long chain acyl-CoAs are more potent inhibitors of bSULT1A1 and also of human dopamine sulfotransferase (SULT1A3) when compared with unesterified CoA and short chain-length acyl-CoAs. A complex pattern of inhibition was revealed by systematic variation of palmitoyl-CoA, PAPS, and 7-hydroxy-coumarin, the acceptor substrate. Convex plots of apparent K-m/V-max versus [palmitoyl-CoA] were adequately modeled using an ordered rapid equilibrium scheme with PAPS as the leading substrate and by accounting for the possible binding of two equivalents of inhibitor to the dimeric enzyme. Interestingly, the first K-i of 2-3 muM was followed by a second K-i of only 0.01-0.05 muM, suggesting that positive subunit cooperativity enhances binding of long chain acyl-CoAs to this sulfotransferase. Simultaneous interaction of palmitoyl-CoA with both the nucleotide and phenol binding sites is suggested by two experiments. First, the acyl-CoA displaced 7-hydroxy-coumarin from the highly fluorescent bSULT1A1-PAP-7-HC complex in a cooperative manner. Second, palmitoyl-CoA prevented the quenching of bSULT1A1 fluorescence observed with pentachlorophenol. Finally, titrations of bSLTLT1A1-pentachlorophenol complex with palmitoyl-CoA caused the return of protein fluorescence, and the binding of palmitoyl-CoA was highly cooperative (Hill constant of 1.9). Overall, these results suggest a model of sulfotransferase inhibition in which the 3'-phosphoadenosine-5'-diphosphate moiety of CoA docks to the PAPS domain, and the acyl-pantetheine group docks to the hydrophobic phenol binding domain.	Alma Coll, Dept Biochem, Alma, MI 48801 USA		Beckman, JD (corresponding author), Alma Coll, Dept Biochem, 614 W Superior St, Alma, MI 48801 USA.		chodavarapu, sundari/Q-3279-2019; Beckman, Joan/V-2579-2019; chodavarapu, sundari/Q-3272-2019	Beckman, Joan/0000-0001-7903-944X; 				ARAND M, 1987, ANAL BIOCHEM, V163, P546, DOI 10.1016/0003-2697(87)90261-2; BAMFORTH KJ, 1993, BIOCHEM PHARMACOL, V46, P1713, DOI 10.1016/0006-2952(93)90575-H; BANERJEE RK, 1968, BIOCHIM BIOPHYS ACTA, V151, P573, DOI 10.1016/0005-2744(68)90004-1; BARTZATT R, 1994, BIOCHEM PHARMACOL, V47, P2087, DOI 10.1016/0006-2952(94)90085-X; BECKMANN JD, 1993, CELL TISSUE RES, V274, P475, DOI 10.1007/BF00314544; Beckmann JD, 1998, CHEM-BIOL INTERACT, V109, P93, DOI 10.1016/S0009-2797(97)00123-3; BRASS EP, 1994, CHEM-BIOL INTERACT, V90, P203, DOI 10.1016/0009-2797(94)90010-8; CAMPBELL NRC, 1987, MOL PHARMACOL, V32, P813; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Dajani R, 1999, PROTEIN EXPRES PURIF, V16, P11, DOI 10.1006/prep.1999.1030; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; DUFFEL MW, 1993, DRUG METAB DISPOS, V21, P400; Eaton EA, 1996, DRUG METAB DISPOS, V24, P232; Falany C N, 1994, Adv Pharmacol, V27, P301, DOI 10.1016/S1054-3589(08)61037-6; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; Leach M, 1999, BIOCHEM BIOPH RES CO, V261, P815, DOI 10.1006/bbrc.1999.1096; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; PENNINGS EJM, 1978, BIOCHEM J, V173, P299, DOI 10.1042/bj1730299; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RAO SI, 1991, DRUG METAB DISPOS, V19, P543; RENSDOMIANO SS, 1987, J NEUROCHEM, V48, P1411, DOI 10.1111/j.1471-4159.1987.tb05679.x; ROBERTS BJ, 1995, BIOCHEM PHARMACOL, V49, P1335, DOI 10.1016/0006-2952(94)00516-O; Roy A.B., 1981, SULFATION DRUGS RELA, P83; SCHAUSS SJ, 1995, BIOCHEM J, V311, P209, DOI 10.1042/bj3110209; Schuur AG, 1998, TOXICOL SCI, V45, P188, DOI 10.1093/toxsci/45.2.188; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA RD, 1979, J BIOL CHEM, V254, P5658; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; Varela A, 1997, ARCH PHYSIOL BIOCHEM, V105, P572, DOI 10.1076/apab.105.6.572.3276; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WHITTEMORE RM, 1986, ARCH BIOCHEM BIOPHYS, V249, P464, DOI 10.1016/0003-9861(86)90023-8; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Yang YS, 1996, PROTEIN EXPRES PURIF, V8, P423, DOI 10.1006/prep.1996.0120; [No title captured]	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39296	39303		10.1074/jbc.M206017200	http://dx.doi.org/10.1074/jbc.M206017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167648	hybrid			2022-12-25	WOS:000178662500032
J	Besteiro, S; Biran, M; Biteau, N; Coustou, V; Baltz, T; Canioni, P; Bringaud, F				Besteiro, S; Biran, M; Biteau, N; Coustou, V; Baltz, T; Canioni, P; Bringaud, F			Succinate secreted by Trypanosoma brucei is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; LEISHMANIA-MEXICANA MEXICANA; PENTOSE-PHOSPHATE PATHWAY; CARBOHYDRATE-METABOLISM; PYRUVATE-KINASE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PROCYCLIC TRYPOMASTIGOTES; PHOSPHOGLYCERATE KINASE; AFFINITY-CHROMATOGRAPHY; ENERGY-METABOLISM	In all trypanosomatids, including Trypanosoma brucei, glycolysis takes place in peroxisome-like organelles called glycosomes. These are closed compartments wherein the energy and redox (NAD(+)/NADH) balances need to be maintained. We have characterized a T. brucei gene called FRDg encoding a protein 35% identical to Saccharomyces cerevisiae fumarate reductases. Microsequencing of FRDg purified from glycosome preparations, immunofluorescence, and Western blot analyses clearly identified this enzyme as a glycosomal protein that is only expressed in the procyclic form of T. brucei but is present in all the other trypanosomatids studied, i.e. Trypanosoma congolense, Crithidia fasciculata and Leishmania amazonensis. The specific inactivation of FRDg gene expression by RNA interference showed that FRDg is responsible for the NADH-dependent fumarate reductase activity detected in glycosomal fractions and that at least 60% of the succinate secreted by the T. brucei procyclic form (in the presence Of D-glucose as the sole carbon source) is produced in the glycosome by FRDg. We conclude that FRDg plays a key role in the energy metabolism by participating in the maintenance of the glycosomal NAD(+)/NADH balance. We have also detected a significant pyruvate kinase activity in the cytosol of the T. brucei procyclic cells that was not observed previously. Consequently, we propose a revised model of glucose metabolism in procyclic trypanosomes that may also be valid for all other trypanosomatids except the T. brucei bloodstream form. Interestingly, H. Gest has hypothesized previously (Gest, H. (1980) FEMS Microbiol. Lett. 7, 73-77) that a soluble NADH-dependent fumarate reductase has been present in primitive organisms and evolved into the present day fumarate reductases, which are quinol-dependent. FRDg may have the characteristics of such an ancestral enzyme and is the only NADH-dependent fumarate reductase characterized to date.	Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bringaud, F (corresponding author), Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Besteiro, Sébastien/F-3622-2014	Besteiro, Sébastien/0000-0003-1853-1494; Biteau, Nicolas/0000-0003-1301-0665				Adje CA, 1997, MOL BIOCHEM PARASIT, V90, P155, DOI 10.1016/S0166-6851(97)00152-7; ADROHER FJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P252, DOI 10.1016/0003-9861(88)90030-6; Arikawa Y, 1998, FEMS MICROBIOL LETT, V165, P111, DOI 10.1111/j.1574-6968.1998.tb13134.x; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; Bastin P, 2000, J CELL SCI, V113, P3321; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; BOWMAN IBR, 1963, COMP BIOCHEM PHYSIOL, V9, P105, DOI 10.1016/0010-406X(63)90014-8; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; CAZZULO JJ, 1989, FEMS MICROBIOL LETT, V59, P259, DOI 10.1111/j.1574-6968.1989.tb03121.x; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; DENICOLASEOANE A, 1992, MOL BIOCHEM PARASIT, V54, P43, DOI 10.1016/0166-6851(92)90093-Y; Denise H, 1999, EUR J BIOCHEM, V259, P339, DOI 10.1046/j.1432-1327.1999.00048.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HUNTER FRISSELL R., 1960, EXPTL PARASITOL, V9, P271, DOI 10.1016/0014-4894(60)90035-7; HYDE GE, 1991, J BIOL CHEM, V266, P23542; Kohl L, 1996, MOL BIOCHEM PARASIT, V76, P159, DOI 10.1016/0166-6851(95)02556-1; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Marche S, 2000, MOL BIOCHEM PARASIT, V106, P83, DOI 10.1016/S0166-6851(99)00204-2; MARR JJ, 1980, BIOCH PHYSL PROTOZOA, V3, P313; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; MISSET O, 1987, EUR J BIOCHEM, V162, P501, DOI 10.1111/j.1432-1033.1987.tb10668.x; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; MURATSUBAKI H, 1994, PREP BIOCHEM, V24, P289, DOI 10.1080/10826069408010100; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Obungu VH, 1999, INDIAN J BIOCHEM BIO, V36, P305; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PEALING SL, 1992, BIOCHEMISTRY-US, V31, P12132, DOI 10.1021/bi00163a023; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS CA, 1987, ACTA TROP, V44, P293; RYLEY JF, 1962, BIOCHEM J, V85, P211, DOI 10.1042/bj0850211; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; TAYLOR AER, 1978, IN VITRO METHODS PAR; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tielens AGM, 1999, PARASITOL TODAY, V15, P347, DOI 10.1016/S0169-4758(99)01480-5; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; TURRENS JF, 1989, BIOCHEM J, V259, P363, DOI 10.1042/bj2590363; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIERENGA RK, 1987, EMBO J, V6, P215, DOI 10.1002/j.1460-2075.1987.tb04741.x; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	68	103	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38001	38012		10.1074/jbc.M201759200	http://dx.doi.org/10.1074/jbc.M201759200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138089	hybrid, Green Published			2022-12-25	WOS:000178529600006
J	Brewer, L; Corzett, M; Balhorn, R				Brewer, L; Corzett, M; Balhorn, R			Condensation of DNA by spermatid basic nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION PROTEIN-2; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; ZINC-DEFICIENCY; MOUSE SPERM; PROTAMINE; TP2; STABILITY; BINDING; GENE	Two transition proteins, TP1 and TP2, participate in the repackaging of the spermatid genome early in mammalian spermiogenesis, coincident with the first detectable changes in chromatin condensation. Using an optical trap and a two-channel flow cell to move single DNA molecules into buffer containing protein, we have measured the rates of DNA condensation and decondensation induced by the binding of Syrian hamster transition proteins TP1 and TP2 and protamines P1 and P2. The results show that both transition proteins condense free DNA, with rates similar to those of protamine 1 and 2. DNA molecules condensed with TP1 were significantly less stable than DNA condensed by protamine or by TP2. Experiments conducted with a peptide corresponding to the C-terminal 25 residues of TP2 showed that this domain is responsible for condensing DNA. Experiments conducted with two fragments of TP1 containing arginine and lysine residues demonstrated that DNA binding by TP1 must involve more than these basic sequences. Zinc facilitated the condensation of DNA by P2 but not by TP2. The dissociation rates of TP2 and P2 from DNA were not affected by the addition of zinc.	Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Brewer, L (corresponding author), Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA.	brewer1@llnl.gov	Brewer, Laurence/G-4056-2012		NICHD NIH HHS [1 K25 HD01387-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K25HD001387] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABBASI AA, 1980, J LAB CLIN MED, V96, P544; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4074, DOI 10.1021/bi00637a021; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; Bench G, 2000, MOL REPROD DEV, V56, P512, DOI 10.1002/1098-2795(200008)56:4&lt;512::AID-MRD9&gt;3.0.CO;2-M; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; BIANCHI F, 1994, BIOCHEM BIOPH RES CO, V201, P1197, DOI 10.1006/bbrc.1994.1832; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; Caceres C, 1999, J BIOL CHEM, V274, P649, DOI 10.1074/jbc.274.2.649; Caron N, 2001, MOL REPROD DEV, V58, P437, DOI 10.1002/1098-2795(20010401)58:4&lt;437::AID-MRD12&gt;3.0.CO;2-Q; COLE KD, 1987, BIOCHEM BIOPH RES CO, V147, P437, DOI 10.1016/S0006-291X(87)80140-7; Corzett M, 1999, MOL REPROD DEV, V54, P273, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;273::AID-MRD8&gt;3.0.CO;2-X; DINCER SL, 1990, HOSP PRACT, V25, P20; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20667; HEIDARAN MA, 1989, GENE, V75, P39, DOI 10.1016/0378-1119(89)90381-8; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1995, P NATL ACAD SCI USA, V92, P3581, DOI 10.1073/pnas.92.8.3581; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KIERSZENBAUM AL, 1975, J CELL BIOL, V65, P258, DOI 10.1083/jcb.65.2.258; Kierszenbaum AL, 2001, MOL REPROD DEV, V58, P357, DOI 10.1002/1098-2795(20010401)58:4<357::AID-MRD1>3.0.CO;2-T; Kistler WS, 1996, EXP CELL RES, V225, P374, DOI 10.1006/excr.1996.0188; KISTLER WS, 1975, J BIOL CHEM, V250, P1847; KLEENE KC, 1990, GENE, V95, P301, DOI 10.1016/0378-1119(90)90376-3; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KUNDU TK, 1995, BIOCHEMISTRY-US, V34, P5143, DOI 10.1021/bi00015a027; Kundu TK, 1996, BIOCHEMISTRY-US, V35, P15626, DOI 10.1021/bi961271i; Levesque D, 1998, BIOCHEM BIOPH RES CO, V252, P602, DOI 10.1006/bbrc.1998.9687; MANNING GS, 1980, BIOPOLYMERS, V19, P37, DOI 10.1002/bip.1980.360190104; Matulis D, 2000, J MOL BIOL, V296, P1053, DOI 10.1006/jmbi.1999.3470; Meetei AR, 2000, J BIOL CHEM, V275, P38500, DOI 10.1074/jbc.M002734200; Meetei AR, 2002, BIOCHEMISTRY-US, V41, P185, DOI 10.1021/bi0117652; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; PERREAULT SD, 1988, BIOL REPROD, V39, P157, DOI 10.1095/biolreprod39.1.157; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; Sato H, 1999, PROTEIN EXPRES PURIF, V16, P454, DOI 10.1006/prep.1999.1095; SINGH J, 1987, J BIOL CHEM, V262, P734; Vijayanathan V, 2001, BIOCHEMISTRY-US, V40, P13644, DOI 10.1021/bi010993t; Ward WS, 1996, CRIT REV EUKAR GENE, V6, P139, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.30; YELICK PC, 1991, GENOMICS, V11, P687, DOI 10.1016/0888-7543(91)90076-Q	45	101	107	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38895	38900		10.1074/jbc.M204755200	http://dx.doi.org/10.1074/jbc.M204755200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140285	hybrid			2022-12-25	WOS:000178529600112
J	Kim, J; Cantwell, CA; Johnson, PF; Pfarr, CM; Williams, SC				Kim, J; Cantwell, CA; Johnson, PF; Pfarr, CM; Williams, SC			Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; DNA-BINDING; C/EBP-BETA; COVALENT MODIFICATION; SUMO-1 MODIFICATION; ACTIVATION DOMAINS; NUCLEAR-BODIES; C-MYB; CCAAT; UBIQUITIN	CCAAT/enhancer-binding proteins (C/EBPs) are basic region/leucine zipper transcription factors that function as regulators of cell growth and differentiation in numerous cell types. We previously localized transcriptional activation and inhibitory regions in one family member, C/EBPepsilon. Here we describe the further characterization of a C/EBPepsilon inhibitory domain termed regulatory domain 1. We show that functionally related domains are present in C/EBPalpha, C/EBPbeta, and C/EBPdelta. These domains contain an evolutionarily conserved five-amino acid motif (the regulatory domain motif (RDM)) that conforms to the consensus sequence (I/V/ L)KXEP. Mutagenesis studies revealed that the residues at positions 1, 2, and 4 of the RDM are critical for inhibitory domain function. Data base searches identified RDM-like sequences in a number of nuclear proteins. We found that small regions from c-Jun, JunB, and JunD containing this sequence also function as transcriptional inhibitory domains. Importantly, the RDM is similar to the recognition sequence for attachment of the ubiquitin-like protein, small ubiquitin-like modifier-1 (SUMO-1), and the conserved lysine residue of each C/EBP RDM served as an attachment site for SUMO-1. SUMO-1 attachment decreased the inhibitory effect of the C/EBPepsilon regulatory domain, suggesting that sumoylation may play an important role in modulating C/EBPepsilon activity as well as that of the other C/EBP family members.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; UMC Lubbock, SW Canc Ctr, Lubbock, TX 79430 USA; NCI Frederick, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA.		Pfarr, Curt/HHD-1410-2022; Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huse B, 1998, MOL ENDOCRINOL, V12, P1334, DOI 10.1210/me.12.9.1334; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee JA, 2001, LEARN MEMORY, V8, P220, DOI 10.1101/lm.40201; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rorth P, 2000, MOL CELL, V6, P23; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187	50	131	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38037	38044		10.1074/jbc.M207235200	http://dx.doi.org/10.1074/jbc.M207235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161447	hybrid			2022-12-25	WOS:000178529600010
J	Kim, PKM; Wang, YN; Gambotto, A; Kim, YM; Weller, R; Zuckerbraun, BS; Hua, Y; Watkins, SC; Billiar, TR				Kim, PKM; Wang, YN; Gambotto, A; Kim, YM; Weller, R; Zuckerbraun, BS; Hua, Y; Watkins, SC; Billiar, TR			Hepatocyte Fas-associating death domain protein/mediator of receptor-induced toxicity (FADD/MORT1) levels increase in response to pro-apoptotic stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; GLIOMAS IN-VITRO; CELL-DEATH; INHIBITS APOPTOSIS; MEDIATED APOPTOSIS; SIGNALING PATHWAY; RAT HEPATOCYTES; GENE-TRANSFER; FADD	We examined the regulation of Fas-associating death domain (FADD) protein as an important adaptor molecule in apoptosis signaling and hypothesized that the regulation of FADD could contribute to hepatocyte death. FADD/mediator of receptor-induced toxicity (MORT1) is required for activation of several signaling pathways of cell death. In this study we report the interesting and unexpected result that actinomycin D increased the expression of FADD protein, and we demonstrate that other cellular stresses like ultraviolet irradiation or heat shock could also increase FADD levels in hepatocytes. In cells treated with actinomycin D, FADD levels were elevated homogeneously in the cytoplasm. The increase in cytoplasmic FADD protein by actinomycin D or FADD overexpression alone both correlated with cell death, and specific antisense inhibition of FADD expression consistently diminished similar to30% of the cell death induced by actinomycin D. These data indicate that FADD protein expression can increase rapidly in hepatocytes exposed to broadly cytotoxic agents.	Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA 15213 USA; Kangwon Natl Univ, Coll Med, Chungchon 200701, Kangwon Do, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kangwon National University	Kim, PKM (corresponding author), NW607 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.		Watkins, Simon/ABG-2590-2021; Weller, Richard/B-4954-2010	Watkins, Simon/0000-0003-4092-1552; Weller, Richard/0000-0003-2550-9586	NIGMS NIH HHS [R01-GM-44100, R01-GM-50441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R01GM050441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Fulda S, 2000, CANCER RES, V60, P3947; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Komata T, 2001, INT J ONCOL, V19, P1015; Kondo S, 1998, HUM GENE THER, V9, P1599, DOI 10.1089/hum.1998.9.11-1599; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LEIST M, 1994, J IMMUNOL, V153, P1778; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; MCGUIRE RF, 1992, HEPATOLOGY, V15, P989, DOI 10.1002/hep.1840150603; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Seino K, 2001, ANN SURG, V234, P681, DOI 10.1097/00000658-200111000-00015; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Suzuki A, 1999, P SOC EXP BIOL MED, V221, P72, DOI 10.1046/j.1525-1373.1999.d01-56.x; Takahashi Y, 2000, SURGERY, V128, P345, DOI 10.1067/msy.2000.107415; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang G, 2001, Zhonghua Gan Zang Bing Za Zhi, V9, P10	52	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38855	38862		10.1074/jbc.M203484200	http://dx.doi.org/10.1074/jbc.M203484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167637	hybrid			2022-12-25	WOS:000178529600107
J	Woodman, SE; Park, DS; Cohen, AW; Cheung, MWC; Chandra, M; Shirani, J; Tang, BY; Jelicks, LA; Kitsis, RN; Christ, GJ; Factor, SM; Tanowitz, HB; Lisanti, MP				Woodman, SE; Park, DS; Cohen, AW; Cheung, MWC; Chandra, M; Shirani, J; Tang, BY; Jelicks, LA; Kitsis, RN; Christ, GJ; Factor, SM; Tanowitz, HB; Lisanti, MP			Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GIRDLE MUSCULAR-DYSTROPHY; DELTA-SARCOGLYCAN GENE; RAT CARDIAC MYOCYTES; GLYCOPROTEIN COMPLEX; BETA-SARCOGLYCAN; ALPHA-SARCOGLYCAN; ADENYLYL-CYCLASE; SYRIAN-HAMSTER; SMOOTH-MUSCLE	A growing body of evidence suggests that muscle cell caveolae may function as specialized membrane microdomains in which the dystrophin-glycoprotein complex and cellular signaling molecules reside. Caveolin-3 (Cav-3) is the only caveolin family member expressed in striated muscle cell types (cardiac and skeletal). Interestingly, skeletal muscle fibers from Cav-3 (-/-) knockout mice show a number of myopathic changes, consistent with a mild-to-moderate muscular dystrophy phenotype. However, it remains unknown whether a loss of Cav-3 affects the phenotypic behavior cardiac myocytes in vivo. Here, we present a detailed characterization of the hearts of Cav-3 knock-out mice. We show that these mice develop a progressive cardiomyopathic phenotype. At four months of age, Cav-3 knock-out hearts display significant hypertrophy, dilation, and reduced fractional shortening, as revealed by gated cardiac MRI and transthoracic echocardiography. Histological analysis reveals marked cardiac myocyte hypertrophy, with accompanying cellular infiltrates and progressive interstitial/peri-vascular fibrosis. Interestingly, loss of Cav-3 expression in the heart does not change the expression or the membrane association of the dystrophin-glycoprotein (DG) complex. However, a marker of the DG complex, alpha-sarcoglycan, was specifically excluded from lipid raft domains in the absence of Cav-3. Because activation of the Ras-p42/44 MAPK pathway in cardiac myocytes can drive cardiac hypertrophy, we next assessed the activation state of this pathway using a phospho-specific antibody probe. We show that p42/44 MAPK (ERK1/2) is hyperactivated in hearts derived from Cav-3 knock-out mice. These results are consistent with previous in vitro data demonstrating that caveolins may function as negative regulators of the p42/44 MAPK cascade. Taken together, our data argue that loss of Cav-3 expression is sufficient to induce a molecular program leading to cardiac myocyte hypertrophy and cardiomyopathy.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Montefiore Med Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Urol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Physiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Jelicks, Linda/L-9740-2019; Lisanti, Michael/B-6131-2018	Jelicks, Linda/0000-0002-6438-1792; Lisanti, Michael/0000-0003-2034-1382	NCI NIH HHS [TG-CA09475] Funding Source: Medline; NIAID NIH HHS [AI-12770] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI012770, R01AI012770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Chan YM, 1998, J CELL BIOL, V143, P2033, DOI 10.1083/jcb.143.7.2033; Chandra M, 2002, INT J PARASITOL, V32, P207, DOI 10.1016/S0020-7519(01)00320-4; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Doyle DD, 1997, CIRC RES, V81, P86, DOI 10.1161/01.RES.81.1.86; Doyle DD, 2000, CIRC RES, V87, P480; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; FACTOR SM, 1988, J AM COLL CARDIOL, V12, P1599, DOI 10.1016/S0735-1097(88)80031-7; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fujita T, 2001, CARDIOVASC RES, V51, P709, DOI 10.1016/S0008-6363(01)00348-0; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; James M, 2000, J CELL SCI, V113, P1717; Jelicks LA, 1999, AM J TROP MED HYG, V61, P207, DOI 10.4269/ajtmh.1999.61.207; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Minetti C, 2002, AM J PATHOL, V160, P265, DOI 10.1016/S0002-9440(10)64370-2; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Piech A, 2002, AM J PHYSIOL-HEART C, V282, pH219, DOI 10.1152/ajpheart.2002.282.1.H219; Politano L, 2001, NEUROMUSCULAR DISORD, V11, P178, DOI 10.1016/S0960-8966(00)00174-7; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHILLER NB, 1991, CIRCULATION, V84, pI280; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V225, P11, DOI 10.1006/bbrc.1996.1123	62	227	235	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38988	38997		10.1074/jbc.M205511200	http://dx.doi.org/10.1074/jbc.M205511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138167	hybrid			2022-12-25	WOS:000178529600123
J	Bommer, M; Benecke, A; Gronemeyer, H; Rochette-Egly, C				Bommer, M; Benecke, A; Gronemeyer, H; Rochette-Egly, C			TIF2 mediates the synergy between RAR alpha 1 activation functions AF-1 and AF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTORS; WW DOMAINS; COACTIVATOR; PROTEINS; PHOSPHORYLATION; TRANSCRIPTION; TRANSACTIVATION	Nuclear receptors recruit coregulator complexes through both their AF-1 and AF-2 activation domains. Here we demonstrate that TIF2, a p160 coactivator, is able to bridge the two activation domains of the retinoic acid (RA) receptor isotype RARalpha1, resulting in synergistic activation of transcription. Bridging requires the presence of motifs in region A of RARalpha1 and in the activation domain AD1 of TIF2. Notably, only RARalpha1 exerted this interaction, which requires additional unknown factors. This is the first observation of a RAR isotype-selective coactivator interaction. Because another p160 coactivator, SRC-1, has no effect, this is also the first demonstration of a difference between the members of this coactivator family.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Benecke, Arndt G./T-1079-2019; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 2000, GENE DEV, V14, P121; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Laudet V., 2001, NUCL RECEPTOR FACTSB; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	34	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37961	37966		10.1074/jbc.M206001200	http://dx.doi.org/10.1074/jbc.M206001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149266	hybrid			2022-12-25	WOS:000178447100134
J	Chiarugi, P; Cirri, P; Taddei, ML; Giannoni, E; Fiaschi, T; Buricchi, F; Camici, G; Raugei, G; Ramponi, G				Chiarugi, P; Cirri, P; Taddei, ML; Giannoni, E; Fiaschi, T; Buricchi, F; Camici, G; Raugei, G; Ramponi, G			Insight into the role of low molecular weight phosphotyrosine phosphatase (LAM-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling - LMW-PTP controls PDGF-r kinase activity through TYR-857 dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-BETA-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR-I; ACTIVATION; PHOSPHORYLATION; STIMULATION; INHIBITION; CELLS	Low molecular weight phosphotyrosine phosphatase (LMW-PTP) is an enzyme involved in platelet-derived growth factor-induced mitogenesis and cytoskeleton rearrangement. Our previous results demonstrated that LMW-PTP is able to bind and dephosphorylate activated platelet-derived growth factor receptor (PDGF-r), thus inhibiting cell proliferation. Here we revisit the role of LMW-PTP on activated PDGF-r dephosphorylation. We demonstrate that LMW-PTP preferentially acts on cell surface PDGF-r, excluding the internalized activated receptor pool. Many phosphotyrosine phosphatases act by site-selective dephosphorylation on several sites of PDGF-r, but until now, there has been no evidence of a direct involvement of a specific phosphotyrosine phosphatase in the dephosphorylation of the 857 kinase domain activation tyrosine. Here we report that LMW-PTP affects the kinase activity of the receptor through the binding and dephosphorylation of Tyr-857 and influences many of the signal outputs from the receptor. In particular, we demonstrate a down-regulation of phosphatidylinositol 3-kinase, Src homology phosphatase-2, and phospholipase C-gamma1 binding but not of MAPK activation. In addition, we report a slight action of LMW-PTP on Tyr-716, which directs MAPK activation through Grb2 binding. On the basis of these results, we propose a key role for LMW-PTP in PDGF-r down-regulation through the dephosphorylation of the activation loop Tyr-857, thus determining a general negative regulation of all downstream signals, with the exception of those elicited by internalized receptors.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy	University of Florence	Raugei, G (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy.		Chiarugi, Paola/CDD-7988-2022; Giannoni, Elisa/AAE-2092-2020; Camici, Giovanni/H-1631-2018	Giannoni, Elisa/0000-0001-7136-1098; Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695; raugei, giovanni/0000-0003-1294-786X				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bernard A, 1999, EXP CELL RES, V253, P704, DOI 10.1006/excr.1999.4715; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 2002, J CELL SCI, V115, P2219; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DeMali KA, 1997, J BIOL CHEM, V272, P9011; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Faure R, 1999, Mol Cell Biol Res Commun, V1, P132, DOI 10.1006/mcbr.1999.0120; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sorby M, 1996, J BIOL CHEM, V271, P10963; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WAY BA, 1993, J BIOL CHEM, V268, P26409	42	39	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37331	37338		10.1074/jbc.M205203200	http://dx.doi.org/10.1074/jbc.M205203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149261	hybrid			2022-12-25	WOS:000178447100055
J	Fezoui, Y; Teplow, DB				Fezoui, Y; Teplow, DB			Kinetic studies of amyloid beta-protein fibril assembly - Differential effects of alpha-helix stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; CENTRAL HYDROPHOBIC CLUSTER; ALZHEIMERS-DISEASE; CIRCULAR-DICHROISM; ALTERNATIVE CONFORMATIONS; SECONDARY STRUCTURE; FIBRILLOGENESIS; PEPTIDES; INTERMEDIATE; PATHWAYS	Amyloid beta-protein (Abeta) fibril assembly is a defining characteristic of Alzheimer's disease. Fibril formation is a complex nucleation-dependent polymerization process characterized in vitro by an initial lag phase. To a significant degree, this phase is a consequence of the energy barrier that must be overcome in order for Abeta monomers to fold and oligomerize into fibril nuclei. Here we show that low concentrations of 2,2,2-trifluoroethanol (TFE) convert predominately unstructured Abeta monomers into partially ordered, quasistable conformers. Surprisingly, this results in a temporal decrease in the lag phase for fibril formation and a significant increase in the rate of fibril elongation. The TFE effect is concentration dependent and is maximal at similar to20% (v/v). In the presence of low concentrations of TFE, fibril formation is observed in Abeta samples at nanomolar concentration, well below the critical concentration for Abeta fibril formation in the absence of TFE. As the amount of TFE is increased above 20%, helix content progressively rises to similar to80%, a change paralleled first by a decrease in elongation rate and then by a complete cessation of fibril growth. These findings are consistent with the hypothesis that a partially folded helix-containing conformer is an intermediate in Abeta fibril assembly. The requirement that Abeta partially folds in order to assemble into fibrils contrasts with the mechanism of amyloidogenesis of natively folded proteins such as transthyretin and lysozyme, in which partial unfolding is a prerequisite. Our results suggest that in vivo, factors that affect helix formation and stability will have significant effects on the kinetics of Abeta fibril formation.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Teplow, DB (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur,HIM-756, Boston, MA 02115 USA.				NIA NIH HHS [T32-AG00222, 1P01AG14366] Funding Source: Medline; NINDS NIH HHS [1R01NS38328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000222, P01AG014366] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 1999, NAT STRUCT BIOL, V6, P380; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1981, PROG HISTOCHEM CYTOC, V13, P1; Gross M, 1999, PROTEIN SCI, V8, P1350, DOI 10.1110/ps.8.6.1350; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Janek K, 2001, BIOCHEMISTRY-US, V40, P5457, DOI 10.1021/bi002005e; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KYTE J, 1995, STRUCTURE PROTEIN CH, P77; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lomakin A, 1999, METHOD ENZYMOL, V309, P429; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Otzen DE, 2000, P NATL ACAD SCI USA, V97, P9907, DOI 10.1073/pnas.160086297; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288; Zhang SS, 1998, FOLD DES, V3, P413, DOI 10.1016/S1359-0278(98)00054-6	50	290	294	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36948	36954		10.1074/jbc.M204168200	http://dx.doi.org/10.1074/jbc.M204168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149256	hybrid			2022-12-25	WOS:000178447100007
J	Fischhaber, PL; Gerlach, VL; Feaver, WJ; Hatahet, Z; Wallace, SS; Friedberg, EC				Fischhaber, PL; Gerlach, VL; Feaver, WJ; Hatahet, Z; Wallace, SS; Friedberg, EC			Human DNA polymerase kappa bypasses and extends beyond thymine glycols during translesion synthesis in vitro, preferentially incorporating correct nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DINB1 GENE; LESION-BYPASS; THYMIDINE GLYCOL; CRYSTAL-STRUCTURE; FREE-RADICALS; ERROR-PRONE; POL-KAPPA; Y-FAMILY; INVITRO; FIDELITY	Human polymerase kappa (polkappa), the product of the human POLK (DINB1) gene, is a member of the Y superfamily of DNA polymerases that support replicative bypass of chemically modified DNA bases (Ohmori, H., Friedberg, E. C., Fuchs, R. P., Goodman, M. F., Hanaoka, F., Hinkle, D., Kunkel, T. A., Lawrence, C. W., Livneh, Z., Nohmi, T., Prakash, L., Prakash, S., Todo, T., Walker, G. C., Wang, Z., and Woodgate, R. (2001) Mol. Cell 8, 7-8; Gerlach, V. L., Aravind, L., Gotway, G., Schultz, R. A., Koonin, E. V., and Friedberg, E. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11922-11927). Polkappa is shown here to bypass 5,6-dihydro-5,6-dihydroxythymine (thymine glycol) generated in two different DNA substrate preparations. Polkappa inserts the correct base adenine opposite thymine glycol in preference to the other three bases. Additionally, the enzyme correctly extends beyond the site of the thymine glycol lesion when presented with adenine opposite thymine glycol at the primer terminus. However, steady state kinetic analysis of nucleotides incorporated opposite thymine glycol demonstrates different misincorporation rates for guanine with each of the two DNA substrates. The two substrates differ only in the relative proportions of thymine glycol stereoisomers, suggesting that polkappa distinguishes among stereoisomers and exhibits reduced discrimination between purines when incorporating a base opposite a 5R thymine glycol stereoisomer. When extending beyond the site of the lesion, the misincorporation rate of polkappa for each of the three incorrect nucleotides (adenine, guanine, and thymine) is dramatically increased. Our findings suggest a role for polkappa in both nonmutagenic and mutagenic bypass of oxidative damage.	Univ Texas, SW Med Ctr, Lab Mol Pathol, Dept Pathol, Dallas, TX 75390 USA; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vermont	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Lab Mol Pathol, Dept Pathol, Dallas, TX 75390 USA.			Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [F32CA075733, F32CA083314, R01CA044247, R01CA052040] Funding Source: NIH RePORTER; NCI NIH HHS [CA83314, CA4424717, CA52040, CA75733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; BACHUR NR, 1978, CANCER RES, V38, P1745; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Creighton S, 1995, METHOD ENZYMOL, V262, P232; DEMPSEY ME, 1974, ANNU REV BIOCHEM, V43, P967, DOI 10.1146/annurev.bi.43.070174.004535; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; IDE H, 1987, BIOCHEMISTRY-US, V26, P964, DOI 10.1021/bi00377a042; IDE H, 1988, NUCLEIC ACIDS RES, V16, P11339, DOI 10.1093/nar/16.23.11339; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Iwai S, 2000, ANGEW CHEM INT EDIT, V39, P3874, DOI 10.1002/1521-3773(20001103)39:21<3874::AID-ANIE3874>3.0.CO;2-O; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LUSTIG MJ, 1992, NUCLEIC ACIDS RES, V20, P4839, DOI 10.1093/nar/20.18.4839; Magalhaes MM, 1997, MICROSC RES TECHNIQ, V36, P493, DOI 10.1002/(SICI)1097-0029(19970315)36:6<493::AID-JEMT6>3.0.CO;2-J; Miller WL, 1998, BAILLIERE CLIN ENDOC, V12, P67, DOI 10.1016/S0950-351X(98)80461-8; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; SCANDALIOS JG, 1997, COLD SPRING HARBOR M, V34, P1; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SINHA BK, 1989, CHEM-BIOL INTERACT, V69, P293, DOI 10.1016/0009-2797(89)90117-8; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Tippin B, 2001, PHILOS T R SOC B, V356, P47, DOI 10.1098/rstb.2000.0747; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; ZHANG Y, 2002, IN PRESS DNA REPAIR; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	50	98	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37604	37611		10.1074/jbc.M206027200	http://dx.doi.org/10.1074/jbc.M206027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145297	hybrid			2022-12-25	WOS:000178447100089
J	Goicoechea, S; Pallero, MA; Eggleton, P; Michalak, M; Murphy-Ullrich, JE				Goicoechea, S; Pallero, MA; Eggleton, P; Michalak, M; Murphy-Ullrich, JE			The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RETICULUM LUMINAL ENVIRONMENT; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TUMOR-GROWTH; IDENTIFICATION; ACTIVATION; RECEPTOR; CONFORMATION	Thrombospondin (TSP) induces reorganization of the actin cytoskeleton and restructuring of focal adhesions through binding of amino acids (aa) 17-35 (hep I peptide) of thrombospondin to a cell surface form of calreticulin (CRT). In this report we provide further evidence for the involvement of calreticulin in thrombospondin signaling and characterize thrombospondin-calreticulin interactions. Wild type but not crt(-/-) cells respond to hep I/TSP. Responsiveness can be restored by incubation of cells with exogenous calreticulin or by transfection with calreticulin. Thrombospondin forms complexes with the CRT-N-domain that are enhanced by physiologic levels of calcium and zinc. Consistent with thrombospondin/CRT-N-domain binding, only the CRT-N-domain blocks hep I- and thrombospondin-stimulated focal adhesion disassembly. A series of glutathione S-transferase-N-domain mutants were used to map the sequence within the N-domain that interacts with TSP/ hep I. A construct containing aa 1-43 but not a construct of aa 1-31 supported thrombospondin binding and focal adhesion disassembly. A series of overlapping peptides were used to further map the thrombospondin-binding site. Peptides spanning aa 19-36 (RWIESKHKSDFGKFVLSS) blocked hep I-stimulated focal adhesion disassembly, indicating that the TSP/hep I-binding site is located to this sequence in calreticulin. A mutant fusion protein lacking aa 19-36 (glutathione S-transferase-CRTDeltahep 1) failed to restore responsiveness to hep I in crt(-/-) cells, bind thrombospondin, or competitively block focal adhesion disassembly, providing evidence for the role of this calreticulin sequence in mediating thrombospondin signaling.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Oxford, MRC, Immunochem Unit, Oxford & Peninsula Med Sch, Oxford 0X1 3QU, Devon, England; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford; University of Alberta; Institute for Work & Health; University of Alberta	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, VH 668B,1530 3rd Ave S, Birmingham, AL 35294 USA.	Murphy@path.uab.edu		Eggleton, Paul/0000-0001-8244-2125; Goicoechea, Silvia/0000-0003-1107-389X	NHLBI NIH HHS [HL44575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Andrin C, 1998, BIOCHEMISTRY-US, V37, P10386, DOI 10.1021/bi980595z; ATREYA CD, 1995, J VIROL, V69, P3848, DOI 10.1128/JVI.69.6.3848-3851.1995; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; HEILMANN C, 1993, BIOCHEM BIOPH RES CO, V193, P611, DOI 10.1006/bbrc.1993.1668; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Kovacs H, 1998, BIOCHEMISTRY-US, V37, P17865, DOI 10.1021/bi973197p; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; NAKHASI HL, 1994, ARCH VIROL, P255; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47	62	87	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37219	37228		10.1074/jbc.M202200200	http://dx.doi.org/10.1074/jbc.M202200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147682	hybrid			2022-12-25	WOS:000178447100042
J	Shiota, C; Larsson, O; Shelton, KD; Shiota, M; Efanov, AM; Hoy, M; Lindner, J; Kooptiwut, S; Juntti-Berggren, L; Gromada, J; Berggren, PO; Magnuson, MA				Shiota, C; Larsson, O; Shelton, KD; Shiota, M; Efanov, AM; Hoy, M; Lindner, J; Kooptiwut, S; Juntti-Berggren, L; Gromada, J; Berggren, PO; Magnuson, MA			Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC BETA-CELL; PEPTIDE-1 GLP-1; EXOCYTOSIS; HORMONE; ISLETS; MOUSE; SUR1; RAT	The ATP-sensitive potassium channel is a key molecular complex for glucose-stimulated insulin secretion in pancreatic beta cells. In humans, mutations in either of the two subunits for this channel, the sulfonylurea type 1 receptor (Sur1) or Kir6.2, cause persistent hyperinsulinemic hypoglycemia of infancy. We have generated and characterized Sur1 null mice. Interestingly, these animals remain euglycemic for a large portion of their life despite constant depolarization of membrane, elevated cytoplasmic free Ca2+ concentrations, and intact sensitivity of the exocytotic machinery to Ca2+. A comparison of glucose- and meal-stimulated insulin secretion showed that, although Sur1 null mice do not secrete insulin in response to glucose,. they secrete nearly normal amounts of insulin in response to feeding. Because Sur1 null mice lack an insulin secretory response to GLP-1, even though their islets exhibit a normal rise in cAMP by GLP-1, we tested their response to cholinergic stimulation. We found that perfused Sur1 null pancreata secreted insulin in response to the cholinergic agonist carbachol in a glucose-dependent manner. Together, these findings suggest that cholinergic stimulation is one of the mechanisms that compensate for the severely impaired response to glucose and GLP-1 brought on by the absence of Sur1, thereby allowing euglycemia to be maintained.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden; Novo Nordisk AS, Lab Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark	Vanderbilt University; Karolinska Institutet; Karolinska University Hospital; Novo Nordisk	Magnuson, MA (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 747 Light Hall, Nashville, TN 37232 USA.	mark.magnusson@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Efanov, Alexander/R-3630-2019; Lindner, Jill/K-5511-2012	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Efanov, Alexander/0000-0002-8630-1503; Lindner, Jill/0000-0002-8897-7494; Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK42612, DK42502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Branstrom R, 1998, J BIOL CHEM, V273, P14113, DOI 10.1074/jbc.273.23.14113; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Holst JJ, 1999, TRENDS ENDOCRIN MET, V10, P229, DOI 10.1016/S1043-2760(99)00157-5; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MA YH, 1995, EUR J ENDOCRINOL, V132, P370, DOI 10.1530/eje.0.1320370; MacFarlane WM, 1999, J BIOL CHEM, V274, P34059, DOI 10.1074/jbc.274.48.34059; Martell A. E., 1974, CRITICAL STABILITY C, V2; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shepherd RM, 2000, ARCH DIS CHILD-FETAL, V82, pF87, DOI 10.1136/fn.82.2.F87; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409	43	166	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37176	37183		10.1074/jbc.M206757200	http://dx.doi.org/10.1074/jbc.M206757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149271	hybrid			2022-12-25	WOS:000178447100036
J	Borman, AM; Michel, YM; Malnou, CE; Kean, KM				Borman, AM; Michel, YM; Malnou, CE; Kean, KM			Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; POLY(A)-BINDING PROTEIN; POLY(A)-TAIL-PROMOTED TRANSLATION; DEPENDENT TRANSLATION; CAP-POLY(A) SYNERGY; INITIATION-FACTORS; TAIL; YEAST; INCREASES; EXTRACTS	The 5' cap and 3' poly(A) tail of classical eukaryotic mRNAs functionally communicate to synergistically enhance translation initiation. Synergy has been proposed to result in part from facilitated ribosome recapture on circularized mRNAs. Here, we demonstrate that this is not the case. In poly(A)-dependent, ribosome-depleted rabbit reticulocyte lysates, the addition of exogenous poly(A) chains of physiological length dramatically stimulated translation of a capped, nonpolyadenylated mRNA. When the poly(A):RNA ratio approached 1, exogenous poly(A) stimulated translation to the same extent as the presence of a poly(A) tail at the mRNA 3' end. In addition, exogenous poly(A) significantly improved translation of capped mRNAs carrying short poly(A,,) tails. Trans stimulation of translation by poly(A) required the eIF4G-poly(A)-binding protein interaction and resulted in increased affinity of eIF4E for the mRNA cap, exactly as we recently described for cap-poly(A) synergy. These results formally demonstrate that mRNA circularization per se is not the cause of cap-poly(A) synergy at least in vitro.	Inst Pasteur, CNRS URA 1966, Unite Postulante RTEV, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Postulante RTEV, 25 Rue Dr Roux, F-75724 Paris 15, France.	Kathiemb@pasteur.fr	Borman, Andy/H-3663-2019; MALNOU, Cécile E/K-1569-2014; MALNOU, Cécile/O-9970-2019	Borman, Andy/0000-0003-0585-5721; MALNOU, Cécile E/0000-0002-1223-0247; MALNOU, Cécile/0000-0002-1223-0247				BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P6485, DOI 10.1093/nar/17.16.6485; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Marczinke B, 1998, J MOL BIOL, V284, P205, DOI 10.1006/jmbi.1998.2186; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Michel YM, 2001, MOL CELL BIOL, V21, P4097, DOI 10.1128/MCB.21.13.4097-4109.2001; Morley SJ, 1997, RNA, V3, P1085; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Searfoss A, 2001, MOL CELL BIOL, V21, P4900, DOI 10.1128/MCB.21.15.4900-4908.2001; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	30	37	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36818	36824		10.1074/jbc.M205065200	http://dx.doi.org/10.1074/jbc.M205065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138105	hybrid			2022-12-25	WOS:000178275100133
J	Duffy, HS; Sorgen, PL; Girvin, ME; O'Donnell, P; Coombs, W; Taffet, SM; Delmar, M; Spray, DC				Duffy, HS; Sorgen, PL; Girvin, ME; O'Donnell, P; Coombs, W; Taffet, SM; Delmar, M; Spray, DC			pH-dependent intramolecular binding and structure involving Cx43 cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; CORRELATION SPECTROSCOPY; NMR-SPECTROSCOPY; H-1-NMR SPECTRA; CHEMICAL-SHIFT; CONNEXIN43; CHANNELS; PHOSPHORYLATION; PROGRAM; CONDUCTANCE	pH-induced closure of connexin43 (Cx43) channels involves interaction of the Cx43 carboxyl-terminal (Cx43CT) with a separate "receptor" domain. The receptor location and structure and whether the interaction is directly intramolecular are unknown. Here we show resonant mirror technology, enzyme-linked sorbent assays, and nuclear magnetic resonance (NMR) experiments demonstrating pH-dependent binding of Cx43CT to region 119-144 of Cx43 (Cx43L2), which we propose is the receptor. NAIR showed that acidification induced a-helical order in Cx43L2, whereas only a minor modification in Cx43CT structure was detected. These data provide the first demonstration of chemically induced structural order and binding between cytoplasmic connexin domains.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Microbiol, Syracuse, NY 13210 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Delmar, M (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 766 Irving Ave, Syracuse, NY 13210 USA.			Delmar, Mario/0000-0002-2085-5589; Spray, David/0000-0001-8368-5073	NINDS NIH HHS [NS07098] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Anumonwo JMB, 2001, CIRC RES, V88, P666, DOI 10.1161/hh0701.088833; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; Chandonia JM, 1999, PROTEINS, V35, P293; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P338; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELAGLIO F, 1995, J BIOMOL NMR, V6, P689; Delmar M, 2000, J CARDIOVASC ELECTR, V11, P118, DOI 10.1111/j.1540-8167.2000.tb00747.x; Duffy HS, 2001, CELL COMMUN ADHES, V8, P225, DOI 10.3109/15419060109080728; DUFFY HS, 2001, SOC NEUR ABSTR, V27; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Homma N, 1998, CIRC RES, V83, P27, DOI 10.1161/01.RES.83.1.27; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LASTOWSKY RA, 1996, J BIOMOL NMR, V8, P477; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Peters NS, 1997, CIRCULATION, V95, P988; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Purnick PEM, 2000, ARCH BIOCHEM BIOPHYS, V381, P181, DOI 10.1006/abbi.2000.1989; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Spray DC, 1999, ADV EXP MED BIOL, V468, P339; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Trexler EB, 1999, J GEN PHYSIOL, V113, P721; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yahuaca P, 2000, BRAZ J MED BIOL RES, V33, P399, DOI 10.1590/S0100-879X2000000400005; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	54	142	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36706	36714		10.1074/jbc.M207016200	http://dx.doi.org/10.1074/jbc.M207016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151412	hybrid			2022-12-25	WOS:000178275100117
J	Murata, Y; Sun-Wada, GH; Yoshimizu, T; Yamamoto, A; Wada, Y; Futai, M				Murata, Y; Sun-Wada, GH; Yoshimizu, T; Yamamoto, A; Wada, Y; Futai, M			Differential localization of the vacuolar H+ pump with G subunit isoforms (G1 and G2) in mouse neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; SYNAPTIC VESICLES; MOLECULAR-CLONING; PROTON PUMP; V-ATPASE; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; 116-KDA SUBUNIT; GENE; EXPRESSION	Vacuolar H+-ATPases (V-ATPases), a family of multimeric proton pumps, are involved in a wide variety of physiological processes. We have identified two mouse genes, Atp6g1 and Atp6g2, encoding the G1 and G2 isoforms of the V-ATPase G subunit, respectively. G1 was distributed ubiquitously in the tissues examined, whereas G2 was specifically distributed in central nervous system neurons. G1 was expressed at an early embryonic stage, whereas G2 transcription was significantly induced at 10.5 days postcoitus (embryonic day 10.5, ie. 2 days before axon outgrowth). Both G1 and G2 were strongly expressed in cortical and hippocampal neurons, cerebellar granule cells, and Purkinje cells. Immunohistochemistry with isoform-specific antibodies revealed that G2 was localized in cell bodies, dendrites, and axons. In addition, electron microscopy and subcellular fractionation indicated that G2 was localized in synaptic vesicles, whereas G1 was not detectable. G1 and G2 exhibit 62% identity, and both isoforms were immunoprecipitated with the c and A subunits of V-ATPase. G2 could complement the yeast deletion mutant Deltavma10, which lacks the G subunit. The V-ATPases containing the G1 and G2 isoforms, respectively, showed similar K-m(ATP) values and maximal velocity. These results indicate that G1 and G2 are bona fide subunits of V-ATPases and that the enzyme with the G2 isoform. is involved in synaptic vesicle acidification.	Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan	Osaka University; Japan Science & Technology Agency (JST); Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, Mihogaoka 8-1, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	Yoshimizu, Takao/A-1339-2011	Yoshimizu, Takao/0000-0002-2553-8195				BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Crider BP, 1997, J BIOL CHEM, V272, P10721; FULDNER HH, 1982, EUR J BIOCHEM, V121, P519, DOI 10.1111/j.1432-1033.1982.tb05817.x; Futai M, 2000, J EXP BIOL, V203, P107; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GRAHAM J, 1994, ANAL BIOCHEM, V220, P367, DOI 10.1006/abio.1994.1351; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; HUBER G, 1984, J NEUROSCI, V4, P151; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; MICHAELSON DM, 1980, LIFE SCI, V27, P39, DOI 10.1016/0024-3205(80)90017-X; Morel N, 1998, J NEUROCHEM, V71, P1702; MORIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P443, DOI 10.1016/S0006-291X(05)81078-2; MORIYAMA Y, 1992, J EXP BIOL, V172, P171; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Neville MJ, 1999, J IMMUNOL, V162, P4745; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; REYNOLDS R, 1989, NEUROSCIENCE, V28, P181, DOI 10.1016/0306-4522(89)90242-X; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STADLER H, 1984, EMBO J, V3, P3333, DOI 10.1002/j.1460-2075.1984.tb02300.x; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Sun-Wada GH, 2000, J BIOCHEM-TOKYO, V127, P703, DOI 10.1093/oxfordjournals.jbchem.a022660; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; SWALLOW CJ, 1990, SURGERY, V108, P363; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	54	56	59	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36296	36303		10.1074/jbc.M200586200	http://dx.doi.org/10.1074/jbc.M200586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133826	hybrid			2022-12-25	WOS:000178275100066
J	Spiegelman, VS; Tang, WG; Chan, AM; Igarashi, M; Aaronson, SA; Sassoon, DA; Katoh, M; Slaga, TJ; Fuchs, SY				Spiegelman, VS; Tang, WG; Chan, AM; Igarashi, M; Aaronson, SA; Sassoon, DA; Katoh, M; Slaga, TJ; Fuchs, SY			Induction of homologue of slimb ubiquitin ligase receptor by mitogen signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; RIBOSOMAL S6 KINASE; H-BETA-TRCP; ONCOGENIC RAS; CYCLIN-E; TRANSCRIPTIONAL ACTIVITY; CELLULAR-TRANSFORMATION; ALPHA UBIQUITINATION; NIH3T3 FIBROBLASTS; VIRUS TYPE-1	Homologue of Slimb (HOS) is the substrate-recognizing component of the SCFHOS-Roc1 E3 ubiquitin protein ligase. This ligase mediates ubiquitination of the inhibitor of NF-kappaB transcription factor (IkappaB). We have found that HOS is highly expressed in a number of human cancer cell lines. The rates of the HOS gene transcription as well as HOS mRNA and protein levels were upregulated in cells treated with mitogens or transfected with the inducers of mitogen-activated protein kinase pathway. Conversely, mitogen withdrawal strikingly reduced HOS levels during differentiation of mouse myoblasts. Activators of mitogen-activated protein kinase accelerated IkappaBalpha degradation and increased NF-kappaB transcriptional activity. Inhibition of HOS function via expression of dominant negative HOS (HOSDeltaF) initiated mouse myoblast differentiation and prevented Ras-mediated acceleration of IkappaBalpha degradation as well as NF-kappaB trans-activation and transformation of NIH3T3 cells. These data link the induction of HOS in proliferating cells with mitogen-signaling-dependent inhibition of cell differentiation and promotion of cell transformation.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan	University of Pennsylvania; AMC Cancer Research Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; National Cancer Center - Japan	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,Rm 161E VET, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu	Chan, Andrew Man-Lok/J-9497-2013; SASSOON, David A/G-2502-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; SASSOON, David A/0000-0001-6074-048X; Chan, Andrew/0000-0001-9923-5464; Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CUADRADO A, 1993, ONCOGENE, V8, P2443; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRIEDMAN J, 1983, CARCINOGENESIS, V4, P1425, DOI 10.1093/carcin/4.11.1425; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Osada M, 1999, MOL CELL BIOL, V19, P6333; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Saitoh T, 2001, INT J ONCOL, V18, P959; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	51	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36624	36630		10.1074/jbc.M204524200	http://dx.doi.org/10.1074/jbc.M204524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151397	hybrid			2022-12-25	WOS:000178275100107
J	Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L				Miyoshi, K; Rosner, A; Nozawa, M; Byrd, C; Morgan, F; Landesman-Bollag, E; Xu, X; Seldin, DC; Schmidt, EV; Taketo, MM; Robinson, GW; Cardiff, RD; Hennighausen, L			Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors	ONCOGENE			English	Article						Wnt signaling; beta-catenin activation; Int2/Fgf3; cytokeratin expression; pilar tumor; transdifferentiation	PROTEIN-KINASE CK2; BETA-CATENIN; TRANSGENIC MICE; CYCLIN D1; FUNCTIONAL INTERACTION; HAIR FOLLICLE; FEMALE MICE; GENE; GLAND; EXPRESSION	The Wnt/beta-catenin signaling pathway controls cell fate and neoplastic transformation. Expression of an endogenous stabilized beta-catenin (DeltaE3 beta-catenin) in mammary epithelium leads to the transdifferentiation into epidermis- and pilar-like structures. Signaling molecules in the canonical Wnt pathway upstream from P-catenin induce glandular tumors but it is not clear whether they also cause squamous transdifferentiation. To address this question we have now investigated mammary epithelium from transgenic mice that express activating molecules of the Wnt pathway: Wnt10b, Int2/Fgf3, CK2alpha, DeltaE3 beta-catenin, Cyclin D1, and dominant negative (dn) GSK3beta. Cytokeratin 5 (CK5), which is expressed in both mammary myoepithelium and epidermis, and the epidermis-specific CK1 and CK6 were used as differentiation markers. Extensive squamous metaplasias and widespread expression of CK1 and CK6 were observed in DeltaE3 beta-catenin transgenic mammary tissue. Wnt10b and Int2 transgenes also induced squamous metaplasias, but expression of CK1 and CK6 was sporadic. While CK5 expression in Wnt I Ob transgenic tissue was still confined to the lining cell layer, its expression in Int2 transgenic tissue was completely disorganized. In contrast, cytokeratin expression in CK2alpha dnGSK3beta and Cyclin D1 transgenic mammary tissues was similar to that in DeltaE3 beta-catenin tissue. In support of transdifferentiation, expression of hard keratins specific for hair and nails was observed in pilar tumors. These results demonstrate that the activation of Wnt signaling components in mammary epithelium induces not only glandular tumors but also squamous differentiation, possibly by activating LEF-1, which is expressed in normal mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Univ Tokushima, Sch Dent, Dept Biochem, Tokushima 7708504, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Boston Univ, Med Ctr, Boston, MA 02118 USA; McLaughlin Res Inst, Great Falls, MT USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Kyoto Univ, Grad Sch Med, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tokushima University; University of California System; University of California Davis; Boston University; McLaughlin Research Institute for Biomedical Sciences, Inc.; Harvard University; Massachusetts General Hospital; Kyoto University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101,8 Ctr Dr, Bethesda, MD 20892 USA.		Robinson, Gertraud/I-2136-2012	Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841; Seldin, David C/0000-0003-0168-2333	NCRR NIH HHS [U42 RR14905] Funding Source: Medline; NIEHS NIH HHS [P01 ES11624] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR014905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; KLINT P, 1999, FRONT BIOSCI, V4, P165; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Niemann C, 2002, DEVELOPMENT, V129, P95; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; ROSNER A, 2002, IN PRESS AM J PATHOL; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tekmal Rajeshwar Rao, 1997, Frontiers in Bioscience, V2, pD519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	46	93	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5548	5556		10.1038/sj.onc.1205686	http://dx.doi.org/10.1038/sj.onc.1205686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165853				2022-12-25	WOS:000177442000004
J	Channavajhala, P; Seldin, DC				Channavajhala, P; Seldin, DC			Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis	ONCOGENE			English	Article						casein kinase II; protein kinase CK2; c-myc; lymphoma; proteasome	II-ALPHA; COMPETITIVE INHIBITOR; PHOSPHORYLATION SITES; EPITHELIAL-CELLS; CASEIN KINASE-2; EXPRESSION; MICE; PROTEASOME; ACTIVATION; SUBUNIT	Protein kinase CK2 (formerly casein kinase II) is frequently upregulated in human cancers, and transgenic expression of CK2alpha in lymphocytes is oncogenic. Lymphomagenesis is dramatically acclerated by coexpression of a c-myc transgene, suggestive of a synergistic interaction between the kinase and the transcription factor. Since c-myc can be phosphorylated by CK2, we hypothesized that the synergy between CK2 and c-myc might be due to a functional interaction of the two molecules. Pharmacologic inhibition of CK2 activity in cell lines established from CK2alpha transgenic T cell lymphomas reduces their proliferation and concomitantly with this, the steady state levels of c-myc protein decline. This is caused by acclerated c-myc protein turnover, which occurs in a proteasome-dependent manner. Transfection of cells with sense or anti-sense CK2 constructs modulates c-myc protein levels in concert with the alteration in CK2 activity, validating the findings obtained using the kinase inhibitors. Thus, CK2 is a critical regulator of c-myc protein stability and of the proliferation of these T cell lymphomas.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Seldin, DC (corresponding author), 650 Albany St, Boston, MA 02118 USA.	dseldin@medicine.bu.edu		Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [R01 CA71796] Funding Source: Medline; NHLBI NIH HHS [T32 HL07501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Battistutta R, 2000, J BIOL CHEM, V275, P29618, DOI 10.1074/jbc.M004257200; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BOLDYREFF B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P32, DOI 10.1016/0167-4781(93)90239-A; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Critchfield JW, 1996, AIDS RES HUM RETROV, V12, P39, DOI 10.1089/aid.1996.12.39; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Dobrowolska G, 1999, MOL CELL BIOCHEM, V191, P3, DOI 10.1023/A:1006882910351; Dumont FJ, 1998, J IMMUNOL, V160, P2579; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Kamei H, 1998, CANCER BIOTHER RADIO, V13, P185, DOI 10.1089/cbr.1998.13.185; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lin JK, 1997, J CELL BIOCHEM, P39; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Penn L J, 1990, Semin Cancer Biol, V1, P69; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; Trochon V, 2000, INT J CANCER, V85, P691, DOI 10.1002/(SICI)1097-0215(20000301)85:5&lt;691::AID-IJC15&gt;3.0.CO;2-Q; VONDEIMLING A, 1990, VERH DEUT G, V74, P432; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; Yin F, 1999, ANTICANCER RES, V19, P4297	54	115	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5280	5288		10.1038/sj.onc.1205640	http://dx.doi.org/10.1038/sj.onc.1205640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149649	Bronze			2022-12-25	WOS:000177193900009
J	Adamson, P; Wilbourn, B; Etienne-Manneville, S; Calder, V; Beraud, E; Milligan, G; Couraud, PO; Greenwood, J				Adamson, P; Wilbourn, B; Etienne-Manneville, S; Calder, V; Beraud, E; Milligan, G; Couraud, PO; Greenwood, J			Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling	FASEB JOURNAL			English	Article						endothelium; lymphocyte migration; EC	CENTRAL-NERVOUS-SYSTEM; TRANSENDOTHELIAL MIGRATION; IN-VITRO; T-LYMPHOCYTES; RETINAL BARRIER; BASIC-PROTEIN; ALPHA-SUBUNIT; ICAM-1; ACTIVATION; ADHESION	We have previously shown that the engagement of ICAM-1 on brain endothelial cells (EC) results in the propagation of EC signaling pathways that are necessary for efficient lymphocyte migration across the tight vascular barriers of the brain. Signaling via this receptor alone, however, is unlikely to explain the differential recruitment of leukocytes at different vascular beds. In this study, we investigated the role of EC heterotrimeric G-protein-mediated signaling in supporting transendothelial migration of T lymphocytes. Treatment of brain EC monolayers with pertussis toxin (PTX) resulted in ADP-ribosylation of G-protein alpha subunits and inhibition (>80%) of lymphocyte migration without affecting lymphocyte adhesion. Aortic and high endothelial venule EC treated identically resulted in only partial inhibition of lymphocyte migration (<40%). Expression of ribosylation-resistant (PTX-insensitive) G-protein alpha subunits in brain EC restored their ability to support lymphocyte migration after pretreatment with PTX. Treatment of brain EC with PTX did not inhibit ICAM-1-stimulated tyrosine phosphorylation of focal adhesion kinase, suggesting the effects of PTX in inhibiting EC facilitation of lymphocyte migration are distinct from activation of EC through ICAM-1. We conclude that a heterotrimeric G-protein-mediated signaling pathway in brain EC is essential for efficient transendothelial migration of T lymphocytes into the brain.	UCL, Inst Ophthalmol, Div Cell Biol, Endothelial & Epithelial Cell Biol Res Unit, London EC1V 9EL, England; Inst Cochin Genet Mol, Dept Biol Cellulaire, CNRS, UMR8104,INSERM567, F-75014 Paris, France; Univ Aix Marseille 2, Fac Med, Immunol Lab, Marseille, France; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; University of Glasgow	Greenwood, J (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, Endothelial & Epithelial Cell Biol Res Unit, Bath St, London EC1V 9EL, England.	J.Greenwood@ucl.ac.uk	Etienne-Manneville, Sandrine/C-5879-2015; Calder, Virginia/AAG-8278-2020; Milligan, Graeme/F-9426-2011	Etienne-Manneville, Sandrine/0000-0001-6651-3675; Calder, Virginia/0000-0003-1422-2926; Milligan, Graeme/0000-0002-6946-3519; Greenwood, John/0000-0003-4496-2984				ABBOTT NJ, 1992, J CELL SCI, V103, P23; Adamson P, 1999, J IMMUNOL, V162, P2964; AGER A, 1987, J CELL SCI, V87, P133; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Andjelkovic AV, 1999, J CELL BIOL, V145, P403, DOI 10.1083/jcb.145.2.403; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERAUD E, 1986, J IMMUNOL, V136, P511; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; BOURDOULOUS S, 1995, EUR J IMMUNOL, V25, P1176, DOI 10.1002/eji.1830250507; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fabian G, 1998, NEUROCHEM INT, V33, P179, DOI 10.1016/S0197-0186(98)00008-4; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; GREENWOOD J, 1992, J NEUROIMMUNOL, V39, P123, DOI 10.1016/0165-5728(92)90181-J; GREENWOOD J, 1993, IMMUNOLOGY, V80, P401; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HUGHES CCW, 1988, IMMUNOLOGY, V64, P677; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; MALE D, 1994, IMMUNOLOGY, V81, P366; MALE D, 1990, CELL IMMUNOL, V127, P1, DOI 10.1016/0008-8749(90)90109-5; MCGUIRE PG, 1987, LAB INVEST, V57, P94; NURNBERG B, 1994, BIOCHEM J, V300, P387; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; Phillips R, 2002, EUR J IMMUNOL, V32, P837, DOI 10.1002/1521-4141(200203)32:3<837::AID-IMMU837>3.0.CO;2-Q; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; Pryce G, 1997, J NEUROIMMUNOL, V75, P84, DOI 10.1016/S0165-5728(97)00006-4; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; ROZDZINSKI E, 1993, J EXP MED, V178, P917, DOI 10.1084/jem.178.3.917; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; WANG YF, 1993, J NEUROIMMUNOL, V48, P161, DOI 10.1016/0165-5728(93)90188-5; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	38	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1185	10.1096/fj.02-0035com	http://dx.doi.org/10.1096/fj.02-0035com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153986				2022-12-25	WOS:000177814000027
J	Guo, J; McLachlan, SM; Rapoport, B				Guo, J; McLachlan, SM; Rapoport, B			Localization of the thyroid peroxidase autoantibody immunodominant region to a junctional region containing portions of the domains homologous to complement control protein and myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPE; CONFORMATIONAL EPITOPES; 3-DIMENSIONAL MODEL; MOLECULAR-CLONING; MAJOR AUTOANTIGEN; DISEASE; ANTIGEN; GENE; IDENTIFICATION; THYROPEROXIDASE	Thyroid peroxidase (TPO) autoantibody epitopes are largely restricted to an immunodominant region (IDR) on the extracellular region of the native molecule. Localization of the IDR has been a longstanding and difficult goal. The TPO extracellular region comprises a large myeloperoxidase-like domain, linked to the plasma membrane by two smaller domains with homology to complement control protein (CCP) and epidermal growth factor (EGF), respectively. Recent studies have focused on the CCP- and EGF-like domains as the putative location of the TPO autoantibody IDR. To address this issue, we attempted to express on the surface of transfected cells native TPO in which the CCP- and EGF-like domains were deleted, either together or individually. We used a quartet of human monoclonal autoantibodies that define the TPO IDR, as well as polyclonal TPO autoantibodies in patients' sera, to detect these mutated TPO molecules by flow cytometry. The combined CCP/EGF-like domain deletion did not produce a signal with TPO autoantibodies but did not traffic to the cell surface. In contrast, both monoclonal and polyclonal autoantibodies recognized TPO with the juxtamembrane EGF-like domain deleted equally as well as the wild-type TPO on the cell surface. TPO with the CCP-like domain deleted expressed normally on the cell surface, as determined using the polyclonal mouse antiserum. Nevertheless, this modified TPO molecule was recognized very poorly by both the human monoclonal autoantibodies and the polyclonal autoantibodies in patients' sera. In conclusion, we have clearly excluded the juxtamembrane EGF-like domain as being part of the IDR. In contrast, a component of the CCP-like domain does contribute to the IDR. These data, together with findings from other studies, localize the TPO autoantibody IDR to the junction of the CCP-like domain and the much larger myeloperoxidase-like domain on TPO.	Cedars Sinai Med Ctr, Autoimmune Dis Unit, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Rapoport, B (corresponding author), Cedars Sinai Med Ctr, Autoimmune Dis Unit, 8700 Beverly Blvd,Suite B-131, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK 36182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arscott PL, 1996, J BIOL CHEM, V271, P4966; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; Estienne V, 2002, INT IMMUNOL, V14, P359, DOI 10.1093/intimm/14.4.359; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; Gardas A, 2000, REDOX REP, V5, P237, DOI 10.1179/135100000101535681; Guo J, 1997, J CLIN ENDOCR METAB, V82, P925, DOI 10.1210/jc.82.3.925; Guo J, 1999, CLIN EXP IMMUNOL, V117, P19; Guo J, 2001, J IMMUNOL, V166, P1327, DOI 10.4049/jimmunol.166.2.1327; Hobby P, 2000, ENDOCRINOLOGY, V141, P2018, DOI 10.1210/en.141.6.2018; Jaume JC, 1999, J CLIN ENDOCR METAB, V84, P1424, DOI 10.1210/jc.84.4.1424; Jaume JC, 1999, J CLIN ENDOCR METAB, V84, P1651, DOI 10.1210/jc.84.5.1651; Jaume JC, 1996, CLIN EXP IMMUNOL, V104, P115, DOI 10.1046/j.1365-2249.1996.d01-659.x; Jones FG, 1999, AUTOIMMUNITY, V30, P157, DOI 10.3109/08916939908993850; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MAASTRICHT J, 1992, J CLIN ENDOCR METAB, V75, P121, DOI 10.1210/jc.75.1.121; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; McLachlan S M, 2000, Int Rev Immunol, V19, P587, DOI 10.3109/08830180009088514; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V79, P1648, DOI 10.1210/jc.79.6.1648; Pichurin P, 2001, THYROID, V11, P301, DOI 10.1089/10507250152039037; PORTMANN L, 1985, J CLIN ENDOCR METAB, V61, P1001, DOI 10.1210/jcem-61-5-1001; Rapoport B, 2001, J CLIN INVEST, V108, P1253, DOI 10.1172/JCI14321; RODIEN P, 1992, AUTOIMMUNITY, V13, P177, DOI 10.3109/08916939209004822; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SETO P, 1987, J CLIN INVEST, V80, P1205, DOI 10.1172/JCI113181; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; TONACCHERA M, 1995, EUR J ENDOCRINOL, V132, P53, DOI 10.1530/eje.0.1320053; Xiong ZG, 2001, THYROID, V11, P227, DOI 10.1089/105072501750159598; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	36	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40189	40195		10.1074/jbc.M205524200	http://dx.doi.org/10.1074/jbc.M205524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167622	hybrid			2022-12-25	WOS:000178791400006
J	Pandini, G; Frasca, F; Mineo, R; Sciacca, L; Vigneri, R; Belfiore, A				Pandini, G; Frasca, F; Mineo, R; Sciacca, L; Vigneri, R; Belfiore, A			Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; THYROID-CANCER; SKELETAL-MUSCLE; PROTEIN-KINASE; MESSENGER-RNA; HIGH-AFFINITY; BETA-SUBUNIT; IGF-II	The insulin receptor (IR) and the insulin-like growth factor I receptor (IGF-IR) have a highly homologous structure, but different biological effects. Insulin and IGF-I half-receptors can heterodimerize, leading to the formation of insulin/IGF-I hybrid receptors (Hybrid-Rs) that bind IGF-I with high affinity. As the IR exists in two isoforms (IR-A and IR-B), we evaluated whether the assembly of the IGF-IR with either IR-A or IR-B moieties may differently affect Hybrid-R signaling and biological role. Three different models were studied: (a) 3T3-like mouse fibroblasts with a disrupted IGF-IR gene (R-cells) cotransfected with the human IGF-IR and with either the IR-A or IR-B cDNA, (b) a panel of human cell lines variably expressing the two IR isoforms; and (c) HepG2 human hepatoblastoma cells predominantly expressing either IR-A or IR-B, depending on their differentiation state. We found that Hybrid-Rs containing IR-A (Hybrid-Rs(A)) bound to and were activated by IGF-I, IGF-II, and insulin. By binding to Hybrid-Rs(A), insulin activated the IGF-I half-receptor beta-subunit and the IGF-IR-specific substrate CrkII. In contrast, Hybrid-Rs(B) bound to and were activated with high affinity by IGF-I, with low affinity by IGF-II, and insignificantly by insulin. As a consequence, cell proliferation and migration in response to both insulin and IGFs were more effectively stimulated in Hybrid-R-A-containing cells than in Hybrid-R-B-containing cells. The relative abundance of IR isoforms therefore affects IGF system activation through Hybrid-Rs, with important consequences for tissue-specific responses to both insulin and IGFs.	Univ Catanzaro, Policlin Mater Domini, Dipartimento Med Clin & Sperimentale, I-88100 Catanzaro, Italy; Ist Mediterraneo Oncol, I-95100 Catania, Italy; Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy	Magna Graecia University of Catanzaro; Mediterranean Institute of Oncology; University of Catania	Belfiore, A (corresponding author), Univ Catanzaro, Policlin Mater Domini, Dipartimento Med Clin & Sperimentale, Via T Campanella 115, I-88100 Catanzaro, Italy.		Sciacca, Laura/B-9368-2014; SCIACCA, Laura/AAS-2896-2020; Frasca, Francesco/J-1332-2018; Belfiore, Antonino/B-4652-2011; Pandini, Giuseppe/AAB-9650-2019; Vigneri, Riccardo/M-3968-2017	Sciacca, Laura/0000-0002-3258-7200; SCIACCA, Laura/0000-0002-3258-7200; Frasca, Francesco/0000-0002-5556-3201; Belfiore, Antonino/0000-0002-6181-4193; Pandini, Giuseppe/0000-0003-3747-7649; Vigneri, Riccardo/0000-0002-4401-3140				Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; BASERGA R, 1995, CANCER RES, V55, P249; Belfiore A, 1999, BIOCHIMIE, V81, P403, DOI 10.1016/S0300-9084(99)80088-1; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Federici M, 1996, J CLIN INVEST, V98, P2887, DOI 10.1172/JCI119117; Federici M, 1998, J CLIN ENDOCR METAB, V83, P2911, DOI 10.1210/jc.83.8.2911; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; FLIER JS, 1993, J CLIN ENDOCR METAB, V76, P1533, DOI 10.1210/jc.76.6.1533; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Koval AP, 1998, BIOCHEM J, V330, P923; KULL FC, 1983, J BIOL CHEM, V258, P6561; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Pandini G, 1999, CLIN CANCER RES, V5, P1935; PAPA V, 1993, CANCER RES, V53, P3736; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P537, DOI 10.1101/SQB.1988.053.01.062; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Sbraccia P, 1996, DIABETOLOGIA, V39, P220, DOI 10.1007/BF00403966; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SEELY BL, 1995, ENDOCRINOLOGY, V136, P1635, DOI 10.1210/en.136.4.1635; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; Spampinato D, 2000, J CLIN ENDOCR METAB, V85, P4219, DOI 10.1210/jc.85.11.4219; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2001, J CLIN PATHOL-MOL PA, V54, P121, DOI 10.1136/mp.54.3.121; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	50	358	385	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39684	39695		10.1074/jbc.M202766200	http://dx.doi.org/10.1074/jbc.M202766200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12138094	hybrid			2022-12-25	WOS:000178662500082
J	Pawar, A; Xu, JH; Jerks, E; Mangelsdorf, DJ; Jump, DB				Pawar, A; Xu, JH; Jerks, E; Mangelsdorf, DJ; Jump, DB			Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor alpha (PPAR alpha) in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 EXPRESSION; GENE-TRANSCRIPTION; NUCLEAR RECEPTORS; SUPPRESSION; EICOSANOIDS; METABOLISM; SREBP-1C; BETA	Fatty acids bind to and regulate the activity of peroxisome proliferator-activated (PPAR) and liver X receptors (LXR). However, the role lipid metabolism plays in the control of intracellular fatty acid ligands is poorly understood. We have identified two strains of HEK293 cells that display differences in fatty acid regulation of nuclear receptors. Using full-length and Ga14-LBD chimeric receptors in functional assays, 20:4,n6 induced PPARalpha activity -2.2-fold and suppressed LXRalpha activity by 80% (ED50 similar to25-50 mum) in HEK293-E (early passage) cells but had no effect on PPARalpha or LXRalpha receptor activity in HEK293-L (late passage) cells. LXRbeta was insensitive to fatty acid regulation in both HEK293 strains. Metabolic labeling studies using [C-14]20:4,n6 (at 100 mum) indicated that the uptake of 20:4,n6 and its assimilation into triacylglycerol, diacylglycerol, and polar lipids revealed no difference between the two strains. Such treatment increased total cellular 20:4,n6 (similar to11-fold) and its elongation product, 22:4,n6 (similar to3.6-fold), within 6 h. Non-esterified 20:4,n6 and 22:4,n6 represented less than or equal to3% of the total cellular 20:4,n6 and 22:4,n6. In HEK293-E cells, non-esterified 20:4,n6 and 22:4,n6 increased 8- and 18-fold, respectively, by 6 h and was sustained at that level for 24 h. In HEK293-L cells, non-esterified 20:4,n6 also increased (5-fold) at 6 h but fell by 70% within 24 h. In contrast to HEK293-E cells, non-esterified 22:4,n6 did not accumulate in HEK293-L cells. Functional assays showed that 22:4,n6 was similar to2-fold more effective than 20: 4,n6 at inhibiting oxysterol-induced LXRa activity in HEK293-E cells, but had no effect on LXRa activity in HEK293-L cells. Taken together, these findings demonstrate that the rate of assimilation of exogenously added fatty acids and their metabolites into complex lipids plays an important role in regulating PPARa and LXRa activity.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biol Mol, E Lansing, MI 48824 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	Michigan State University; Michigan State University; Michigan State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.		Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663; Mangelsdorf, David/0000-0002-4355-0796	NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KARARA A, 1989, J BIOL CHEM, V264, P19822; KIM HY, 1990, J LIPID RES, V31, P2285; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SNYDER F, 1985, BIOCH LIPIDS MEMBRAN, P271; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	23	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39243	39250		10.1074/jbc.M206170200	http://dx.doi.org/10.1074/jbc.M206170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161442	hybrid			2022-12-25	WOS:000178662500025
J	Hu, WW; Feng, ZH; Chasin, LA; Tang, MS				Hu, WW; Feng, ZH; Chasin, LA; Tang, MS			Transcription-coupled and transcription-independent repair of cyclobutane pyrimidine dimers in the dihydrofolate reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; HAMSTER OVARY CELLS; INDUCED DNA-DAMAGE; ACTIVE GENES; DHFR GENE; COCKAYNES-SYNDROME; MAMMALIAN-CELLS; CHO CELLS; STRAND; NUCLEOSOME	Using a ligation-mediated polymerase chain reaction technique, we have mapped the repair of ultraviolet light-induced cyclobutane pyrimidine dimers (CPDs) at the nucleotide level in exons 1, 2, and 5 of the dihydrofolate reductase (DHFR) gene in Chinese hamster ovary cells. We found that CPDs are preferentially repaired in the transcribed strand (T strand) and that the order of repair efficiency is exon 1 > exon 2 > exon 5. In the cells with a deletion of the DHFR gene encompassing the promoter region and the first four exons, CPDs are not repaired in the T strand of the residual DHFR gene. These results substantiate the idea that the preferential repair of CPDs in the T strand is transcription dependent. However, in the wild type gene we have found that CPDs are efficiently repaired in the nontranscribed strand (NT strand) of exon 1 but not in the NT strand of exons 2 and 5. Probing the chromatin structure of exons 1, 2, and 5 of the DHFR gene with micrococcal nuclease revealed that the exon 1 region is much more sensitive to micrococcal nuclease digestion than the exon 2 and exon 5 regions, suggesting that the chromatin structure in the exon 1 region is much more open. These results suggest that, although preferential repair of the T strand of the DHFR gene is transcription dependent, repair of the NT strand is greatly affected by chromatin structure.	NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	New York University; Columbia University	Tang, MS (corresponding author), NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124, R01ES008389] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03124, ES08389] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Feng ZH, 2002, J BIOL CHEM, V277, P12777, DOI 10.1074/jbc.M112297200; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; FRIEDBERG EC, 1985, DNA REPAIR, P1; George JW, 2001, MOL CELL BIOL, V21, P7355, DOI 10.1128/MCB.21.21.7355-7365.2001; Hanawalt PC, 2001, ENVIRON MOL MUTAGEN, V38, P89, DOI 10.1002/em.1057; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; ISLAS AL, 1995, CANCER RES, V55, P336; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; Morales V, 2001, BIOCHIMIE, V83, P1029, DOI 10.1016/S0300-9084(01)01347-5; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Spivak G, 1996, MUTAT RES-FUND MOL M, V350, P207, DOI 10.1016/0027-5107(95)00107-7; TANG MS, 1994, J BIOL CHEM, V269, P12749; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENEMA J, 1992, J BIOL CHEM, V267, P8852; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Zheng Y, 2001, J BIOL CHEM, V276, P16786, DOI 10.1074/jbc.M010973200	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38305	38310		10.1074/jbc.M206375200	http://dx.doi.org/10.1074/jbc.M206375200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167651	hybrid			2022-12-25	WOS:000178529600041
J	Lazetic, S; Leong, SR; Chang, JCC; Ong, R; Dawes, G; Punnonen, J				Lazetic, S; Leong, SR; Chang, JCC; Ong, R; Dawes, G; Punnonen, J			Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CD28-DEFICIENT MICE; DIRECTED EVOLUTION; IMMUNE-RESPONSE; DOWN-REGULATION; IGE SYNTHESIS; CLASS-II; B-CELLS; INDUCTION; ANTIGEN	CD28 and CTLA-4 (CD152) play a pivotal role in the regulation of T cell activation. Upon ligation by CD80 (B7-1) or CD86 (B7-2), CD28 induces T cell proliferation, cytokine production, and effector functions, whereas CTLA-4 signaling inhibits expansion of activated T cells and induces tolerance. Therefore, we hypothesized that co-stimulatory molecules that preferentially bind CD28 or CTLA-4 would have dramatically altered biological properties. We describe directed molecular evolution of CD80 genes derived from human, orangutan, rhesus monkey, baboon, cat, cow, and rabbit by DNA shuffling and screening. In contrast to wild-type CD80, the evolved co-stimulatory molecules, termed CD28-binding protein (CD28BP) and CTLA-4-binding protein (CTLA-4BP), selectively bind to CD28 or CTLA-4, respectively. Furthermore, CD28BP has improved capacity to induce human T cell proliferation and interferon-gamma production compared with wild-type CD80. In contrast, CTLA-4BP inhibited human mixed leukocyte reaction (MLR) and enhanced interleukin 10 production in MLR, supporting a role for CTLA-BP in inducing T cell anergy and tolerance. In addition, co-stimulation of purified human T cells was significantly suppressed when CTLA-4BP was cotransfected with either CD80 or CD28BP. The amino acid sequences of CD28BP and CTLA-4BP were 61 and 96% identical with that of human CD80 and provide insight into the residues that are critical in the ligand binding. These molecules provide a new approach to characterization of CD28 and CTLA-4 signals and to manipulation of the T cell response.	Maxygen Inc, Dept Vaccines, Redwood City, CA 94063 USA		Punnonen, J (corresponding author), Maxygen Inc, Dept Vaccines, Redwood City, CA 94063 USA.							Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Darlington PJ, 2002, J EXP MED, V195, P1337, DOI 10.1084/jem.20011868; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; FARGEAS CA, 1995, J EXP MED, V182, P667, DOI 10.1084/jem.182.3.667; Ferguson SE, 1996, J IMMUNOL, V156, P4576; FERNANDEZRUIZ E, 1995, EUR J IMMUNOL, V25, P1453, DOI 10.1002/eji.1830250548; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Greenwald RJ, 2001, IMMUNITY, V14, P145, DOI 10.1016/S1074-7613(01)00097-8; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HODGE JW, 1995, CANCER RES, V55, P3598; ISONO T, 1995, IMMUNOGENETICS, V42, P217, DOI 10.1007/BF00191228; Kim JJ, 1998, VACCINE, V16, P1828, DOI 10.1016/S0264-410X(98)00177-7; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; MALEFYT RD, 1991, J EXP MED, V174, P915; McAdam AJ, 1998, IMMUNOL REV, V165, P231; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; OZATO K, 1981, J IMMUNOL, V126, P317; Parsons KR, 1999, IMMUNOGENETICS, V49, P231, DOI 10.1007/s002510050484; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Prud'Homme GJ, 2002, HUM GENE THER, V13, P395, DOI 10.1089/10430340252792521; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Punnonen J, 2000, INT ARCH ALLERGY IMM, V121, P173, DOI 10.1159/000024315; Rizzo LV, 1999, J IMMUNOL, V162, P2613; Schwartz JCD, 2002, NAT IMMUNOL, V3, P427, DOI 10.1038/ni0502-427; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Sturmhoefel K, 1999, CANCER RES, V59, P4964; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tobin MB, 2000, CURR OPIN STRUC BIOL, V10, P421, DOI 10.1016/S0959-440X(00)00109-3; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Zhang YX, 2002, NATURE, V415, P644, DOI 10.1038/415644a	56	18	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38660	38668		10.1074/jbc.M205808200	http://dx.doi.org/10.1074/jbc.M205808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167647	hybrid			2022-12-25	WOS:000178529600083
J	Ranganathan, G; Song, W; Dean, N; Monia, B; Barger, SW; Kern, PA				Ranganathan, G; Song, W; Dean, N; Monia, B; Barger, SW; Kern, PA			Regulation of lipoprotein lipase by protein kinase Ca in 3T3-F442A adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL REGULATION; DOWN-REGULATION; MESSENGER-RNA; ANTISENSE OLIGONUCLEOTIDES; DE-NOVO; ALPHA; EXPRESSION; INSULIN; GLUCOSE; HORMONE	Lipoprotein lipase (LPL) is an important enzyme in adipocyte and lipid metabolism with complex cellular regulation. Previous studies demonstrated an inhibition of LPL activity and synthesis following depletion of protein kinase C (PKC) isoforms with long term treatment of 3T3-F442A adipocytes with 12-O-tetradecanoylphorbol-13-acetate. To identify the specific PKC isoforms involved, we treated cells with antisense oligonucleotides that block expression of specific PKC isoforms. An antisense oligonucleotide to PKCalpha inhibited LPL activity by 78 +/- 8%, whereas antisense oligonucleotides directed against PKCdelta or PKCepsilon had no effect on LPL activity. The change in LPL activity was maximal at 72 h and was accompanied by a decrease in LPL protein and LPL synthetic rate but no change in LPL mRNA, suggesting regulation at the level of translation. However, PKC depletion resulted in no change in the polysome profile, indicating that translation initiation was not affected. However, the addition of cytoplasmic extracts from adipocytes treated with 12-O-tetradecanoylphorbol-13-acetate or PKCa antisense oligomers inhibited LPL translation in vitro. This inhibition of LPL translation in vitro was lost when the LPL mRNA transcript did not contain nucleotides 1599-3200, thus implicating the 3'-untranslated region of LPL in the regulation of translation by PKC depletion. Both LPL activity and Raf1 activity were decreased in parallel following depletion of either total PKC or specific inhibition of PKCa. An antisense oligonucleotide to RAF1, which inhibited RAF1 activity, also inhibited LPL activity by 48 +/- 10%, and this decrease in LPL activity was not accompanied by a change in LPL mRNA. Cells were treated with U0126, a specific inhibitor of the ERK-activating kinases MEK1 and MEK2. Although U0126 inhibited ERK1 and ERK2 phosphorylation, U0126 had no effect on LPL activity, indicating that MEK/ERK pathways were not involved in this mechanism of LPL regulation. Together, these data indicate that PKCa and RAF1 are important in the translational regulation of LPL in adipocytes and that the mechanism of regulation is probably through an ERK-independent pathway.	Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; ISIS Pharmaceut, San Diego, CA 92008 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc	Ranganathan, G (corresponding author), Cent Arkansas Healthcare Syst, 151LR,4300 W 7th St, Little Rock, AR 72205 USA.	Ranganathangovx1@UAMS.edu		Barger, Steven/0000-0001-6049-6480				ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; Dean NM, 1996, BIOCHEM SOC T, V24, P623, DOI 10.1042/bst0240623; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEAN NM, 2000, ANTISENSE NUCLEIC A, V7, P229; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FARESE RV, 1994, J CLIN INVEST, V93, P1894, DOI 10.1172/JCI117180; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Keller U, 1995, Biotechnology, V28, P173; Kern PA, 1996, J LIPID RES, V37, P2332; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MAIER JAM, 1993, EXP CELL RES, V205, P52, DOI 10.1006/excr.1993.1057; Marcusson EG, 1998, NUCLEIC ACIDS RES, V26, P2016, DOI 10.1093/nar/26.8.2016; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; ONG JM, 1988, J BIOL CHEM, V263, P12933; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; Ranganathan G, 1999, METH MOL B, V109, P329; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	45	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38669	38675		10.1074/jbc.M206917200	http://dx.doi.org/10.1074/jbc.M206917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149272	hybrid			2022-12-25	WOS:000178529600084
J	Vercammen, J; Maertens, G; Gerard, M; De Clercq, E; Debyser, Z; Engelborghs, Y				Vercammen, J; Maertens, G; Gerard, M; De Clercq, E; Debyser, Z; Engelborghs, Y			DNA-induced polymerization of HIV-1 integrase analyzed with fluorescence fluctuation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; TERMINAL DOMAINS; BINDING; MULTIMERIZATION; ANISOTROPY; PROMOTES; ASSAYS; CORE; FORM	Human immunodeficiency virus type 1 (HIV-1) integrase is essential for viral replication. Integrase inserts the viral DNA into the host DNA. We studied the association of integrase to fluorescently labeled oligonucleotides using fluorescence correlation spectroscopy. The binding of integrase to the fluorescent oligonucleotides resulted in the appearance of bright spikes during fluorescence correlation spectroscopy measurements. These spikes arise from the formation of high molecular mass protein-DNA complexes. The fluorescence of the free DNA was separated from the spikes with a statistical method. From the decrease of the concentration of free oligonucleotides, a site association constant was determined. The DNA-protein complexes were formed rapidly in a salt-dependent manner with site association constants ranging between 5 and 40 muM(-1) under different conditions. We also analyzed the kinetics of the DNA-protein complex assembly and the effect of different buffer components. The formation of the fluorescent protein-DNA complex was inhibited by guanosine quartets, and the inhibition constant was determined at 1.8 +/- 0.6 x 10(8) M-1. Displacement of bound DNA with G-quartets allowed the determination of the dissociation rate constant and proves the reversibility of the association process.	Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Engelborghs, Y (corresponding author), Katholieke Univ Leuven, Lab Biomol Dynam, Celestijnenlaan 200D, B-3001 Louvain, Belgium.		Maertens, Goedele/D-8628-2015; Gerard, Melanie/B-6898-2019	Maertens, Goedele/0000-0002-1963-8026; Gerard, Melanie/0000-0003-0585-6978; De Clercq, Erik/0000-0002-2985-8890				BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; Brown P.O., 1997, INTEGRATION RETROVIR, P161; Cai ML, 1997, NAT STRUCT BIOL, V4, P839; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; Connolly KM, 1999, J BIOMOL NMR, V14, P95, DOI 10.1023/A:1008328323180; Debyser Z, 1995, METHOD ENZYMOL, V262, P457; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Deprez E, 2001, P NATL ACAD SCI USA, V98, P10090, DOI 10.1073/pnas.181024498; ELSON EL, 1974, BIOPOLYMERS, V17, P1; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; Haugan IR, 1995, BIOCHEM BIOPH RES CO, V217, P802, DOI 10.1006/bbrc.1995.2843; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; MADGE D, 1974, BIOPOLYMERS, V13, P29; Magde D, 1977, Mol Biol Biochem Biophys, V24, P43; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Pluymers Wim, 2001, Current Drug Targets - Infectious Disorders, V1, P133, DOI 10.2174/1568005014606044; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Van Craenenbroeck E, 1999, BIOCHEMISTRY-US, V38, P5082, DOI 10.1021/bi9821925; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Van Craenenbroeck E, 2001, BIOL CHEM, V382, P355; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wennmalm S, 1997, P NATL ACAD SCI USA, V94, P10641, DOI 10.1073/pnas.94.20.10641; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	34	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38045	38052		10.1074/jbc.M205842200	http://dx.doi.org/10.1074/jbc.M205842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147698	hybrid			2022-12-25	WOS:000178529600011
J	Yaguchi, H; Ohkura, N; Tsukada, T; Yamaguchi, K				Yaguchi, H; Ohkura, N; Tsukada, T; Yamaguchi, K			Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; PROTEIN; RAS; INTERACTS; EXPRESSION; DYNAMIN; PHOSPHORYLATION; MECHANISM; CLONING; P190	MEN1, the gene responsible for multiple endocrine neoplasia type 1, is a tumor suppressor gene that encodes a protein called menin, of unknown function with no homology to any known protein. Here we demonstrate that menin interacts with a putative tumor metastasis suppressor nm23H1/nucleoside diphosphate (NDP) kinase A in mammalian cells. Given the roles of nm23 as a multi-functional protein, we searched for the possible function of menin. Menin has no effect on the known activities of nm23; that is, nucleoside diphosphate kinase, protein kinase, or GTPase-activating protein for Ras-related GTPase Rad. However, we found that menin hydrolyzes GTP to GDP efficiently in the presence of nm23, whereas nm23 or menin alone shows little or no detectable GTPase activity. Furthermore, menin contains sequence motifs similar to those found in all known GTPases or GTP-binding proteins and shows low affinity but specific binding to GTP/GDP. These results suggest that menin is an atypical GTPase stimulated by nm23.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Ohkura, N (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	nohkura@gan2.ncc.go.jp						Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Huang SC, 1999, LAB INVEST, V79, P301; JOHN J, 1993, J BIOL CHEM, V268, P923; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KANTOR JD, 1993, CANCER RES, V53, P1971; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Maruyama K, 1999, MOL CELL ENDOCRINOL, V156, P25, DOI 10.1016/S0303-7207(99)00150-1; Maruyama K, 2000, MOL CELL ENDOCRINOL, V168, P135, DOI 10.1016/S0303-7207(00)00307-5; Min K, 2002, PROTEINS, V46, P340, DOI 10.1002/prot.10038; Morra M, 2001, J BIOL CHEM, V276, P36809, DOI 10.1074/jbc.M101305200; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; Recio JA, 2000, CANCER RES, V60, P1720; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukada T, 2001, ENDOCR PATHOL, V12, P259, DOI 10.1385/EP:12:3:259; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; Yang WN, 1999, CURR BIOL, V9, pR511, DOI 10.1016/S0960-9822(99)80323-6; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	51	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38197	38204		10.1074/jbc.M204132200	http://dx.doi.org/10.1074/jbc.M204132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145286	hybrid			2022-12-25	WOS:000178529600029
J	Darman, RB; Forbush, B				Darman, RB; Forbush, B			A regulatory locus of phosphorylation in the N terminus of the Na-K-Cl cotransporter, NKCC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; FUNCTIONAL EXPRESSION; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; MOLECULAR-CLONING; PROTEIN; ACTIVATION; DOMAINS; KINASE; CAMP	The secretory Na-K-Cl cotransporter NKCC1 is activated by secretagogues through a phosphorylation-dependent mechanism. We found a phosphorylation stoichiometry of 3.0 +/- 0.4 phosphorylated residues/ NKCC1 protein harvested from shark rectal gland tubules maximally stimulated with forskolin and calyculin A, showing that at least three sites on the cotransporter are phosphorylated upon stimulation. Three phosphoacceptor sites were identified in the N-terminal domain of the protein (at Thr(184), Thr(189), and Thr(202)) using high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight mass spectrometry to analyze tryptic fragments of the radiolabeled cotransporter. None of these residues occurs in the context of strong consensus sites for known Ser/Thr kinases. The threonines and the surrounding amino acids are highly conserved between NKCC1 and NKCC2, and similarities are also present in the Na-Cl cotransporter NCC (or TSC). This strongly suggests that the phosphoregulatory mechanism is conserved among isoforms. Through expression of shark NKCC1 mutants in HEK-293 cells, Thr(189) was found to be necessary for activation of the protein, whereas phosphorylation at Thr(184) and Thr(202) was modulatory, but not required. In conjunction with the recent finding (Darmen, R. B., Flemmer, A., and Forbush, B. (2001) J. Biol. Chem. 276, 34359-34362) that protein phosphatase-1 binds to residues 107-112 in the shark NKCC1 sequence, these results demonstrate that the N terminus of NKCC1 constitutes a phosphoregulatory domain of the transporter.	Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	Darman, RB (corresponding author), Harvard Univ, Sch Med, Dept Mol Med, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	rdarman@caregroup.harvard.edu			NIDDK NIH HHS [DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gimenez Ignacio, 2000, Journal of the American Society of Nephrology, V11, p28A; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Kurihara K, 2002, AM J PHYSIOL-CELL PH, V282, pC817, DOI 10.1152/ajpcell.00352.2001; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; QUIRK PG, 1995, FEBS LETT, V370, P175, DOI 10.1016/0014-5793(95)00812-N; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; Waldegger S, 1998, PFLUG ARCH EUR J PHY, V436, P575, DOI 10.1007/s004240050674; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	29	185	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37542	37550		10.1074/jbc.M206293200	http://dx.doi.org/10.1074/jbc.M206293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145304	hybrid			2022-12-25	WOS:000178447100081
J	Ross, K; Yang, L; Dower, S; Volpe, F; Guesdon, F				Ross, K; Yang, L; Dower, S; Volpe, F; Guesdon, F			Identification of threonine 66 as a functionally critical residue of the interleukin-1 receptor-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; IL-1 RECEPTOR; ACCESSORY PROTEIN; DEATH DOMAIN; TNF RECEPTOR; IRAK; ACTIVATION; COMPLEX; PATHWAY; FAMILY	We have mutated a conserved residue of the death domain of the interleukin-1 (IL-1) receptor-associated kinase (IRAK), threonine 66. The substitution of Thr-66 with alanine or glutamate prevented spontaneous activation of NF-kappaB by overexpressed IRAK but enhanced IL-1-induced activation of the factor. Like the kinase-inactivating mutation, K239S, the T66A and T66E mutations interfered with the ability of IRAK to autophosphorylate and facilitated the interactions of IRAK with TRAF6 and with the IL-1 receptor accessory protein, AcP. Wild-type IRAK constructs tagged with fluorescent proteins formed complexes that adopted a punctate distribution in the cytoplasm. The Thr-66 mutations prevented the formation of these complexes. Measurements of fluorescence resonance energy transfer among fluorescent constructs showed that the Thr-66 mutations abolished the capacity of IRAK to dimerize. In contrast, the K239S mutation did not inhibit dimerization of IRAK as evidenced by fluorescence resonance energy transfer measurements, even though microscopy showed that it prevented the formation of punctate complexes. Our results show that Thr-66 plays a crucial role in the ability of IRAK to form homodimers and that its kinase activity regulates its ability to form high molecular weight complexes. These properties in turn determine key aspects of the signaling function of IRAK.	Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; GlaxoSmithKline R&D, Dept Mol Pharmacol, Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Sheffield; GlaxoSmithKline	Guesdon, F (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, M Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			dower, steve/0000-0002-4675-4225				Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cooke EL, 2001, BIOCHEM J, V359, P403, DOI 10.1042/0264-6021:3590403; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	37	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37414	37421		10.1074/jbc.M205160200	http://dx.doi.org/10.1074/jbc.M205160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138165	hybrid			2022-12-25	WOS:000178447100065
J	Singh, R; Pervin, S; Chaudhuri, G				Singh, R; Pervin, S; Chaudhuri, G			Caspase-8-mediated BID cleavage and release of mitochondrial cytochrome c during N-omega-hydroxy-L-arginine-induced apoptosis in MDA-MB-468 cells - Antagonistic effects of L-ornithine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NITRIC-OXIDE; INHIBITOR; ARGINASE; IDENTIFICATION; BIOSYNTHESIS; CARDIOLIPIN; POLYAMINES; ACTIVATION; MEMBRANE	We have previously reported that N-omega-hydroxy-L-arginine (NOHA), a stable intermediate product formed during the conversion Of L-arginine to nitric oxide, induced apoptosis in MDA-MB-468 cells, and this action was antagonized in the presence of L-ornithine. We also reported that apoptosis induced by NOHA in this cell line could not be explained on the basis of a reduction of intracellular polyamines. In the current study, we investigated other potential mechanism(s) by which NOHA may have induced apoptosis in this cell line. We observed that NOHA initially activated caspase-8 and induced cleavage of BH3 interacting domain. This was followed by release of cytochrome c and subsequently, activation of downstream caspases-9 and -3 to cleave poly(ADP-ribose) polymerase. We also observed that NOHA induced a rapid and persistent hyperpolarization of the mitochondrial membrane potential rather than depolarization indicating that the release of cytochrome c by NOHA was by a mechanism independent of the mitochondrial transition pore. Exogenous L-ornithine did not inhibit NOHA-induced caspase-8 activation and cleavage of BH3 interacting domain but acted at the mitochondrial level and inhibited the NOHA-induced cytochrome c release and apoptosis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chaudhuri, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA078357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; De Nadai C, 2000, P NATL ACAD SCI USA, V97, P5480, DOI 10.1073/pnas.070062397; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DORHOUT B, 1995, INT J CANCER, V62, P738, DOI 10.1002/ijc.2910620615; Esch F, 1998, J NEUROSCI, V18, P4083; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Fukuto JM, 1996, METHOD ENZYMOL, V268, P365; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hatch GM, 1998, INT J MOL MED, V1, P33; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Kaneko H, 1998, ANTICANCER RES, V18, P891; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; PEGG AE, 1982, AM J PHYSIOL, V243, P212; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pervin S, 2001, CANCER RES, V61, P4701; REGENASS U, 1994, CANCER RES, V54, P3210; Saio M, 2001, J IMMUNOL, V167, P5583, DOI 10.4049/jimmunol.167.10.5583; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; SHAPIRO HM, 1997, CURRENT PROTOCOLS CY; Singh R, 2000, CANCER RES, V60, P3305; Singh R, 2001, CARCINOGENESIS, V22, P1863, DOI 10.1093/carcin/22.11.1863; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	35	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37630	37636		10.1074/jbc.M203648200	http://dx.doi.org/10.1074/jbc.M203648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145284	hybrid			2022-12-25	WOS:000178447100093
J	Sasaki, T; Taoka, M; Ishiguro, K; Uchida, A; Saito, T; Isobe, T; Hisanaga, S				Sasaki, T; Taoka, M; Ishiguro, K; Uchida, A; Saito, T; Isobe, T; Hisanaga, S			In vivo and in vitro phosphorylation at Ser-493 in the glutamate (E)-segment of neurofilament-H subunit by glycogen synthase kinase 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL DOMAIN; CDC2 KINASE; NF-H; PROTEIN; IDENTIFICATION; SITES; DEPHOSPHORYLATION; KINASE-3-BETA; LOCALIZATION; DEFICIENCY	Neurofilament (NF), a major neuronal intermediate filament, is composed of three subunits, NF-L, NF-M, and NF-H. All three subunits contain a well conserved glutamate (E)-rich region called "E-segment" in the N terminus of the tail region. Although the E-segments of NF-L and NF-M are phosphorylated by casein kinases, it has not been observed in NF-H. Using mass spectrometric analysis, we identified phosphorylation of the E-segment of NF-H, prepared from rat spinal cords, at Ser-493 and Ser-501 in the Ser-Pro sequences. The E-segment kinase was isolated from rat brain extract using column chromatography and identified as glycogen synthase kinase (GSK) 3beta. GSK3beta was shown to phosphorylate at Ser-493 in vitro by phosphopeptide mapping and site-directed mutagenesis, and in vivo in HEK293 cells using the phospho-Ser-493 antibody, but did not phosphorylate Ser-501. GSK3beta preferred Ser-493 to the KSP-repeated sequences for phosphorylation sites in the NF-H tail domain. Moreover, Ser-493 was a better phosphorylation site for GSK3beta than other proline-directed protein kinases, Cdk5/p35 and ERK. GSK3beta in the spinal cord extract was associated with NF cytoskeletons. Taken together, we concluded that Ser-493 in the E-segment of NF-H is phosphorylated by GSK3beta in rat spinal cords.	Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Integrated Prote Syst Project,MEXT, Hachioji, Tokyo 1920397, Japan	Tokyo Metropolitan University; Tokyo Metropolitan University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Tokyo Metropolitan University	Sasaki, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Minami Ohsawa, Hachioji, Tokyo 1920397, Japan.	sasaki-takahiro@c.metro-u.ac.jp	Isobe, Toshiaki/Q-9279-2017; Uchida, Atsuko/E-3081-2010	Uchida, Atsuko/0000-0002-4658-1504; Taoka, Masato/0000-0001-5554-4951				Bajaj NPS, 1997, J NEUROCHEM, V69, P737; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIN SSM, 1990, J NEUROSCI, V10, P3714; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; Guidato S, 1996, J NEUROCHEM, V66, P1698; Hashimoto R, 2000, J NEUROCHEM, V75, P373, DOI 10.1046/j.1471-4159.2000.0750373.x; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HISANAGA SI, 1995, CELL MOTIL CYTOSKEL, V31, P283, DOI 10.1002/cm.970310405; Hollander BA, 1996, J NEUROCHEM, V66, P412; HOLLANDER BA, 1992, BRAIN RES, V599, P237, DOI 10.1016/0006-8993(92)90397-R; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NAKAMURA Y, 1993, EUR J BIOCHEM, V212, P565, DOI 10.1111/j.1432-1033.1993.tb17694.x; Nakamura Y, 1999, FEBS LETT, V455, P83, DOI 10.1016/S0014-5793(99)00832-7; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Shaw G, 1997, J NEUROCHEM, V69, P1729; SHAW G, 1998, NEUROFILAMENTS; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Veeranna, 1998, J NEUROSCI, V18, P4008; XU ZS, 1990, J NEUROSCI, V10, P1838; Yabe JT, 2001, J NEUROSCI, V21, P2195; YAMASAKI H, 1991, ACTA NEUROPATHOL, V82, P427, DOI 10.1007/BF00293376; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	43	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36032	36039		10.1074/jbc.M206674200	http://dx.doi.org/10.1074/jbc.M206674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130654	hybrid			2022-12-25	WOS:000178275100035
J	You, ZB; Madrid, LV; Saims, D; Sedivy, J; Wang, CY				You, ZB; Madrid, LV; Saims, D; Sedivy, J; Wang, CY			c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; TNF; EXPRESSION; PHOSPHORYLATION; PROTEINS; DEATH; ACTIVATION; INDUCTION; RELA/P65; SUBUNIT	Nuclear factor kappaB (NF-kappaB) plays a key role in suppression of tumor necrosis factor (TNF)-mediated apoptosis by inducing a variety of anti-apoptotic genes. Expression of c-Myc has been shown to sensitize cells to TNF-mediated apoptosis by inhibiting NF-kappaB activation. However, the precise step in the NF-kappaB signaling pathway and apoptosis modified by c-Myc has not been identified. Using the inducible c-MycER system and c-Myc null fibroblasts, we found that expression of c-Myc inhibited NF-kappaB activation by interfering with ReLA/p65 transactivation but not nuclear translocation of NF-kappaB. Activation of c-Myc promoted TNF-induced release of cytochrome c from mitochondria to the cytosol because of the inhibition of NF-kappaB. Furthermore, we found that NF-kappaB-inducible gene A1 was attenuated by expression of c-Myc and that the restoration of A1 expression suppressed c-Myc-induced TNF sensitization. Our results elucidate the molecular mechanisms by which c-Myc increases cell susceptibility to TNF-mediated apoptosis, indicating that c-Myc may exhibit its pro-apoptotic activities by repression of cell survival genes.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA USA; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center; Brown University	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013335, R01DE013788, R01DE013848] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13788, DE13335, DE13848] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang XD, 2001, GENE DEV, V15, P2922; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	49	53	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36671	36677		10.1074/jbc.M203213200	http://dx.doi.org/10.1074/jbc.M203213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12149248	hybrid			2022-12-25	WOS:000178275100113
J	Li, PTX; Gollnick, P				Li, PTX; Gollnick, P			Using hetero-11-mers composed of wild type and mutant subunits to study tryptophan binding to TRAP and its role in activating RNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATION PROTEIN TRAP; TRP LEADER RNA; BACILLUS-SUBTILIS BINDS; UNKNOWN FUNCTION; OPERON; EXPRESSION; NUCLEOTIDES; TRANSLATION; INITIATION; FEATURES	Expression of genes involved in tryptophan metabolism in Bacillus subtilis is regulated by the TRAP protein in response to changes in L-tryptophan levels. TRAP binding to several RNA targets that contain between 9 and 11 (GIU)AG repeats regulates transcription and/or translation of these genes. TRAP consists of 11 identical subunits and is activated to bind RNA by binding up to 11 molecules of tryptophan. To investigate the mechanism by which tryptophan binding activates TRAP, we generated hetero-11-mers containing different proportions of subunits from wild type (WT) TRAP that bind tryptophan and from a mutant TRAP (Thr(25) to Ala) defective in tryptophan binding. Studies of these hetero-11-mers show that tryptophan-binding sites created from active subunits bind tryptophan with similar affinity to those in WT homo-11-mers, whereas sites containing the T25A substitution do not bind tryptophan. Hetero-11-mers with very few (one or two) bound tryptophans show only 10-fold lower affinity than WT TRAP for an RNA with 11 GAG repeats, whereas TRAP with no bound tryptophan shows no detectable binding to this RNA. We also demonstrate that tryptophan binding induces a conformational change in TRAP in the vicinity of the RNA-binding site, suggesting a possible mechanism for activation of RNA binding.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gollnick, P (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.				NIGMS NIH HHS [GM62750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P864; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; Elliott MB, 2001, RNA, V7, P85, DOI 10.1017/S135583820100173X; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; Henner Dennis, 1993, P269; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; Li PTX, 2002, J BIOL CHEM, V277, P11838, DOI 10.1074/jbc.M110860200; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; Segel I. H., 1975, ENZYME KINETICS, P360; Valbuzzi A, 2002, J BIOL CHEM, V277, P10608, DOI 10.1074/jbc.M111813200; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Xirasagar S, 1998, J BIOL CHEM, V273, P27146, DOI 10.1074/jbc.273.42.27146; Yakhnin AV, 2000, J BIOL CHEM, V275, P4519, DOI 10.1074/jbc.275.6.4519; Yakhnin H, 2001, J BACTERIOL, V183, P5918, DOI 10.1128/JB.183.20.5918-5926.2001; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	30	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35567	35573		10.1074/jbc.M205910200	http://dx.doi.org/10.1074/jbc.M205910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133840	hybrid			2022-12-25	WOS:000178117000116
J	Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K				Darbinyan, A; Darbinian, N; Safak, M; Radhakrishnan, S; Giordano, A; Khalili, K			Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein	ONCOGENE			English	Article						JCU; leader protein; agnoprotein; PML	HUMAN NEUROTROPIC POLYOMAVIRUS; T-ANTIGEN; NUCLEAR-LOCALIZATION; TUMOR-ANTIGEN; VIRUS; SIMIAN-VIRUS-40; AGNOPROTEIN; EXPRESSION; REPLICATION; ATTENUATION	The late region of the human neurotropic JC virus encodes a 71 amino acid protein, named Agnoprotein, whose biological function remains elusive. Here we demonstrate that in the absence of other viral proteins, expression of Agnoprotein can inhibit cell growth by deregulating cell progression through the cell cycle stages. Cells with constitutive expression of Agnoprotein were largely accumulated at the G2/M stage and that decline in the activity of cyclins A and B is observed in these cells. Agnoprotein showed the ability to augment p21 promoter activity in transient transfection assay and a noticeable increase in the level of p21 is detected in cells continuously expressing Agnoprotein. Results from binding studies revealed the interaction of Agnoprotein with p53 through the N-terminal of the Agnoprotein spanning residues 1 - 36. Co-expression of p53 and Agnoprotein further stimulated transcription of the p21 promoter. Thus, the interaction of p53 and Agnoprotein can lead to a higher level of p21 expression and suppression of cell cycle progression during the cell cycle.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96, Philadelphia, PA 19122 USA.	kkhalili@astro.temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ALWINE JC, 1982, J VIROL, V42, P798, DOI 10.1128/JVI.42.3.798-803.1982; Berger JR, 1998, J NEUROVIROL, V4, P59, DOI 10.3109/13550289809113482; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1982, CELL, V29, P183, DOI 10.1016/0092-8674(82)90102-7; HAY N, 1985, MOL CELL BIOL, V5, P1327, DOI 10.1128/MCB.5.6.1327; Ishii N, 1996, J VIROL, V70, P1317, DOI 10.1128/JVI.70.2.1317-1322.1996; KHALILI K, 1988, P NATL ACAD SCI USA, V85, P354, DOI 10.1073/pnas.85.2.354; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOMURA S, 1983, J VIROL, V45, P428, DOI 10.1128/JVI.45.1.428-433.1983; Okada Y, 2001, J NEUROVIROL, V7, P302; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; Rinaldo CH, 1998, J VIROL, V72, P6233, DOI 10.1128/JVI.72.7.6233-6236.1998; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989	27	75	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5574	5581		10.1038/sj.onc.1205744	http://dx.doi.org/10.1038/sj.onc.1205744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165856				2022-12-25	WOS:000177442000007
J	Scales, SJ; Hesser, BA; Masuda, ES; Scheller, RH				Scales, SJ; Hesser, BA; Masuda, ES; Scheller, RH			Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MATRIX PROTEIN; MEMBRANE-FUSION; PLASMA-MEMBRANE; SYNAPTIC EXOCYTOSIS; ALPHA-SNAP; NEUROTRANSMITTER RELEASE; STRUCTURAL INSIGHTS; CYTOSOLIC PROTEINS; KINETIC COMPONENTS; CHROMAFFIN CELLS	The regulation of SNARE complex assembly likely plays an important role in governing the specificity as well as the timing of membrane fusion. Here we identify a novel brain-enriched protein, amisyn, with a tomosyn-and VAMP-like coiled-coil-forming domain that binds specifically to syntaxin 1a and syntaxin 4 both in vitro and in vivo, as assessed by co-immunoprecipitation from rat brain. Amisyn is mostly cytosolic, but a fraction co-sediments with membranes. The amisyn coil domain can form SNARE complexes of greater thermostability than can VAMP2 with syntaxin 1a and SNAP-25 in vitro, but it lacks a transmembrane anchor and so cannot act as a v-SNARE in this complex. The amisyn coil domain prevents the SNAP-25 C-terminally mediated rescue of botulinum neurotoxin E inhibition of norepinephrine exocytosis in permeabilized PC12 cells to a greater extent than it prevents the regular exocytosis of these vesicles. We propose that amisyn forms nonfusogenic complexes with syntaxin la and SNAP-25, holding them in a conformation ready for VAMP2 to replace it to mediate the membrane fusion event, thereby contributing to the regulation of SNARE complex formation.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Rigel Inc, San Francisco, CA 94080 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	Scheller@gene.com	Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283; Masuda, Esteban/0000-0002-3175-2868				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Bui TD, 1998, GENOMICS, V54, P579, DOI 10.1006/geno.1998.5596; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; INOUE A, 1992, J BIOL CHEM, V267, P10613; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KUNIMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190, DOI 10.1093/oxfordjournals.jbchem.a122638; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; MAGEE AI, 1989, J CELL SCI, P149; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Prekeris R, 2000, EUR J CELL BIOL, V79, P771, DOI 10.1078/0171-9335-00109; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, BIOCHEM BIOPH RES CO, V245, P627, DOI 10.1006/bbrc.1998.8490; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	74	69	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28271	28279		10.1074/jbc.M204929200	http://dx.doi.org/10.1074/jbc.M204929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12145319	hybrid			2022-12-25	WOS:000177189800086
J	Siems, W; Sommerburg, O; Schild, L; Augustin, W; Langhans, CD; Wiswedel, I				Siems, W; Sommerburg, O; Schild, L; Augustin, W; Langhans, CD; Wiswedel, I			beta-Carotene cleavage products induce oxidative stress in vitro by impairing mitochondrial respiration	FASEB JOURNAL			English	Article						carotenoid cleavage products; oxidative phosphorylation; glutathione; rat liver mitochondria	NA+-K+-ATPASE; VITAMIN-A; LUNG-CANCER; ANTIOXIDANT REACTIONS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; IDENTIFICATION; SUPPLEMENTATION; DEGRADATION; PREVENTION	Carotenoids are widely used as important micronutrients in food. Furthermore, carotenoid supplementation has been used in the treatment of diseases associated with oxidative stress. However, in some clinical studies harmful effects have been observed, for example, a higher incidence of lung cancer in individuals exposed to extraordinary oxidative stress. The causal mechanisms are still unclear. Carotenoid cleavage products (CCPs), including highly reactive aldehydes and epoxides, are formed during oxidative attacks in the course of antioxidative action. Here, we tested the hypothesis that CCPs may increase oxidative stress by impairing mitochondrial function. We found that CCPs strongly inhibit state 3 respiration of isolated rat liver mitochondria even at concentrations between 0.5 and 20 muM. This was true for retinal, beta-ionone, and mixtures of cleavage products, which were generated in the presence of hypochlorite to mimic their formation in inflammatory regions. The inhibition of mitochondrial respiration was accompanied by a reduction in protein sulfhydryl content, decreasing glutathione levels and redox state, and elevated accumulation of malondialdehyde. Changes in mitochondrial membrane potential favor functional deterioration of the adenine nucleotide translocator. The findings may reflect a basic mechanism of increasing the risk of cancer induced by CCPs.	Univ Magdeburg, Fac Med, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Herzog Julius Hosp Rheumatol & Orthoped, Bad Harzburg, Germany; Univ Heidelberg, Childrens Hosp, D-6900 Heidelberg, Germany; Univ Ulm, Childrens Hosp, D-89069 Ulm, Germany	Otto von Guericke University; Ruprecht Karls University Heidelberg; Ulm University	Wiswedel, I (corresponding author), Univ Magdeburg, Fac Med, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	ingrid.wiswedel@medizin.uni-magdeburg.de						Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Bianchi-Santamaria A, 1999, INT J VITAM NUTR RES, V69, P3, DOI 10.1024/0300-9831.69.1.3; Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; Buege J A, 1978, Methods Enzymol, V52, P302; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHEN JJ, 1995, FREE RADICAL BIO MED, V19, P583, DOI 10.1016/0891-5849(95)00066-7; Chen YQ, 1999, CANCER RES, V59, P3985; CHIRICO S, 1994, METHOD ENZYMOL, V233, P314; DAVIES JMS, 1993, FREE RADICAL BIO MED, V15, P637, DOI 10.1016/0891-5849(93)90167-S; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOODMAN DS, 1966, J BIOL CHEM, V241, P1929; HANDELMAN GJ, 1991, FREE RADICAL BIO MED, V10, P427, DOI 10.1016/0891-5849(91)90051-4; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HOMNICK DN, 1993, J PEDIATR-US, V122, P703, DOI 10.1016/S0022-3476(06)80008-9; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KENNEDY TA, 1992, J BIOL CHEM, V267, P4658; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Krinsky NI, 1998, ANN NY ACAD SCI, V854, P443, DOI 10.1111/j.1749-6632.1998.tb09923.x; LIEBLER DC, 1993, ANN NY ACAD SCI, V691, P20, DOI 10.1111/j.1749-6632.1993.tb26154.x; Liebler DC, 1996, CHEM RES TOXICOL, V9, P8, DOI 10.1021/tx950151t; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADER I, 1964, SCIENCE, V144, P533, DOI 10.1126/science.144.3618.533; Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686; Mayne ST, 1996, J NATL CANCER I, V88, P1513; MORDI RC, 1993, TETRAHEDRON, V49, P911, DOI 10.1016/S0040-4020(01)80333-1; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1993, ANN NY ACAD SCI, V691, P156, DOI 10.1111/j.1749-6632.1993.tb26167.x; Olson JA, 1995, FASEB J, V9, P1547, DOI 10.1096/fasebj.9.15.8529833; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x; Pappalardo G, 1997, EUR J CLIN NUTR, V51, P661, DOI 10.1038/sj.ejcn.1600457; Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; Quiles JL, 1999, INT J VITAM NUTR RES, V69, P243, DOI 10.1024/0300-9831.69.4.243; RIBAYAMERCADO JD, 1995, J NUTR, V125, P1854, DOI 10.1093/jn/125.7.1854; Schild L, 2001, FASEB J, V15, P565; SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; Siems WG, 2000, FREE RADICAL RES, V33, P427, DOI 10.1080/10715760000300961; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; SIES H, 1992, ANN NY ACAD SCI, V669, P7, DOI 10.1111/j.1749-6632.1992.tb17085.x; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Sommerburg O, 2000, EUR J PEDIATR, V159, P86, DOI 10.1007/PL00013811; SOMMERBURG O, COMMUNICATION; STEINBRECHT I, 1970, ACTA BIOL MED GER, V25, P731; STRATTON SP, 1993, CHEM RES TOXICOL, V6, P542, DOI 10.1021/tx00034a024; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; Wang XD, 1999, NUTR REV, V57, P263; Wiswedel I, 2002, FREE RADICAL RES, V36, P1, DOI 10.1080/10715760210170; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	58	92	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1289	+		10.1096/fj.01-0765fje	http://dx.doi.org/10.1096/fj.01-0765fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154001				2022-12-25	WOS:000176683900029
J	Smedberg, JL; Smith, ER; Capo-chichi, CD; Frolov, A; Yang, DH; Godwin, AK; Xu, XX				Smedberg, JL; Smith, ER; Capo-chichi, CD; Frolov, A; Yang, DH; Godwin, AK; Xu, XX			Ras/MAPK pathway confers basement membrane dependence upon endoderm differentiation of embryonic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ELK-1; F9 TERATOCARCINOMA CELLS; MAP KINASE ACTIVATION; C-FOS EXPRESSION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; VISCERAL ENDODERM; PARIETAL ENDODERM	The formation of extraembryonic endoderm is one of the earliest steps in the differentiation of pluripotent cells of the inner cell mass during the early stages of embryonic development. The primitive endoderm cells and the derived parietal and visceral endoderm cells gain the capacity to produce collagen IV and laminin. The deposition of these components results in the formation of basement membrane and epithelium of the endoderm, with polarized cells covering the inner surface of the blastocoels. We used retinoic acid-induced endoderm differentiation of stem cell-like F9 embryonic carcinoma cells to study the role of the Ras pathway and its regulation in the formation of the visceral endoderm. Upon endoderm differentiation of F9 cells induced by retinoic acid, c-Fos expression, the downstream target of the Ras pathway, is suppressed by uncoupling Elk-1 phosphorylation/activation to MAPK activity. However, attachment to matrix gel greatly enhances the activation of MAPK in endoderm cells but not in undifferentiated F9 cells. Enhanced MAPK activation as a result of contact with basement membrane is able to compensate for reduced Elk-1 phosphorylation and c-Fos expression. We conclude that endoderm differentiation renders the activation of the Ras pathway basement membrane dependent, contributing to the epithelial organization of the visceral endoderm.	Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	X_XU@fccc.edu	Capo-chichi, Deylosse Callinice/AAP-4937-2020		NCI NIH HHS [R01 CA 095071, R01 CA 75389, P50 CA 83638, R01 CA 79716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, P50CA083638, R01CA075389, R01CA095071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arteaga CL, 1996, CANCER RES, V56, P1098; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; Bielinska M, 1999, INT J DEV BIOL, V43, P183; BISSELL MJ, 1987, J CELL SCI, P327; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; CAPOCHICHI CD, 2002, IN PRESS CANCER; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cho SY, 1999, MOL CELLS, V9, P179; COUCHMAN JR, 1990, J INVEST DERMATOL, V94, pS7, DOI 10.1111/1523-1747.ep12874973; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; CURRAN T, 1985, CANCER SURV, V4, P655; DENNEFORS B, 1982, PROSTAGLANDINS, V24, P295, DOI 10.1016/0090-6980(82)90156-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gajovic S, 1998, EXP CELL RES, V242, P138, DOI 10.1006/excr.1998.4058; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; GROVE A, 1986, DEV BIOL, V114, P492, DOI 10.1016/0012-1606(86)90213-7; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Holt J, 1992, Cancer Treat Res, V63, P301; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; INGBER DE, 1986, AM J PATHOL, V122, P129; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Martin G R, 1983, Monogr Pathol, V24, P16; MARTINEZHERNANDEZ A, 1976, LAB INVEST, V34, P455; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Okamura H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P597; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; PANARETTO BA, 1994, J CELL SCI, V107, P747; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Sheng ZJ, 2001, GENE, V268, P31, DOI 10.1016/S0378-1119(01)00401-2; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Smith ER, 2001, J BIOL CHEM, V276, P32094, DOI 10.1074/jbc.M105009200; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TALBOT P, 1987, GAMETE RES, V17, P287, DOI 10.1002/mrd.1120170403; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; YANG DH, 2002, IN PRESS DEV BIOL; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	69	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40911	40918		10.1074/jbc.M205178200	http://dx.doi.org/10.1074/jbc.M205178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12145292	hybrid			2022-12-25	WOS:000178791400097
J	Thoden, JB; Huang, XY; Raushel, FM; Holden, HM				Thoden, JB; Huang, XY; Raushel, FM; Holden, HM			Carbamoyl-phosphate synthetase - Creation of an escape route for ammonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SUBSTRATE; GLUTAMINE; SUBUNIT; PRODUCT; TUNNEL; SYNTHASE; PROGRAM; JOURNEY	Carbamoyl-phosphate synthetase catalyzes the production of carbamoyl phosphate through a reaction mechanism requiring one molecule of bicarbonate, two molecules of MgATP, and one molecule of glutamine. The enzyme from Escherichia coli is composed of two polypeptide chains. The smaller of these belongs to the Class I amidotransferase superfamily and contains all of the necessary amino acid side chains required for the hydrolysis of glutamine to glutamate and ammonia. Two homologous domains from the larger subunit adopt conformations that are characteristic for members of the ATP-grasp superfamily. Each of these ATP-grasp domains contains an active site responsible for binding one molecule of MgATP. High resolution x-ray crystallographic analyses have shown that, remarkably, the three active sites in the E. coli enzyme are connected by a molecular tunnel of similar to100 Angstrom in total length. Here we describe the high resolution x-ray crystallographic structure of the G359F (small subunit) mutant protein of carbamoyl phosphate synthetase. This residue was initially targeted for study because it resides within the interior wall of the molecular tunnel leading from the active site of the small subunit to the first active site of the large subunit. It was anticipated that a mutation to the larger residue would "clog" the ammonia tunnel and impede the delivery of ammonia from its site of production to the site of utilization. In fact, the G359F substitution resulted in a complete change in the conformation of the loop delineated by Glu-355 to Ala-364, thereby providing an "escape" route for the ammonia intermediate directly to the bulk solvent. The substitution also effected the disposition of several key catalytic amino acid side chains in the small subunit active site.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK30343] Funding Source: Medline; NIGMS NIH HHS [GM55513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030343, R56DK030343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KS, 1999, METHOD ENZYMOL, V308, P111; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; Holden HM, 1999, CELL MOL LIFE SCI, V56, P507, DOI 10.1007/s000180050448; Huang XY, 2000, J BIOL CHEM, V275, P26233, DOI 10.1074/jbc.275.34.26233; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; Huang XY, 2000, BIOCHEMISTRY-US, V39, P3240, DOI 10.1021/bi9926173; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599	34	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39722	39727		10.1074/jbc.M206915200	http://dx.doi.org/10.1074/jbc.M206915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12130656	hybrid			2022-12-25	WOS:000178662500086
J	Callejo, M; Alvarez, D; Price, GB; Zannis-Hadjopoulos, M				Callejo, M; Alvarez, D; Price, GB; Zannis-Hadjopoulos, M			The 14-3-3 protein homologues from Saccharomyces cerevisiae, Bmh1p and Bmh2p, have cruciform DNA-binding activity and associate in vivo with ARS307	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FREQUENCY TRANSFORMATION; MONOCLONAL-ANTIBODIES; 14-3-3-PROTEIN FAMILY; REPLICATION ORIGIN; MAMMALIAN ORIGINS; MOLECULAR-CLONING; CHROMOSOME-III; YEAST; BRAIN; SPECIFICITY	We have previously shown that, in human cells, cruciform DNA-binding activity is due to 14-3-3 proteins (Todd, A., Cossons, N., Aitken, A., Price, G. B., and Zannis-Hadjopoulos, M. (1998) Biochemistry 37, 14317-14325). Here, wild-type and single- and double-knockout nuclear extracts from the 14-3-3 Saccharomyces cerevisiae homologues Bmh1p and Bmh2p were analyzed for similar cruciform-binding activities in relation to these proteins. The Bmh1p-Bmh2p heterodimer, present in the wild-type strain, bound efficiently to cruciform-containing DNA in a structure-specific manner because cruciform DNA efficiently competed with the formation of the complex, whereas linear DNA did not. In contrast, the band-shift ability of the Bmh1p-Bmh1p and Bmh2p-Bmh2p homodimers present in the bmh2(-) and bmh1(-) single-knockout cells, respectively, was reduced by similar to93 and 82%, respectively. The 14-3-3 plant homologue GF14 was also able to bind to cruciform DNA, suggesting that cruciform-binding activity is a common feature of the family of 14-3-3 proteins across species. Bmh1p and Bmh2p were found to associate in vivo with the yeast autonomous replication sequence ARS307, as assayed by formaldehyde cross-linking, followed by immunoprecipitation with anti-Bmh1p/Bmh2p antibody and conventional PCR. In agreement with the finding of an association of Bmh1p and Bmh2p with ARS307, another immunoprecipitation experiment using 2D3, an anti-cruciform DNA monoclonal antibody, revealed the presence of cruciform-containing DNA in ARS307.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Zannis-Hadjopoulos, M (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	maria.zannis@mcgill.ca						AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AUSUBEL F, 2001, CURRENT PROTOCOLS MO, V2; BELL D, 1991, BIOCHIM BIOPHYS ACTA, V1089, P299, DOI 10.1016/0167-4781(91)90169-M; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FRAPPIER L, 1987, J MOL BIOL, V193, P751, DOI 10.1016/0022-2836(87)90356-1; FRAPPIER L, 1989, J BIOL CHEM, V264, P334; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Jin RZ, 2001, PLASMID, V46, P95, DOI 10.1006/plas.2001.1535; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; LIN LS, 1987, NUCLEIC ACIDS RES, V15, P8319, DOI 10.1093/nar/15.20.8319; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; PALZKILL TG, 1986, NUCLEIC ACIDS RES, V14, P6247, DOI 10.1093/nar/14.15.6247; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PEARSON CE, 1994, BIOCHEMISTRY-US, V33, P14185, DOI 10.1021/bi00251a030; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; STEINMETZER K, 1995, J MOL BIOL, V254, P29, DOI 10.1006/jmbi.1995.0596; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAKAHASHI K, 2000, SCI STKE, V56, P1; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; vanHeusden GPH, 1996, FEBS LETT, V391, P252, DOI 10.1016/0014-5793(96)00746-6; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; Wang WF, 1996, J MOL EVOL, V43, P384; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x	44	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38416	38423		10.1074/jbc.M202050200	http://dx.doi.org/10.1074/jbc.M202050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167636	hybrid			2022-12-25	WOS:000178529600055
J	Lu, M; Vergara, S; Zhang, L; Holliday, LS; Aris, J; Gluck, SL				Lu, M; Vergara, S; Zhang, L; Holliday, LS; Aris, J; Gluck, SL			The amino-terminal domain of the E subunit of vacuolar H+-ATPase (V-ATPase) interacts with the H subunit and is required for V-ATPase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SYNTHASE; MEMBRANE; PROTEIN; COMPLEX; KIDNEY; (H+)-ATPASE; STALK; FORMS; YEAST	Vacuolar H+-ATPases (V-ATPases) are highly conserved proton pumps that couple hydrolysis of cytosolic ATP to proton transport out of the cytosol. Although it is generally believed that V-ATPases transport protons by a rotary catalytic mechanism analogous to that used by F1F0-ATPases, the structure and subunit composition of the central or peripheral stalk of the multisubunit complex are not well understood. We searched for proteins that bind to the E subunit of V-ATPase using the yeast two-hybrid assay and identified the H subunit as an interacting partner. Physical association between the E and H subunits of V-ATPase was confirmed in vitro by precipitation assays. Deletion mapping analysis revealed that a 78-amino acid fragment at the amino terminus of the E subunit was sufficient for binding to the H subunit. Expression of the amino-terminal fragments of the E subunits from human and yeast as dominant-negative mutants resulted in dramatic decreases in bafilomycin A(1)-sensitive ATP hydrolysis and proton transport activities of V-ATPase. Our data demonstrate the physiological significance of the interaction between the E and H subunits of V-ATPase and extend previous studies on the arrangement of subunits on the peripheral stalk of V-ATPase.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lu, M (corresponding author), Univ Florida, Coll Med, Dept Med, Campus Box 100224,Rm CG-98,1600 SW Archer Rd, Gainesville, FL 32610 USA.		Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965; Aris, John/0000-0002-6475-064X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054362, R01DK038848] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54362, R01 DK38848] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; FOURY F, 1990, J BIOL CHEM, V265, P18554; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; James P, 1996, GENETICS, V144, P1425; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	28	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38409	38415		10.1074/jbc.M203521200	http://dx.doi.org/10.1074/jbc.M203521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163484	hybrid			2022-12-25	WOS:000178529600054
J	Benesch, S; Lommel, S; Steffen, A; Stradal, TEB; Scaplehorn, N; Way, M; Wehland, J; Rottner, K				Benesch, S; Lommel, S; Steffen, A; Stradal, TEB; Scaplehorn, N; Way, M; Wehland, J; Rottner, K			Phosphatidylinositol 4,5-biphosphate (PIP2)-induced vesicle movement depends on N-WASP and involves Nck, WIP, and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN-BASED MOTILITY; ARP2/3 COMPLEX; CDC42; RECRUITMENT; ACTIVATION; ENDOSOMES; LYSOSOMES; PATHWAYS; SIGNALS	Wiskott-Aldrich syndrome protein (WASP)/Scar family proteins promote actin polymerization by stimulating the actin-nucleating activity of the Arp2/3 complex. While Scar/WAVE proteins are thought to be involved in lamellipodia protrusion, the hematopoietic WASP has been implicated in various actin-based processes such as chemotaxis, podosome formation, and phagocytosis. Here we show that the ubiquitously expressed N-WASP is essential for actin assembly at the surface of endomembranes induced as a consequence of increased phosphatidylinositol 4,5-biphosphate (PIP2) levels. This process resulting in the motility of intracellular vesicles at the tips of actin comets involved the recruitment of the Src homology 3 (SH3)-SH2 adaptor proteins Nck and Grb2 as well as of WASP interacting protein (WIP). Reconstitution of vesicle movement in N-WASP-defective cells by expression of various N-WASP mutant proteins revealed three independent domains capable of interaction with the vesicle surface, of which both the WH1 and the polyproline domains contributed significantly to N-WASP recruitment and/or activation. In contrast, the direct interaction of N-WASP with the Rho-GTPase Cdc42 was not required for reconstitution of vesicle motility. Our data reveal a distinct cellular phenotype for N-WASP loss of function, which adds to accumulating evidence that the proposed link between actin and membrane dynamics may, at least partially, be reflected by the actin-based movement of vesicles through the cytoplasm.	Gesell Biotechnol Forsch mbH, Dept Cell Biol, D-38124 Braunschweig, Germany; Canc Res UK, Cell Motil Grp, Lincolns Inn Fields Labs, London WC2A 3PX, England	Gesellschaft fur Biotechnologische Forschung mbH; Cancer Research UK	Rottner, K (corresponding author), Gesell Biotechnol Forsch mbH, Dept Cell Biol, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	kro@gbf.de	Rottner, Klemens/AAE-5030-2020	Scaplehorn, Niki/0000-0001-9451-8748; Rottner, Klemens/0000-0003-4244-4198; Stradal, Theresia/0000-0002-0352-9474; Way, Michael/0000-0001-7207-2722; Steffen, Anika/0000-0002-2933-0543				Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Cooper JA, 2001, CELL, V107, P703, DOI 10.1016/S0092-8674(01)00605-5; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Hahne P, 2001, FEBS LETT, V492, P215, DOI 10.1016/S0014-5793(01)02239-6; HERZOG M, 1994, CELL BIOL LAB HDB, P355; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mimuro H, 2000, J BIOL CHEM, V275, P28893, DOI 10.1074/jbc.M003882200; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schafer DA, 2000, TRAFFIC, V1, P892; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Takenawa T, 2001, J CELL SCI, V114, P1801; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2	34	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37771	37776		10.1074/jbc.M204145200	http://dx.doi.org/10.1074/jbc.M204145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147689	hybrid			2022-12-25	WOS:000178447100110
J	Huang, TM; Deng, HT; Wolkoff, AW; Stockert, RJ				Huang, TM; Deng, HT; Wolkoff, AW; Stockert, RJ			Phosphorylation-dependent interaction of the asialoglycoprotein receptor with molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MANNOSE 6-PHOSPHATE RECEPTOR; PROTEIN-KINASE CK2; VARICELLA-ZOSTER VIRUS; CELL-LINE HUH-7; CYTOPLASMIC DOMAIN; INTRACELLULAR TRAFFICKING; RAT HEPATOCYTES; GLYCOPROTEIN-I; MDCK CELLS	A membrane protein trafficking mutant (Trf1) of HuH-7 alters the asialoglycoprotein (ASGPR) and transferrin receptor subcellular distribution. Expression cloning of a cDNA complementing the trf1 mutation led to the discovery of a novel casein Kinase 2 catalytic subunit (CK2alpha"). To purify potential CK2alpha" phosphorylation-dependent sorting proteins from cytosol, the ASGPR cytoplasmic domain was expressed as a GST fusion protein and immobilized on glutathione-agarose. In the absence of phosphorylation, only trace amounts of cytosol protein were bound and eluted. When the fusion protein was phosphorylated, a heterocomplex of potential sorting proteins was recovered. Mass spectrometer and immunoblot analysis identified five of these proteins as gp96, HSP70, HSP90, cyclophilin-A, and FKBP18. Treatment of HuH-7 with rapamycin to disrupt the heterocomplex reduced surface ASGPR binding activity by 65 +/- 5.7%. In Trf1 cells, surface-binding activity was 48 +/- 7% of that in HuH-7 and was not further reduced by rapamycin treatment. Immunoanalysis showed significantly fewer surface receptors on rapamycin-treated HuH7 cells than on nontreated cells, with no affect on the level of surface receptors in Trf1 cells. The data presented provide evidence that phosphorylation of the ASGPR cytoplasmic domain is required for the binding of specific molecular chaperones with the potential to regulate receptor trafficking.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Stockert, RJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave,Ullmann 611, Bronx, NY 10461 USA.				NIDDK NIH HHS [DK 17702, DK 41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, P50DK017702] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Bananis E, 2000, J CELL BIOL, V151, P179, DOI 10.1083/jcb.151.1.179; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Ishii T, 1999, J IMMUNOL, V162, P1303; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; RON D, 1992, BIOTECHNIQUES, V13, P866; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Simmen T, 1999, MOL CELL BIOL, V19, P3136; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; STOCKERT RJ, 1980, J BIOL CHEM, V255, P9028; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TREICHEL U, 1994, J CELL PHYSIOL, V158, P527, DOI 10.1002/jcp.1041580319; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996	47	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37798	37803		10.1074/jbc.M204786200	http://dx.doi.org/10.1074/jbc.M204786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167617	hybrid			2022-12-25	WOS:000178447100114
J	Hut, QH; Bhattacharya, C; Maity, SN				Hut, QH; Bhattacharya, C; Maity, SN			CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase II alpha - Conventional CBF activation domains are not required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA TOPOISOMERASE; TRANSCRIPTION ACTIVATION; GENE PROMOTER; B1 GENE; SUBUNIT; EXPRESSION; MUTATIONS; COMPLEX; GROWTH; BOX	To understand the role of the CCAAT binding factor (CBF) in transcription during the cell cycle, we studied the mouse topoisomerase IIalpha (topo IIalpha) promoter, which is activated during the late S and G(2)/M phases of the cell cycle and contains multiple CBF binding sites. Mutational analysis of the promoter shows that CBF binding to an inverted orientation of the CCAAT motif in the topo IIalpha promoter, but not to a direct orientation, is required for transcription activation during the cell cycle. In contrast, analysis of the promoter in an in vitro reconstituted transcription system shows that CBF activates transcription of the topo IIalpha promoter irrespective of the orientation of the CBF binding sites. This analysis demonstrates that only one of the three transcription start sites of the topo IIalpha promoter is stimulated by CBF, indicating that transcription activation by CBF is dependent on basal promoter structure. Interestingly, mutations of the start site that abolish CBF-dependent transcription activation in vitro do not inhibit activation of the promoter during the cell cycle. Consistent with this observation, expression of a truncated CBF-B subunit lacking a transcription activation domain, which inhibits activity of a collagen promoter, does not affect activity of the topo IIalpha promoter in fibroblast cells. In contrast, expression of an allele-specific CBF-B mutant that binds high affinity to a mutant CBF binding site containing a CCAAC motif revives transcription activation of an inactive mutant topo IIalpha promoter containing CCAAC during the cell cycle. Altogether, this study indicates that CBF binding, but not conventional CBF activation domains, are required for activation of the topo IIalpha promoter during the cell cycle. Considering these results together with results of another recent study, we hypothesize that binding of CBF that disrupts the nucleosomal. structure in the topo IIalpha promoter is a major function of CBF by which it regulates the cell cycle-dependent transcription of the topo IIalpha promoter and possibly many other cell cycle-regulated promoters containing CBF binding sites.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Maity, SN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NIAMS NIH HHS [R01 AR46264] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046264] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; Falck J, 1999, J BIOL CHEM, V274, P18753, DOI 10.1074/jbc.274.26.18753; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Sinha S, 1996, MOL CELL BIOL, V16, P328; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Withoff S, 1996, ANTICANCER RES, V16, P1867; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	21	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37191	37200		10.1074/jbc.M205985200	http://dx.doi.org/10.1074/jbc.M205985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149265	hybrid			2022-12-25	WOS:000178447100038
J	Su, LF; Wang, Z; Garabedian, MJ				Su, LF; Wang, Z; Garabedian, MJ			Regulation of GRIP1 and CBP coactivator activity by Rho GDI modulates estrogen receptor transcriptional enhancement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; KINASE PATHWAY; ACTIVATION; BINDING; ALPHA; PHOSPHORYLATION; PROTEIN; COMPLEX; P300; TRANSACTIVATION	Estrogen receptor alpha (ER) coordinates gene expression with cellular physiology in part by controlling receptor-cofactor interactions in response to extracellular signals. We have previously shown that the Rho signaling pathway modulates ER transcriptional activation. We now demonstrate that Rho GDI-dependent increase in ER transactivation is dependent on the ER AF-2 coactivator binding site, prompting us to examine regulation of receptor coactivators by Rho GDI. Indeed, Rho GDI cooperates with GRIP1 to increase ER ligand-independent and ligand-dependent transactivation and also enhances GRIP1 transcriptional activity when GRIP1 is tethered to DNA. The GRIP1 activation domain 1 (AD1), which binds CBP/p300, is necessary for Rho GDI to modulate GRIP1 activity. Using E1A to inhibit the endogenous CBP/p300 and a Gal4-CBP fusion protein to assay CBP activity, we rind that the effect of Rho GDI on ER transactivation is CBP/p300-dependent. Importantly, the ability of CBP/p300 to transduce the Rho GDI signal to ER occurs through both GRIP1-dependent and -independent pathways. These data suggest a complex interplay between ER transcriptional activation and the Rho signaling pathways through modulation of receptor cofactors, which may have evolved to coordinate receptor-dependent gene expression with Rho-regulated events, such as cell migration. We speculate that dysregulation of the Rho-ER axis may participate in cancer progression.	NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA.				NIGMS NIH HHS [T32 GM07308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Bilodeau D, 1999, BIOCHEM CELL BIOL, V77, P59, DOI 10.1139/bcb-77-1-59; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Mak HY, 1999, MOL CELL BIOL, V19, P3895; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; ONATE SA, 1995, SCIENCE, V270, P1354; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; van Golen KL, 2000, CANCER RES, V60, P5832; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37037	37044		10.1074/jbc.M111607200	http://dx.doi.org/10.1074/jbc.M111607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138084	hybrid			2022-12-25	WOS:000178447100019
J	Toniato, E; Chen, XP; Losman, J; Flati, V; Donahue, L; Rothman, P				Toniato, E; Chen, XP; Losman, J; Flati, V; Donahue, L; Rothman, P			TRIM8/GERP RING finger protein interacts with SOCS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; BOX MOTIF; T-CELLS; CYTOKINE; REGULATORS; GENE; TRANSCRIPTION; EXPRESSION; FAMILY; PHOSPHATASE	Members of the suppressor of cytokine signaling (SOCS) family of signaling molecules regulate the activation of cytokine signaling. Experimental evidence indicates that SOCS expression is induced by cytokines and pro-inflammatory stimuli and is controlled at both the transcriptional and post-transcriptional levels. SOCS proteins are unstable and seem to be rapidly degraded by proteasomal pathways. However, the mechanisms by which SOCS protein levels are regulated remain unclear. Here, we show that TRIM8/GERP, a RING finger protein, interacts with SOCS-1 in vitro and in vivo. TRIM8/GERP, previously identified as a new member of the family of proteins containing a tripartite motif (TRIM), is a 551-amino acid RING finger protein conserved across species. TRIM8/GERP expression can be induced by interferon-gamma in epithelial and lymphoid cells. Coexpression of TRIM8/GERP with SOCS-1 decreases SOCS-1 protein stability and levels. Functionally, expression of TRIM8/GERP decreases the repression of interferon-gamma signaling mediated by SOCS-1. These data suggest that TRIM8/GERP may be a regulator of SOCS-1 function.	Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, New York, NY 10032 USA	Columbia University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, P&S 8-425,630 W 168th St, New York, NY 10032 USA.	pbr3@columbia.edu	FLATI, VINCENZO/R-6231-2018	FLATI, VINCENZO/0000-0003-1014-297X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050514] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI50514] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HUSSEINI AEE, 1999, J BIOL CHEM, V274, P19771; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; LEDUARIN B, EMBO J, V14, P2020; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PELLE R, 1993, NUCLEIC ACIDS RES, V21, P2783, DOI 10.1093/nar/21.11.2783; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto H, 2000, LEUKEMIA LYMPHOMA, V38, P49, DOI 10.3109/10428190009060318; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Terstegen L, 2000, FEBS LETT, V478, P100, DOI 10.1016/S0014-5793(00)01826-3; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	45	88	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37315	37322		10.1074/jbc.M205900200	http://dx.doi.org/10.1074/jbc.M205900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163497	hybrid			2022-12-25	WOS:000178447100053
J	Tumbula-Hansen, D; Feng, L; Toogood, H; Stetter, KO; Soll, D				Tumbula-Hansen, D; Feng, L; Toogood, H; Stetter, KO; Soll, D			Evolutionary divergence of the archaeal aspartyl-tRNA synthetases into discriminating and nondiscriminating forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; COMPLETE GENOME SEQUENCE; ASPARAGINYL-TRANSFER-RNA; PYROCOCCUS SP KOD1; HYPERTHERMOPHILIC ARCHAEON; THERMOPLASMA-ACIDOPHILUM; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; AMINO-ACIDS	Asparaginyl-tRNA (Asn-tRNA) is generated in nature via two alternate routes, either direct acylation of tRNA with asparagine by asparaginyl-tRNA synthetase (AsnRS) or in a two-step pathway that requires misacylated Asp-tRNA(Asn) as an intermediate. This misacylated aminoacyl-tRNA is formed by a nondiscriminating aspartyl-tRNA synthetase (AspRS), an enzyme that in addition to forming Asp-tRNA(Asp) also misacylates tRNA(Asn). In contrast, a discriminating AspRS cannot acylate tRNA(Asn). It has been suggested that the archaeal AspRS enzymes are nondiscriminating, whereas the bacterial ones discriminate. The archaeal and bacterial AspRS proteins are indeed distinct in sequence and structure. However, we show that both discriminating and nondiscriminating forms of AspRS exist among the archaea. Using unfractionated methanobacterial and pyrococcal tRNA, the Methanothermobacter thermautotrophicus AspRS acylated approximately twice as much tRNA as did AspRS from Pyrococcus kodakaraensis or Ferroplasma acidarmanus. Proof that Asp-tRNA(Asn) was generated by the methanogen synthetase was the conversion of Asp-tRNA formed by M. thermautotrophicus AspRS to Asn-tRNA by M. thermautotrophicus Asp-tRNA(Asn) amidotransferase. In contrast, Asp-tRNA formed by the Pyrococcus or Ferroplasma enzymes was not a substrate for the amidotransferase. Also, although all three AspRS enzymes charged tRNA(Asp) transcripts, only M. thermautotrophicus AspRS aspartylated the tRNA(Asn) transcript. Genomic analysis provides a rationale for the nature of these enzymes. The mischarging AspRS correlates with the absence in the genome of AsnRS and the presence of Asp-tRNA(Asn) amidotransferase, employed by the transamidation pathway. In contrast, the discriminating AspRS correlates with the absence of the amidotransferase and the presence of AsnRS, forming Asn-tRNA by direct aminoacylation. The high sequence identity, up to 60% between discriminating and nondiscriminating archaeal AspRSs, suggests that few mutational steps may be necessary to convert the tRNA-discriminating ability of a tRNA synthetase.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Regensburg, Lehrstuhl Mikrobiol, D-8400 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-8400 Regensburg, Germany	Yale University; Yale University; University of Regensburg; University of Regensburg	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Toogood, Helen/0000-0003-4797-0293; Hansen, Debra T./0000-0003-4395-8297				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson JC, 2002, CHEM BIOL, V9, P237, DOI 10.1016/S1074-5521(02)00094-7; Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; Edwards KJ, 2000, SCIENCE, V287, P1796, DOI 10.1126/science.287.5459.1796; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fujiwara S, 1996, FEBS LETT, V394, P66, DOI 10.1016/0014-5793(96)00904-0; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; IMANAKA T, 1995, GENE, V164, P153, DOI 10.1016/0378-1119(95)00491-N; Kanaya S, 1999, GENE, V238, P143, DOI 10.1016/S0378-1119(99)00225-5; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kawashima T, 1999, P JPN ACAD B-PHYS, V75, P213, DOI 10.2183/pjab.75.213; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; MICHELS M, 1985, J BACTERIOL, V161, P231, DOI 10.1128/JB.161.1.231-237.1985; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; RUFF M, 1988, J MOL BIOL, V201, P235, DOI 10.1016/0022-2836(88)90450-0; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shiba K, 1998, NUCLEIC ACIDS RES, V26, P5045, DOI 10.1093/nar/26.22.5045; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf YI, 1999, GENOME RES, V9, P689; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	43	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37184	37190		10.1074/jbc.M204767200	http://dx.doi.org/10.1074/jbc.M204767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149259	hybrid			2022-12-25	WOS:000178447100037
J	Rubin, H; Ravid, S				Rubin, H; Ravid, S			Polarization of myosin II heavy chain-protein kinase C in chemotaxing Dictyostelium cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; LEADING-EDGE; FUSION PROTEIN; LIVING CELLS; IN-VIVO; CHEMOATTRACTANT; DYNAMICS; LOCALIZATION; ACTIVATION; PHOSPHORYLATION	Eukaryotic cells need morphological polarity to carry out chemotaxis (Parent, C. A., Blacklock, B. J., Froehlich, W. M., Murphy, D. B., and Devreotes, P. N. (1998) Cell 95, 81-91; Jin, T., Zhang, N., Long, Y., Parent, C., and Devreotes, P. N. (2000) Science 287, 1034-1036; Servant, G., Weiner, O. D., Herzmark, P., Balla, T., Sedat, J. W., and Bourne, H. R. (2000) Science 287, 1037-1040), but sensing direction does not require polarization of chemoattractant receptors. When cells are exposed to a gradient of chemoattractant, activation occurs selectively at the stimulated edge. Such localized activation, transmitted by the recruitment of cytosolic proteins, may be a general mechanism for gradient sensing by G protein-linked chemotactic systems. Here we show that in Dictyostelium discoideum cells exposed to a cAMP gradient the myosin 11 heavy chain kinase (MHC-PKC) and myosin H translocate to opposite ends of the cell. We further show that MHC-PKC C1 domain is responsible for the localization of MHC-PKC to the cell leading edge, but it is not sufficient to promote cell polarization. Our findings suggest a mechanism by which MHC-PKC regulates myosin H, allowing cell polarization and movement in the direction of the cAMP source.	Hebrew Univ Jerusalem, Dept Biochem, Hadassah Med Sch, Inst Med Sci, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Ravid, S (corresponding author), Hebrew Univ Jerusalem, Dept Biochem, Hadassah Med Sch, Inst Med Sci, IL-91120 Jerusalem, Israel.	ravid@md.huji.ac.il						AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; Aizawa H, 1997, J CELL SCI, V110, P2333; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chu QA, 1996, CELL MOTIL CYTOSKEL, V35, P254, DOI 10.1002/(SICI)1097-0169(1996)35:3<254::AID-CM7>3.0.CO;2-8; Dembinsky A, 1996, J CELL BIOL, V134, P911, DOI 10.1083/jcb.134.4.911; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALCHOW D, 1981, EUR J BIOCHEM, V117, P213; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SPUDICH JA, 1989, CELL REGUL, V1, P1; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P3; TRINKAUS JP, 1984, CELL ORGANS FORCE SH; WANG M, 1988, DEV BIOL, V128, P72, DOI 10.1016/0012-1606(88)90268-0; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; ZIGMOND SH, 1988, METHOD ENZYMOL, V162, P65	36	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36005	36008		10.1074/jbc.M205986200	http://dx.doi.org/10.1074/jbc.M205986200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130648	hybrid			2022-12-25	WOS:000178275100031
J	Swain, E; Stukey, J; McDonough, V; Germann, M; Liu, Y; Sturley, SL; Nickels, JT				Swain, E; Stukey, J; McDonough, V; Germann, M; Liu, Y; Sturley, SL; Nickels, JT			Yeast cells lacking the ARV1 gene harbor defects in sphingolipid metabolism - Complementation by human ARV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPID BIOSYNTHESIS; SUBCELLULAR-LOCALIZATION; ALKALINE CERAMIDASE; GOLGI-APPARATUS; ACYL-COENZYME; CHOLESTEROL	arv1Delta mutant cells have an altered sterol distribution within cell membranes (Tinkelenberg, A.H., Liu, Y., Alcantara, F., Khan, S., Guo, Z., Bard, M., and Sturley, S. L. (2000) J. Biol. Chem. 275, 40667-40670), and thus it has been suggested that Arv1p may be involved in the trafficking of sterol in the yeast Saccharomyces cerevisiae and also in humans. Here we present data showing that arv1Delta mutants also harbor defects in sphingolipid metabolism. [3H]inositol and [H-3]dihydrosphingosine radiolabeling studies demonstrated that mutant cells had reduced rates of biosynthesis and lower steady-state levels of complex sphingolipids while accumulating certain hydroxylated ceramide species. Phospholipid radiolabeling studies showed that arv1Delta cells harbored defects in the rates of biosynthesis and steady-state levels of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylglycerol. Neutral lipid radiolabeling studies indicated that the rate of biosynthesis and steady-state levels of sterol ester were increased in arv1Delta cells. Moreover, these same studies demonstrated that arv1Delta cells had decreased rates of biosynthesis and steady-state levels of total fatty acid and fatty acid alcohols. Gas chromatography/mass spectrometry analyses examining different fatty acid species showed that arv1Delta cells had decreased levels of C18:1 fatty acid. Additional gas chromatography/mass spectrometry analyses determining the levels of various molecular sterol species in arv1Delta cells showed that mutant cells accumulated early sterol intermediates. Using fluorescence microscopy we found that GFP-Arv1p localizes to the endoplasmic reticulum and Golgi. Interestingly, the heterologous expression of the human ARV1 cDNA suppressed the sphingolipid metabolic defects of arv1Delta cells. We hypothesize that in eukaryotic cells, Arv1p functions in the sphingolipid metabolic pathway perhaps as a transporter of ceramides between the endoplasmic reticulum and Golgi.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA; Hope Coll, Dept Biol, Holland, MI 49422 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA	Drexel University; Hope College; Columbia University; Columbia University	Nickels, JT (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA.	Joseph.Nickels@drexel.edu			NHLBI NIH HHS [HL67401-01A1] Funding Source: Medline; NIDDK NIH HHS [DK54320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Beh CT, 2001, GENETICS, V157, P1117; Bischoff F, 1977, Adv Lipid Res, V15, P61; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHAMBAZ EM, 1969, ANAL BIOCHEM, V30, P7, DOI 10.1016/0003-2697(69)90368-6; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; Kragelund BB, 1999, BBA-MOL CELL BIOL L, V1441, P150, DOI 10.1016/S1388-1981(99)00151-1; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lechner M, 1999, J CHROMATOGR A, V857, P231, DOI 10.1016/S0021-9673(99)00751-7; LESTER RL, 1993, ADV LIPID RES, V26, P253; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, METHOD ENZYMOL, V311, P223; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NES W D, 1989, Steroids, V53, P533, DOI 10.1016/0039-128X(89)90030-5; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; Phillips KM, 1999, J CHROMATOGR B, V732, P17, DOI 10.1016/S0378-4347(99)00257-1; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WHITNEY JA, 1995, CELL, V83, P703; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	78	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36152	36160		10.1074/jbc.M206624200	http://dx.doi.org/10.1074/jbc.M206624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145310	hybrid			2022-12-25	WOS:000178275100050
J	Wang, DK; Li, ZB; Messing, EM; Wu, G				Wang, DK; Li, ZB; Messing, EM; Wu, G			Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASING COMPLEXITY; SIGNALING PATHWAY; TYROSINE KINASES; DOCKING SITE; SH3 DOMAIN; RAS; BINDING	MET is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. MET overexpression has been identified in a variety of human cancers. Oncogenic missense mutations of the tyrosine kinase domain of the MET gene have been identified in human papillary renal cell carcinomas. In this study, RanBPM, also known as RanBP9, is identified as a novel interacting protein of MET through yeast two-hybrid screen. RanBPM contains a conserved SPRY (repeats in VIA and RyR) domain. We demonstrate that RanBPM can interact with MET in vitro and in vivo, and the interaction can be strengthened by HGF stimulation. RanBPM interacts with the tyrosine kinase domain of MET through its SPRY domain. We show that RanBPM can induce GTP-Ras association and Erk phosphorylation and elevate serum response element-luciferase (SRE-LUC) expression, indicating that RanBPM can activate the Ras-Erk-SRE pathway. We demonstrate that RanBPM, which itself is not a guanine exchange protein, stimulates Ras activation by recruiting Sos. On the cellular level, A704 cells, a human renal carcinoma cell line, transfected with RanBPM exhibit increased migration ability. Our data suggest that RanBPM, functioning as an adaptor protein for the MET tyrosine kinase domain, can augment the HGF-MET signaling pathway and that RanBPM overexpression may cause constitutive activation of the Ras signaling pathway.	Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.							Balkovetz DF, 1999, INT REV CYTOL, V186, P225; BARDELLI A, 1992, ONCOGENE, V7, P1973; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Grisendi S, 2001, J BIOL CHEM, V276, P46632, DOI 10.1074/jbc.M104323200; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; LINNEMANN T, 2001, J BIOL CHEM, V17, P17; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Steiner G, 2000, J BIOMOL NMR, V18, P73, DOI 10.1023/A:1008373529242; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	38	122	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36216	36222		10.1074/jbc.M205111200	http://dx.doi.org/10.1074/jbc.M205111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147692	hybrid			2022-12-25	WOS:000178275100057
J	Wang, QD; Wang, XF; Hernandez, A; Hellmich, MR; Gatalica, Z; Evers, BM				Wang, QD; Wang, XF; Hernandez, A; Hellmich, MR; Gatalica, Z; Evers, BM			Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; APOPTOSIS-INDUCING LIGAND; CHAIN FATTY-ACIDS; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY; TUMOR SUPPRESSION; CYCLE PROGRESSION; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; ENDOMETRIAL CANCER	The intestinal mucosa is a rapidly-renewing tissue characterized by cell proliferation, differentiation, and eventual apoptosis with progression up the vertical gut axis. The inhibition of phosphatidylinositol (PI) 3-kinase by specific chemical inhibitors or overexpression of the lipid phosphatase PTEN enhances enterocyte-like differentiation in human colon cancer cell models of intestinal differentiation. In this report, we examined the role of PI 3-kinase inhibition in the regulation of apoptotic gene expression in human colon cancer cell lines HT29, HCT-116, and Caco-2. Inhibition of PI 3-kinase with the chemical inhibitor wortmannin increased TNF-related apoptosis-inducing ligand (TRAIL; Apo2) mRNA and protein expression. Similarly, overexpression of the tumor suppressor protein PTEN, an antagonist of PI 3-kinase signaling, resulted in the increased expression of TRAIL. Activation of PI 3-kinase by pretreatment with IGF-1, a gut trophic factor, markedly attenuated the induction of TRAIL by wortmannin. Moreover, overexpression of active Akt, a downstream target of PI 3-kinase, or inhibition of GSK-3, a downstream target of active Akt, completely blocked the induction of TRAIL by wortmannin. Consistent with findings that TRAIL is induced by agents that enhance intestinal cell differentiation, TRAIL expression was specifically localized to the differentiated cells of the colon and small bowel. Adenovirus-mediated overexpression of TRAIL increased DNA fragmentation of HCT-116 cells, demonstrating the functional activity of TRAIL induction. Taken together, our findings demonstrate induction of the TRAIL by inhibition of PI 3-kinase in colon cancer cell lines. These results identify TRAIL, a novel TNF family member, as a downstream target of the PI 3-kinase/Akt/GSK-3 pathway and may have important implications for better understanding the role of the PI 3-kinase pathway in intestinal cell homeostasis.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.				NIA NIH HHS [R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [R01 DK48498, T32 DK07639, P01 DK305608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498, T32DK007639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Basson MD, 1998, P SOC EXP BIOL MED, V217, P476, DOI 10.3181/00379727-217-44261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; Dong ZZ, 2000, AM J PHYSIOL-GASTR L, V279, pG1139, DOI 10.1152/ajpgi.2000.279.6.G1139; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; EVERS BM, 1995, J CLIN INVEST, V95, P2822, DOI 10.1172/JCI117987; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; HEERDT BG, 1994, CANCER RES, V54, P3288; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kayagaki N, 1999, J IMMUNOL, V162, P2639; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lacour S, 2001, CANCER RES, V61, P1645; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Musgrave BL, 1999, EXP CELL RES, V252, P96, DOI 10.1006/excr.1999.4631; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PODOLSKY DK, 1995, TXB GASTROENTEROLOGY, P546; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; READ LC, 1991, MODERN CONCEPTS INSU, P225; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakurada A, 1999, INT J ONCOL, V15, P1069; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Strater J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	71	96	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36602	36610		10.1074/jbc.M206306200	http://dx.doi.org/10.1074/jbc.M206306200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140294	hybrid			2022-12-25	WOS:000178275100104
J	Xu, XL; Lockamy, VL; Chen, KJ; Huang, Z; Shields, H; King, SB; Ballas, SK; Nichols, JS; Gladwin, MT; Noguchi, CT; Schechter, AN; Kim-Shapiro, DB				Xu, XL; Lockamy, VL; Chen, KJ; Huang, Z; Shields, H; King, SB; Ballas, SK; Nichols, JS; Gladwin, MT; Noguchi, CT; Schechter, AN; Kim-Shapiro, DB			Effects of iron nitrosylation on sickle cell hemoglobin solubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NITRIC-OXIDE HEMOGLOBIN; DEOXYHEMOGLOBIN-S; OXYGEN-BINDING; LIGAND-BINDING; SPIN-RESONANCE; TREATED RATS; IN-VIVO; TRANSPORT; 2,3-DIPHOSPHOGLYCERATE	One mechanism by which nitric oxide (NO) has been proposed to benefit patients with sickle cell disease is by reducing intracellular polymerization of sickle hemoglobin (HbS). In this study we have examined the ability of nitric oxide to inhibit polymerization by measuring the solubilizing effect of iron nitrosyl sickle hemoglobin (HbS-NO). Electron paramagnetic resonance spectroscopy was used to confirm that, as found in vivo, the primary type of NO ligation produced in our partially saturated NO samples is pentacoordinate a-nitrosyl. Linear dichroism spectroscopy and delay time measurements were used to confirm polymerization. Based on sedimentation studies we found that, although fully ligated (100% tetranitrosyl) HbS is very soluble, the physiologically relevant, partially ligated species do not provide a significant solubilizing effect. The average solubilizing effect of 26% NO saturation was 0.045; much less than the 0.15 calculated for the effect of 26% oxygen saturation. Given the small amounts of NO-ligated hemoglobin achievable through any kind of NO therapy, we conclude that NO therapy does not benefit patients through any direct solubilizing effect.	Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Wake Forest Univ, Dept Chem, Winston Salem, NC 27109 USA; Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; NIH, Warren G Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA; NIH, Biol Chem Lab, Bethesda, MD 20892 USA	Wake Forest University; Wake Forest University; Jefferson University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Kim-Shapiro, DB (corresponding author), Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA.	shapiro@wfu.edu	Kim-Shapiro, Daniel/HGA-2682-2022	Lockamy, Virginia/0000-0002-6545-7859; Schechter, Alan N/0000-0002-5235-9408	NCRR NIH HHS [RR15018] Funding Source: Medline; NHLBI NIH HHS [R01 HL058091, HL58091, HL62198, R29 HL058091] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R41RR015018] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058091, R37HL058091, R01HL062198, R29HL058091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093, Z01DK025021] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold EV, 1996, METHOD ENZYMOL, V269, P41; Atz AM, 1997, ANESTHESIOLOGY, V87, P988, DOI 10.1097/00000542-199710000-00037; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BRIEHL RW, 1975, J MOL BIOL, V96, P733, DOI 10.1016/0022-2836(75)90149-7; BRIEHL RW, 1974, J MOL BIOL, V89, P759, DOI 10.1016/0022-2836(74)90050-3; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMULITRAT W, 1994, MOL PHARMACOL, V46, P391; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; Embury Stephen H., 1994, P311; ERIKSSON LEG, 1994, BIOCHEM BIOPH RES CO, V203, P176, DOI 10.1006/bbrc.1994.2165; GERACI G, 1969, J BIOL CHEM, V244, P4664; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Gladwin MT, 2001, SEMIN HEMATOL, V38, P333, DOI 10.1053/shem.2001.27574; Gladwin MT, 2001, FREE RADICAL RES, V35, P175, DOI 10.1080/10715760100300721; Head CA, 1997, J CLIN INVEST, V100, P1193, DOI 10.1172/JCI119631; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; HUANG TH, 1979, J BIOL CHEM, V254, P1467; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; Jiang JJ, 1997, MOL PHARMACOL, V52, P1081, DOI 10.1124/mol.52.6.1081; KAPERONIS AA, 1979, BR J HEMATOL, V43, P472; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; McDade WA, 1997, ANESTHESIOLOGY, V87, pA512, DOI 10.1097/00000542-199709001-00512; McDade WA, 1999, ANESTHESIOLOGY, V91, pU348; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NOGUCHI CT, 1985, ANNU REV BIOPHYS BIO, V14, P239, DOI 10.1146/annurev.biophys.14.1.239; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; POILLON WN, 1985, J BIOL CHEM, V260, P3897; POILLON WN, 1990, BLOOD, V76, P1028; REIN H, 1972, FEBS LETT, V24, P24, DOI 10.1016/0014-5793(72)80817-2; SHAPIRO DB, 1995, J BIOL CHEM, V270, P26078, DOI 10.1074/jbc.270.44.26078; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; SUNSHINE HR, 1982, J MOL BIOL, V158, P251, DOI 10.1016/0022-2836(82)90432-6; SZABO A, 1976, BIOCHEMISTRY-US, V15, P4427, DOI 10.1021/bi00665a013; TOMITA S, 1971, J BIOL CHEM, V246, P547; TRITTELVITZ E, 1972, EUR J BIOCHEM, V31, P578, DOI 10.1111/j.1432-1033.1972.tb02568.x; UEDA Y, 1979, BLOOD, V53, P472; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	46	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36787	36792		10.1074/jbc.M205350200	http://dx.doi.org/10.1074/jbc.M205350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138112	hybrid			2022-12-25	WOS:000178275100129
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction	ONCOGENE			English	Article						NQO1; ARE; t-BHQ; c-Maf	ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; SUBUNIT GENE; NRF2; PROTEIN; BINDING; FAMILY	Anti-oxidant response element (ARE) and nuclear factors including Nrf2 and small Maf (MafG and MafK) proteins are known to regulate expression and induction of detoxifying enzyme genes including quinone oxidoreductase1 (NQO1). Nrf2 upregulates and small Maf proteins lacking the transcriptional activation domain down regulates ARE-mediated expression and induction. In this report, we have investigated the role of c-Maf (large Mal) containing the transcriptional activation domain in the regulation of ARE-mediated genes expression. The overexpression of c-Maf in human hepatoblastoma (Hep-G2) cells led to the repression of ARE-mediated NQO1 and GST Ya genes expression and induction in response to tert-butyl hydroquinone (t-BHQ). This was in contrast to the role of c-Maf in the activation of Maf recognition element (MARE) mediated p53 gene expression. Deletion of transcriptional activation domain of c-Maf (<^>c-Maf) led to significant loss of MARE-mediated p53 gene expression but had no effect on the repression of ARE-mediated NQO1 gene expression. The overexpression of MafG in Hep-G2 cells repressed both ARE and MARE-mediated genes expression. The co-expression of c-Maf with MafG rescued the MafG repression of MARE but not ARE-mediated gene expression. Band and super shift assays showed the presence of c-Maf in the ARE-nuclear protein complex. Similar assays with in vitro translated proteins revealed that both c-Maf and <^>c-Maf bound to NQO1 gene ARE as homodimers and heterodimers with small Maf but not as heterodimers with Nrf2. Mutational analysis of the NQO1 gene ARE indicated that core ARE sequence is essential for binding of c-Maf leading to repression of NQO1 gene expression. Northern analysis revealed that c-Maf expression increases 2 h after t-BHQ treatment. It reached a plateau at 4 h after t-BHQ treatment. The results together led to the conclusion that c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and induction in response to anti-oxidants.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Matsushima-Hibiya Y, 1998, BIOCHEM BIOPH RES CO, V245, P412, DOI 10.1006/bbrc.1998.8447; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; VASLIOU V, 1995, BIOCHEM PHARMACOL, V12, P2057; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	36	62	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5301	5312		10.1038/sj.onc.1205642	http://dx.doi.org/10.1038/sj.onc.1205642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149651				2022-12-25	WOS:000177193900011
J	Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L				Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L			Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation	ONCOGENE			English	Article						HPV E6; MAGUK; PDZ; MAGI	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; DISCS LARGE PROTEIN; GUANYLATE-KINASE; PDZ DOMAIN; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	The E6 proteins from the high-risk human papillomavirus (HPV) types have previously been shown to target a number of PDZ domain-containing proteins for proteasome-mediated degradation. These include the hDIg tumour suppressor and the MAGI-I protein. In this study we show that high-risk HPV E6 proteins also target the related MAGI-2 and MAGI-3 proteins for degradation. Moreover, we show that the interaction is specific to one PDZ domain, and that co-expression of this domain can protect each of the full-length MAGI proteins from E6-mediated degradation. These data provide clear indicators for the potential design of compounds that could specifically inhibit the interaction of oncogenic HPV E6 proteins with an important class of target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Roche Holding; Genentech; University of California System; University of California Los Angeles	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Sawyers, Charles/G-5327-2016; guccione, ernesto/G-9874-2011					Adey NB, 2000, CANCER RES, V60, P35; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li J, 1998, CANCER RES, V58, P5667; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	56	161	172	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5088	5096		10.1038/sj.onc.1205668	http://dx.doi.org/10.1038/sj.onc.1205668			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140759				2022-12-25	WOS:000176975900007
J	Bourguignon, LYW; Singleton, PA; Zhu, HB; Zhou, B				Bourguignon, LYW; Singleton, PA; Zhu, HB; Zhou, B			Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; LYMPHOCYTE HOMING RECEPTOR; ANKYRIN-BINDING DOMAIN; TGF-BETA; CANCER CELLS; TRANSMEMBRANE GLYCOPROTEIN; EXPRESSION; CARCINOMA; OVARIAN; CYTOSKELETON	In this study we have examined the interaction between CD44 (a hyaluronan (HA) receptor) and the transforming growth factor beta (TGF-beta) receptors (a family of serine/threonine kinase membrane receptors) in human metastatic breast tumor cells (MDA-MB-231 cell line). Immunological data indicate that both CD44 and TGF-beta receptors are expressed in NMA-MB-231 cells and that CD44 is physically linked to the TGF-beta receptor I (TGF-betaRI) (and to a lesser extent to the TGF-beta receptor II (TGF-betaRII)) as a complex in vivo. Scatchard plot analyses and in vitro binding experiments show that the cytoplasmic domain of CD44 binds to TGF-betaRI at a single site with high affinity (an apparent dissociation constant (K-d) of similar to1.78 nm). These findings indicate that TGF-betaRI contains a CD44-binding site. Furthermore,we have found that the binding of HA to CD44 in MDA-MB-231 cells stimulates TGF-betaRI serine/threonine kinase activity which, in turn, increases Smad2/Smad3 phosphorylation and parathyroid hormone-related protein (PTHrP) production (well known downstream effector functions of TGF-13 signaling). Most importantly, TGF-betaRI kinase activated by RA phosphorylates CD44, which enhances its binding interaction with the cytoskeletal protein, ankyrin, leading to HA-mediated breast tumor cell migration. Overexpression of TGF-betaRI by transfection of MDA-MB-231 cells with TGF-betaRIcDNA stimulates formation of the CD44.TGF-betaRI complex, the association of ankyrin with membranes, and HA-dependent/CD44-specific breast tumor migration. Taken together, these findings strongly suggest that CD44 interaction with the TGF-betaRI kinase promotes activation of multiple signaling pathways required for ankyrin-membrane interaction, tumor cell migration, and important oncogenic events (e.g. Smad2/Smad3 phosphorylation and PTH-rP production) during HA and TGF-beta-mediated metastatic breast tumor progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NCI NIH HHS [CA66163, CA78633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARON AD, 1994, JAMA-J AM MED ASSOC, V272, P1206, DOI 10.1001/jama.272.15.1206; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Goltzman David, 1996, P809; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; HAWKER CD, 1983, ASSAY CALCIUM REGULA, P218; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KAI HY, 1996, PRINCIPLES BONE BIOL, P347; KALISH ED, 1999, FRONT BIOSCI, V4, P1; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Koli KM, 1997, CANCER RES, V57, P970; LEWIS CA, 2001, BIOCHEM J, V357, P834; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; LOCCI P, 1995, CELL TISSUE RES, V281, P317; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1992, CANCER SURV, V12, P81; MERRYMAN JI, 1994, ENDOCRINOLOGY, V134, P2424, DOI 10.1210/en.134.6.2424; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Peck D, 1998, J CELL SCI, V111, P1595; POWELL GJ, 1991, CANCER RES, V51, P3059; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Segre Gino V., 1996, P377; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Smith H S, 1991, Basic Life Sci, V57, P329; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; Xie W, 2002, CANCER RES, V62, P497; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yin JJ, 1996, J BONE MINER RES, V11, P180; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yu Q, 2000, GENE DEV, V14, P163; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	70	178	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39703	39712		10.1074/jbc.M204320200	http://dx.doi.org/10.1074/jbc.M204320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145287	hybrid			2022-12-25	WOS:000178662500084
J	Baird, TR; Walsh, PN				Baird, TR; Walsh, PN			The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; MOLECULAR-WEIGHT KININOGEN; HEPARIN-BINDING SITE; BOUND FACTOR-XIA; FUNCTIONAL-CHARACTERIZATION; CHRISTMAS-FACTOR; APPLE-3 DOMAIN; HEAVY-CHAIN; SURFACE; THROMBIN	We have previously shown that the zymogen factor XI (FXI) binds to activated platelets but not to human umbilical vein endothelial cells (HUVEC), a conclusion that is in conflict with previous reports stating that FXI binds to 2.7-13 x 10(6) high affinity sites per HUVEC (Berrettini, M., Schleef, R. R., Heeb, M. J., Hopmeier, P., and Griffin, J. H. (1992) J. Biol. Chem. 267, 19833-19839; Shariat-Madar, Z., Mahdi, F., and Schmaier, A. H. (2001) Thromb. Haemostasis 85, 544-551). It has also been reported that activated FXI (FXIa) binds to 1.5 x 10(6) sites per HUVEC and promotes the activation of factor IX by cell bound FXIa (Berrettini, M., Schleef, R. R., Heeb, M. J., Hopmeier, P., and Griffin, J. H. (1992) J. Biol. Chem. 267, 19833-19839). Therefore, the binding of FXIa to activated platelets was compared with FXIa binding to HUVEC and HEK293 cells immobilized on microcarrier beads. Specific and saturable zinc-dependent FXIa binding was demonstrated to 250 +/- 48 sites per activated platelet (K-D 1.7 +/- 0.78 nM) and 6.5 +/- 0.4 x 10(4) sites per HUVEC (K-D 2.4 +/- 0.5 nM), whereas no binding to HEK293 cells was detected. A titration with high molecular weight kininogen had no effect on FXIa binding to platelets, but revealed a concentration-dependent decrease in the amount of FXIa bound to HUVEC. The rate of factor IXa generation catalyzed by FXIa was unaffected by the presence of surfaces; however only the activated platelet surface protected FXIa from inhibition by protease nexin 2. The results presented here confirm the conclusion that activated platelets are procoagulant while unstimulated endothelial cells are not.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL46213, HL64943, HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914, P01HL064943, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P3244; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MANNHALTER C, 1984, BRIT J HAEMATOL, V56, P261, DOI 10.1111/j.1365-2141.1984.tb03954.x; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; SINHA D, 1992, METHOD ENZYMOL, V215, P361; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; Walsh P N, 1977, Br J Haematol, V36, P287; WALSH PN, 1986, BLOOD, V68, P225; WALSH PN, 1987, J CLIN INVEST, V80, P1578, DOI 10.1172/JCI113244; Walsh PN, 2001, THROMB HAEMOSTASIS, V86, P75; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	43	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38462	38467		10.1074/jbc.M205902200	http://dx.doi.org/10.1074/jbc.M205902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167623	hybrid			2022-12-25	WOS:000178529600061
J	Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P				Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P			High level expression of recombinant porcine coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-VIII; HEMOPHILIA-A; SECRETION; CDNA; ANTIGENICITY; DISSOCIATION; INHIBITORS; SEQUENCES; RESIDUES; THERAPY	Recombinant human factor VIII expression levels, in vitro and in vivo, are significantly lower than levels obtained for other recombinant coagulation proteins. Here we describe the generation, high level expression and characterization of a recombinant B-domain-deleted porcine factor VIII molecule. Recombinant B-domain-deleted porcine factor VIII expression levels are 10- to 14-fold greater than recombinant B-domain-deleted human factor VIII levels by transient and stable expression in multiple cell lines. Peak expression of 140 units.10(6) cells(-1).24 h(-1) was observed from a baby hamster kidney-derived cell line stably expressing recombinant porcine factor VIII. Factor VIII expression was performed in serum-free culture medium and in the absence of exogenous von Willebrand factor, thus greatly simplifying protein purification. Real time reverse transcription-PCR analysis demonstrated that the differences in protein production were not caused by differences in steady-state factor VIII mRNA levels. The identification of sequence(s) in porcine factor VIII responsible for high level expression may lead to a better understanding of the mechanisms that limit factor VIII expression.	Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Lollar, P (corresponding author), Emory Univ, Winship Canc Inst, 1639 Pierce Dr,Room 1003,Woodruff Mem Bldg, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrow RT, 2001, BLOOD, V97, P169, DOI 10.1182/blood.V97.1.169; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; CHUAH MKL, 1995, HUM GENE THER, V6, P1363, DOI 10.1089/hum.1995.6.11-1363; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; Fang XD, 2001, THROMB RES, V102, P177, DOI 10.1016/S0049-3848(01)00229-8; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; Garber K, 2000, NAT BIOTECHNOL, V18, P1133, DOI 10.1038/81098; GATTI L, 1984, THROMB HAEMOSTASIS, V51, P379; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Hay CRM, 1996, THROMB HAEMOSTASIS, V75, P25; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1996, BLOOD, V88, P4209; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kaufman RJ, 1997, BLOOD COAGUL FIBRIN, V8, pS3; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KINGSTON RE, 1997, CURRENT PROTOCOLS MO, V37; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pipe SW, 2001, BLOOD, V97, P685, DOI 10.1182/blood.V97.3.685; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1993, BLOOD, V81, P2925; Plantier JL, 2001, THROMB HAEMOSTASIS, V86, P596, DOI 10.1055/s-0037-1616092; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Tagliavacca L, 2000, BIOCHEMISTRY-US, V39, P1973, DOI 10.1021/bi991896r; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0	39	79	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38345	38349		10.1074/jbc.M206959200	http://dx.doi.org/10.1074/jbc.M206959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138172	hybrid			2022-12-25	WOS:000178529600046
J	Huang, XL; Pawliczak, R; Cowan, MJ; Gladwin, MT; Madara, P; Logun, C; Shelhamer, JH				Huang, XL; Pawliczak, R; Cowan, MJ; Gladwin, MT; Madara, P; Logun, C; Shelhamer, JH			Epidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ANNEXIN-II TETRAMER; GLOMERULAR MESANGIAL CELLS; PROSTAGLANDIN GENERATION; PLASMINOGEN ACTIVATION; BINDING PROTEINS; KINASE; PHOSPHORYLATION; INHIBITION; PLATELETS	p11, a member of the S-100 family of proteins, is the cellular ligand of annexin II and also interacts with the C-terminal region of cytosolic phospholipase A(2) (cPLA(2)), inhibiting cPLA(2) activity and arachidonic acid (AA) release. It has been reported that epidermal growth factor (EGF) induces cPLA(2), activation or cPLA(2) expression and subsequent AA release. It was of interest to study the effect of EGF on p11 production and on AA release in human epithelial cells (HeLa). EGF (20 ng/ml) treatment of HeLa cells increased the cellular p11. protein and the steady-state levels of p11 mRNA in a time- and dose-dependent manner but did not affect cPLA(2) protein expression over a 4-48-h incubation time. Transient transfection experiments of a reporter gene construct containing 1498 bp of the 5'-flanking region of p11 promoter demonstrated that EGF induced p11. gene expression at the transcriptional level. EGF caused a rapid phosphorylation of p44/42 and p38 kinases with a maximum level at 10 min. AG 1478 (EGF receptor tyrosine kinase inhibitor), PD 98059 (ERK1/2 inhibitor), and SB 203580 (p38 inhibitor) significantly inhibited EGF-induced p11. expression. EGF-induced AA release was significantly suppressed by AG 1478, PD 98059, SB 203580, and methyl arachidonyl fluorophosphate (a specific cPLA2 inhibitor). Methyl arachidonyl fluorophosphate (50 pm) also significantly inhibited EGF-induced p11 expression, demonstrating that the activation of cPLA(2) may have a role in the EGF-induced p11. expression. Immunoprecipitation experiments showed that EGF induced increased p11 binding to cPLA(2) in a time- and dose-dependent manner. EGF treatment for 30 min increased A23187-induced AA release, whereas EGF treatment for 24 h inhibited A23187-induced AA release. These results suggest that EGF treatment increased p11. bound to cPLA(2), may lead to the late suppression of AA release induced by EGF.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92213 Lodz, Poland	National Institutes of Health (NIH) - USA; Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,Rm 7D43,10 Ctr Dr,MSC1662, Bethesda, MD 20892 USA.		Pawliczak, Rafal Tomasz/S-9649-2016; Pawliczak, Rafa/S-2021-2019	Pawliczak, Rafa/0000-0001-6784-453X	CLINICAL CENTER [Z01CL001160] Funding Source: NIH RePORTER	CLINICAL CENTER		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; FRITZPATRICK SL, 2000, BIOCHEMISTRY-US, V39, P1021; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gladwin MT, 2000, AM J PHYSIOL-LUNG C, V279, pL1103, DOI 10.1152/ajplung.2000.279.6.L1103; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	34	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38431	38440		10.1074/jbc.M207406200	http://dx.doi.org/10.1074/jbc.M207406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163506	hybrid			2022-12-25	WOS:000178529600057
J	Jones, SM; Luo, M; Healy, AM; Peters-Golden, M; Brock, TG				Jones, SM; Luo, M; Healy, AM; Peters-Golden, M; Brock, TG			Structural and functional criteria reveal a new nuclear import sequence on the 5-lipoxygenase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CRYSTALLOGRAPHIC ANALYSIS; ALVEOLAR MACROPHAGES; KARYOPHERIN-ALPHA; LOCALIZATION; TRANSLOCATION; RECOGNITION; ACTIVATION; PHOSPHORYLATION; NEUTROPHILS	Leukotrienes are lipid mediators with important roles in immunity. The enzyme 5-lipoxygenase initiates leukotriene synthesis; nuclear import of 5-lipoxygenase modulates leukotriene synthetic capacity. In this study, we used structural and functional criteria to identify potential nuclear import sequences. Specifically, we sought basic residues that 1) were common to different 5-lipoxygenases but not shared with other lipoxygenases, 2) were found on random coil/loop structures, and 3) could be replaced without eliminating catalytic activity. Application of these criteria to the putative bipartite nuclear import sequence of 5-lipoxygenase revealed that this region formed an a-helix rather than a random coil, that the critical residue arginine 651 serves a structural role, and that mutation of this residue eliminated catalytic activity. A previously unrecognized region corresponding to residues 518-530 on human 5-lipoxygenase was found to be unique to 5-lipoxygenase and on a random coil. This region alone was sufficient to drive import of green fluorescent protein to the same degree as complete 5-lipoxygenase. Replacement of basic residues in this region of the complete protein was capable of eliminating nuclear import without abolishing catalytic activity. Surprisingly, two subpopulations of cells expressing 5-lipoxygenase with this mutated region could be discerned: those with strongly impaired import and those with normal import. Taken together, these results show that the previously identified region with a bipartite motif is not a functional import sequence, whereas the newly identified basic region constitutes a true nuclear import sequence. Moreover, we suggest that another sequence that can mediate nuclear import of 5-lipoxygenase remains to be identified.	Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574, R21AI048141] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI48141, R29 AI43574] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; Brock TG, 1999, J IMMUNOL, V162, P1669; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HOFFMAN T, 1991, J IMMUNOL, V146, P692; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; Sud'ina GF, 2001, BIOCHEM J, V359, P621, DOI 10.1042/0264-6021:3590621; Sweitzer TD, 2000, CURR TOP CELL REGUL, V36, P77; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38550	38556		10.1074/jbc.M206070200	http://dx.doi.org/10.1074/jbc.M206070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140292	hybrid			2022-12-25	WOS:000178529600071
J	Zschocke, J; Manthey, D; Bayatti, N; van der Burg, B; Goodenough, S; Behl, C				Zschocke, J; Manthey, D; Bayatti, N; van der Burg, B; Goodenough, S; Behl, C			Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HUMAN BREAST-CANCER; DNA-METHYLTRANSFERASE; DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; TYROSINE KINASE; PLASMA-MEMBRANE	Estrogen receptors (ERalpha/ERbeta) are expressed in neuronal cells and exhibit a variety of activities in the central nervous system. ER activity is regulated in a ligand-dependent manner and by co-regulatory factors. Caveolin-1 is a recently identified co-activator of ERalpha mediating the ligand-independent activation of this steroid receptor. Here the influence of ERs on caveolin expression in human neuroblastoma SK-N-MC cells as well as in rodent brain was investigated. We found that ectopic expression of ERalpha in SK-N-MC cells (SK-ERalpha) leads to a ligand-independent transcriptional suppression of caveolin-1/-2 genes. This suppression is specifically mediated by ERalpha and not ERbeta because ERbeta counteracts the observed caveolin-silencing process. Interestingly, decreased caveolin expression in SK-ERalpha is accompanied by changes in the methylation pattern of caveolin promoters. The analysis of selected promoter regions of the human caveolin-1 gene showed that certain CpG dinucleotides were hypermethylated in SK-ERalpha cells, whereas the same sites were unmethylated in control, ERbeta-, and ERalpha/beta co-expressing SK-N-MC cells. Inhibition of DNA methylation or histone deacetylation led to partial re-expression of caveolin-1/-2 genes in SK-ERalpha. In vivo analysis revealed a down-regulation of caveolin-1 expression after long term estrogen exposure in certain regions of the mouse brain. In conclusion, we have shown for the first time that ERalpha and not ERbeta silences caveolin-1/-2 expression in an epigenetic fashion in neuronal cells. The observed mechanism of gene silencing by ERalpha may have implications for the transcriptional regulation of further ERalpha target genes.	Max Planck Inst Psychiat, Neurodegenerat Grp, D-80804 Munich, Germany; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Max Planck Society; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Behl, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany.	chris@mpipsykl.mpg.de	Zschocke, Johannes/C-5885-2013	Zschocke, Johannes/0000-0002-0046-8274; Behl, Christian/0000-0001-8453-2378				Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Braun JEA, 2000, J NEUROSCI, V20, P5997, DOI 10.1523/JNEUROSCI.20-16-05997.2000; Cameron PL, 1997, J NEUROSCI, V17, P9520; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; DRYDEN GL, 1977, SCIENCE, V197, P782, DOI 10.1126/science.887921; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HERMAN JG, 1995, CANCER RES, V55, P4525; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Jayachandran M, 2001, AM J PHYSIOL-HEART C, V281, pH1327, DOI 10.1152/ajpheart.2001.281.3.H1327; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kamiya K, 1996, EXP CLIN ENDOCR DIAB, V104, P111, DOI 10.1055/s-0029-1211432; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McLachlan JA, 2001, TOXICOL LETT, V120, P161, DOI 10.1016/S0378-4274(01)00295-8; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Pelligrino DA, 2000, BIOCHEM BIOPH RES CO, V269, P165, DOI 10.1006/bbrc.2000.2206; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Turi A, 2001, CELL BIOL INT, V25, P785, DOI 10.1006/cbir.2001.0769; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	62	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38772	38780		10.1074/jbc.M205664200	http://dx.doi.org/10.1074/jbc.M205664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138116	hybrid			2022-12-25	WOS:000178529600097
J	Cox, KH; Tate, JJ; Cooper, TG				Cox, KH; Tate, JJ; Cooper, TG			Cytoplasmic Compartmentation of Gln3 during nitrogen catabolite repression and the mechanism of its nuclear localization during carbon starvation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SIGNALING PATHWAYS; TOR PROTEINS; RAPAMYCIN; MITOCHONDRIA; TARGET; TAP42; URE2P; MKS1P; RTG1	Regulated intracellular localization of Gln3, the transcriptional activator responsible for nitrogen catabolite repression (NCR)-sensitive transcription, permits Saccharomyces cerevisiae to utilize good nitrogen sources (e.g. glutamine and ammonia) in preference to poor ones (e.g. proline). During nitrogen starvation or growth in medium containing a poor nitrogen source, Gln3 is nuclear and NCR-sensitive transcription is high. However, when cells are grown in excess nitrogen, Gln3 is localized to the cytoplasm with a concomitant decrease in gene expression. Treating cells with the Tor protein inhibitor, rapamycin, mimics nitrogen starvation. Recently, carbon starvation has been reported to cause nuclear localization of Gln3 and increased NCR-sensitive transcription. Here we show that nuclear localization of Gln3 during carbon starvation derives from its indirect effects on nitrogen metabolism, i.e. Gln3 does not move into the nucleus of carbon-starved cells if glutamine rather than ammonia is provided as the nitrogen source. In addition, these studies have clearly shown Gln3 is not uniformly distributed in the cytoplasm, but rather localizes to punctate or tubular structures. Analysis of these images by deconvolution microscopy suggests that Gln3 is concentrated in or associated with a highly structured system in the cytosol, one that is possibly vesicular in nature. This finding may impact significantly on how we view (i) the mechanism by which Tor regulates the intracellular localization of Gln3 and (ii) how proteins move into and out of the nucleus.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BOSSINGER J, 1976, J BACTERIOL, V126, P198, DOI 10.1128/JB.126.1.198-204.1976; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Cooper TG, 1996, MYCOTA, V3, P139; COOPER TG, 2002, FEMS MICROBIOL REV, V737, P1; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Edskes HK, 1999, GENETICS, V153, P585; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Smart WC, 1996, MOL CELL BIOL, V16, P5876; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3	33	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37559	37566		10.1074/jbc.M204879200	http://dx.doi.org/10.1074/jbc.M204879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140287	hybrid, Green Accepted			2022-12-25	WOS:000178447100083
J	Foukas, LC; Daniele, N; Ktori, C; Anderson, KE; Jensen, J; Shepherd, PR				Foukas, LC; Daniele, N; Ktori, C; Anderson, KE; Jensen, J; Shepherd, PR			Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases - Differential effects on lipid kinase and protein kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; RADIOSENSITIZING AGENT; INSULIN-RECEPTOR; SKELETAL-MUSCLE; RAT ADIPOCYTES; INHIBITION; WORTMANNIN; ADENOSINE; SPECIFICITY	We investigated the effects of methylxanthines on enzymatic activity of phosphoinositide 3-kinases (PI3Ks). We found that caffeine inhibits the in vitro lipid kinase of class I PI3Ks (IC(50) = 75 muM for p110delta, 400 muM for p110alpha and p110beta, and 1 mM for p110gamma), and theophylline has similar effects (IC(50) = 75 muM for p110delta, 300 muM for p110alpha, and 800 muM for p110beta and p110gamma) and also inhibits the alpha isoform. of class II PI3K (PI3K-C2alpha) (IC(50) approximate to 400 muM). However, four other xanthine derivatives tested (3-isobutyl-1-methylxanthine, 3-propylxanthine, alloxazine, and PD116948 (8-cyclopentyl-1,3-dipropylxanthine)) were an order of magnitude less effective. Surprisingly the triazoloquinazoline CGS15943 (9-chloro-2-(2-furyl)(1,2,d)triazolo(1,5-c)quinazolin-5-amine) also selectively inhibits P110delta (IC(50) < 10 mu M). Caffeine and theophylline also inhibit the intrinsic protein kinase activity of the class IA PI3Ks and DNA-dependent protein kinase, although with a much lower potency than that for the lipid kinase (IC(50) approximate to 10 mM for p110 alpha, 3 mM for p110 beta, and 10 mM for DNA-dependent protein kinase). In CHO-IR cells and rat soleus muscle, theophylline and caffeine block the ability of insulin to stimulate protein kinase B with IC(50). values similar to those for inhibition of PI3K activity, whereas insulin stimulation of ERK1 or ERK2 was not inhibited at concentrations up to 10 mm. Theophylline and caffeine also blocked insulin stimulation of glucose transport in CHO-IR cells. These results demonstrate that these methylxanthines are direct inhibitors of PI3K lipid kinase activity but are distinctly less effective against serine kinase activity and thus could be of potential use in dissecting these two distinct kinase activities. Theophylline, caffeine, and CGS15943 may be of particular use in dissecting the specific role of the p110 delta lipid kinase. Finally, we conclude that inhibition of PI3K (p110 delta in particular) is likely explain some of the physiological and pharmacological properties of caffeine and theophylline.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Monash Univ, Dept Med, Melbourne, Vic 3128, Australia; Natl Inst Occupat Hlth, Dept Physiol, N-0033 Oslo, Norway	University of London; University College London; Monash University	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	p.shepherd@ucl.ac.uk	Jensen, Jørgen/O-2245-2013; Danièle, Nathalie/J-7432-2013	Anderson, Karen/0000-0002-7394-6660; Daniele, Nathalie/0000-0002-7985-2788				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Basu S, 2000, HAEMATOLOGIA, V30, P225, DOI 10.1163/156855900300109242; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BUCKLEY JT, 1977, BIOCHIM BIOPHYS ACTA, V498, P1; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; COX LR, 1990, EXP MOL PATHOL, V53, P52, DOI 10.1016/0014-4800(90)90023-7; Daly JW, 2000, J AUTONOM NERV SYST, V81, P44, DOI 10.1016/S0165-1838(00)00110-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; GREEN A, 1987, DIABETOLOGIA, V30, P188, DOI 10.1007/BF00274226; Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349; Han DH, 1998, DIABETES, V47, P1671, DOI 10.2337/diabetes.47.11.1671; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; HONEYMAN TW, 1983, BIOCHEM J, V212, P489, DOI 10.1042/bj2120489; JOOST HG, 1983, MOL CELL BIOCHEM, V57, P177, DOI 10.1007/BF00849194; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; Kim YC, 1996, J MED CHEM, V39, P4142, DOI 10.1021/jm960482i; LAM K, 1994, J BIOL CHEM, V269, P20648; Okkenhaug K, 2002, SCIENCE, V297, P1031; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Soos MA, 2001, ARCH BIOCHEM BIOPHYS, V396, P244, DOI 10.1006/abbi.2001.2587; STEELE TA, 1988, CELL IMMUNOL, V112, P402, DOI 10.1016/0008-8749(88)90309-7; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; STEINFELDER HJ, 1990, BIOCHEM PHARMACOL, V40, P1154, DOI 10.1016/0006-2952(90)90508-I; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Takasuga S, 1999, J BIOL CHEM, V274, P19545, DOI 10.1074/jbc.274.28.19545; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yasui K, 2001, INT J HEMATOL, V73, P87, DOI 10.1007/BF02981908; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555	46	121	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37124	37130		10.1074/jbc.M202101200	http://dx.doi.org/10.1074/jbc.M202101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145276	hybrid			2022-12-25	WOS:000178447100029
J	Hilber, K; Sandtner, W; Kudlacek, O; Schreiner, B; Glaaser, I; Schutz, W; Fozzard, HA; Dudley, SC; Todt, H				Hilber, K; Sandtner, W; Kudlacek, O; Schreiner, B; Glaaser, I; Schutz, W; Fozzard, HA; Dudley, SC; Todt, H			Interaction between fast and ultra-slow inactivation in the voltage-gated sodium channel - Does the inactivation gate stabilize the channel structure?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOKALEMIC PERIODIC PARALYSIS; INHERITED CARDIAC-ARRHYTHMIA; EPICARDIAL BORDER ZONE; LONG-QT SYNDROME; NA+-CHANNEL; FUNCTIONAL EXPRESSION; ALPHA-SUBUNIT; SEGMENT IVS6; INFARCTED HEART; DOMAIN-IV	Recently, we reported that mutation A1529D in the domain (D) IV P-loop of the rat skeletal muscle Na+ channel mu(1), (DIV-A1529D) enhanced entry to an inactivated state from which the channels recovered with an abnormally slow time constant on the order of similar to100 s. Transition to this "ultra-slow" inactivated state (USI) was substantially reduced by binding to the outer pore of a mutant mu-conotoxin GIIIA. This indicated that USI reflected a structural rearrangement of the outer channel vestibule and that binding to the pore of a peptide could stabilize the pore structure (Hilber, K., Sandtner, W., Kudlacek, O., Glaaser, I. W., Weisz, E., Kyle, J. W., French, R. J., Fozzard, H. A., Dudley, S. C., and Todt, H. (2001) J. Biol. Chem. 276, 27831-27839). Here, we tested the hypothesis that occlusion of the inner vestibule of the Na+ channel by the fast inactivation gate inhibits ultra-slow inactivation. Stabilization of the fast inactivated state (FI) by coexpression of the rat brain beta(1) subunit in Xenopus oocytes significantly prolonged the time course of entry to the USI. A reduction in USI was also observed when the FI was stabilized in the absence of the 131 subunit, suggesting a causal relation between the occurrence of the FI and inhibition of USI. This finding was further confirmed in experiments where the FI was destabilized by introducing the mutations I1303Q/ F1304Q/M1305Q. In DIV-A1529D + I1303Q/F1304Q/ M1305Q channels, occurrence of USI was enhanced at strongly depolarized potentials and could not be prevented by coexpression of the 6, subunit. These results strongly suggest that FI inhibits USI in DIV-A1529D channels. Binding to the inner pore of the fast inactivation gate may stabilize the channel structure and thereby prevent USI. Some of the data have been published previously in abstract form (Hilber, K., Sandtner, W., Kudlacek, O., Singer, E., and Todt, H. (2002) Soc. Neurosci. Abstr. 27, program number 46.12).	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Chicago, Cardiac Electrophysiol Labs, Chicago, IL 60637 USA; Atlanta Vet Affairs Hosp, Decatur, GA 30033 USA; Emory Univ, Div Cardiol, Atlanta, GA 30033 USA	University of Vienna; University of Chicago; Emory University	Todt, H (corresponding author), Univ Vienna, Inst Pharmacol, Wahringerstr 13A, A-1090 Vienna, Austria.		Dudley, Samuel/AAR-7950-2021; Dudley, Samuel C/A-7085-2009	Dudley, Samuel/0000-0001-5843-5961; Hilber, Karlheinz/0000-0002-3033-0874; Kudlacek, Oliver/0000-0002-3086-8551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL064828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-P01-20592, HL64828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNEW WS, 1991, ANN NY ACAD SCI, V625, P200, DOI 10.1111/j.1749-6632.1991.tb33842.x; ALDRICH RW, 1981, BIOPHYS J, V36, P519, DOI 10.1016/S0006-3495(81)84750-9; Alekov AK, 2001, NEUROSCI LETT, V306, P173, DOI 10.1016/S0304-3940(01)01895-X; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Balser JR, 1996, J GEN PHYSIOL, V107, P643, DOI 10.1085/jgp.107.5.643; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; Bendahhou S, 2001, ANN NEUROL, V50, P417, DOI 10.1002/ana.1144; Bendahhou S, 2000, J CLIN INVEST, V106, P431, DOI 10.1172/JCI9654; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; Chang SY, 1996, BIOPHYS J, V70, P2581, DOI 10.1016/S0006-3495(96)79829-6; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cummins TR, 1996, BIOPHYS J, V71, P227, DOI 10.1016/S0006-3495(96)79219-6; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Featherstone DE, 1996, BIOPHYS J, V71, P3098, DOI 10.1016/S0006-3495(96)79504-8; Fleidervish IA, 1996, J PHYSIOL-LONDON, V493, P83, DOI 10.1113/jphysiol.1996.sp021366; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; French R J, 1999, Methods Enzymol, V294, P575; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Hayward LJ, 1999, NEUROLOGY, V52, P1447, DOI 10.1212/WNL.52.7.1447; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hilber K, 2001, J BIOL CHEM, V276, P27831, DOI 10.1074/jbc.M101933200; HILBER K, 2002, SOC NEUR ABSTR, V27; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Kontis KJ, 1997, J GEN PHYSIOL, V110, P403, DOI 10.1085/jgp.110.4.403; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Mitrovic N, 2000, J GEN PHYSIOL, V115, P707, DOI 10.1085/jgp.115.6.707; Nuss HB, 1996, J PHYSIOL-LONDON, V494, P411, DOI 10.1113/jphysiol.1996.sp021502; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Pu JL, 1998, CIRC RES, V83, P431, DOI 10.1161/01.RES.83.4.431; Pu JL, 1997, CIRC RES, V81, P110, DOI 10.1161/01.RES.81.1.110; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Richmond JE, 1998, BIOPHYS J, V74, P2945, DOI 10.1016/S0006-3495(98)78001-4; RUDY B, 1978, J PHYSIOL-LONDON, V283, P1; RUFF RL, 1987, J PHYSIOL-LONDON, V383, P339; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; Sheets MF, 2000, J GEN PHYSIOL, V115, P609, DOI 10.1085/jgp.115.5.609; Stevens EB, 2001, PFLUG ARCH EUR J PHY, V441, P481, DOI 10.1007/s004240000449; Struyk AF, 2000, J NEUROSCI, V20, P8610; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; Vedantham V, 1998, J GEN PHYSIOL, V111, P83, DOI 10.1085/jgp.111.1.83; Vedantham V, 2000, BIOPHYS J, V78, P2943, DOI 10.1016/S0006-3495(00)76834-2; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang DW, 1996, BIOPHYS J, V70, P1700, DOI 10.1016/S0006-3495(96)79732-1; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37105	37115		10.1074/jbc.M205661200	http://dx.doi.org/10.1074/jbc.M205661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138168	hybrid			2022-12-25	WOS:000178447100027
J	Mandal, S; Kundu, P; Roy, B; Mandal, RK				Mandal, S; Kundu, P; Roy, B; Mandal, RK			Precursor of the inactive 2S seed storage protein from the Indian mustard Brassica juncea is a novel trypsin inhibitor - Characterization, post-translational processing studies, and transgenic expression to develop insect-resistant plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE; PURIFICATION; QUALITY; CLONING; SYSTEM; SITES; NAPIN	A number of trypsin inhibitor (TI) genes have been used to generate insect-resistant plants. Here we report a novel trypsin inhibitor from Indian mustard Brassica juncea (BjTI) that is unique in being the precursor of a 2S seed storage protein. The inhibitory activity is lost upon processing. The predicted amino acid sequence of the precursor based on the B. juncea 2S albumin (Bj2S) gene cloned and sequenced in this laboratory (Bj2Sc; GenBank(TM) accession number X65972) showed a soybean-TI active site-like motif GPFRI at the expected processing site. The BjTI was found to be a thermostable Kunitz type TI that inhibits trypsin at a molar ratio of 1:1. The 20-kDa BjTI was purified from midmature seeds and found to be processed in vitro to 9- and 4-kDa subunits upon incubation with seed extract. The Bj2Sc sequence was expressed in Escherichia coli pET systems as the inhibitor precursor. The radiolabeled gene product was expressed in vitro in a coupled transcription-translation system and showed the expected processing into subunits. Two in vitro expressed pre-2S proteins, mutated at Gly and Asp residues, were processed normally to mature subunits, showing thereby no absolute requirement of Gly and Asp residues for processing. Finally, the 2S gene was introduced into tobacco and tomato plants. Third generation transgenics expressing BjTI at 0.28-0.83% of soluble leaf proteins showed remarkable resistance against the tobacco cutworm, Spodoptera litura. This novel TI can be used in transforming seed crops for protection to their vegetative parts and early seed stages, when insect damage is maximal; as the seeds mature, the TI will be naturally processed to the inactive storage protein that is safe for consumption.	Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Mandal, RK (corresponding author), Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India.	rkmandal@hotmail.com		Kundu, Surekha/0000-0003-0480-8624				Adamovskaya VG, 2000, RUSS J PLANT PHYSL+, V47, P186; Altpeter F, 1999, MOL BREEDING, V5, P53, DOI 10.1023/A:1009659911798; Bell JM, 1996, CAN J ANIM SCI, V76, P423, DOI 10.4141/cjas96-061; Brauer ABE, 2001, J MOL BIOL, V306, P799, DOI 10.1006/jmbi.2000.4410; Castellino F J, 1976, Methods Enzymol, V45, P273; Czapinska H, 2000, J MOL BIOL, V295, P1237, DOI 10.1006/jmbi.1999.3445; DASGUPTA J, 1995, INDIAN J BIOCHEM BIO, V32, P378; DASGUPTA S, 1993, SEED SCI TECHNOL, V21, P291; DASGUPTA S, 1993, GENE, V133, P301, DOI 10.1016/0378-1119(93)90656-N; delaPena MAG, 1996, EUR J BIOCHEM, V237, P827, DOI 10.1111/j.1432-1033.1996.0827p.x; Draper J., 1988, PLANT GENETIC TRANSF, P199; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; FUKUSHIMA D, 1991, Food Reviews International, V7, P323; GATEHOUSE AMR, 1980, PHYTOCHEMISTRY, V19, P751, DOI 10.1016/0031-9422(80)85104-1; Genov N, 1997, BBA-PROTEIN STRUCT M, V1341, P157, DOI 10.1016/S0167-4838(97)00049-6; Ghose M, 2001, FEBS LETT, V509, P337, DOI 10.1016/S0014-5793(01)03202-1; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; HEATH RL, 1995, EUR J BIOCHEM, V230, P250, DOI 10.1111/j.1432-1033.1995.tb20558.x; Hilder VA, 1999, CROP PROT, V18, P177, DOI 10.1016/S0261-2194(99)00028-9; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; Hou WC, 1999, J AGR FOOD CHEM, V47, P2168, DOI 10.1021/jf980738o; HUNG CH, 1993, GENE, V127, P215, DOI 10.1016/0378-1119(93)90722-F; KIM SH, 1985, J BIOCHEM, V98, P435, DOI 10.1093/oxfordjournals.jbchem.a135298; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; KRYZANIAK A, 1998, NAHRUNG, V42, P201; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lee SI, 1999, MOL BREEDING, V5, P1; LING MH, 1993, J BIOL CHEM, V268, P810; Mandal S, 2000, CURR SCI INDIA, V79, P576; Mandal Surekha, 1999, Science & Culture, V65, P169; Mandal Surekha, 2000, Environment and Ecology (Kalyani), V18, P177; MENEGATTI E, 1992, FEBS LETT, V301, P10, DOI 10.1016/0014-5793(92)80199-Q; MILLERD A, 1975, ANNU REV PLANT PHYS, V26, P53, DOI 10.1146/annurev.pp.26.060175.000413; MOGEN BD, 1990, PLANT CELL, V2, P1261; Muntz K, 1998, PLANT MOL BIOL, V38, P77, DOI 10.1023/A:1006020208380; MUREN E, 1995, EUR J BIOCHEM, V227, P316, DOI 10.1111/j.1432-1033.1995.tb20391.x; Muren E, 1996, EUR J BIOCHEM, V242, P214, DOI 10.1111/j.1432-1033.1996.0214r.x; Prakash S., 1980, OPERA BOT, V55, P1, DOI DOI 10.1016/B978-1-891127-79-3.50001-9; Rico M, 1996, BIOCHEMISTRY-US, V35, P15672, DOI 10.1021/bi961748q; Ruoppolo M, 2000, EUR J BIOCHEM, V267, P6486, DOI 10.1046/j.1432-1327.2000.01741.x; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SVENDSEN I, 1994, INT J PEPT PROT RES, V43, P425; Ussuf KK, 2001, CURR SCI INDIA, V80, P847; VANDRIESSCHE E, 1988, ADV LECTIN RES, V1, P73; VISENTIN M, 1992, PHYTOCHEMISTRY, V31, P3677, DOI 10.1016/S0031-9422(00)97507-1; Volpicella M, 2001, BIOCHEM BIOPH RES CO, V280, P813, DOI 10.1006/bbrc.2000.4182; Welham T, 2000, PLANT SCI, V159, P289, DOI 10.1016/S0168-9452(00)00358-7; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; YOSHIKAWA H, 1995, BIOSCI BIOTECH BIOCH, V59, P117, DOI 10.1271/bbb.59.117	51	42	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37161	37168		10.1074/jbc.M205280200	http://dx.doi.org/10.1074/jbc.M205280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147695	hybrid			2022-12-25	WOS:000178447100034
J	Shibayama, S; Shibata-Seita, R; Miura, K; Kirino, Y; Takishima, K				Shibayama, S; Shibata-Seita, R; Miura, K; Kirino, Y; Takishima, K			Identification of a C-terminal region that is required for the nuclear translocation of ERK2 by passive diffusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; DOCKING SITE; SUBSTRATE-SPECIFICITY; PORE COMPLEX; PTP-SL; TRANSPORT; PHOSPHORYLATION; BINDING; SEQUENCE	Extracellular signal-regulated kinase 2 (ERK2) is located in the cytoplasm of resting cells and translocates into the nucleus upon extracellular stimuli by active transport of a dimer. Passive transport of an ERK2 monomer through the nuclear pore is also reported to coexist. We attempted to characterize the cytoplasmic retention and nuclear translocation of fusion proteins between deletion and site-directed mutants of ERK2 and green fluorescent protein (GFP). The overexpressed ERK2-GFP fusion protein is usually localized to both the cytoplasm and the nucleus unless a cytoplasmic anchoring protein is coexpressed. Deletion of 45 residues, but not 43 residues, from the C terminus of ERK2 prevented the nuclear distribution of the ERK2-GFP fusion protein. Substitution of a part of residues 299-313 to alanine residues also prevented the nuclear distribution of the ERK2-GFP fusion protein without abrogation of its nuclear active transport. These observations may indicate that the passive diffusion of ERK2 into the nucleus is not simple diffusion but includes a specific interaction process between residues 299-313 and the nuclear pore complex and that this interaction is not required for the active transport. We also showed that substitution of Tyr(314) to alanine residue abrogated the cytoplasmic retention of the ERK2-GFP fusion protein by PTP-SL but not by MEK1.	Natl Def Med Coll, Dept Biochem 1, Tokorozawa, Saitama 3598513, Japan; Univ Tokyo, Lab Neurobiophys, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	National Defense Medical College - Japan; University of Tokyo	Takishima, K (corresponding author), Natl Def Med Coll, Dept Biochem 1, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	ktakishi@cc.ndmc.ac.jp	shibayama, sotaro/N-9565-2019; shibayama, sotaro/K-6005-2012	shibayama, sotaro/0000-0002-6701-9828; shibayama, sotaro/0000-0002-6701-9828				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Meili R, 1996, FEBS LETT, V394, P34, DOI 10.1016/0014-5793(96)00927-1; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	31	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37777	37782		10.1074/jbc.M206163200	http://dx.doi.org/10.1074/jbc.M206163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149268	hybrid			2022-12-25	WOS:000178447100111
J	Stano, NM; Levin, MK; Patel, SS				Stano, NM; Levin, MK; Patel, SS			The+2 NTP binding drives open complex formation in T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; KINETIC MECHANISM; PROMOTER; DNA; EQUILIBRIUM; RELEASE; HAIRPIN; ROLES	Transcription initiation as catalyzed by T7 RNA polymerase consists primarily of promoter binding, strand separation, nucleotide binding, and synthesis of the first phosphodiester bond. The promoter strand separation process occurs at a very fast rate, but promoter opening is incomplete in the absence of the initiating NTPs. In this paper, we investigate how initiating NTPs affect the kinetics and thermodynamics of open complex formation. Transient state kinetic studies show that the open complex, EDo, is formed via an intermediate EDc, and the conversion of EDc to EDo occurs with an unfavorable equilibrium constant. In the presence of the initiating NTP that base-pairs with the template at position +2, the process of open complex formation is nearly complete. Our studies reveal that the nucleotide that drives open complex formation needs to be a triphosphate and to be correctly base-paired with the template. These results indicate that the melted template DNA in the open complex is positioned to bind the +2 NTP. The addition of +1 NTP alone does not stabilize the open complex; nor is it required for +2 NTP binding. However, there appears to be cooperativity in initiating NTP binding in that the binding of +2 NTP facilitates + 1 NTP binding. The dissection of the initiation pathway provides insights into how open complex formation steps that are sensitive to the promoter sequence upstream from the initiation start site modulate the affinity of initiating NTPs and allow transcription initiation to be regulated by initiating NTP concentration.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2002, BIOCHEMISTRY-US, V41, P3586, DOI 10.1021/bi0158472; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; JOHNSON KA, 1992, ENZYMES; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Lozinski T, 2001, ACTA BIOCHIM POL, V48, P495; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; PATEL SS, 2002, KINETIC ANAL MACROMO; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; Steitz T A, 1997, Harvey Lect, V93, P75; STRAUME M, 1992, METHOD ENZYMOL, V210, P117; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Weston BF, 1997, J MOL BIOL, V272, P21, DOI 10.1006/jmbi.1997.1199; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000	34	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37292	37300		10.1074/jbc.M201600200	http://dx.doi.org/10.1074/jbc.M201600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151383	hybrid			2022-12-25	WOS:000178447100050
J	Wissing, F; Sanchez, CP; Rohrbach, P; Ricken, S; Lanzer, M				Wissing, F; Sanchez, CP; Rohrbach, P; Ricken, S; Lanzer, M			Illumination of the malaria parasite plasmodium falciparum alters intracellular pH - Implications for live cell imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACRIDINE-ORANGE FLUORESCENCE; GLUTATHIONE-PEROXIDASE GENE; DIGESTIVE VACUOLAR PH; INFECTED ERYTHROCYTES; FERRIPROTOPORPHYRIN IX; LIPID-PEROXIDATION; CHLOROQUINE; INHIBITION; MECHANISM; RESISTANT	Live cell fluorescence microscopy has been widely used to study physiological processes in the human malarial parasite Plasmodium falciparum, including pH homeostasis, Ca2+ signaling and protein targeting. However, the reproducibility of the data is often poor. Controversial statements exist regarding cytosolic and vacuolar baseline pH, as well as regarding the subcellular localization of some of the fluorochromes used. When trying to reproduce published baseline values, we observed an unexpected light sensitivity of P. falciparum, which manifests itself in the form of a strong cytoplasmic acidification. Even short exposure times with moderate to low light intensities caused the parasite cytosol to acidify. We show that this effect arises from the selective disruption of the parasite's acidic food vacuole, brought about by lipid peroxidation initiated by light-induced generation of hydroxyl radicals. Our data suggest that heme serves as a photosensitizer in this process. Our findings have major implications for the use of live cell microscopy in P. falciparum and add a cautionary note to previous studies where live cell fluorometry has been used to determine physiological parameters in P. falciparum.	Heidelberg Univ, Inst Hyg, Abt Parasitol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Lanzer, M (corresponding author), Heidelberg Univ, Inst Hyg, Abt Parasitol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	michael_lanzer@med.uni-heidelberg.de	Lanzer, Michael/E-9752-2013; Rohrbach, Petra/F-3201-2011	Lanzer, Michael/0000-0002-0220-6526; 				ATAMNA H, 1993, MOL BIOCHEM PARASIT, V61, P231, DOI 10.1016/0166-6851(93)90069-A; Becuwe P, 1996, MOL BIOCHEM PARASIT, V76, P125, DOI 10.1016/0166-6851(95)02552-9; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P311, DOI 10.1016/S0166-6851(01)00405-4; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P301, DOI 10.1016/S0166-6851(01)00403-0; Bray PG, 1999, PARASITOL TODAY, V15, P360, DOI 10.1016/S0169-4758(99)01500-8; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Clarebout G, 1998, BRIT J HAEMATOL, V103, P52; Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Dzekunov SM, 2002, MOL BIOCHEM PARASIT, V119, P307, DOI 10.1016/S0166-6851(01)00406-6; Edwards AM, 2001, J PHOTOCH PHOTOBIO B, V63, P126, DOI 10.1016/S1011-1344(01)00209-3; Famin O, 1999, BIOCHEM PHARMACOL, V58, P59, DOI 10.1016/S0006-2952(99)00059-3; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Ginsburg H, 2000, PARASITOL TODAY, V16, P40, DOI 10.1016/S0169-4758(99)01583-5; Hayashi M, 2000, J BIOL CHEM, V275, P34353, DOI 10.1074/jbc.M003323200; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Makrigiorgos GM, 1997, J BIOCHEM BIOPH METH, V35, P23, DOI 10.1016/S0165-022X(97)00020-1; MARTIN JP, 1990, METHOD ENZYMOL, V186, P635; Martiney James A., 1999, Novartis Foundation Symposium, V226, P265; Millot C, 1997, J HISTOCHEM CYTOCHEM, V45, P1255, DOI 10.1177/002215549704500909; Mylonas C, 1999, IN VIVO, V13, P295; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; PAILLOUS N, 1994, BIOCHIMIE, V76, P355, DOI 10.1016/0300-9084(94)90109-0; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; Pandey AV, 2001, BIOCHEM J, V355, P333, DOI 10.1042/0264-6021:3550333; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; van Meer G, 2000, TRENDS CELL BIOL, V10, P550, DOI 10.1016/S0962-8924(00)01851-1; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; Wunsch S, 1999, PARASITOL TODAY, V15, P198, DOI 10.1016/S0169-4758(99)01432-5; Wunsch S, 1997, Behring Inst Mitt, P44	42	47	53	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37747	37755		10.1074/jbc.M204845200	http://dx.doi.org/10.1074/jbc.M204845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140286	hybrid			2022-12-25	WOS:000178447100107
J	Zipper, LM; Mulcahy, RT				Zipper, LM; Mulcahy, RT			The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; NAPHTHOFLAVONE-INDUCED EXPRESSION; PROTEIN INTERACTION MOTIF; HUMAN NEUROBLASTOMA-CELLS; REGULATORY SUBUNIT GENE; HEME OXYGENASE-1 GENE; ACTIN-BINDING PROTEIN; SMALL MAF PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE	Transactivation of phase 11 detoxification enzymes and antioxidant proteins is mediated by the Cap'N' Collar transcription factor, Nrf2, which is sequestered in the cytoplasm by the actin-binding protein Keap1. Mutation of a conserved serine (S104A) within the Keap1 BTB/POZ domain disrupts Keap1 dimerization and eliminates the ability of Keap1 to sequester Nrf2 in the cytoplasm and repress Nrf2 transactivation. Disruption of endogenous Keap1 dimerization using BTB/POZ dominant negative proteins also inhibits the ability of Keap1 to retain Nrf2 in the cytoplasm. Exposure to an electrophilic agent that induces Nrf2 release and nuclear translocation disrupts formation of a Keap1 complex in vivo. Collectively, these data support the conclusion that Keap1 dimerization is required for Nrf2 sequestration and transcriptional repression. Furthermore, exposure to inducing agents disrupts the Keap1 dimerization function and results in Nrf2 release.	Univ Wisconsin, Dept Pharmacol, Ctr Comprehens Canc, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Zipper, LM (corresponding author), Univ Wisconsin, Dept Pharmacol, Ctr Comprehens Canc, 600 Highland Ave,CSC K4-549, Madison, WI 53792 USA.				NIEHS NIH HHS [ES09749] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009749] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Kensler T W, 2000, Drug Metabol Drug Interact, V17, P3; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lecuyer C, 2000, BIOL REPROD, V63, P1801, DOI 10.1095/biolreprod63.6.1801; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Li XM, 1999, CANCER RES, V59, P5275; McMahon M, 2001, CANCER RES, V61, P3299; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Myhrstad MCW, 2001, BBA-GENE STRUCT EXPR, V1517, P212, DOI 10.1016/S0167-4781(00)00276-1; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830	55	268	282	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36544	36552		10.1074/jbc.M206530200	http://dx.doi.org/10.1074/jbc.M206530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145307	hybrid			2022-12-25	WOS:000178275100097
J	Ma, K; Cabrero, A; Saha, PK; Kojima, H; Li, L; Chang, BHJ; Paul, A; Chan, L				Ma, K; Cabrero, A; Saha, PK; Kojima, H; Li, L; Chang, BHJ; Paul, A; Chan, L			Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; PROTEIN ACRP30; OBESITY; GENE; EXPRESSION; MUSCLE; LIVER; MOUSE	Previous reports showed that recombinant fragments of adiponectin (adipo) displayed pharmacological effects when injected into rodents, but the relevance of these observations to the physiological function of adipo is unclear. We generated Adipo(-/-) mice by gene targeting. Adipo(-/-) mice are fertile with normal body and fat pad weights. Plasma glucose and insulin levels of Adipo(-/-) and Adipo(+/+) mice are similar under fasting conditions and during an intraperitoneal glucose tolerance test (GTT). Insulin tolerance test (ITT) also produces similar plasma glucose and insulin levels in the two groups of mice. Hyperinsulinemic-euglycemic clamp analysis showed that Adipo(-/-) and Adipo(+/+) mice have similar glucose infusion rates to maintain a similar serum glucose. High-fat diet feeding for 7 months led to similar weight gain and similar GTT and ITT responses. We next measured beta-oxidation and found it to be significantly increased in muscle and liver of Adipo(-/-) mice. In conclusion, our study indicates that absence of adipo causes increased beta-oxidation but does not cause glucose intolerance or insulin resistance in mice.	Baylor Coll Med, Div Endocrinol & Metab, Dept Med, Sect Endocrinol & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saint Lukes Episcopal Hospital	Chan, L (corresponding author), Baylor Coll Med, Div Endocrinol & Metab, Dept Med, Sect Endocrinol & Metab, 1 Baylor Plaza, Houston, TX 77030 USA.				NHLBI NIH HHS [HL-16512, HL-51568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512, R01HL051568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fujita Y, 1998, DIABETOLOGIA, V41, P1459, DOI 10.1007/s001250051092; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SHARON N, 1997, GLYCOSCIENCES, P95; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu XX, 1997, J NUTR, V127, P1814, DOI 10.1093/jn/127.9.1814	21	250	261	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34658	34661		10.1074/jbc.C200362200	http://dx.doi.org/10.1074/jbc.C200362200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12151381	hybrid			2022-12-25	WOS:000178117000002
J	Kaminski, JM; Huber, MR; Summers, JB; Ward, MB				Kaminski, JM; Huber, MR; Summers, JB; Ward, MB			Design of a nonviral vector for site-selective, efficient integration into the human genome	FASEB JOURNAL			English	Article						gene therapy; transposon; recombination	IMMUNODEFICIENCY-VIRUS TYPE-1; DROSOPHILA ELEMENT MARINER; DIRECT GENE-TRANSFER; IN-VIVO; TRANSPOSABLE ELEMENT; HOMOLOGOUS RECOMBINATION; GERMLINE TRANSFORMATION; RETROVIRAL INTEGRASE; MAMMALIAN-CELLS; SLEEPING-BEAUTY	Gene therapy in eukaryotes has met many obstacles. Research into the design of suitable nonviral vectors has been slow. To our knowledge, no nonviral vector has been proposed that allows for the possibility of highly efficient, site-selective integration into the genome of mammalian cells. On the basis of prior studies investigating the components necessary for transposon, retrovirus-like retrotransposon, and retroviral integration, we propose a nonviral system that would potentially allow for site-selective, efficient integration into the mammalian genome. Transposons have been developed that can transform a variety of cell lines. For example, the Sleeping Beauty transposon (SB) can transform a wide range of vertebrate cells from fish to human, and it mediates stable integration and long-term transgene expression in mice. However, the efficiency of transposition varies significantly among cell lines, suggesting the possible involvement of host factors in SB transposition. Here, we propose the use of a chimeric transposase (i.e., transposase-host DNA binding domain) to bypass the potential requirement of a host DNA-directing factor (or factors) for efficient, site-selective integration. We also discuss another potential method of docking the transposon-based vector adjacent to the host DNA, utilizing repetitive sequences for homologous recombination to promote efficient site-selective integration, as well as other site-selective nonviral approaches.	Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA; Univ S Alabama Hosp, Dept Internal Med, Mobile, AL 36617 USA; Univ Chicago Hosp, Dept Radiol, Chicago, IL 60637 USA	Fox Chase Cancer Center; Mayo Clinic; University of South Alabama; University of Chicago; University of Illinois System	Kaminski, JM (corresponding author), Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	JM_Kaminski@fccc.edu	Kaminski, Joseph/AAB-6493-2020; Wilson, Matthew H/K-3193-2013	Kaminski, Joseph/0000-0002-7518-4962				Albuquerque-Silva J, 2001, NAT BIOTECHNOL, V19, P1011, DOI 10.1038/nbt1101-1011a; Boulikas T, 1997, ANTICANCER RES, V17, P1471; BUSHMAN F, 1995, SCIENCE, V267, P1443, DOI 10.1126/science.7878462; BUSHMAN FD, 1994, P NATL ACAD SCI USA, V91, P9233, DOI 10.1073/pnas.91.20.9233; Bushman FD, 1997, J VIROL, V71, P458, DOI 10.1128/JVI.71.1.458-464.1997; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CHESNOKOV IN, 1995, J BIOL CHEM, V270, P18539, DOI 10.1074/jbc.270.31.18539; Chiang YP, 1996, MOL CELL BIOCHEM, V155, P131; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Coates CJ, 1997, MOL GEN GENET, V253, P728, DOI 10.1007/s004380050377; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COX GS, 1998, BIOCHIM BIOPHYS ACTA, V1493, P302; CURIEL DT, 1994, ANN NY ACAD SCI, V716, P36, DOI 10.1111/j.1749-6632.1994.tb21702.x; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Diaz V, 1999, J BIOL CHEM, V274, P6634, DOI 10.1074/jbc.274.10.6634; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; FARHOOD H, 1994, ANN NY ACAD SCI, V716, P23, DOI 10.1111/j.1749-6632.1994.tb21701.x; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; FLINT SJ, 2000, PRINCIPLES VIROLOGY, P199; Goldhaber-Gordon I, 2002, J BIOL CHEM, V277, P7694, DOI 10.1074/jbc.M110341200; GOTTSCHALK S, 1994, GENE THER, V1, P185; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Holmes-Son M L, 2001, Adv Genet, V43, P33, DOI 10.1016/S0065-2660(01)43003-3; Holmes-Son ML, 2000, J VIROL, V74, P11548, DOI 10.1128/JVI.74.24.11548-11556.2000; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KAMINSKI JM, IN PRESS CANC TREAT; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Kang YK, 1999, J BIOL CHEM, V274, P36585, DOI 10.1074/jbc.274.51.36585; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; Kay MA, 1997, P NATL ACAD SCI USA, V94, P4686, DOI 10.1073/pnas.94.9.4686; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Koduri RK, 2001, GENE, V280, P87, DOI 10.1016/S0378-1119(01)00772-7; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee SE, 2000, ANTICANCER RES, V20, P417; Lestini BJ, 2002, J CONTROL RELEASE, V78, P235, DOI 10.1016/S0168-3659(01)00505-3; Li XG, 2001, CANCER GENE THER, V8, P555, DOI 10.1038/sj.cgt.7700337; LIDHOLM DA, 1993, GENETICS, V134, P859; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Lohe AR, 1996, GENETICS, V143, P365; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Moreira JN, 2001, BBA-BIOMEMBRANES, V1515, P167, DOI 10.1016/S0005-2736(01)00411-4; NABEL EG, 1994, HUM GENE THER, V5, P1089, DOI 10.1089/hum.1994.5.9-1089; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7; Raz E, 1998, CURR BIOL, V8, P82, DOI 10.1016/S0960-9822(98)70038-7; Rubin EJ, 1999, P NATL ACAD SCI USA, V96, P1645, DOI 10.1073/pnas.96.4.1645; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X; Schagen FHE, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e104; Schouten GJ, 1998, NUCLEIC ACIDS RES, V26, P3013, DOI 10.1093/nar/26.12.3013; Shaik MS, 2001, J CONTROL RELEASE, V76, P285, DOI 10.1016/S0168-3659(01)00450-3; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; SKALKA AM, 1993, GENE, V135, P175, DOI 10.1016/0378-1119(93)90063-9; Stevens SW, 1996, J VIROL, V70, P6459, DOI 10.1128/JVI.70.9.6459-6462.1996; STEVENS SW, 1994, P NATL ACAD SCI USA, V91, P5557, DOI 10.1073/pnas.91.12.5557; Strauss M, 1998, NAT MED, V4, P274, DOI 10.1038/nm0398-274; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; van der Steege G, 2001, NAT BIOTECHNOL, V19, P305, DOI 10.1038/86664; VEGA MA, 1991, HUM GENET, V87, P245; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WU GY, 1994, J BIOL CHEM, V269, P11542; Xu L, 2001, MOL MED, V7, P723, DOI 10.1007/BF03401962; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang L, 2001, NUCLEIC ACIDS RES, V29, P3566, DOI 10.1093/nar/29.17.3566; Zhang LN, 1998, NUCLEIC ACIDS RES, V26, P3687, DOI 10.1093/nar/26.16.3687	80	33	41	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1242	10.1096/fj.02-0127hyp	http://dx.doi.org/10.1096/fj.02-0127hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153992				2022-12-25	WOS:000177814000033
J	Chiu, CM; Tsay, YG; Chang, CJ; Lee, SC				Chiu, CM; Tsay, YG; Chang, CJ; Lee, SC			Nopp140 is a mediator of the protein kinase A signaling pathway that activates the acute phase response alpha(1)-acid glycoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; ALPHA-1-ACID GLYCOPROTEIN; C/EBP-BETA; TRANSCRIPTION FACTOR; SOMATOSTATIN GENE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOCORTICOID RECEPTOR; CAMP; PHOSPHORYLATION; EXPRESSION	The acute phase response (APR) in liver during inflammation is one of the well known examples for elucidating the signaling pathways that lead to the combinatorial regulation of gene expression. The APR is exemplified by alpha(1)-acid glycoprotein gene (agp) expression. A number of transcription factors, including CCAAT/enhancer-binding protein beta (C/EBPbeta), glucocorticoid receptor, cAMP-response element-binding protein (CREB), and Nopp140, are known to participate in its induction. The underlying mechanism of Nopp140 and other factors for regulating agp expression remains unclear. Here we demonstrate that protein kinase A (PKA)-dependent phosphorylation of Nopp140, together with C/EBPbeta, induces agp gene expression synergistically. The cooperative activation of the agp gene by Nopp140 and forskolin is sensitive to inhibition by PKI. Results from biochemical and functional characterizations of Nopp140 mutants defective in PKA phosphorylation sites suggest that PKA-dependent Nopp140 phosphorylation is important for its role in agp gene activation. Furthermore, maximal activation of the agp gene by PKA-phosphorylated Nopp140 depends on the presence of CREB and C/EBPbeta. The participation of CREB in the activation is, however, independent of its PKA-mediated phosphorylation. In summary, we demonstrate the existence of a novel Nopp140-mediated PKA signaling pathway that leads to the activation of agp, one of the major acute phase response genes.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan.		Chang, Ching-Jin/G-4511-2019; Tsay, Yeou-Guang/HGE-2076-2022	Chang, Ching-Jin/0000-0001-7129-8092				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1993, J BIOL CHEM, V268, P15681; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HK, 1999, MOL CELL BIOL, V19, P8536; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; FOURNIER T, 1995, J IMMUNOL, V155, P2123; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Higuchi T, 2002, MOL CELL BIOL, V22, P1, DOI 10.1128/MCB.22.1.1-11.2002; HOFFMANN J, 1989, BIOCHEM J, V263, P785, DOI 10.1042/bj2630785; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Isaac C, 2001, J CELL SCI, V114, P4253; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; Lee YM, 1996, MOL CELL BIOL, V16, P4257; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Liu XD, 2001, AM J PHYSIOL-RENAL, V281, pF649, DOI 10.1152/ajprenal.2001.281.4.F649; MEIER UT, 1992, CELL, V70, P127; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; PAI CY, 1995, J CELL SCI, V108, P1911; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; Welm AL, 2000, J BIOL CHEM, V275, P27406; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567	53	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39102	39111		10.1074/jbc.M205915200	http://dx.doi.org/10.1074/jbc.M205915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167624	hybrid			2022-12-25	WOS:000178662500008
J	Geisen, C; Moroy, T				Geisen, C; Moroy, T			The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE AMPLIFICATION; TRANSGENIC MICE; CDK2/CYCLIN E; HA-RAS; EXPRESSION; P27(KIP1); PHASE	We have previously shown that cyclin E can malignantly transform primary rat embryo fibroblasts in cooperation with constitutively active Ha-Ras. In addition, we demonstrated that high level cyclin E expression potentiates the development of methyl-nitroso-urea-induced T-cell lymphomas in mice. To further investigate the mechanism underlying cyclin E-mediated malignant transformation, we have performed a mutational analysis of cyclin E function. Here we show that cyclin E mutants defective to form an active kinase complex with Cdk2 are unable to drive cells from G, into S phase but can still malignantly transform rat embryo fibroblasts in cooperation with Ha-Ras. In addition, Cdk2 activation is not a prerequisite for the ability of cyclin E to rescue yeast triple cln mutations. We also find that the oncogenic properties of cyclin E did not entirely correspond with its ability to interact with the negative cell cycle regulator p27(Kip1) or the pocket protein p130. These findings suggest that the oncogenic activity of cyclin E does not exclusively rely on its ability as a positive regulator of G, progression. Rather, we propose that cyclin E harbors other functions, independent of Cdk2 activation and P27(Kip1) binding, that contribute significantly to its oncogenic activity.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Moroy, Tarik/D-9923-2011					AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Erlanson M, 1998, BLOOD, V92, P770; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Juan G, 2001, CANCER RES, V61, P1220; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	63	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39909	39918		10.1074/jbc.M205919200	http://dx.doi.org/10.1074/jbc.M205919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149264	hybrid			2022-12-25	WOS:000178662500108
J	Qian, SB; Ott, DE; Schubert, U; Bennink, JR; Yewdell, JW				Qian, SB; Ott, DE; Schubert, U; Bennink, JR; Yewdell, JW			Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-LIVED PROTEIN; A-FACTOR RECEPTOR; DEGRADATION SIGNAL; TAGGED UBIQUITIN; ANTIGEN; RECOGNITION; SUBUNIT; HIV-1; INTERNALIZATION; LOCALIZATION	The ubiquitin (Ub) fusion degradation pathway functions to degrade fusion proteins containing a nonremovable Ub moiety at their NH2 terminus (Johnson, E. S., Ma, P. C., Ota, I. M., and Varshavsky, A. (1995) J. Biol. Chem. 270, 17442-17456). Here we show that ubiquitin fusion degradation also targets proteins for proteasomal degradation when Ub is present in the middle of fusion proteins (X-Ub-Y), in a process that entails polyubiquitylation of Ub Lys(48). By contrast, fusion proteins bearing COOH-terminal Ub (X-Ub) are metabolically stable. Such fusion proteins, either newly biosynthesized or generated by Ub hydrolases, are reversibly conjugated to heterogeneous target proteins in a manner similar to wild-type Ub. Most importantly, the NH2-terminal fusion partner (X) can maintain its structure and function in the formed X-Ub conjugates as inferred from the fluorescence of green fluorescent protein-Ub conjugates and the incorporation of human immunodeficiency virus type 1 Gag-Ub into viral particles. These findings strongly suggest that 26S proteasomes exhibit spatial discrimination of Ub-conjugated proteins, sparing domains extended from the NH2 terminus of Ub from unfolding and degradation. The multifunctionality of X-Ub fusion proteins opens the possibility for a number of novel practical applications, including the imaging of Ub conjugate formation in living cells.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NCI, AIDS Vaccine Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, NIH, Rm 205,Bldg 4,4 Ctr Dr, Bethesda, MD 20892 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000658] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BEERS EP, 1993, J BIOL CHEM, V268, P21645; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SOKOLIK CW, 1992, J BIOL CHEM, V267, P1067; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	42	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38818	38826		10.1074/jbc.M205547200	http://dx.doi.org/10.1074/jbc.M205547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163494	hybrid			2022-12-25	WOS:000178529600103
J	Rolland, JF; Henquin, JC; Gilon, P				Rolland, JF; Henquin, JC; Gilon, P			G protein-independent activation of an inward Na+ current by muscarinic receptors in mouse pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; B-CELLS; ACETYLCHOLINE-RECEPTOR; CATION CHANNELS; CALCIUM INFLUX; GLUCOSE; CA2+; SECRETION; INCREASES; CARBACHOL	Depolarization of pancreatic beta-cells is critical for stimulation of insulin secretion by acetylcholine but remains unexplained. Using voltage-clamped beta-cells, we identified a small inward current produced by acetylcholine, which was suppressed by atropine or external Na+ omission, but was not mimicked by nicotine, and was insensitive to nicotinic antagonists, tetrodotoxin, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DiDS), thapsigargin pretreatment, and external Ca2+ and K+ removal. This suggests that muscarinic receptor stimulation activates voltage-insensitive Na+ channels distinct from store-operated channels. No outward Na+ current was produced by acetylcholine when the electrochemical Na+ gradient was reversed, indicating that the channels are inward rectifiers. No outward K+ current occurred either, and the reversal potential of the current activated by acetylcholine in the presence of Na+ and K+ was close to that expected for a Na+-selective membrane, suggesting that the channels opened by acetylcholine are specific for Na+. Overnight pretreatment with pertussis toxin or the addition of guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) or guanosine-5'-O-(2-thiodiphosphate) (GDP-beta-S) instead of GTP to the pipette solution did not alter this current, excluding involvement of G proteins. Injection of a current of a similar amplitude to that induced by acetylcholine elicited electrical activity in beta-cells perifused with a subthreshold glucose concentration. These results demonstrate that muscarinic receptor activation in pancreatic beta-cells triggers, by a G protein-independent mechanism, a selective Na+ current that explains the plasma membrane depolarization.	Univ Louvain, Fac Med, Unite Endocrinol & Metab, B-1200 Brussels, Belgium	Universite Catholique Louvain	Gilon, P (corresponding author), Univ Louvain, Fac Med, Unite Endocrinol & Metab, UCL 55-30,Av Hippocrate 55, B-1200 Brussels, Belgium.			Rolland, Jean-Francois/0000-0002-7420-8272				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; Best L, 2000, J MEMBRANE BIOL, V177, P169, DOI 10.1007/s002320001110; BROWN LD, 1993, BRAIN RES, V612, P200, DOI 10.1016/0006-8993(93)91661-B; BRUNICARDI FC, 1987, AM J SURG, V153, P34, DOI 10.1016/0002-9610(87)90198-X; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Eberhardson M, 2000, CELL SIGNAL, V12, P781, DOI 10.1016/S0898-6568(00)00122-4; GAGERMAN E, 1980, J PHYSIOL-LONDON, V300, P505, DOI 10.1113/jphysiol.1980.sp013175; Gilon P, 1997, J PHYSIOL-LONDON, V499, P65, DOI 10.1113/jphysiol.1997.sp021911; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; GILON P, 1995, BIOCHEM J, V311, P259, DOI 10.1042/bj3110259; GILON P, 1993, FEBS LETT, V315, P353, DOI 10.1016/0014-5793(93)81193-4; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HENQUIN JC, 1982, J PHYSIOL-LONDON, V332, P529, DOI 10.1113/jphysiol.1982.sp014429; HENQUIN JC, 1980, BIOCHEM J, V186, P541, DOI 10.1042/bj1860541; HERMANS MP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P205, DOI 10.1016/0167-4889(91)90158-T; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; IACONO G, 1989, AM J PHYSIOL, V256, pH1407, DOI 10.1152/ajpheart.1989.256.5.H1407; INOUE M, 1995, EUR J PHARMACOL, V276, P123, DOI 10.1016/0014-2999(95)00029-K; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MATSUMOTO K, 1989, J PHYSIOL-LONDON, V415, P487, DOI 10.1113/jphysiol.1989.sp017733; MEISSNER HP, 1990, METHOD ENZYMOL, V192, P235; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; NENQUIN M, 1984, FEBS LETT, V176, P457, DOI 10.1016/0014-5793(84)81218-1; OLESEN SP, 1988, CIRC RES, V62, P1059, DOI 10.1161/01.RES.62.6.1059; PLANT TD, 1988, PFLUG ARCH EUR J PHY, V411, P429, DOI 10.1007/BF00587723; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Rolland JF, 2002, DIABETES, V51, P376, DOI 10.2337/diabetes.51.2.376; SAHA S, 1991, EUR J PHARMACOL, V204, P211, DOI 10.1016/0014-2999(91)90707-W; Satin LS, 1998, ENDOCRINE, V8, P213, DOI 10.1385/ENDO:8:3:213; SEHLIN J, 1974, J PHYSIOL-LONDON, V242, P505, DOI 10.1113/jphysiol.1974.sp010720; Sehlin J, 1978, AM J PHYSIOL, V235, P501; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; SHIRAYAMA T, 1993, J PHARMACOL EXP THER, V265, P641; TEPEL M, 1994, BBA-MOL CELL RES, V1220, P248, DOI 10.1016/0167-4889(94)90145-7; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; WORLEY JF, 1994, J BIOL CHEM, V269, P32055	49	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38373	38380		10.1074/jbc.M203888200	http://dx.doi.org/10.1074/jbc.M203888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161432	hybrid			2022-12-25	WOS:000178529600050
J	Ruas, JL; Poellinger, L; Pereira, T				Ruas, JL; Poellinger, L; Pereira, T			Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation - identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR PROTEIN; ESTROGEN-RECEPTOR-ALPHA; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; LIVING CELLS; HIF-ALPHA; DOMAINS; RECRUITMENT	The hypoxia-inducible factor-1alpha (HIF-1alpha) is a key regulator of adaptive responses to hypoxia. HIF-1alpha has two independent transactivation domains (TADs). Whereas the N-terminal TAD (N-TAD) also constitutes a degradation box, the C-terminal TAD (C-TAD) functions in a strictly hypoxia-inducible fashion. Oxygen-dependent hydroxylation of an asparagine residue has recently been reported to regulate C-TAD function by disrupting the interaction with the CH1 domain of the p300/CBP coactivator at normoxia. Here we have performed alanine-scanning mutagenesis of a predicted alpha-helix within the C-TAD of mouse HIF-1alpha to identify residues important for transactivation and interaction of the C-TAD with transcriptional coactivators. We observed that several hydrophobic residues, Ile(802), Leu(808), Leu(814), Leu(815), and Leu(818), were critical for transactivation and binding to the CH1 domain of CBP in hypoxic cells. Moreover, E812A/E813A and D819A mutations impaired hypoxia-dependent transactivation without disrupting binding to CH1. In the context of full-length HIF-1alpha, mutation of the leucine residues conferred conformational changes to the protein and significantly reduced the transactivation function as well as functional interaction with the transcriptional coactivators CBP and SRC-1. These mutations also affected intranuclear redistribution of HIF-1alpha in the presence of CBP, indicating that the integrity of the C-TAD is critical for intracellular localization of mouse HIF-1alpha.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.		Pereira, Teresa/AAP-8197-2020; Ruas, Jorge/AAE-6094-2019	Pereira, Teresa/0000-0001-8654-2385; Ruas, Jorge/0000-0002-1110-2606				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845	47	93	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38723	38730		10.1074/jbc.M205051200	http://dx.doi.org/10.1074/jbc.M205051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12133832	hybrid			2022-12-25	WOS:000178529600091
J	Tam, EM; Wu, YI; Butler, GS; Stack, MS; Overall, CM				Tam, EM; Wu, YI; Butler, GS; Stack, MS; Overall, CM			Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain - The ectodomain of the 44-kDa autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; GELATINASE-A ACTIVATION; TISSUE INHIBITOR; FIBROBLAST COLLAGENASE; SUBSTRATE-SPECIFICITY; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; 1-MATRIX METALLOPROTEINASE; 72-KDA GELATINASE; COMPLEX-FORMATION	Up-regulation of the collagenolytic membrane type-1 matrix metalloproteinase (MT1-AMP) leads to increased MMP2 (gelatinase A) activation and MT1-MMP autolysis. The autocatalytic degradation product is a cell surface 44-kDa fragment of MT1-MMP (Gky(285)-Val(582)) in which the ectodomain consists of only the linker, hemopexin C domain and the stalk segment found before the transmembrane sequence. In the collagenases, hemopexin C domain exosites bind native collagen, which is required for triple helicase activity during collagen cleavage. Here we investigated the collagen binding properties and the role of the hemopexin C domain of MT1-MMP and of the 44-kDa MT1-MMP ectodomain in collagenolysis. Recombinant proteins, MT1-LCD (Gly(285)-Cys(508)), consisting of the linker and the hemopexin C domain, and MT1-CD (Gly(315)-Cys(508)), which consists of the hemopexin C domain only, were found to bind native type I collagen but not gelatin. Functionally, MT1-LCD inhibited collagen-induced MMP2 activation in fibroblasts, suggesting that interactions between collagen and endogenous MT1-MMP directly stimulate the cellular activation of pro-MMP2. MT1-LCD, but not MT1-CD, also blocked the cleavage of native type I collagen by MT1-MMP in vitro, indicating an important role for the MT1-MMP linker region in triple helicase activity. Similarly, soluble MT1-LCD, but not MT1-CD or peptide analogs of the MT1-AMP linker, reduced the invasion of type I collagen matrices by NDA-MB-231 cells as did the expression of recombinant 44-kDa MT1-MMP on the cell surface. Together, these studies demonstrate that generation of the 44-kDa MT1-MMP autolysis product regulates collagenolytic activity and subsequent invasive potential, suggesting a novel feedback mechanism for the control of pericellular proteolysis.	Univ British Columbia, Dept Biochem & Mol Biol, CIHR Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, CIHR Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of British Columbia; University of British Columbia; Northwestern University	Overall, CM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, CIHR Grp Matrix Dynam, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALLAN JA, 1991, J CELL SCI, V99, P789; Aznavoorian S, 2001, CANCER RES, V61, P6264; AZZAM HS, 1992, CANCER RES, V52, P4540; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bigg HF, 2001, CANCER RES, V61, P3610; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DESOUZA SJ, 1992, J BIOL CHEM, V267, P13763; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fishman DA, 2001, CANCER RES, V61, P3194; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1998, CANCER RES, V58, P5529; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Knauper V, 2001, EUR J BIOCHEM, V268, P1888, DOI 10.1046/j.1432-1033.2001.02062.x; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Mancini S, 1999, J PERIODONTOL, V70, P1292, DOI 10.1902/jop.1999.70.11.1292; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; OVERALL CM, 1988, BIOL MECH TOOTH ERUP, P303; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ruangpanit N, 2001, MATRIX BIOL, V20, P193, DOI 10.1016/S0945-053X(01)00135-4; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Sodek J, 1992, Matrix Suppl, V1, P352; Stanton H, 1998, J CELL SCI, V111, P2789; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	81	119	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39005	39014		10.1074/jbc.M206874200	http://dx.doi.org/10.1074/jbc.M206874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145314	hybrid			2022-12-25	WOS:000178529600125
J	Ueda, T; Mawji, NR; Bruchovsky, N; Sadar, MD				Ueda, T; Mawji, NR; Bruchovsky, N; Sadar, MD			Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; N-TERMINAL DOMAIN; GROWTH-FACTOR-I; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; KINASE; BINDING; INDUCTION; PHOSPHORYLATION	The androgen receptor (AR) can be activated in the absence of androgens by interleukin-6 (IL-6) in human prostate cancer cells. The events involved in ligand-independent activation of the AR are unknown, but have been suggested to involve phosphorylation of the AR itself or a receptor-associated protein. Steroid receptor coactivator-1 (SRC-1) has been shown to interact with the human AR and to modulate ligand-dependent AR transactivation and is regulated by phosphorylation by MAPK. To date, no one has examined the role of SRC-1 in ligand-independent activation of the AR by IL-6 or other signaling pathways known to activate the full-length receptor. This study addressed this and has revealed the following. 1) SRC-1 similarly enhanced ligand-independent activation of the AR by IL-6 to the same magnitude as that obtained via ligand-dependent activation. 2) Androgen and IL-6 stimulated the MAPK pathway. 3) MAPK was required for both ligand-dependent and ligand-independent activation of the AR. 4) Phosphorylation of SRC-1 by MAPK was required for optimal ligand-independent activation of the AR by IL-6. 5) Protein-protein interaction between endogenous AR and SRC-1 was dependent upon treatment of LNCaP cells with IL-6 or R1881. 6) Protein-protein interaction between the AR N-terminal domain and SRC-1 was independent of MAPK. 7) Ligand-independent activation of the AR did not occur by a mechanism of overexpression of either solely wild-type SRC-1 or mutant SRC-1 that mimics its phosphorylated form.	British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Dept Canc Endocrinol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	msadar@bccancer.bc.ca	Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK47656] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BORSELLINO N, 1995, CANCER RES, V55, P4633; Borsellino N, 1999, CANCER, V85, P134, DOI 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Chen TS, 2000, CANCER RES, V60, P2132; Chung TDK, 1999, PROSTATE, V38, P199; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; CULIG Z, 1994, CANCER RES, V54, P5474; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gioeli D, 1999, CANCER RES, V59, P279; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; HAQ M, 1992, CANCER RES, V52, P4613; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; Hoosein N, 1995, Urol Oncol, V1, P246, DOI 10.1016/1078-1439(96)00012-9; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Ma H, 1999, MOL CELL BIOL, V19, P6164; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; ONATE SA, 1995, SCIENCE, V270, P1354; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadar MD, 1996, J BIOL CHEM, V271, P17635, DOI 10.1074/jbc.271.30.17635; SIEGSMUND MJ, 1994, CANCER RES, V50, P7786; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; WILSON EM, 1976, J BIOL CHEM, V251, P5620; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	54	232	251	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38087	38094		10.1074/jbc.M203313200	http://dx.doi.org/10.1074/jbc.M203313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163482	hybrid			2022-12-25	WOS:000178529600016
J	White, AK; Metcalf, WW				White, AK; Metcalf, WW			Isolation and biochemical characterization of hypophosphite/2-oxoglutarate dioxygenase - A novel phosphorus-oxidizing enzyme from Pseudomonas Stutzeri WM88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROLYL 4-HYDROXYLASE ACTIVITY; ISOPENICILLIN-N SYNTHASE; ESCHERICHIA-COLI; KETOGLUTARATE DIOXYGENASE; DEPENDENT DIOXYGENASE; PROLINE 4-HYDROXYLASE; ENDOGENOUS LIGANDS; HISTIDINE-RESIDUES; CATALYTIC ACTIVITY	The htxA gene is required for the oxidation of hypophosphite in Pseudomonas stutzeri WM88 (Metcalf, W. W., and Wolfe, R. S. (1998) J. Bacteriol. 180, 5547-5558). Amino acid sequence comparisons suggest that hypophosphite:2-oxoglutarate dioxygenase (HtxA) is a novel member of the 2-oxoglutarate-dependent dioxygenase enzyme family. To provide experimental support for this hypothesis, HtxA was overproduced in Escherichia coli and purified to apparent homogeneity. Recombinant HtxA is identical to the native enzyme based on amino terminus sequencing and mass spectral analysis, and it catalyzes the oxidation of hypophosphite to phosphite in a process strictly dependent on 2-oxoglutarate, ferrous ions, and oxygen. Succinate and phosphite are stoichiometrically produced, indicating a strict coupling of the reaction. Size exclusion analysis suggests that HtxA is active as a homodimer, and maximal activity is observed at pH 7.0 and at 27 degreesC. The apparent K-m values for hypophosphite and 2-oxoglutarate were 0.58 +/- 0.04 mm and 10.6 +/- 1.4 muM, respectively. V-max and k(cat) values were determined to be 10.9 +/- 0.30 mumol min(-1) mg(-1) and 355 min(-1), respectively. 2-Oxoadipate and pyruvate substitute poorly for 2-oxoglutarate as a cosubstrate. The highest specific activity is observed with hypophosphite as substrate, but HtxA is also able to oxidize formate and arsenite at significant rates. The substrate analog inhibitors, formate and nitrate, significantly reduce HtxA activity.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Metcalf, WW (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.				NCRR NIH HHS [RR 11966] Funding Source: Medline; NIGMS NIH HHS [GM59334] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059334] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS F, 1953, SOIL SCI, V75, P361, DOI 10.1097/00010694-195305000-00004; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLANCHARD JS, 1983, BIOCHEMISTRY-US, V22, P5922, DOI 10.1021/bi00294a036; Borovok I, 1996, BIOCHEMISTRY-US, V35, P1981, DOI 10.1021/bi951534t; CASIDA LE, 1960, J BACTERIOL, V80, P237, DOI 10.1128/JB.80.2.237-241.1960; Costas AMG, 2001, J BIOL CHEM, V276, P17429, DOI 10.1074/jbc.M011764200; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; DEJONG L, 1982, BIOCHIM BIOPHYS ACTA, V704, P326, DOI 10.1016/0167-4838(82)90162-5; DEVAI I, 1988, NATURE, V333, P343, DOI 10.1038/333343a0; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FOSTER TL, 1978, APPL ENVIRON MICROB, V35, P937, DOI 10.1128/AEM.35.5.937-944.1978; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; FUKUMORI F, 1993, J BACTERIOL, V175, P2083, DOI 10.1128/JB.175.7.2083-2086.1993; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HEINEN W, 1974, ARCH MICROBIOL, V95, P267, DOI 10.1007/BF02451767; Hogan DA, 1999, J BACTERIOL, V181, P5876, DOI 10.1128/JB.181.18.5876-5879.1999; Hogan DA, 2000, J BIOL CHEM, V275, P12400, DOI 10.1074/jbc.275.17.12400; HOPPER S, 1994, J BIOL CHEM, V269, P19597; Imazu K, 1998, APPL ENVIRON MICROB, V64, P3754; Kahnert A, 2000, J BIOL CHEM, V275, P31661, DOI 10.1074/jbc.M005820200; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; Khaleeli N, 2000, BIOCHEMISTRY-US, V39, P8666, DOI 10.1021/bi000534c; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Larsen RA, 2002, ARCH MICROBIOL, V178, P193, DOI 10.1007/s00203-002-0442-2; LAUWERS AM, 1977, ARCH MICROBIOL, V112, P103, DOI 10.1007/BF00446661; Lawrence CC, 1996, BIOCHEM J, V313, P185, DOI 10.1042/bj3130185; Lukacin R, 1997, EUR J BIOCHEM, V249, P748, DOI 10.1111/j.1432-1033.1997.t01-2-00748.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MALACINS.GM, 1967, J BACTERIOL, V93, P1906, DOI 10.1128/JB.93.6.1906-1910.1967; MALACINSKI G, 1966, J BACTERIOL, V91, P578, DOI 10.1128/JB.91.2.578-582.1966; METCALF WW, 1991, J BACTERIOL, V173, P587, DOI 10.1128/jb.173.2.587-600.1991; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Metcalf WW, 1998, J BACTERIOL, V180, P5547, DOI 10.1128/JB.180.21.5547-5558.1998; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; NIETFELD JJ, 1981, BIOCHIM BIOPHYS ACTA, V657, P159, DOI 10.1016/0005-2744(81)90139-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Shibasaki T, 1999, APPL ENVIRON MICROB, V65, P4028; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUBOTA G., 1959, Soil and Plant Food, V5, P10; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vrtis JM, 2001, J AM CHEM SOC, V123, P2672, DOI 10.1021/ja004301k; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3	55	23	24	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38262	38271		10.1074/jbc.M204605200	http://dx.doi.org/10.1074/jbc.M204605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161433	hybrid			2022-12-25	WOS:000178529600037
J	Javelaud, D; Besancon, F				Javelaud, D; Besancon, F			Inactivation of p21(WAF1) sensitizes cells to apoptosis via an increase of both p14(ARF) and p53 levels and an alteration of the Bax/Bcl-2 ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN CANCER-CELLS; INHIBITORY ACTIVITY; THERAPEUTIC AGENTS; TUMOR SUPPRESSION; CARCINOMA CELLS; GROWTH ARREST; P21; DIFFERENTIATION; SURVIVAL	p21(WAF1) appears to be a major determinant of the cell fate in response to anticancer therapy. It was shown previously that HCT116 human colon cancer cells growing in vitro enter a stable arrest upon DNA damage, whereas cells with a defective p21(WAF1) response undergo apoptosis. Here we report that the enhanced sensitivity of HCT116/p21(-/-) cells to chemotherapeutic drug-induced apoptosis correlates with an increased expression of p53 and a modification of their Bax/Bcl-2 ratio in favor of the pro-apoptotic protein Bax. Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis. Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-a reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(-/-) cells. Enhancement of p53 expression after disruption of p21(WAF1) resulted from a stabilization of p53, which correlated with an increased expression of the tumor suppressor p14(ARF), an inhibitor of the ubiquitin ligase activity of Mdm2. In accordance with the role of p14ARF in p53 stabilization, overexpression of p14(ARF) in HCT116/p21(+/+) cells resulted in a strong increase in p53 activity. Our results identify a novel mechanism for the antiapoptotic effect of p21(WAF1) consisting in maintenance of mitochondrial homeostasis that occurs in consequence of a negative control of p14(ARF) expression.	Inst Curie, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grad JM, 2001, DRUG RESIST UPDATE, V4, P85, DOI 10.1054/drup.2001.0192; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARPER JW, 1993, CELL, V75, P805; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SIONOV RV, 2001, MOL CELL BIOL, V274, P8371; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tian H, 2000, CANCER RES, V60, P679; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walczak H, 2000, CANCER RES, V60, P3051; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XD, 2001, GENE DEV, V15, P2922; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	48	107	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37949	37954		10.1074/jbc.M204497200	http://dx.doi.org/10.1074/jbc.M204497200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151395	hybrid			2022-12-25	WOS:000178447100132
J	Norwitz, ER; Xu, SY; Xu, J; Spiryda, LB; Park, JS; Jeong, KH; McGee, EA; Kaiser, UB				Norwitz, ER; Xu, SY; Xu, J; Spiryda, LB; Park, JS; Jeong, KH; McGee, EA; Kaiser, UB			Direct binding of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR-BETA; RAT PITUITARY; TRANSGENIC MICE; EXPRESSION; PROMOTER; FOLLISTATIN; INHIBIN; CELLS; ALPHA	The response of pituitary gonadotropes to gonadotropin-releasing hormone (GnRH) correlates directly with the concentration of GnRH receptors (GnRHR) on the cell surface, which is mediated in part at the level of gene expression. Several factors are known to affect expression of the mouse GnRHR (mGnRHR) gene, including GnRH and activin. We have previously shown that activin augments GnRH-mediated transcriptional activation of mGnRHR gene, and that region -387/-308 appears to be necessary to mediate this effect. This region contains two overlapping cis-regulatory elements of interest: GnRHR activating sequence (GRAS) and a putative SALAD-binding element (SBE). This study investigates the role of these elements and their cognate transcription factors in transactivation of the mGnRHR gene. Transfection studies confirm the presence of GnRH- and activin-response elements within -387/-308 of mGnRHR gene promoter. Competition electrophoretic mobility shift assay experiments using -335/-312 as probe and alphaT3-1 nuclear extract or SMAD, Jun, and Fos proteins demonstrate direct binding of AP-1 (Fos/Jun) protein complexes to -327/-322 and SALAD proteins to -329/-328. Further transfection studies using mutant constructs of these cis-regulatory elements confirm that both are functionally important. These data define a novel cis-regulatory element comprised of an overlapping SBE and newly characterized non-consensus AP-1 binding sequence that integrates the stimulatory transcriptional effects of both GnRH and activin on the mGnRHR gene.	Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Div Maternal Fetal Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Med, Boston, MA 02115 USA; Magee Womens Res Inst, Dept Obstet & Gynecol, Pittsburgh, PA 15213 USA; Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Seoul National University (SNU)	Norwitz, ER (corresponding author), Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Div Maternal Fetal Med, 75 Francis St, Boston, MA 02115 USA.		Park, Joong Shin/D-5741-2012	Park, Joong Shin/0000-0002-5246-0477	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD019938, R37HD019938] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001255] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD19938, K12-HD00840, K12-HD01255] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albarracin CT, 1999, ENDOCRINOLOGY, V140, P2415, DOI 10.1210/en.140.5.2415; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ATTARDI B, 1995, MOL ENDOCRINOL, V9, P1737, DOI 10.1210/me.9.12.1737; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Blumenfeld Z, 2001, ANN NY ACAD SCI, V943, P34, DOI 10.1111/j.1749-6632.2001.tb03788.x; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CORRIGAN AZ, 1991, ENDOCRINOLOGY, V128, P1682, DOI 10.1210/endo-128-3-1682; DEPAOLO LV, 1992, ENDOCRINOLOGY, V130, P1741, DOI 10.1210/en.130.3.1741; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Drouin J, 1998, MOL CELL ENDOCRINOL, V140, P31, DOI 10.1016/S0303-7207(98)00026-4; Duval DL, 1999, ENDOCRINOLOGY, V140, P1949, DOI 10.1210/en.140.4.1949; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; ESCUDERO KW, 2002, 84 ANN M END SOC END, pR1; FernandezVazquez G, 1996, MOL ENDOCRINOL, V10, P356, DOI 10.1210/me.10.4.356; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Halvorson LM, 1996, FERTIL STERIL, V65, P459; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JAIN J, 1992, J IMMUNOL, V148, P1240; KAISER UB, 1992, ENDOCRINOLOGY, V130, P3048, DOI 10.1210/en.130.5.3048; KAISER UB, 1993, ENDOCRINOLOGY, V133, P931, DOI 10.1210/en.133.2.931; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KATT JA, 1985, ENDOCRINOLOGY, V116, P2113, DOI 10.1210/endo-116-5-2113; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARIAN J, 1981, MOL PHARMACOL, V19, P399; McCue JM, 1997, ENDOCRINOLOGY, V138, P3154, DOI 10.1210/en.138.8.3154; Mercer JE, 1995, HUM REPROD UPDATE, V1, P363, DOI 10.1093/humupd/1.4.363; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; Norwitz ER, 2002, ENDOCRINOLOGY, V143, P985, DOI 10.1210/en.143.3.985; Norwitz ER, 1999, J BIOL CHEM, V274, P867, DOI 10.1074/jbc.274.2.867; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STOJILKOVIC SS, 1995, RECENT PROG HORM RES, V50, P161; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Xu J, 2002, BIOL REPROD, V66, P1571, DOI 10.1095/biolreprod66.6.1571; YASIN M, 1995, ENDOCRINOLOGY, V136, P1559, DOI 10.1210/en.136.4.1559; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHOU W, 1994, DNA CELL BIOL, V13, P605, DOI 10.1089/dna.1994.13.605	55	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37469	37478		10.1074/jbc.M206571200	http://dx.doi.org/10.1074/jbc.M206571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145309	hybrid			2022-12-25	WOS:000178447100072
J	Watson, JD; Oster, SK; Shago, M; Khosravi, F; Penn, LZ				Watson, JD; Oster, SK; Shago, M; Khosravi, F; Penn, LZ			Identifying genes regulated in a Myc-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; RIBOSOME BIOGENESIS; MYC/MAX/MAD NETWORK; ESSENTIAL COFACTOR; BETA-RECEPTOR; CELL-CYCLE; E-BOX; EXPRESSION; TARGET; TRANSCRIPTION	The c-myc proto-oncogene can direct a diverse array of biological activities, including cell cycle progression, apoptosis, and differentiation. It is believed that Myc can affect this wide variety of activities by functioning as a regulator of gene transcription, although few targets have been identified to date. To delineate the molecular program regulated downstream of Myc, we used a cDNA microarray approach and identified 52 putative targets out of >6000 cDNAs analyzed. To further distinguish the subset of genes whose regulation was dependent upon Myc per se from those regulated in response to activation of general mitogenic or apoptotic programs, the putative cDNA targets were then screened by a series of assays. By this approach 37 putative targets were ruled out and 15 Myc target genes were uncovered. Interestingly, comparing our results with other high throughput screens reveals that certain putative Myc targets previously reported are shown not to be regulated downstream of Myc (e.g. ribosomal proteins, HSP90beta), whereas others are further supported by our analyses (e.g. pdgfbetar, nucleolin). The identity of genes specifically regulated downstream of Myc provides the critical tools required to understand the role Myc holds in the transformation process and to delineate how Myc functions as a regulator of gene transcription.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Penn, Linda/0000-0001-8133-5459				BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Guo QM, 2000, CANCER RES, V60, P5922; Izumi H, 2001, J CELL SCI, V114, P1533; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kim S, 2001, ANAL BIOCHEM, V288, P141, DOI 10.1006/abio.2000.4900; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	41	101	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36921	36930		10.1074/jbc.M201493200	http://dx.doi.org/10.1074/jbc.M201493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145275	Green Published, hybrid			2022-12-25	WOS:000178447100004
J	Zhang, D; Li, F; Weidner, D; Mnjoyan, ZH; Fujise, K				Zhang, D; Li, F; Weidner, D; Mnjoyan, ZH; Fujise, K			Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin - The potential role of MCL1 as a fortilin chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBER; HAMSTER OVARY CELLS; SIGNALING PATHWAY; INDUCED APOPTOSIS; RNA INTERFERENCE; KINASE PATHWAY; CYCLIN PCNA; EXPRESSION; SURVIVAL; DIFFERENTIATION	Myeloid cell leukemia 1 protein (MCL1) is an anti-apoptotic protein that is structurally related to Bcl-2. Unlike other Bcl-2 family proteins that are constitutively expressed, MCL1 is inducibly expressed in cells that are recently exposed to growth and differentiation stimuli. Here, we report the identification of fortilin as a novel MCL1-interacting protein by screening of a yeast two-hybrid library with MCL1 as bait. Fortilin specifically interacted with MCL1 both in vitro and in vivo. The intracellular localization of fortilin was predominantly nuclear and identical to that of MCL1, as shown by immunostaining and confocal microscopy analysis. Fortilin, like MCL1, was rapidly inducible in serum-stimulated human aortic vascular smooth muscle cells. Although the depletion of intracellular fortilin by small interfering RNA (siRNA) against fortilin (siRNA-fortilin) did not affect intracellular MCL1 level, the depletion of intracellular MCL1 by siRNA-MCL1 was associated with the significant reduction of the fortilin protein level, without affecting the fortilin transcript numbers. In addition, a pulse-chase experiment showed that the depletion of MCL1 by siRNA-MCL1 was associated with the rapid degradation of fortilin protein, which was found quite stable in the presence of MCL1. Furthermore, the half-life of fortilinl(R21A), a point mutant of fortilin lacking the binding to MCL1, was significantly shorter than that of wild-type fortilin as shown by a pulse-chase experiment. These data suggest that MCL1, in addition to being an anti-apoptotic molecule, serves as a chaperone of fortilin, binding and stabilizing fortilin in vivo. Taken together with our previous observation that fortilin overexpression prevents cells from undergoing apoptosis (Li, F., Zhang, D., and Fujise, K. (2001) J. Biol. Chem. 276, 47542-47549), it is likely that MCL1, an anti-apoptotic protein inducible by growth and differentiation stimuli, stabilizes another anti-apoptotic protein fortilin maximizing the prosurvival environment in cells.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of North Carolina; East Carolina University	Fujise, K (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, 6431 Fannin St,Suite 1-246, Houston, TX 77030 USA.			Weidner, Douglas/0000-0003-1397-1757	NHLBI NIH HHS [HL04015, HL68024] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068024] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Klampfer L, 1999, CYTOKINE, V11, P849, DOI 10.1006/cyto.1999.0514; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Leo CP, 1999, ENDOCRINOLOGY, V140, P5469, DOI 10.1210/en.140.12.5469; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Lomo J, 1996, CANCER RES, V56, P40; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANFORD KK, 1948, J NATL CANCER I, V9, P229; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	32	119	134	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37430	37438		10.1074/jbc.M207413200	http://dx.doi.org/10.1074/jbc.M207413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149273	hybrid			2022-12-25	WOS:000178447100067
J	Bodding, M; Wissenbach, U; Flockerzi, V				Bodding, M; Wissenbach, U; Flockerzi, V			The recombinant human TRPV6 channel functions as Ca2+ sensor in human embryonic kidney and rat basophilic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; STORE DEPLETION; MOLECULAR-CLONING; CAT-LIKE; I-CRAC; MODULATION; JURKAT; ENTRY	The activation mechanism of the recently cloned human transient receptor potential vanilloid type 6 (TRPV6) channel, originally termed C2+ transporter-like protein and Ca2+ transporter type 1, was investigated in whole-cell patch-clamp experiments using transiently transfected human embryonic kidney and rat basophilic leukemia cells. The TRPV6-mediated currents are highly Ca2+-selective, show a strong inward rectification, and reverse at positive potentials, which is similar to store-operated Ca2+ entry in electrically non-excitable cells. The gating of TRPV6 channels is strongly dependent on the cytosolic free Ca2+ concentration; lowering the intracellular free Ca2+ concentration results in Ca2+ influx, and current amplitude correlates with the intracellular EGTA or BAPTA concentration. This is also the case for TRPV6-mediated currents in the absence of extracellular divalent cations; compared with endogenous currents in nontransfected rat basophilic leukemia cells, these TRPV6-mediated monovalent currents reveal differences in reversal potential, inward rectification, and slope at very negative potentials. Release of stored Ca2+ by inositol 1,4,5-trisphosphate and/or the sarco/endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin appears not to be involved in TRPV6 channel gating in both cell lines but, in rat basophilic leukemia cells, readily activates the endogenous Ca2+ release-activated Ca2+ current. In conclusion, TRPV6, expressed in human embryonic kidney cells and in rat basophilic leukemia cells, functions as a Ca2+- sensing Ca2+ channel independently of procedures known to deplete Ca2+ stores.	Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.	matthias.boedding@uniklinik-saarland.de						Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	31	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36656	36664		10.1074/jbc.M202822200	http://dx.doi.org/10.1074/jbc.M202822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138163	hybrid			2022-12-25	WOS:000178275100111
J	Chen, AJ; Zhou, GS; Juan, T; Colicos, SM; Cannon, JP; Cabriera-Hansen, M; Meyer, CF; Jurecic, R; Copeland, NG; Gilbert, DJ; Jenkins, NA; Fletcher, F; Tan, TH; Belmont, JW				Chen, AJ; Zhou, GS; Juan, T; Colicos, SM; Cannon, JP; Cabriera-Hansen, M; Meyer, CF; Jurecic, R; Copeland, NG; Gilbert, DJ; Jenkins, NA; Fletcher, F; Tan, TH; Belmont, JW			The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PROTEIN-TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; MITOGEN; MAP; JNK; PHOSPHORYLATION; RAF-1; CELLS; APOPTOSIS	The involvement of dual specificity phosphatases (DSPs) in the mitogen-activated protein kinase (MAPK) signaling has been mostly limited to the inactivation of MAPKs by the direct dephosphorylation of the TXY motif within their activation loop. We report the cloning and characterization of a murine DSP, called JNK pathway-associated phosphatase (JKAP), which lacks the regulatory region present in most other MAP kinase phosphatases (MKPs) and is preferentially expressed in murine Lin(-)Sca-1(+) stem cells. Overexpression of JKAP in human embryonic kidney 293T cells specifically activated c-Jun N-terminal kinase (JNK) but not p38 and extracellular signal-regulated kinase 2. Overexpression of a mutant JKAP, JKAP-C88S, blocked tumor necrosis factor-a-induced JNK activation. Targeted gene disruption in murine embryonic stem cells abolished JNK activation by tumor necrosis factor-a and transforming growth factor-beta, but not by ultraviolet-C irradiation, indicating that JKAP is necessary for optimal JNK activation. JKAP associated with JNK and MKK7, but not SEK1, in vivo. However, JKAP did not interact with JNK in vitro, suggesting that JKAP exerts its effect on JNK in an indirect manner. Taken together, these studies identify a positive regulator for the JNK pathway and suggest a novel role for DSP in mitogen-activated protein kinase regulation.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Amgen Inc, Dept Expt Hematol, Newbury Pk, CA 91320 USA; NCI, Frederick Canc Res & Dev Ctr, Mammalian Genet Lab, ABL Basic Res Program, Ft Detrick, MD 21702 USA	Baylor College of Medicine; Baylor College of Medicine; Amgen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Belmont, JW (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Belmont, John W/0000-0001-7409-3578; Tan, Tse-Hua/0000-0003-4969-3170	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA087076] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008307] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA87076] Funding Source: Medline; NHGRI NIH HHS [T32 HG00003] Funding Source: Medline; NIAID NIH HHS [R01 AI42532] Funding Source: Medline; NICHD NIH HHS [HD36280] Funding Source: Medline; NIDDK NIH HHS [R01 DK48647] Funding Source: Medline; NIGMS NIH HHS [T32 GM08307] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Batard P, 2000, J CELL SCI, V113, P383; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dorfman K, 1996, ONCOGENE, V13, P925; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	51	78	81	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36592	36601		10.1074/jbc.M200453200	http://dx.doi.org/10.1074/jbc.M200453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138158	hybrid			2022-12-25	WOS:000178275100103
J	Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P				Benihoud, K; Bonardelle, D; Soual-Hoebeke, E; Durand-Gasselin, I; Emilie, D; Kiger, N; Bobe, P			Unusual expression of LINE-1 transposable element in the MRL autoimmune lymphoproliferative syndrome-prone strain	ONCOGENE			English	Article						LINE-1; retrotransposon; endogenous retroviruses; Fas; autoimmunity	MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IA ANTIGENS; L1 ELEMENT; CELL; INSERTION; RNA; SEQUENCE; MICE; TRANSCRIPTION	LINE-1 are endogenous mobile genetic elements that have dispersed and accumulated in the genomes of eukaryotes via germline transposition, with up to 100 000 copies in mammalian genomes. LINE- I elements transpose by reverse transcription of their own transcript. Transposition requires synthesis of a full-length, sense-strand transcripts and proteins encoded by open reading frame (ORF) 1 and ORF2. Although severely repressed in most normal tissues, LINE-I occasionally leads to disease by insertional mutagenesis. In the present study, Northern blot and in situ hybridization analyses revealed a template-strand transcription of LINE-I ORF2 (encoding reverse transcriptase, RT) in lymphoid organs and the liver from MRL-+/+ and Fas-deficient MRL/lpr strains and their normal ancestors. While these Sense transcripts are restricted to the nucleus in hepatocytes, they are also found in the cytoplasm in splenocytes. In contrast to transcription, ORF2 translation was detected only in MRL strains, as shown by the cytoplasmic labelling of splenic cells obtained with a monoclonal antibody recognizing the LINE-1 RT. This antibody coprecipitated two proteins of 45 and 12 kDa from MRL/lpr lymphoid organ lysates that were removed by pretreatment with anti-beta2-microglobulin antiserum, suggesting a structural association between a LINE-I product and a major histocompatibility complex class I or class I-like molecule.	CNRS, UPR 9045, Inst Andre Lwoff, F-94801 Villejuif, France; INSERM, U 267, F-94807 Villejuif, France; INSERM, U 131, F-92140 Clamart, France; Univ Paris 11, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bobe, P (corresponding author), CNRS, UPR 9045, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94801 Villejuif, France.	bobe@infobiogen.fr	, BENIHOUD/O-4334-2019	Bobe, Pierre/0000-0002-8835-6786				BEHARKA AA, 1995, P NATL ACAD SCI USA, V92, P6294, DOI 10.1073/pnas.92.14.6294; BOBE P, 1987, IMMUNOGENETICS, V25, P251, DOI 10.1007/BF00404695; BOBE P, 1993, J IMMUNOL, V151, P2813; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; CHVATCHKO Y, 1983, FEBS LETT, V163, P207, DOI 10.1016/0014-5793(83)80820-5; DELARBRE C, 1988, J IMMUNOGENET, V15, P307; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUDLEY JP, 1987, NUCLEIC ACIDS RES, V15, P2581, DOI 10.1093/nar/15.6.2581; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; Herrmann Martin, 1998, Current Opinion in Rheumatology, V10, P347; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; JACKSON M, 1985, NUCLEIC ACIDS RES, V13, P3389, DOI 10.1093/nar/13.9.3389; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Kono D H, 2000, Int Rev Immunol, V19, P367, DOI 10.3109/08830180009055504; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nakagawa K, 1996, IMMUNOL REV, V152, P193, DOI 10.1111/j.1600-065X.1996.tb00917.x; NATORI T, 1974, TRANSPLANTATION, V18, P550, DOI 10.1097/00007890-197412000-00015; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PADGETT RW, 1988, NUCLEIC ACIDS RES, V16, P739, DOI 10.1093/nar/16.2.739; PEUCHMAUR M, 1990, AM J PATHOL, V136, P383; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; SCHICHMAN SA, 1992, J MOL BIOL, V224, P559, DOI 10.1016/0022-2836(92)90544-T; SEVERYNSE DM, 1992, MAMM GENOME, V2, P41, DOI 10.1007/BF00570439; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEBER T, 1987, GENE, V53, P105, DOI 10.1016/0378-1119(87)90097-7; Wilson IA, 1998, CURR OPIN IMMUNOL, V10, P67, DOI 10.1016/S0952-7915(98)80034-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	46	19	22	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5593	5600		10.1038/sj.onc.1205730	http://dx.doi.org/10.1038/sj.onc.1205730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165858				2022-12-25	WOS:000177442000009
J	Cantarella, G; Lempereur, L; Presta, M; Ribatti, D; Lombardo, G; Lazarovici, P; Zappala, G; Pafumi, C; Bernardini, R				Cantarella, G; Lempereur, L; Presta, M; Ribatti, D; Lombardo, G; Lazarovici, P; Zappala, G; Pafumi, C; Bernardini, R			Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo	FASEB JOURNAL			English	Article						growth factors; endothelium; trkA(NGFR); proliferation; blood vessels	EMBRYO CHORIOALLANTOIC MEMBRANE; FACTOR-LIKE PROTEIN; FACTOR RECEPTOR; PC12 CELLS; HUMAN PROSTATE; EXPRESSION; AFFINITY; TRK; ADENOCARCINOMA; PROLIFERATION	Nerve growth factor (NGF) has important functions during embryonic development and on various tissues and organs under normal and pathological conditions during the extrauterine life. RT-PCR analysis and immunological methods demonstrate that human umbilical vein endothelial cells (HUVECs) express the NGF receptors trkA(NGFR) and p75(NTR). NGF treatment caused a rapid phosphorylation of trkA(NGFR) in HUVECs, determining a parallel increase of phosphorylated ERK1/2. Accordingly, NGF induced a significant increase in HUVEC proliferation that was abolished by the trkA(NGFR) inhibitor K252a. Also, HUVECs express significant levels of NGF under standard culture conditions that were up-regulated during serum starvation. Endogenous NGF was responsible for the basal levels of trkA(NGFR) and ERK1/2 phosphorylation observed in untreated HUVEC cultures. Finally, NGF exerted a potent, direct, angiogenic activity in vivo when delivered onto the chorioallantoic membrane of the chicken embryo. The data indicate that NGF may play an important role in blood vessel formation in the nervous system and in several pathological processes, including tumors and inflammatory diseases. Unraveling mechanisms of NGF-dependent angiogenesis could provide valuable tools for novel therapeutic approaches in antiangiogenic therapy.	Univ Catania, Sch Med, Dept Expt & Clin Pharmacol, I-95125 Catania, Italy; Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Brescia, Italy; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel	University of Catania; Universita degli Studi di Bari Aldo Moro; University of Brescia; Hebrew University of Jerusalem	Bernardini, R (corresponding author), Univ Catania, Sch Med, Dept Expt & Clin Pharmacol, Cittadella Univ,Ed 12,3P,Viale Andrea Doria, I-95125 Catania, Italy.	bernardi@unict.it	Presta, Marco/B-4345-2010; Bernardini, Renato/AAF-6680-2021; Cantarella, Giuseppina/AHD-9609-2022	bernardini, renato/0000-0002-4765-0663; PRESTA, Marco/0000-0002-4398-8376; pafumi, carlo/0000-0001-9253-4592				Aloe L, 1999, MICROSC RES TECHNIQ, V45, P285, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<285::AID-JEMT12>3.0.CO;2-3; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Boss V, 2001, J NEUROSCI, V21, P18, DOI 10.1523/JNEUROSCI.21-01-00018.2001; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Chiarenza A, 2001, CANCER RES, V61, P3002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DJAKIEW D, 1991, CANCER RES, V51, P3304; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; GRAHAM CW, 1992, J UROLOGY, V147, P1444, DOI 10.1016/S0022-5347(17)37590-0; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang H, 1997, J CELL BIOCHEM, V66, P229, DOI 10.1002/(SICI)1097-4644(19970801)66:2<229::AID-JCB10>3.0.CO;2-C; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; PFLUG BR, 1992, CANCER RES, V52, P5403; Pincelli C, 2000, EUR J DERMATOL, V10, P85; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 2001, INT J MOL MED, V8, P265; Sortino MA, 2000, MOL ENDOCRINOL, V14, P124, DOI 10.1210/me.14.1.124; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Yano H, 2000, Pharm Acta Helv, V74, P253, DOI 10.1016/S0031-6865(99)00036-9	33	194	205	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1307	+		10.1096/fj.01-1000fje	http://dx.doi.org/10.1096/fj.01-1000fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154004				2022-12-25	WOS:000176683900020
J	Guillebault, D; Sasorith, S; Derelle, E; Wurtz, JM; Lozano, JC; Bingham, S; Tora, L; Moreau, H				Guillebault, D; Sasorith, S; Derelle, E; Wurtz, JM; Lozano, JC; Bingham, S; Tora, L; Moreau, H			A new class of transcription initiation factors, intermediate between TATA box-binding proteins (TBPs) and TBP-like factors (TLFs), is present in the marine unicellular organism, the dinoflagellate Crypthecodinium cohnii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; UBIQUITOUS PROMOTER ELEMENT; CRYSTAL-STRUCTURE; EUKARYOTIC TRANSCRIPTION; SEQUENCE ALIGNMENT; GENE; CHROMATIN; DNA; ORGANIZATION; DICTYOSTELIUM	Dinoflagellates are marine unicellular eukaryotes that exhibit unique features including a very low level of basic proteins bound to the chromatin and the complete absence of histones and nucleosomal structure. A cDNA encoding a protein with a strong homology to the TATA box-binding proteins (TBP) has been isolated from an expressed sequence tag library of the dinoflagellate Crypthecodinium cohnii. The typical TBP repeat signature and the amino acid motives involved in TFHA and TFHB interactions were conserved in this new TBP-like protein. However, the four phenylalanines known to interact with the TATA box were substituted with hydrophilic residues (His(77), Arg(94), Tyr(171), Thr(188)) as has been described for TBP-like factors (TLF)/TBP-related proteins (TRP). A phylogenetic analysis showed that cTBP is intermediate between TBP and TLF/TRP protein families, and the structural similarity of cTBP with TLF was confirmed by low affinity binding to a consensus' TATA box in an equivalent manner to that usually observed for TLFs. Six 5'-upstream gene regions of dinoflagellate genes have been analyzed and neither a TATA box nor a consensus-promoting element could be found within these different sequences. Our results showed that cTBP could bind stronger to a TTTT box sequence than to the canonical TATA box, especially at high salt concentration. Same binding results were obtained with a mutated cTBP (mcTBP), in which the four phenylalanines were restored. To our knowledge, this is the first description of a TBP-like protein in a unicellular organism, which also appears as the major form of TBP present in C. cohnii.	Univ Paris 06, CNRS, UMR 7628, Observ Oceanol,Lab Arago, F-66651 Banyuls sur Mer, France; CU Strasbourg, CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Arizona State University; Arizona State University-Tempe	Moreau, H (corresponding author), Univ Paris 06, CNRS, UMR 7628, Observ Oceanol,Lab Arago, BP 44, F-66651 Banyuls sur Mer, France.	h.moreau@arago.obs-banyuls.fr	Tora, Laszlo/E-9999-2018; Wurtz, Jean-Marie/P-4652-2016; Guillebault, Delphine/A-4541-2011	Tora, Laszlo/0000-0001-7398-2250; Wurtz, Jean-Marie/0000-0003-2963-8617; Guillebault, Delphine/0000-0002-1847-4138; Derelle, Evelyne/0000-0002-1499-4240				Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Ausseil J, 1999, PROTIST, V150, P197, DOI 10.1016/S1434-4610(99)70022-2; Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berk AJ, 2000, CELL, V103, P5, DOI 10.1016/S0092-8674(00)00098-2; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bhaud Y, 2000, J CELL SCI, V113, P1231; Bhaud Y, 1999, J EUKARYOT MICROBIOL, V46, P259, DOI 10.1111/j.1550-7408.1999.tb05123.x; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Buratowski S, 2000, CURR OPIN CELL BIOL, V12, P320, DOI 10.1016/S0955-0674(00)00095-8; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; Cox JM, 1998, CURR OPIN CHEM BIOL, V2, P11, DOI 10.1016/S1367-5931(98)80030-6; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Guillebault D, 2001, PROTIST, V152, P127, DOI 10.1078/1434-4610-00051; HERZOG M, 1982, EUR J CELL BIOL, V27, P151; HERZOG M, 1981, EUR J CELL BIOL, V23, P295; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; HUANG WB, 1995, J BIOL CHEM, V270, P28839, DOI 10.1074/jbc.270.48.28839; Johnson KM, 2001, CURR BIOL, V11, pR510, DOI 10.1016/S0960-9822(01)00306-2; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; Klug A, 2001, SCIENCE, V292, P1844, DOI 10.1126/science.1062384; Le QH, 1997, MOL GEN GENET, V255, P595, DOI 10.1007/s004380050533; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Li LM, 1998, PLANT MOL BIOL, V36, P275, DOI 10.1023/A:1005941421474; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Luo H, 1999, J BIOL CHEM, V274, P31947, DOI 10.1074/jbc.274.45.31947; McAdams HH, 2000, CURR BIOL, V10, pR318, DOI 10.1016/S0960-9822(00)00440-1; MCANDREW MB, 1993, GENE, V124, P165, DOI 10.1016/0378-1119(93)90390-O; Moore PA, 1999, MOL CELL BIOL, V19, P7610; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Plewniak F, 2000, BIOINFORMATICS, V16, P750, DOI 10.1093/bioinformatics/16.9.750; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; QUON DVK, 1994, P NATL ACAD SCI USA, V91, P4579, DOI 10.1073/pnas.91.10.4579; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; RAIKOV IB, 1995, ACTA PROTOZOOL, V34, P239; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; RIZZO PJ, 1991, J PROTOZOOL, V38, P246, DOI 10.1111/j.1550-7408.1991.tb04437.x; RIZZO PJ, 1979, J PROTOZOOL, V26, P290, DOI 10.1111/j.1550-7408.1979.tb02783.x; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIGEE DC, 1983, BIOSYSTEMS, V16, P203, DOI 10.1016/0303-2647(83)90004-7; SOYERGOBILLARD MO, 2000, ENCY MICROBIOLOGY, P42; Spector D.L., 1984, P1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uhlmann F, 2001, CURR BIOL, V11, pR384, DOI 10.1016/S0960-9822(01)00214-7; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	65	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40881	40886		10.1074/jbc.M205624200	http://dx.doi.org/10.1074/jbc.M205624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154093	hybrid			2022-12-25	WOS:000178791400093
J	Bontron, S; Lin-Marq, N; Strubin, M				Bontron, S; Lin-Marq, N; Strubin, M			Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; GLOBAL GENOMIC REPAIR; NF-KAPPA-B; DAMAGED-DNA; HBX PROTEIN; GENE-PRODUCT; HEPATOCELLULAR CARCINOMAS; VIRAL REPLICATION; EXCISION-REPAIR; MAMMALIAN-CELLS	The hepatitis B virus X protein (HBx) is essential for viral infection and strongly interferes with cell growth and viability in culture. These activities involve interaction of HBx with the DDB1 subunit of UV-damaged DNA-binding factor UV-DDB. UV-DDB consists of DDB1 and a DDB2 subunit that mediates nuclear import and has recognized functions in DNA repair and E2F1-mediated transcription. Here we show that HBx retains DDB1-binding-dependent cytotoxic activities when engineered to accumulate in the nucleus but not when excluded from the nucleus. Nuclear localization of HBx does not require binding to DDB1 and remains unaffected by ectopically expressed UV-DDB subunits, indicating that HBx reaches the nuclear compartment independently of UV-DDB. Unexpectedly, HBx appears to largely exist in association with DDB1 and is in direct competition with DDB2 for binding to DDB1. Hence, HBx-mediated cell death can be relieved by increased levels of DDB2, an effect that is not observed with a naturally occurring mutant of DDB2 that lacks DDB1-binding activity. These findings indicate that HBx acts through a pathway that involves a DDB2-independent nuclear function of DDB1 and that this activity will depend on the relative concentration of DDB1 and DDB2 in cells.	Ctr Med Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Geneva	Strubin, M (corresponding author), Ctr Med Univ Geneva, Dept Genet & Microbiol, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	Michel.Strubin@medecine.unige.ch						ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; CHANG H, 1988, Taiwan yixuehui zazhi, V87, P948; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jacob JR, 1997, HEPATOLOGY, V26, P1607; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim HT, 2001, BIOCHEM BIOPH RES CO, V286, P886, DOI 10.1006/bbrc.2001.5496; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin-Marq N, 2001, VIROLOGY, V287, P266, DOI 10.1006/viro.2001.1036; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1997, J CELL SCI, V110, P1159; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Weil R, 1999, MOL CELL BIOL, V19, P6345; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	57	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38847	38854		10.1074/jbc.M205722200	http://dx.doi.org/10.1074/jbc.M205722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151405	hybrid			2022-12-25	WOS:000178529600106
J	Gaidarova, S; Jimenez, SA				Gaidarova, S; Jimenez, SA			Inhibition of basal and transforming growth factor-beta-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-SCLEROSIS FIBROBLASTS; ALPHA-1(I) PROCOLLAGEN GENE; ALPHA-2(I) COLLAGEN GENE; MESSENGER-RNA LEVELS; PRO-ALPHA-1(I) COLLAGEN; SCLERODERMA FIBROBLASTS; IN-VITRO; EXTRACELLULAR-MATRIX; FUNCTIONAL-ANALYSIS; PROMOTER ACTIVITY	The Sp1 transcription factor plays a crucial role in COL1A1 transcriptional regulation under normal and pathologic conditions and under the effects of transforming growth factor-beta (TGF-beta). Sp1 activity is elevated in numerous diseases characterized by tissue fibrosis. Therefore, inhibition of Sp1 binding to COL1A1 regulatory elements may represent an effective treatment for these diseases. Here we examined the effect of two DNA intercalators that prevent Sp1 binding on the expression of COL1A1 in human dermal fibroblasts. Cultured human adult dermal fibroblasts were treated with WP631 (50 pM/ml to 500 nM/ml) or mitoxantrone (5-500 nM/ml). Cytotoxicity, cellular apoptosis, and collagen deposition were examined by fluorescence microscopy. Collagen production was examined by enzyme-linked immunosorbent assay and metabolic labeling, COL1A1 steady-state mRNA levels, and stability were assessed by Northern hybridizations, and COL1A1 transcription by in vitro nuclear transcription assays and transient transfections. Competition of the drugs for Sp1 binding and their effect on TGF-beta-induced stimulation of COL1A1 transcription was also examined. Both drugs caused a dose-related inhibition of COL1A1 production and mRNA levels without cytotoxicity or apoptosis. COL1A1 transcriptional activity showed a profound reduction mediated by a short proximal promoter region containing an Sp1-binding element at -87 to -82 bp. Furthermore, both drugs inhibited Sp1 DNA complex formation and abrogated the stimulation of COL1A1 transcription induced by TGF-beta. WP631 showed 10-fold higher potency than mitoxantrone. These data indicate that mitoxantrone and WP631 are very potent inhibitors of basal and TGF-beta-stimulated COL1A1 expression and suggest that Sp1-DNA intercalators may be an effective and novel approach for the treatment of fibrotic diseases and modulation of profibrogenic effects of TGF-beta.	Thomas Jefferson Univ, Div Rheumatol, Dept Med, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Div Rheumatol, Dept Med, Rm 509 BLSB,233 S 10th St, Philadelphia, PA 19107 USA.	Sergio.Jimenez@mail.tju.edu		Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19616] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; BASHEY RI, 1977, BIOCHEM BIOPH RES CO, V76, P1214, DOI 10.1016/0006-291X(77)90985-8; BELLON G, 1985, ANAL BIOCHEM, V150, P188, DOI 10.1016/0003-2697(85)90459-2; BOAST S, 1990, J BIOL CHEM, V265, P13351; Bornstein P, 1996, MATRIX BIOL, V15, P3, DOI 10.1016/S0945-053X(96)90121-3; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaires JB, 1997, J MED CHEM, V40, P261, DOI 10.1021/jm9607414; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1985, J BIOL CHEM, V260, P2315; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; DIAZ A, 1993, J BIOL CHEM, V268, P10364; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gottesfeld JM, 2000, GENE EXPRESSION, V9, P77; Green DR, 2000, METHOD ENZYMOL, V322, P15; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; KAHARI VM, 1987, FEBS LETT, V215, P331, DOI 10.1016/0014-5793(87)80172-2; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Leng FF, 1998, BIOCHEMISTRY-US, V37, P1743, DOI 10.1021/bi9720742; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liska Deann J., 1992, Gene Expression, V2, P379; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Mitsuyama K, 2001, DIGESTION, V63, P68, DOI 10.1159/000051914; Morgan D M, 1998, Methods Mol Biol, V79, P179; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Norman JT, 1999, EXP NEPHROL, V7, P167; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Poppleton HM, 1997, BIOCHEM J, V323, P225, DOI 10.1042/bj3230225; Portugal J, 2001, CURR MED CHEM, V8, P1; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Robinson H, 1997, BIOCHEMISTRY-US, V36, P8663, DOI 10.1021/bi970842j; Rosenbloom J, 2000, ARTHRITIS RHEUM-US, V43, P1624, DOI 10.1002/1529-0131(200007)43:7<1624::AID-ANR28>3.3.CO;2-5; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Zewail-Foote M, 1999, ANTI-CANCER DRUG DES, V14, P1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	61	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38737	38745		10.1074/jbc.M201742200	http://dx.doi.org/10.1074/jbc.M201742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138160	hybrid			2022-12-25	WOS:000178529600093
J	Herbig, K; Chiang, EP; Lee, LR; Hills, J; Shane, B; Stover, PJ				Herbig, K; Chiang, EP; Lee, LR; Hills, J; Shane, B; Stover, PJ			Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE COMBINED DEGENERATION; METHYL-GROUP DEFICIENCY; ONE-CARBON METABOLISM; METHIONINE SYNTHETASE; CEREBROSPINAL-FLUID; GLYCINE; CELLS; REMETHYLATION; EXPRESSION; CATABOLISM	Folate-dependent one-carbon metabolism is required for the synthesis of purines and thymidylate and for the remethylation of homocysteine to methionine. Methionine is subsequently adenylated to S-adenosylmethionine (SAM), a cofactor that methylates DNA, RNA, proteins, and many metabolites. Previous experimental and theoretical modeling studies have indicated that folate cofactors are limiting for cytoplasmic folate-dependent reactions and that the synthesis of DNA precursors competes with SAM synthesis. Each of these studies concluded that SAM synthesis has a higher metabolic priority than dTMP synthesis. The influence of cytoplasmic serine hydroxymethyltransferase (cSHMT) on this competition was examined in MCF-7 cells. Increases in cSHMT expression inhibit SAM concentrations by two proposed mechanisms: (1) cSHMT-catalyzed serine synthesis competes with the enzyme methylenetetrahydrofolate reductase for methylenetetrahydrofolate in a glycine-dependent manner, and (2) cSHMT, a high affinity 5-methyltetrahydrofolate-binding protein, sequesters this cofactor and inhibits methionine synthesis in a glycine-independent manner. Stable isotope tracer studies indicate that cSHMT plays an important role in mediating the flux of one-carbon units between dTMP and SAM syntheses. We conclude that cSHMT has three important functions in the cytoplasm: (1) it preferentially supplies one-carbon units for thymidylate biosynthesis, (2) it depletes methylenctetrahydrofolate pools for SAM synthesis by synthesizing serine, and (3) it sequesters 5-methyltetrahydrofolate and inhibits SAM synthesis. These results indicate that cSHMT is a metabolic switch that, when activated, gives dTMP synthesis higher metabolic priority than SAM synthesis.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	Cornell University; University of California System; University of California Berkeley	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.		Chiang, EnPei/K-1694-2013	Chiang, EnPei/0000-0002-0158-0962	NIDDK NIH HHS [DK42033, DK58144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042033, R01DK058144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; BAUMGARTNER ER, 1985, PEDIATR RES, V19, P1288, DOI 10.1203/00006450-198512000-00017; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; DUDLEY MA, 1992, J NUTR, V122, P528, DOI 10.1093/jn/122.3.528; FELL D, 1990, BIOCHIM BIOPHYS ACTA, V1033, P80, DOI 10.1016/0304-4165(90)90197-5; Fowler B, 1997, PEDIATR RES, V41, P145, DOI 10.1203/00006450-199701000-00023; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; LICHTENSTEIN AH, 1990, J LIPID RES, V31, P1693; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Nakshatri H, 1996, GENE, V174, P79, DOI 10.1016/0378-1119(96)00391-5; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; PENAFIEL R, 1990, BIOCHEM INT, V22, P649; PETZKE KJ, 1986, J NUTR, V116, P742, DOI 10.1093/jn/116.5.742; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; REEDS PJ, 1992, J NUTR, V122, P457; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCOTT JM, 1981, LANCET, V2, P334; SCOTT JM, 1981, LANCET, V2, P337; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Shane B., 1995, FOLATE HLTH DIS, V2, P1; STOVER P, 1991, J BIOL CHEM, V266, P1543; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; STRONG WB, 1990, J BIOL CHEM, V265, P12149; Struys EA, 2000, CLIN CHEM, V46, P1650; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Van Hove JLK, 1998, J INHERIT METAB DIS, V21, P799, DOI 10.1023/A:1005462400552; Wagner PJ, 1995, WOMEN HEALTH, V23, P1; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559	36	195	206	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38381	38389		10.1074/jbc.M205000200	http://dx.doi.org/10.1074/jbc.M205000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161434	hybrid			2022-12-25	WOS:000178529600051
J	Lye, LF; Cunningham, ML; Beverley, SM				Lye, LF; Cunningham, ML; Beverley, SM			Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PARASITE LEISHMANIA; PROTOZOAN PARASITE; METHOTREXATE RESISTANCE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; PHENYLALANINE-HYDROXYLASE; PTERIDINE REDUCTASE-1; GENE REPLACEMENT; FERRIC REDUCTASE	Biopterin is required for growth of the protozoan parasite Leishmania and is salvaged from the host through the activities of a novel biopterin transporter (BT1) and broad-spectrum pteridine reductase (PTR1). Here we characterize Leishmania major quinonoid-dihydropteridine reductase (LmQDPR), the key enzyme required for regeneration and maintenance of H(4)biopterin pools. LmQDPR shows good homology to metazoan quinonoid-dihydropteridine reductase and conservation of domains implicated in catalysis and regulation. Unlike other organisms, LmQDPR is encoded by a tandemly repeated array of 8-9 copies containing LmQDPR plus two other genes. QDPR mRNA and enzymatic activity were expressed at similar levels throughout the infectious cycle. The pH optima, kinetic properties, and substrate specificity of purified LmQDPR were found to be similar to that of other qDPRs, although it lacked significant activity for non-quinonoid pteridines. These and other data suggest that LmQDPR is unlikely to encode the dihydrobiopterin reductase activity (PTR2) described previously. Similarly LmQDPR is not inhibited by a series of antifolates showing anti-leishmanial activity beyond that attributable to dihydrofolate reductase or PTR1 inhibition. qDPR activity was found in crude lysates of Trypanosoma brucei and Trypanosoma cruzi, further emphasizing the importance of H(4)biopterin throughout this family of human parasites.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI29646, AI21903] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021903, R37AI021903, R01AI029646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akopyants NS, 2001, MOL BIOCHEM PARASIT, V113, P337, DOI 10.1016/S0166-6851(01)00227-4; Basu NK, 1997, FEMS MICROBIOL LETT, V156, P43, DOI 10.1016/S0378-1097(97)00401-1; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; Blau N, 1996, J INHERIT METAB DIS, V19, P8, DOI 10.1007/BF01799342; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Chang CF, 1999, ADV EXP MED BIOL, V463, P403; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COLIGAN JE, 1997, CURRENT PROTOCOLS PR, V1; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; Dianzani I, 1998, HUM MUTAT, V12, P267, DOI 10.1002/(SICI)1098-1004(1998)12:4<267::AID-HUMU8>3.3.CO;2-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRGAIRA FA, 1981, BIOCHEM J, V197, P31, DOI 10.1042/bj1970031; Golderer G, 2001, GENE DEV, V15, P1299, DOI 10.1101/gad.890501; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HARDY LW, 1997, EXP PARASITOL, V87, P158; HAUER CR, 1993, J BIOL CHEM, V268, P4828; HIRAYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V612, P337, DOI 10.1016/0005-2744(80)90116-3; Homuth M, 1998, INFECT IMMUN, V66, P710, DOI 10.1128/IAI.66.2.710-716.1998; Huang L, 2001, J BIOL CHEM, V276, P28327, DOI 10.1074/jbc.M008342200; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; IWAI K, 1976, BIOCHIM BIOPHYS ACTA, V444, P618, DOI 10.1016/0304-4165(76)90406-2; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; Kaufman S., 1997, TETRAHYDROBIOPTERIN; KERLER F, 1990, EXP CELL RES, V189, P151, DOI 10.1016/0014-4827(90)90229-4; Kiefer PM, 1997, BIOCHEMISTRY-US, V36, P9438, DOI 10.1021/bi970585i; Kiefer PM, 1996, J BIOL CHEM, V271, P3437; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Lee PL, 2000, BIOCHEM BIOPH RES CO, V271, P788, DOI 10.1006/bbrc.2000.2708; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; MYLER PJ, 1994, MOL BIOCHEM PARASIT, V66, P11, DOI 10.1016/0166-6851(94)90031-0; Nagatsu T, 1999, MOL NEUROBIOL, V19, P79, DOI 10.1007/BF02741379; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; Nare B, 1997, PARASITOLOGY, V114, pS101, DOI 10.1017/S0031182097001133; Ouellette M, 1996, TROP MED INT HEALTH, V1, pA33; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; Park D, 2000, BBA-GENE STRUCT EXPR, V1492, P247, DOI 10.1016/S0167-4781(00)00084-1; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; PETRILLOPEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SAMBROOK J, 1989, MOL CLONING, V1, P7; SCOTT DA, 1987, MOL BIOCHEM PARASIT, V23, P139, DOI 10.1016/0166-6851(87)90149-6; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SMOOKER PM, 1993, BIOCHEMISTRY-US, V32, P6443, DOI 10.1021/bi00076a018; SMOOKER PM, 1995, HUM MUTAT, V5, P279, DOI 10.1002/humu.1380050402; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU Y, 1993, J BIOL CHEM, V268, P26836; Timmerman MM, 1999, INFECT IMMUN, V67, P6403; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TRAGER W, 1969, J PROTOZOOL, V16, P372, DOI 10.1111/j.1550-7408.1969.tb02284.x; VARUGHESE KI, 1994, P NATL ACAD SCI USA, V91, P5582, DOI 10.1073/pnas.91.12.5582; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; VASUDEVAN SG, 1988, BIOCHEM J, V255, P581; Wang YX, 1998, MOL BIOCHEM PARASIT, V96, P139, DOI 10.1016/S0166-6851(98)00121-2; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2000, BIOCHEM J, V348, P579, DOI 10.1042/0264-6021:3480579; WHITELEY JM, 1993, ADV EXP MED BIOL, V338, P115; WHO Expert Committee, 1984, LEISHM; WILLIAMS CD, 1976, J BACTERIOL, V127, P1197, DOI 10.1128/JB.127.3.1197-1207.1976; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	76	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38245	38253		10.1074/jbc.M206543200	http://dx.doi.org/10.1074/jbc.M206543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151409	hybrid			2022-12-25	WOS:000178529600035
J	Bultmann, H; Brandt, CR				Bultmann, H; Brandt, CR			Peptides containing membrane-transiting motifs inhibit virus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; INTRACELLULAR DELIVERY; PLASMA-MEMBRANE; TYPE-1; LOCALIZATION; PROTEIN; MODEL; CELLS; TAT	Several exceptional peptides have been identified that can cross plasma membranes and deliver various covalently linked moieties into cells. We report the surprising observation that each of four structurally distinct transiting peptides tested displayed antiviral activity and inhibited herpes simplex virus entry into cells. All four peptides inhibited infection at concentrations in the low micromolar range. Some of the peptides selectively and reversibly blocked entry without inactivating virions in a persistent manner. For other peptides, the effects on virus entry were not readily distinguishable from virus inactivation. High concentrations of nearly all peptides lead to irreversible inactivation of virions. By various criteria, the peptides differed in their ability to inactivate virions and in the temperature dependence of inactivation. Testing of peptides with modifications known to disrupt transport revealed that, in some instances, transport activity did not correlate with antiviral activity. These results identify inhibition of viral entry as another common property of membrane-transiting peptides in addition to their ability to cross membranes and transport materials into cells. These or related peptides may be useful as agents to prevent infection and to study the process of viral entry.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Brandt, CR (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 6630 MSC,1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL EYE INSTITUTE [R01EY007336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI052049] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY07336] Funding Source: Medline; NIAID NIH HHS [P01-AI 52049] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brandt CR, 1996, ANTIMICROB AGENTS CH, V40, P1078, DOI 10.1128/AAC.40.5.1078; Bultmann H, 2001, J VIROL, V75, P2634, DOI 10.1128/JVI.75.6.2634-2645.2001; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; FIELDS C G, 1991, Peptide Research, V4, P95; Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P42; GRAU DR, 1989, INVEST OPHTH VIS SCI, V30, P2474; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P7129; Oehlke J, 1996, PROTEIN PEPTIDE LETT, V3, P393; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198; Truant R, 1999, MOL CELL BIOL, V19, P1210; TRYBALA E, 1994, J GEN VIROL, V75, P743, DOI 10.1099/0022-1317-75-4-743; Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184	22	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36018	36023		10.1074/jbc.M204849200	http://dx.doi.org/10.1074/jbc.M204849200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130644	hybrid			2022-12-25	WOS:000178275100033
J	Sarkar, S; Roy, BC; Hatano, N; Aoyagi, T; Gohji, K; Kiyama, R				Sarkar, S; Roy, BC; Hatano, N; Aoyagi, T; Gohji, K; Kiyama, R			A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL COMPETITIVE REASSOCIATION; DIFFERENTIAL CLONING; GENOMIC DNA; CANCER; HYPERMETHYLATION; HETEROZYGOSITY; TUMORIGENESIS	By a combination of genome subtraction and comprehensive analysis of loss of heterozygosity based on mapping hemizygous deletions for a potential tumor-related locus, a minimum overlapping region of deletions at 9p24 the size of 165 kb was identified and found to harbor a new potential tumor suppressor gene for renal cell carcinoma, the Kank gene. Kank (for kidney ankyrin repeat-containing protein) contains four ankyrin repeats at its C terminus. Expression of the gene was suppressed in 6 of 8 or 6 of 10 cancer tissues examined by reverse transcription-PCR or Western blotting, respectively, and in several kidney tumor cell lines due to methylation at CpG sites in the gene. Epigenetic methylation or imprinting seemed to be the first hit, which was followed by a second hit of deletion, resulting in loss of function in many of these deletion cases. Expression of this gene in expression-negative HEK293 cells induced growth retardation at G(0)/G(1) as well as morphological changes.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Ichikawa Gen Hosp, Dept Urol, Tokyo Dent Coll, Chiba 2728513, Japan; Osaka Med Coll, Dept Urol, Takatsuki, Osaka 5960801, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Dental College; Osaka Medical College	Kiyama, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	kiyama.r@aist.go.jp	Hatano, Naoya/F-6147-2011					Aoyagi T, 1996, Int J Urol, V3, P392, DOI 10.1111/j.1442-2042.1996.tb00560.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAIRNS P, 1995, CANCER RES, V55, P224; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Druck T, 1998, ONCOL RES, V10, P341; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Hatano N, 2001, MOL CARCINOGEN, V31, P161, DOI 10.1002/mc.1051; Inoue S, 1996, GENOMICS, V31, P271, DOI 10.1006/geno.1996.0048; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KIYAMA R, 1995, ADV BIOPHYS, V31, P151, DOI 10.1016/0065-227X(95)99389-7; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; MACH H, 1996, CANCER RES, V56, P27; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; MORITA R, 1991, CANCER RES, V51, P820; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ohki R, 1998, MOL CARCINOGEN, V22, P158, DOI 10.1002/(SICI)1098-2744(199807)22:3<158::AID-MC3>3.0.CO;2-H; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; YOKOTA H, 1990, P NATL ACAD SCI USA, V87, P6398, DOI 10.1073/pnas.87.16.6398	29	77	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36585	36591		10.1074/jbc.M204244200	http://dx.doi.org/10.1074/jbc.M204244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133830	hybrid			2022-12-25	WOS:000178275100102
J	Hill, WG; An, B; Johnson, JP				Hill, WG; An, B; Johnson, JP			Endogenously expressed epithelial sodium channel is present in lipid rafts in A6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE; ALPHA-SUBUNIT; NA+ CHANNEL; C2 DOMAIN; ALDOSTERONE; CAVEOLAE; SURFACE; PROTEIN; LOCALIZATION; MICRODOMAINS	The epithelial sodium channel (ENaC) present in the kidney collecting duct, distal colon, and the lung is responsible for salt reabsorption and whole body volume regulation. It is composed of three homologous subunits, alpha, beta, and gamma, and mutations to these subunits can lead to the salt wasting disease pseudohypoaldosteronism type I, associated with decreased channel density at the plasma membrane or to the hypertensive disorder, Liddle's syndrome, in which channel residency time at the plasma membrane is enhanced. Regulation of ENaC trafficking and turnover is therefore critical to sodium homeostasis. In this study we examined whether ENaC is present in the cholesterol-enriched microdomains commonly called lipid rafts, in the endogenously expressing A6 cell line. We demonstrate that a fraction of alpha, beta, and gamma ENaC is present in detergent-insoluble membranes, that subunits exist in membranes that float on discontinuous sucrose density gradients, and that methyl-beta-cyclodextrin treatment causes a redistribution of ENaC subunits to higher density membranes. Furthermore, chronic aldosterone stimulation results in a shift in the membrane density of all three subunits. Biotinylation of apical membrane proteins revealed that ENaC is present in lipid rafts on the plasma membrane. In conclusion, these results show that ENaC is present in lipid rafts both intracellularly and on the cell surface. Raft association may be important for trafficking and/or function of the channel.	Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hill, WG (corresponding author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, A1222 Scaife Hall, Pittsburgh, PA 15261 USA.	whill@pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NIDDK NIH HHS [DK 57718, DK 47874] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047874, R01DK057718] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOODMAN DBP, 1975, BIOCHEMISTRY-US, V14, P2803, DOI 10.1021/bi00684a003; GOODMAN DBP, 1971, BIOCHEMISTRY-US, V10, P3825, DOI 10.1021/bi00797a004; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; LIEN EL, 1975, BIOCHEMISTRY-US, V14, P2749, DOI 10.1021/bi00683a030; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mrnka L, 2000, J STEROID BIOCHEM, V73, P11, DOI 10.1016/S0960-0760(00)00050-9; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Trouet D, 2001, BIOCHEM BIOPH RES CO, V284, P461, DOI 10.1006/bbrc.2001.4995; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; Yarbrough TL, 2002, CIRC RES, V90, P443, DOI 10.1161/hh0402.105177	31	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33541	33544		10.1074/jbc.C200309200	http://dx.doi.org/10.1074/jbc.C200309200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167633	hybrid			2022-12-25	WOS:000177959100003
J	Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ				Stein, T; Crighton, D; Warnock, LJ; Milner, J; White, RJ			Several regions of p53 are involved in repression of RNA polymerase III transcription	ONCOGENE			English	Article						p53; repression; RNA polymerase III; TFIIIB; transcription	TATA-BINDING-PROTEIN; WILD-TYPE P53; TUMOR SUPPRESSORS; DNA-BINDING; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; FACTOR-TFIIIB; AMINO-ACIDS; DAMAGED DNA	The tumour suppressor p53 has been shown to regulate RNA polymerase (pol) III transcription both in vitro and in vivo. We have characterized the regions of p53 that contribute to this effect. Repression of pol III transcription in vivo does not require residues 13-19 near the N-terminus of p53 that are highly conserved through evolution. However, amino acids 22 and 23 in the adjacent transactivation domain do contribute to the inhibition of pol III activity. Deletions within the central DNA-binding core domain (residues 102-292) of p53 can entirely abolish the repression function in these assays, despite the fact that pol III templates contain no recognized p53 binding site. Deletion or substitution within the C-terminal domain of p53 can also compromise its ability to repress pol III activity in vitro and in transfected cells. These observations reveal that repression of pol III transcription is a complex function involving multiple regions of p53 extending throughout much of the protein.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England	University of Glasgow; University of York - UK	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN KV, 1992, SCIENCE, V255, P459; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; Molinari M, 1996, ONCOGENE, V13, P2077; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOUSSI T, 1990, ONCOGENE, V5, P945; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; White RJ, 1998, INT J ONCOL, V12, P741; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	65	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5540	5547		10.1038/sj.onc.1205739	http://dx.doi.org/10.1038/sj.onc.1205739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165852				2022-12-25	WOS:000177442000003
J	Bianco, NR; Montano, MM				Bianco, NR; Montano, MM			Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth	ONCOGENE			English	Article						estrogen; estrogen receptor alpha; prothymosin alpha	QUINONE REDUCTASE GENE; TRANSCRIPTIONAL ACTIVATION; LINKER HISTONES; EXPRESSION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION; CLONING; REGION	Prothymosin alpha (PTalpha) is a small highly acidic protein found in the nuclei of virtually all mammalian tissues. Its high conservation in mammals and wide tissue distribution suggest an essential biological role. While the exact mechanism of action of PTalpha remains elusive, the one constant has been its relationship with the proliferative state of the cell and its requirement for cellular growth and survival. Recently PTalpha was found to promote transcriptional activity by sequestering the anticoactivator, REA from the Estrogen Receptor (ER) complex. We now report that Estradiol (E-2) upregulates PTa mRNA and protein expression. Further studies indicate that ERalpha regulates PTa gene transcriptional activity. We have also delimited the region of PTalpha gene promoter involved in ERalpha-mediated transcriptional regulation and identified a novel ERalpha-binding element. Increased intracellular PTalpha expression in the presence of estrogens is accompanied by increased nuclear/decreased cytoplasmic localization. Increased nuclear expression of PTalpha is correlated with increased proliferation as measured by expression of Ki67 nuclear antigen. Conversely, inhibition of nuclear PTalpha expression in breast cancer cells using antisense methodology resulted in the inhibition of E-2-induced breast cancer cell proliferation. Overall these studies underscore the importance of PTalpha in estrogen-induced breast cell proliferation.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44122 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER; NCI NIH HHS [CA80959] Funding Source: Medline; NIGMS NIH HHS [T32 GM08056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; AUSUBEL FM, 1992, SHORT PROTOCALS MOL; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Enkemann SA, 2000, J HISTOCHEM CYTOCHEM, V48, P1341, DOI 10.1177/002215540004801005; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; Garnier M, 1997, J NEUROSCI, V17, P4591; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Loidi L, 1999, LIFE SCI, V64, P2125, DOI 10.1016/S0024-3205(99)00161-7; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Magdalena C, 2000, BRIT J CANCER, V82, P584, DOI 10.1054/bjoc.1999.0968; MANROW RE, 1991, J BIOL CHEM, V266, P3916; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; MOL PC, 1995, MOL CELL BIOL, V15, P6999; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PerezEstevez A, 1997, J BIOL CHEM, V272, P10506; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SZABO P, 1993, HUM GENET, V90, P629; Tsitsilonis OE, 1998, ANTICANCER RES, V18, P1501; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wu CL, 1997, LIFE SCI, V61, P2091, DOI 10.1016/S0024-3205(97)00882-5; ZALVIDE JB, 1992, J BIOL CHEM, V267, P8692; Zhao RB, 2000, GENE DEV, V14, P981	53	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5233	5244		10.1038/sj.onc.1205645	http://dx.doi.org/10.1038/sj.onc.1205645			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149645				2022-12-25	WOS:000177193900005
J	Schwerin, M; Dorroch, U; Beyer, M; Swalve, H; Metges, CC; Junghans, P				Schwerin, M; Dorroch, U; Beyer, M; Swalve, H; Metges, CC; Junghans, P			Dietary protein modifies hepatic gene expression associated with oxidative stress responsiveness in growing pigs	FASEB JOURNAL			English	Article						protein diets; soy protein	HIGH-DENSITY-LIPOPROTEINS; MESSENGER-RNA; SOY PROTEIN; DIFFERENTIAL DISPLAY; METHIONINE RESIDUES; SIGNALING PATHWAYS; APOLIPOPROTEINS AI; CASEIN PROTEIN; BREAST-CANCER; AMINO-ACIDS	Understanding the basis for differences in nutrient requirements and for nutrient effects on health and performance requires an appreciation of the links between nutrition and gene expression. We developed and applied molecular probes to characterize diet-associated postabsorptive hepatic gene expression in growing pigs chronically fed protein-restricted diets based on either casein (CAS) or soy protein isolate (SPI). Eighty-eight expressed sequence tags (ESTs) were identified on the basis of diet-related changes in expression, by using an mRNA differential display method. Expression profiling based on transcription analysis by real-time reverse transcriptase-polymerase chain reaction showed that the SPI diet significantly changed the pattern of gene expression as compared with the CAS diet and allowed identification of coregulated genes. The expression of six genes involved in the metabolism of stress response (glutathione S-transferase, peptide methionine sulfoxide reductase, apolipoprotein A-I, organic anion transport polypeptide 2, calnexin, heat shock transcription factor 1) exhibited significant changes in the transcription level and indicated an increased oxidative stress response in pigs fed the SPI diet. Hierarchical clustering of gene expression data of all 33 ESTs analyzed across 14 pigs fed the two different diets resulted in clustering of genes related to the oxidative stress response with genes related to the regulation of gene expression and neuronal signaling.	Res Inst Biol Farm Anim, Res Unit Mol Biol, D-18196 Dummerstorf, Germany; Res Inst Biol Farm Anim, Res Unit Nutr Physiol Oskar Kellner, D-18196 Dummerstorf, Germany; Res Inst Biol Farm Anim, Res Unit Genet & Biometr, D-18196 Dummerstorf, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN)	Schwerin, M (corresponding author), Res Inst Biol Farm Anim, Res Unit Mol Biol, Wilhelm Stahl Alee 2, D-18196 Dummerstorf, Germany.	schwerin@fbn-dummerstorf.de	Swalve, Hermann/ABB-4625-2020	Swalve, Hermann/0000-0002-8398-3115; Junghans, Peter/0000-0002-4061-2517				AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; Allred CD, 2001, CARCINOGENESIS, V22, P1667, DOI 10.1093/carcin/22.10.1667; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Appelt LC, 1997, NUTR CANCER, V28, P270, DOI 10.1080/01635589709514587; Aubel C, 2001, CELL SIGNAL, V13, P417, DOI 10.1016/S0898-6568(01)00159-0; Backlund M, 1997, J BIOL CHEM, V272, P31755, DOI 10.1074/jbc.272.50.31755; Desai M, 1997, AM J PHYSIOL-GASTR L, V273, pG899, DOI 10.1152/ajpgi.1997.273.4.G899; Deutz NEP, 1998, J NUTR, V128, P2435, DOI 10.1093/jn/128.12.2435; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Gardner CD, 2001, AM J CLIN NUTR, V73, P728; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Greaves KA, 2000, J NUTR, V130, P820, DOI 10.1093/jn/130.4.820; Harman H.H., 1976, MODERN FACTOR ANAL; Hesketh JE, 1998, BRIT J NUTR, V80, P307, DOI 10.1079/096582198388265; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; Iritani N, 1996, J NUTR, V126, P380, DOI 10.1093/jn/126.2.380; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; JOUSSE C, 1998, BIOCHEM J, V15, P147; Khan N, 2001, PHARMACOL TOXICOL, V88, P294, DOI 10.1034/j.1600-0773.2001.d01-120.x; Koletzko B, 1998, BRIT J NUTR, V80, pS5, DOI 10.1079/BJN19980104; Lamartiniere CA, 2000, AM J CLIN NUTR, V71, p1705S, DOI 10.1093/ajcn/71.6.1705S; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; LI FS, 1994, NUCLEIC ACIDS RES, V22, P1764, DOI 10.1093/nar/22.9.1764; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lohrke B, 2001, BRIT J NUTR, V85, P447, DOI 10.1079/BJN2000291; Lovati MR, 2000, J NUTR, V130, P2543, DOI 10.1093/jn/130.10.2543; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Lyons J, 2000, P NATL ACAD SCI USA, V97, P5071, DOI 10.1073/pnas.090083297; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; Metges CC, 2000, AM J PHYSIOL-ENDOC M, V278, pE868, DOI 10.1152/ajpendo.2000.278.5.E868; Morita T, 1997, J NUTR, V127, P470, DOI 10.1093/jn/127.3.470; MOUNDRAS C, 1995, METABOLISM, V44, P1146, DOI 10.1016/0026-0495(95)90007-1; NISHIO Y, 1994, FASEB J, V8, P103, DOI 10.1096/fasebj.8.1.8299882; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Saggau E, 2000, J ANIM PHYSIOL AN N, V84, P29, DOI 10.1046/j.1439-0396.2000.00278.x; SAS Institute, 1999, SAS STAT US GUID VER; SCHMITZ M, 1991, J NUTR, V121, P1575, DOI 10.1093/jn/121.10.1575; Schwerin M, 1999, J ANIM PHYSIOL AN N, V81, P113, DOI 10.1046/j.1439-0396.1999.813177.x; Seneviratne CK, 1999, AM J PHYSIOL-HEART C, V277, pH2124, DOI 10.1152/ajpheart.1999.277.6.H2124; Taniguchi M, 2000, BRIT J NUTR, V84, P211; Tovar-Palacio C, 1998, J NUTR, V128, P839, DOI 10.1093/jn/128.5.839; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Vasquez OL, 2001, J NEUROCHEM, V76, P1593, DOI 10.1046/j.1471-4159.2001.00223.x; Wang ST, 1997, J NUTR, V127, P2135, DOI 10.1093/jn/127.11.2135	48	27	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1322	+		10.1096/fj.01-0734fje	http://dx.doi.org/10.1096/fj.01-0734fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154008				2022-12-25	WOS:000176683900019
J	Biot, C; Buisine, E; Kwasigroch, JM; Wintjens, R; Rooman, M				Biot, C; Buisine, E; Kwasigroch, JM; Wintjens, R; Rooman, M			Probing the energetic and structural role of amino acid/nucleobase cation-pi interactions in protein-ligand complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONEMPIRICAL AB-INITIO; AROMATIC INTERACTIONS; AQUEOUS-SOLUTION; BASE-PAIRS; RECOGNITION; RECEPTOR; STACKING; DNA; BIOLOGY; BINDING	structures of proteins bound to ligand molecules containing a nucleic acid base were systematically searched for cation-pi interactions between the base and a positively charged or partially charged side chain group located above it, using geometric criteria. Such interactions were found in 38% of the complexes and are thus even more frequent than pi-pi stacking interactions. They are moreover well conserved in families of related proteins. The overwhelming majority of cation-pi contacts involve Ade bases, as these constitute by far the most frequent ligand building block; Arg-Ade is; the most frequent cation-pi pair. Ab initio energy calculations at MP2 level were performed on all recorded pairs. Though cation-pi interactions involving the net positive charge carried by Arg or Lys side chains are the most favorable energetically, those involving the partial positive charge of Asn and Gln side chain amino groups (sometimes referred to as amino-pi interactions) are favorable too, owing to the electron correlation energy contribution. Chains of cation-pi interactions with a nucleobase bound simultaneously to two charged groups or a charged group sandwiched between two aromatic moieties are found in several complexes. The systematic association of these motifs with specific ligand molecules in unrelated protein sequences raises the question of their role in protein-ligand structure, stability, and recognition.	Free Univ Brussels, B-1050 Brussels, Belgium; Univ Sci & Tech Lille Flandres Artois, URRESA 8009, CNRS, Lab Chim Organ & Macromol, F-59655 Villeneuve Dascq, France; Univ Lille 2, CNRS, UMR 8525, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Biot, C (corresponding author), Free Univ Brussels, 50 Av F Roosevelt,CP 165-64, B-1050 Brussels, Belgium.		Biot, Christophe/ABG-3796-2020	Biot, Christophe/0000-0002-7396-1959				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOUTONNET NS, 1995, PROTEIN ENG, V8, P647, DOI 10.1093/protein/8.7.647; BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUFFY EM, 1993, J AM CHEM SOC, V115, P9271, DOI 10.1021/ja00073a050; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Florian J, 1999, J PHYS CHEM B, V103, P884, DOI 10.1021/jp983699s; Frisch M. J., 1998, GAUSSIAN 98; Gallivan JP, 2000, J AM CHEM SOC, V122, P870, DOI 10.1021/ja991755c; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hendlich M, 1998, ACTA CRYSTALLOGR D, V54, P1178, DOI 10.1107/S0907444998007124; Hobza P, 1999, CHEM REV, V99, P3247, DOI 10.1021/cr9800255; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hunter CA, 2002, P NATL ACAD SCI USA, V99, P4873, DOI 10.1073/pnas.072647899; Jansen HB, 1969, CHEM PHYS LETT, V3, P140, DOI 10.1016/0009-2614(69)80118-1; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Luisi B, 1998, J MOL BIOL, V279, P1123, DOI 10.1006/jmbi.1998.1833; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Minoux H, 1999, J AM CHEM SOC, V121, P10366, DOI 10.1021/ja990914p; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rooman M, 2002, J MOL BIOL, V319, P67, DOI 10.1016/S0022-2836(02)00263-2; SCHWARTZ AW, 1989, SCIENCE, V245, P1102, DOI 10.1126/science.11538344; Scrutton NS, 1996, BIOCHEM J, V319, P1; SHAPIRO R, 1995, ORIGINS LIFE EVOL B, V25, P83, DOI 10.1007/BF01581575; Shi ZS, 2002, J AM CHEM SOC, V124, P3284, DOI 10.1021/ja0174938; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; Sponer J, 1996, J PHYS CHEM-US, V100, P5590, DOI 10.1021/jp953306e; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wintjens R, 2000, J MOL BIOL, V302, P395, DOI 10.1006/jmbi.2000.4040; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	70	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40816	40822		10.1074/jbc.M205719200	http://dx.doi.org/10.1074/jbc.M205719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167645	hybrid			2022-12-25	WOS:000178791400085
J	Wiklund, L; Sokolowski, M; Carlsson, A; Rush, M; Schwartz, S				Wiklund, L; Sokolowski, M; Carlsson, A; Rush, M; Schwartz, S			Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEGATIVE ELEMENT; CELLULAR FACTORS; HUR PROTEIN; REV PROTEIN; TYPE-1; SEQUENCE; DEGRADATION; INITIATION	The human papillomavirus type I (HPV-1) late mRNAs contain a 57-nucleotide adenosine- and uridine-rich RNA instability element termed MARE in their late 3' untranslated regions. Here we show that five sequence motifs in the h1ARE (named I-V) affect the mRNA half-life in an additive manner. The minimal inhibitory sequence in motifs I and II was mapped to UAUUUAU, and the minimal inhibitory sequence in motifs III-V was mapped to UAUUUUUAU. We also provide evidence that the same motifs in the AU-RNA instability element inhibit mRNA translation, an effect that was entirely dependent on the presence of a poly(A) tail on the mRNA. Additional experiments demonstrated that the h1ARE interacted directly with the poly(A)-binding protein, suggesting that the h1ARE inhibits translation by interfering with the function of the poly(A)-binding protein.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden	Uppsala University	Schwartz, S (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Husargatan 3,Box 582, S-75123 Uppsala, Sweden.			Sokolowski, Marcus/0000-0003-3931-1810				ANTIC D, 1999, GENE DEV, V13, P8684; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BAKER CC, 1997, HUMAN PAPILLOMAVIRUS, P11; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carlsson A, 2000, ARCH VIROL, V145, P491, DOI 10.1007/s007050050041; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; LAGANDO CA, 1994, MOL CELL BIOL, V14, P7984; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; RAMIREZSOLIS R, 1990, GENE, V87, P291, DOI 10.1016/0378-1119(90)90315-I; ROSS J, 1995, MICROBIOL REV, V59, P15; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Schwartz S, 1998, SEMIN VIROL, V8, P291, DOI 10.1006/smvy.1997.0131; Schwartz S, 2000, UPSALA J MED SCI, V105, P171; SCHWARTZ S, 1999, RRD VIROLOGY 1, V1, P53; Sokolowski M, 1997, ONCOGENE, V15, P2303, DOI 10.1038/sj.onc.1201415; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; Sokolowski M, 2001, VIRUS RES, V73, P163, DOI 10.1016/S0168-1702(00)00238-0; Sokolowski M, 1998, J VIROL, V72, P1504, DOI 10.1128/JVI.72.2.1504-1515.1998; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; Wiklund L, 2001, J HUMAN VIROL, V4, P74; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; Zhao CP, 1998, VIRUS RES, V55, P1, DOI 10.1016/S0168-1702(98)00033-1; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; zur Hausen H, 1996, BIOCHIM BIOPHYS ACTA, V1288, P55	36	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40462	40471		10.1074/jbc.M205929200	http://dx.doi.org/10.1074/jbc.M205929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12147699	hybrid			2022-12-25	WOS:000178791400041
J	Renaud-Young, M; Gallin, WJ				Renaud-Young, M; Gallin, WJ			In the first extracellular domain of E-cadherin, heterophilic interactions, but not the conserved His-Ala-Val motif, are required for adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; CELL-CELL ADHESION; N-CADHERIN; L-CAM; MOLECULE UVOMORULIN; EARLY EMBRYOGENESIS; NEURITE OUTGROWTH; EPITHELIAL-CELLS; STRUCTURAL BASIS; CARCINOMA-CELLS	The classical cadherins, definitive proteins of the cadherin superfamily, are characterized functionally by their ability to mediate calcium-dependent cell aggregation in vitro. To test hypothetical mechanisms of adhesion, we have constructed two mutants of the chicken E-cadherin protein, one with the highly conserved His-Ala-Val (HAV) sequence motif reversed to Val-Ala-His (VAH), the other lacking the first extracellular domain (EC1). The inversion of HAV to VAH has no effect on the capacity of E-cadherin to mediate adhesion. Deletion of EC1 completely eliminates the ability of E-cadherin to mediate homophilic adhesion, but the deletion mutant is capable of adhering heterophilically to both unmutated E-cadherin and to the HAV/VAH mutant. These results demonstrate that the conserved HAV sequence motif is not involved in cadherin-mediated adhesion as has been suggested previously and supports the idea that in the context of the cell surface, cadherin-mediated cell-cell adhesion involves an interaction of EC1 with other domains of the cadherin extracellular moiety and not the "linear zipper" model, which posits trans interactions only between EC1 on apposing cell surfaces.	Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2E9, Canada	University of Alberta; University of Alberta	Gallin, WJ (corresponding author), Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E9, Canada.		Gallin, Warren/A-2640-2014; Renaud-Young, Margaret M/V-9801-2017	Gallin, Warren/0000-0002-9937-3880; Renaud-Young, Margaret M/0000-0003-0569-6126				ACHESON A, 1992, CELL CELL INTERACTIO, P31; Babb SG, 2001, DEV DYNAM, V221, P231, DOI 10.1002/dvdy.1132; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; Gallin WJ, 1998, MOL BIOL EVOL, V15, P1099, DOI 10.1093/oxfordjournals.molbev.a026017; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Handschuh G, 2001, J MOL BIOL, V314, P445, DOI 10.1006/jmbi.2001.5143; Hoffman S., 1992, P1; Huber O, 1999, J CELL SCI, V112, P4415; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Li Z, 1998, J CELL SCI, V111, P1005; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; Noe V, 1999, J CELL SCI, V112, P127; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OGOU SI, 1983, J CELL BIOL, V97, P944, DOI 10.1083/jcb.97.3.944; OGOU SI, 1982, DEV BIOL, V92, P521, DOI 10.1016/0012-1606(82)90196-8; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Runswick SK, 2001, NAT CELL BIOL, V3, P823, DOI 10.1038/ncb0901-823; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; SOFRONIEW MV, 1982, J HISTOCHEM CYTOCHEM, V30, P504, DOI 10.1177/30.6.6178778; STAPPERT J, 1992, CELL CELL INTERACTIO, P75; STRAUSS W, 1998, CURRENT PROTOCOLS MO, V1; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7	61	30	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39609	39616		10.1074/jbc.M201256200	http://dx.doi.org/10.1074/jbc.M201256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154084	hybrid			2022-12-25	WOS:000178662500072
J	Golubovskaya, V; Beviglia, L; Xu, LH; Earp, HS; Craven, R; Cance, W				Golubovskaya, V; Beviglia, L; Xu, LH; Earp, HS; Craven, R; Cance, W			Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-TERMINAL DOMAIN; EGF RECEPTOR; FACTOR-ALPHA; TUMOR-CELLS; EXPRESSION; FAK; SURVIVAL; MIGRATION; SUPPRESSION	The focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) are protein-tyrosine kinases that are overexpressed and activated in human breast cancer. To determine the role of EGFR and FAK survival signaling in breast cancer, EGFR was stably overexpressed in BT474 breast cancer cells, and each signaling pathway was specifically targeted for inhibition. FAK and EGFR constitutively co-immunoprecipitated in EGFR-overexpressing BT474 cells. In low EGFR-expressing BT474-pcDNA3 vector control cells, inhibition of FAK by the FAK C-terminal domain caused detachment and apoptosis via pathways involving activation of caspase-3 and -8, cleavage of poly(ADP-ribose) polymerase, and caspase-3-dependent degradation of AKT. This apoptosis could be rescued by the dominant-negative Fas-associated death domain, indicating involvement of the death receptor pathway. EGFR overexpression did not inhibit detachment induced by the FAK C-terminal domain, but did suppress apoptosis, activating AKT and ERK1/2 survival pathways and inhibiting cleavage of FAK, caspase-3 and -8, and poly(ADPribose) polymerase. Furthermore, this protective effect of EGFR signaling was reversed by EGFR kinase inhibition with AG1478. In addition, inhibition of FAK and EGFR in another breast cancer cell line (BT20) endogenously overexpressing these kinases also induced apoptosis via the same mechanism as in the EGFR-overexpressing BT474 cells. The results of this study indicate that dual inhibition of FAK and EGFR signaling pathways can cooperatively enhance apoptosis in breast cancers.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cance, W (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7210,3010 Old Clin Bldg, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA65910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; BELLACOSA A, 1993, ONCOGENE, V8, P745; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BORLINGHAUS P, 1993, CLIN INVESTIGATOR, V71, P903; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Gibson EM, 2002, CANCER RES, V62, P488; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hauck CR, 2001, CANCER RES, V61, P7079; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; Ilekis JV, 1997, GYNECOL ONCOL, V66, P250, DOI 10.1006/gyno.1997.4764; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic D, 1997, J CELL SCI, V110, P401; Issing WJ, 1996, ANTICANCER RES, V16, P283; Jones G, 2001, CANCER RES, V61, P4978; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Moulder SL, 2001, CANCER RES, V61, P8887; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Price JT, 1999, CANCER RES, V59, P5475; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; Westermark K, 1996, HISTOPATHOLOGY, V28, P221, DOI 10.1046/j.1365-2559.1996.d01-427.x; Witters L, 1999, BREAST CANCER RES TR, V53, P41, DOI 10.1023/A:1006127527107; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Zachary I, 1997, INT J BIOCHEM CELL B, V29, P929, DOI 10.1016/S1357-2725(97)00008-3	59	125	129	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38978	38987		10.1074/jbc.M205002200	http://dx.doi.org/10.1074/jbc.M205002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167618	Green Published, hybrid			2022-12-25	WOS:000178529600122
J	Longo, KA; Kennell, JA; Ochocinska, MJ; Ross, SE; Wright, WS; MacDougald, OA				Longo, KA; Kennell, JA; Ochocinska, MJ; Ross, SE; Wright, WS; MacDougald, OA			Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS APOPTOSIS; SURVIVAL FACTOR; P-GLYCOPROTEIN; CELL-SURVIVAL; GENE; AKT; ADIPOGENESIS; ACTIVATION; RESISTANCE; EXPRESSION	Ectopic expression of Wnt-1 in 3T3-L1 preadipocytes stabilizes beta-catenin, activates TCF-dependent gene transcription, and blocks adipogenesis. Here we report that upon serum withdrawal, Wnt-1 causes 3T3-L1 cells to resist apoptosis through a mechanism that is partially dependent on phosphatidylinositol 3-kinase. Although activation of Wnt signaling by inhibition of GSK-3 activity or ectopic expression of dominant stable beta-catenin blocks apoptosis, inhibition of Wnt signaling through expression of dominant negative TCF-4 increases apoptosis. Wnt-1 stimulates 3T3-L1 preadipocytes to secrete factors that increase PKB/Akt phosphorylation at levels comparable with treatment with 10% serum. With DNA microarrays, we identified several secreted antiapoptotic genes that are induced by Wnt-1, notably insulin-like growth factor I (IGF-I) and IGF-II. Consistent with IGFs mediating the antiapoptotic effects of Wnt-1 in preadipocytes, conditioned medium from Wnt-1 expressing 3T3-L1 cells was unable to promote protein kinase B phosphorylation after the addition of recombinant IGFBP-4. Thus, we demonstrated that Wnt-1 induces expression of antiapoptotic genes in 3T3-L1 preadipocytes such as IGF-I and IGF-II, which allows these cells to resist apoptosis in response to serum deprivation.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7620 Med Sci Bldg 2,1301 E Catherine Dr, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Longo, Kenneth A/A-5631-2010	MacDougald, Ormond/0000-0001-6907-7960; Kennell, Jennifer/0000-0001-9793-6259; Hahn, Wendy/0000-0002-4374-5876	NIDDK NIH HHS [T32 DK007245, DK 51563, T32-DK07245] Funding Source: Medline; NIGMS NIH HHS [T32-GM08322, T32 GM008322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007245, R01DK051563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Fang Y, 1999, ENDOCRINOLOGY, V140, P5239, DOI 10.1210/en.140.11.5239; Fassett JT, 2001, ENDOCRINOLOGY, V142, P2129, DOI 10.1210/en.142.5.2129; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gollapudi S, 2001, J CLIN IMMUNOL, V21, P420, DOI 10.1023/A:1013177710941; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; Howe LR, 1999, CANCER RES, V59, P1572; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Magun R, 1998, INT J OBESITY, V22, P567, DOI 10.1038/sj.ijo.0800626; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Niesler CU, 2000, J ENDOCRINOL, V167, P165, DOI 10.1677/joe.0.1670165; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Persidis A, 1999, NAT BIOTECHNOL, V17, P94, DOI 10.1038/5289; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wulf P, 1999, DEV BRAIN RES, V116, P169, DOI 10.1016/S0165-3806(99)00092-9; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9; Zoubine MN, 2001, BIOCHEM BIOPH RES CO, V282, P421, DOI 10.1006/bbrc.2001.4584	50	172	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38239	38244		10.1074/jbc.M206402200	http://dx.doi.org/10.1074/jbc.M206402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154096	hybrid			2022-12-25	WOS:000178529600034
J	Olalla, L; Gutierrez, A; Campos, JA; Khan, ZU; Alonso, FJ; Segura, JA; Marquez, J; Aledo, JC				Olalla, L; Gutierrez, A; Campos, JA; Khan, ZU; Alonso, FJ; Segura, JA; Marquez, J; Aledo, JC			Nuclear localization of L-type glutaminase in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-ACTIVATED GLUTAMINASE; PDZ-DOMAIN; MOLECULAR-CLONING; EXPRESSION; PROTEIN; PURIFICATION; ASSOCIATION; GLUTAMATE; BINDING	In mammals, there are two different genes encoding for glutaminase isoforms, named liver (LGA) and kidney (KGA) types. LGA has long been believed to be present only in liver mitochondria from adult animals. However, we have recently reported the presence of LGA mRNA in human brain. We now describe the expression of LGA mRNA in the brain of other mammals (cow, mouse, rabbit, and rat) and in different areas of human brain as assessed by Northern blot analysis. The presence of mRNA encoding for this isoform in rat brain was further confirmed by reverse transcriptase-PCR cloning and sequencing. Although it has been well accepted that glutaminase is a mitochondrial enzyme, using newly generated isoform-specific antibodies, we have found a differential intracellular immunolocalization of both glutaminase isoforms in rat and monkey brain. In both species, KGA protein was present in mitochondria, whereas LGA protein was localized in nuclei. Furthermore, subcellular fractionation and Western blot analysis revealed that brain LGA was enriched in nuclei where it was catalytically active. Nuclear glutaminase exhibited a kinetic behavior that resembles that of the liver-type enzyme with regard to the low phosphate concentration requirement; however, nuclear glutaminase was susceptible to glutamate inhibition, a property that is absent in the rat liver enzyme.	Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, Lab Quim Prot, E-29071 Malaga, Spain; Univ Malaga, Fac Ciencias, Dept Biol Celular Genet & Fisiol, E-29071 Malaga, Spain; Univ Malaga, Dept Med, Ctr Invest Medicosanitarias, E-29071 Malaga, Spain	Universidad de Malaga; Universidad de Malaga; Universidad de Malaga	Aledo, JC (corresponding author), Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, Lab Quim Prot, Campus Teatinos, E-29071 Malaga, Spain.	caledo@uma.es	Aledo, Juan Carlos/Z-4236-2019; marquez, javier/K-3289-2012; KHAN, Zafaruddin/J-6217-2012; Campos-Sandoval, José/I-7375-2018; Aledo, Juan C/E-6029-2011	Aledo, Juan Carlos/0000-0002-3497-9945; marquez, javier/0000-0003-3317-3963; KHAN, Zafaruddin/0000-0003-0742-399X; Campos-Sandoval, José/0000-0002-2457-9884; Alonso Carrion, Francisco Jose/0000-0002-9431-163X; Gutierrez Perez, Antonia/0000-0002-6264-6152				Aledo JC, 2000, MAMM GENOME, V11, P1107, DOI 10.1007/s003350010190; Aledo JC, 2001, PROTEIN EXPRES PURIF, V23, P411, DOI 10.1006/prep.2001.1522; ALEDO JC, 1994, FEBS LETT, V341, P39, DOI 10.1016/0014-5793(94)80236-X; ALEDO JC, 1996, BIOCHIM BIOPHYS ACTA, V1323, P173; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BILLETT EE, 1984, BIOCHEM J, V221, P765, DOI 10.1042/bj2210765; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Gomez-Fabre PM, 2000, BIOCHEM J, V345, P365, DOI 10.1042/0264-6021:3450365; Harlow E., 1988, ANTIBODIES LABORATOR, P1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HEINI HG, 1987, EUR J BIOCHEM, V162, P541, DOI 10.1111/j.1432-1033.1987.tb10673.x; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Khan ZU, 1998, P NATL ACAD SCI USA, V95, P7731, DOI 10.1073/pnas.95.13.7731; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; Laake JH, 1999, NEUROSCIENCE, V88, P1137, DOI 10.1016/S0306-4522(98)00298-X; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NICKLAS WJ, 1987, BIOCHEM SOC T, V15, P208, DOI 10.1042/bst0150208; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; SMITH EM, 1990, J BIOL CHEM, V265, P10631; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; TANIGAWA Y, 1978, EUR J BIOCHEM, V92, P261, DOI 10.1111/j.1432-1033.1978.tb12744.x; Watkins JC, 2000, BIOCHEM SOC T, V28, P297, DOI 10.1042/0300-5127:0280297; Wischmeyer PE, 2002, NUTRITION, V18, P225, DOI 10.1016/S0899-9007(01)00796-1	28	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38939	38944		10.1074/jbc.C200373200	http://dx.doi.org/10.1074/jbc.C200373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163477	hybrid			2022-12-25	WOS:000178529600117
J	Sandgren, S; Cheng, F; Belting, M				Sandgren, S; Cheng, F; Belting, M			Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide - Role for cell-surface proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST-GROWTH-FACTOR; MEDIATED GENE-TRANSFER; INTRACELLULAR DELIVERY; BASIC DOMAIN; PROTEIN TRANSDUCTION; IN-VITRO; GLYCOSAMINOGLYCANS; ACCUMULATION	New therapies based on gene transfer and protein delivery require a better understanding of the basic mechanisms of macromolecular membrane transport. We have studied cellular uptake of macromolecular polyanions, i.e. DNA and glycosaminoglycans, and a polybasic HIV-Tat derived peptide (GRKKRRQRRRPPQC) using fluorescence assisted cell sorting and confocal fluorescence microscopy. The transactivator of HIV transcription (Tat) peptide stimulated cellular uptake of both DNA and heparan sulfate in a time-, concentration-, and temperature-dependent manner. Peptide-polyanion complexes accumulated in large, acidic, cytoplasmic vesicles formed de novo. This was followed by transfer of polyanion into the nuclear compartment and subsequent disappearance of the endolysosomal vesicles. In the absence of polyanion the Tat peptide displayed rapid accumulation in the nuclear compartment. However, in the presence of polyanion the peptide was almost exclusively retained in cytoplasmic vesicles. Cell-surface proteoglycans played a pivotal role in the uptake of complexes exhibiting a relatively high peptide to polyanion ratio, corresponding to a net positive charge of the complexes. Uptake of polyanions per se or complexes with a relatively low peptide to polyanion ratio was favored by proteoglycan deficiency in the recipient cells, indicating the existence of distinct transport mechanisms. Moreover, expression of full-length HIV-Tat as well as exogenous addition of HIV-Tat peptide resulted in cellular accumulation of endogenous proteoglycans. We conclude that an HIV-Tat derived peptide efficiently targets extraneous DNA and glycosaminoglycans to the nuclear compartment and that proteoglycans serve a regulatory role in these processes, which may have implications for directed gene and drug delivery in vivo.	Lund Univ, BMC, Sect Cell & Matrix Biol, Dept Cell & Mol Biol, S-22184 Lund, Sweden	Lund University	Belting, M (corresponding author), Lund Univ, BMC, Sect Cell & Matrix Biol, Dept Cell & Mol Biol, C13, S-22184 Lund, Sweden.			Belting, Mattias/0000-0003-1585-5434				Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1999, BIOCHEM J, V342, P281, DOI 10.1042/0264-6021:3420281; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cheng F, 2001, J CELL BIOCHEM, V83, P597, DOI 10.1002/jcb.1254; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hengge UR, 1996, J CLIN INVEST, V97, P2911, DOI 10.1172/JCI118750; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Mahley RW, 1999, J LIPID RES, V40, P1; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tumova S, 1997, J BIOL CHEM, V272, P9078; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; Wiethoff CM, 2001, J BIOL CHEM, V276, P32806, DOI 10.1074/jbc.M007940200; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	44	153	164	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38877	38883		10.1074/jbc.M205395200	http://dx.doi.org/10.1074/jbc.M205395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163493	hybrid			2022-12-25	WOS:000178529600110
J	Zhang, LQ; Ikegami, M; Dey, CR; Korfhagen, TR; Whitsett, JA				Zhang, LQ; Ikegami, M; Dey, CR; Korfhagen, TR; Whitsett, JA			Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TARGETED MICE; IN-VIVO; EXPRESSION; LUNG; LOCALIZATION; HOMEOSTASIS	Surfactant protein D (SP-D) gene-targeted mice develop severe pulmonary disease associated with emphysema, pulmonary lipidosis, and foamy macrophage infiltrations. To determine the potential reversibility of these abnormalities, transgenic mice were developed in which SP-D was conditionally replaced in the respiratory epithelium of SP-D-/- mice. SP-D was not detected in the absence of doxycycline. Treatment with doxycycline after birth restored pulmonary SP-D concentrations and corrected pulmonary pathology at adulthood. When SP-D was replaced in adult SP-D-/- mice, alveolar SP-D was restored within 3 days, pulmonary lipid abnormalities were corrected, but emphysema persisted. In corrected adult SP-D-/- mice, loss of SP-D caused focal emphysema and pulmonary inflammation but did not cause phospholipid abnormalities characteristic of SP-D-/- mice. Thus, abnormalities in surfactant phospholipid homeostasis and alveolar macrophage abnormalities were readily corrected by restoration of SP-D. However, once established, emphysema was not reversed by SP-D. SP-D-dependent processes regulating surfactant lipid homeostasis were disassociated from those mediating emphysema.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NCI NIH HHS [SCOR HL56387] Funding Source: Medline; NHLBI NIH HHS [HL33865, HL63329] Funding Source: Medline; OAPP OPHS HHS [PPG HL61646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329, R01HL033865] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OAPP OPHS HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; HULL W, 2000, AM J RESP CRIT CARE, V161, pA42; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; MASON RJ, 1976, J LIPID RES, V17, P281; Massaro D, 2002, AM J PHYSIOL-LUNG C, V282, pL345, DOI 10.1152/ajplung.00374.2001; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	21	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38709	38713		10.1074/jbc.M206200200	http://dx.doi.org/10.1074/jbc.M206200200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163500	hybrid			2022-12-25	WOS:000178529600089
J	Gilquin, B; Racape, J; Wrisch, A; Visan, V; Lecoq, A; Grissmer, S; Menez, A; Gasparini, S				Gilquin, B; Racape, J; Wrisch, A; Visan, V; Lecoq, A; Grissmer, S; Menez, A; Gasparini, S			Structure of the BgK-Kv1.1 complex based on distance restraints identified by double mutant cycles - Molecular basis for convergent evolution of Kv1 channel blockers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-CONOTOXIN PVIIA; PROTEIN-PROTEIN INTERACTIONS; GATED POTASSIUM CHANNELS; K+ CHANNEL; ION CONDUCTION; PORE; CHARYBDOTOXIN; DENDROTOXIN; RECEPTOR; TOXINS	A structural model of BgK, a sea anemone toxin, complexed with the S5-S6 region of Kv1.1, a voltage-gated potassium channel, was determined by flexible docking under distance restraints identified by a double mutant cycles approach. This structure provides the molecular basis for identifying the major determinants of the BgK-Kv1.1 channel interactions involving the BgK dyad residues Lys(25) and Tyr(26). These interactions are (i) electrostatic interactions between the extremity of Lys(25) side chain and carbonyl oxygen atoms of residues from the channel selectivity filter that may be strengthened by solvent exclusion provided by (ii) hydrophobic interactions involving BgK residues Tyr(26) and Phe(6) and Kv1.1 residue Tyr(379). whose side chain protrudes in the channel vestibule. In other Kv1 channel-BgK complexes, these interactions are likely to be conserved, implicating both conserved and variable residues from the channels. The data suggest that the conservation in sea anemone and scorpion potassium channel blockers of a functional dyad composed of a lysine, and a hydrophobic residue reflects their use of convergent binding solutions based on a crucial interplay between these important conserved interactions.	CEA Saclay, Dept Ingn Etudes & Prot, F-91191 Gif Sur Yvette, France; Univ Ulm, Dept Appl Physiol, D-89081 Ulm, Germany	CEA; UDICE-French Research Universities; Universite Paris Saclay; Ulm University	Gilquin, B (corresponding author), CEA Saclay, Dept Ingn Etudes & Prot, Bat 152, F-91191 Gif Sur Yvette, France.	bgilquin@cea.fr; gasparin@dsvidf.cea.fr	Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Alessandri-Haber N, 1999, J BIOL CHEM, V274, P35653, DOI 10.1074/jbc.274.50.35653; Berneche S, 2000, BIOPHYS J, V78, P2900, DOI 10.1016/S0006-3495(00)76831-7; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Garcia E, 1999, J GEN PHYSIOL, V114, P141, DOI 10.1085/jgp.114.1.141; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; Jager H, 1998, J PHYSIOL-LONDON, V506, P291, DOI 10.1111/j.1469-7793.1998.291bw.x; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kim M, 1997, J NEUROSCI, V17, P8213; KLEANTHOUS C, 2000, PROTEIN PROTEIN RECO, P280; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Racape J, 2002, J BIOL CHEM, V277, P3886, DOI 10.1074/jbc.M109886200; RACAPE J, 2001, THESIS U PARIS SUD 1; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Savarin P, 1999, PROTEIN SCI, V8, P2672; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; Wrisch A, 2000, J BIOL CHEM, V275, P39345, DOI 10.1074/jbc.M006827200; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37406	37413		10.1074/jbc.M206205200	http://dx.doi.org/10.1074/jbc.M206205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133841	hybrid			2022-12-25	WOS:000178447100064
J	Hunter, HN; Fulton, DB; Ganz, T; Vogel, HJ				Hunter, HN; Fulton, DB; Ganz, T; Vogel, HJ			The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; CYSTEINE RESIDUES; GENE; IDENTIFICATION; CONTAINS; PROGRAM; ANEMIA; SITE	The antibacterial and antifungal peptide hepcidin (LEAP-1) is expressed in the liver. This circulating peptide has recently been found to also act as a signaling molecule in iron metabolism. As such, it plays an important role in hereditary hemochromatosis, a serious iron overload disease. In this study, we report the solution structures of the hepcidin-20 and -25 amino acid peptides determined by standard two-dimensional H-1 NMR spectroscopy. These small cysteine-rich peptides form a distorted beta-sheet with an unusual vicinal disulfide bridge found at the turn of the hairpin, which is probably of functional significance. Both peptides exhibit an overall amphipathic structure with six of the eight Cys involved in maintaining interstrand connectivity. Hepcidin-25 assumes major and minor conformations centered about the Pro residue near the N-terminal end. Further NMR diffusion studies indicate that hepcidin-20 exists as a monomer in solution, whereas hepcidin-25 readily aggregates, a property that may contribute to the different activities of the two peptides. The nuclear Overhauser enhancement spectroscopy spectra of the hepcidin-25 aggregates indicate an interface for peptide interactions that again involves the first five residues from the N-terminal end.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90059 USA	University of Calgary; Iowa State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca	Ganz, Tomas/AAN-3308-2020; Girelli, Domenico/B-1183-2008; Ganz, Tomas/D-4567-2009	Girelli, Domenico/0000-0001-9684-1899; Ganz, Tomas/0000-0002-2830-5469				Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Berrocal-Lobo M, 2002, PLANT PHYSIOL, V128, P951, DOI 10.1104/pp.010685; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; KAO PN, 1986, J BIOL CHEM, V261, P8085; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; MERRILL MR, 1993, J MAGN RESON SER A, V103, P223, DOI 10.1006/jmra.1993.1157; MOORE MJ, 1992, BIOCHEMISTRY-US, V31, P1677, DOI 10.1021/bi00121a015; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zahn R, 2001, J MOL BIOL, V313, P923, DOI 10.1006/jmbi.2001.5099	32	306	363	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37597	37603		10.1074/jbc.M205305200	http://dx.doi.org/10.1074/jbc.M205305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138110	hybrid			2022-12-25	WOS:000178447100088
J	Zoll, WL; Horton, LE; Komar, AA; Hensold, JO; Merrick, WC				Zoll, WL; Horton, LE; Komar, AA; Hensold, JO; Merrick, WC			Characterization of mammalian eIF2A and identification of the yeast homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; START-SITE; PURIFICATION; SUBUNIT; EXPRESSION; RIBOSOMES; SELECTION; ENCODES; BINDING	To begin the physical characterization of eukaryotic initiation factor (eIF) 2A, a translation initiation factor that binds Met-tRNA., tryptic peptides from rabbit reticulocyte eIF2A were analyzed to obtain amino acid sequence information. Sequences for 8 peptides were matched to three different expressed sequence tag clones. The sequence predicted for eIF2A is 585 amino acids. Matching of the cDNA sequence to the human genome revealed that the eIF2A mRNA is made up of 15 or 16 exons, and the gene is contained on chromosome 3. A homolog in Saccharomyces cerevisiae was identified, YGR054W, which is a non-essential gene. Hemagglutinin-tagged yeast eIF2A localizes on both 40 S and 80 S ribosomes. A knockout of both eIF2A and eIF5B yielded a "synthetically sick" yeast strain with a severe slow growth phenotype. The phenotype of this double mutant and the biochemical localization suggest that eIF2A participates in translation initiation. eIF2A does not appear to participate in re-initiation as the DeltaeIF2A strain shows the same level of GCN4 induction with amino acid starvation as seen in wild type yeast. The lack of any apparent phenotype in the DeltaeIF2A strain suggests that eIF2A functions in a minor pathway, perhaps internal initiation or in the translation of a small number of specific mRNAs.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	wcm2@po.ewru.edu		Komar, Anton/0000-0003-4188-0633	NIDDK NIH HHS [DK43414, DK09915] Funding Source: Medline; NIGMS NIH HHS [GM26796, GM08056] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; BECKER D M, 1991, P182; BENNE R, 1978, J BIOL CHEM, V253, P3078; Castilho-Valavicius Beatriz, 1992, Gene Expression, V2, P297; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; Donahue TF, 2000, COLD SPRING HARBOR M, V39, P487; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GUPTA NK, 1973, J BIOL CHEM, V248, P4500; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LEVIN DH, 1973, P NATL ACAD SCI USA, V70, P41, DOI 10.1073/pnas.70.1.41; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1975, J BIOL CHEM, V250, P1197; MERRICK WC, 1979, J BIOL CHEM, V254, P3708; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonenberg N, 2000, TRANSLATIONAL CONTRO; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	35	47	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37079	37087		10.1074/jbc.M207109200	http://dx.doi.org/10.1074/jbc.M207109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133843	hybrid			2022-12-25	WOS:000178447100024
J	Palancade, B; Dubois, MF; Bensaude, O				Palancade, B; Dubois, MF; Bensaude, O			FCP1 phosphorylation by casein kinase 2 enhances binding to TFIIF and RNA polymerase II carboxyl-terminal domain phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CODING GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ELONGATION COMPLEXES; LARGEST SUBUNIT; HELA-CELLS; P-TEFB; CK2; DEPHOSPHORYLATION; YEAST	Dephosphorylation of RNA polymerase H carboxyl-terminal domain (CTD) is required to resume sequential transcription cycles. FCP1 (TFIIF-dependent CTD phosphatase 1) is the only known phosphatase targeting RNAP H CTD. Here we show that in Xenopus laevis cells, xFCP1 is a phosphoprotein. On the basis of biochemical fractionation and drug sensitivity, casein kinase 2 (CK2) is shown to be the major kinase involved in xFCP1 phosphorylation in X. laevis egg extracts. CK2 phosphorylates xFCP1 mainly at a cluster of serines centered on Ser(457). CK2-dependent phosphorylation enhances 4-fold the CTD phosphatase activity of FCP1 and its binding to the RAP74 subunit of general transcription factor TFIIF. These findings unravel a new mechanism regulating CTD phosphorylation and hence class II gene transcription.	Ecole Normale Super, CNRS, UMR 8541, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bensaude, O (corresponding author), Ecole Normale Super, CNRS, UMR 8541, 46 Rue Ulm, F-75230 Paris 05, France.	bensaude@wotan.ens.fr		Bensaude, Olivier/0000-0002-0259-6608; PALANCADE, Benoit/0000-0002-3894-9735				Ackermann K, 2001, MOL CELL BIOCHEM, V227, P59, DOI 10.1023/A:1013104705100; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; CARDENAS ME, 1993, J CELL SCI, V104, P219; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dubois MF, 1999, NUCLEIC ACIDS RES, V27, P1338, DOI 10.1093/nar/27.5.1338; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hirose Y, 2000, GENE DEV, V14, P1415; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Licciardo P, 2001, AIDS, V15, P301, DOI 10.1097/00002030-200102160-00002; Maldonado E, 1999, FEBS LETT, V443, P256, DOI 10.1016/S0014-5793(98)01734-7; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rossignol M, 1999, J BIOL CHEM, V274, P22387, DOI 10.1074/jbc.274.32.22387; Saez-Vasquez J, 2001, PLANT MOL BIOL, V47, P449, DOI 10.1023/A:1011619413393; SELDIN DC, 1995, SCIENCE, V267, P834; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Trott RL, 2001, J BIOL CHEM, V276, P2159, DOI 10.1074/jbc.M005996200; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	47	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36061	36067		10.1074/jbc.M205192200	http://dx.doi.org/10.1074/jbc.M205192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138108	hybrid			2022-12-25	WOS:000178275100039
J	Wadhwa, R; Sugihara, T; Hasan, MK; Taira, K; Reddel, RR; Kaul, SC				Wadhwa, R; Sugihara, T; Hasan, MK; Taira, K; Reddel, RR; Kaul, SC			A major functional difference between the mouse and human ARF tumor suppressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INK4A LOCUS; ALTERNATIVE PRODUCT; STABILIZES P53; IN-VIVO; P16(INK4A); P19(ARF); MDM2; GENE; P14(ARF); PEX19P	Suppression of tumorigenesis is considerably more stringent in the human than in the much shorter lived mouse species, and the reasons for this difference are poorly understood. We investigated functional differences in the control of the ARF (alternative reading frame) protein that acts upstream of p53 and is encoded along with p16(INK4a) at a major tumor suppressor locus in both the human and mouse genomes. The mouse and human ARF proteins are substantially divergent at their carboxyl termini. We have shown that the mouse ARF protein (p19ARF) interacts with Pex19p in the cell cytoplasm leading to its nuclear exclusion and repression of its p53 activation function. The human ARF protein (p14ARF) is substantially smaller than its mouse counterpart and is not subject to this functional inactivation by Pex19p. In an identical cellular background, ribozymes directed against Pex19p enhanced p19ARF- but not p14ARF-activated p53 function. This is the first demonstration of a functional difference between the mouse and human ARF proteins. In view of the major role of ARF in tumor suppression, this distinction may contribute to the different levels of tumor proneness of these species.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Lab, Tsukuba, Ibaraki 3058566, Japan; Chugai Res Inst Med Sci, Ibaraki 3004101, Japan; Inst Environm Sci, Dept Radiobiol, Kamikita, Aomori 0393212, Japan; Childrens Med Res Inst, Westmead, NSW 2145, Australia	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; Children's Medical Research Institute - Australia	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	s-kaul@aist.go.jp	Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107				Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fujita S, 1997, P NATL ACAD SCI USA, V94, P391, DOI 10.1073/pnas.94.2.391; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gotte K, 1998, MOL CELL BIOL, V18, P616; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; Ichimura K, 2000, CANCER RES, V60, P417; Iwato M, 2000, CANCER RES, V60, P2113; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; James M C, 2000, Prog Cell Cycle Res, V4, P71; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; Kumar R, 1999, MELANOMA RES, V9, P138, DOI 10.1097/00008390-199904000-00005; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Louvet O, 1997, BIOTECHNIQUES, V23, P816, DOI 10.2144/97235bm11; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Munro J, 1999, CANCER RES, V59, P2516; Parkinson EK, 2000, BIOCHEM SOC T, V28, P226, DOI 10.1042/bst0280226; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugihara T, 2001, J BIOL CHEM, V276, P18649, DOI 10.1074/jbc.C100011200; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Weitzman JB, 2001, TRENDS MOL MED, V7, P489, DOI 10.1016/S1471-4914(01)02201-8; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	54	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36665	36670		10.1074/jbc.M203222200	http://dx.doi.org/10.1074/jbc.M203222200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145279	hybrid			2022-12-25	WOS:000178275100112
J	Dargis, R; Pearlstone, JR; Barrette-Ng, I; Edwards, H; Smillie, LB				Dargis, R; Pearlstone, JR; Barrette-Ng, I; Edwards, H; Smillie, LB			Single mutation (A162H) in human cardiac troponin I corrects acid pH sensitivity of Ca2+-regulated actomyosin S1 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TROPOMYOSIN; EXPRESSION; BINDING; COMPLEX; DOMAIN; ACTIN; IDENTIFICATION; MYOFILAMENTS; CONTRACTION	In contrast to skeletal muscle, the efficiency of the contractile apparatus of cardiac tissue has long been known to be severely compromised by acid pH as in the ischemia of myocardial infarction and other cardiac myopathies. Recent reports (Westfall, M. V., and Metzger, J. M. (2001) News Physiol. Sci. 16,278-281; Li, G., Martin, A. F., and Solaro, R. J. (2001) J. Mol. Cell. Cardiol. 33, 1309-1320) have indicated that the reduced Ca2+ sensitivity of cardiac contractility at low pH (less than or equal topH 6.5) is attributable to structural difference(s) in the cardiac and skeletal inhibitory components (TnIs) of their troponins. Here, using a reconstituted Ca2+-regulated human cardiac troponin-tropomyosin actomyosin S1 ATPase assay, we report that a single TnI mutation, A162H, restores Ca2+ sensitivity at pH 6.5 to that at pH 7.0. Levels of inhibition (pCa 7.0), activation (pCa 4.0), and cooperativity of ATPase activity were minimally affected. Two other mutations (Q155R and E164V) also previously suggested by us (Pearlstone, J. R., Sykes, B. D., and Smillie, L. B. (1997) Biochemistry 36, 7601-7606) and involving charged residues showed no such effects. With fast skeletal muscle troponin, a single TnI H130A mutation reduced Ca2+ sensitivity at pH 6.5 to levels approaching the cardiac system at pH 6.5. These observations provide structural insight into long-standing physiological and clinical phenomena and are of potential relevance to therapeutic treatments of heart disease by gene transfer, stem cell, and cell transplantation approaches.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Smillie, LB (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	l.smillie@ualberta.ca						ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gaskell W H, 1880, J Physiol, V3, P48; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; KLUWE L, 1993, FEBS LETT, V323, P83, DOI 10.1016/0014-5793(93)81453-7; Li G, 2001, J MOL CELL CARDIOL, V33, P1309, DOI 10.1006/jmcc.2000.1392; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; MAK AS, 1983, J BIOL CHEM, V258, P4330; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Mukherjea P, 1999, BIOCHEMISTRY-US, V38, P13296, DOI 10.1021/bi9906120; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; Pearlstone JR, 2000, J BIOL CHEM, V275, P35106, DOI 10.1074/jbc.M001000200; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Wang X, 2002, J BIOL CHEM, V277, P31124, DOI 10.1074/jbc.M203896200; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2001, NEWS PHYSIOL SCI, V16, P278; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x	31	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34662	34665		10.1074/jbc.C200419200	http://dx.doi.org/10.1074/jbc.C200419200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12151382	hybrid			2022-12-25	WOS:000178117000003
J	Mishra-Gorur, K; Singer, HA; Castellot, JJ				Mishra-Gorur, K; Singer, HA; Castellot, JJ			The S18 ribosomal protein is a putative substrate for Ca2+/calmodulin-activated protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TRANSFER-RNA; CROSS-LINKS; HEPARIN; PHOSPHORYLATION; BINDING; IDENTIFICATION; PROLIFERATION; NEIGHBORHOOD; EXPRESSION	The delta-isoform of Ca2+/calmodulin-activated protein kinase II (CaMK II) is abundantly expressed in vascular smooth muscle, but relatively little is known about its regulation or its potential cellular substrates. There are few, if any, known substrates of CaMK II that are physiologically relevant in vascular smooth muscle cells. Studies presented earlier (Mishra-Gorur, K., Singer, H. A., and Castellot, J. J., Jr. (2002) Am. J. Pathol, in press) by our laboratory show an inhibitory effect of heparin on CaMK II phosphorylation and activity. During these studies we observed the specific co-immuno-precipitation of a 20-kDa protein with CaMK II. Purification and sequence analysis indicate that this protein is the S18 protein of the 40 S ribosome. S18 was found to be abundantly phosphorylated in response to serum treatment, and this effect was strongly inhibited by heparin. In addition, KN-93, a specific CaMK II inhibitor, blocks S18 phosphorylation in vascular smooth muscle cells; a concomitant 24% reduction in protein synthesis was observed. Taken together these data support the idea that S18 could be a novel substrate for CaMK II, thus providing a potential link between Ca2+-mobilizing agents and protein translation.	Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Tufts University; Tufts University; Albany Medical College	Castellot, JJ (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cell Biol, 136 Harrison Ave, Boston, MA 02111 USA.				NHLBI NIH HHS [HL 49973, HL 49426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049426, R56HL049426, R01HL049973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; AUSEBEL FM, 1996, CURRENT PROTOCOLS MO, P286; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BOILEAU G, 1983, BIOCHEMISTRY-US, V22, P3162, DOI 10.1021/bi00282a020; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; Caleb BL, 1996, J CELL PHYSIOL, V167, P185, DOI 10.1002/(SICI)1097-4652(199605)167:2<185::AID-JCP1>3.0.CO;2-L; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CHAN YL, 1991, BIOCHEM BIOPH RES CO, V178, P1212, DOI 10.1016/0006-291X(91)91022-5; COCHRAN DL, 1985, J CELL PHYSIOL, V124, P29, DOI 10.1002/jcp.1041240106; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAWELL EH, 1989, J BIOL CHEM, V264, P1650; FAXEN M, 1994, BBA-GENE STRUCT EXPR, V1218, P27, DOI 10.1016/0167-4781(94)90097-3; GARWOOD J, 1994, GENE, V141, P231, DOI 10.1016/0378-1119(94)90577-0; GULVE EA, 1989, BIOCHEM J, V260, P377, DOI 10.1042/bj2600377; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P113; Heilek GM, 1996, RNA, V2, P597; Herbert JM, 1996, J BIOL CHEM, V271, P25928; ISSINGER OG, 1975, EUR J BIOCHEM, V59, P137, DOI 10.1111/j.1432-1033.1975.tb02434.x; Mishra-Gorurt K., 1997, Molecular Biology of the Cell, V8, p401A; MISHRAGORUR K, 2002, IN PRESS AM J PATHOL; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; POHL T, 1988, J BIOL CHEM, V263, P4293; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; Pukac LA, 1997, J CELL PHYSIOL, V172, P69, DOI 10.1002/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B; SCHWARZBAUER J, 1985, NUCLEIC ACIDS RES, V13, P6767, DOI 10.1093/nar/13.18.6767; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TAZI KA, 1995, BIOCHEM J, V307, P557, DOI 10.1042/bj3070557; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOWER J, 1990, BIOCHIM BIOPHYS ACTA, V1050, P38, DOI 10.1016/0167-4781(90)90138-R	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33537	33540		10.1074/jbc.C200342200	http://dx.doi.org/10.1074/jbc.C200342200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12145273	hybrid			2022-12-25	WOS:000177959100002
J	Lampinen, M; Settimo, L; Pentikainen, OT; Jouppila, A; Mottershead, DG; Johnson, MS; Keinanen, K				Lampinen, M; Settimo, L; Pentikainen, OT; Jouppila, A; Mottershead, DG; Johnson, MS; Keinanen, K			Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING CORE; AMPA RECEPTOR; NUCLEIC-ACIDS; NMDA RECEPTOR; FORCE-FIELD; PROTEINS; IDENTIFICATION; SITE; ACTIVATION; MECHANISM	dThe crystal structures of the ligand-binding core of the agonist complexes of the glutamate receptor-B (GluR-B) subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptor indicate that the distal anionic group of agonist molecules are stabilized by interactions with an N-terminal region of an a-helix (helix F) in the lobe 2 ("domain 2," Armstrong, N., and Gouaux, E. (2000) Neuron 28, 165-181) of the two-lobed ligand-binding domain. We used site-directed mutagenesis to further analyze the role of this region in the recognition of both agonists and antagonists by the AMPA receptor. Wild-type and mutated versions of the ligand-binding domain of GluR-D were expressed in insect cells as secreted soluble polypeptides and subjected to binding assays using [H-3]AMPA, an agonist, and [H-3]Ro 48-8587 (9-imidazol-1-yl-8-nitro-2,3,5,6-tetrahydro[1,2,4]triazolo[1,5-c] quinazoline-2,5-dione), a high affinity AMPA receptor antagonist, as radioligands. Single alanine substitutions at residues Leu-672 and Thr-677 severely affected the affinities for all agonists, as seen in ligand competition assays, whereas similar mutations at residues Asp-673, Ser-674, Gly-675, Ser-676, and Lys-678 selectively affected the binding affinities of one or two of the agonists. In striking contrast, the binding affinities of [H-3]Ro 48-8587 and of another competitive antagonist, 6,7-dinitroquinoxaline-2,3-dione, were not affected by any of these alanine mutations, suggesting the absence of critical side-chain interactions. Together with ligand docking experiments, our results indicate a selective engagement of the side chains of the helix F region in agonist binding, and suggest that conformational changes involving this region may play a critical role in receptor activation.	Univ Helsinki, Dept Biosci, Div Biochem, Helsinki 00014, Finland; Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Helsinki 00014, Finland; Abo Akad Univ, Dept Biochem & Pharm, Turku 20520, Finland	University of Helsinki; University of Helsinki; Abo Akademi University	Keinanen, K (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikinkaari 5D, Helsinki 00014, Finland.		Keinanen, Kari/E-9122-2010; Mottershead, David G/B-7749-2013; Pentikäinen, Olli T/E-1980-2012	Mottershead, David G/0000-0003-2593-0725; Pentikäinen, Olli T/0000-0001-7188-4016				Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HONORE T, 1988, J NEUROCHEM, V51, P457, DOI 10.1111/j.1471-4159.1988.tb01060.x; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; Matzen L, 1997, J MED CHEM, V40, P520, DOI 10.1021/jm9607212; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mutel V, 1998, J NEUROCHEM, V71, P418; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STEMBACH Y, 1994, NEURON, V13, P1345; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wo ZG, 1996, MOL PHARMACOL, V50, P770	28	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41940	41947		10.1074/jbc.M205242200	http://dx.doi.org/10.1074/jbc.M205242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167621	hybrid			2022-12-25	WOS:000178985300082
J	Shanks, RA; Steadman, BT; Schmidt, PH; Goldenring, JR				Shanks, RA; Steadman, BT; Schmidt, PH; Goldenring, JR			AKAP350 at the Golgi apparatus - I. Identification of a distinct Golgi apparatus targeting motif in AKAP350	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ASSOCIATION; CENTROSOME; INTERACTS; SUBUNIT; FAMILY	The protein kinase A-anchoring proteins (AKAPs) are defined by their ability to scaffold protein kinase A to specific subcellular compartments. Each of the AKAP family members utilizes unique targeting domains specific for a particular subcellular compartment. AKAP350 is a multiply spliced AKAP family member localized to the centrosome and the Golgi apparatus. Three splicing events in the carboxyl terminus of AKAP350 generate the AKAP350A, AKAP350B, and AKAP350C proteins. A monoclonal antibody recognizing all three splice variants as well as a polyclonal antibody specific for AKAP350A demonstrated both centrosomal and Golgi apparatus staining in paraformaldehyde-fixed HCA-7 cells. Golgi apparatus-associated ARAP350A staining was dispersed following brefeldin A treatment. Using GFP chimeric constructs of the carboxyl-terminal regions of AKAP350A, a Golgi apparatus targeting domain was identified between amino acids 3259 and 3307 of AKAP350A. This domain was functionally distinguishable from the recently described centrosomal targeting domain (PACT domain, amino acids 3308-3324) located adjacent to the Golgi targeting domain. These data definitively establish the specific association of AKAP350A with the Golgi apparatus in HCA-7 cells.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Anat, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Goldenring, JR (corresponding author), Vanderbilt Univ, Sch Med, Epithelial Biol Program, 4160A MRB 3,465 21st Ave So, Nashville, TN 37232 USA.	jim.goldenring@vanderbilt.edu			NIDDK NIH HHS [DK 48370, DK 43405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043405, R29DK043405, R01DK048370] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gillingham AK, 2000, EMBO REP, V1, P524; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; Lin JW, 1998, J NEUROSCI, V18, P2017; Puthenveedu MA, 2001, J CELL BIOL, V155, P227, DOI 10.1083/jcb.200105005; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; Steadman BT, 2002, J BIOL CHEM, V277, P30165, DOI 10.1074/jbc.M201914200; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	19	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40967	40972		10.1074/jbc.M203307200	http://dx.doi.org/10.1074/jbc.M203307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12163481	hybrid			2022-12-25	WOS:000178791400104
J	Bahar, R; O-Wang, JY; Kawamura, K; Seimiya, M; Wang, YQ; Hatano, M; Okada, S; Tokuhisa, T; Watanabe, T; Tagawa, M				Bahar, R; O-Wang, JY; Kawamura, K; Seimiya, M; Wang, YQ; Hatano, M; Okada, S; Tokuhisa, T; Watanabe, T; Tagawa, M			Growth retardation, polyploidy, and multinucleation induced by Clast3, a novel cell cycle-regulated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS KINASE CHK; CHECKPOINT; EXPRESSION; OVEREXPRESSION; ANEUPLOIDY; ANTIGEN; GENE; ONCOPROTEIN; INSTABILITY; APOPTOSIS	We have identified a novel gene, Clast3, by subtraction of cDNAs derived from activated and naive B lymphocytes. Clast3 expression is elevated in cycling cells and down-regulated in cells undergoing growth arrest, indicating that its expression is controlled in a cell cycle-dependent manner. The deduced amino acid sequence of Clast3 cDNA exhibits no significant homology to the known proteins in mammalian and other species. Immunofluorescence staining revealed that Clast3 localizes into discrete nuclear foci. Forced expression of Clast3 results in growth retardation, polyploidy, and generation of multinucleated cells. Treatment of Clast3 transfectants with nocodazole, a spindle-damaging agent, greatly enhances the incidence of the multinucleated cells, suggesting that Clast3 overexpression impairs the same checkpoint activated by nocodazole. Down-regulation of Clast3 expression by antisense oligonucleotides results in a decrease of cells at G2-M phase and a concomitant increase of apoptotic cells. These findings indicate that Clast3 is a novel cell cycle-regulated protein and that its constitutive overexpression induces polyploidy and multinucleation by interfering with the mitotic spindle checkpoint.	Chiba Canc Ctr, Inst Res, Div Pathol, Chou Ku, Chiba 2608717, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba 2608670, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Fukuoka 8128582, Japan	Chiba Cancer Center; Chiba University; Chiba University; Kyushu University	O-Wang, JY (corresponding author), Chiba Canc Ctr, Inst Res, Div Pathol, Chou Ku, 666-2 Nitona Cho, Chiba 2608717, Japan.	oh@chiba-cc.pref.chiba.jp	Okada, Seiji/F-5785-2013					Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fode C, 1996, MOL CELL BIOL, V16, P4665; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; JALLEPALLI VP, 2001, NATURE MILESTONES, pS36; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Khan SH, 1998, CANCER RES, V58, P396; Knecht H, 1996, ONCOGENE, V13, P947; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEONARDO DA, 1997, CANCER RES, V57, P1013; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Samokhvalov I, 1997, BIOCHEM MOL BIOL INT, V43, P115; Seimiya M, 2002, BIOCHEM BIOPH RES CO, V292, P121, DOI 10.1006/bbrc.2002.6605; Shekhar MPV, 2002, CANCER RES, V62, P2115; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Townson SM, 2000, CLIN CANCER RES, V6, P3788; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Yamaguchi N, 2001, J CELL SCI, V114, P1631	30	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40012	40019		10.1074/jbc.M205345200	http://dx.doi.org/10.1074/jbc.M205345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12147697	hybrid			2022-12-25	WOS:000178662500121
J	Marchal, S; Branlant, G				Marchal, S; Branlant, G			Characterization of the amino acids involved in substrate specificity of nonphosphorylating glyceraldehyde-3-phosphate dehydrogenase from Streptococcus mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; ANGSTROM RESOLUTION; METABOLISM; GLUTAMATE-268	In order to address the molecular basis of the specificity of aldehyde dehydrogenase for aldehyde substrates, enzymatic characterization of the glyceraldehyde 3-phosphate (G3P) binding site of non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Streptococcus mutans has been undertaken. In this work, residues Arg-124, Tyr-170, Arg-301, and Arg-459 were changed by site-directed mutagenesis and the catalytic properties of GAPN mutants investigated. Changing Tyr-170 into phenylalanine induces no major effect on k(cat) and K-m for D-G3P in both acylation and deacylation steps. Substitutions of Arg-124 and Arg-301 by leucine and Arg-459 by isoleucine led to distinct effects on K-m, on k(cat), or on both. The rate-limiting step of the R124L GAPN remains deacylation. Pre-steady-state analysis and substrate isotope measurements show that hydride transfer remains rate-determining in acylation. Only the apparent affinity for D-G3P is decreased in both acylation and deacylation steps. Substitution of Arg-459 by isoleucine leads to a drastic effect on the catalytic efficiency by a factor of 10(5). With this R459L GAPN, the rate-limiting step is prior to hydride transfer, and the K-m of D-G3P is increased by at least 2 orders of magnitude. Binding of NADP leads to a time-dependent formation of a charge transfer transition at 333 nm between the pyridinium ring of NADP and the thiolate of Cys-302, which is not observed with the holo-wild type. Accessibility of Cys-302 is shown to be strongly decreased within the holostructure. The substitution of Arg-301 by leucine leads to an even more drastic effect with a change of the rate-limiting step similar to that observed for R4591 GAPN. Taking into account the three-dimensional structure of GAPN from S. mutans and the data of the present study, it is proposed that 1) Tyr-170 is not essential for the catalytic event, 2) Arg-124 is only involved in stabilizing D-G3P binding via an interaction with the C-3 phosphate, and 3) Arg-301 and Arg-459 participate not only in D-G3P binding via interaction with C-3 phosphate but also in positioning efficiently D-G3P relative to Cys-302 within the ternary complex GAPN-NADP-D-G3P.	Univ Nancy 1, Fac Sci, UMR CNRS 7567, Lab Maturat ARN & Enzymol Mol, F-54506 Vandoeuvre Les Nancy, France	Universite de Lorraine	Branlant, G (corresponding author), Univ Nancy 1, Fac Sci, UMR CNRS 7567, Lab Maturat ARN & Enzymol Mol, BP 239, F-54506 Vandoeuvre Les Nancy, France.		MARCHAL, stéphane/M-4324-2017	MARCHAL, stéphane/0000-0002-1101-7890				Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; Casati DFG, 2000, PLANT SCI, V154, P107, DOI 10.1016/S0168-9452(99)00241-1; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; CORBIER C, 1990, BIOCHIMIE, V72, P545, DOI 10.1016/0300-9084(90)90119-2; HOCHACHKA PW, 2002, BIOCH ADAPTATION MEC, P290; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4445, DOI 10.1021/bi9521093; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Marchal S, 2000, BIOCHEMISTRY-US, V39, P3327, DOI 10.1021/bi9914208; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; MOUGIN A, 1988, PROTEIN ENG, V2, P45, DOI 10.1093/protein/2.1.45; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; Ni L, 1999, PROTEIN SCI, V8, P2784; Pohl E, 2002, J BIOL CHEM, V277, P19938, DOI 10.1074/jbc.M112244200; RACKER E, 1952, J BIOL CHEM, V198, P731; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; Vasiliou V, 2000, PHARMACOLOGY, V61, P192, DOI 10.1159/000028400; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028	24	12	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39235	39242		10.1074/jbc.M205633200	http://dx.doi.org/10.1074/jbc.M205633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163495	hybrid			2022-12-25	WOS:000178662500024
J	Elad-Sfadia, G; Haklai, R; Ballan, E; Gabius, HJ; Kloog, Y				Elad-Sfadia, G; Haklai, R; Ballan, E; Gabius, HJ; Kloog, Y			Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL LINES; K-RAS; HUMAN GLIOMAS; H-RAS; FAMILY; PROTEIN; BINDING; COMPLEX; SURFACE; GROWTH	Ras proteins activate diverse effector molecules. Depending on the cellular context, Ras activation may have different biological consequences: induction of cell proliferation, senescence, survival, or death. Augmentation and selective activation of particular effector molecules may underlie various Ras actions. In fact, Ras effector-loop mutants interacting with distinctive effectors provide evidence for such selectivity. Interactions of active Ras with escort proteins, such as galectin-1, could also direct Ras selectivity. Here we show that in comparison with Ras transfectants, H-Ras/galectin-1 or K-Ras4B/galectin-1 co-transfectants exhibit enhanced and prolonged epidermal growth factor (EGF)-stimulated increases in Ras-GTP, Raf-1 activity, and active extracellular signal-regulated kinase. Galectin-1 antisense RNA inhibited these EGF responses. Conversely, Ras and galectin-1 co-transfection inhibited the EGF-stimulated increase in phosphoinositide 3-kinase (PI3K) activity. Galectin-1 transfection also inhibited Ras(G12V)-induced PI3K but not Raf-1 activity. Galectin-1 co-immunoprecipitated with Ras(G12V) or with Ras(G12V/T35S) that activate Raf-1 but not with Ras(G12V/ Y40C) that activates PI3K. Thus, galectin-1 binds active Ras and diverts its signal to Raf-1 at the expense of PI3K. This demonstrates a novel mechanism controlling the duration and selectivity of the Ras signal. Ras gains selectivity when it is associated with galectin-1, mimicking the selectivity of Ras(T35S), which activates Raf-1 but not PI3K.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Munich, Fac Med Vet, Inst Physiol Chem, D-80539 Munich, Germany	Tel Aviv University; University of Munich	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il		Gabius, Hans-Joachim/0000-0003-3467-3900				Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORI Y, 1991, ONCOGENE, V6, P515; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VICIANA PR, 1997, CELL, V89, P457; VICIANA PR, 1996, EMBO J, V15, P2442; VICIANA PR, 1994, NATURE, V370, P527; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	45	181	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37169	37175		10.1074/jbc.M205698200	http://dx.doi.org/10.1074/jbc.M205698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149263	hybrid			2022-12-25	WOS:000178447100035
J	Paolini, R; Molfetta, R; Beitz, LO; Zhang, J; Scharenberg, AM; Piccoli, M; Frati, L; Siraganian, R; Santoni, A				Paolini, R; Molfetta, R; Beitz, LO; Zhang, J; Scharenberg, AM; Piccoli, M; Frati, L; Siraganian, R; Santoni, A			Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fc epsilon RI and Syk in RBL cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; HUMAN NK CELLS; HIGH-AFFINITY; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; RECEPTOR-ZETA; BETA-SUBUNIT; PHOSPHORYLATION; ANTIGEN; CHAIN	Engagement of the high affinity receptor for IgE (FcepsilonRI) on mast cells and basophils results in FcepsilonRI beta and gamma subunits ubiquitination by an as yet undefined mechanism. Here we show that, upon FcepsilonRI engagement on RBL-2H3 cells Syk undergoes ubiquitination and Syk kinase activity is required for its own ubiquitination and that of FcepsilonRI beta and gamma chains. This requirement was demonstrated by overexpression of Syk wild-type or its kinase-dead mutant in RBL cells or using an Syk-deficient RBL-derived cell line transfected with wild-type or a kinase inactive form of Syk. We also identify c-Cbl as the E3 ligase responsible for both Syk and receptor ubiquitination. Furthermore, we demonstrate that Syk controls tyrosine phosphorylation of Syk-associated Cbl induced after receptor engagement. These data suggest a mutual regulation between Syk and Cbl activities. Finally, we show that a selective inhibitor of proteasome degradation induces persistence of tyrosine-phosphorylated receptor complexes, of activated Syk, and of FcepsilonRI-triggered degranulation. Our results provide a molecular mechanism for down-regulation of engaged receptor complexes by targeting ubiquitinated FcepsilonRI and activated Syk to the proteasome for degradation.	Univ Roma La Sapienza, Dept Expt Med & Pathol, Inst Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Washington, Dept Pediat Rheumatol, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; NIDCR, Receptors & Signal Transduct Sect, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Mediterranean Inst Neurosci Neuromed, I-86077 Pozzilli, IS, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); IRCCS Neuromed	Paolini, R (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Inst Pasteur, Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	rossella.paolini@uniroma1.it	Frati, Luigi/ABI-7437-2020; Molfetta, Rosa/N-4529-2015; santoni, angela/K-8997-2016	Molfetta, Rosa/0000-0003-2904-6371; santoni, angela/0000-0003-1206-7731; PAOLINI, Rossella/0000-0001-7605-1531	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000696, Z01DE000696] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHUN DH, 1998, IMMUNOL REV, V165, P176; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Nadler M J, 2000, Adv Immunol, V76, P325; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 1996, J BIOL CHEM, V271, P15987, DOI 10.1074/jbc.271.27.15987; Paolini R, 1999, EUR J IMMUNOL, V29, P3179, DOI 10.1002/(SICI)1521-4141(199910)29:10<3179::AID-IMMU3179>3.0.CO;2-9; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; Sada K, 2001, BLOOD, V97, P1352, DOI 10.1182/blood.V97.5.1352; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V147, P4263; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Weiss RA, 2000, EMBO REP, V1, P2, DOI 10.1093/embo-reports/kvd017; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	54	70	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36940	36947		10.1074/jbc.M204948200	http://dx.doi.org/10.1074/jbc.M204948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145291	hybrid			2022-12-25	WOS:000178447100006
J	Saxowsky, TT; Matsumoto, Y; Englund, PT				Saxowsky, TT; Matsumoto, Y; Englund, PT			The mitochondrial DNA polymerase beta from Crithidia fasciculata has 5 '-deoxyribose phosphate (dRP) lyase activity but is deficient in the release of dRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; N-TERMINAL DOMAIN; KINETOPLAST DNA; TOPOISOMERASE-II; MAMMALIAN-CELLS; REPLICATION; SITE; MECHANISM; SEQUENCE; BINDING	DNA polymerase beta (pol beta) has long been described as a nuclear enzyme involved in DNA repair. A pol beta from the trypanosomatid parasite Crithidia fasciculata, however, is the first example of a mitochondrial enzyme of this type. The mammalian nuclear enzyme functions not only as a nucleotidyl transferase but also has a dRP lyase activity that cleaves 5'-deoxyribose phosphate (dRP) groups from DNA, thus contributing to two consecutive steps of the base excision repair pathway. We find that the mitochondrial pol beta also has dRP lyase activity. Interestingly, the K-m of this enzyme for a dRP-containing substrate is similar to that for the rat enzyme, but its k(cat) is very low. This difference is due to a deficiency of the mitochondrial enzyme in the release of dRP from the enzyme following its cleavage from the DNA.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Johns Hopkins University; Johns Hopkins Medicine; Fox Chase Cancer Center	Englund, PT (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027608, R37GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Engel ML, 1999, P NATL ACAD SCI USA, V96, P8455, DOI 10.1073/pnas.96.15.8455; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; Hausler T, 1997, EUR J CELL BIOL, V73, P240; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hines JC, 2001, MOL BIOCHEM PARASIT, V115, P63, DOI 10.1016/S0166-6851(01)00272-9; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Maciejewski MW, 2000, J MOL BIOL, V296, P229, DOI 10.1006/jmbi.1999.3455; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; Piersen CE, 2000, MUTAT RES-DNA REPAIR, V459, P43, DOI 10.1016/S0921-8777(99)00054-3; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674	36	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37201	37206		10.1074/jbc.M206654200	http://dx.doi.org/10.1074/jbc.M206654200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151410	hybrid			2022-12-25	WOS:000178447100039
J	Walzel, B; Speer, O; Zanolla, E; Eriksson, O; Bernardi, P; Wallimann, T				Walzel, B; Speer, O; Zanolla, E; Eriksson, O; Bernardi, P; Wallimann, T			Novel mitochondrial creatine transport activity - Implications for intracellular creatine compartments and bioenergetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SKELETAL-MUSCLE; HEART-MITOCHONDRIA; DOWN-REGULATION; PROTEIN-CONTENT; IN-VIVO; KINASE; GENE; EXPRESSION; EVOLUTION	Immunoblotting of isolated mitochondria from rat heart, liver, kidney, and brain with antibodies made against N- and C-terminal peptide sequences of the creatine transporter, together with in situ immunofluorescence staining and immunogold electron microscopy of adult rat myocardium, revealed two highly related polypeptides with molecular masses of similar to70 and similar to55 kDa in mitochondria. These polypeptides were localized by immunoblotting of inner and outer mitochondrial membrane fractions, as well as by immunogold labeling in the mitochondrial inner membrane. In addition, a novel creatine uptake via a mitochondrial creatine transport activity was demonstrated by [Cl-14]creatine uptake studies with isolated mitochondria from rat liver, heart, and kidney showing a saturable low affinity creatine transporter, which was largely inhibited in a concentration- dependent manner by the sulfhydryl-modifying reagent NEM, as well as by the addition of the above anti-creatine transporter antibodies to partially permeabilized mitochondria. Mitochondrial creatine transport was to a significant part dependent on the energetic state of mitochondria and was inhibited by arginine, and to some extent also by lysine, but not by other creatine analogues and related compounds. The existence of an active creatine uptake mechanism in mitochondria indicates that not only creatine kinase isoenzymes, but also creatine transporters and thus a certain proportion of the creatine kinase substrates, might be subcellularly compartmentalized. Our data suggest that mitochondria, shown here to possess creatine transport activity, may harbor such a creatine/phosphocreatine pool.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Helsinki, Inst Biomed Biochem, Biomedicum, FIN-00014 Helsinki, Finland; Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Helsinki; University of Padua	Wallimann, T (corresponding author), ETH Honggerberg, Inst Cell Biol, HPM F42, CH-8093 Zurich, Switzerland.		Eriksson-Rosenberg, Ove/GVU-6692-2022; Bernardi, Paolo/C-3656-2008; Wallimann, Theo/C-6047-2008	Bernardi, Paolo/0000-0001-9187-3736; Wallimann, Theo/0000-0003-4957-5836				AFOLAYAN A, 1986, COMP BIOCHEM PHYS B, V85, P463, DOI 10.1016/0305-0491(86)90028-3; BARNWELL LFS, 1995, GENE, V159, P287, DOI 10.1016/0378-1119(95)00104-E; Eichler EE, 1996, HUM MOL GENET, V5, P899, DOI 10.1093/hmg/5.7.899; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Fiermonte G, 1999, BIOCHEM J, V344, P953, DOI 10.1042/0264-6021:3440953; FITCH CD, 1966, J BIOL CHEM, V241, P3611; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; HEBISCH S, 1986, PFLUG ARCH EUR J PHY, V406, P20, DOI 10.1007/BF00582947; HENRY HO, 2001, CELL BIOL INT, V25, P940; Hochachka PW, 1998, AM J PHYSIOL-REG I, V274, pR868, DOI 10.1152/ajpregu.1998.274.3.R868; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iyer GS, 1996, GENOMICS, V34, P143, DOI 10.1006/geno.1996.0254; Joubert F, 2000, BIOPHYS J, V79, P1, DOI 10.1016/S0006-3495(00)76269-2; Joubert F, 2001, BIOCHEMISTRY-US, V40, P2129, DOI 10.1021/bi001695j; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Kreis R, 1999, J MAGN RESON, V137, P350, DOI 10.1006/jmre.1998.1683; Menin L, 2001, MOL CELL BIOCHEM, V220, P149, DOI 10.1023/A:1010960309898; MOZO T, 1995, PLANT J, V7, P1015, DOI 10.1046/j.1365-313X.1995.07061015.x; MUNN EA, 1968, J ULTRA MOL STRUCT R, V25, P362, DOI 10.1016/S0022-5320(68)80092-9; Murphy R, 2001, AM J PHYSIOL-CELL PH, V280, pC415, DOI 10.1152/ajpcell.2001.280.3.C415; MUSCATELLO U, 1968, J ULTRA MOL STRUCT R, V25, P73, DOI 10.1016/S0022-5320(68)80061-9; NASH SR, 1994, RECEPTOR CHANNEL, V2, P165; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Sahlin K, 1997, AM J PHYSIOL-CELL PH, V273, pC172, DOI 10.1152/ajpcell.1997.273.1.C172; Salomons GS, 2001, AM J HUM GENET, V68, P1497, DOI 10.1086/320595; Sandoval N, 1996, GENOMICS, V35, P383, DOI 10.1006/geno.1996.0373; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Soboll S, 1997, BBA-BIOENERGETICS, V1320, P27, DOI 10.1016/S0005-2728(97)00004-2; SORA I, 1994, BIOCHEM BIOPH RES CO, V204, P419, DOI 10.1006/bbrc.1994.2475; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055; Territo PR, 2001, CELL CALCIUM, V30, P19, DOI 10.1054/ceca.2001.0211; Tran TT, 2000, J BIOL CHEM, V275, P35708, DOI 10.1074/jbc.M005636200; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1996, J MUSCLE RES CELL M, V17, P177, DOI 10.1007/BF00124240; Walzel B, 2002, AM J PHYSIOL-ENDOC M, V283, pE390, DOI 10.1152/ajpendo.00428.2001; WALZEL B, 2001, CELL BIOL INT, V25, P949; WALZEL B, 2000, EUR J MED RES S, V5, P28; WOLFEL R, 1989, BRIT J PHARMACOL, V97, P1308; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Yeung CH, 1996, MOL HUM REPROD, V2, P591, DOI 10.1093/molehr/2.8.591	46	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37503	37511		10.1074/jbc.M201168200	http://dx.doi.org/10.1074/jbc.M201168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145274	hybrid			2022-12-25	WOS:000178447100076
J	Han, R; Smith, TJ				Han, R; Smith, TJ			Cytoplasmic prostaglandin E-2 synthase is dominantly expressed in cultured KAT-50 thyrocytes, cells that express constitutive prostaglandin-endoperoxide H synthase-2 - Basis for low prostaglandin E-2 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ORBITAL FIBROBLASTS; THYROID-CELLS; PANCREATIC-ISLET; GRAVES-DISEASE; UP-REGULATION; CYCLOOXYGENASE-2; INDUCTION; GENE; IMMUNOGLOBULINS; IDENTIFICATION	The recent identification and cloning of two glutathione-dependent prostaglandin E-2 synthase (PGES) genes has yielded important insights into the terminal step of PGE(2) synthesis. These enzymes form efficient functional pairs with specific members of the prostaglandin-endoperoxide H synthase (PGHS) family. Microsomal PGES (mPGES) is inducible and works more efficiently with PGHS-2, the inflammatory cyclooxygenase, while the cytoplasmic isoform (cPGES) pairs functionally with PGHS-1, the cyclooxygenase that ordinarily exhibits constitutive expression. KAT-50, a well differentiated thyroid epithelial cell line, expresses high levels of PGHS-2 but surprisingly low levels of PGE2 when compared with human orbital fibroblasts. Moreover, PGHS-1 protein cannot be detected in KAT-50. We report here that KAT-50 cells express high basal levels of cPGES but mPGES mRNA and protein are undetectable. Thus, KAT-50 cells express the inefficient PGHS-2/ePGES pair, and this results in modest PGE2 production. The high levels of cPGES and the absence of mPGES expression result from dramatic differences in the activities of their respective gene promoters. When mPGES is expressed in KAT-50 by transiently transfecting the cells, PGE2 production is up-regulated substantially. These observations indicate that naturally occurring cells can express a suboptimal profile of PGHS and PGES isoforms, resulting in diminished levels of PGE2 generation.	Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Smith, TJ (corresponding author), Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Bldg C-2,1124 W Carson St, Torrance, CA 90502 USA.		Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NEI NIH HHS [EY08976, EY11708] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011708, R01EY008976] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; Atwa MA, 1996, EUR J ENDOCRINOL, V135, P322, DOI 10.1530/eje.0.1350322; BETZ M, 1991, J IMMUNOL, V146, P108; Cao HJ, 1999, AM J PHYSIOL-CELL PH, V277, pC1075, DOI 10.1152/ajpcell.1999.277.6.C1075; Cao HJ, 1998, J BIOL CHEM, V273, P29615, DOI 10.1074/jbc.273.45.29615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; DiPaola R, 1997, J CLIN ENDOCR METAB, V82, P670, DOI 10.1210/jc.82.2.670; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FOX BS, 1993, IMMUNOMETHODS, V2, P255; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gianoukakis AG, 2001, AM J PHYSIOL-CELL PH, V280, pC701, DOI 10.1152/ajpcell.2001.280.3.C701; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HU ZQ, 1995, J IMMUNOL, V155, P2134; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OBANION MK, 1991, J BIOL CHEM, V266, P23261; RANKIN JHG, 1976, AM J PHYSIOL, V231, P754, DOI 10.1152/ajplegacy.1976.231.3.754; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; ROPER RL, 1990, J IMMUNOL, V145, P2644; Smith TJ, 1999, J BIOL CHEM, V274, P15622, DOI 10.1074/jbc.274.22.15622; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Venkataraman GM, 1998, THYROID, V8, P63, DOI 10.1089/thy.1998.8.63; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36897	36903		10.1074/jbc.M206949200	http://dx.doi.org/10.1074/jbc.M206949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145315	hybrid			2022-12-25	WOS:000178275100143
J	Kwok, JBJ; Kapoor, R; Gotoda, T; Iwamoto, Y; Iizuka, Y; Yamada, N; Isaacs, KE; Kushwaha, VV; Church, WB; Schofield, PR; Kapoor, V				Kwok, JBJ; Kapoor, R; Gotoda, T; Iwamoto, Y; Iizuka, Y; Yamada, N; Isaacs, KE; Kushwaha, VV; Church, WB; Schofield, PR; Kapoor, V			A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC RECEPTOR ACTIVITY; BLOOD-PRESSURE; GLUTAMATE; MEDULLA; ACID; SHR; RESPONSIVENESS; EXPRESSION; CD36; KAT	Spontaneously hypertensive rats (SHR) are the most extensively used animal model for genetic hypertension, increased stroke damage, and insulin resistance syndromes; however, the identification of target genes has proved difficult. SHR show elevated sympathetic nerve activity, and stimulation of the central blood pressure control centers with glutamate or nicotine results in exaggerated blood pressure responses, effects that appear to be genetically determined. Kynurenic acid, a competitive glutamate antagonist and a non-competitive nicotinic antagonist, can be synthesized in the brain by the enzyme kynurenine aminotransferase-1 (KAT-1). We have previously shown that KAT-1 activity is significantly reduced in SHR compared with normotensive Wistar Kyoto rats (WKY). Here we show that KAT-1 contains a missense mutation, E61G, in all the strains of SHR examined but not in any of the WKY or outbred strains. Previous studies on F2 rats from a cross of stroke-prone SHR and WKY have shown a suggestive level of linkage between elevated blood pressure and the KAT-1 locus on chromosome 3. In addition, the mutant enzyme expressed in Escherichia coli displays altered kinetics. This mutation may explain the enhanced sensitivity to glutamate and nicotine seen in SHR that may be related to an underlying mechanism of hypertension and increased sensitivity to stroke.	Univ New S Wales, Dept Pharmacol & Physiol, Sydney, NSW 2052, Australia; Garvan Inst Med Res, Sydney, NSW 2010, Australia; Tokyo Womens Med Univ, Ctr Diabet, Tokyo 1628666, Japan; Univ Tokyo, Dept Metab Dis, Tokyo 1138655, Japan; Univ Tsukuba, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan	University of New South Wales Sydney; Garvan Institute of Medical Research; Tokyo Women's Medical University; University of Tokyo; University of Tsukuba	Kapoor, V (corresponding author), Univ New S Wales, Dept Pharmacol & Physiol, Sydney, NSW 2052, Australia.	V.Kapoor@unsw.edu.au	Church, William/H-6040-2013; Schofield, Peter/C-9669-2011	Church, William/0000-0002-8033-5518; Kushwaha, Virag/0000-0002-3383-7785; Schofield, Peter/0000-0003-2967-9662; Kwok, John/0000-0001-9574-6195				ABRAHAM DG, 1995, J BIOL CHEM, V270, P180, DOI 10.1074/jbc.270.1.180; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Azzariti A, 1998, BBA-PROTEIN STRUCT M, V1386, P29, DOI 10.1016/S0167-4838(98)00057-0; Clark JS, 1996, HYPERTENSION, V28, P898, DOI 10.1161/01.HYP.28.5.898; Collison M, 2000, DIABETES, V49, P2222, DOI 10.2337/diabetes.49.12.2222; Colombari E, 2001, HYPERTENSION, V38, P549, DOI 10.1161/01.HYP.38.3.549; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323, DOI 10.1152/physrev.1994.74.2.323; Erhardt S, 2001, N-S ARCH PHARMACOL, V363, P21; Garrett MR, 2000, PHYSIOL GENOMICS, V3, P33, DOI 10.1152/physiolgenomics.2000.3.1.33; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; Ito S, 2000, HYPERTENSION, V35, P413, DOI 10.1161/01.HYP.35.1.413; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; Kapoor R, 1997, NEUROREPORT, V8, P3619, DOI 10.1097/00001756-199711100-00039; KAPOOR V, 1994, CLIN EXP PHARMACOL P, V21, P891, DOI 10.1111/j.1440-1681.1994.tb02460.x; Kapoor V, 1996, NEUROREPORT, V7, P1409, DOI 10.1097/00001756-199605310-00017; Kapoor V, 1998, NEUROREPORT, V9, P1431, DOI 10.1097/00001756-199805110-00033; Khan IM, 2001, CLIN EXP HYPERTENS, V23, P555, DOI 10.1081/CEH-100106826; MALHERBE P, 1995, FEBS LETT, V367, P141, DOI 10.1016/0014-5793(95)00546-L; Mashimo T, 1999, AM J HYPERTENS, V12, P1098, DOI 10.1016/S0895-7061(99)00084-9; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; PERRY S, 1995, FEBS LETT, V360, P277, DOI 10.1016/0014-5793(95)00123-Q; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Tsuchihashi T, 1998, HYPERTENSION, V31, P73, DOI 10.1161/01.HYP.31.1.73	25	43	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35779	35782		10.1074/jbc.C200303200	http://dx.doi.org/10.1074/jbc.C200303200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145272	hybrid			2022-12-25	WOS:000178275100001
J	Sowa, H; Kaji, H; Yamaguchi, T; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Yamaguchi, T; Sugimoto, T; Chihara, K			Activations of ERK1/2 and JNK by transforming growth factor beta negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FYVE DOMAIN PROTEIN; BONE-FORMATION; MEDIATED TRANSCRIPTION; GENE-EXPRESSION; ONCOGENIC RAS; CROSS-TALK; C-JUN; SMAD; DIFFERENTIATION; PATHWAYS	Transforming growth factor (TGF) beta inhibits alkaline phosphatase (ALP) activity and mineralization in mouse osteoblastic MC3T3-E1 cells, whereas local administration of TGF-beta stimulates bone formation in vivo. We recently demonstrated that Smad3, a TGF-beta signaling molecule, promotes ALP activity and mineralization in MC3T3-E1 cells. Moreover, the target disruption of Smad3 in mouse is reported to cause a decrease in bone mineral density. These findings indicate that Smad3 plays an important role in the regulation of bone formation. However, why the effects of TGF-beta and Smad3 on ALP activity and mineralization are different remains unknown. The purpose of the present study is to clarify the role of mitogen-activated protein kinase (MAPK) in TGF-beta and Smad3 pathways in osteoblast. TGF-beta activated extracellular signal-regulated kinases/p42/p44 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK) in mouse osteoblastic MC3T3-E1 cells. The expression of dominant negative type Smad3, Smad3DeltaC, affected neither TGF-beta-activated ALAPKs nor TGF-beta-inhibited ALP activity. Specific inhibitors of ERK1/2 activation (PD98059 and U0126), as well as JNK inhibitors (curcumin and dicumarol) antagonized the inhibitory effects of TGF-beta on ALP activity and mineralization, whereas the specific inhibitor of p38 MAPK (SB203580) did not affect them. PD98059 and curcumin enhanced Smad3-induced ALP activity and mineralization, whereas SB203580 inhibited them. In the luciferase reporter assay using 3TP-lux with the specific Smad3-responsive element, PD98059, and curcumin enhanced TGF-beta- and Smad3-induced transcriptional activity in MC3T3-E1 cells. On the other hand, TGF-beta-induced production of type I collagen was antagonized by curcumin but not by PD98059. The present study indicated that TGF-beta-responsive ERK1/2 and JNK cascades negatively regulate Smad3-induced transcriptional activity as well as ALP activity and mineralization in osteoblasts.	Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Sugimoto, T (corresponding author), Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	sugimot@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; BECK LS, 1993, J BONE MINER RES, V8, P753; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; ELFORD PR, 1987, BONE, V8, P259, DOI 10.1016/8756-3282(87)90174-8; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SE, 1994, J BONE MINER RES, V9, P855; IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; LOWRY OH, 1954, J BIOL CHEM, V207, P19; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nishimori S, 2001, J BIOL CHEM, V276, P10700, DOI 10.1074/jbc.M007499200; NODA M, 1986, BIOCHEM BIOPH RES CO, V140, P56, DOI 10.1016/0006-291X(86)91057-0; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Reinholz GG, 2000, CANCER RES, V60, P6001; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756-3282(94)90300-X; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	42	109	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36024	36031		10.1074/jbc.M206030200	http://dx.doi.org/10.1074/jbc.M206030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130649	hybrid			2022-12-25	WOS:000178275100034
J	Mitsunaga, Y; Ciric, B; Van Keulen V; Warrington, AE; Soldan, MMP; Bieber, AJ; Rodriguez, M; Pease, LR				Mitsunaga, Y; Ciric, B; Van Keulen, V; Warrington, AE; Soldan, MMP; Bieber, AJ; Rodriguez, M; Pease, LR			Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease	FASEB JOURNAL			English	Article						recombinant IgM expression vector; Theiler's virus-induced demyelination; remyelination; dhfr	MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; NATURAL AUTOANTIBODY; REMYELINATION; OLIGODENDROCYTES	Certain human sera from patients with monoclonal gammopathies contain factors that induce myelin repair in animals with demyelinating disease. We hypothesize that antibodies functionally distinguish the serum of one patient from another. However, pooled normal polyclonal human IgM antibodies also induce remyelination. Definitive proof that specific antibodies are the biologically active components of serum is missing because unquestionably pure preparations of antibody molecules cannot be generated by fractionation. To demonstrate definitively that antibody is the biologically active component of patient serum, recombinant antibody was generated for evaluation in bioassays. The induction of remyelination in vivo requires milligram quantities of antibody. Consequently, an expression system was engineered to express high-titer, recombinant human IgM antibodies in vitro. A resulting recombinant antibody (rHIgM22) was evaluated for its ability to induce remyelination in the Theiler's virus mouse model of chronic-progressive demyelinating disease. We demonstrate that a single recombinant monoclonal antibody recapitulates the key characteristics of patient serum, including binding specificity, the induction of calcium signals in oligodendrocytes in vitro, and the induction of myelin repair within demyelinated plaques in vivo. The rHIgM22 antibody provides a new venue for the analysis of mechanisms governing remyelination and may prove useful in the treatment of demyelinating diseases.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu		Paz Soldan, M. Mateo/0000-0003-0521-7789; Rodriguez, Moses/0000-0001-6328-6497				Asakura K, 1997, J NEUROCHEM, V68, P2281; Ciric B, 2001, BLOOD, V97, P321, DOI 10.1182/blood.V97.1.321; KISHIMOTO T, 1989, NUCLEIC ACIDS RES, V17, P4385, DOI 10.1093/nar/17.11.4385; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Losman MJ, 1997, CANCER-AM CANCER SOC, V80, P2660, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2660::AID-CNCR43>3.3.CO;2-I; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; MILLER DJ, 1995, J IMMUNOL, V154, P2460; MILLER DJ, 1994, J NEUROSCI, V14, P6230; Niedbala WG, 1998, HYBRIDOMA, V17, P299, DOI 10.1089/hyb.1998.17.299; Pavelko KD, 1998, J NEUROSCI, V18, P2498; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TSUJIMOTO Y, 1984, NUCLEIC ACIDS RES, V12, P8407, DOI 10.1093/nar/12.22.8407; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820	14	65	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1325	+		10.1096/fj.01-0994fje	http://dx.doi.org/10.1096/fj.01-0994fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154009				2022-12-25	WOS:000176683900023
J	Pecheur, I; Peyruchaud, O; Serre, CM; Guglielmi, J; Voland, C; Bourre, F; Margue, C; Cohen-Solal, M; Buffet, A; Kieffer, N; Clezardin, P				Pecheur, I; Peyruchaud, O; Serre, CM; Guglielmi, J; Voland, C; Bourre, F; Margue, C; Cohen-Solal, M; Buffet, A; Kieffer, N; Clezardin, P			Integrin alpha v beta 3 expression confers on tumor cells a greater propensity to metastasize to bone	FASEB JOURNAL			English	Article						metastasis; breast cancer; bone tropism; vitronectin receptor	BREAST-CANCER CELLS; N-TERMINAL DOMAIN; BISPHOSPHONATE IBANDRONATE; ADHESION; ALPHA(V)BETA(3); RECEPTORS; INVOLVEMENT; ACTIVATION; PROSTATE; BINDING	The reasons why tumor cells metastasize to bone remain obscure. There is some evidence to support the theory that integrins (acting as cell surface adhesion receptors) play a role in mediating metastasis in certain organs. Here, we report that overexpression of a functionally active integrin alphavbeta3 in Chinese hamster ovary (CHO) tumor cells drastically increased the incidence, number, and area of bone metastases in nude mice compared with those observed in mock-transfected CHO cells (CHO dhfr(+)) or in CHO cells expressing a functionally inactive integrin alphavbeta3 (CHO 3 744). Moreover, a breast cancer cell line (B02) established from bone metastases caused by MDA-MB-231 cells constitutively overexpressed integrin alphavbeta3, whereas the cell surface expression level of other integrins remained unchanged. In vivo, the extent of bone metastases in B02-bearing mice was significantly increased compared with that of MDAMB-231-bearing mice. In vitro, B02 cells and CHO cells expressing a functionally active integrin alphavbeta3 exhibited substantially increased invasion of and adhesion to mineralized bone, bone sialoprotein, and collagen compared with those found with MDA-MB-231, CHO dhfr(+), and CHO 3 744 cells, respectively. Overall, our findings suggest that integrin alphavbeta3 expression in tumor cells accelerates the development of osteolytic lesions, presumably through increased invasion of and adhesion to bone.	Fac Med Laennec, INSERM, Res Unit 403, F-69372 Lyon 08, France; CNRS, UMR 5533, Pessac, France; CRP Sante, CNRS, Lab Franco Luxembourgeois Rech Biomed, Luxembourg, Luxembourg; Lariboisiere Hosp, INSERM, Res Unit 349, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Luxembourg Institute of Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Clezardin, P (corresponding author), Fac Med Laennec, INSERM, Res Unit 403, Rue Guillaume Paradin, F-69372 Lyon 08, France.	clezardin@lyon151.inserm.fr	Clezardin, Philippe/M-8071-2014	Clezardin, Philippe/0000-0003-0149-4463; Peyruchaud, Olivier/0000-0002-5393-4945				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Boissier S, 1997, CANCER RES, V57, P3890; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; CLEZARDIN P, 1993, CANCER RES, V53, P1421; Clezardin P, 1997, BIOCHEM J, V321, P819, DOI 10.1042/bj3210819; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FISHER L, 1999, EXTRACELLULAR MATRIX, P368; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; Hiraga T, 2001, CANCER RES, V61, P4418; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Liapis H, 1996, DIAGN MOL PATHOL, V5, P127, DOI 10.1097/00019606-199606000-00008; Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T; MasellisSmith A, 1997, CANCER RES, V57, P930; MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1; MIETTINEN M, 1993, AM J PATHOL, V142, P1009; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGLE RB, 1995, AM J PATHOL, V146, P1498; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peyruchaud O, 1998, BLOOD, V92, P4178, DOI 10.1182/blood.V92.11.4178.423k08_4178_4187; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; van der Pluijm G, 1997, LAB INVEST, V77, P665; Voland C, 2000, J BONE MINER RES, V15, P361, DOI 10.1359/jbmr.2000.15.2.361; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	36	194	204	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1266	+		10.1096/fj.01-0911fje	http://dx.doi.org/10.1096/fj.01-0911fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153995				2022-12-25	WOS:000176683900022
J	Narisawa-Saito, M; Iwakura, Y; Kawamura, M; Araki, K; Kozaki, S; Takei, N; Nawa, H				Narisawa-Saito, M; Iwakura, Y; Kawamura, M; Araki, K; Kozaki, S; Takei, N; Nawa, H			Brain-derived neurotrophic factor regulates surface expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors by enhancing the N-ethylmaleimide-sensitive factor/GluR2 interaction in developing neocortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; AMPA RECEPTORS; SYNAPTIC TRANSMISSION; CORTICAL-NEURONS; BINDING-PROTEIN; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL-NEURONS; SILENT SYNAPSES; KINASE-C; BDNF	In hippocampal neurons, the exocytotic process of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA)-type glutamate receptors is known to depend on activation of N-methyl-D-aspartate channels and its resultant Ca2+ influx from extracellular spaces. Here we found that brain-derived neurotrophic factor (BDNF) induced a rapid surface translocation of AMPA receptors in an activity-independent manner in developing neocortical neurons. The receptor translocation became evident within hours as monitored by [H-3]AMPA binding and was resistant against ionotropic glutamate receptor antagonists as evidenced with surface biotinylation assay. This process required intracellular Ca2+ and was inhibited by the blockers of conventional exocytosis, brefeldin A, botulinuin toxin B, and N-ethylmaleimide. To explore the translocation mechanism of individual AMPA receptor subunits, we utilized the human embryonic kidney (HEK) 293 cells carrying the BDNF receptor TrkB. After the single transfection of GluR2 cDNA or GluR1 cDNA into HEK/TrkB cells, BDNF triggered the translocation of GluR2 but not that of GluR1. Subsequent mutation analysis of GluR2 carboxyl-terminal region indicated that the translocation of GluR2 subunit in HEK293 cells involved its N-ethylmaleimide-sensitive factor-binding domain but not its PDZ-interacting site. Following co-transfection of GluR1 and GluR2 cDNAs, solid phase cell sorting revealed that GluR1 subunits were also able to translocate to the cell surface in response to BDNF. An immunoprecipitation assay confirmed that BDNF stimulation can enhance the interaction of GluR2 with N-ethylmaleimide-sensitive factor. These results reveal a novel role of BDNF in regulating the surface expression of AMPA receptors through a GluR2-NSF interaction.	Niigata Univ, Inst Brain Res, Div Mol Biol, Niigata 9518585, Japan; Niigata Univ, Inst Brain Res, Dept Mol Neurobiol, Niigata 9518585, Japan; Coll Agr, Dept Vet Sci, Sakai, Osaka 5998531, Japan	Niigata University; Niigata University	Nawa, H (corresponding author), Niigata Univ, Inst Brain Res, Div Mol Biol, Asahimachidori 1-757, Niigata 9518585, Japan.							BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Burette A, 2001, J NEUROSCI, V21, P495, DOI 10.1523/JNEUROSCI.21-02-00495.2001; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Griesbeck O, 1999, MICROSC RES TECHNIQ, V45, P262, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<262::AID-JEMT10>3.0.CO;2-K; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HUNTLEY CW, 1994, TRENDS NEUROSCI, V17, P536; Ibaraki K, 1999, J NEUROCHEM, V73, P408, DOI 10.1046/j.1471-4159.1999.0730408.x; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kleiman RJ, 2000, J NEUROPHYSIOL, V84, P472, DOI 10.1152/jn.2000.84.1.472; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liu Y, 2001, J NEUROSCI, V21, P5660, DOI 10.1523/JNEUROSCI.21-15-05660.2001; Lom B, 1999, J NEUROSCI, V19, P9928; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Mammen AL, 1997, J NEUROSCI, V17, P7351; Matveeva EA, 2001, J BIOL CHEM, V276, P12174, DOI 10.1074/jbc.M007394200; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; Narisawa-Saito M, 1999, NEUROSCIENCE, V88, P1009, DOI 10.1016/S0306-4522(98)00496-5; Narisawa-Saito M, 1999, P NATL ACAD SCI USA, V96, P2461, DOI 10.1073/pnas.96.5.2461; Nawa H, 2001, TRENDS NEUROSCI, V24, P683, DOI 10.1016/S0166-2236(00)01955-X; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Sato M, 2001, J NEUROSCI, V21, P3797, DOI 10.1523/JNEUROSCI.21-11-03797.2001; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Takei N, 1997, J NEUROCHEM, V68, P370; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Wang YZ, 1997, NATURE, V389, P502, DOI 10.1038/39062; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xiong HB, 1999, EUR J NEUROSCI, V11, P1567, DOI 10.1046/j.1460-9568.1999.00567.x; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000	57	78	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40901	40910		10.1074/jbc.M202158200	http://dx.doi.org/10.1074/jbc.M202158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12130635	hybrid			2022-12-25	WOS:000178791400096
J	Komano, H; Shiraishi, H; Kawamura, Y; Sai, X; Suzuki, R; Serneels, L; Kawaichi, M; Kitamura, T; Yanagisawa, K				Komano, H; Shiraishi, H; Kawamura, Y; Sai, X; Suzuki, R; Serneels, L; Kawaichi, M; Kitamura, T; Yanagisawa, K			A new functional screening system for identification of regulators for the generation of amyloid beta-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; C-TERMINAL FRAGMENTS; PRECURSOR PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DOMAIN; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; WILD-TYPE; PRESENILIN-1; CELLS	Presenilin (PS) is essential for gamma-cleavage, which is required for the generation of amyloid beta-protein (Abeta) from the beta-amyloid precursor protein. However, it remains to be clarified how gamma-cleavage is regulated. To elucidate the regulation of PS-mediated gamma-cleavage, we developed a new functional screening method for identifying cDNA that enhances gamma-cleavage. This screening system utilizes our own developed cell line, where the expression of cDNA that enhances gamma-cleavage confers puromycin resistance. The cDNA library is retrovirally delivered to the above-mentioned cell line, allowing the identification of our target cDNAs by a combination of puromycin resistance selection and Abeta assay screening. With this screening method, we isolated several cDNAs enhancing gamma-cleavage, including the previously reported Herp. Here we also demonstrate that Rab1A, identified with this screening, can be a regulator of All generation. Thus, our established screening method is a powerful tool for identifying multiple regulators involved in gamma-cleavage in the All generation pathway, including modulators of gamma-secretase activity or the intracellular trafficking of factors necessary for gamma-cleavage.	Natl Inst Longev Sci, Dept Dementia Res, Obu, Aichi 4748522, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 63001, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Adv Clin Res Ctr, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); KU Leuven; Nara Institute of Science & Technology; University of Tokyo	Komano, H (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.		Kitamura, Toshio/AAA-2071-2021					Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1993, J BIOL CHEM, V268, P3021; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Perez E, 2000, BIOCHEM BIOPH RES CO, V275, P910, DOI 10.1006/bbrc.2000.3404; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MARUYAMA K, 1995, BIOCHEM BIOPH RES CO, V207, P971, DOI 10.1006/bbrc.1995.1280; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Onishi M, 1996, EXP HEMATOL, V24, P324; Paganetti PA, 1996, J NEUROSCI RES, V46, P283, DOI 10.1002/(SICI)1097-4547(19961101)46:3<283::AID-JNR1>3.0.CO;2-G; Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Sudoh S, 1998, J NEUROCHEM, V71, P1535; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	50	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39627	39633		10.1074/jbc.M205255200	http://dx.doi.org/10.1074/jbc.M205255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161439	hybrid			2022-12-25	WOS:000178662500074
J	Hernandez, MP; Sullivan, WP; Toft, DO				Hernandez, MP; Sullivan, WP; Toft, DO			The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI DNAJ; PROGESTERONE-RECEPTOR; TETRATRICOPEPTIDE REPEAT; STEROID-RECEPTORS; TERMINAL DOMAIN; ATP BINDING; GLUCOCORTICOID-RECEPTOR; COGNATE PROTEIN; PEPTIDE BINDING	The highly coordinated interactions of several molecular chaperones, including hsp70 and hsp90, are required for the folding and conformational regulation of a variety of proteins in eukaryotic cells, such as steroid hormone receptors and many other signal transduction regulators. The protein called Hop serves as an adaptor protein for hsp70 and hsp90 and is thought to optimize their functional cooperation. Here we characterize the assembly of the hsp70-Hop-hsp90 complex and reveal interactions that cause conformational changes between the proteins in the complex. We found that hsp40 plays an integral role in the assembly by enhancing the binding of hsp70 to the Hop complex. This is accomplished by stimulating the conversion of hsp70-ATP to hsp70-ADP, the hsp70 conformation favored for Hop binding. The hsp70-Hop-hsp90 complex is highly dynamic, as has been observed previously for hsp90 in its interaction with client proteins. Nonetheless, hsp90 binds with high affinity to Hop (K-d = 90 nm), and this binding is not affected by hsp70. hsp70 binds with lower affinity to Hop (K-d = 1.3 muM) on its own, but this affinity is increased (K-d = 250 nm) in the presence of hsp90. hsp90 also reduces the number of hsp70 binding sites on the Hop dimer from two sites in the absence of hsp90 to one site in its presence. Hop can inhibit the ATP binding and p23 binding activity of hsp90, yet this can be reversed if hsp70 is present in the complex. Taken together, our results suggest that the assembly of hsp70-Hop-hsp90 complexes is selective and influences the conformational state of each protein.	Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	toft.david@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059284] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59284] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; CYR DM, 1994, J BIOL CHEM, V269, P9798; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	75	155	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38294	38304		10.1074/jbc.M206566200	http://dx.doi.org/10.1074/jbc.M206566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161444	hybrid			2022-12-25	WOS:000178529600040
J	Lotharius, J; Barg, S; Wiekop, P; Lundberg, C; Raymon, HK; Brundin, P				Lotharius, J; Barg, S; Wiekop, P; Lundberg, C; Raymon, HK; Brundin, P			Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; OXIDATIVE STRESS; LENTIVIRAL VECTOR; PHOSPHOLIPASE-D; NEURONAL DEATH; WILD-TYPE; HIPPOCAMPAL-NEURONS; SUBSTANTIA-NIGRA	Mutations in alpha-synuclein have been linked to rare, autosomal dominant forms of Parkinson's disease. Despite its ubiquitous expression, mutant alpha-synuclein primarily leads to the loss of dopamine-producing neurons in the substantia nigra. alpha-Synuclein is a presynaptic nerve terminal protein of unknown function, although several studies suggest it is important for synaptic plasticity and maintenance. The present study utilized a new human mesencephalic cell line, MESC2.10, to study the effect of A53T mutant alpha-synuclein on dopamine homeostasis. In addition to expressing markers of mature dopamine neurons, differentiated MESC2.10 cells are electrically active, produce dopamine, and express wildtype human alpha-synuclein. Lentivirus-induced overexpression of A53T mutant alpha-synuclein in differentiated MESC2.10 cells resulted in down-regulation of the vesicular dopamine transporter (VMAT2), decreased potassium-induced and increased amphetamine-induced dopamine release, enhanced cytoplasmic dopamine immunofluorescence, and increased intracellular levels of superoxide. These results suggest that mutant alpha-synuclein leads to an impairment in vesicular dopamine storage and consequent accumulation of dopamine in the cytosol, a pathogenic mechanism that underlies the toxicity of the psychostimulant amphetamine and the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium. Interestingly, cells expressing A53T mutant alpha-synuclein were resistant to amphetamine-induced toxicity. Because extravesicular, cytoplasmic dopamine can be easily oxidized into reactive oxygen species and other toxic metabolites, mutations in alpha-synuelein might lead to Parkinson's disease by triggering protracted, low grade dopamine toxicity resulting in terminal degeneration and ultimately cell death.	Lund Univ, Wallenberg Neurosci Ctr, Sect Neuronal Survival, S-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, S-22184 Lund, Sweden; NeuroSearch AS, Sect Microdialysis, DK-2750 Ballerup, Denmark; Celgene Corp, Signal Res Div, San Diego, CA 92121 USA	Lund University; Lund University; Bristol-Myers Squibb; Celgene Corporation	Brundin, P (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Sect Neuronal Survival, BMC A10, S-22184 Lund, Sweden.	julie.lotharius@mphy.lu.se	Barg, Sebastian/F-9523-2010	Barg, Sebastian/0000-0003-4661-5724; Lundberg, Cecilia/0000-0002-6959-2564				Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Brismar H, 1998, P NATL ACAD SCI USA, V95, P5573, DOI 10.1073/pnas.95.10.5573; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Carvalho F, 2001, ADDICT BIOL, V6, P213, DOI 10.1080/13556210120056544; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ericson C, 2002, EXP NEUROL, V173, P22, DOI 10.1006/exnr.2001.7829; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORNSTEDT B, 1990, ACTA NEUROL SCAND, V82, P12; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Galvin JE, 2001, EXP NEUROL, V168, P347, DOI 10.1006/exnr.2000.7615; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hansson O, 2001, EUR J NEUROSCI, V14, P1492, DOI 10.1046/j.0953-816x.2001.01767.x; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jakowec MW, 2001, DEV NEUROSCI-BASEL, V23, P91, DOI 10.1159/000048700; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jones SR, 1998, J NEUROSCI, V18, P1979; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P2479, DOI 10.1016/0006-2952(82)90057-0; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P983, DOI 10.1016/0006-2952(82)90332-X; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; Lotharius J, 2001, ANN NEUROL, V49, P79, DOI 10.1002/1531-8249(200101)49:1<79::AID-ANA11>3.0.CO;2-D; Lotharius J, 1999, J NEUROSCI, V19, P1284; LOTHARIUS J, 2002, IN PRESS HUMAN MOL G; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuoka Y, 2001, NEUROBIOL DIS, V8, P535, DOI 10.1006/nbdi.2001.0392; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ohta S, 1996, J CEREBR BLOOD F MET, V16, P915, DOI 10.1097/00004647-199609000-00015; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rathke-Hartlieb S, 2001, J NEUROCHEM, V77, P1181, DOI 10.1046/j.1471-4159.2001.00366.x; RAYMON HK, 1999, SOC NEUR ABSTR; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schapira AHV, 2001, ADV NEUROL, V86, P155; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SCHULDINER S, 1993, MOL PHARMACOL, V44, P1227; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; SULZER D, 1995, J NEUROSCI, V15, P4102; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; WAYMIRE JC, 1972, P NATL ACAD SCI USA, V69, P2241, DOI 10.1073/pnas.69.8.2241; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P820; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P830; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	89	256	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38884	38894		10.1074/jbc.M205518200	http://dx.doi.org/10.1074/jbc.M205518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145295	Green Published, hybrid			2022-12-25	WOS:000178529600111
J	Nielsen, PA; Beahm, DL; Giepmans, BNG; Baruch, A; Hall, JE; Kumar, NM				Nielsen, PA; Beahm, DL; Giepmans, BNG; Baruch, A; Hall, JE; Kumar, NM			Molecular cloning, functional expression, and tissue distribution of a novel human gap junction-forming protein, connexin-31.9 - Interaction with zona occludens protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELLS; DIRECT ASSOCIATION; CARDIAC MYOCYTES; TIGHT JUNCTIONS; SMOOTH-MUSCLE; HELA-CELLS; C-SRC; MOUSE; ZO-1; COMMUNICATION	A novel human connexin gene (GJA11) was cloned from a genomic library. The open reading frame encoded a hypothetical protein of 294 amino acid residues with a predicted molecular mass of 31,933, hence referred to as connexin-31.9 (Cx31.9) or all connexin. A clone in GenBank(TM) containing the Cx31.9 gene localized to chromosome 17q21.2. Northern analysis of Cx31.9 showed a major 4.4-kilobase transcript, which was expressed at varying levels in all tissues analyzed. Two monoclonal antibodies generated against different domains of Cx31.9 recognized a 30-33-kDa protein from cells overexpressing Cx31.9. Immunofluorescence of overexpressing cells indicated the presence of Cx31.9 between adjacent cells, consistent with its localization to gap junctions. Double voltage clamp analyses of Cx31.9-overexpressing cells, and of paired Xenopus oocytes injected with Cx31.9 cRNA, demonstrated junctional currents indicative of gap junction channel formation. In contrast to previously characterized connexins, Cx31.9 showed no voltage-dependent gating within a physiologically relevant range. Cx31.9 was detected in human tissues by immunoblot analysis, and immunofluorescence localized Cx31.9 expression to vascular smooth muscle cells. Furthermore, it was demonstrated that Cx31.9 interacted with ZO-1. Thus, Cx31.9 represents a novel connexin gene that in vivo generates a protein with unique voltage gating properties.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Scripps Research Institute; University of California System; University of California Irvine; Netherlands Cancer Institute	Kumar, NM (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Giepmans, Ben N.G./R-4564-2016	Giepmans, Ben N.G./0000-0001-5105-5915	NATIONAL EYE INSTITUTE [R01EY012142] Funding Source: NIH RePORTER; NEI NIH HHS [EY12142] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; BEYER EC, 1992, J MEMBRANE BIOL, V127, P69, DOI 10.1007/BF00232759; Christ GJ, 1996, CIRC RES, V79, P631, DOI 10.1161/01.RES.79.4.631; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; Hungerford JE, 1997, J CELL BIOL, V137, P925, DOI 10.1083/jcb.137.4.925; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jacob A, 2001, DNA CELL BIOL, V20, P11, DOI 10.1089/10445490150504657; KANTER HL, 1994, J MOL CELL CARDIOL, V26, P861, DOI 10.1006/jmcc.1994.1103; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kruger O, 2000, DEVELOPMENT, V127, P4179; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Manthey D, 1999, J BIOL CHEM, V274, P14716, DOI 10.1074/jbc.274.21.14716; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER AG, 1992, J MEMBRANE BIOL, V128, P91; Plum A, 2000, CURR BIOL, V10, P1083, DOI 10.1016/S0960-9822(00)00690-4; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; Willecke K, 1999, NOVART FDN SYMP, V219, P76; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128	45	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38272	38283		10.1074/jbc.M205348200	http://dx.doi.org/10.1074/jbc.M205348200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154091	hybrid			2022-12-25	WOS:000178529600038
J	Kos, M; Denger, S; Reid, G; Gannon, F				Kos, M; Denger, S; Reid, G; Gannon, F			Upstream open reading frames regulate the translation of the multiple mRNA variants of the estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; EUKARYOTIC MESSENGER-RNAS; SECONDARY STRUCTURE; INTERCISTRONIC DISTANCE; 5'-UNTRANSLATED REGION; PROMOTER USAGE; INITIATION; GENE; REINITIATION; SEQUENCES	It is by now well established that the estrogen receptor alpha (ERalpha) is transcribed from multiple promoters. One direct consequence of multiple promoters is the generation of mRNA variants with different 5'-untranslated regions (5'-UTRs). However, the potential roles of these individual mRNA variants are not known. All 5'-UTRs of ERalpha contain between one and six upstream open reading frames. In this study the effect of the 5'-UTRs of major human and mouse ERa mRNA variants on translation was evaluated. Some of the 5'-UTRs were found to strongly inhibit translation of the downstream open reading frame. Mutation of the upstream AUG codons partially or completely restored translation efficiency. A toeprinting analysis and assessment of the contribution of each AUG codon to the inhibitory effect on translation showed that leaky scanning and reinitiation occurs with these mRNAs. In conclusion, the upstream open reading frames in the 5'-UTRs of ERa mRNAs have the potential to regulate estrogen receptor alpha expression.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Gannon, F (corresponding author), European Mol Biol Org, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Frank.Gannon@embo.org	Gannon, Frank/G-1194-2015; Kos, Martin/E-2534-2011	Kos, Martin/0000-0002-3337-9681; Reid, George/0000-0002-0298-693X				AUCHUS RJ, 1994, BAILLIERE CLIN ENDOC, V8, P433, DOI 10.1016/S0950-351X(05)80260-5; Auwerx J, 1999, CELL, V97, P161; Brand H, 2002, ENDOCRINOLOGY, V143, P3397, DOI 10.1210/en.2001-210832; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; George F.W., 1988, P3; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENDERSON BE, 1988, CANCER RES, V48, P246; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; Kos M, 2000, FEBS LETT, V477, P15, DOI 10.1016/S0014-5793(00)01750-6; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NORMAN AW, 1987, HORMONES, P550; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Osterlund MK, 2000, J NEUROCHEM, V75, P1390, DOI 10.1046/j.1471-4159.2000.0751390.x; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Sambrook J., 2001, MOL CLONING; Svitkin YV, 2001, RNA, V7, P1743; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WEIGEL RJ, 1995, CELL GROWTH DIFFER, V6, P707; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	41	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37131	37138		10.1074/jbc.M206325200	http://dx.doi.org/10.1074/jbc.M206325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147702	hybrid			2022-12-25	WOS:000178447100030
J	Matsui, E; Musti, KV; Abe, J; Yamasaki, K; Matsui, I; Harata, K				Matsui, E; Musti, KV; Abe, J; Yamasaki, K; Matsui, I; Harata, K			Molecular structure and novel DNA binding sites located in loops of flap endonuclease-1 from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SUBSTRATE-BINDING; HYPERTHERMOPHILIC ARCHAEON; REPLICATION FORK; CLEAVAGE; 5'-EXONUCLEASE; MUTAGENESIS; AMYLASE; FEN-1; 3'-EXONUCLEASE	The crystal structure of flap endonuclease-1 from Pyrococcus horikoshii (phFEN-1) was determined to a resolution of 3.1 Angstrom. The active cleft of the phFEN-1 molecule is formed with one large loop and four small loops. We examined the function of the conserved residues and positively charged clusters on these loops by kinetic analysis with 45 different mutants. Arg(40) and Arg(42) on small loop 1, a cluster Lys(193)-Lys(195) on small loop 2, and two sites, Arg(94) and Arg(118)-Lys(119), on the large loop were identified as binding sites. Lys(87) on the large loop may play significant roles in catalytic reaction. Furthermore, we successfully elucidated the function of the four DNA binding sites that form productive ES complexes specific for each endo- or exo-type hydrolysis, probably by bending the substrates. For the endo-activity, Arg(94) and Lys(193)-Lys(195) located at the top and bottom of the molecule were key determinants. For the exo-activity, all four sites were needed, but Arg(118)-Lys(119) was dominant. The major binding sites for both the nick substrate and double-stranded DNA might be the same.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 305566, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 305566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Higashi 1-1-1, Tsukuba, Ibaraki 305566, Japan.		Hu, Ruogu/B-2203-2008; Yamasaki, Kazuhiko/L-7108-2018	Yamasaki, Kazuhiko/0000-0003-0320-9697				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kelman Z, 2000, TRENDS BIOCHEM SCI, V25, P521, DOI 10.1016/S0968-0004(00)01687-X; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Matsui E, 1999, J BIOL CHEM, V274, P18297, DOI 10.1074/jbc.274.26.18297; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUI I, 1992, BIOCHEMISTRY-US, V31, P5232, DOI 10.1021/bi00137a019; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Rao HGV, 1998, J BACTERIOL, V180, P5406, DOI 10.1128/JB.180.20.5406-5412.1998; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	40	30	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37840	37847		10.1074/jbc.M205235200	http://dx.doi.org/10.1074/jbc.M205235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147694	hybrid			2022-12-25	WOS:000178447100119
J	Nakahara, M; Fujii, H; Maloney, PR; Shimizu, M; Sato, R				Nakahara, M; Fujii, H; Maloney, PR; Shimizu, M; Sato, R			Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LEUCINE ZIPPER PROTEIN; REGULATORY ELEMENT; TRANSCRIPTIONAL REGULATION; NUCLEAR RECEPTORS; KINASE; IDENTIFICATION; ACTIVATION; CYP7A1; CELLS	Recent studies have indicated that bile acids regulate the expression of several genes involved in bile acid and lipid metabolism as ligands for the farnesoid X receptor (FIAR). We report here that bile acids are directly able to govern cholesterol metabolism by a novel mechanism. We show that chenodeoxycholic acid (CDCA) enhances low density lipoprotein (LDL) receptor gene expression in human cultured cell lines (HeLa, Hep G2, and Caco-2). The proteolytic activation of sterol regulatory element-binding protein-2 (SREBP-2), a major regulator for LDL receptor gene expression, is not affected by CDCA. Both deoxycholic acid and lithocholic acid as well as CDCA, but not ursodeoxycholic acid, increase the mRNA level for the LDL receptor, even when Hep G2 cells are cultured with 25-hydroxycholesterol, a potent suppressor of gene expression for the LDL receptor. Although it seems possible that FXR might be involved in genetic regulation, both reporter assays with a reporter gene containing the LDL receptor promoter as well as Northern blot analysis reveal that FXR is not involved in the process. On the other hand, inhibition of mitogen-activated protein (MAP) kinase activities, which are found to be induced by CDCA, abolishes the CDCA-mediated up-regulation of LDL receptor gene expression. We further demonstrate that CDCA stabilizes LDL receptor mRNA and that the MAP kinase inhibitors accelerate its turnover. Taken together, these results indicate that bile acids increase LDL uptake and the intracellular cholesterol levels through the activation of MAP kinase cascades in conjunction with a down-regulation of bile acid biosynthesis by FXR. This work opens up a new avenue for developing pharmaceutical interventions that lower plasma LDL by stabilizing LDL receptor mRNA.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Signal Transduct Res, Niigata 9518510, Japan; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	University of Tokyo; Niigata University; GlaxoSmithKline	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ece.u-tokyo.ac.jp						Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Bouscarel B, 1999, GASTROENTEROLOGY, V117, P433, DOI 10.1053/gast.1999.0029900433; Brady LM, 1996, BIOCHEM J, V316, P765, DOI 10.1042/bj3160765; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CARLSON TL, 1989, BIOCHEM J, V264, P241, DOI 10.1042/bj2640241; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; KAWABE Y, 1995, BIOCHEM BIOPH RES CO, V208, P405, DOI 10.1006/bbrc.1995.1352; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Knouff C, 2001, J BIOL CHEM, V276, P3856, DOI 10.1074/jbc.M009423200; Kotzka J, 2000, J LIPID RES, V41, P99; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makar RSJ, 2000, J LIPID RES, V41, P762; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MARRIOTT SJ, 1987, J VIROL, V61, P375, DOI 10.1128/JVI.61.2.375-382.1987; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; Wilson GM, 1998, J LIPID RES, V39, P1025; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	40	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37229	37234		10.1074/jbc.M206749200	http://dx.doi.org/10.1074/jbc.M206749200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149270	hybrid			2022-12-25	WOS:000178447100043
J	Shiojima, I; Yefremashvili, M; Luo, ZY; Kureishi, Y; Takahashi, A; Tao, JZ; Rosenzweig, A; Kahn, CR; Abel, ED; Walsh, K				Shiojima, I; Yefremashvili, M; Luo, ZY; Kureishi, Y; Takahashi, A; Tao, JZ; Rosenzweig, A; Kahn, CR; Abel, ED; Walsh, K			Akt signaling mediates postnatal heart growth in response to insulin and nutritional status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR MASS; REGULATE CARDIAC-HYPERTROPHY; PROTEIN-KINASE-B; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; CELL-GROWTH; IN-VIVO; CARDIOMYOCYTE HYPERTROPHY; TRANSLATION INITIATION; MOLECULAR MECHANISMS	Akt is a serine-threonine kinase that mediates a variety of cellular responses to external stimuli. During postnatal development, Akt signaling in the heart was up-regulated when the heart was rapidly growing and was down-regulated by caloric restriction, suggesting a role of Akt in nutrient-dependent regulation of cardiac growth. Consistent with this notion, reductions in Akt, 70-kDa S6 kinase 1, and eukaryotic initiation factor 4E-binding protein 1 phosphorylation were observed in mice with cardiac-specific deletion of insulin receptor gene, which exhibit a small heart phenotype. In contrast to wild type animals, caloric restriction in these mice had little effect on Akt phosphorylation in the heart. Furthermore, forced expression of Akt1 in these hearts restored 70-kDa S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1 phosphorylation to normal levels and rescued the small heart phenotype. Collectively, these results indicate that Akt signaling mediates insulin-dependent physiological heart growth during postnatal development and suggest a mechanism by which heart size is coordinated with overall body size as the nutritional status of the organism is varied.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Utah, Sch Med, Program Human Biol & Genet, Salt Lake City, UT 84112 USA; Massachusetts Gen Hosp E, Program Cardiovasc Gene Therapy, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	Boston University; St. Elizabeth's Medical Center; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.		Kahn, Ronald/AAY-2435-2021; Bando, Yasuko K./M-4831-2014	Kahn, Ronald/0000-0002-7583-9228; Bando, Yasuko K./0000-0003-4166-6784; Abel, E. Dale/0000-0001-5290-0738	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061557, R21HL062886, R01HL050692, P01HL066957, R01HL059521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092065, R03DK058073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66957, HL61557, HL62886, HL50692, HL59521] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, AG17241] Funding Source: Medline; NIDDK NIH HHS [R01 DK092065, DK58073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Crisostomo LL, 1999, AM J CARDIOL, V84, P1127, DOI 10.1016/S0002-9149(99)00519-6; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; DESIMONE GD, 1994, BRIT HEART J, V71, P287; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Himeno E, 1996, AM HEART J, V131, P313, DOI 10.1016/S0002-8703(96)90360-9; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hudlicka O, 1996, J VASC RES, V33, P266, DOI 10.1159/000159155; ISNER JM, 1979, CIRCULATION, V60, P1401, DOI 10.1161/01.CIR.60.6.1401; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Keys A, 1950, BIOL HUMAN STARVATIO; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; MCMAHON T, 1973, SCIENCE, V179, P1201, DOI 10.1126/science.179.4079.1201; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Proud CG, 1997, BIOCHEM J, V328, P329; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Rakusan, 1984, GROWTH HEART HLTH DI, P131; Richey PA, 1998, J SPORT SCI, V16, P129; Rother KI, 2000, PEDIATR NEPHROL, V14, P558, DOI 10.1007/s004670000351; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; SHEPARD RJ, 1999, EXERCISE HEART HLTH, P223; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; WHITE MF, 1994, J BIOL CHEM, V269, P1	68	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37670	37677		10.1074/jbc.M204572200	http://dx.doi.org/10.1074/jbc.M204572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163490	hybrid			2022-12-25	WOS:000178447100098
J	Zeng, HY; Hawrot, E				Zeng, HY; Hawrot, E			NMR-based binding screen and structural analysis of the complex formed between alpha-cobratoxin and an 18-mer cognate peptide derived from the alpha 1 subunit of the nicotinic acetylcholine receptor from Torpedo californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; CATION-PI INTERACTIONS; CRYSTAL-STRUCTURE; OPHIOPHAGUS-HANNAH; LONG NEUROTOXIN; PROTON NMR; BUNGAROTOXIN; SPECTROSCOPY; SITE; SENSITIVITY	The alpha18-mer peptide, spanning residues 181-198 of the Torpedo nicotinic acetylcholine receptor alpha1 subunit, contains key binding determinants for agonists and competitive antagonists. To investigate whether the alpha18-mer can bind other alpha-neurotoxins besides alpha-bungarotoxin, we designed a two-dimensional H-1-N-15 heteronuclear single quantum correlation experiment to screen four related neurotoxins for their binding ability to the peptide. Of the four toxins tested (erabutoxin a, erabutoxin b, LSIII, and alpha-cobratoxin), only alpha-cobratoxin binds the alpha18-mer to form a 1:1 complex. The NMR solution structure of the alpha-cobratoxin-alpha18-mer complex was determined with a backbone root mean square deviation of 1.46 Angstrom. In the structure, alpha-cobratoxin contacts the alpha18-mer at the tips of loop I and II and through C-terminal cationic residues. The contact zone derived from the intermolecular nuclear Overhauser effects is in agreement with recent biochemical data. Furthermore, the structural models support the involvement of cation-pi interactions in stabilizing the complex. In addition, the binding screen results suggest that C-terminal cationic residues of alpha-bungarotoxin and a-cobratoxin contribute significantly to binding of the alpha18-mer. Finally, we present a structural model for nicotinic acetylcholine receptor-alpha-cobratoxin interaction by superimposing the alpha-cobratoxin-alpha18-mer complex onto the crystal structure of the acetylcholine-binding protein (Protein Data Bank code 1I9B).	Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Hawrot, E (corresponding author), Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Box G-B391, Providence, RI 02912 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08240] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ENDO T, 1986, BIOCHEMISTRY-US, V25, P395, DOI 10.1021/bi00350a019; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GODDARD TD, 2001, SPARKY 3 VERSION 3 1; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LABHARDT AM, 1988, EUR J BIOCHEM, V177, P295, DOI 10.1111/j.1432-1033.1988.tb14376.x; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; Lin SR, 1996, J PROTEIN CHEM, V15, P95, DOI 10.1007/BF01886815; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MACURA SI, 1994, METHOD ENZYMOL, V239, P100; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; Peng SS, 1997, J BIOL CHEM, V272, P7817, DOI 10.1074/jbc.272.12.7817; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; Scherf T, 2001, P NATL ACAD SCI USA, V98, P6629, DOI 10.1073/pnas.111164298; SCHLEUCHER J, 1993, ANGEW CHEM, V105, P1518; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Thompson GS, 2000, PROTEIN SCI, V9, P846, DOI 10.1110/ps.9.5.846; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	49	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37439	37445		10.1074/jbc.M205483200	http://dx.doi.org/10.1074/jbc.M205483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133834	hybrid			2022-12-25	WOS:000178447100068
J	Chen, JF; Steyn, S; Staal, R; Petzer, JP; Xu, K; Van der Schyf, CJ; Castagnoli, K; Sonsalla, PK; Castagnoli, N; Schwarzschild, MA				Chen, JF; Steyn, S; Staal, R; Petzer, JP; Xu, K; Van der Schyf, CJ; Castagnoli, K; Sonsalla, PK; Castagnoli, N; Schwarzschild, MA			8-(3-chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A(2A) receptor antagonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; HUMAN-PLACENTA; CAFFEINE; BRAIN; MICE; MODELS; RISK	Caffeine and more specific antagonists of the adenosine A(2A) receptor recently have been found to be neuroprotective in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease. Here we show that 8-(3-chlorostyryl)caffeine (CSC), a specific A(2A) antagonist closely related to caffeine, also attenuates MPTP-induced neurotoxicity. Because the neurotoxicity of MPTP relies on its oxidative metabolism to the mitochondrial toxin MPP+, we investigated the actions of CSC on striatal MPTP metabolism in vivo. CSC elevated striatal levels of MPTP but lowered levels of the oxidative intermediate MPDP+ and of MPP+, suggesting that CSC blocks the conversion of MPTP to MPDP+ in vivo. In assessing the direct effects of CSC and A(2A) receptors on monoamine oxidase (MAO) activity, we found that CSC potently and specifically inhibited mouse brain mitochondrial MAO-B activity in vitro with a K-i value of 100 nm, whereas caffeine and another relatively specific A(2A) antagonist produced little or no inhibition. The A(2A) receptor independence of MAO-B inhibition by CSC was further supported by the similarity of brain MAO activities derived from A(2A) receptor knockout and wild-type mice and was confirmed by demonstrating potent inhibition of A(2A) receptor knockout-derived MAO-B by CSC. Together, these data indicate that CSC possesses dual actions of MAO-B inhibition and A(2A) receptor antagonism, a unique combination suggesting a new class of compounds with the potential for enhanced neuroprotective properties.	Massachusetts Gen Hosp, Mol Neurobiol Lab, Dept Neurol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Virginia Tech, Dept Chem, Harvey W Peters Ctr, Blacksburg, VA 24061 USA; Univ Med & Dent New Jersey, Dept Neurol, Piscataway, NJ 08854 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Virginia Polytechnic Institute & State University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schwarzschild, MA (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.	chenjf@bu.edu; michaels@helix.mgh.harvard.edu	Van der Schyf, Cornelis J/I-7310-2017	Petzer, Jacobus/0000-0002-7114-8120; Chen, Jiang-Fan/0000-0003-3582-3448; Staal, Roland/0000-0002-2857-2241	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037403, R01NS041083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008479, R03AG018167] Funding Source: NIH RePORTER; NIA NIH HHS [AG18167, AG08479] Funding Source: Medline; NIEHS NIH HHS [ES10804] Funding Source: Medline; NINDS NIH HHS [NS41083, NS37403] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castagnoli K, 1997, CHEM RES TOXICOL, V10, P364, DOI 10.1021/tx970001d; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng JS, 2001, J RECEPT SIGNAL TR R, V21, P1, DOI 10.1081/RRS-100107138; El Yacoubi M, 2001, BRIT J PHARMACOL, V134, P68, DOI 10.1038/sj.bjp.0704240; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Hettinger BD, 2001, J COMP NEUROL, V431, P331, DOI 10.1002/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Inoue H, 1999, J PHARMACOL EXP THER, V291, P856; JACOBSON KA, 1993, FEBS LETT, V323, P141, DOI 10.1016/0014-5793(93)81466-D; KALGUTKAR AS, 1994, J MED CHEM, V37, P944, DOI 10.1021/jm00033a012; KANTHASAMY AG, NEUROPROTECTION, P603; Khalil AA, 2000, CHEM RES TOXICOL, V13, P31, DOI 10.1021/tx990146f; KITAHAMA K, 1991, NEUROSCIENCE, V44, P185, DOI 10.1016/0306-4522(91)90260-U; KRUEGER MJ, 1995, BIOCHEM BIOPH RES CO, V206, P556, DOI 10.1006/bbrc.1995.1079; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Marian T, 1999, APPL RADIAT ISOTOPES, V50, P887, DOI 10.1016/S0969-8043(98)00162-6; RILEY LA, 1989, MOL PHARMACOL, V36, P54; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; SALACH JI, 1987, METHOD ENZYMOL, V142, P627; Schwarzschild MA, 2002, NEUROLOGY, V58, P1154, DOI 10.1212/WNL.58.8.1154; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Yu PH, 1995, PROG BRAIN RES, V106, P113	28	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36040	36044		10.1074/jbc.M206830200	http://dx.doi.org/10.1074/jbc.M206830200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130655	hybrid			2022-12-25	WOS:000178275100036
J	Esteve, PO; Chicoine, E; Robledo, O; Aoudjit, F; Descoteaux, A; Potworowski, EF; St-Pierre, Y				Esteve, PO; Chicoine, E; Robledo, O; Aoudjit, F; Descoteaux, A; Potworowski, EF; St-Pierre, Y			Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; IV COLLAGENASE; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PRIMARY ASTROCYTES; GLUCOSE-TRANSPORT; PKC-ZETA; EXPRESSION	The regulation of matrix metalloproteinase-9 (MMP-9) expression in glioma cells is one of the key processes in tumor invasion through the brain extracellular matrix. Although some studies have demonstrated the implication of classic protein kinase C (PKC) isoforms in the regulation of AMP-9 production by phorbol esters or lipopolysaccharide, the involvement of specific PKC isoforms in the signaling pathways leading to MMP-9 expression by inflammatory cytokines remains unclear. Here we report that the atypical PKC-zeta isoform participates in the induction of AMP-9 expression by interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) in rat C6 glioma cells. Indeed, zymography and semi-quantitative reverse transcriptase-PCR analysis showed that pretreatment of C6 cells with PKC-zeta pseudosubstrate abolished AMP-9 activity and gene expression induced by IL-1 or TNIF-alpha. Accordingly, IL-1 and TNF-alpha were able to induce PKC-zeta activity, as demonstrated by in vitro kinase assay using immunoprecipitated PKC-zeta. Furthermore, stable C6 clones overexpressing PKC-zeta, but not PKC-epsilon, displayed an up-regulation of NMP-9 constitutive expression as well as an increase of mmp-9 promoter activity. These processes were inhibited by an NF-kappaB-blocking peptide and completely prevented by NF-kappaB-binding site mutation in the mmp-9 promoter. Taken together, these results indicate that PKC-zeta plays a key role in the regulation of MMP-9 expression in C6 glioma cells through NF-kappaB.	Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada; Univ Laval, Ctr Rech Immunol & Rheumatol, St Foy, PQ G1V 4G2, Canada	University of Quebec; Institut national de la recherche scientifique (INRS); Laval University	St-Pierre, Y (corresponding author), Univ Quebec, Inst Armand Frappier, INRS, 531 Boul Prairies, Laval, PQ H7V 1B7, Canada.			St-Pierre, Yves/0000-0002-1948-2041				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Esteve PO, 1998, BBA-MOL CELL RES, V1403, P85, DOI 10.1016/S0167-4889(98)00020-2; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; Han YP, 2001, J CELL SCI, V114, P131; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kondraganti S, 2000, CANCER RES, V60, P6851; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Misse D, 2001, BLOOD, V98, P541, DOI 10.1182/blood.V98.3.541; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P1175, DOI 10.1006/bbrc.1993.1540; RAO JS, 1993, CANCER RES, V53, P2208; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SATO H, 1993, ONCOGENE, V8, P395; Segain JP, 1996, CANCER RES, V56, P5506; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; XIE B, 1994, J IMMUNOL, V152, P3637; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	45	157	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35150	35155		10.1074/jbc.M108600200	http://dx.doi.org/10.1074/jbc.M108600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130632	hybrid			2022-12-25	WOS:000178117000063
J	Fukuoka, SI; Ishiguro, K; Yanagihara, K; Tanabe, A; Egashira, Y; Sanada, H; Shibata, K				Fukuoka, SI; Ishiguro, K; Yanagihara, K; Tanabe, A; Egashira, Y; Sanada, H; Shibata, K			Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD) - A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS EXCITANT; ACID SEQUENCE; RATS; METABOLISM; LESIONS; DISEASE; BRAIN	Quinolinate (quinolinic acid) is a potent endogenous excitotoxin of neuronal cells. Elevation of quinolinate levels in the brain has been implicated in the pathogenesis of various neurodegenerative disorders, the so-called "quinolinate hypothesis." Quinolinate is nonenzymatically derived from alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS). alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD) is the only known enzyme that can process ACMS to a benign catabolite and thus prevent the accumulation of quinolinate from ACMS. ACMSD seems to be regulated by nutritional and hormonal signals, but its molecular mechanism has, to date, been largely unknown. Utilizing partial amino acid sequences obtained from highly purified porcine kidney ACMSD, a cDNA encoding human ACMSD was cloned and characterized. The cDNA encodes a unique open reading frame of 336 amino acids and displays little homology to any known enzymes or motifs in mammalian databases, suggesting that ACMSD may contain a new kind of protein fold. Real-time PCR-based quantification of ACMSD revealed very low but significant levels of the expression in the brain. Brain ACMSD messages were down- and up-regulated in response to low protein diet and streptozocin-induced diabetes, respectively. The enzyme activities measured from partially purified brains were closely correlated with the changes in the message levels. Expression of quinolinate phosphoribosyltransferase (QPRT), another enzyme that catabolizes quinolinate, was also found in the brain. This suggests that a pathway does exist by which the levels of quinolinate in the brain are regulated. In this report, we address the molecular basis underlying quirtolinate metabolism and the regulation of ACMSD expression.	Kyoto Univ, Grad Sch Agr, Kyoto 6110011, Japan; Chiba Univ, Grad Sch Sci & Technol, Chiba 2718510, Japan; Univ Shiga Prefecture, Sch Human Cultures, Dept Life Style Studies, Shiga 5228533, Japan	Kyoto University; Chiba University; University Shiga Prefecture	Fukuoka, SI (corresponding author), Kyoto Univ, Grad Sch Agr, Kyoto 6110011, Japan.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAL MF, 1988, J NEUROSCI, V8, P3901; Egashira Y, 1996, J NUTR SCI VITAMINOL, V42, P173, DOI 10.3177/jnsv.42.173; Esaki K, 1996, BIOSCI BIOTECH BIOCH, V60, P1444, DOI 10.1271/bbb.60.1444; FOSTER AC, 1984, EXP NEUROL, V84, P428, DOI 10.1016/0014-4886(84)90239-5; Fukuoka S, 1998, BBA-GENE STRUCT EXPR, V1395, P192, DOI 10.1016/S0167-4781(97)00143-7; FUKUOKA SI, 1990, PANCREAS, V5, P1, DOI 10.1097/00006676-199001000-00001; ICHIYAMA A, 1965, J BIOL CHEM, V240, P740; IKEMURA T, 1991, NUCLEIC ACIDS RES, V19, P4333, DOI 10.1093/nar/19.16.4333; NASU S, 1981, BIOCHIM BIOPHYS ACTA, V677, P109, DOI 10.1016/0304-4165(81)90151-3; Nishizuka Y, 1970, METHODS ENZYMOLOGY A, V17A, P471; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; SANADA H, 1980, J NUTR SCI VITAMINOL, V26, P449, DOI 10.3177/jnsv.26.449; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1984, LIFE SCI, V35, P19, DOI 10.1016/0024-3205(84)90148-6; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; Schwarcz R., 1987, P19; SCHWARCZ R, 1986, EXCITATORY AMINO ACI, P697; SHIBATA K, 1989, J NUTR, V119, P896, DOI 10.1093/jn/119.6.896; Shibata K, 1999, ADV EXP MED BIOL, V467, P711; Shibata Katsumi, 1998, Vitamins (Kyoto), V72, P85; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762	25	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35162	35167		10.1074/jbc.M200819200	http://dx.doi.org/10.1074/jbc.M200819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12140278	hybrid			2022-12-25	WOS:000178117000065
J	Stoletov, KV; Ratcliffe, KE; Terman, BI				Stoletov, KV; Ratcliffe, KE; Terman, BI			Fibroblast growth factor receptor substrate 2 participates in vascular endothelial growth factor-induced signaling	FASEB JOURNAL			English	Article						VEGF; KDR; angiogenesis; FRS2; endothelial cells	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; DOCKING-PROTEIN; PERMEABILITY FACTOR; CELL PROLIFERATION; FOCAL ADHESIONS; ADAPTER PROTEIN; TUMOR-GROWTH; KDR; IDENTIFICATION	Vascular endothelial growth factor (VEGF) activates endothelial cells, in part, by interacting with the kinase insert domain-containing receptor (KDR) receptor tyrosine kinase. Although progress has been made in the identification of cell-signaling proteins that participate in the VEGF-induced response, questions remain concerning the molecular interactions that allow coupling of receptor activation with an increased cellular response. Evidence is provided in this manuscript that indicates a role for the fibroblast growth factor receptor substrate 2 (FRS2) in VEGF-induced signal transduction. VEGF treatment of human umbilical vein endothelial cells (HUVECs) and KDR-transfected porcine aortic endothelial cells leads to the rapid tyrosine phosphorylation of FRS2. FRS2 is associated constitutively with KDR, and VEGF treatment has no effect on this interaction. VEGF treatment of KDR-expressing cells leads to the recruitment of Nck, p21-activated kinase, Crk, Grb2, and protein kinase C to FRS2. The ability of FRS2 to recruit cell-signaling proteins to the cell is significant because it provides a mechanism for enhancing the repertoire of VEGF-induced signaling pathways.	Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Dept Med, Div Cardiol, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Delahaye L, 2000, ENDOCRINOLOGY, V141, P621, DOI 10.1210/en.141.2.621; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lai KMV, 2000, GENE DEV, V14, P1132; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; SHIBUYA M, 1990, ONCOGENE, V14, P2079; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang JK, 1996, ONCOGENE, V13, P721; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	46	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1283	+		10.1096/fj.01-0835fje	http://dx.doi.org/10.1096/fj.01-0835fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154000				2022-12-25	WOS:000176683900016
J	Streller, T; Huckstorf, C; Pfeiffer, C; Acker, H				Streller, T; Huckstorf, C; Pfeiffer, C; Acker, H			Unusual cytochrome a(592) with low PO2 affinity correlates as putative oxygen sensor with rat carotid body chemoreceptor discharge	FASEB JOURNAL			English	Article						cytochrome c oxidase; light absorption photometry; electrophysiology	MITOCHONDRIAL RESPIRATORY-CHAIN; C-OXIDASE; NADPH OXIDASE; CELLS; PROTEIN	Light-absorption spectra and afferent chemoreceptor discharge were simultaneously recorded on superfused rat carotid bodies (CBs) under the influence of cytochrome a3-Cu-B ligands (O-2, CN-, CO) in order to identify the primary mitochondrial cytochrome c oxidase (CCO) oxygen sensor. Spectra could be described on the basis of weighted light-absorption spectra of cytochrome b(558) of the NAD(P)H oxidase and mitochondrial cytochromes b and c, CCO, cytochrome a3, and an unusual cytochrome a peaking at 592 nm. Discharge signals were deconvoluted into phasic and tonic activity for comparing different CB responses. The spectral weight of cytochrome a(592) decreased significantly starting at high PO2 (100 mm Hg) and low sodium cyanide (CN-, 10 muM) accompanied by increasing phasic peak discharge. Combined CO-hypoxia or CO-CN- application inhibited photolysis of CO-stimulated chemoreceptor discharge, revealing photometrically cytochrome a(592) as central in oxygen sensing. Control spectra in tissue from sympathetic and nodose ganglia did not show any cytochrome a(592) contribution. According to these results, cytochrome a(592) is assumed as a unique component of CB CCO, revealing in contrast to other cytochromes an apparent low PO2 and high CN- affinity, probably due to a shortcut of electron flow within CCO between Cu-A and cytochrome a3-Cu-B.	Univ Rostock, Inst Physiol, D-18057 Rostock, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Rostock; Max Planck Society	Streller, T (corresponding author), Univ Rostock, Inst Physiol, Gertrudenstr 9, D-18057 Rostock, Germany.	tino.streller@medizin.uni-rostock.de	Acker, Helmut Anton Josef/AAS-6841-2020; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; 				Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burke PV, 1998, J EXP BIOL, V201, P1163; Carr A B, 1993, J Prosthodont, V2, P2, DOI 10.1111/j.1532-849X.1993.tb00373.x; Das TK, 2000, BIOPOLYMERS, V57, P316, DOI 10.1002/1097-0282(2000)57:5<316::AID-BIP80>3.0.CO;2-3; DELPIANO M, 1980, BRAIN RES, V195, P85, DOI 10.1016/0006-8993(80)90868-9; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; HILL BC, 1993, FEBS LETT, V354, P284; Kannt A, 1999, J BIOL CHEM, V274, P37974, DOI 10.1074/jbc.274.53.37974; Lahiri S, 1999, RESP PHYSIOL, V115, P169, DOI 10.1016/S0034-5687(99)00014-6; Lahiri S, 1999, P NATL ACAD SCI USA, V96, P9427, DOI 10.1073/pnas.96.16.9427; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; NAIR PK, 1986, AM J PHYSIOL, V250, P202; O'Kelly I, 2001, BIOCHEM BIOPH RES CO, V283, P1131, DOI 10.1006/bbrc.2001.4919; Porwol T, 2001, RESP PHYSIOL, V128, P331, DOI 10.1016/S0034-5687(01)00310-3; Prabhakar NR, 2000, J APPL PHYSIOL, V88, P2287, DOI 10.1152/jappl.2000.88.6.2287; Strohmaier AR, 1997, J HISTOCHEM CYTOCHEM, V45, P975, DOI 10.1177/002215549704500707; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	27	32	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1277	+		10.1096/fj.02-0166fje	http://dx.doi.org/10.1096/fj.02-0166fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153998				2022-12-25	WOS:000176683900014
J	Sitry, D; Seeliger, MA; Ko, TK; Ganoth, D; Breward, SE; Itzhaki, LS; Pagano, M; Hershko, A				Sitry, D; Seeliger, MA; Ko, TK; Ganoth, D; Breward, SE; Itzhaki, LS; Pagano, M; Hershko, A			Three different binding sites of Cks1 are required for p27-ubiquitin ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; CELL-CYCLE CONTROL; XENOPUS SUC1/CKS PROTEIN; S-PHASE KINASE; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; UBIQUITIN LIGASES; COMPLEX-FORMATION; CDK2 COMPLEX; P27	Previous studies have shown that the cyclin-dependent kinase (Cdk) inhibitor P27(Kipl) is targeted for degradation by an SCF(Skp2) ubiquitin ligase complex and that this process requires Cks1, a member of the highly conserved Suc1/Cks family of cell cycle regulatory proteins. All proteins of this family have Cdk-binding and anion-binding sites, but only mammalian Cks1 binds to Skp2 and promotes the association of Skp2 with p27 phosphorylated on Thr-187. The molecular mechanisms by which Cks1 promotes the interaction of the Skp2 ubiquitin ligase subunit to p27 remained obscure. Here we show that the Skp2-binding site of Cks1 is located on a region including the alpha2- and alpha1-helices and their immediate vicinity, well separated from the other two binding sites. All three binding sites of Cks1 are required for p27-ubiquitin ligation and for the association of Skp2 with Cdk-bound, Thr-187-phosphorylated p27. Cks1 and Skp2 mutually promote the binding of each other to a peptide similar to the 19 C-terminal amino acids of p27 containing phosphorylated Thr-187. This latter process requires the Skp2- and anion-binding sites of Cks1, but not its Cdk-binding site. It is proposed that the Skp2-Cks1 complex binds initially to the C-terminal region of phosphorylated p27 in a process promoted by the anion-binding site of Cks1. The interaction of Skp2 with the substrate is further strengthened by the association of the Cdk-binding site of Cks1 with Cdk2/cyclin E, to which phosphorylated p27 is bound.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Cambridge; New York University; New York University	Hershko, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.	hershko@tx.technion.ac.il	Seeliger, Markus A/D-6409-2013	Seeliger, Markus/0000-0003-0990-1756; pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bartek J, 2001, NAT CELL BIOL, V3, pE95, DOI 10.1038/35070160; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P2206; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Mongay L, 2001, J BIOL CHEM, V276, P25030, DOI 10.1074/jbc.M102184200; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	41	69	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42233	42240		10.1074/jbc.M205254200	http://dx.doi.org/10.1074/jbc.M205254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12140288	hybrid			2022-12-25	WOS:000178985300118
J	Boesen, TP; Soni, B; Schwartz, TW; Halkier, T				Boesen, TP; Soni, B; Schwartz, TW; Halkier, T			Single-chain vascular endothelial growth factor variant with antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; FACTOR VEGF; MITOGENIC ACTIVITY; TYROSINE KINASE; FLT-1 RECEPTOR; ANGIOGENESIS; BINDING; GLYCOSYLATION	Vascular endothelial growth factor is a specific endothelial cell mitogen that is essential for the formation of the vascular system but in the adult individual is involved in several pathological conditions, including cancer. It is a homodimeric protein that activates its receptor by binding two receptor molecules and inducing dimerization. By mixing two vascular endothelial growth factor monomers, each with different substitutions, heterodimers with only one active receptor binding site have previously been prepared. These heterodimers bind the receptor molecule but are unable to induce dimerization and activation. However, preparation of heterodimers is cumbersome, involving separate expression of different monomers, refolding the mixture, and separating heterodimers from homodimers. Here we show that a fully functional ligand can efficiently be expressed as a single protein chain containing two monomers. Single-chain vascular endothelial growth factor is functionally equivalent to the wild-type protein. By monomer-specific mutagenesis, one receptor binding site was altered. This variant competitively and specifically antagonizes the mitogenic effect of the wild-type protein on endothelial cells. The results obtained with the single-chain antagonist show the feasibility of the single-chain approach in directing alterations to single specific regions in natural homodimeric proteins that would be impossible to target in other ways.	Maxygen ApS, DK-2970 Horsholm, Denmark; Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Halkier, T (corresponding author), Maxygen ApS, Agern Alle 1, DK-2970 Horsholm, Denmark.	th@maxygen.dk		Schwartz, Thue W./0000-0002-0261-6904				Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Robinson CJ, 2001, J CELL SCI, V114, P853; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Siemeister G, 1998, J BIOL CHEM, V273, P11115, DOI 10.1074/jbc.273.18.11115; Wiesmann C, 1998, BIOCHEMISTRY-US, V37, P17765, DOI 10.1021/bi9819327; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; YEO TK, 1991, BIOCHEM BIOPH RES CO, V179, P1568, DOI 10.1016/0006-291X(91)91752-X	33	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40335	40341		10.1074/jbc.M204107200	http://dx.doi.org/10.1074/jbc.M204107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12151391	hybrid			2022-12-25	WOS:000178791400024
J	Shanks, RA; Larocca, MC; Berryman, M; Edwards, JC; Urushidani, T; Navarre, J; Goldenring, JR				Shanks, RA; Larocca, MC; Berryman, M; Edwards, JC; Urushidani, T; Navarre, J; Goldenring, JR			AKAP350 at the Golgi apparatus - II. Association of AKAP350 with a novel chloride intracellular channel (CLIC) family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; REGULATORY SUBUNIT; SCAFFOLD PROTEINS; ION CHANNEL; CG-NAP; EXPRESSION; CENTROSOME; CELLS; P64	AKAP350 can scaffold a number of protein kinases and phosphatases at the centrosome and the Golgi apparatus. We performed a yeast two-hybrid screen of a rabbit parietal cell library with a 3.2-kb segment of AKAP350 (nucleotides 3611-6813). This screen yielded a full-length clone of rabbit chloride intracellular channel 1 (CLIC1). CLIC1 belongs to a family of proteins, all of which contain a high degree of homology in their carboxyl termini. All CLIC family members were able to bind a 133-amino acid domain within AKAP350 through the last 120 amino acids in the conserved CLIC carboxyl termini. Antibodies developed against a bovine CLIC, p64, immunoprecipitated AKAP350 from HCA-7 colonic adenocareinoma cell extracts. Antibodies against CLIC proteins recognized at least five CLIC species including a novel 46-kDa CLIC protein. We isolated the human homologue of bovine p64, CLIC5B, from HCA-7 cell cDNA. A splice variant of CLIC5, the predicted molecular mass of CLIC5B corresponds to the molecular mass of the 46-kDa CLIC immunoreactive protein in HCA-7 cells. Antibodies against CLIC5B colocalized with AKAP350 at the Golgi apparatus with minor staining of the centrosomes. AKAP350 and CLIC5B association with Golgi elements was lost following brefeldin A treatment. Furthermore, GFP-CLIC5B-(178-410) targeted to the Golgi apparatus in HCA-7 cells. The results suggest that AKAP350 associates with CLIC proteins and specifically that CLIC5B interacts with AKAP350 at the Golgi apparatus in HCA-7 cells.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; St Louis Univ, Dept Med, St Louis, MO 63106 USA; St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Ohio; Ohio University; Saint Louis University; University of Tokyo	Goldenring, JR (corresponding author), Vanderbilt Univ, Sch Med, Epithelial Biol Program, 4160A MRB III,465 21st Ave So, Nashville, TN 37232 USA.				NIAMS NIH HHS [R01 AR 44838] Funding Source: Medline; NIDDK NIH HHS [DK 43405, DK 48370] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043405, R01DK048370, R01DK043405] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARR DW, 1991, J BIOL CHEM, V266, P14188; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Martin ME, 1999, J CELL SCI, V112, P3869; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40967, DOI 10.1074/jbc.M203307200; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	28	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40973	40980		10.1074/jbc.M112277200	http://dx.doi.org/10.1074/jbc.M112277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12163479	hybrid			2022-12-25	WOS:000178791400105
J	Barrette-Ng, IH; Ng, KKS; Mark, BL; van Aken, D; Cherney, MM; Garen, C; Kolodenko, Y; Gorbalenya, AE; Snijder, EJ; James, MNG				Barrette-Ng, IH; Ng, KKS; Mark, BL; van Aken, D; Cherney, MM; Garen, C; Kolodenko, Y; Gorbalenya, AE; Snijder, EJ; James, MNG			Structure of arterivirus nsp4 - The smallest chymotrypsin-like proteinase with an alpha/beta C-terminal extension and alternate conformations of the oxyanion hole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUINE ARTERITIS VIRUS; SERINE-PROTEASE; CORE PROTEIN; REPLICASE; REFINEMENT; MOLSCRIPT; PROGRAM; DENSITY; BINDING	Arteriviruses are enveloped, positive-stranded RNA viruses and include pathogens of major economic concern to the swine- and horse-breeding industries. The arterivirus replicase gene encodes two large precursor polyproteins that are processed by the viral main proteinase nonstructural protein 4 (nsp4). The three-dimensional structure of the 21-kDa nsp4 from the arterivirus prototype equine arteritis virus has been determined to 2.0 Angstrom resolution. Nsp4 adopts the smallest known chymotrypsin-like fold with a canonical catalytic triad of Ser-120, His-39, and Asp-65, as well as a novel alpha/beta C-terminal extension domain that may play a role in mediating protein-protein interactions. In different copies of nsp4 in the asymmetric unit, the oxyanion hole adopts either a collapsed inactive conformation or the standard active conformation, which may be a novel way of regulating proteolytic activity.	Univ Alberta, Canadian Inst Hlth Res Grp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands	University of Alberta; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	James, MNG (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Snijder, Eric J./E-6073-2018; Gorbalenya, Alexander E/J-4818-2012	Snijder, Eric J./0000-0003-3297-2309; Gorbalenya, Alexander E/0000-0002-4967-7341; Mark, Brian/0000-0002-7344-1355; Garen, Craig/0000-0002-7772-9890; Ng, Kenneth K.S./0000-0001-7280-8445	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi HK, 1997, PROTEINS, V27, P345, DOI 10.1002/(SICI)1097-0134(199703)27:3<345::AID-PROT3>3.0.CO;2-C; Delano W.L., 2002, DELANO SCI; DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991; DOLL E. R., 1957, CORNELL VET, V47, P3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gunasekaran K, 1998, J MOL BIOL, V284, P1505, DOI 10.1006/jmbi.1998.2154; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 2001, PROTEIN SCI, V10, P2219, DOI 10.1110/ps.23101; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864; SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994; Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961; SNIJDER EJ, 2001, FIELDS VIROLOGY, V1, P1205; Stennicke HR, 1996, PROTEIN SCI, V5, P2266, DOI 10.1002/pro.5560051113; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Timoney PJ, 2002, EQUINE RESP DIS; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; van Dinten LC, 1999, J VIROL, V73, P2027, DOI 10.1128/JVI.73.3.2027-2037.1999; Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	38	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39960	39966		10.1074/jbc.M206978200	http://dx.doi.org/10.1074/jbc.M206978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163505	hybrid			2022-12-25	WOS:000178662500114
J	Rallabhandi, P; Hashimoto, K; Mo, YY; Beck, WT; Moitra, PK; D'Arpa, P				Rallabhandi, P; Hashimoto, K; Mo, YY; Beck, WT; Moitra, PK; D'Arpa, P			Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; COVALENT MODIFICATION; SUBCELLULAR-LOCALIZATION; PROTEIN SUMO-1; CELL-NUCLEUS; DNA; CONJUGATION; P53; IDENTIFICATION; REDISTRIBUTION	Previous studies identified a small fraction of putatively sumoylated topoisomerase I (TOP1) under basal conditions (similar to1%), and anticancer camptothecins that trap the TOP1-DNA covalent intermediate markedly increase the sumoylation of TOP1 (less than or equal to10%). To study the role of the sumoylation of TOP1, we mutated sites on green fluorescent protein (GFP)-TOP1 corresponding to the consensus sequence for protein sumoylation (WKXE, where Psi is a hydrophobic residue) and assayed the mutants for basal and camptothecin-induced sumoylation. Only one of the eight mutants, K117R, located in the highly charged NH2-terminal region, showed a substantial reduction (similar to5-fold) in basal and camptothecin-induced sumoylation; thus, Lys-117 appears to be the major sumoylation site. A triple mutant having the PsiKXE sequences flanking K117R additionally mutated (K103R/K117R/K153R) showed little if any sumoylation, but was degraded like wild-type GFP-TOP1 during camptothecin treatment. However, K103R/K117R/K153R-GFP-TOP1 was markedly concentrated within nucleoli, depleted from the remainder of nucleus, and failed to be cleared from nucleoli in response to camptothecin treatment. These data are consistent with a model wherein basal transient sumoylation of the NH2-terminal, highly charged, disordered region prevents TOP1 binding to sites in nucleoli, thus driving it to bind in the nucleoplasm; and camptothecin treatment, which increases TOP1 sumoylation, further shifts the binding resulting in delocalization of TOP1 from nucleoli to nucleoplasm.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	Uniformed Services University of the Health Sciences - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	D'Arpa, P (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011	D'Arpa, Peter/0000-0002-0562-0263				BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Buckwalter CA, 1996, CANCER RES, V56, P1674; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chen TC, 2000, CANCER LETT, V153, P169, DOI 10.1016/S0304-3835(00)00366-9; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Danks MK, 1996, CANCER RES, V56, P1664; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Duprez E, 1999, J CELL SCI, V112, P381; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; van Eenennaam H, 2001, MOL BIOL CELL, V12, P3680, DOI 10.1091/mbc.12.11.3680; Wadkins RM, 1998, EXP CELL RES, V241, P332, DOI 10.1006/excr.1998.4033; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366	46	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40020	40026		10.1074/jbc.M200388200	http://dx.doi.org/10.1074/jbc.M200388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149243	hybrid			2022-12-25	WOS:000178662500122
J	Lee, DK; Kim, BC; Kim, IY; Cho, EA; Satterwhite, DJ; Kim, SJ				Lee, DK; Kim, BC; Kim, IY; Cho, EA; Satterwhite, DJ; Kim, SJ			The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding or the Smad complex to its target sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; PROTEINS; TGF-BETA-1; EXPRESSION; GENE; PHOSPHORYLATION; INACTIVATION	The human papillomavirus (HPV) oncoprotein E7 is implicated in the etiology of cervical cancer associated with infection by HPV. HPV-positive cells develop resistance to TGF-beta growth inhibitory activity through the inhibition of hypophosphorylation of pRb by papillomavirus type 16 E7 oncoprotein. In this study, we examined whether E7, in addition to its well known effects on pRb, might directly target the Smad proteins that mediate TGF-beta signaling. Here, we show that E7 significantly blocks both Smad transcriptional activity and the ability of TGF-beta to inhibit DNA synthesis. We found that E7 interacts constitutively with Smad2, Smad3, and Smad4. Confocal microscopic studies confirm that E7 and Smads co-localize in vivo. Using a canonical Smad DNA binding sequence, we found that E7 blocks Smad3 binding to its target sequence on DNA. These results suggest that suppression of Smad-mediated signaling by E7 may contribute to HPV-associated carcinogenesis.	NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Univ Utah, Div Neonatol, Salt Lake City, UT 84132 USA	National Institutes of Health (NIH) - USA; Utah System of Higher Education; University of Utah	Kim, SJ (corresponding author), NIH, Lab Cell Regulat & Carcinogenesis, Bldg 10, Bethesda, MD 20892 USA.							Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Farley J, 2000, GYNECOL ONCOL, V78, P113, DOI 10.1006/gyno.2000.5879; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Pei XF, 1998, CARCINOGENESIS, V19, P1481, DOI 10.1093/carcin/19.8.1481; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Satterwhite DJ, 2000, BIOCHEM BIOPH RES CO, V276, P686, DOI 10.1006/bbrc.2000.3510; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; Satterwhite DJ, 2000, CANCER RES, V60, P6989; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	36	65	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38557	38564		10.1074/jbc.M206786200	http://dx.doi.org/10.1074/jbc.M206786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145312	hybrid			2022-12-25	WOS:000178529600072
J	Cai, XA; Gu, ZL; Zhong, P; Ren, Y; Yan, Z				Cai, XA; Gu, ZL; Zhong, P; Ren, Y; Yan, Z			Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITY PROTEIN; GLUTAMATE-RECEPTOR; DENDRITIC SPINES; CHOLINERGIC INTERNEURONS; PHOSPHORYLATION SITES; ANTIPSYCHOTIC-DRUGS; SYNAPTIC PLASTICITY	We have studied the regulation of AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor channels by serotonin signaling in pyramidal neurons of prefrontal cortex (PFC). Application of serotonin reduced the amplitude of AMPA-evoked currents, an effect mimicked by 5-HT1A receptor agonists and blocked by 5-HT1A antagonists, indicating the mediation by 5-HT1A receptors. The serotonergic modulation of AMPA receptor currents was blocked by protein kinase A (PKA) activators and occluded by PKA inhibitors. Inhibiting the catalytic activity of protein phosphatase 1 (PP1) also, eliminated the effect of serotonin on AMPA currents. Furthermore, the serotonergic modulation of AMPA currents was occluded by application of the Ca2+/calmodulin-dependent kinase II (CaMKII) inhibitors and blocked by intracellular injection of calmodulin or recombinant CaMKII. Application of serotonin or 5-HT1A agonists to PFC slices reduced CaMKII activity and the phosphorylation of AMPA receptor subunit GluR1 at the CaMKII site in a PP1-dependent manner. We concluded that serotonin, by activating 5-HT1A receptors, suppress glutamatergic signaling through the inhibition of CaMKII, which is achieved by the inhibition of PKA and ensuing activation of PP1. This modulation demonstrates the critical role of CaMKII in serotonergic regulation of PFC neuronal activity, which may explain the neuropsychiatric behavioral phenotypes seen in CaAMKII knockout mice.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu	Cai, Xiang/AAD-8012-2021		NIMH NIH HHS [MH63128] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert PR, 2001, TRENDS ENDOCRIN MET, V12, P453, DOI 10.1016/S1043-2760(01)00498-2; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Andrade R, 1998, ANN NY ACAD SCI, V861, P190, DOI 10.1111/j.1749-6632.1998.tb10191.x; Bachus SE, 1996, J CLIN PSYCHIAT, V57, P72; Bantick RA, 2001, J PSYCHOPHARMACOL, V15, P37, DOI 10.1177/026988110101500108; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENSON DL, 1992, NEUROSCIENCE, V46, P825, DOI 10.1016/0306-4522(92)90188-8; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BREIER A, 1995, SCHIZOPHR RES, V14, P187, DOI 10.1016/0920-9964(94)00043-8; Buhot MC, 1997, CURR OPIN NEUROBIOL, V7, P243, DOI 10.1016/S0959-4388(97)80013-X; Busatto GF, 1997, J PSYCHOPHARMACOL, V11, P3, DOI 10.1177/026988119701100102; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; DUBOVSKY SL, 1995, J CLIN PSYCHIAT, V56, P38; Edagawa Y, 1998, EUR J PHARMACOL, V349, P221, DOI 10.1016/S0014-2999(98)00286-6; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; FITZGERALD LW, 1995, J NEUROSCI, V15, P2453, DOI 10.1523/JNEUROSCI.15-03-02453.1995; FUXE K, 1983, NEUROPHARMACOLOGY, V22, P389, DOI 10.1016/0028-3908(83)90188-0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Gurevich EV, 1997, BIOL PSYCHIAT, V42, P529, DOI 10.1016/S0006-3223(97)00321-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON PJ, 1991, LANCET, V337, P450, DOI 10.1016/0140-6736(91)93392-M; Hayashi K, 1999, J NEUROSCI, V19, P3918; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kia HK, 1996, J NEUROSCI RES, V46, P697; Kia HK, 1996, J COMP NEUROL, V365, P289; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MELTZER HY, 1995, CLIN NEUROSCI, V3, P64; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SAKAI N, 1993, BRAIN RES, V613, P326, DOI 10.1016/0006-8993(93)90921-9; SCHREIBER R, 1993, PROG NEURO-PSYCHOPH, V17, P87, DOI 10.1016/0278-5846(93)90034-P; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; Simpson MDC, 1996, BIOL PSYCHIAT, V39, P919, DOI 10.1016/0006-3223(95)00026-7; Sokolov BP, 1998, J NEUROCHEM, V71, P2454; Stockmeier CA, 1997, ANN NY ACAD SCI, V836, P220, DOI 10.1111/j.1749-6632.1997.tb52362.x; Sumiyoshi T, 1996, BRAIN RES, V708, P209, DOI 10.1016/0006-8993(95)01361-X; Tukey JW, 1977, EXPLORATORY DATA ANA; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yan Z, 1996, J NEUROSCI, V16, P2592; Yan Z, 1997, NEURON, V19, P1115, DOI 10.1016/S0896-6273(00)80402-X; Zhabotinsky AM, 2000, BIOPHYS J, V79, P2211, DOI 10.1016/S0006-3495(00)76469-1	69	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36553	36562		10.1074/jbc.M203752200	http://dx.doi.org/10.1074/jbc.M203752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12149253	hybrid			2022-12-25	WOS:000178275100098
J	Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D				Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D			Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators	ONCOGENE			English	Article						microtubules; mitosis; breast cancer; mRNA processing; Sm proteins; TACC proteins	CHROMOSOME ARM 8P; COILED-COIL; TUMOR-SUPPRESSOR; GENE FAMILY; CYCLIN B1; PROTEIN; EXPRESSION; SM; CPEB; INTERACTS	The three human TACC genes encode a family of proteins that are suspected to play a role in carcinogenesis. Their function is not precisely known; a Xenopus TACC protein called Maskin is involved in translational control, while the Drosophila D-TACC associates with microtubules and centrosomes. We have characterized the human TACC1 gene and its products. The TACC1 gene is located in region p12 of chromosome 8; its mRNA is ubiquitously expressed and encodes a protein with an apparent molecular mass of 125 kDa, which is cytoplasmic and mainly perinuclear. We show that TACC1 mRNA gene expression is down-regulated in various types of tumors. Using immunohistochemistry of tumor tissue-microarrays and sections, we confirm that the level of TACC1 protein is down-regulated in breast cancer. Finally, using the two-hybrid screen in yeast, GST pull-downs and co-immunoprecipitations, we identified two potential binding partners for TACC1, LSM7 and SmG. They constitute a conserved subfamily of Sm-like small proteins that associate with U6 snRNPs and play a role in several aspects of mRNA processing. We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes.	Dept Mol Oncol, INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Pathol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Atelier Bioimagerie, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Dept Mol Oncol, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017; ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	Ginestier, Christophe/0000-0002-7477-3837; ADELAIDE, José JA/0000-0003-4364-9857; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Conte, Nathalie/0000-0002-1010-3121				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kelley JR, 2000, SURGERY, V128, P353, DOI 10.1067/msy.2000.107605; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	46	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5619	5630		10.1038/sj.onc.1205658	http://dx.doi.org/10.1038/sj.onc.1205658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165861				2022-12-25	WOS:000177442000012
J	Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B				Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B			ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene	ONCOGENE			English	Article						spectrin; ankyrin; cytoskeleton; neuronal stem cells; gene structure	CENTRAL-NERVOUS-SYSTEM; MEMBRANE SKELETON; EPITHELIAL-CELLS; MESSENGER-RNA; ERYTHROCYTE SPECTRIN; MOLECULAR-CLONING; LIVER DEVELOPMENT; NEURAL CELLS; IN-VITRO; IDENTIFICATION	Spectrins play a pivotal role in axonal transport, neurite extension, the organization of synaptic vesicles, as well as for protein sorting in the Golgi apparatus and cell membrane. Among spectrins there is great variability in sequence composition, tissue distribution, and function, with two known genes encoding the alpha-chain, and at least five encoding the beta-chain. It remains unclear as to whether novel beta-spectrins such as elf1-4 are distinct genes or alpha-G-spectrin isoforms. The role for ELF in the developing nervous system has not been identified to date. In this study we demonstrate the genomic structure of elf-3, as well as the expression of ELF in the developing mouse brain using a peptide specific antibody against its distinctive amino-terminal end. Full genomic structural analyses reveal that elf-3 is composed of 31 exons spanning similar to67 kb, and confirm that elf and mouse brain beta-G-spectrin share multiple exons, with a complex form of exon/intron usage. In embryonic stages, E9-12, anti-ELF localized to the primary brain vesicular cells that also labeled strongly with anti-nestin but not anti-vimentin. At E12-14, anti-ELF localized to axonal sprouts in the developing neuroblasts of cortex and purkinje cell layer of the cerebellum, as well as in cell bodies in the diencephalon and metencephalon. Double labeling identified significant co-localization of anti-ELF, nestin and dystrophin in sub ventricular zone cells and in stellate-like cells of the developing forebrain. These studies define clearly the expression of ELF, a new isoform of beta-G-spectrin in the developing brain. Based on its expression pattern, ELF may have a role in neural stem cell development and is a marker of axonal sprouting in mid stages of embryonic development.	Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; DVAMC, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Childrens Hosp, Philadelphia, PA 19104 USA; NHGRI, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Georgetown University	Mishra, L (corresponding author), Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lopamishra@yahoo.com		Mishra, Lopa/0000-0002-6850-0808	NIDDK NIH HHS [1R01 DK56111, 1R03 DK53861, 1R01 DK 58637] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111, R03DK053861] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BIRKENMEIER CS, 1988, P NATL ACAD SCI USA, V85, P8121, DOI 10.1073/pnas.85.21.8121; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Chen YW, 2001, J MOL NEUROSCI, V17, P59, DOI 10.1385/JMN:17:1:59; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAVIS J, 1983, J BIOL CHEM, V258, P7757; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Doetsch F, 1997, J NEUROSCI, V17, P5046; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Emery A, 1988, DUCHENNE MUSCULAR DY; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GLENNEY JR, 1983, J CELL BIOL, V96, P1491, DOI 10.1083/jcb.96.5.1491; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Hayes NVL, 2000, J CELL SCI, V113, P2023; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; JOOSTEN EAJ, 1989, NEUROSCIENCE, V31, P439, DOI 10.1016/0306-4522(89)90386-2; JUNG D, 1991, NEUROSCI LETT, V124, P87, DOI 10.1016/0304-3940(91)90828-H; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1998, J NEUROCHEM, V71, P2585; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MARINPADILLA M, 1985, J COMP NEUROL, V235, P82, DOI 10.1002/cne.902350107; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1999, MAMM GENOME, V10, P62, DOI 10.1007/s003359900944; Mishra L, 1998, INT J DEV BIOL, V42, P221; MOON RT, 1987, BIOESSAYS, V7, P159, DOI 10.1002/bies.950070405; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; MORROW JS, 1997, HDB PHYSIOL 14, P485; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Ohara O, 1998, MOL BRAIN RES, V57, P181, DOI 10.1016/S0169-328X(98)00068-0; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Sakaguchi G, 1998, BIOCHEM BIOPH RES CO, V248, P846, DOI 10.1006/bbrc.1998.9067; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; Sikorski AF, 2000, BRAIN RES, V852, P161, DOI 10.1016/S0006-8993(99)02253-2; SIMAN R, 1987, J NEUROSCI, V7, P55; SOBUE K, 1990, NEUROSCI RES, pS80, DOI 10.1016/0921-8696(90)90035-2; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Stabach PR, 2000, J BIOL CHEM, V275, P21385, DOI 10.1074/jbc.C000159200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; TAKASHIMA S, 1981, BRAIN RES, V225, P1, DOI 10.1016/0006-8993(81)90314-0; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; WINKELMANN JC, 1988, BLOOD, V72, P328; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zarnescu DC, 1999, J CELL BIOL, V146, P1075, DOI 10.1083/jcb.146.5.1075; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681; ZIMMER WE, 1991, BRAIN RES BULL, V27, P187, DOI 10.1016/0361-9230(91)90066-S	85	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5255	5267		10.1038/sj.onc.1205548	http://dx.doi.org/10.1038/sj.onc.1205548			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149647				2022-12-25	WOS:000177193900007
J	Isoyama, T; Kuge, S; Nomoto, A				Isoyama, T; Kuge, S; Nomoto, A			The core protein of hepatitis C virus is imported into the nucleus by transport receptor Kap123p but inhibits Kap121p-dependent nuclear import of yeast AP1-like transcription factor in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EMBRYO FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MEDIATED APOPTOSIS; NON-A; EXPORT; GENE; RNA; LOCALIZATION; GENOME	The core protein of hepatitis C virus (HCV) is a major component of the viral nucleocapsid. The HCV core protein includes nuclear localization signal-like sequences and has various effects on cellular metabolism, playing roles, for example, in the regulation of transcription, apoptosis, and transformation. To examine the possibility of an effect of the core protein on nucleocytoplasmic transport, we used the yeast Saccharomyces cerevisiae as a model system. The core protein (p23) is processed to p21 and is localized in both the cytoplasm and nucleus in yeast cells, similar to that observed in mammalian cells in several cases. The nuclear import of the core protein requires the activity of small GTPase Ran/Gsp1p and is mediated by Kap123p in yeast cells. When the core protein was expressed in yeast cells, the import of the yeast AP1-like transcription factor Yap1p into the nucleus was inhibited. Experiments in vitro involving Kap121p, also known as Pse1p, a receptor for the nuclear import of Yap1p, indicated that the amount of Yap1p bound to Kap121p was reduced in the presence of core protein. These results suggest that the HCV core protein affects cellular metabolism by disturbing transport of proteins to the nucleus.	Tohoku Univ, Lab Mol & Biochem Toxicol, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Univ Tokyo, Grad Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1130033, Japan	Tohoku University; University of Tokyo	Kuge, S (corresponding author), Tohoku Univ, Lab Mol & Biochem Toxicol, Grad Sch Pharmaceut Sci, Aoba Ku, Aza Aoba, Sendai, Miyagi 9808578, Japan.	skuge@mail.pharm.tohoku.ac.jp						Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; AUSBEL I, 2000, CURRENT PROTOCOLS MO, V3; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Ferrigno P, 1999, METHOD CELL BIOL, V58, P107; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Isoyama T, 2001, J BIOL CHEM, V276, P21863, DOI 10.1074/jbc.M009258200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kashiwakuma T, 1996, J IMMUNOL METHODS, V190, P79, DOI 10.1016/0022-1759(95)00261-8; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Moriya K, 2001, CANCER RES, V61, P4365; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Rullier A, 2001, MODERN PATHOL, V14, P496, DOI 10.1038/modpathol.3880338; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	68	24	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39634	39641		10.1074/jbc.M203939200	http://dx.doi.org/10.1074/jbc.M203939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167639	hybrid			2022-12-25	WOS:000178662500075
J	Ghatak, S; Misra, S; Toole, BP				Ghatak, S; Misra, S; Toole, BP			Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; PROTEIN-KINASE; SURFACE CD44; CANCER CELLS; IN-VIVO; MEDIATED TRANSFORMATION; EPITHELIAL-CELLS; BINDING; ACID; TUMORIGENICITY	Hyaluronan oligosaccharides (molecular weight: similar to2.5 x 10(3)) inhibit growth of several types of tumors in vivo. In vitro, the oligomers inhibit anchorage-independent growth of several tumor cell types. In accordance with this finding, the oligomers also induce apoptosis and stimulate caspase-3 activity under anchorage-independent conditions. Since inhibitors of phosphoinositide 3-kinase (PI 3-kinase) mimic the action of hyaluronan oligomers and since the PI 3-kinase/Akt (protein kinase B) cell survival pathway has previously been implicated in anchorage-independent growth of tumor cells, we examined the effect of oligomers on PI 3-kinase and its downstream activities in TA3/St murine mammary carcinoma and HCT 116 human colon carcinoma cells. We observed that 50-150 mug/ml hyaluronan oligomers inhibit PI 3-kinase activity and phosphorylation of Akt to approximately the same extent as optimal doses of wortmannin and LY294002, known inhibitors of PI, 3-kinase. Similar inhibition of downstream events, i.e. phosphorylation of BAD and FKHR, was also observed. These effects were not observed on treatment with similar concentrations of chitin oligomers, chondroitin sulfate, or hyaluronan polymer. High molecular weight (similar to2 x 10(6)) and low molecular weight (similar to8 x 10(4)) preparations of hyaluronan polymer were equally ineffective. The effects of hyaluronan oligomers on these parameters were similar in magnitude to the effect of treatment with activity-blocking antibody against CD44. We interpret these results to indicate that the oligomers competitively block binding of endogenous hyaluronan polymer to CD44, consequently giving rise to attenuated signaling. Finally, we observed that hyaluronan oligomers, but not chitin oligomers, chondroitin sulfate, or hyaluronan polymer, stimulate expression of PTEN, a phosphatase that degrades the major signaling product of PI 3-kinase action, phosphoinositide 3,4,5-trisphosphate. We conclude that perturbation of hyaluronan-CD44 binding leads to suppression of the PI 3-kinase/Akt cell survival pathway and consequently to inhibition of anchorage-independent growth in culture and tumor growth in vivo.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA073839] Funding Source: NIH RePORTER; NCI NIH HHS [CA73839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BISWAS C, 1984, CANCER LETT, V24, P201, DOI 10.1016/0304-3835(84)90137-X; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; Itano N, 1999, CANCER RES, V59, P2499; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Kosaki R, 1999, CANCER RES, V59, P1141; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Liu NF, 2001, CANCER RES, V61, P5207; Liu NF, 2001, CANCER RES, V61, P1022; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MACPHERSON JN, 1969, J MED MICROBIOL, V2, P161, DOI 10.1099/00222615-2-2-161; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Moore SM, 1998, CANCER RES, V58, P5239; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Sleeman JP, 1996, CANCER RES, V56, P3134; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SUSA M, 1992, J BIOL CHEM, V267, P22951; Takahashi K, 1995, ONCOGENE, V11, P2223; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zeng CX, 1998, INT J CANCER, V77, P396; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	58	286	302	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38013	38020		10.1074/jbc.M202404200	http://dx.doi.org/10.1074/jbc.M202404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145277	hybrid			2022-12-25	WOS:000178529600007
J	Vannahme, C; Smyth, N; Miosge, N; Gosling, S; Frie, C; Paulsson, M; Maurer, P; Hartmann, U				Vannahme, C; Smyth, N; Miosge, N; Gosling, S; Frie, C; Paulsson, M; Maurer, P; Hartmann, U			Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NULL MICE EXHIBIT; GROWTH-FACTOR; CRYSTAL-STRUCTURE; ZONA-PELLUCIDA; PROTEOGLYCAN SPOCK; SPARC; FOLLISTATIN; EXPRESSION; BM-40; DEFICIENT	We have isolated the novel gene SMOC-1 that encodes a secreted modular protein containing an EF-hand calcium-binding domain homologous to that in BM-40. It further consists of two thyroglobulin-like domains, a follistatin-like domain and a novel domain. Recombinant expression in human cells showed that SMOC-1 is a glycoprotein with a calcium-dependent conformation. Results from Northern blots, reverse transcriptase-PCR, and immunoblots revealed a widespread expression in many tissues. Immunofluorescence studies with an antiserum directed against recombinant human SMOC-1 demonstrated a basement membrane localization of the protein and additionally its presence in other extracellular matrices. Immunogold electron microscopy confirmed the localization of SMOC-1 within basement membranes in kidney and skeletal muscle as well as its expression in the zona pellucida surrounding the oocyte.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Univ Gottingen, Dept Histol, Ctr Anat, D-37075 Gottingen, Germany	University of Cologne; University of Gottingen	Hartmann, U (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	ursula.hartmann@uni-koeln.de	Miosge, Nicolai/E-3244-2010	Smyth, Neil/0000-0002-3734-2149				ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; BaSalamah MAM, 2001, BIOCHEM BIOPH RES CO, V283, P1083, DOI 10.1006/bbrc.2001.4900; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; Bonnet F, 1996, J BIOL CHEM, V271, P4373; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Charbonnier F, 2000, MECH DEVELOP, V90, P317, DOI 10.1016/S0925-4773(99)00255-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cifuentes-Diaz C, 2000, MECH DEVELOP, V94, P277, DOI 10.1016/S0925-4773(00)00285-9; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; Eib DW, 1996, J NEUROCHEM, V67, P1047; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig John J., 1997, Human Reproduction (Oxford), V12, P127; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; LENARCIC B, BIOL CHEM HOPPESEYLE, V379, P105; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Marr HS, 1997, ENDOTHELIUM-NEW YORK, V5, P209, DOI 10.3109/10623329709053399; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MAURER P, 1996, GUIDEBOOK CALCIUM BI, P169; McKinnon PJ, 1996, BRAIN RES, V709, P27, DOI 10.1016/0006-8993(95)01224-9; McKinnon PJ, 2000, MOL CELL BIOL, V20, P656, DOI 10.1128/MCB.20.2.656-660.2000; Miosge N, 2000, J HISTOCHEM CYTOCHEM, V48, P229, DOI 10.1177/002215540004800208; Miosge N, 2001, HISTOL HISTOPATHOL, V16, P1239, DOI 10.14670/HH-16.1239; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; Nakada M, 2001, CANCER RES, V61, P8896; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nischt R, 2001, CANCER LETT, V162, P223, DOI 10.1016/S0304-3835(00)00659-5; Norose K, 2000, EXP EYE RES, V71, P295, DOI 10.1006/exer.2000.0884; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; Rankin T, 2000, REV REPROD, V5, P114, DOI 10.1530/ror.0.0050114; Rankin TL, 2001, DEVELOPMENT, V128, P1119; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Savani RC, 2000, AM J PHYSIOL-LUNG C, V279, pL743, DOI 10.1152/ajplung.2000.279.4.L743; Schneyer A, 2001, MOL CELL ENDOCRINOL, V180, P33, DOI 10.1016/S0303-7207(01)00501-9; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200; Strandjord TP, 1999, AM J PHYSIOL-LUNG C, V277, pL628, DOI 10.1152/ajplung.1999.277.3.L628; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Towers P, 1999, DEV BIOL, V214, P298, DOI 10.1006/dbio.1999.9421; TSCHESCHE H, 1987, BIOL CHEM H-S, V368, P1297, DOI 10.1515/bchm3.1987.368.2.1297; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	67	81	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37977	37986		10.1074/jbc.M203830200	http://dx.doi.org/10.1074/jbc.M203830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12130637	hybrid			2022-12-25	WOS:000178529600003
J	Davaille, J; Li, LY; Mallat, A; Lotersztajn, S				Davaille, J; Li, LY; Mallat, A; Lotersztajn, S			Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY PROPERTIES; NECROSIS-FACTOR-ALPHA; STELLATE CELLS; ENDOTHELIAL-CELLS; MEDIATED PATHWAY; KINASE PATHWAYS; LIVER FIBROSIS; RECEPTOR EDG-1; ITO CELLS; SPHINGOSINE-1-PHOSPHATE	Hepatic myofibroblasts (hMFs) are central in the development of liver fibrosis during chronic liver diseases, and their removal by apoptosis contributes to the resolution of liver fibrosis. We previously identified Edg receptors for sphingosine 1-phosphate (S1P) in human hMFs. Here, we investigated the effects of S1P on hMF apoptosis. S1P reduced viability of serum-deprived hMFs by an apoptotic process that was unrelated to the conversion of S1P into sphingosine and ceramide. The apoptotic effects of S1P were receptor-independent because dihydro-S1P, an Edg agonist, had no effect. S1P also stimulated a receptor-dependent survival pathway, revealed by enhanced activation of caspase-3 by S1P in the presence of pertussis toxin. Cell survival relied on two pertussis toxin-sensitive events, activation of ERK and activation of phosphatidylinositol 3-kinase (PI3K)/Akt by S1P. Both pathways were also activated by dihydro-S1P. Blunting either ERK or PI3K enhanced caspase-3 stimulation by S1P, and simultaneous inhibition of both pathways resulted in additive effects on caspase-3 activation. In conclusion, S1P induces apoptosis of human hMFs via a receptor-independent mechanism and stimulates a survival pathway following activation of Edg receptors. The survival pathway arises from the sequential activation of G(i)/G(o) proteins and independent stimulations of ERK and PI3K/Akt. Therefore, blocking Edg receptors may sensitize hepatic myofibroblasts to apoptosis by S1P.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Lotersztajn, Sophie/K-9160-2017	lotersztajn, Sophie/0000-0002-0053-7807				An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chin TY, 2002, MOL PHARMACOL, V61, P486, DOI 10.1124/mol.61.3.486; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Fischer R, 2001, GASTROENTEROLOGY, V120, P1212, DOI 10.1053/gast.2001.23260; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; Gong WR, 1998, HEPATOLOGY, V28, P492, DOI 10.1002/hep.510280229; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hatano E., 2002, AM J PHYSIOL-GASTR L, V282, pG1357; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Iwamoto H, 1999, J LAB CLIN MED, V134, P83, DOI 10.1016/S0022-2143(99)90057-4; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kinloch RA, 1999, TRENDS PHARMACOL SCI, V20, P35, DOI 10.1016/S0165-6147(98)01277-2; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li LY, 2001, J BIOL CHEM, V276, P38152; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	47	83	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37323	37330		10.1074/jbc.M202798200	http://dx.doi.org/10.1074/jbc.M202798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138095	hybrid			2022-12-25	WOS:000178447100054
J	Kimura, Y; Koitabashi, S; Kakizuka, A; Fujita, T				Kimura, Y; Koitabashi, S; Kakizuka, A; Fujita, T			Circumvention of chaperone requirement for aggregate formation of a short polyglutamine tract by the co-expression of a long polyglutamine tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; EXPANDED POLYGLUTAMINE; HUNTINGTONS-DISEASE; IN-VITRO; NEURODEGENERATIVE DISEASES; CAENORHABDITIS-ELEGANS; GLUTAMINE REPEATS; CELL-DEATH; TRANSCRIPTION; VIVO	Polyglutamine disease is now recognized as one of the conformational, amyloid-related diseases. In this disease, polyglutamine expansion in proteins has toxic effects on cells and also results in the formation of aggregates. Polyglutamine aggregate formation is accompanied by conversion of the polyglutamine from a soluble to an insoluble form. In yeast, the efficiency of the aggregate formation is determined by the balance of various parameters, including the length of the polyglutamine tract, the function of Hsp104, and the level of polyglutamine, expression. In this study, we found that the co-expression of a long polyglutamine tract, which formed aggregates independently of the function of Hsp104, enhanced the formation of aggregates of a short polyglutamine tract in wild-type cells as well as in Deltahsp104 mutant cells. Thus, the expression of a long polyglutamine tract would be an additional parameter determining the efficiency of aggregate formation of a short polyglutamine tract. The co-localization of aggregates of long and short polyglutamine tracts suggests the possibility that the enhancement occurs due to the seeding of aggregates of the long polyglutamine tracts.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Dept Funct Biol, Gard Sch Biostudies, Kyoto 6068501, Japan	Tokyo Metropolitan Institute of Medical Science; Kyoto University	Kimura, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	ykimura@rinshoken.or.jp	Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kimura Y, 2001, GENES CELLS, V6, P887, DOI 10.1046/j.1365-2443.2001.00472.x; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Westermark GT, 1999, METHOD ENZYMOL, V309, P3	30	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37536	37541		10.1074/jbc.M201721200	http://dx.doi.org/10.1074/jbc.M201721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161426	hybrid			2022-12-25	WOS:000178447100080
J	Zayzafoon, M; Botolin, S; McCabe, LR				Zayzafoon, M; Botolin, S; McCabe, LR			p38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; DNA-BINDING ACTIVITY; MAP KINASE PATHWAY; PROTEIN-KINASE; C-JUN; DIABETES-MELLITUS; BONE MASS; TYROSINE PHOSPHORYLATION; MINERAL METABOLISM; INDUCED INHIBITION	Poorly controlled or untreated type I diabetes mellitus is characterized by hyperglycemia and is associated with decreased bone mass and osteoporosis. We have demonstrated that osteoblasts are sensitive to hyperglycemia-associated osmotic stress and respond to elevated extracellular glucose or mannitol by increasing c-jun and collagen I expression. To determine whether MAPKs are involved in this response, MC3T3-E1 osteoblasts were treated with 16.5 mm glucose, mannitol, or contrast dye for 1 h. Immunoblotting of phosphorylated p38 demonstrated activation of p38 MAPK by hyperosmotic stress in vitro and in vivo. Activation peaked at 20 min, remained detectable after 24 h, and was protein kinase C-independent. Activating transcription factor-2 (ATF-2) activation followed the same pattern as phospho-p38. Transactivation of cAMP response element (CRE)- and c-jun promoter (containing a CRE-like element)-reporter constructs increased following hyperosmotic treatment. SB 203580 (a p38 MAPK inhibitor) blocked ATF-2 phosphorylation, CRE transactivation, and c-jun promoter activation. Hyperosmotic activation of collagen I promoter activity was also inhibited by SB 203580, consistent with the involvement of c-jun in collagen I up-regulation. Therefore, we propose that hyperglycemia-induced increases in p38 MAPK activity and ATF-2 phosphorylation contribute to CRE activation and modulation of c-jun and collagen I expression in osteoblasts.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	McCabe, LR (corresponding author), Michigan State Univ, Dept Physiol, 2201 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.			McCabe, Laura/0000-0001-5407-162X				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1988, DIABETES, V37, P8, DOI 10.2337/diabetes.37.1.8; Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756-3282(00)00426-9; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dunstan CR, 1999, J BONE MINER RES, V14, P953, DOI 10.1359/jbmr.1999.14.6.953; Duzgun SA, 2000, J CELL BIOCHEM, V76, P567, DOI 10.1002/(SICI)1097-4644(20000315)76:4<567::AID-JCB5>3.0.CO;2-W; Emancipator K, 1999, AM J CLIN PATHOL, V112, P665; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1996, ONCOGENE, V13, P1531; Fujimoto R, 1999, J BONE MINER METAB, V17, P11, DOI 10.1007/s007740050057; GRINSTEIN S, 1986, J CELL PHYSIOL, V128, P33, DOI 10.1002/jcp.1041280107; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; HUI SL, 1985, J CLIN ENDOCR METAB, V60, P74, DOI 10.1210/jcem-60-1-74; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishida T, 1999, DIABETES, V48, P595, DOI 10.2337/diabetes.48.3.595; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775; KWON HM, 1992, J BIOL CHEM, V267, P6297; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee HW, 1998, J MOL CELL CARDIOL, V30, P2495, DOI 10.1006/jmcc.1998.0811; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC1067, DOI 10.1152/ajpcell.1995.268.4.C1067; ODONNELL ME, 1993, AM J PHYSIOL, V264, pC1316, DOI 10.1152/ajpcell.1993.264.5.C1316; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Park CW, 2000, DIABETOLOGIA, V43, P1544, DOI 10.1007/s001250051567; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SASAKI T, 1991, ANAT REC, V231, P25, DOI 10.1002/ar.1092310105; Schaffler A, 2000, EUR J CLIN INVEST, V30, P586; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tsai EY, 1996, MOL CELL BIOL, V16, P459; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; VERHAEGHE J, 1990, DIABETES, V39, P477, DOI 10.2337/diabetes.39.4.477; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Watts BA, 1998, AM J PHYSIOL-RENAL, V275, pF478, DOI 10.1152/ajprenal.1998.275.4.F478; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1; Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097-4644(20001101)79:2<301::AID-JCB130>3.0.CO;2-0; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	73	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37212	37218		10.1074/jbc.M200129200	http://dx.doi.org/10.1074/jbc.M200129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149242	hybrid			2022-12-25	WOS:000178447100041
J	Munoz, E; Brewer, M; Baler, R				Munoz, E; Brewer, M; Baler, R			Circadian transcription - Thinking outside the E-Box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; C-MYC; GENE-EXPRESSION; REGULATORY ELEMENTS; FIRST INTRON; IN-VIVO; PROMOTER; LOOP; UPSTREAM; PROTEINS	The E-Box is a widely used DNA control element. Despite its brevity and broad distribution the E-Box is a remarkably versatile sequence that affects many different genetic programs, including proliferation, differentiation, tissue-specific responses, and cell death. The circadian clock is one of the latest pathways shown to employ this element. In this context, E-Boxes are likely to play a key role in establishing the robust waves of gene expression characteristic of circadian transcription. The regulatory flexibility of the E-Box hinges on the sequence ambiguity allowed at its core, the strong influence of the surrounding sequences, and the recruitment of spatially and temporally regulated E-Box-binding factors. Therefore, understanding how a particular E-Box can accomplish a specific task entails the identification and systematic analysis of these cis- and transacting E-Box modifiers. In the present study we compared the E-Box-containing minimal promoters of vasopressin and cyclin B1, two genes that can respond to the transcriptional oscillators driving the circadian clock and cell cycle, respectively. Results of this comparison will help elucidate the manner in which discreet DNA modules associate to either augment or restrain the activation of potential circadian E-Boxes in response to competing regulatory signals.	NIMH, Unit Temporal Gene Express, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Baler, R (corresponding author), NIH, Bldg 36,Rm 2A-09, Bethesda, MD 20892 USA.			Munoz, Estela/0000-0002-6701-1535	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002767] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; BARGMANN WOLFGANG, 1951, AMER SCI, V39, P255; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Camara-Clayette V, 1999, BIOCHEM BIOPH RES CO, V265, P170, DOI 10.1006/bbrc.1999.1634; Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1; Chong NW, 2000, J BIOL CHEM, V275, P32991, DOI 10.1074/jbc.M005671200; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coulson JM, 1999, BIOCHEM J, V344, P961, DOI 10.1042/0264-6021:3440961; Darlington TK, 2000, J BIOL RHYTHM, V15, P462, DOI 10.1177/074873000129001576; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Farina A, 1996, ONCOGENE, V13, P1287; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; FUNK WD, 1991, MOL BIOL MED, V8, P185; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Grace CO, 1999, NEUROPEPTIDES, V33, P81, DOI 10.1054/npep.1999.0018; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang J, 1996, MOL CELL BIOL, V16, P3893; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kraner SD, 1998, J BIOL CHEM, V273, P11327, DOI 10.1074/jbc.273.18.11327; Kyriacou CP, 2000, J BIOL RHYTHM, V15, P483, DOI 10.1177/074873000129001594; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Littlewood T D, 1990, Adv Dent Res, V4, P69; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Lyons LC, 2000, J BIOL RHYTHM, V15, P472, DOI 10.1177/074873000129001585; McDonald MJ, 2001, MOL CELL BIOL, V21, P1207, DOI 10.1128/MCB.21.4.1207-1217.2001; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ripperger JA, 2000, GENE DEV, V14, P679; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493; Wang YG, 2000, INT FED INFO PROC, V47, P161; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	54	64	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36009	36017		10.1074/jbc.M203909200	http://dx.doi.org/10.1074/jbc.M203909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130638	hybrid			2022-12-25	WOS:000178275100032
J	Lee, DCW; Chan, KW; Chan, SY				Lee, DCW; Chan, KW; Chan, SY			RET receptor tyrosine kinase isoforms in kidney function and disease	ONCOGENE			English	Article						RET; GDNF; kidney; mIMCD3; polycystic kidney disease	URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; CELL-LINE; NEUROTROPHIC FACTOR; MOUSE KIDNEY; PROTOONCOGENE; EXPRESSION; GDNF; BINDING; EMBRYOGENESIS	The RET proto-oncogene encodes two major isoforms, RET9 and RET51, which differ at the carboxyl-terminal. Loss-of-function mutations in RET result in gut aganglionosis while gain of function mutations result in cancer syndromes. From studies on transgenic mice, RET9 is important for early development of the kidney and the enteric nervous system. Little is known about the function of RET isoforms in later life. Here we report the expression of RET isoforms and its signalling complex, GDNF and GFRalpha1, in foetal and adult human kidneys. We found their expression in both the developing and the adult renal collecting system. We further show that only RET51 but not RET9 could promote the survival and tubulogenesis of mIMCD3 (mouse inner medullary collecting duct) cells in collagen gel. Our results agree with the hypothesis that RET51 signalling is related to differentiation events in later kidney organogenesis. In addition, it may also have a function in the adult kidney. We further extend our study by showing increased RET and GDNF expression in collecting duct cysts of polycystic kidney patients. This suggests that GDNF/RET signalling may contribute to proliferation of the collecting duct epithelium in an autocrine/paracrine manner.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Ctr Human Dev & Birth Defects, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.			Chan, Siu Yuen/0000-0001-7262-1293				Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brenner BM, 1996, BRENNER RECTORS KIDN; Chan SY, 1998, ONCOGENE, V17, P661, DOI 10.1038/sj.onc.1201970; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Fisher CE, 2001, DEVELOPMENT, V128, P4329; Grimm L, 1998, HUM MOL GENET, V7, P1873, DOI 10.1093/hmg/7.12.1873; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLTHOFER H, 1981, LAB INVEST, V45, P391; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Lanoix J, 1996, ONCOGENE, V13, P1153; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; O'Rourke DA, 1999, AM J PHYSIOL-RENAL, V276, pF581, DOI 10.1152/ajprenal.1999.276.4.F581; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Sainio K, 1997, DEVELOPMENT, V124, P4077; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885	36	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5582	5592		10.1038/sj.onc.1205741	http://dx.doi.org/10.1038/sj.onc.1205741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165857				2022-12-25	WOS:000177442000008
J	Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E				Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E			Base excision repair of adenine/8-oxoguanine mispairs by an aphidicolin-sensitive DNA polymerase in human cell extracts	ONCOGENE			English	Article						DNA repair; oxidative damage; mammalian cell extracts; base excision repair; 8oxo G/A mismatch	TRANSCRIPTION-COUPLED REPAIR; MISMATCH-CONTAINING DNA; RETRACTED ARTICLE. SEE; THYMINE DIMER BYPASS; COLI MUTY GENE; ESCHERICHIA-COLI; HUMAN HOMOLOG; SUBCELLULAR-LOCALIZATION; GLYCOSYLASE DETERMINES; SUBSTRATE-SPECIFICITY	Replication of DNA containing 8-oxo-7,8-dihydroguanine (8oxoG) can generate 8oxoG/A base pairs which, if uncorrected, lead to G-->T transversions. It is generally accepted that the repair of these promutagenic base pairs in human cells is initiated by the MutY DNA glycosylase homolog (hMYH). Here we provide biochemical evidence that human cell extracts perform base excision repair (BER) on both DNA strands of an 8oxoG/A mismatch. At early repair times the specificity of nucleotide incorporation indicates a preferential insertion of C opposite 8oxoG leading to the formation of 8oxoG/C pairs. This is followed by repair synthesis on the opposite DNA strand that is consistent with hOGG1-mediated correction of 8oxoG/C to G/C. Repair synthesis on either strand is completely inhibited by aphidicolin suggesting that a replicative DNA polymerase is involved in the gap filling. This is the first demonstration that repair of 8oxoG/A base pairs is by two BER events likely mediated by Poldelta/epsilon. We suggest that the Poldelta/epsilon-mediated BER is the general mode of repair when BER lesions are formed at replication forks.	Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy; Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms, Herts, England; Inst Gustave Roussy, Grp Reparat ADN, UMR 1772 CNRS, F-94805 Villejuif, France	Istituto Superiore di Sanita (ISS); Cancer Research UK; UNICANCER; Gustave Roussy	Dogliotti, E (corresponding author), Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, Via Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Fortini, Paola/K-1197-2018; Parlanti, Eleonora/AAC-5978-2021	Fortini, Paola/0000-0001-6206-8498; 				AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leadon SA, 1997, CANCER RES, V57, P3784; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Tissier A, 2000, GENE DEV, V14, P1642; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; WEISER T, 1991, J BIOL CHEM, V266, P10420; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5204	5212		10.1038/sj.onc.1205561	http://dx.doi.org/10.1038/sj.onc.1205561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149642				2022-12-25	WOS:000177193900002
J	Hung, SP; Baldi, P; Hatfield, GW				Hung, SP; Baldi, P; Hatfield, GW			Global gene expression profiling in Escherichia coli K12 - The effects of leucine-responsive regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY-PHASE SURVIVAL; THREONINE OPERON; NUCLEOTIDE-SEQUENCE; TYPE-1 FIMBRIATION; ISOLEUCINE CODONS; TRANSPORT-SYSTEM; STRESS-RESPONSE; ILVGMEDA OPERON; DNA MICROARRAY; CONTROL REGION	Leucine-responsive regulatory protein (Lrp) is a global regulatory protein that affects the expression of multiple genes and operons in bacteria. Although the physiological purpose of Lrp-mediated gene regulation remains unclear, it has been suggested that it functions to coordinate cellular metabolism with the nutritional state of the environment. The results of gene expression profiles between otherwise isogenic Irp(+) and Irp(-)strains of Escherichia coli support this suggestion. The newly discovered Lrp-regulated genes reported here are involved either in small molecule or macromolecule synthesis or degradation, or in small molecule transport and environmental stress responses. Although many of these regulatory effects are direct, others are indirect consequences of Lrp-mediated changes in the expression levels of other global regulatory proteins. Because computational methods to analyze and interpret high dimensional DNA microarray data are still an early stage, much of the emphasis of this work is directed toward the development of methods to identify differentially expressed genes with a high level of confidence. In particular, we describe a Bayesian statistical framework for a posterior estimate of the standard deviation of gene measurements based on a limited number of replications. We also describe an algorithm to compute a posterior estimate of differential expression for each gene based on the experiment-wide global false positive and false negative level for a DNA microarray data set. This allows the experimenter to compute posterior probabilities of differential expression for each individual differential gene expression measurement.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genomics & Bioinformat, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Informat & Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Engn, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM 55073] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUHAMAD WN, 1991, MOL MICROBIOL, V5, P1035, DOI 10.1111/j.1365-2958.1991.tb01876.x; ALEXANDER DM, 1994, MOL MICROBIOL, V11, P1059, DOI 10.1111/j.1365-2958.1994.tb00383.x; AMBARTSOUMIAN G, 1994, MICROBIOL-UK, V140, P1737, DOI 10.1099/13500872-140-7-1737; Arfin SM, 2000, J BIOL CHEM, V275, P29672, DOI 10.1074/jbc.M002247200; AUSTIN EA, 1989, ABSTR MOL GEN BACT, P153; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412; BAUMINGER ER, 1994, BIOCHEM J, V302, P813, DOI 10.1042/bj3020813; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Bhagwat SP, 1997, J BACTERIOL, V179, P6254, DOI 10.1128/jb.179.20.6254-6263.1997; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; BLOMFIELD IC, 1993, J BACTERIOL, V175, P27, DOI 10.1128/JB.175.1.27-36.1993; Blomfield IC, 2001, ADV MICROB PHYSIOL, V45, P1, DOI 10.1016/S0065-2911(01)45001-6; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; COLE JA, 1980, J GEN MICROBIOL, V120, P475; Cronan Jr. J. E., 1996, ESCHERICHIA COLI SAL, VI, P206; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DEBARBOUILLE M, 1982, MOL GEN GENET, V185, P88, DOI 10.1007/BF00333795; ERNSTING BR, 1993, J BACTERIOL, V175, P7160, DOI 10.1128/JB.175.22.7160-7169.1993; ERNSTING BR, 1992, J BACTERIOL, V174, P1109, DOI 10.1128/jb.174.4.1109-1118.1992; FERRANTE AA, 1995, P NATL ACAD SCI USA, V92, P7617, DOI 10.1073/pnas.92.17.7617; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Free A, 1997, J BACTERIOL, V179, P909, DOI 10.1128/jb.179.3.909-918.1997; GARDNER JF, 1982, J BIOL CHEM, V257, P3896; GARDNER JF, 1979, P NATL ACAD SCI USA, V76, P1706, DOI 10.1073/pnas.76.4.1706; GAZEAU M, 1992, FEBS LETT, V300, P254, DOI 10.1016/0014-5793(92)80857-D; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; Ghrist AC, 1998, J BACTERIOL, V180, P1803, DOI 10.1128/JB.180.7.1803-1807.1998; Gill RT, 2000, J MOL MICROB BIOTECH, V2, P283; GROSS CA, 1996, ESCHERICHIA COLI SAL, V1, P1382; GUEST JR, 1983, J BACTERIOL, V153, P588, DOI 10.1128/JB.153.2.588-596.1983; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HANEY SA, 1992, J BACTERIOL, V174, P108, DOI 10.1128/jb.174.1.108-115.1992; Hatfield GW, 2002, ANNU REV GENET, V36, P175, DOI 10.1146/annurev.genet.36.032902.111815; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V1, P1497; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; King ND, 1997, J BACTERIOL, V179, P1828, DOI 10.1128/jb.179.5.1828-1831.1997; Landgraf JR, 1999, J BACTERIOL, V181, P6547, DOI 10.1128/JB.181.20.6547-6551.1999; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; Levinthal M, 1996, RES MICROBIOL, V147, P333, DOI 10.1016/0923-2508(96)84708-5; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIN RT, 1992, J BACTERIOL, V174, P1948, DOI 10.1128/jb.174.6.1948-1955.1992; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; LYNN SP, 1987, J MOL BIOL, V194, P59, DOI 10.1016/0022-2836(87)90715-7; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; Maki Y, 2000, GENES CELLS, V5, P965, DOI 10.1046/j.1365-2443.2000.00389.x; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MECSAS J, 1995, J BACTERIOL, V177, P799, DOI 10.1128/jb.177.3.799-804.1995; MILLER CG, 1978, J BACTERIOL, V135, P603, DOI 10.1128/JB.135.2.603-611.1978; Miller J.H., 1972, EXPT MOL GENETICS; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, V1, P1310; NEWMAN EB, 1996, ESCHERICHIA COLI SAL, V1, P1513; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Patte J. C., 1996, ESCHERICHIA COLI SAL, V1, P528; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; PORCO A, 1991, Acta Cientifica Venezolana, V42, P270; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; SAINTGIRONS I, 1978, MOL GEN GENET, V162, P101, DOI 10.1007/BF00333856; Schaechter M, 2001, MICROBIOL MOL BIOL R, V65, P119, DOI 10.1128/MMBR.65.1.119-130.2001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHAO ZQ, 1994, EUR J BIOCHEM, V222, P901, DOI 10.1111/j.1432-1033.1994.tb18938.x; SIRKO A, 1995, J BACTERIOL, V177, P4134, DOI 10.1128/jb.177.14.4134-4136.1995; SPENCER ME, 1982, J BACTERIOL, V151, P542, DOI 10.1128/JB.151.2.542-552.1982; Stathopoulos C, 1998, Membr Cell Biol, V12, P1; STAUFFER LT, 1994, J BACTERIOL, V176, P6159, DOI 10.1128/jb.176.20.6159-6164.1994; Stauffer LT, 1999, MICROBIOL-SGM, V145, P569, DOI 10.1099/13500872-145-3-569; TCHETINA E, 1995, J BACTERIOL, V177, P2679, DOI 10.1128/jb.177.10.2679-2683.1995; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Ussery D, 2001, BIOCHIMIE, V83, P201, DOI 10.1016/S0300-9084(00)01225-6; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WISSENBACH U, 1995, MOL MICROBIOL, V17, P675, DOI 10.1111/j.1365-2958.1995.mmi_17040675.x; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YASUZAWA K, 1992, GENE, V122, P9; Zinser ER, 2000, J BACTERIOL, V182, P4361, DOI 10.1128/JB.182.15.4361-4365.2000	87	109	111	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40309	40323		10.1074/jbc.M204044200	http://dx.doi.org/10.1074/jbc.M204044200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12130640	hybrid			2022-12-25	WOS:000178791400022
J	MacDiarmid, CW; Milanick, MA; Eide, DJ				MacDiarmid, CW; Milanick, MA; Eide, DJ			Biochemical properties of vacuolar zinc transport systems of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION-TRANSPORT; PROTON-MOTIVE FORCE; ESCHERICHIA-COLI; GENE ENCODES; H+-ATPASE; YEAST; RESISTANCE; METABOLISM; EXPRESSION; PROTEIN	The yeast vacuole plays an important role in zinc homeostasis by storing zinc for later use under deficient conditions, sequestering excess zinc for its detoxification, and buffering rapid changes in intracellular zinc levels. The mechanisms involved in vacuolar zinc sequestration are only poorly characterized. Here we describe the properties of zinc transport systems in yeast vacuolar membrane vesicles. The major zinc transport activities in these vesicles were ATP-dependent, requiring a H+ gradient generated by the V-ATPase for function. One system we identified was dependent on the ZRC1 gene, which encodes a member of the cation diffusion facilitator family of metal transporters. These data are consistent with the proposed role of Zrc1 as a vacuolar zinc transporter. Zrc1-independent activity was also observed that was not dependent on the closely related vacuolar Cot1 protein. Both Zrc1-dependent and independent activities showed a high specificity for Zn2+ over other physiologically relevant substrates such as Ca2+, Fe2+, and Mn2+. Moreover, these systems had high affinities for zinc with apparent K-m values in the 100-200 nm range. These results provide biochemical insight into the important role of Zrc1 and related proteins in eukaryotic zinc homeostasis.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		MacDiarmid, Colin/AAV-5920-2021	MacDiarmid, Colin/0000-0001-8578-5756	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton A, 1999, J BACTERIOL, V181, P6876, DOI 10.1128/JB.181.22.6876-6881.1999; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Krezel A, 1999, ACTA BIOCHIM POL, V46, P567, DOI 10.18388/abp.1999_4129; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Nelson N, 2000, J EXP BIOL, V203, P89; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Sensi SL, 1997, J NEUROSCI, V17, P9554; WHITE C, 1987, J GEN MICROBIOL, V133, P727; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	40	144	154	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39187	39194		10.1074/jbc.M205052200	http://dx.doi.org/10.1074/jbc.M205052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161436	hybrid			2022-12-25	WOS:000178662500018
J	Adamson, AW; Kim, WJ; Shangary, S; Baskaran, R; Brown, KD				Adamson, AW; Kim, WJ; Shangary, S; Baskaran, R; Brown, KD			ATM is activated in response to N-methyl-N '-nitro-N-nitrosoguanidine-induced DNA alkylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; MISMATCH REPAIR; PROTEIN-KINASE; STRAND BREAKS; UP-REGULATION; HUMAN P53; APOPTOSIS	p53 plays an important role in response to ionizing radiation by regulating cell cycle progression and triggering apoptosis. These activities are controlled, in part, by the phosphorylation of p53 by the protein kinase ATM. Recent evidence indicates that the monofunctional DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) also triggers up-regulation and phosphorylation of p53; however, the mechanism(s) responsible for this are unknown. We observed that in MNNG-treated normal human fibroblasts, up-regulation and phosphorylation of p53 was sensitive to the ATM kinase inhibitor wortmannin. ATM-deficient fibroblasts exhibited a delay in p53 up-regulation indicating a role for ATM in triggering the MNNG-induced response. Likewise, a mismatch repair (MMR)-deficient colorectal tumor line failed to show rapid up-regulation of p53. However, unlike ATM-deficient cells, these MMR-deficient cells displayed rapid phosphorylation of the p53 residue serine 15 after MNNG. In vitro kinase assays indicate that ATM is rapidly activated in both normal and MMR-deficient cells in response to MNNG. Using a number of morphological and biochemical approaches, we failed to observe MNNG-induced apoptosis in normal human fibroblasts, suggesting that apoptosis-induced DNA strand breaks are not required for the activation of ATM in response to MNNG. Comet assays indicated that strand breaks accumulated, and p53 up-regulation/phosphorylation occurred quite rapidly (within 30 min) after MNNG treatment, suggesting that DNA strand breaks that arise during the repair process activate ATM. These findings indicate that ATM activation is not limited to the ionizing radiation-induced response and potentially plays an important role in response to DNA alkylation.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Univ Pittsburgh, Med Ctr, Dept Biochem & Mol Genet, Pittsburgh, PA 15261 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brown, KD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,MEB 7101, New Orleans, LA 70112 USA.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P143; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAWN MT, 1995, CANCER RES, V55, P3721; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KALAMEGHAM R, 1988, CARCINOGENESIS, V9, P1749, DOI 10.1093/carcin/9.10.1749; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Ochs K, 2000, CANCER RES, V60, P5815; Pantazis P, 1995, LEUKEMIA RES, V19, P775, DOI 10.1016/0145-2126(95)00048-8; Pegg AE, 1999, ADV EXP MED BIOL, V472, P253; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1981, CANCER RES, V41, P5114; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Takagi M, 1998, CANCER RES, V58, P4923; TEO IA, 1982, CARCINOGENESIS, V3, P33, DOI 10.1093/carcin/3.1.33; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Walker LSK, 1999, IMMUNOLOGY, V98, P569, DOI 10.1046/j.1365-2567.1999.00925.x; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	48	55	55	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38222	38229		10.1074/jbc.M204409200	http://dx.doi.org/10.1074/jbc.M204409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151394	hybrid			2022-12-25	WOS:000178529600032
J	Beigneux, A; Withycombe, SK; Digits, JA; Tschantz, WR; Weinbaum, CA; Griffey, SM; Bergo, M; Casey, PJ; Young, SG				Beigneux, A; Withycombe, SK; Digits, JA; Tschantz, WR; Weinbaum, CA; Griffey, SM; Bergo, M; Casey, PJ; Young, SG			Prenylcysteine lyase deficiency in mice results in the accumulation of farnesylcysteine and geranylgeranylcysteine in brain and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; CELLS; PRENYLATION; TRANSFERASE; EXPRESSION; ANALOGS; CLONING	In in vitro experiments, prenylcysteine lyase (Pcly) cleaves the thioether bond of prenylcysteines to yield free cysteine and the aldehyde of the isoprenoid lipid. However, the importance of this enzyme has not yet been fully defined at the biochemical or physiologic level. In this study, we show that Pcly is expressed at high levels in mouse liver, kidney, heart, and brain. To test whether Pcly deficiency would cause prenylcysteines to accumulate in tissues and result in pathologic consequences, we produced Pcly-deficient cell lines and Pcly-deficient mice (Pcly-/-). Pcly activity levels were markedly reduced in Pcly-/- cells and tissues. Pcly-/- fibroblasts were more sensitive than wild-type fibroblasts to growth inhibition when prenylcysteines were added to the cell culture medium. To determine if the reduced Pcly enzyme activity levels led to an accumulation of prenylcysteines within cells, mass spectrometry was used to measure farnesylcysteine and geranylgeranylcysteine levels in the tissues of Pcly-/- mice and wild-type controls. These studies revealed a striking accumulation of both farnesyleysteine and geranylgeranylcysteine in the brain and liver of Pcly-/- mice. This accumulation did not appear to be accompanied by significant pathologic consequences. Pcly-/- mice were healthy and fertile, and surveys of more than 30 tissues did not uncover any abnormalities. We conclude that prenylcysteine lyase does play a physiologic role in cleaving prenylcysteines in mammals, but the absence of this activity does not lead to major pathologic consequences.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Calif Davis, Comparat Pathol Lab, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Duke University; University of California System; University of California Davis; University of California System; University of California San Francisco	Beigneux, A (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Young, Stephen/0000-0001-7270-3176; Casey, Patrick/0000-0002-7366-9309	NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1992, J LIPID RES, V33, P1731; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; HUZOORAKBAR W, 1993, P NATL ACAD SCI USA, V90, P868; JONES DH, 1991, BIOTECHNIQUES, V10, P62; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Parish CA, 1997, BIOCHEMISTRY-US, V36, P2686, DOI 10.1021/bi961844r; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Sambrook J., 2002, MOL CLONING LAB MANU; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Soyombo AA, 1997, J BIOL CHEM, V272, P27456, DOI 10.1074/jbc.272.43.27456; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tschantz WR, 2001, J BIOL CHEM, V276, P2321, DOI 10.1074/jbc.C000616200; Tschantz WR, 1999, J BIOL CHEM, V274, P35802, DOI 10.1074/jbc.274.50.35802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YOUNG SG, 2000, ENZYMES, V21, P153; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859; Zhang LL, 1997, J BIOL CHEM, V272, P23354, DOI 10.1074/jbc.272.37.23354	27	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38358	38363		10.1074/jbc.M205183200	http://dx.doi.org/10.1074/jbc.M205183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151402	hybrid			2022-12-25	WOS:000178529600048
J	Zhang, YJ; Chen, K; Guo, LD; Wu, CY				Zhang, YJ; Chen, K; Guo, LD; Wu, CY			Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; ABL TYROSINE KINASE; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CAENORHABDITIS-ELEGANS; LIM PROTEIN; GROWTH; CYTOSKELETON; PAXILLIN; DOMAIN	Integrin-linked kinase (ILK) is a multidomain protein that plays important roles at cell-extracellular matrix (ECM) adhesion sites. We describe here a new LIM-domain containing protein (termed as PINCH-2) that forms a complex with ILK. PINCH-2 is co-expressed with PINCH-1 (previously known as PINCH), another member of the PINCH protein family, in a variety of human cells. Immunofluorescent staining of cells with PINCH-2-specific antibodies show that PINCH-2 localizes to both cell-ECM contact sites and the nucleus. Deletion of the first LIM (LIM1) domain of PINCH-2 abolished the ability of PINCH-2 to form a complex with ILK. The ILK-binding defective LIM1-deletion mutant, unlike the wild type PINCH-2 or the ILK-binding competent LIM5-deletion mutant, was incapable of localizing to cell-ECM contact sites, suggesting that ILK binding is required for this process. Importantly, the PINCH-2-ILK and PINCH-1-ILK interactions are mutually exclusive. Overexpression of PINCH-2 significantly inhibited the PINCH-1-ILK interaction and reduced cell spreading and migration. These results identify a novel nuclear and focal adhesion protein that associates with ILK and reveals an important role of PINCH-2 in the regulation of the PINCH-1-ILK interaction, cell shape change, and migration.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; Lin XY, 2000, MOL BIOL CELL, V11, p515A; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Olski TM, 2001, J CELL SCI, V114, P525; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thomas SM, 1999, J CELL SCI, V112, P181; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Zamir E, 2001, J CELL SCI, V114, P3583; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	46	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38328	38338		10.1074/jbc.M205576200	http://dx.doi.org/10.1074/jbc.M205576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167643	hybrid			2022-12-25	WOS:000178529600044
J	Failer, BU; Braun, N; Zimmermann, H				Failer, BU; Braun, N; Zimmermann, H			Cloning, expression, and functional characterization of a Ca2+-dependent endoplasmic reticulum nucleoside diphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; APYRASE; TRIPHOSPHATE; DIPHOSPHOHYDROLASE; PROTEIN; ATP; IDENTIFICATION; GLYCOSYLATION; TRANSPORT; 5-NUCLEOTIDASE	We have isolated and characterized the cDNA encoding a Ca2+-dependent nucleoside diphosphatase (EC 3.6.1.6) related to two secreted ATP- and ADP-hydrolyzing apyrases of the bloodsucking insects, Cimex lectularius and Phlebotomus papatasi. The rat brain-derived cDNA has an open reading frame of 1209 bp encoding a protein of 403 amino acids and a calculated molecular mass of 45.7 kDa. The mRNA was expressed in all tissues investigated, revealing two major transcripts with varying preponderance. The immunohistochemical analysis of the Myc-His-tagged enzyme expressed in Chinese hamster ovary cells revealed its association with the endoplasmic reticulum And also with pre-Golgi intermediates. Ca2+-dependent nucleoside diphosphatase is a membrane protein with its catalytic site facing the organelle lumen. It hydrolyzes nucleoside 5'-diphosphates in the order UDP >GDP = IDP > > >CDP but not ADP. Nucleoside 5'-triphosphates were hydrolyzed to a minor extent, and no hydrolysis of nucleoside 5'-monophosphates was observed. The enzyme was strongly activated by Ca2+, insensitive to Mg2+, and had a K-m for UDP of 216 muM. Ca2+-dependent nucleoside diphosphatase may support glycosylation reactions related to quality control in the endoplasmic reticulum.	Goethe Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Zimmermann, H (corresponding author), Goethe Univ Frankfurt, Biozentrum, Marie Curie Str 9, D-60439 Frankfurt, Germany.	h.zimmermann@zoology.uni-frankfurt.de						ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Biederbick A, 1999, J CELL SCI, V112, P2473; Biederbick A, 2000, J BIOL CHEM, V275, P19018, DOI 10.1074/jbc.M001245200; Braun N, 2000, BIOCHEM J, V351, P639, DOI 10.1042/0264-6021:3510639; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Dunwiddie TV, 1997, J NEUROSCI, V17, P7673; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gomord V, 1999, BIOCHIMIE, V81, P607, DOI 10.1016/S0300-9084(99)80118-7; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HEILBRONN A, 1995, CELL TISSUE RES, V280, P123, DOI 10.1007/BF00304517; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Hicks-Berger CA, 2000, J BIOL CHEM, V275, P34041, DOI 10.1074/jbc.M004723200; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lopez-Avalos MD, 2001, GLYCOBIOLOGY, V11, P413, DOI 10.1093/glycob/11.5.413; Mulero JJ, 2000, BIOCHEMISTRY-US, V39, P12924, DOI 10.1021/bi000960y; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; Parkkinen JJ, 1997, J CELL BIOCHEM, V66, P165, DOI 10.1002/(SICI)1097-4644(19970801)66:2<165::AID-JCB4>3.3.CO;2-D; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shi JD, 2001, J BIOL CHEM, V276, P17474, DOI 10.1074/jbc.M011569200; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Valenzuela JG, 2001, J EXP BIOL, V204, P229; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Yang F, 2001, BIOCHEMISTRY-US, V40, P3943, DOI 10.1021/bi002711f; Yeung G, 2000, BIOCHEMISTRY-US, V39, P12916, DOI 10.1021/bi000959z; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 2001, J BIOL CHEM, V276, P41518, DOI 10.1074/jbc.M104415200; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; Zimmermann H, 2001, HANDB EXP PHARM, V151, P209; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	41	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36978	36986		10.1074/jbc.M201656200	http://dx.doi.org/10.1074/jbc.M201656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167635	hybrid			2022-12-25	WOS:000178447100011
J	Langevin, C; Jaaro, H; Bressanelli, S; Fainzilber, M; Tuffereau, C				Langevin, C; Jaaro, H; Bressanelli, S; Fainzilber, M; Tuffereau, C			Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; OLIGOMERIC STRUCTURE; HIPPOCAMPAL-NEURONS; CELLULAR RECEPTOR; BINDING DOMAIN; P75(NTR); APOPTOSIS; PROTEIN; DEATH	Rabies virus glycoprotein (RVG) is a trimeric and surface-exposed viral coat protein that has been shown to interact with the murine p75 neurotrophin receptor. We have investigated binding of RVG to p75 and describe several features that distinguish the p75-RVG interaction from conventional neurotrophin binding to p75. RVG binds mammalian but not avian p75 and does not bind to any of the Trk neurotrophin receptors. The mammalian p75 specificity of RVG binding may partly explain the phyletic specificity of rabies infection. Radioiodinated nerve growth factor (NGF) and RVG both bind to rat p75 but do not compete with each other's binding site. Although neurotrophins bind to the second and third cysteine-rich domains (CRD) of p75, RVG specifically interacts with high affinity (K-d 30-35 pm) with the first CRD (CRD1). Substitution of Gln(33) in p75-CRD1 by Glu completely abolishes RVG binding. Our data therefore firmly establish RVG as a trimeric high affinity ligand for a non-neurotrophin binding site on p75. Interestingly, the CRD1 in another TNF/NGF family receptor was recently shown to be involved in the binding of the herpes virus glycoprotein gD, suggesting that the CRI)l of TNF/NGF family members may be a widely used binding domain for viral glycoproteins.	CNRS, INRA, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Weizmann Inst Sci, Mol Neurobiol Lab, Dept Biol Chem, IL-76100 Rehovot, Israel	Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; Universite Paris Saclay; Weizmann Institute of Science	Tuffereau, C (corresponding author), CNRS, INRA, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France.		Jaaro-Peled, Hanna/D-1046-2012	Jaaro-Peled, Hanna/0000-0002-8950-391X; Bressanelli, Stephane/0000-0002-0921-6727; Langevin, Christelle/0000-0002-6013-4460; Fainzilber, Mike/0000-0001-8173-8557				Adkins HB, 1997, P NATL ACAD SCI USA, V94, P11617, DOI 10.1073/pnas.94.21.11617; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALDWIN AN, 1995, J BIOL CHEM, V270, P4594, DOI 10.1074/jbc.270.9.4594; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAPMAN BS, 1995, PROTEIN SCI, V4, P1696, DOI 10.1002/pro.5560040905; CHARLTON KM, 1994, LYSSAVIRUSES, P95; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Dietaschold B, 1996, FIELDS VIROLOGY, P1137; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; Fainzilber M, 1996, SCIENCE, V274, P1540, DOI 10.1126/science.274.5292.1540; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; Handler CG, 1996, J VIROL, V70, P6067, DOI 10.1128/JVI.70.9.6067-6070.1996; Hutson LD, 2001, J NEUROBIOL, V49, P79, DOI 10.1002/neu.1067; Ibanez CF, 2002, TRENDS NEUROSCI, V25, P284, DOI 10.1016/S0166-2236(02)02169-0; Jackson AC, 1999, ACTA NEUROPATHOL, V98, P641, DOI 10.1007/s004010051130; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LENTZ TL, 1984, SCIENCE, V226, P847, DOI 10.1126/science.6494916; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; Thoulouze MI, 1998, J VIROL, V72, P7181, DOI 10.1128/JVI.72.9.7181-7190.1998; Tuffereau C, 1998, EMBO J, V17, P7250, DOI 10.1093/emboj/17.24.7250; Tuffereau C, 2001, J GEN VIROL, V82, P2861, DOI 10.1099/0022-1317-82-12-2861; Tuffereau C, 1998, J VIROL, V72, P1085, DOI 10.1128/JVI.72.2.1085-1091.1998; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; Whitbeck JC, 2001, J VIROL, V75, P171, DOI 10.1128/JVI.75.1.171-180.2001; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; YAN H, 1991, J BIOL CHEM, V266, P12099	51	57	65	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37655	37662		10.1074/jbc.M201374200	http://dx.doi.org/10.1074/jbc.M201374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163480	hybrid			2022-12-25	WOS:000178447100096
J	Matsuda, M; Shimomura, I; Sata, M; Arita, Y; Nishida, M; Maeda, N; Kumada, M; Okamoto, Y; Nagaretani, H; Nishizawa, H; Kishida, K; Komuro, R; Ouchi, N; Kihara, S; Nagai, R; Funahashi, T; Matsuzawa, Y				Matsuda, M; Shimomura, I; Sata, M; Arita, Y; Nishida, M; Maeda, N; Kumada, M; Okamoto, Y; Nagaretani, H; Nishizawa, H; Kishida, K; Komuro, R; Ouchi, N; Kihara, S; Nagai, R; Funahashi, T; Matsuzawa, Y			Role of adiponectin in preventing vascular stenosis - The missing link of adipo-vascular axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PLASMA-PROTEIN; INSULIN-RESISTANCE; OBESITY; EXPRESSION; APOPTOSIS; INJURY; FAT	Obesity is more linked to vascular disease, including atherosclerosis and restenotic change, after balloon angioplasty. The precise mechanism linking obesity and vascular disease is still unclear. Previously we have demonstrated that the plasma levels of adiponectin, an adipose-derived hormone, decreases in obese subjects, and that hypoadiponectinemia is associated to ischemic heart disease. In current the study, we investigated the in vivo role of adiponectin on the neointimal thickening after artery injury using adiponectin-deficient mice and adiponectin-producing adenovirus. Adiponectin-deficient mice showed severe neointimal thickening and increased proliferation of vascular smooth muscle cells in mechanically injured arteries. Adenovirus-mediated supplement of adiponectin attenuated neointimal proliferation. In cultured smooth muscle cells, adiponectin attenuated DNA synthesis induced by growth factors including platelet-derived growth factor, heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), basic fibroblast growth factor, and EGF and cell proliferation and migration induced by HB-EGF. In cultured endothelial cells, adiponectin attenuated HB-EGF expression stimulated by tumor necrosis factor a. The current study suggests an adipo-vascular axis, a direct link between fat and artery. A therapeutic strategy to increase plasma adiponectin should be useful in preventing vascular restenosis after angioplasty.	Osaka Univ, Dept Internal Med & Mol Sci, Grad Sch Med, Osaka 5650871, Japan; Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan	Osaka University; University of Tokyo	Shimomura, I (corresponding author), Osaka Univ, Dept Organismal Biosyst, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka, Osaka 5650871, Japan.		OUCHI, Noriyuki/I-7306-2014	Nisihida, Makoto/0000-0002-0309-7106				Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsumoto S, 2002, BIOCHEM BIOPH RES CO, V292, P781, DOI 10.1006/bbrc.2002.6720; Okamoto Y, 2000, HORM METAB RES, V32, P47, DOI 10.1055/s-2007-978586; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu SM, 1996, CIRCULATION, V94, P547, DOI 10.1161/01.CIR.94.3.547; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134, DOI 10.1681/ASN.V131134	25	651	751	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37487	37491		10.1074/jbc.M206083200	http://dx.doi.org/10.1074/jbc.M206083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138120	hybrid			2022-12-25	WOS:000178447100074
J	Romero-Isart, N; Jensen, LT; Zerbe, O; Winge, DR; Vasak, M				Romero-Isart, N; Jensen, LT; Zerbe, O; Winge, DR; Vasak, M			Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; NUCLEAR-MAGNETIC-RESONANCE; III MESSENGER-RNA; ALZHEIMERS-DISEASE; BIOLOGICAL-ACTIVITY; THIOLATE CLUSTERS; DOWN-REGULATION; RAT-BRAIN; MT-III; PROTEINS	The third isoform of mammalian metallothioneins (MT-3), mainly expressed in brain and down-regulated in Alzheimer's disease, exhibits neuroinhibitory activity in vitro and a highly flexible structure that distinguishes it from the widely expressed MT-1/-2 isoforms. Previously, we showed that two conserved prolyl residues of MT-3 are crucial for both the bioactivity and cluster dynamics of this isoform. We have now used genetic engineering to introduce these residues into mouse MT-1. The S6P,S8P MT-1 mutant is inactive in neuronal survival assays. However, the additional introduction of the unique Thr5 insert of MT-3 resulted in a bioactive MT-1 form. Temperature-dependent and saturation transfer Cd-113 NMR experiments performed on the Cd-113-reconstituted wild-type and mutant Cd-7-MT-1 forms revealed that the gain of MT-3-like neuronal inhibitory activity is paralleled by an increase in conformational flexibility and intersite metal exchange in the N-terminal Cd-3-thiolate cluster. The observed correlation suggests that structure/cluster dynamics are critical for the biological activity of MT-3. We propose that the interplay between the specific Pro-induced conformational requirements and those of the metal-thiolate bonds gives rise to an alternate and highly fluctuating cluster ensemble kinetically trapped by the presence of the (TCPCP9)-T-5 motif. The functional significance of such heterogeneous cluster ensemble is discussed.	Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich, Dept Pharm, CH-8057 Zurich, Switzerland	Utah System of Higher Education; University of Utah; University of Zurich; University of Zurich	Vasak, M (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010	Jensen, Laran/0000-0003-3199-1743	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amoureux MC, 1997, MOL CHEM NEUROPATHOL, V32, P101, DOI 10.1007/BF02815170; Bogumil R, 1998, EUR J BIOCHEM, V255, P172, DOI 10.1046/j.1432-1327.1998.2550172.x; BRAUN W, 1992, P NATL ACAD SCI USA, V89, P10124, DOI 10.1073/pnas.89.21.10124; Bruinink A, 1998, CHEM-BIOL INTERACT, V115, P167, DOI 10.1016/S0009-2797(98)00062-3; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; CARSON GK, 1981, INORG CHIM A-BIOINOR, V56, P59, DOI 10.1016/S0020-1693(00)88548-5; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; HAGEN KS, 1982, INORG CHEM, V21, P3928, DOI 10.1021/ic00141a015; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kohmura E, 1997, RESTOR NEUROL NEUROS, V11, P169, DOI 10.3233/RNN-1997-11307; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MESSERLE BA, 1992, J MOL BIOL, V225, P433, DOI 10.1016/0022-2836(92)90930-I; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Otvos J D, 1987, Experientia Suppl, V52, P171; Oz G, 2001, BIOCHEMISTRY-US, V40, P11433, DOI 10.1021/bi010827l; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; Quaife CJ, 1998, TOXICOL APPL PHARM, V148, P148, DOI 10.1006/taap.1997.8321; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; Smyth E, 2001, BIOPOLYMERS, V58, P138, DOI 10.1002/1097-0282(200102)58:2<138::AID-BIP30>3.0.CO;2-W; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1995, J BIOL CHEM, V270, P3365, DOI 10.1074/jbc.270.7.3365; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLNER H, 1987, BIOCHEMISTRY-US, V26, P6287, DOI 10.1021/bi00393a049; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; Zangger K, 1999, PROTEIN SCI, V8, P2630, DOI 10.1110/ps.8.12.2630; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S	45	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37023	37028		10.1074/jbc.M205730200	http://dx.doi.org/10.1074/jbc.M205730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130647	hybrid			2022-12-25	WOS:000178447100017
J	Li, XJ; Alvarez, B; Casey, JR; Reithmeier, RAF; Fliegel, L				Li, XJ; Alvarez, B; Casey, JR; Reithmeier, RAF; Fliegel, L			Carbonic anhydrase II binds to and enhances activity of the Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ANION-EXCHANGER; INTRACELLULAR PH; TERMINAL REGION; FUNCTIONAL-ROLE; RESIDUES; SITE; IDENTIFICATION; LOCALIZATION; MYOCARDIUM	We examined the ability of carbonic anhydrase II to bind to and affect the transport efficiency of the NHE1 isoform of the mammalian Na+/H+ exchanger. The C-terminal region of NHE1 was expressed in Escherichia coli fused with an N-terminal glutathionine S-transferase or with a C-terminal polyhistidine tag. Using a microtiter plate binding assay we showed that the C-terminal region of NHE1 binds carbonic anhydrase 11 (CAII) and binding was stimulated by low pH and blocked by antibodies against the C-terminal of NHE1 The binding to NHE1 was confirmed by demonstrating protein-protein interaction using affinity blotting with CAII and immobilized NHE1 fusion proteins. CAII co-immunoprecipitated with NHE1 from CHO cells suggesting the proteins form a complex in vivo. In cells expressing CAII and NHE1, the H+ transport rate was almost 2-fold greater than in cells expressing NHE1 alone. The CAII inhibitor acetazolamide significantly decreased the H+ transport rate of NHE1 and transfection with a dominant negative CAII inhibited NHE1 activity. Phosphorylation of the C-terminal of NHE1 greatly increased the binding of CAII. Our study suggests that NHE1 transport efficiency is influenced by CAII, likely through a direct interaction at the C-terminal region. Regulation of NHE1 activity by phosphorylation could involve modulation of CAII binding.	Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Canadian Inst Hlth Res Grp Membrane Biol, Dept Med & Biochem, Toronto, ON M5S 1A8, Canada	University of Alberta; University of Alberta; University of Toronto	Fliegel, L (corresponding author), Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Biochem, 347 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; COUSIN JL, 1975, J PHYSIOL-LONDON, V253, P385, DOI 10.1113/jphysiol.1975.sp011195; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Fliegel L, 1999, J THROMB THROMBOLYS, V8, P9, DOI 10.1023/A:1008934312429; Fliegel L, 2001, BASIC RES CARDIOL, V96, P301, DOI 10.1007/s003950170036; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MASON MJ, 1989, AM J PHYSIOL, V256, pC428, DOI 10.1152/ajpcell.1989.256.2.C428; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Murray G, 2001, BIOTECHNIQUES, V30, P1036, DOI 10.2144/01305rr02; MURTAZINA BR, 2001, EUR J BIOCHEM, V268, P1; Noel J, 1996, J CELL SCI, V109, P929; PEREZ NG, 1995, CIRC RES, V77, P1192, DOI 10.1161/01.RES.77.6.1192; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; ROTIN D, 1989, CANCER RES, V49, P205; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Tang XB, 1999, J BIOL CHEM, V274, P3557, DOI 10.1074/jbc.274.6.3557; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Wang HY, 1998, ARCH BIOCHEM BIOPHYS, V358, P116, DOI 10.1006/abbi.1998.0833; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001; Wu Q, 1998, J MEMBRANE BIOL, V162, P31, DOI 10.1007/s002329900339; Yao H, 1999, J CLIN INVEST, V104, P637, DOI 10.1172/JCI6785	33	167	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36085	36091		10.1074/jbc.M111952200	http://dx.doi.org/10.1074/jbc.M111952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138085	hybrid			2022-12-25	WOS:000178275100042
J	Litterst, CM; Pfitzner, E				Litterst, CM; Pfitzner, E			An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR FUNCTION; CREB-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; COACTIVATOR COMPLEXES; INHIBITION; GENE; IL-4; CELLS; ACETYLTRANSFERASE	Signal transducer and activator of transcription 6 (STAT6) regulates transcriptional activation in response to interleukin-4 (IL-4)-induced tyrosine phosphorylation by direct interaction with coactivators. The CREB-binding protein and the nuclear coactivator 1 (NCoA-1), a member of the p160/steroid receptor coactivator family, bind independently to specific regions of STAT6 and act as coactivators. In this study we show that an LXXLL motif in the STAT6 transactivation domain mediates the interaction with NCoA-1. Peptides representing this motif as well as antibodies generated against this motif inhibited STAT6/NCoA-1 interaction in glutathione S-transferase pulldown assays. Peptides derived from the STAT6 transactivation domain adjacent to the LXXLL motif as well as antibodies against these peptides showed no inhibitory effect. Mutagenesis of the LXXLL motif eliminated the STAT6/NCoA-1 interaction in vitro and in vivo, supporting the specific role of this motif in NCoA-1 binding. Importantly, mutagenesis of the STAT-LXXLL motif strongly diminished the IL-4-regulated activation of the endogenous STAT6 target gene eotaxin-3. Taken together, these results indicate that the STAT6-LXXLL-binding motif mediates the interaction with NCoA-1 in transcriptional activation and represents a new potential drug target for the inhibition of the STAT6 transactivation function in allergic diseases.	Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Germany	Octapharma	Pfitzner, E (corresponding author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Pfitzner, Edith/AAU-7927-2021	Pfitzner, Edith/0000-0002-3484-9649				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen Lin, 1999, Current Opinion in Structural Biology, V9, P48; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Goodman RH, 2000, GENE DEV, V14, P1553; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Igaz P, 2001, INFLAMM RES, V50, P435, DOI 10.1007/PL00000267; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Lu BF, 1997, J IMMUNOL, V159, P1255; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; ONATE SA, 1995, SCIENCE, V270, P1354; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shinkai A, 1999, J IMMUNOL, V163, P1602; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stolzenberger S, 2001, EUR J BIOCHEM, V268, P4809, DOI 10.1046/j.1432-1327.2001.02417.x; Stutz AM, 2001, J BIOL CHEM, V276, P11759, DOI 10.1074/jbc.M010260200; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Worm M, 1998, BLOOD, V92, P1713, DOI 10.1182/blood.V92.5.1713.417k20_1713_1720; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	45	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36052	36060		10.1074/jbc.M203556200	http://dx.doi.org/10.1074/jbc.M203556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138096	hybrid			2022-12-25	WOS:000178275100038
J	Schneider, E; Kartarius, S; Schuster, N; Montenarh, M				Schneider, E; Kartarius, S; Schuster, N; Montenarh, M			The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H	ONCOGENE			English	Article						protein kinase CK-2; cyclin dependent kinases; phosphorylation regulation	CDK-ACTIVATING KINASE; RING FINGER PROTEIN; TRANSCRIPTION FACTOR; IN-VITRO; P53; TFIIH; CAK; COMPLEX; SUBUNIT; MAT1	Cyclin dependent kinases are regulated by phosphorylation and dephosphorylation of the catalytic cdk subunits, by assembly with specific cyclins and by specific inhibitor molecules. Recently, it turned out that cyclins are also phosphoproteins, which means that they are also potential targets for a regulation by phosphorylation and dephosphorylation. Here, we show that cyclin H was phosphorylated by protein kinase CK2. Like most other CK2 substrates cyclin H was much better phosphorylated by the CK2 holoenzyme than by the alpha-subunit alone. By using point mutants derived from the cyclin H sequence we mapped the CK2 phosphorylation site at threonine 315 at the C-terminal end of cyclin H. Phosphorylation at this position had no influence on the assembly of the cyclin H/cdk7/Mat1 complex. However, phosphorylation at amino acid 315 of cyclin H turned out to be critical for a full cyclin H/cdk7/Mat1 kinase activity when the CTD peptide of RNA polymerase II or cdk2 was used as a substrate.	Univ Saarland, D-66424 Homburg, Germany	Saarland University	Montenarh, M (corresponding author), Univ Saarland, Bldg 44, D-66424 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; ANGIOLILLO A, 1993, MOL CELL BIOCHEM, V125, P65, DOI 10.1007/BF00926836; APPEL K, 1995, ONCOGENE, V11, P1971; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gotz C, 1996, ONCOGENE, V13, P391; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x	30	34	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5031	5037		10.1038/sj.onc.1205690	http://dx.doi.org/10.1038/sj.onc.1205690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140753				2022-12-25	WOS:000176975900001
J	Hazan, U; Romero, IA; Cancello, R; Valente, S; Perrin, V; Mariot, V; Dumonceaux, J; Gerhardt, CC; Strosberg, AD; Couraud, PO; Pietri-Rouxel, F				Hazan, U; Romero, IA; Cancello, R; Valente, S; Perrin, V; Mariot, V; Dumonceaux, J; Gerhardt, CC; Strosberg, AD; Couraud, PO; Pietri-Rouxel, F			Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1?	FASEB JOURNAL			English	Article						expression of CD4; coreceptors; HIV entry; adipocytes	CHEMOKINE RECEPTORS; TNF-ALPHA; DC-SIGN; INFECTION; HIV-1; ENTRY; SECRETION; TISSUE; MACROPHAGES; CORECEPTORS	The concept that adipocytes belong to an essential endocrine system with some characteristics of immune cells has recently emerged. The aim of this paper is to present evidence of the expression of CD4, CXCR4, and CCR5 receptors by human adipocytes and to test whether adipose cells support HIV entry. Primary human preadipocytes were cultured and differentiated in vitro. Expression of the three receptors on preadipocytes and adipocytes was demonstrated by reverse transcriptase-polymerase chain reaction, immunocytochemical, and immunohistochemical analysis. Infection of adipose cells to HIV-1 was then investigated. The measurement of the viral p24 antigen in preadipocyte culture medium showed an increase of p24 levels between 24 and 72 h postexposure and then a progressive decrease to reach a low level at 10-15 days. Ten days after the infection test, supernatant of preadipocytes contained infectious particles able to infect the susceptible T-CD4 CEM cell line. The expression of viral proteins by adipocytes was confirmed using a fusion test. The presence of viral DNA was exhibited by gag-specific polymerase chain reaction, supporting the hypothesis of HIV-1 X4- and R5-virus entry in preadipocytes. Adipose cells represent the first cell type that does not belong to the immune system expressing all specific HIV receptors and may represent new HIV-1 target cells.	Inst Cochin Genet Mol, CNRS, UPR 0415, F-75014 Paris, France; Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Univ Paris 07, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Pietri-Rouxel, F (corresponding author), Inst Cochin Genet Mol, CNRS, UPR 0415, 22 Rue Mechain, F-75014 Paris, France.	pietri-rouxel@cochin.inserm.fr	Dumonceaux, Julie/H-3621-2013; Romero, Ignacio/A-7381-2008	Pietri-Rouxel, France/0000-0002-6258-7594; Romero, Ignacio/0000-0002-0322-9180				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ailhaud G, 2000, INT J OBESITY, V24, pS1, DOI 10.1038/sj.ijo.0801267; Bailer RT, 2000, EUR J IMMUNOL, V30, P1340, DOI 10.1002/(SICI)1521-4141(200005)30:5<1340::AID-IMMU1340>3.0.CO;2-L; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bornstein SR, 2000, DIABETES, V49, P532, DOI 10.2337/diabetes.49.4.532; Clapham PR, 1999, MOL MEMBR BIOL, V16, P49, DOI 10.1080/096876899294751; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; ELLRODT A, 1984, LANCET, V1, P1383; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Ghorpade A, 1998, J VIROL, V72, P3351, DOI 10.1128/JVI.72.4.3351-3361.1998; Gottschling-Zeller H, 2000, METABOLISM, V49, P666, DOI 10.1016/S0026-0495(00)80046-3; Hornung F, 2000, J IMMUNOL, V164, P6180, DOI 10.4049/jimmunol.164.12.6180; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hung CS, 1999, VIROLOGY, V264, P278, DOI 10.1006/viro.1999.0013; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Naif HM, 1998, J VIROL, V72, P830, DOI 10.1128/JVI.72.1.830-836.1998; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Zilberfarb V, 1997, J CELL SCI, V110, P801	24	57	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1254	+		10.1096/fj.01-0947fje	http://dx.doi.org/10.1096/fj.01-0947fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153994				2022-12-25	WOS:000176683900015
J	Judex, S; Donahue, LR; Rubin, C				Judex, S; Donahue, LR; Rubin, C			Genetic predisposition to low bone mass is paralleled by an enhanced sensitivity to signals anabolic to the skeleton	FASEB JOURNAL			English	Article						trabecular bone; mechanical intervention; high-frequency mechanical stimuli; genetic variation; bone formation; osteoporosis	MINERAL DENSITY; ESTROGEN-RECEPTOR; LOW-MAGNITUDE; STRAIN; POLYMORPHISM; EXERCISE; HISTOMORPHOMETRY; SUSCEPTIBILITY; OSTEOPOROSIS; ARCHITECTURE	The structure of the adult skeleton is determined, in large part, by its genome. Whether genetic variations may influence the effectiveness of interventions to combat skeletal diseases remains unknown. The differential response of trabecular bone to an anabolic (low-level mechanical vibration) and a catabolic (disuse) mechanical stimulus were evaluated in three strains of adult mice. In low bone-mineral-density C57BL/6J mice, the low-level mechanical signal caused significantly larger bone formation rates (BFR) in the proximal tibia, but the removal of functional weight bearing did not significantly alter BFR. In mid-density BALB/cByJ mice, mechanical stimulation also increased BFR, whereas disuse significantly decreased BFR. In contrast, neither anabolic nor catabolic mechanical signals influenced any index of bone formation in high-density C3H/HeJ mice. Together, data from this study indicate that the sensitivity of trabecular tissue to both anabolic and catabolic stimuli is influenced by the genome. Extrapolated to humans, these results may explain in part why prophylaxes for low bone mass are not universally effective, yet also indicate that there may be a genotypic indication of people who are at reduced risk of suffering from bone loss.	SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; Jackson Lab, Bar Harbor, ME 04609 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jackson Laboratory	Judex, S (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Psychol A Bldg,3rd Floor, Stony Brook, NY 11794 USA.	stefan.judex@sunysb.edu						Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554; Aloia JF, 1999, CALCIFIED TISSUE INT, V65, P29, DOI 10.1007/s002239900653; ANDERSON JJB, 1994, ADV NUTR RES, V9, P129; [Anonymous], 2000, NIH Consens Statement, V17, P1; Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756-3282(96)00047-6; Bohannon AD, 1999, J WOMEN HEALTH GEN-B, V8, P609, DOI 10.1089/jwh.1.1999.8.609; Brown MA, 2001, J BONE MINER RES, V16, P758, DOI 10.1359/jbmr.2001.16.4.758; CHAMBERS TJ, 1993, BONE MINER, V20, P167, DOI 10.1016/S0169-6009(08)80025-6; Eisman JA, 1999, ENDOCR REV, V20, P788, DOI 10.1210/er.20.6.788; Ensrud KE, 1997, ARCH INTERN MED, V157, P2617, DOI 10.1001/archinte.157.22.2617; Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215; Fritton JC, 1997, ANN BIOMED ENG, V25, P831, DOI 10.1007/BF02684167; Hanley DA, 2000, J CLIN DENSITOM, V3, P79, DOI 10.1385/JCD:3:1:079; HEANEY RP, 1995, J CLIN ENDOCR METAB, V80, P2289, DOI 10.1210/jc.80.8.2289; HOUDE JP, 1995, CLIN ORTHOP RELAT R, P199; Judex S, 1997, J BONE MINER RES, V12, P1737, DOI 10.1359/jbmr.1997.12.10.1737; Jurada S, 2001, J STEROID BIOCHEM, V78, P15, DOI 10.1016/S0960-0760(01)00069-3; KANIS JA, 1993, OSTEOPOROSIS INT, V3, pS10; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; Kodama Y, 2000, CALCIFIED TISSUE INT, V66, P298, DOI 10.1007/s002230010060; Kodama Y, 1999, BONE, V25, P183, DOI 10.1016/S8756-3282(99)00155-6; Koller DL, 2000, J CLIN ENDOCR METAB, V85, P3116, DOI 10.1210/jc.85.9.3116; LeBlanc A., 1999, 1 BIENN SPAC BIOM IN, V1, P17; Lorentzon M, 2001, J BONE MINER METAB, V19, P302, DOI 10.1007/s007740170014; Morey E R, 1979, Physiologist, V22, pS23; Mosley JR, 1997, BONE, V20, P191, DOI 10.1016/S8756-3282(96)00385-7; Obermayer-Pietsch BM, 2000, J BONE MINER RES, V15, P1950, DOI 10.1359/jbmr.2000.15.10.1950; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PEAD MJ, 1988, J BONE MINER RES, V3, P647; Qin YX, 1998, J ORTHOPAED RES, V16, P482, DOI 10.1002/jor.1100160414; Rubin C, 2000, J BONE MINER RES, V15, pS557; Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; RUBIN CT, 1984, CALCIFIED TISSUE INT, V36, pS11, DOI 10.1007/BF02406128; Rubin CT, 2001, DRUG DISCOV TODAY, V6, P848, DOI 10.1016/S1359-6446(01)01872-4; Snow CM, 2000, J GERONTOL A-BIOL, V55, pM489, DOI 10.1093/gerona/55.9.M489; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569	39	120	126	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1280	+		10.1096/fj.01-0913fje	http://dx.doi.org/10.1096/fj.01-0913fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153999				2022-12-25	WOS:000176683900027
J	Bailly, V; Zhang, ZW; Meier, W; Cate, R; Sanicola, M; Bonventre, JV				Bailly, V; Zhang, ZW; Meier, W; Cate, R; Sanicola, M; Bonventre, JV			Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL INTERACTIONS; MEDIATED RELEASE; TNF-ALPHA; MATRIX; ECTODOMAIN; INTEGRIN; IDENTIFICATION; EXPRESSION; MUCIN; L1	KIM-1 (kidney injury molecule-1) is a type I transmembrane glycoprotein expressed on dedifferentiated renal proximal tubule epithelial cells undergoing regeneration after toxic or ischemic injury. The extracellular domain of KIM-1 is composed of an immunoglobulin-like domain topping a long mucin-like domain, a structure that points to a possible role in cell adhesion by homology to several known adhesion proteins. Two splice variants (a and b), of the human KIM-1 having identical extracellular domains, differ in their cytoplasmic domains and tissue distributions. In this study, we report that the KIM-1b transcript is expressed predominantly in adult human kidney. We describe the generation of 10 monoclonal antibodies against the extracellular domain of human KIM-1, the mapping of their binding sites, and their use in identifying various forms of the protein. We show that human KIM-1b is expressed in adult kidney cell lines, and we demonstrate that a soluble form of KIM-1 is shed constitutively into the culture medium of the cell lines expressing endogenous or recombinant KIM-1b by membrane-proximal cleavage. A monoclonal antibody that binds at or close to the proteolytic site can partially block the shedding of KIM-1. Release of soluble KIM-1 is enhanced by activating the cells with phorbol 12-myristate 13-acetate and can be inhibited with two metalloproteinase inhibitors, BB-94 (Batimastat) and GM6001 (Ilomastat), suggesting that the cleavage is mediated by a metalloproteinase. We propose that the shedding of KIM-1 in the kidney undergoing regeneration constitutes an active mechanism allowing dedifferentiated regenerating cells to scatter on denuded patches of the basement membrane and reconstitute a continuous epithelial layer.	Harvard Univ, Sch Med,Div Hlth Serv & Technol, Dept Med,Harvard Massachusetts Inst Technol, Massachusetts Gen Hosp,Med Serv, Charlestown, MA 02129 USA; Biogen Inc, Cambridge, MA 02142 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Broad Institute; Biogen	Bailly, V (corresponding author), 14th Cambridge Ctr, Cambridge, MA 02142 USA.	Veronique_Bailly@biogen.com						Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Barclay AN, 1999, P NATL ACAD SCI USA, V96, P14672, DOI 10.1073/pnas.96.26.14672; Beer S, 1999, J CELL SCI, V112, P2667; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; DeLoia JA, 1998, HUM REPROD, V13, P2902, DOI 10.1093/humrep/13.10.2902; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; Han WK, 2002, J AM SOC NEPHROL, V13, p472A; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jimenez RE, 2000, ANN SURG, V231, P644, DOI 10.1097/00000658-200005000-00004; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kreidberg JA, 2000, AM J PHYSIOL-RENAL, V279, pF233, DOI 10.1152/ajprenal.2000.279.2.F233; LECA G, 1995, J IMMUNOL, V154, P1069; Leung KH, 1999, BIOCHEM BIOPH RES CO, V260, P734, DOI 10.1006/bbrc.1999.0965; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Molina MA, 2001, CANCER RES, V61, P4744; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NYBROE O, 1989, J NEUROCHEM, V53, P1372, DOI 10.1111/j.1471-4159.1989.tb08527.x; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wills-Karp M, 2001, NAT IMMUNOL, V2, P1095, DOI 10.1038/ni1201-1095; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	46	254	292	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39739	39748		10.1074/jbc.M200562200	http://dx.doi.org/10.1074/jbc.M200562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12138159	hybrid			2022-12-25	WOS:000178662500088
J	Calzada, MJ; Alvarez, MV; Gonzalez-Rodriguez, J				Calzada, MJ; Alvarez, MV; Gonzalez-Rodriguez, J			Agonist-specific structural rearrangements of integrin alpha(IIb)beta(3) - Confirmation of the bent conformation in platelets at rest and after activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; FIBRINOGEN RECEPTOR; ELECTRON-MICROSCOPY; GPIIB-IIIA; HUMAN FIBRONECTIN; DISULFIDE BONDS; PLASMA-MEMBRANE; BETA(3) SUBUNIT	Concrete structural features of integrin a,bp, on the surface of platelets (at rest and after activation) have been obtained from epitope maps based on cross-competition among monoclonal antibodies directed against the alpha(IIb) subunit calf-2 domain and the beta(3) subunit betaA domain of alpha(IIb)beta(3). At rest, the observed intersubunit interface is formed by the sequence stretches beta(3)-(150-216), alpha(IIb) light chain-(1-92), and alpha(IIb) heavy chain-(826-856); and the alpha(IIb) interchain interface is formed by the two latter sequence stretches, disulfide-bonded between alpha(IIb) heavy chain Cys(826) and alpha(IIb) light chain Cys(9). These structural features agree with those observed in the alpha(IIb)beta(3) rudimentary connectivity map in solution and with the alpha(v)beta(3) V-shaped crystal structure (Xiong, J.-P., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Science 294, 339-345), but they disagree with the domain disposition suggested by the actual ultrastructural model. The epitope maps in platelets activated by ADP, thrombin receptor activation peptide, and arachidonic acid differ not only from those in platelets at rest, but also among themselves. The structural rearrangements observed confirm the presence in activated platelets of the crystallographically observed knee and argue against the switchblade mechanism proposed for activation (Beglova, N., Blacklow, S. C., Takagi, J., and Springer, T. A. (2002) Nat. Struct. Biol. 9, 282-287), demonstrate the existence of alpha(IIb)beta(3) agonist-specific activation states, explain the specificity for ligand binding and functional inhibition for some agonists, and predict the existence of agonist-specific final effectors and receptor activation mechanisms. The distinct non-reciprocal competition patterns observed at rest and after activation support the agonist-specific activation states and the existence of intrasubunit and intersubunit allosteric effects, previously proposed as the mechanism for alpha(IIb)beta(3) transmembrane activation.	CSIC, Inst Quim Fis, Dept Biofis Mol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC)	Gonzalez-Rodriguez, J (corresponding author), CSIC, Inst Quim Fis, Dept Biofis Mol, Serrano 119, E-28006 Madrid, Spain.	J.Gonzalez-Rodriguez@iqfr.csic.es						BACHELOT C, 1995, SEMIN THROMB HEMOST, V21, P23, DOI 10.1055/s-2007-1000376; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; deCastellarnau C, 1997, PLATELETS, V8, P243, DOI 10.1080/09537109777285; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; GONZALEZRODRIGUEZ J, 1994, BIOCHEMISTRY-US, V33, P266, DOI 10.1021/bi00167a035; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MELERO JA, 1984, EUR J BIOCHEM, V141, P421, DOI 10.1111/j.1432-1033.1984.tb08208.x; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEWMAN PJ, 1987, BLOOD, V69, P668; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Rivas G A, 1991, Protein Expr Purif, V2, P248, DOI 10.1016/1046-5928(91)90080-3; RIVAS GA, 1991, EUR BIOPHYS J BIOPHY, V19, P335, DOI 10.1007/BF00183324; Schootemeijer A, 1997, THROMB HAEMOSTASIS, V77, P143; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i	50	37	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39899	39908		10.1074/jbc.M205886200	http://dx.doi.org/10.1074/jbc.M205886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12140290	hybrid			2022-12-25	WOS:000178662500107
J	Sarg, B; Koutzamani, E; Helliger, W; Rundquist, I; Lindner, HH				Sarg, B; Koutzamani, E; Helliger, W; Rundquist, I; Lindner, HH			Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE CAPILLARY ELECTROPHORESIS; INTERACTION LIQUID-CHROMATOGRAPHY; ARGININE-RICH HISTONE; HP1 CHROMO DOMAIN; CORE HISTONES; METHYL GROUPS; GLYCINE-RICH; CELL-CYCLE; IN-VIVO; H3	Methylation of the N-terminal region of histories was first described more than 35 years ago, but its biological significance has remained unclear. Proposed functions range from transcriptional regulation to the higher order packing of chromatin in progress of mitotic condensation. Primarily because of the recent discovery of the SET domain-depending H3-specific historic methyl-transferases SUV39H1 and Suv39h1, which selectively methylate lysine 9 of the H3 N terminus, this posttranslational modification has regained scientific interest. In the past, investigations concerning the biological significance of histone methylation were largely limited because of a lack of simple and sensitive analytical procedures for detecting this modification. The present work investigated the methylation pattern of histone H4 both in different mammalian organs of various ages and in cell lines by applying mass spectrometric analysis and a newly developed hydrophilic-interaction liquid chromatographic method enabling the simultaneous separation of methylated and acetylated forms, which obviates the need to work with radioactive materials. In rat kidney and liver the dimethylated lysine 20 was found to be the main methylation product, whereas the monomethyl derivative was present in much smaller amounts. In addition, for the first time a trimethylated form of lysine 20 of H4 was found in mammalian tissue. A significant increase in this trimethylated histone H4 was detected in organs of animals older than 30 days, whereas the amounts of mono- and dimethylated forms did not essentially change in organs from young (10 days old) or old animals (30 and 450 days old). Trimethylated H4 was also detected in transformed cells; although it was present in only trace amounts in logarithmically growing cells, we found an increase in trimethylated lysine 20 in cells in the stationary phase.	Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden	University of Innsbruck; Linkoping University	Lindner, HH (corresponding author), Univ Innsbruck, Dept Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@uibk.ac.at	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; BAXTER CS, 1975, BIOCHEM BIOPH RES CO, V63, P286, DOI 10.1016/S0006-291X(75)80041-6; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BORUN TW, 1972, J BIOL CHEM, V247, P4288; BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V148, P558, DOI 10.1016/0003-9861(72)90174-9; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DELANGE RJ, 1970, BIOCHEM BIOPH RES CO, V40, P989, DOI 10.1016/0006-291X(70)91001-6; DESAI LS, 1970, BIOCHEM J, V119, P165, DOI 10.1042/bj1190165; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; DUERRE JA, 1985, BIOCHIM BIOPHYS ACTA, V843, P58, DOI 10.1016/0304-4165(85)90049-2; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; HEMPEL K, 1979, H-S Z PHYSIOL CHEM, V360, P869, DOI 10.1515/bchm2.1979.360.2.869; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; Lindner H, 1998, J BIOL CHEM, V273, P13324, DOI 10.1074/jbc.273.21.13324; OGAWA Y, 1969, J BIOL CHEM, V244, P4387; Paik W. K., 1980, PROTEIN METHYLATION; PAIK WK, 1969, ARCH BIOCHEM BIOPHYS, V134, P632, DOI 10.1016/0003-9861(69)90327-0; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; SARNOW P, 1981, BIOCHIM BIOPHYS ACTA, V655, P349, DOI 10.1016/0005-2787(81)90045-9; STARBUCK WC, 1968, J BIOL CHEM, V243, P2038; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; SUNG MT, 1977, BIOCHEMISTRY-US, V16, P279, DOI 10.1021/bi00621a019; THOMAS G, 1975, EUR J BIOCHEM, V51, P609, DOI 10.1111/j.1432-1033.1975.tb03963.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	41	190	195	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39195	39201		10.1074/jbc.M205166200	http://dx.doi.org/10.1074/jbc.M205166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154089	hybrid			2022-12-25	WOS:000178662500019
J	Huttunen, HJ; Kuja-Panula, J; Rauvala, H				Huttunen, HJ; Kuja-Panula, J; Rauvala, H			Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; PROTEIN-KINASE PATHWAY; NEURITE OUTGROWTH; TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; SECRETOGRANIN-II; BINDING-PROTEINS; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Receptor for advanced glycation end products (RAGE) mediates neurite outgrowth and cell migration upon stimulation with its ligand, amphoterin. We show here that RAGE-dependent changes in cell morphology are associated with proliferation arrest and changes in gene expression in neuroblastoma cells. Chromogranin B, a component of secretory vesicles in endocrine cells and neurons, was found to be up-regulated by RAGE signaling during differentiation of neuroblastoma cells along with the two other members of the chromogranin family, chromogranin A and secretogranin II. Ligation of RAGE by amphoterin lead to rapid phosphorylation and nuclear localization of cyclic AMP response element-binding protein (CREB), a major regulator of chromogranin expression. Furthermore, inhibition of ERK1/2-Rsk2-dependent CREB phosphorylation efficiently inhibited up-regulation of chromogranin gene expression upon RAGE activation. To further study the effects of RAGE and amphoterin on cellular differentiation, we stimulated embryonic stem cells expressing RAGE or a signaling-deficient mutant of RAGE with amphoterin. Amphoterin was found to promote RAGE-dependent neuronal differentiation of embryonic stem cells characterized by up-regulation of neuronal markers light neurofilament protein and beta-III-tubulin, activation of CREB, and increased expression of chromogranins A and B. These data suggest that RAGE signaling is capable of driving neuronal differentiation involving CREB activation and induction of chromogranin expression.	Univ Helsinki, Programme Mol Neurobiol, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Huttunen, HJ (corresponding author), Univ Helsinki, Programme Mol Neurobiol, Inst Biotechnol, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.		li, tao/B-2402-2008	Huttunen, Henri/0000-0002-9867-4438; Rauvala, Heikki/0000-0001-7809-9811				Abe K, 1996, BRAIN RES, V723, P206, DOI 10.1016/0006-8993(96)00253-3; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; Bierhaus A, 1997, CIRCULATION, V96, P2262; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200; Crain BJ, 1996, AM J PATHOL, V149, P1087; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Fages C, 2000, J CELL SCI, V113, P611; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; GIUDICI AM, 1992, EUR J CELL BIOL, V58, P383; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huang CM, 2001, MOL BRAIN RES, V92, P181, DOI 10.1016/S0169-328X(01)00118-8; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Lamberts SWJ, 2001, FRONT NEUROENDOCRIN, V22, P309, DOI 10.1006/frne.2001.0218; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Ozawa H, 1995, CELL STRUCT FUNCT, V20, P415, DOI 10.1247/csf.20.415; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Pons S, 2001, DEVELOPMENT, V128, P1481; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RONG LL, 2001, SOC NEUR ABSTR; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; Scammell JG, 2000, MOL BRAIN RES, V75, P8, DOI 10.1016/S0169-328X(99)00269-7; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen PJ, 1996, EUR J NEUROSCI, V8, P988, DOI 10.1111/j.1460-9568.1996.tb01586.x; Sparatore B, 1996, BIOCHEM J, V320, P253, DOI 10.1042/bj3200253; Sparatore B, 2001, BIOCHEM J, V357, P569, DOI 10.1042/0264-6021:3570569; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Weiss C, 2001, NEUROCHEM INT, V38, P43, DOI 10.1016/S0197-0186(00)00046-2; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	62	136	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38635	38646		10.1074/jbc.M202515200	http://dx.doi.org/10.1074/jbc.M202515200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167613	hybrid			2022-12-25	WOS:000178529600081
J	Locascio, A; Vega, S; de Frutos, CA; Manzanares, M; Nieto, MA				Locascio, A; Vega, S; de Frutos, CA; Manzanares, M; Nieto, MA			Biological potential of a functional human SNAIL retrogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; NEURAL CREST; CARCINOMA-CELLS; GENE FAMILY; P-CADHERIN; REPRESSOR; ORGANIZATION; SUPERFAMILY; TRANSITION	Snail genes encode zinc finger transcription factors required for the development of vertebrate and invertebrate embryos. They trigger epithelial to mesenchymal transitions (EMTs), thereby allowing epithelial cells to emigrate from their place of origin and form tissues such as the mesoderm and the neural crest. Snail genes are also involved in the EMTs responsible for the acquisition of invasiveness during tumor progression. This aspect of their activity is associated with their ability to directly repress E-cadherin transcription. Here we describe the existence of an active human Snail retrogene, inserted within an intron of a novel evolutionarily conserved gene and expressed in different human tissues and cell lines. Functional analyses in cell culture show that this retrogene maintains the potential to induce EMTs, conferring migratory and invasive properties to epithelial cells. In light of this data, we have renamed it SNAIL-like, a new player that must be considered in both physiological and pathological studies of SNAIL function in humans.	CSIC, Inst Cajal, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Manzanares, M (corresponding author), UAM, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	mmanzanares@iib.uam.es	Nieto, M. Angela/A-6531-2008; Manzanares, Miguel/AAZ-8305-2021; Manzanares, Miguel/E-1702-2015; Locascio, Annamaria/E-8714-2015; Vega, Sonia/R-1883-2018	Nieto, M. Angela/0000-0002-3538-840X; Manzanares, Miguel/0000-0003-4849-2836; Manzanares, Miguel/0000-0003-4849-2836; Locascio, Annamaria/0000-0001-6956-2157; Vega, Sonia/0000-0002-3895-6265				ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Duband JL, 1995, ACTA ANAT, V154, P63; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; FITZGERALD J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P83, DOI 10.1016/0167-4781(92)90102-6; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GOMEZ M, 1994, INVAS METAST, V14, P17; GRAU Y, 1984, GENETICS, V108, P347; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hughes AL, 2000, P NATL ACAD SCI USA, V97, P3319, DOI 10.1073/pnas.050002797; Kataoka H, 2000, NUCLEIC ACIDS RES, V28, P626, DOI 10.1093/nar/28.2.626; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; Llorens A, 1998, LAB INVEST, V78, P1131; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; NAVARRO P, 1993, J CELL SCI, V105, P923; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nieto MA, 2001, MECH DEVELOP, V105, P27, DOI 10.1016/S0925-4773(01)00394-X; Pan YZ, 1999, GENOMICS, V59, P282, DOI 10.1006/geno.1999.5874; Paznekas WA, 1999, GENOMICS, V62, P42, DOI 10.1006/geno.1999.6010; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5; SARGENT CA, 1994, HUM MOL GENET, V3, P1317, DOI 10.1093/hmg/3.8.1317; SPENCER N, 1980, ANN HUM GENET, V43, P335, DOI 10.1111/j.1469-1809.1980.tb01567.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Twigg SRF, 1999, HUM GENET, V105, P320, DOI 10.1007/s004390051108; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X	48	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38803	38809		10.1074/jbc.M205358200	http://dx.doi.org/10.1074/jbc.M205358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151403	hybrid			2022-12-25	WOS:000178529600101
J	Patel, VA; Dunn, MJ; Sorokin, A				Patel, VA; Dunn, MJ; Sorokin, A			Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; COLON-CANCER CELLS; APOPTOSIS; EXPRESSION; ACTIVATION; CARCINOGENESIS; BIOCHEMISTRY; TRANSPORTER; MODULATION; LEUKEMIA	Cyclooxygenase-2 (Cox-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, has been shown to be overexpressed in a wide range of tumors and possesses proangiogenic and antiapoptotic properties. To understand the molecular mechanism of Cox-2 action we used adenovirus-mediated transfer of rat Cox-2 cDNA into renal rat mesangial cells and determined the differential gene expression using cDNA microarrays. One of the several genes that were highly up-regulated by over expressed Cox-2 was MDR1. MDR1 or P-glycoprotein (P-gp), the product of the MDR1 gene, is implicated as the primary cause of multidrug resistance (MDR) in tumors where it acts as an efflux pump for chemotherapeutic agents. It is also expressed in normal tissues of the liver and kidney where it functions to actively transport lipophilic xenobiotics. Reverse transcriptase-PCR analysis confirmed the results of the microarray, showing increased mRNA levels for MDR1 in Cox-2 overexpressing cells. This increase in mRNA translated to an increase in MDR1 protein expression, which was dose-dependent on Cox-2 expression. Furthermore, using rhodamine 123 efflux assay we observed a significant increase in P-gp activity in Cox-2 overexpressing renal mesangial cells. The specific Cox-2 inhibitor NS398 was able to block the Cox-2-mediated increase in MDRI expression and activity, suggesting that Cox-2 products may be implicated in this response. These results prove the existence of a causal link between Cox-2 and P-gp activity, which would have implications for kidney function and multidrug resistance in tumors where Cox-2 is overexpressed.	Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007792, R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07792, HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOREUSS E, 1994, AM J PHYSIOL-CELL PH, V267, pC1351, DOI 10.1152/ajpcell.1994.267.5.C1351; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; BRUNE K, 1999, CYCLOOXYGENASE INHIB; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Ernest S, 1997, NEPHRON, V77, P284, DOI 10.1159/000190289; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Kawamori T, 1998, CANCER RES, V58, P409; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ratnasinghe D, 2001, ANTICANCER RES, V21, P2141; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Sheng HM, 1998, CANCER RES, V58, P362; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7	25	152	179	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38915	38920		10.1074/jbc.M206855200	http://dx.doi.org/10.1074/jbc.M206855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138126	hybrid			2022-12-25	WOS:000178529600114
J	Soler, F; Fortea, MI; Lax, A; Fernandez-Belda, F				Soler, F; Fortea, MI; Lax, A; Fernandez-Belda, F			Dissecting the hydrolytic activities of sarcoplasmic reticulum ATPase in the presence of acetyl phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; CA2+-ATPASE; TRANSPORT; SUBSTRATE; CYCLE; CA2+; THAPSIGARGIN; MECHANISM; MEMBRANES; VESICLES	Sarcoplasmic reticulum vesicles and purified Ca2+-ATPase hydrolyze acetyl phosphate both in the presence and absence of Ca2+. The Ca2+-independent activity was fully sensitive to vanadate, insensitive to thapsigargin, and proceeded without accumulation of phosphorylated enzyme. Acetyl phosphate hydrolysis in the absence of Ca2+ was activated by dimethyl sulfoxide. The Ca2+-dependent activity was partially sensitive to vanadate, fully sensitive to thapsigargin, and associated with steady phosphoenzyme accumulation. The Ca2+/P-i coupling ratio at neutral pH sustained by 10 mm acetyl phosphate was 0.57. Addition of 30% dimethyl sulfoxide completely blocked Ca2+ transport and partially inhibited the hydrolysis rate. Uncoupling induced by dimethyl sulfoxide included the accumulation of vanadate-insensitive phosphorylated enzyme. When acetyl phosphate was the substrate, the hydrolytic pathway was dependent on experimental conditions that might or might not allow net Ca2+ transport. The interdependence of both Ca2+-dependent and Ca2+-independent hydrolytic activities was demonstrated.	Univ Murcia, Dept Bioquim & Biol Mol A, E-30071 Murcia, Spain	University of Murcia	Fernandez-Belda, F (corresponding author), Univ Murcia, Dept Bioquim & Biol Mol A, Edificio Vet,Campus Espinardo, E-30071 Murcia, Spain.	fbelda@um.es	LAX, ANTONIO MANUEL/AAB-2135-2020; LAX, ANTONIO/Q-3177-2016	LAX, ANTONIO MANUEL/0000-0001-5452-8781; LAX, ANTONIO/0000-0001-5452-8781				ASANO S, 1992, J BIOL CHEM, V267, P6590; BARRABIN H, 1990, BIOCHIM BIOPHYS ACTA, V1023, P266, DOI 10.1016/0005-2736(90)90422-K; BERBERIAN G, 1985, BIOCHIM BIOPHYS ACTA, V821, P17, DOI 10.1016/0005-2736(85)90148-8; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; CHINI EN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P152, DOI 10.1016/0005-2736(90)90250-R; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1969, J BIOL CHEM, V244, P3733; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fernandez-Belda F, 2001, J BIOL CHEM, V276, P7998, DOI 10.1074/jbc.M008648200; Fortea MI, 2001, J BIOL CHEM, V276, P37266, DOI 10.1074/jbc.M103949200; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; Hua SM, 1999, BIOPHYS J, V77, P2217, DOI 10.1016/S0006-3495(99)77062-1; INESI G, 1980, J BIOL CHEM, V255, P6040; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LIGURI G, 1980, ARCH BIOCHEM BIOPHYS, V200, P357, DOI 10.1016/0003-9861(80)90365-3; LIPMANN F, 1945, J BIOL CHEM, V159, P21; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; NAKAMURA Y, 1978, J BIOCHEM-TOKYO, V83, P571, DOI 10.1093/oxfordjournals.jbchem.a131945; PUCELL A, 1971, J BIOL CHEM, V246, P3389; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; WANG G, 1977, ARCH BIOCHEM BIOPHYS, V344, P309; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	35	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38127	38132		10.1074/jbc.M203966200	http://dx.doi.org/10.1074/jbc.M203966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12130639	hybrid			2022-12-25	WOS:000178529600021
J	Kominato, Y; Hata, Y; Takizawa, H; Matsumoto, K; Yasui, K; Tsukada, J; Yamamoto, F				Kominato, Y; Hata, Y; Takizawa, H; Matsumoto, K; Yasui, K; Tsukada, J; Yamamoto, F			Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; GROUP ANTIGENS; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSOR; HUMAN CANCER; A-ANTIGEN; CBF/NF-Y; EXPRESSION; BINDING; DIFFERENTIATION	We have studied the expression of human histo-blood group ABO genes during erythroid differentiation, using an ex vivo culture of AC133(-)CD34(+) cells obtained from peripheral blood. 5'-Rapid amplification of cDNA ends analysis of RNA from those cells revealed a novel transcription start site, which appeared to mark an alternative starting exon (1a) comprising 27 bp at the 5'-end of a CpG island in ABO genes. Results from reverse transcription-PCR specific to exon la indicated that the cells of both erythroid and epithelial lineages utilize this exon as the transcription starting exon. Transient transfection experiments showed that the region just upstream from the transcription start site possesses promoter activity in a cell type-specific manner when placed 5' adjacent to the reporter luciferase gene. Results from bisulfite genomic sequencing and reverse transcription-PCR analysis indicated that hypermethylation of the distal promoter region correlated with the absence of transcripts containing exon 1a, whereas hypermethylation in the interspersed repeats 5' adjacent to the distal promoter was commonly observed in all of the cell lines examined. These results suggest that a functional alternative promoter is located between the hypermethylated region of repetitive elements and the CpG island in the ABO genes.	Toyama Med & Pharmaceut Univ, Dept Internal Med 1, Fac Med, Toyama 9300194, Japan; Osaka Red Cross Blood Ctr, Osaka 5368505, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan; Burnham Inst, La Jolla, CA 92037 USA	University of Toyama; Osaka Red Cross Hospital; University of Occupational & Environmental Health - Japan; Sanford Burnham Prebys Medical Discovery Institute	Kominato, Y (corresponding author), Toyama Med & Pharmaceut Univ, Dept Legal Med, Fac Med, 2630 Sugitani, Toyama 9300194, Japan.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CORDONCARDO C, 1986, LAB INVEST, V55, P444; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DABELSTEEN E, 1982, J INVEST DERMATOL, V79, P3, DOI 10.1111/1523-1747.ep12510411; DAVID L, 1993, CANCER RES, V53, P5494; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GROCE LD, 2002, SCIENCE, V295, P1079; Hata Y, 2002, VOX SANG, V82, P39, DOI 10.1046/j.0042-9007.2001.00134.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HSIEH CH, 1994, MOL CELL BIOL, P5487; Iwamoto S, 1999, GLYCOCONJUGATE J, V16, P659, DOI 10.1023/A:1007085202379; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; KABAT EA, 1973, CARBOHYDRATES SOLUTI, P334; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Kominato Y, 1999, J BIOL CHEM, V274, P37240, DOI 10.1074/jbc.274.52.37240; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Landsteiner K., 1900, ZBL BAKT, V27, P357; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MATSUMOTO H, 1993, CANCER-AM CANCER SOC, V72, P75, DOI 10.1002/1097-0142(19930701)72:1<75::AID-CNCR2820720116>3.0.CO;2-Z; Matsumoto K, 2000, STEM CELLS, V18, P196, DOI 10.1634/stemcells.18-3-196; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MORGAN WTJ, 1969, BRIT MED BULL, V25, P30, DOI 10.1093/oxfordjournals.bmb.a070666; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORNTOFT TF, 1990, APMIS S17, V98, P1; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schenkel-Brunner H, 2000, HUMAN BLOOD GROUPS C, V2nd, P54, DOI [10.1007/978-3-7091-6294-1, DOI 10.1007/978-3-7091-6294-1]; Shimada I, 1999, Leg Med (Tokyo), V1, P217, DOI 10.1016/S1344-6223(99)80041-8; SIEFF C, 1982, BLOOD, V60, P703; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; Turker MS, 1999, SEMIN CANCER BIOL, V9, P329, DOI 10.1006/scbi.1999.0133; WADA H, 1990, BLOOD, V75, P505, DOI 10.1182/blood.V75.2.505.505; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Yin JL, 2001, IMMUNOL CELL BIOL, V79, P213, DOI 10.1046/j.1440-1711.2001.01002.x; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	59	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37936	37948		10.1074/jbc.M204238200	http://dx.doi.org/10.1074/jbc.M204238200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151392	hybrid			2022-12-25	WOS:000178447100131
J	Liu, ZY; Chatterjee, TK; Fisher, RA				Liu, ZY; Chatterjee, TK; Fisher, RA			RGS6 interacts with SCG10 and promotes neuronal differentiation - Role of the G gamma subunit-like (GGL) domain of RGS6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; HETEROTRIMERIC G-PROTEINS; SIGNALING RGS; IN-VITRO; REGULATORS; LOCALIZATION; STATHMIN; NUCLEAR; BINDING; COMPLEX	RGS proteins comprise a large family of proteins named for their ability to negatively regulate heterotrimeric G protein signaling. RGS6 is a member of the R7 RGS protein subfamily endowed with DEP (disheveled, Egl-10, pleckstrin) and GGL (G protein gamma subunit-like) domains in addition to the RGS domain present in all RGS proteins. RGS6 exists in multiple splice variant forms with identical RGS domains but possessing complete or incomplete GGL domains and distinct N- and C-terminal domains. Here we report that RGS6 interacts with SCG10, a neuronal growth-associated protein. Using yeast two-hybrid analysis to map protein interaction domains, we identified the GGL domain of RGS6 as the SCG10-interacting region and the stathmin domain of SCG10 as the RGS6-interacting region. Pull-down studies in COS-7 cells expressing: SCG10 and RGS6 splice variants revealed that SCG10 co-precipitated RGS6 proteins with complete GGL domains but not those with incomplete GGL domains, and vice versa. Expression of SCG10-interacting forms of RGS6 with SCG10 in PC12 or COS-7 cells resulted in co-localization of both proteins. RGS6 potentiated the ability of SCG10 to disrupt microtubule organization in PC12 and COS-7 cells. Furthermore, expression of SCG10 and RGS6 each enhanced NGF-induced PC12 cell differentiation, and co-expression of SCG10 with RGS6 produced synergistic effects on NGF-induced PC12 differentiation. These effects of RGS6 on microtubules and neuronal differentiation were observed only with RGS6 proteins with complete GGL domains. Mutation of a critical residue required for interaction of RGS proteins with G proteins did not affect the ability of RGS6 to induce neuronal differentiation. These findings identify SCG10 as a binding partner for the GGL domain of RGS6 and provide the first evidence for regulatory effects of an RGS protein on neuronal differentiation. Our results suggest that RGS6 induces neuronal differentiation by a novel mechanism involving interaction of SCG10 with its GGL domain and independent of RGS6 interactions with heterotrimeric G proteins.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836	NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cordes SP, 2001, NAT REV NEUROSCI, V2, P611, DOI 10.1038/35090039; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Gavet O, 1998, J CELL SCI, V111, P3333; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Nixon AB, 2002, J BIOL CHEM, V277, P18127, DOI 10.1074/jbc.M201065200; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	30	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37832	37839		10.1074/jbc.M205908200	http://dx.doi.org/10.1074/jbc.M205908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140291	hybrid			2022-12-25	WOS:000178447100118
J	Pepio, AM; Thibault, GL; Sossin, WS				Pepio, AM; Thibault, GL; Sossin, WS			Phosphoinositide-dependent kinase phosphorylation of protein kinase C Apl II increases during intermediate facilitation in Aplysia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; S6 KINASE; ACTIVATION; EXPRESSION; MEMBRANE; ISOFORMS; TRANSLOCATION; MECHANISM; ISOZYMES; NEURONS	Phosphorylation of protein kinase Cs (PKCs) by phosphoinositide-dependent kinase I (PDK) is critical for PKC activity. In the nervous system of the marine mollusk Aplysia, there are only two major PKC isoforms, the calcium-activated PKC Apl I and the calcium-independent PKC Apl II, and both PKCs are persistently activated during intermediate memory. We monitored the PDK-dependent phosphorylation of PKC Apl I and PKC Apl II using phosphopeptide antibodies. During persistent activation of PKCs in Aplysia neurons, there is a significant increase in the amount of PDK-phosphorylated PKC Apl II in the particulate fraction but no increase in the amount of PKC Apl I phosphorylated by PDK. PDK phosphorylation of PKCs was not sensitive to inhibitors of phosphatidylinositol 3-kinase, PKC, or expression of a kinase-inactive PDK. Localization of PDK-phosphorylated PKC Apl II using immunocytochemistry revealed an enrichment of phosphorylated PKC Apl II at the plasma membrane. These data suggest that increased PDK phosphorylation of PKC Apl II is important for persistent kinase activation.	McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), Elan Pharmaceut, 7475 Lusk Blvd, San Diego, CA 92121 USA.	wayne.sossin@mcgill.ca						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Byrne JH, 1996, J NEUROSCI, V16, P425; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Dyer JR, 1998, J BIOL CHEM, V273, P29469, DOI 10.1074/jbc.273.45.29469; EISENSTADT M, 1973, P NATL ACAD SCI USA, V70, P3371, DOI 10.1073/pnas.70.12.3371; Ekinci FJ, 1997, INT J DEV NEUROSCI, V15, P867, DOI 10.1016/S0736-5748(97)00037-3; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Khan A, 2001, J NEUROSCI, V21, P382, DOI 10.1523/JNEUROSCI.21-02-00382.2001; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu KP, 2000, J NEUROSCI, V20, P1365; Manseau F, 2001, J NEUROSCI, V21, P1247; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; Nakhost A, 1998, J NEUROCHEM, V71, P1221; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pascale A, 1996, NEUROSCI LETT, V214, P99, DOI 10.1016/0304-3940(96)12901-3; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1994, MOL BRAIN RES, V24, P210, DOI 10.1016/0169-328X(94)90134-1; SOSSIN WS, 1993, J BIOL CHEM, V268, P5763; Sossin WS, 1997, LEARN MEMORY, V3, P389, DOI 10.1101/lm.3.5.389; Sossin WS, 1996, J NEUROCHEM, V67, P220; Sossin WS, 1996, J NEUROSCI, V16, P10; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sutton MA, 2000, NEURON, V26, P219, DOI 10.1016/S0896-6273(00)81152-6; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0	40	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37116	37123		10.1074/jbc.M202264200	http://dx.doi.org/10.1074/jbc.M202264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140280	hybrid			2022-12-25	WOS:000178447100028
J	Vorberg, I; Priola, SA				Vorberg, I; Priola, SA			Molecular basis of scrapie strain glycoform variation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN ISOFORMS; TRANSMISSIBLE MINK ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; CULTURED-CELLS; AGENT; PRP; BSE; CONVERSION; PHOSPHOLIPASE; CONFORMATIONS	Transmissible spongiform encephalopathies (TSE) are characterized by the conversion of a protease-sensitive host glycoprotein, prion protein or PrP-sen, to a protease-resistant form (PrP-res). PrP-res molecules that accumulate in the brain and lymphoreticular system of the host consist of three differentially glycosylated forms. Analysis of the relative amounts of the PrP-res glycoforms has been used to discriminate TSE strains and has become increasingly important in the differential diagnosis of human TSEs. However, the molecular basis of PrP-res glycoform. variation between different TSE agents is unknown. Here we report that PrP-res itself can dictate strain-specific PrP-res glycoforms. The final PrP-res glycoform pattern, however, can be influenced by the cell and significantly altered by subtle changes in the glycosylation state of PrP-sen. Thus, strain-specific PrP-res glycosylation profiles are likely the consequence of a complex interaction between PrP-res, PrP-sen, and the cell and may indicate the cellular compartment in which the strain-specific formation of PrP-res occurs.	NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Carp RI, 1997, J GEN VIROL, V78, P283, DOI 10.1099/0022-1317-78-1-283; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SHINAGAWA M, 1985, MICROBIOL IMMUNOL, V29, P543, DOI 10.1111/j.1348-0421.1985.tb00856.x; Somerville RA, 1999, J GEN VIROL, V80, P1865, DOI 10.1099/0022-1317-80-7-1865; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851	47	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36775	36781		10.1074/jbc.M206865200	http://dx.doi.org/10.1074/jbc.M206865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138171	hybrid			2022-12-25	WOS:000178275100127
J	Muller, R; Altmann, F; Zhou, DP; Hennet, T				Muller, R; Altmann, F; Zhou, DP; Hennet, T			The Drosophila melanogaster brainiac protein is a glycolipid-specific beta 1,3N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; EXPRESSION ANALYSIS; CELL-GROWTH; CLONING; FRINGE; GENE; IDENTIFICATION; RECEPTOR; NOTCH	Mutations at the Drosophila melanogaster brainiac locus lead to defective formation of the follicular epithelium during oogenesis and to neural hyperplasia. The brainiac gene encodes a type H transmembrane protein structurally similar to mammalian beta1,3-glycosyltransferases. We have cloned the brainiac gene from D. melanogaster genomic DNA and expressed it as a FLAG-tagged recombinant protein in Sf9 insect cells. Glycosyltransferase assays showed that brainiac is capable of transferring N-acetylglucosamine (GlcNAc) to beta-linked mannose (Man), with a marked preference for the disaccharide Man(beta1,4)Glc, the core of arthro-series glycolipids. The activity of brainiac toward arthro-series glycolipids was confirmed by showing that the enzyme efficiently utilized glycolipids from insects as acceptors whereas it did not with glycolipids from mammalian cells. Methylation analysis of the brainiac reaction product revealed a beta1,3 linkage between GlcNAc and Man, proving that brainiac is a beta1,3GlcNAc-transferase. Human beta1,3GlcNAc-transferases structurally related to brainiac were unable to transfer GlcNAc to Man(beta1,4)Glc-based acceptor substrates and failed to rescue a homozygous lethal brainiac allele, indicating that these proteins are paralogous and not orthologous to brainiac.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria	University of Zurich; University of Natural Resources & Life Sciences, Vienna	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Zhou, Dapeng/A-6446-2019; zhou, dapeng/GXG-9715-2022	Zhou, Dapeng/0000-0003-1347-3811; Altmann, Friedrich/0000-0002-0112-7877				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Cole SE, 2001, MAMM GENOME, V12, P177, DOI 10.1007/s003350010241; Dennis R D, 1986, Biomed Chromatogr, V1, P31, DOI 10.1002/bmc.1130010108; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Egan S, 2000, GLYCOCONJUGATE J, V17, P867, DOI 10.1023/A:1010921313314; GANS M, 1975, GENETICS, V81, P683; Gerdt S, 1997, GLYCOBIOLOGY, V7, P265, DOI 10.1093/glycob/7.2.265; Goode S, 1997, COLD SPRING HARB SYM, V62, P177; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEVELOPMENT, V122, P3863; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Hacker U, 1997, DEVELOPMENT, V124, P3565; Henion TR, 2001, J BIOL CHEM, V276, P30261, DOI 10.1074/jbc.M102979200; Hennet T, 1999, BBA-GEN SUBJECTS, V1473, P123, DOI 10.1016/S0304-4165(99)00173-7; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; Marroquin LD, 2000, GENETICS, V155, P1693; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERRIMON N, 1989, GENETICS, V121, P333; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Swan A, 2001, GENOME RES, V11, P67, DOI 10.1101/gr.156001; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; WIEGANDT H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P117, DOI 10.1016/0005-2760(92)90101-Z; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	45	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32417	32420		10.1074/jbc.C200381200	http://dx.doi.org/10.1074/jbc.C200381200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12130631	hybrid			2022-12-25	WOS:000177859000004
J	Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Lakka, SS; Jasti, SL; Gondi, C; Boyd, D; Chandrasekar, N; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro	ONCOGENE			English	Article						extracellular signal regulated kinase; invasion; gliomas; stable transfectants; MMP-9	ACTIVATED PROTEIN-KINASE; HUMAN GLIOBLASTOMA CELLS; IV COLLAGENASE GENE; TRANSCRIPTION FACTOR; GELATINASE-B; C-JUN; HA-RAS; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INVASIVENESS	We previously showed that enhanced expression of MMP-9, an endopeptidase that digests basement-membrane type IV collagen, is related to tumor progression in vitro and in vivo; antisense-MMP-9 stably transfected clones were less invasive than untransfected parental cells and did not form tumors in nude mice. In this study, we examined the role of ERK-1 in the regulation of MMP-9 production and the invasive behavior of the human glioblastoma cell line SNB19, in which ERK1 is constitutively activated. SNB19 cells were stably transfected with mt-ERK, a vector encoding ERK-1 cDNA in which the conserved lysine at codon 71 was changed to arginine, thus impairing the catalytic efficiency of this enzyme. Gelatin zymography showed reduced levels of MMP-9 in the mt-ERK-transfected cell lines relative to those in vector-transfected and parental control cells. Reductions in MMP-9 protein mRNA levels were also detected in the mt-ERK-transfected cells by Western and Northern blotting. The mt-ERK-transfected cells were much less invasive than parental or vector control cells in a Matrigel invasion assay and in a spheroid coculture assay. Thus an ERK-dependent signaling pathway seems to regulate MMP-9 mediated glioma invasion in SNB19 cells; interfering with this pathway could be developed into a therapeutic approach, which aims at a reduction of cancer cell invasion.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76350, CA75557, CA-85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL S, 1995, ONCOGENE, V11, P427; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Forsyth PA, 1998, J NEURO-ONCOL, V36, P21, DOI 10.1023/A:1005879027267; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Genersch E, 2000, J CELL SCI, V113, P4319; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Simon C, 1998, CANCER RES, V58, P1135; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOZERI O, 1992, ONCOGENE, V7, P2259; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	38	92	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5601	5608		10.1038/sj.onc.1205646	http://dx.doi.org/10.1038/sj.onc.1205646			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165859				2022-12-25	WOS:000177442000010
J	Parker, KK; Brock, AL; Brangwynne, C; Mannix, RJ; Wang, N; Ostuni, E; Geisse, NA; Adams, JC; Whitesides, GM; Ingber, DE				Parker, KK; Brock, AL; Brangwynne, C; Mannix, RJ; Wang, N; Ostuni, E; Geisse, NA; Adams, JC; Whitesides, GM; Ingber, DE			Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces	FASEB JOURNAL			English	Article						migration; motility; focal adhesion; cell tension; microspike; microcontact printing	SMOOTH-MUSCLE-CELLS; FOCAL ADHESIONS; RHO FAMILY; MECHANICAL TENSION; GEOMETRIC CONTROL; CARCINOMA-CELLS; LIVING CELLS; RAC; MIGRATION; CYTOSKELETON	Directed cell migration is critical for tissue morphogenesis and wound healing, but the mechanism of directional control is poorly understood. Here we show that the direction in which cells extend their leading edge can be controlled by constraining cell shape using micrometer-sized extracellular matrix (ECM) islands. When cultured on square ECM islands in the presence of motility factors, cells preferentially extended lamellipodia, filopodia, and microspikes from their corners. Square cells reoriented their stress fibers and focal adhesions so that tractional forces were concentrated in these corner regions. When cell tension was dissipated, lamellipodia extension ceased. Mechanical interactions between cells and ECM that modulate cytoskeletal tension may therefore play a key role in the control of directional cell motility.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; MRC, Mol Cell Biol Lab, London, England; UCL, Dept Biochem & Mol Biol, London, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston University; University of London; University College London	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Enders 1007,300 Longwood Ave, Boston, MA 02115 USA.	donald.ingber@tch.harvard.edu	Ingber, Donald E/AAC-5894-2019; Adams, Josephine C/B-1121-2009; Wang, Ning/B-6966-2008; Brock, Amy/S-9947-2019	Adams, Josephine C/0000-0002-2225-4947; Geisse, Nicholas/0000-0002-0901-0307	NCI NIH HHS [CA-45548] Funding Source: Medline; NIGMS NIH HHS [GM30367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030367, R01GM030367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLANCHARD EM, 1990, PFLUG ARCH EUR J PHY, V416, P219, DOI 10.1007/BF00370248; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Chen CS, 2000, METH MOL B, V139, P209; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Goldmann WH, 1996, EXP CELL RES, V226, P234, DOI 10.1006/excr.1996.0223; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Holly SP, 2000, EXP CELL RES, V261, P69, DOI 10.1006/excr.2000.5040; INGBER DE, 1993, J CELL SCI, V104, P613; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kishi H, 2000, J BIOCHEM, V128, P719, DOI 10.1093/oxfordjournals.jbchem.a022806; Knight B, 2000, CURR BIOL, V10, P576, DOI 10.1016/S0960-9822(00)00486-3; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NAKATSUJI N, 1984, NATURE, V307, P453, DOI 10.1038/307453a0; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OSTER GF, 1983, J EMBRYOL EXP MORPH, V78, P83; Ostuni E, 2000, LANGMUIR, V16, P7811, DOI 10.1021/la000382m; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Pelham RJ, 1999, MOL BIOL CELL, V10, P935, DOI 10.1091/mbc.10.4.935; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Verkhovsky AB, 1999, CURR BIOL, V9, P11, DOI 10.1016/S0960-9822(99)80042-6; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WANG N, 2002, IN PRESS CELL MOTIL; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622	55	365	379	1	63	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1195	10.1096/fj.02-0038com	http://dx.doi.org/10.1096/fj.02-0038com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153987				2022-12-25	WOS:000177814000028
J	Junankar, PR; Karjalainen, A; Kirk, K				Junankar, PR; Karjalainen, A; Kirk, K			The role of P2Y(1) purinergic receptors and cytosolic Ca2+ in hypotonically activated osmolyte efflux from a rat hepatoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ATP RELEASE; FREE CALCIUM-CONCENTRATION; VOLUME REGULATION; POTASSIUM CHANNELS; EPITHELIAL-CELLS; EXTRACELLULAR NUCLEOTIDES; HUMAN HEPATOCYTES; ANION CHANNELS; PROTEIN; IDENTIFICATION	Exposure of HTC rat hepatoma cells to a 33% decrease in extracellular osmolality caused the cytosolic Ca2+ concentration ([Ca2+](i)) to increase transiently by similar to90 nm. This rise in [Ca2+](i) was inhibited strongly by apyrase, grade VII (which has a low ATP/ADPase ratio) but not by apyrase grade VI (which has a high ATP/ADPase ratio) or hexokinase, indicating that extracellular ADP and/or ATP play a role in the [Ca2+](i) increase. The hypotonically induced rise in [Ca2+](i) was prevented by the prior discharge of the intracellular Ca2+ store of the cells by thapsigargin. Removal of extracellular Ca2+ or inhibition of Ca2+ influx by 1-10 muM Gd3+ depleted the thapsigargin-sensitive Ca2+ stores and thereby diminished the rise in [Ca2+](i). The hypotonically induced rise in [Ca2+](i) was prevented by adenosine 2'-phosphate-5'-phosphate (AMP) and pyridoxyl-5'-phosphate-6-azophenyl-2',4'-disulfonate, inhibitors of purinergic P2Y(1) receptors for which ADP is a major agonist. Both inhibitors also blocked the rise in [Ca2+](i) elicited by addition of ADP to cells in isotonic medium, whereas A2P5P had no effect on the rise in [Ca2+](i) elicited by the addition of the P2Y(2) and P2Y(4) receptor agonist, UTP. HTC cells were shown to express mRNA encoding for rat P2Y1, P2Y(2), and P2Y(6) receptors. Inhibition of the hypotonically induced rise in [Ca2+](i) blocked hypotonically induced K+ (Rb-86(+)) efflux, modulated the hypotonically induced efflux of taurine, but had no significant effect on Cl- (I-125-) efflux. The interaction of extracellular ATP and/or ADP with P2Y(1) purinergic receptors therefore plays a role in the response of HTC cells to osmotic swelling but does not account for activation of all the efflux pathways involved in the volume-regulatory response.	Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University	Junankar, PR (corresponding author), Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622				Bergeron LJ, 1996, AM J PHYSIOL-REG I, V270, pR801, DOI 10.1152/ajpregu.1996.270.4.R801; Bodily K, 1997, HEPATOLOGY, V25, P403; Boudreault F, 2002, AM J PHYSIOL-CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Chen ZP, 1996, ENDOCRINOLOGY, V137, P1833, DOI 10.1210/en.137.5.1833; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Dezaki K, 2000, JPN J PHYSIOL, V50, P235, DOI 10.2170/jjphysiol.50.235; Dixon CJ, 2000, BRIT J PHARMACOL, V130, P664, DOI 10.1038/sj.bjp.0703350; Dixon CJ, 2000, BRIT J PHARMACOL, V129, P764, DOI 10.1038/sj.bjp.0703103; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FOSKETT JK, 1994, CELLULAR MOL PHYSL C, P259; Galietta LJV, 1997, AM J PHYSIOL-CELL PH, V273, pC57, DOI 10.1152/ajpcell.1997.273.1.C57; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamill OP, 1996, PHARMACOL REV, V48, P231; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1998, CONTRIB NEPHROL, V123, P185, DOI 10.1159/000059913; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; Junankar PR, 2000, CELL PHYSIOL BIOCHEM, V10, P355, DOI 10.1159/000016368; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; Kirk K, 1997, J MEMBRANE BIOL, V158, P1, DOI 10.1007/s002329900239; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; LIPPMANN BJ, 1995, BRAIN RES, V686, P29, DOI 10.1016/0006-8993(95)00447-X; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; Mongin AA, 1999, AM J PHYSIOL-CELL PH, V277, pC823, DOI 10.1152/ajpcell.1999.277.4.C823; Morris H P, 1965, Adv Cancer Res, V9, P227, DOI 10.1016/S0065-230X(08)60448-0; Nicholas RA, 2001, MOL PHARMACOL, V60, P416; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Oike M, 2000, AM J PHYSIOL-HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Ralevic V, 1998, PHARMACOL REV, V50, P413; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Schlenker T, 1997, AM J PHYSIOL-GASTR L, V273, pG1108, DOI 10.1152/ajpgi.1997.273.5.G1108; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Schofl C, 1999, AM J PHYSIOL-GASTR L, V276, pG164, DOI 10.1152/ajpgi.1999.276.1.G164; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; Sevigny J, 2000, J BIOL CHEM, V275, P5640, DOI 10.1074/jbc.275.8.5640; Shinozuka K, 2001, CLIN EXP PHARMACOL P, V28, P799, DOI 10.1046/j.1440-1681.2001.03525.x; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Vohringer C, 2000, BIOCHEM PHARMACOL, V59, P791, DOI 10.1016/S0006-2952(99)00390-1; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	60	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40324	40334		10.1074/jbc.M204712200	http://dx.doi.org/10.1074/jbc.M204712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12138101	hybrid			2022-12-25	WOS:000178791400023
J	Gallie, DR; Fortner, D; Peng, J; Puthoff, D				Gallie, DR; Fortner, D; Peng, J; Puthoff, D			ATP-dependent hexameric assembly of the heat shock protein Hsp101 involves multiple interaction domains and a functional C-proximal nucleotide-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; CLPAP PROTEASE; CHAPERONE SYSTEM; ACTIVATED ATPASE; YEAST; THERMOTOLERANCE; SITES; PDZ; ARABIDOPSIS	Members of the Hsp100 family of heat stress proteins are present in species throughout the bacterial, plant, and fungal kingdoms. Most Hsp100 proteins are composed of five domains that include two nucleotide-binding domains required for their ATP-dependent oligomerization. Mutations within the first but not the second nucleotide-binding site disrupt self-assembly of bacterial Hsp100, whereas the reverse is true for yeast Hsp104. We have examined the functional requirements for oligomerization of plant Hsp101 and have found that Hsp101 resembles Hsp104 in that it assembles into a hexameric complex in an ATP-dependent manner. Self-assembly of Hsp101 involves at least three distinct interaction domains located in the N-proximal domain and in the first and second nucleotide-binding domains. The interaction domain in the second nucleotide-binding domain included the Walker A motif, and mutations within this element disrupted self-assembly of Hsp101. In contrast, mutations affecting conserved residues of the Walker A motif within the first nucleotide-binding site did not affect self-assembly. No interaction between Hsp101 and Hsp104 was observed. These results suggest that plant Hsp101 self-assembly involves multiple evolutionarily diverged interaction domains as well as an evolutionarily conserved requirement for a functional C-proximal nucleotide-binding site.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu	Peng, Jamy/N-1134-2018	Peng, Jamy/0000-0002-4043-8475				Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; CLARK KL, 1993, MOL CELL BIOL, V13, P1; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hong SW, 2000, P NATL ACAD SCI USA, V97, P4392, DOI 10.1073/pnas.97.8.4392; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim KI, 1998, BIOCHEM J, V333, P671, DOI 10.1042/bj3330671; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; LEE YRJ, 1994, PLANT CELL, V6, P1889, DOI 10.1105/tpc.6.12.1889; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Miernyk JA, 1999, PLANT PHYSIOL, V121, P695, DOI 10.1104/pp.121.3.695; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Nieto-Sotelo J, 1999, GENE, V230, P187, DOI 10.1016/S0378-1119(99)00060-8; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Tanguay RL, 1996, J BIOL CHEM, V271, P14316, DOI 10.1074/jbc.271.24.14316; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wells DR, 1998, GENE DEV, V12, P3236, DOI 10.1101/gad.12.20.3236; Winter J, 1991, Results Probl Cell Differ, V17, P85; Young TE, 2001, PLANT PHYSIOL, V127, P777, DOI 10.1104/pp.010160; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	60	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39617	39626		10.1074/jbc.M204998200	http://dx.doi.org/10.1074/jbc.M204998200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151400	hybrid			2022-12-25	WOS:000178662500073
J	Hackzell, A; Uramoto, H; Izumi, H; Kohno, K; Funa, K				Hackzell, A; Uramoto, H; Izumi, H; Kohno, K; Funa, K			p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; P53; FAMILY; LIGAND; P63; DIFFERENTIATION; PHENOTYPES; MECHANISM; SUBUNIT; DOMAINS	We recently reported that c-Myc represses the transcription of platelet-derived growth factor (PDGF) beta-receptor (Izumi, H., Molander, C., Penn, L. Z., Ishisaki, A., Kohno, K., and Funa, K. (2001) J. Cell Sci. 114, 15331544). We demonstrate here that the p53 family protein p73alpha represses PDGF beta-receptor transcription essentially by the same mechanism. p73alpha but not p73,6 or p53 represses the transcription in concordance with its ability to bind NF-YC and NF-YB. None of other p73 isoforms (i.e. p73beta, p73gamma, p73is an element of), C-terminal deletion mutants of p73alpha, and p53 is able to bind NF-Y with the exception of p63alpha. This finding suggests that the sterile alpha-motif domain present only in p73alpha and p63alpha is the interaction site. For the repression, the N-terminal transactivation domain of p73alpha is also indispensable, arguing for the importance of the activity of p73alpha in the mechanism. p73alpha binds the C-terminal HAP domain of NF-YC previously found to be the interaction site with c-Myc and TBP. Because c-Myc induces and activates p73alpha (Zaika, A., Irwin, M., Sansome, C., and Moll, U. M. (2001) J. Biol. Chem. 276, 11310-11316) and they bind each other (Uramoto, H., Izumi, H., Ise, T., Tada, M., Uchiumi, T., Kuwano, M., Yasumoto, K., Funa, K., and Kohno, K. (2002) J. Biol. Chem. 277, in press), we examined whether the repression by p73 is dependent on c-Myc. However, Myc-null rat fibroblasts are also susceptible to p73alpha-induced repression. Serum stimulation of NIH3T3 cells gradually decreased the amount of endogenous NF-Y binding to the PDGF beta-receptor promoter, whereas NF-YA expression in the nuclear extracts remains unchanged. Our results indicate that serum stimulation induces c-Myc and p73alpha, leading to the downregulation of PDGF beta-receptor expression by repressing its transcription.	Univ Gothenburg, Inst Anat & Cell Biol, Dept Cell Biol, SE-40530 Gothenburg, Sweden; Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan	University of Gothenburg; University of Occupational & Environmental Health - Japan	Funa, K (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, Dept Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	keiko.funa@anatcell.gu.se						BALLAGI AE, 1995, BIOCHEM BIOPH RES CO, V210, P165, DOI 10.1006/bbrc.1995.1642; BALLAGIPORDANY A, 1991, ANAL BIOCHEM, V196, P89, DOI 10.1016/0003-2697(91)90122-A; Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishisaki A, 1997, EUR J BIOCHEM, V246, P142, DOI 10.1111/j.1432-1033.1997.t01-2-00142.x; Izumi H, 2001, J CELL SCI, V114, P1533; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Levrero M, 2000, J CELL SCI, V113, P1661; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Molander C, 2001, MOL BIOL REP, V28, P223, DOI 10.1023/A:1015701232589; MORI S, 1994, J BIOL CHEM, V269, P4917; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; Serra E, 1998, NUCLEIC ACIDS RES, V26, P3800, DOI 10.1093/nar/26.16.3800; Shimizu A, 2001, J BIOL CHEM, V276, P27749, DOI 10.1074/jbc.C100286200; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; URAMOTO H, 2002, IN PRESS J BIOL CHEM, V277; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39769	39776		10.1074/jbc.M204483200	http://dx.doi.org/10.1074/jbc.M204483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167641	hybrid			2022-12-25	WOS:000178662500091
J	Leppanen, A; Penttila, L; Renkonen, O; McEver, RP; Cummings, RD				Leppanen, A; Penttila, L; Renkonen, O; McEver, RP; Cummings, RD			Glycosulfopeptides with O-glycans containing sialylated and polyfucosylated polylactosamine bind with low affinity to P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-LEUKOCYTES; LEUKEMIA HL-60 CELLS; GLYCOPROTEIN LIGAND-1; FUCT-VII; FUCOSYL-TRANSFERASE; ADHESION MOLECULE-1; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PSGL-1; IDENTIFICATION	P-selectin glycoprotein ligand-1 (PSGL-1), a dimeric mucin on leukocytes, is the best characterized ligand for selectins. P-selectin binds stereospecifically to the extreme N terminus of PSGL-1, which contains three clustered tyrosine sulfates (TyrSO(3)(-)) adjacent to a Thr residue with a core 2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)). GSP-6, a synthetic glycosulfopeptide modeled after the N terminus of PSGL-1, containing three TyrSO(3)(-) residues and a short, monofucosylated C2-O-sLe(x) bound to P-selectin with high affinity (K-d similar to650 nm). However, PSGL-1 from human HL-60 cells contains higher levels of O-glycans that are sialylated and poly-fucosylated polylactosamines (PFPL). Furthermore, studies with fucosyltransferase-deficient mice suggest that sialylated PFPL structures contribute to binding to P-selectin. To resolve whether sialylated PFPL O-glycans participate in binding of PSGL-1 to human P-selectin, we synthesized glycosulfopeptides, designated GSP-6' and GSP-6", with three TyrSO(3) residues and either difucosylated polylactosamine (C2-O-Le(x)-sLe(x)) or trifucosylated polylactosamine (C2-O-Le(x)-Le(x)-sLe(x)). Binding of the GSPs to P-selectin was measured by affinity chromatography, fluorescence solid-phase assays, and equilibrium gel filtration. Unexpectedly, both GSP-6' and GSP-6" bound to P-selectin with low affinity (K-d similar to37 muM for GSP-6' and K-d similar to50 muM for GSP-6"). Binding of GSP-6' and GSP-6" to P-selectin required fucosylation and, to a lesser extent, sialylation as well as the sulfated peptide backbone of GSP-6' and GSP-6". These results demonstrate that contrary to expectations, a core 2 O-glycan containing sialylated PFPL does not promote high affinity binding of PSGL-1 to P-selectin.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Helsinki, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Helsinki; Oklahoma Medical Research Foundation	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC-417, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65631] Funding Source: Medline; NIAID NIH HHS [AI48075] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERS GK, 1973, METHOD ENZYMOL, V27, P441; Andre P, 2000, P NATL ACAD SCI USA, V97, P3400, DOI 10.1073/pnas.040569797; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; Blixt O, 1999, GLYCOBIOLOGY, V9, P1061, DOI 10.1093/glycob/9.10.1061; Britten CJ, 1998, GLYCOBIOLOGY, V8, P321, DOI 10.1093/glycob/8.4.321; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Figarella-Branger D, 1999, AM J PATHOL, V155, P1261, DOI 10.1016/S0002-9440(10)65228-5; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Herron MJ, 2000, SCIENCE, V288, P1653, DOI 10.1126/science.288.5471.1653; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; PATEL TP, 1995, CIBA F SYMP, V189, P212; PILLER F, 1983, J BIOL CHEM, V258, P2293; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; STROUD MR, 1995, BIOCHEM BIOPH RES CO, V209, P777, DOI 10.1006/bbrc.1995.1568; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Toppila S, 1999, EUR J BIOCHEM, V261, P208, DOI 10.1046/j.1432-1327.1999.00257.x; Tu LL, 1996, J IMMUNOL, V157, P3995; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xia LJ, 2002, J CLIN INVEST, V109, P939; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	49	48	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39749	39759		10.1074/jbc.M206281200	http://dx.doi.org/10.1074/jbc.M206281200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145302	hybrid			2022-12-25	WOS:000178662500089
J	Swiatecka-Urban, A; Duhaime, M; Coutermarsh, B; Karlson, KH; Collawn, J; Milewski, M; Cutting, GR; Guggino, WB; Langford, G; Stanton, BA				Swiatecka-Urban, A; Duhaime, M; Coutermarsh, B; Karlson, KH; Collawn, J; Milewski, M; Cutting, GR; Guggino, WB; Langford, G; Stanton, BA			PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; GAMMA-AMINOBUTYRIC-ACID; CL-SECRETION; PROTEIN; CFTR; TRANSPORTERS; EXPRESSION; RECEPTOR; SURFACE; DETERMINANTS	The C terminus of CFTR contains a PDZ interacting domain that is required for the polarized expression of cystic fibrosis transmembrane conductance regulator (CFTR) in the apical plasma membrane of polarized epithelial cells. To elucidate the mechanism whereby the PDZ interacting domain mediates the polarized expression of CFTR, Madin-Darby canine kidney cells were stably transfected with wild type (wt-CFTR) or C-terminally truncated human CFTR (CFTR-DeltaTRL). We tested the hypothesis that the PDZ interacting domain regulates sorting of CFTR from the Golgi to the apical plasma membrane. Pulse-chase studies in combination with domain-selective cell surface biotinylation revealed that newly synthesized wt-CFTR and CFTR-DeltaTRL were targeted equally to the apical and basolateral membranes in a nonpolarized fashion. Thus, the PDZ interacting domain is not an apical sorting motif. Deletion of the PDZ interacting domain reduced the half-life of CFTR in the apical membrane from similar to24 to similar to13 h but had no effect on the half-life of CFTR in the basolateral membrane. Thus, the PDZ interacting domain is an apical membrane retention motif. Next, we examined the hypothesis that the PDZ interacting domain affects the apical membrane half-life of CFTR by altering its endocytosis and/or endocytic recycling. Endocytosis of wt-CFTR and CFTR-DeltaTRL did not differ. However, endocytic recycling of CFTR-DeltaTRL was decreased when compared with wt-CFTR. Thus, deletion of the PDZ interacting domain reduced the half-life of CFTR in the apical membrane by decreasing CFTR endocytic recycling. Our results identify a new role for PDZ proteins in regulating the endocytic recycling of CFTR in polarized epithelial cells.	Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Johns Hopkins Univ, Johns Hopkins Hosp, Ctr Med Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Dartmouth College	Stanton, BA (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA.	Bruce.A.Stanton@Dartmouth.edu	Milewski, Michal/C-7144-2012; SWIATECKA-URBAN, AGNIESZKA/H-6494-2015; Milewski, Michał/AAK-4243-2021; Swiatecka-Urban, Agnieszka/AAP-6041-2020	Milewski, Michal/0000-0001-7982-2565; SWIATECKA-URBAN, AGNIESZKA/0000-0002-6575-0334; Milewski, Michał/0000-0001-7982-2565; Collawn, James/0000-0002-2528-2759; Langford, George/0000-0001-9737-2182	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044003, R01DK045881, P50DK048977, R01DK032753, R01DK044003, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753, DK-45881, DK 48977, DK44003] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caplan MJ, 2001, KIDNEY INT, V60, P427, DOI 10.1046/j.1523-1755.2001.060002427.x; Chang XB, 1998, METHOD ENZYMOL, V292, P616; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; de Beauregard MAC, 2000, EUR J CELL BIOL, V79, P795, DOI 10.1078/0171-9335-00116; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li Y, 2002, AM J PHYSIOL-RENAL, V282, pF1129, DOI 10.1152/ajprenal.00131.2001; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Loffing J, 1999, AM J PHYSIOL-LUNG C, V277, pL700, DOI 10.1152/ajplung.1999.277.4.L700; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; McCarthy JB, 2001, J BIOL CHEM, V276, P9133, DOI 10.1074/jbc.M008290200; Milewski MI, 2001, J CELL SCI, V114, P719; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murer H, 2001, MOL MEMBR BIOL, V18, P3, DOI 10.1080/09687680116941; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Weixel Kelly, 2002, Methods Mol Med, V70, P323; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200	56	169	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40099	40105		10.1074/jbc.M206964200	http://dx.doi.org/10.1074/jbc.M206964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167629	hybrid			2022-12-25	WOS:000178662500131
J	Bannach, FG; Gutierrez, A; Fowler, BJ; Bugge, TH; Degen, JL; Parmer, RJ; Miles, LA				Bannach, FG; Gutierrez, A; Fowler, BJ; Bugge, TH; Degen, JL; Parmer, RJ; Miles, LA			Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	2nd Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology	MAY 11-13, 2001	ARLINGTON, VA				ACUTE-PHASE; DEFICIENCY; ACTIVATION; PROMOTER; MICE; ATHEROSCLEROSIS; COAGULATION; THROMBOSIS; PROTEINS; CORONARY	The activity of plasmin, the major enzyme responsible for dissolving fibrin clots, is regulated by plasminogen activators, plasminogen activator inhibitors, alpha(2)-antiplasmin, and inflammatory mediators. Recent studies suggest that plasmin activity can be regulated also at the level of plasminogen gene expression. In this study, we characterized the murine plasminogen promoter and 5'-flanking region. The major transcription start site was identified at -83 bp relative to the ATG translational initiation codon. A series of 5'-flanking sequences up to 2400 bp upstream of the transcription initiation site were fused to the luciferase reporter gene and transfected into hepatocytic cells. A 106-bp 5'-flanking region of the murine plasminogen gene demonstrated sufficient functional promoter activity in plasminogen-expressing cells. IL-6 treatment stimulated luciferase activity driven by the 5'-flanking region, and an intact consensus IL-6-responsive element at -791, was required for maximal stimulation by this cytokine. These results indicate the presence of regulatory elements in the 5'-flanking region of the murine plasminogen promoter that may regulate murine plasminogen gene expression and, hence, plasmin activity.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol CVN26, La Jolla, CA 92037 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Vet Adm Med Ctr, San Diego, CA 92161 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bannach, FG (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol CVN26, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fbannach@ucsd.edu	Gutierrez-Fernandez, Ana/ABG-6678-2020; Gutierrez-Fernandez, Ana/AAS-9954-2021	Gutierrez-Fernandez, Ana/0000-0002-9287-8843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063194, R29HL038272, R01HL047826, R01HL038272, R01HL050398, R01HL045934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47826, HL-45934, HL-63194, HL-38272, HL-50398] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Biasiutti FD, 1998, THROMB HAEMOSTASIS, V80, P167, DOI 10.1055/s-0037-1615157; BOHMFALK JF, 1980, SCIENCE, V209, P408, DOI 10.1126/science.7384814; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; Drew AF, 2000, CIRC RES, V87, P133, DOI 10.1161/01.RES.87.2.133; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; Fey G H, 1990, Prog Liver Dis, V9, P89; Folsom AR, 2001, ARTERIOSCL THROM VAS, V21, P611, DOI 10.1161/01.ATV.21.4.611; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P561; HEINRICH J, 1995, THROMB HAEMOSTASIS, V73, P374; Jenkins GR, 1997, BLOOD, V89, P2394, DOI 10.1182/blood.V89.7.2394; Kao WWY, 1998, INVEST OPHTH VIS SCI, V39, P502; Kirschning CJ, 1997, IMMUNOBIOLOGY, V198, P124; LACKNER H, 1973, AM J CLIN PATHOL, V60, P175; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Liu SB, 2000, GENE, V250, P137, DOI 10.1016/S0378-1119(00)00179-7; MALGARETTI N, 1990, BIOCHEM BIOPH RES CO, V173, P1013, DOI 10.1016/S0006-291X(05)80887-3; Matsuoka Y, 1998, NEUROSCI LETT, V252, P119, DOI 10.1016/S0304-3940(98)00562-X; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; Mingers AM, 1997, SEMIN THROMB HEMOST, V23, P259, DOI 10.1055/s-2007-996099; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Ramharack R, 1998, ARTERIOSCL THROM VAS, V18, P984, DOI 10.1161/01.ATV.18.6.984; RAUM D, 1980, SCIENCE, V208, P1036, DOI 10.1126/science.6990488; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; Rijken DC, 2001, THROMB RES, V103, pS41, DOI 10.1016/S0049-3848(01)00296-1; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAITO H, 1980, P NATL ACAD SCI-BIOL, V77, P6837, DOI 10.1073/pnas.77.11.6837; Sakkinen PA, 1998, THROMB HAEMOSTASIS, V80, P134, DOI 10.1055/s-0037-1615152; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schott D, 1998, NEW ENGL J MED, V339, P1679, DOI 10.1056/NEJM199812033392305; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SUH TT, 1994, J BIOL CHEM, V269, P25992; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Topper MJ, 1998, AM J VET RES, V59, P542; Tsirka SE, 1997, J NEUROSCI, V17, P543; Twining SS, 1999, BIOCHEM J, V339, P705, DOI 10.1042/0264-6021:3390705; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu GD, 1997, J BIOL CHEM, V272, P2396; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493	50	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38579	38588		10.1074/jbc.M202509200	http://dx.doi.org/10.1074/jbc.M202509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	602XK	12149246	hybrid			2022-12-25	WOS:000178529600075
J	Catchpole, S; Tavner, F; Le Cam, L; Sardet, C; Watson, RJ				Catchpole, S; Tavner, F; Le Cam, L; Sardet, C; Watson, RJ			A B-myb promoter corepressor site facilitates in vivo occupation of the adjacent E2F site by p107-E2F and p130-E2F complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; TRANSCRIPTIONAL REPRESSION; IN-VIVO; GENE-EXPRESSION; A PROMOTER; PRB; BINDING; FAMILY; ELEMENT; BETA	Transcription from the B-myb (MybL2 gene) promoter is strictly cell cycle-regulated by repression mediated through an E2F site during G(0)/early G(1). We report here the characterization of a corepressor site (downstream repression site (DRS)) required for this activity that is closely linked to the E2F site. Systematic mutagenesis of the DRS enabled a consensus to be derived, and it is notable that this sequence is compatible with cell cycle gene homology region sequences associated with cell cycle-dependent elements in the cyclin A, cdc2, and CDC25C promoters. The B-myb promoter is inappropriately active during Go in mouse embryo fibroblasts lacking the p107 and p130 pocket proteins, and we show that the ability of transfected p107 and p130 to re-impose repression on the promoter is dependent on the DRS. In contrast, transfected Rb was unable to repress the B-myb promoter. Consistent with the notion that Rb-E2F complexes are unable to bind the B-myb promoter E2F site in vivo, footprinting showed that this site is unoccupied in cells lacking p107 and p130. Chromatin immunoprecipitation assays showed a requirement for the DRS in recruiting p107 and p130 complexes to the B-myb promoter, indicating that in vivo the DRS governs the occupancy of the adjacent E2F site by transcriptional repressors.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Sect Virol & Cell Biol, London W2 1PG, England; Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier, France	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Le Cam, Laurent/O-1408-2016					Bennett JD, 1996, ONCOGENE, V13, P1073; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chen X, 1999, MOL CELL BIOL, V19, P4695; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Otaki M, 2000, BBA-GENE STRUCT EXPR, V1493, P188, DOI 10.1016/S0167-4781(00)00142-1; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Stiegler P, 1998, CANCER RES, V58, P5049; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WU CL, 1995, MOL CELL BIOL, V15, P2536; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39015	39024		10.1074/jbc.M202960200	http://dx.doi.org/10.1074/jbc.M202960200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147683	Green Published, hybrid			2022-12-25	WOS:000178529600126
J	Maggi, LB; Moran, JM; Scarim, AL; Ford, DA; Yoon, JW; Howat, JM; Buller, RML; Corbett, JA				Maggi, LB; Moran, JM; Scarim, AL; Ford, DA; Yoon, JW; Howat, JM; Buller, RML; Corbett, JA			Novel role for calcium-independent phospholipase A(2) in the macrophage antiviral response of inducible nitric-oxide synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; ARACHIDONIC-ACID INCORPORATION; P388D(1) MACROPHAGES; BROMOENOL LACTONE; INTERFERON-GAMMA; ACTIVATION; INHIBITION; INDUCTION	The double-stranded (ds) RNA-dependent protein kinase (PKR) is a primary regulator of antiviral responses; however, the ability of dsRNA to activate nuclear factor-kappaB (NF-kappaB) and dsRNA + interferon gamma (IFN-gamma) to stimulate inducible nitric-oxide synthase (iNOS) expression by macrophages isolated from PKR(-/-) mice suggests that signaling pathways in addition to PKR participate in antiviral activities. We have identified a novel phospholipid-signaling cascade that mediates macrophage activation by dsRNA and viral infection. Bromoenol lactone (BEL), a selective inhibitor of the calcium-independent phospholipase A(2) (iPLA(2)), prevents dsRNA- and virus-induced iNOS expression by RAW 264.7 cells and mouse macrophages. BEL does not modulate dsRNA-induced interleukin 1 expression, nor does it affect dsRNA-induced NF-kappaB activation. Protein kinase A (PKA) and the cAMP response element binding protein (CREB) are downstream targets of iPLA(2), because selective PKA inhibition prevents dsRNA-induced iNOS expression, and the inhibitory actions of BEL on dsRNA-induced iNOS expression are overcome by the direct activation of PKA. In addition, BEL inhibits dsRNA-induced CREB phosphorylation and CRE reporter activation. PKR does not participate in iPLA(2) activation or iNOS expression, because dsRNA stimulates iPLA(2) activity and dsRNA + IFN-gamma induces iNOS expression and nitric oxide production to similar levels by macrophages isolated from PKR(+/+) and PKR(-/-) mice. These findings support a PKR-independent signaling role for iPLA(2) in the antiviral response of macrophages.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Saint Louis University; Saint Louis University; Saint Louis University; University of Calgary	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	corbettj@slu.edu	Maggi, Leonard/L-5217-2019; Ford, David/D-1819-2018	Maggi, Leonard/0000-0003-0138-0984; Ford, David/0000-0002-0029-1560; McHowat, Jane/0000-0003-3133-3388				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Balsinde J, 1997, ADV EXP MED BIOL, V407, P99; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gross RW, 1998, BIOCHEM SOC T, V26, P345, DOI 10.1042/bst0260345; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; Horrocks L A, 1978, Adv Exp Med Biol, V100, P423; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; MALEWICZ B, 1981, BIOCHEM BIOPH RES CO, V101, P404, DOI 10.1016/0006-291X(81)91274-2; McHowat J, 2000, AM J PHYSIOL-HEART C, V278, pH1933, DOI 10.1152/ajpheart.2000.278.6.H1933; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Schwacha MG, 1998, J LEUKOCYTE BIOL, V64, P740, DOI 10.1002/jlb.64.6.740; Walev I, 2000, J IMMUNOL, V164, P5120, DOI 10.4049/jimmunol.164.10.5120; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; Williams SD, 2000, J LIPID RES, V41, P1585; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WOLF RA, 1985, J BIOL CHEM, V260, P7295; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	50	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38449	38455		10.1074/jbc.M206247200	http://dx.doi.org/10.1074/jbc.M206247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167650	hybrid			2022-12-25	WOS:000178529600059
J	Radford, JC; Davies, SA; Dow, JAT				Radford, JC; Davies, SA; Dow, JAT			Systematic G-protein-coupled receptor analysis in Drosophila melanogaster identifies a leucokinin receptor with novel roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; MYOTROPIC PEPTIDES; MALPIGHIAN TUBULES; LEUCOPHAEA-MADERAE; FLUID SECRETION; HEAD EXTRACTS; NEUROPEPTIDES; EXPRESSION; CLONING; FAMILY	Leucokinins are insect neuropeptides that stimulate hindgut motility and renal fluid secretion. Drosophila has a single leucokinin gene, pp, encoding the longest known leucokinin, Drosokinin. To identify its receptor, a genome-wide scan for G-protein-coupled receptors was performed in silico and candidate receptors identified by similarity to known tachykinin receptors. The deduced peptides were expressed, with a transgene for the calcium reporter aequorin, in S2 cells and only one gene (CG10626) encoded a protein that responded to Drosokinin. The properties of the heterologously expressed receptor (action through intracellular calcium with an EC50 of 4 x 10(-11) m and a t(1/2) <1 s) match closely those reported for the action of Drosokinin on Malpighian (renal) tubules. Antibodies raised against the receptor identified known sites of leucokinin action: stellate cells of the Malpighian tubule, two triplets of cells in the pars intercerebralis of the adult central nervous system, and additional cells in larval central nervous system. Western blots and reverse transcription-PCR confirmed these locations, but also identified expression in male and female gonads. These tissues also displayed elevated calcium in response to Drosokinin, demonstrating novel roles for leucokinin. A functional genomic approach has thus yielded the first complete characterization of a leucokinin receptor in an insect.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Dow, JAT (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	j.a.t.dow@bio.gla.ac.uk	Radford, Jonathan/AAN-5046-2020; Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; BLACKBURN MB, 1995, J INSECT PHYSIOL, V41, P723, DOI 10.1016/0022-1910(95)00005-F; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; COAST GM, 1990, J INSECT PHYSIOL, V36, P481, DOI 10.1016/0022-1910(90)90098-Z; Cox KJA, 1997, J NEUROSCI, V17, P1197; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; HAYES TK, 1989, LIFE SCI, V44, P1259, DOI 10.1016/0024-3205(89)90362-7; HAYES TK, 1994, REGUL PEPTIDES, V52, P235, DOI 10.1016/0167-0115(94)90058-2; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P205, DOI 10.1016/0742-8413(86)90084-8; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P271, DOI 10.1016/0742-8413(86)90093-9; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P31, DOI 10.1016/0742-8413(87)90043-0; Holman GM, 1999, PEPTIDES, V20, P1, DOI 10.1016/S0196-9781(98)00150-8; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P27, DOI 10.1016/0742-8413(87)90042-9; HOLMAN GM, 1984, COMP BIOCHEM PHYS C, V77, P1, DOI 10.1016/0742-8413(84)90122-1; Holmes SP, 2000, INSECT MOL BIOL, V9, P457, DOI 10.1046/j.1365-2583.2000.00208.x; Katanosaka K, 1998, FEBS LETT, V424, P149, DOI 10.1016/S0014-5793(98)00160-4; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LI XJ, 1992, J BIOL CHEM, V267, P9; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; MacPherson MR, 2001, AM J PHYSIOL-CELL PH, V280, pC394, DOI 10.1152/ajpcell.2001.280.2.C394; MONNIER D, 1992, J BIOL CHEM, V267, P1298; Nieto J, 1998, BIOCHEM BIOPH RES CO, V248, P406, DOI 10.1006/bbrc.1998.8964; O'Donnell MJ, 1998, AM J PHYSIOL-REG I, V274, pR1039, DOI 10.1152/ajpregu.1998.274.4.R1039; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rosay P, 1997, J CELL SCI, V110, P1683; ROSAY P, 1995, MECH DEVELOP, V51, P329, DOI 10.1016/0925-4773(95)00382-7; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHOOFS L, 1992, REGUL PEPTIDES, V37, P49, DOI 10.1016/0167-0115(92)90063-Z; Sozen MA, 1997, P NATL ACAD SCI USA, V94, P5207, DOI 10.1073/pnas.94.10.5207; Terhzaz S, 1999, J EXP BIOL, V202, P3667; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V202, P715, DOI 10.1006/bbrc.1994.1989; Veenstra JA, 1997, J BIOL CHEM, V272, P10402, DOI 10.1074/jbc.272.16.10402; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063	44	137	141	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38810	38817		10.1074/jbc.M203694200	http://dx.doi.org/10.1074/jbc.M203694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163486	hybrid			2022-12-25	WOS:000178529600102
J	Wen, J; You, KR; Lee, SY; Song, CH; Kim, DG				Wen, J; You, KR; Lee, SY; Song, CH; Kim, DG			Oxidative stress-mediated apoptosis - The anticancer effect of the sesquiterpene lactone parthenolide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA; CYTOCHROME-C; GENE GADD153; CANCER CELLS; IN-VITRO; GLUTATHIONE; INHIBITION; INDUCTION	The sesquiterpene lactone parthenolide, the principal active component in medicinal plants, has been used conventionally to treat migraines, inflammation, and tumors. However, the antitumor effects of parthenolide and the mechanism(s) involved are poorly understood. We found that parthenolide effectively inhibits hepatoma cell growth in a tumor cell-specific manner and triggers apoptosis of hepatoma cells. Parthenolide triggered apoptosis in invasive sarcomatoid hepatocellular carcinoma cells (SH-J1) as well as in other ordinary hepatoma cells at 5-10 muM concentrations and arrested the cell growth (at G(2)/M) at sublethal concentrations (1-3 muM). During parthenolide-induced apoptosis, depletion of glutathione, generation of reactive oxygen species, reduction of mitochondrial transmembrane potential, activation of caspases (caspases-7, -8, and -9), overexpression of GADD153 (an oxidative stress or anticancer agent inducible gene), and subsequent apoptotic cell death was observed. This induced apoptosis could be effectively inhibited or abrogated by an antioxidant N-acetyl-L-eysteine, whereas L-buthionine-(S,R)-sulfoximine enhanced it. Furthermore, stable overexpression of GADD153 sensitized the cells to apoptosis induced by parthenolide, and this susceptibility could be reversed by transfection with an antisense to GADD153. Parthenolide did not alter the expression of Bcl-2 or Bcl-X-L proteins during apoptosis in hepatoma cells. Oxidative stress may contribute to parthenolide-induced apoptosis and to GADD153 overexpression in a glutathione-sensitive manner. The sensitivity of tumor cells to parthenolide appears to result from the low expression level of the multifunctional detoxification enzyme glutathione S-transferase pi. Finally, parthenolide and its derivatives may be useful chemotherapeutic agents to treat these invasive cancers.	Chonbuk Natl Univ Med Sch & Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ Med Sch & Hosp, Dept Anat Res, Inst Clin Med, Chonju 561712, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University Hospital; Jeonbuk National University; Jeonbuk National University Hospital	Kim, DG (corresponding author), Chonbuk Natl Univ Med Sch & Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, 634-18 Keumam Dong, Chonju 561712, Chonbuk, South Korea.	daeghon@moak.chonbuk.ac.kr						ANDERSON ME, 1983, P NATL ACAD SCI-BIOL, V80, P707, DOI 10.1073/pnas.80.3.707; ARRICK BA, 1983, J CLIN INVEST, V71, P258, DOI 10.1172/JCI110766; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIGGS MJ, 1982, LANCET, V2, P776; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; DOUROS J, 1978, CANCER CHEMOTH PHARM, V1, P91; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Friedman AD, 1996, CANCER RES, V56, P3250; Fukuda K, 2000, BIOCHEM PHARMACOL, V60, P595, DOI 10.1016/S0006-2952(00)00340-3; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; GROENEWEGEN WA, 1990, J PHARM PHARMACOL, V42, P553, DOI 10.1111/j.2042-7158.1990.tb07057.x; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Guillet G, 2000, PHOTOCHEM PHOTOBIOL, V71, P111, DOI 10.1562/0031-8655(2000)071&lt;0111:SIPSIM&gt;2.0.CO;2; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; HALL IH, 1979, J PHARM SCI, V68, P537, DOI 10.1002/jps.2600680505; HARATAKE J, 1991, CANCER, V68, P93, DOI 10.1002/1097-0142(19910701)68:1<93::AID-CNCR2820680119>3.0.CO;2-G; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hwang D, 1996, BIOCHEM BIOPH RES CO, V226, P810, DOI 10.1006/bbrc.1996.1433; JOHNSON ES, 1985, BRIT MED J, V291, P569, DOI 10.1136/bmj.291.6495.569; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; Kim DG, 2002, CANCER GENET CYTOGEN, V132, P120, DOI 10.1016/S0165-4608(01)00543-X; Kim R, 1999, ANTICANCER RES, V19, P1779; Kito M, 2002, BIOCHEM BIOPH RES CO, V291, P861, DOI 10.1006/bbrc.2002.6525; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEE KH, 1977, SCIENCE, V196, P533, DOI 10.1126/science.191909; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LUETHY JD, 1994, CANCER RES, V54, pS1902; Maeda T, 1996, CANCER, V77, P51, DOI 10.1002/(SICI)1097-0142(19960101)77:1<51::AID-CNCR10>3.0.CO;2-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meister A., 1988, MECHANISMS DRUG RESI, P99; NAKAJIMA T, 1993, CANCER-AM CANCER SOC, V72, P1872, DOI 10.1002/1097-0142(19930915)72:6<1872::AID-CNCR2820720614>3.0.CO;2-N; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OConnor PM, 1997, CANCER RES, V57, P4285; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; PICMAN AK, 1979, CHEM-BIOL INTERACT, V28, P83, DOI 10.1016/0009-2797(79)90116-9; RAO PN, 1980, MOL CELL BIOCHEM, V29, P47; Ross JJ, 1999, PLANTA MED, V65, P126, DOI 10.1055/s-1999-13972; SABURI Y, 1989, CANCER RES, V49, P7020; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; TEW KD, 1994, CANCER RES, V54, P4313; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOERDENBAG HJ, 1989, BRIT J CANCER, V59, P68, DOI 10.1038/bjc.1989.13; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; You KR, 2001, HEPATOLOGY, V34, P1119, DOI 10.1053/jhep.2001.29199; ZHANG W, 1995, CANCER LETT, V96, P31, DOI 10.1016/0304-3835(95)03914-I; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	58	280	302	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38954	38964		10.1074/jbc.M203842200	http://dx.doi.org/10.1074/jbc.M203842200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151389	hybrid			2022-12-25	WOS:000178529600119
J	Young, ET; Kacherovsky, N; Van Riper, K				Young, ET; Kacherovsky, N; Van Riper, K			Snf1 protein kinase regulates Adr1 binding to chromatin but not transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ALCOHOL-DEHYDROGENASE; YEAST SACCHAROMYCES-CEREVISIAE; ADH2 EXPRESSION; PEROXISOME PROLIFERATION; DNA-BINDING; GLUCONEOGENIC ENZYMES; GLUCOSE REPRESSION; GENE-EXPRESSION; 3 GENES; PHOSPHORYLATION	The yeast transcriptional activator Adr1 controls the expression of genes required for ethanol, glycerol, and fatty acid utilization. We show that Adr1 acts directly on the promoters of ADH2, ACS1, GUT1, CTA1, and POT1 using chromatin immunoprecipitation assays. The yeast homolog of the AMP-activated protein kinase, Snf1; promotes Adr1 chromatin binding in the absence of glucose, and the protein phosphatase complex, Glc7.Reg1, represses its binding in the presence of glucose. A posttranslational process is implicated in the regulation of Adr1 binding activity. Chromatin binding by Adr1 is not the only step in ADH2 transcription that is regulated by glucose repression. Adr1 can bind to chromatin in repressed conditions in the presence of hyperacetylated histones. To study steps subsequent to promoter binding we utilized miniAdr1 transcription factors to characterize Adr1-dependent transcription in vitro. Yeast nuclear extracts prepared from glucose-repressed and glucose-derepressed cells are equally capable of supporting miniAdr1-dependent transcription and pre-initiation complex formation. Nuclear extracts prepared from a snf1 mutant support miniAdr1-dependent transcription but are partially defective in the formation of pre-initiation complexes with Mediator components being particularly depleted. We conclude that Snf1 regulates Adr1-dependent transcription primarily at the level of chromatin binding.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	ety@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG H, 1988, MOL CELL BIOL, V8, P1868, DOI 10.1128/MCB.8.5.1868; BLUMBERG H, 1987, THESIS U WASHINGTON; Bowers PW, 1999, NAT STRUCT BIOL, V6, P478; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; COOK WJ, 1993, CURR GENET, V23, P192, DOI 10.1007/BF00351495; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; DENIS CL, 1991, MOL GEN GENET, V229, P395, DOI 10.1007/BF00267461; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Di Mauro E, 2002, J BIOL CHEM, V277, P7002, DOI 10.1074/jbc.M106719200; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grauslund M, 1999, NUCLEIC ACIDS RES, V27, P4391, DOI 10.1093/nar/27.22.4391; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; IRANI M, 1987, MOL CELL BIOL, V7, P1233, DOI 10.1128/MCB.7.3.1233; KARNITZ L, 1992, GENETICS, V132, P351; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; NAVARRO B, 1994, BIOCHEM BIOPH RES CO, V202, P960, DOI 10.1006/bbrc.1994.2023; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; Sloan JS, 1999, J BIOL CHEM, V274, P37575, DOI 10.1074/jbc.274.53.37575; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; Verdone L, 2002, EMBO J, V21, P1101, DOI 10.1093/emboj/21.5.1101; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; Verdone L, 1996, MOL CELL BIOL, V16, P1978; Vincent O, 2001, MOL CELL BIOL, V21, P5790, DOI 10.1128/MCB.21.17.5790-5796.2001; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Walther K, 2001, MICROBIOL-SGM, V147, P2037, DOI 10.1099/00221287-147-8-2037; Young ET, 1998, J BIOL CHEM, V273, P32080, DOI 10.1074/jbc.273.48.32080; Young ET, 2000, BIOCHEMISTRY-US, V39, P567, DOI 10.1021/bi992049r; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	55	66	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38095	38103		10.1074/jbc.M206158200	http://dx.doi.org/10.1074/jbc.M206158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167649	hybrid			2022-12-25	WOS:000178529600017
J	Gomez, MF; Stevenson, AS; Bonev, AD; Hill-Eubanks, DC; Nelson, MT				Gomez, MF; Stevenson, AS; Bonev, AD; Hill-Eubanks, DC; Nelson, MT			Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; DEPENDENT TRANSCRIPTIONAL PATHWAY; NF-AT; CEREBRAL-ARTERIES; PLASMA-MEMBRANE; CA2+ SPARKS; PHOSPHATASE CALCINEURIN; MEDIATED TRANSCRIPTION; INTRACELLULAR CALCIUM; PROTEIN PHOSPHATASE	The nuclear factor of activated T-cells (NFAT), originally identified in T-cells, has since been shown to play a role in mediating Ca2+-dependent gene transcription in diverse cell types outside of the immune system. We have previously shown that nuclear accumulation of NFATc3 is induced in ileal smooth muscle by platelet-derived growth factor in a manner that depends on Ca2+ influx through L-type, voltage-dependent Ca2+ channels. Here we show that NFATc3 is also the predominant NFAT isoform expressed in cerebral artery smooth muscle and is induced to accumulate in the nucleus by UTP and other G(q/11)-coupled receptor agonists. This induction is mediated by calcineurin and is, dependent on sarcoplasmic reticulum Ca2+ release through inositol 1,4,5-trisphosphate receptors and extracellular Ca2+ influx through L-type, voltage-dependent Ca2+ channels. Consistent with results obtained in ileal smooth muscle, depolarization-induced Ca2+ influx fails to induce NFAT nuclear accumulation in cerebral arteries. We also provide evidence that Ca2+ release by ryanodine receptors in the form of Ca2+ sparks may exert an inhibitory influence on UTP-induced NFATc3 nuclear accumulation and further suggest that UTP may act, in part, by inhibiting Ca2+ sparks. These results are consistent with a multifactorial regulation of NFAT nuclear accumulation in smooth muscle that is likely to involve several intracellular signaling pathways, including local effects of sarcoplasmic reticulum. Ca2+ release and effects attributable to global elevations in intracellular Ca2+.	Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Nelson, MT (corresponding author), Univ Vermont, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.		Gomez, Maria F/D-3696-2014	Gomez, Maria F/0000-0001-6210-3142; Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [T32 HL/AR 07944, HL63722, HL07647-12, HL44455] Funding Source: Medline; NIDDK NIH HHS [DDK53832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063722, R01HL044455, T32HL007944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK053832] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boss V, 1998, MOL PHARMACOL, V54, P264, DOI 10.1124/mol.54.2.264; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Gollasch M, 1998, CIRC RES, V83, P1104, DOI 10.1161/01.RES.83.11.1104; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Iino M, 1999, MOL CELL BIOCHEM, V190, P185, DOI 10.1023/A:1006951317052; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1528, DOI 10.1152/ajpcell.2000.279.5.C1528; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Lewis CJ, 2000, J PHYSIOL-LONDON, V527, P315, DOI 10.1111/j.1469-7793.2000.00315.x; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liu J, 1997, MOL BIOL CELL, V8, P157, DOI 10.1091/mbc.8.1.157; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MAYER EA, 1992, J MEMBRANE BIOL, V125, P107; Miriel VA, 1999, J PHYSIOL-LONDON, V518, P815, DOI 10.1111/j.1469-7793.1999.0815p.x; Mironneau J, 1996, CELL CALCIUM, V20, P153, DOI 10.1016/S0143-4160(96)90104-9; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NELSON MT, 1995, AM J PHYSIOL, V268, P799; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Pabelick CM, 2001, J APPL PHYSIOL, V91, P488, DOI 10.1152/jappl.2001.91.1.488; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Torgerson TR, 1998, J IMMUNOL, V161, P6084; URQUILLA PR, 1978, STROKE, V9, P133, DOI 10.1161/01.STR.9.2.133; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; WORLEY JF, 1991, AM J PHYSIOL, V261, pH1951, DOI 10.1152/ajpheart.1991.261.6.H1951; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	67	78	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37756	37764		10.1074/jbc.M203596200	http://dx.doi.org/10.1074/jbc.M203596200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145283	hybrid			2022-12-25	WOS:000178447100108
J	Jain, S; Tang, XN; Narayanan, CS; Agarwal, Y; Peterson, SM; Brown, CD; Ott, J; Kumar, A				Jain, S; Tang, XN; Narayanan, CS; Agarwal, Y; Peterson, SM; Brown, CD; Ott, J; Kumar, A			Angiotensinogen gene polymorphism at-217 affects basal promoter activity and is associated with hypertension in African-Americans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LEUCINE-ZIPPER; TRANSCRIPTION INITIATION; SERUM ANGIOTENSINOGEN; MOLECULAR-GENETICS; BLOOD-PRESSURE; MESSENGER-RNA; RISK FACTOR; TATA BOX; EXPRESSION	Hypertension is a serious health problem in Western society, in particular for the African-American population. Although previous studies have suggested that the angiotensinogen (AGT) gene locus is involved in human essential hypertension, the molecular mechanisms involved in hypertension in African-Americans remain unknown. We show that an A/G polymorphism at -217 in the promoter of the AGT gene plays a significant role in hypertension in African-Americans. The frequency of the -217A allele was increased significantly in African-American hypertensive subjects compared with normotensive controls. We also show that the nucleotide sequence of this region of the AGT gene promoter bound strongly to CAAT/enhancer-binding protein (C/EBP) family transcription factors when nucleoside A was present at -217. In addition, we show that reporter constructs containing the human AGT gene promoter with nucleoside A at -217 had increased basal transcriptional activity upon transient transfection in HepG2 cells compared with reporter constructs with nucleoside G at -217. Finally, we show that interleukin-6 treatment in the presence or absence of overexpressed C/EBPbeta increased the promoter activities of reporter constructs containing nucleoside A at -217 compared with reporter constructs containing nucleoside G at -217. Because the AGT gene is expressed primarily in liver and adipose tissue, and C/EBP family transcription factors play an important role in gene expression in these tissues, we propose that increased transcriptional activity of the -217A allele of the human AGT gene is associated with hypertension in African-Americans.	New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; New York Med Coll, Dept Internal Med, Valhalla, NY 10595 USA; SUNY Hlth Sci Ctr, Dept Med, Div Renal, Brooklyn, NY 11203 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA	New York Medical College; New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University	Kumar, A (corresponding author), New York Med Coll, Dept Pathol, Basic Sci Bldg,Rm 455, Valhalla, NY 10595 USA.		Jain, Sudhir/A-2976-2008		NHGRI NIH HHS [HG00008] Funding Source: Medline; NHLBI NIH HHS [HL59547, HL49884] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059547, R01HL049884] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; Bloem LJ, 1997, HYPERTENSION, V29, P1078, DOI 10.1161/01.HYP.29.5.1078; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; Brasier AR, 1999, VITAM HORM, V57, P217; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CAMPBELL DJ, 1987, ENDOCRINOLOGY, V121, P1616, DOI 10.1210/endo-121-5-1616; CAO Z, 1991, GENE DEV, V5, P1528; Carson P, 2001, CLIN CARDIOL, V24, P183, DOI 10.1002/clc.4960240303; CAULFIELD M, 1995, J CLIN INVEST, V96, P687, DOI 10.1172/JCI118111; Cooper R, 1998, J HYPERTENS, V16, P571, DOI 10.1097/00004872-199816050-00003; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; CORVOL P, 1995, RECENT PROG HORM RES, V50, P287; Cui Y, 1998, GENE, V224, P97, DOI 10.1016/S0378-1119(98)00512-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farzaneh-Far A, 2001, J BIOL CHEM, V276, P32466, DOI 10.1074/jbc.M104909200; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KALINYAK JE, 1987, J BIOL CHEM, V262, P460; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lewis PO, 2001, GENETIC DATA ANAL GD; MANATUNGA AK, 1993, HYPERTENSION, V22, P84, DOI 10.1161/01.HYP.22.1.84; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Narayanan CS, 1999, MOL CELL ENDOCRINOL, V148, P79, DOI 10.1016/S0303-7207(98)00236-6; Narayanan CS, 2000, MOL CELL BIOCHEM, V212, P81, DOI 10.1023/A:1007180322263; Narayanan CS, 1998, BIOCHEM BIOPH RES CO, V251, P388, DOI 10.1006/bbrc.1998.9430; OHTANI R, 1992, ENDOCRINOLOGY, V130, P1331, DOI 10.1210/en.130.3.1331; ROTIMI C, 1994, HYPERTENSION, V24, P591, DOI 10.1161/01.HYP.24.5.591; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; TAKAHASHI S, 1992, J VET MED SCI, V54, P367, DOI 10.1292/jvms.54.367; TAKANO M, 1993, BIOCHEM PHARMACOL, V45, P201; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Zhao YY, 1999, HYPERTENSION, V33, P108, DOI 10.1161/01.HYP.33.1.108	46	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36889	36896		10.1074/jbc.M204732200	http://dx.doi.org/10.1074/jbc.M204732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145290	hybrid			2022-12-25	WOS:000178275100142
J	Kataoka, K; Muta, T; Yamazaki, S; Takeshige, K				Kataoka, K; Muta, T; Yamazaki, S; Takeshige, K			Activation of macrophages by linear (1 -> 3)-beta-D-glucans - Implications for the recognition of fungi by innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; GEL-FORMING (1->3)-BETA-D-GLUCANS; NUCLEAR MAGNETIC-RESONANCE; BETA-GLUCAN; CELL ACTIVATION; HELICAL CONFORMATION; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; TLR4; LIPOPOLYSACCHARIDE	Although (1-->3)-beta-D-glucans, which are one of major fungal cell wall components, are known to activate invertebrate innate immune systems, their activities on mammalian cells remain elusive. Here, we report their activities on mouse macrophages. Among the various (1-->3)-p-D-glucans, curdlan, a linear (1-->3)-beta-D-glucan, although not branched beta-glucans, exhibits significant activity to stimulate nuclear factor-kappaB in macrophages. The activity of curdlan is dramatically enhanced by pretreatment with sodium hydroxide or dimethyl sulfoxide, which disrupts multiple-stranded helices of (1-->3)-beta-Dglucans, and is dose-dependently inhibited by a (1-->3)-beta-D-glucan-binding protein and by laminarioligosaccharides with (1-->3)-beta-D-glucosidic linkages. Intriguingly, the activity of curdlan is also augmented by incubation with zymolyase, which releases (1-->3)-beta-D-glucans with a single helical structure from the glucan-networks assembled by multiple-stranded helices. The activation of macrophages culminates in the production of inducible nitric-oxide synthase, tumor necrosis factor-alpha, and macrophage inflammatory protein-2. Furthermore, a dominant-negative mutant of MyD88, an adaptor protein mediating signaling through the Toll-like receptor/inerleukin-1 receptor-like (TIR) domain, inhibits the activation of macrophages by curdlan. These results strongly suggest that macrophages respond to linear (1-->3)-beta-D-glucans, possibly released from fungal cell walls, via a receptor(s) harboring the TIR domain, such as a Toll-like receptor, to induce inflammatory reactions.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan	Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan.	tmuta@mailserver.med.kyushuu.ac.jp						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Asai K, 1996, CANCER IMMUNOL IMMUN, V42, P275, DOI 10.1007/s002620050282; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; CASTLEY BJ, 1988, CARBOHYD RES, V183, P83; CASU B, 1966, TETRAHEDRON, V22, P3061, DOI 10.1016/S0040-4020(01)82286-9; CHIHARA G, 1969, Nature (London), V222, P687; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COTE F, 1994, PLANT MOL BIOL, V26, P1379, DOI 10.1007/BF00016481; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; GLOVSKY MM, 1983, J RETICULOENDOTH SOC, V33, P401; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; HARADA T, 1968, ARCH BIOCHEM BIOPHYS, V124, P292, DOI 10.1016/0003-9861(68)90330-5; Hashimoto T, 1997, BIOL PHARM BULL, V20, P1006; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kerekgyarto C, 1996, INT J IMMUNOPHARMACO, V18, P347, DOI 10.1016/S0192-0561(96)00038-0; Kiemer AK, 2000, J IMMUNOL, V165, P175, DOI 10.4049/jimmunol.165.1.175; KIHO T, 1985, CARBOHYD RES, V142, P344, DOI 10.1016/0008-6215(85)85038-2; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; OGAWA K, 1972, CARBOHYD RES, V23, P399, DOI 10.1016/S0008-6215(00)82709-3; OHNO N, 1990, CARBOHYD RES, V207, P311, DOI 10.1016/0008-6215(90)84058-3; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Read SM, 1996, CARBOHYD RES, V281, P187, DOI 10.1016/0008-6215(95)00350-9; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; SAITO H, 1977, BIOCHEMISTRY-US, V16, P908, DOI 10.1021/bi00624a015; SAITO H, 1978, MACROMOLECULES, V11, P1244, DOI 10.1021/ma60066a035; SASAKI T, 1978, CANCER RES, V38, P379; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHARP JK, 1984, J BIOL CHEM, V259, P1312; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Soltys J, 1999, INFECT IMMUN, V67, P244, DOI 10.1128/IAI.67.1.244-252.1999; SPEERT DP, 1985, J LEUKOCYTE BIOL, V38, P655, DOI 10.1002/jlb.38.5.655; STITELER RD, 1978, J RETICULOENDOTH SOC, V24, P687; Stone BA, 1992, CHEM BIOL 1 3 BETA G; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thornton BP, 1996, J IMMUNOL, V156, P1235; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vassallo R, 2000, J IMMUNOL, V164, P3755, DOI 10.4049/jimmunol.164.7.3755; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; ZELENSKI SG, 1974, BOT MAR, V17, P191, DOI 10.1515/botm.1974.17.4.191; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	56	245	256	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36825	36831		10.1074/jbc.M206756200	http://dx.doi.org/10.1074/jbc.M206756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140296	hybrid			2022-12-25	WOS:000178275100134
J	Kohno, T; Sasaki, T; Kobayashi, K; Fainzilber, M; Sato, K				Kohno, T; Sasaki, T; Kobayashi, K; Fainzilber, M; Sato, K			Three-dimensional solution structure of the sodium channel agonist/antagonist delta-conotoxin TxVIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						5	POTATO CARBOXYPEPTIDASE INHIBITOR; OMEGA-CONOTOXIN; INACTIVATION GATE; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; PEPTIDE TOXINS; COSY; PROTEINS; VENOM; SITE	The three-dimensional solution structure of delta-conotoxin TxVIX a 27-mer peptide agonist/antagonist of sodium channels, was determined by two-dimensional H-1 NMR spectroscopy with simulated annealing calculations. A total of 20 converged structures of delta-conotoxin TxVIA were obtained on the basis of 360 distance constraints obtained from nuclear Overhauser effect connectivities, 28 torsion angle constraints, and 27 constraints associated with hydrogen bonds and disulfide bonds. The atomic root mean square difference about the averaged coordinate positions is 0.35 +/- 0.07 Angstrom for the backbone atoms (N, C-alpha, C) and 0.98 +/- 0.14 Angstrom for all heavy atoms of the entire peptide. The molecular structure of delta-conotoxin TxVIA is composed of a short triple-stranded antiparallel beta-sheet. The overall beta-sheet topology is +2x, -1, which is the same as those for other conotoxins. However, the three-dimensional structure of delta-conotoxin TxVIIA has an unusual hydrophobic patch on one side of the molecule, which may play an important role in the sodium channel binding. These results provide a molecular basis for understanding the mechanism of sodium channel modulation through the toxin-channel interaction and insight into the discrimination of different ion channels.	Mitsubishi Kagaku Inst Life Sci, MITILS, Machida, Tokyo 1948511, Japan; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Weizmann Institute of Science	Kohno, T (corresponding author), Mitsubishi Kagaku Inst Life Sci, MITILS, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	tkohno@libra.ls.m-kagaku.co.jp		Fainzilber, Mike/0000-0001-8173-8557				BASUS VJ, 1995, FEBS LETT, V370, P163, DOI 10.1016/0014-5793(95)00819-U; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brunger A. T, 1993, XPLOR MANUAL VERSION; Bulaj G, 2001, BIOCHEMISTRY-US, V40, P13201, DOI 10.1021/bi010683a; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; Eaholtz G, 1998, J GEN PHYSIOL, V111, P75, DOI 10.1085/jgp.111.1.75; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; HILLYARD DR, 1989, BIOCHEMISTRY-US, V28, P358, DOI 10.1021/bi00427a049; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kellenberger S, 1996, J BIOL CHEM, V271, P30971, DOI 10.1074/jbc.271.48.30971; Kellenberger S, 1997, J GEN PHYSIOL, V109, P589, DOI 10.1085/jgp.109.5.589; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P14761, DOI 10.1021/bi001506x; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVRAM V, 1994, BRAIN RES, V640, P48, DOI 10.1016/0006-8993(94)91856-2; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; PENNINGTON MW, 1992, TOXICON, V30, P755, DOI 10.1016/0041-0101(92)90009-T; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rohl CA, 1999, BIOCHEMISTRY-US, V38, P855, DOI 10.1021/bi9823380; SABO T, 1992, PEPTIDES CHEM BIOL, P159; Sasaki T, 1999, BIOCHEMISTRY-US, V38, P12876, DOI 10.1021/bi990731f; SEVILLA P, 1993, BIOCHEM BIOPH RES CO, V192, P1238, DOI 10.1006/bbrc.1993.1549; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SKALICKY JJ, 1993, PROTEIN SCI, V2, P1591, DOI 10.1002/pro.5560021005; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; VONKIENLIN M, 1991, J MAGN RESON, V93, P423, DOI 10.1016/0022-2364(91)90020-T; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P125	55	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36387	36391		10.1074/jbc.M206833200	http://dx.doi.org/10.1074/jbc.M206833200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145313	hybrid			2022-12-25	WOS:000178275100078
J	Niwa, J; Ishigaki, S; Hishikawa, N; Yamamoto, M; Doyu, M; Murata, S; Tanaka, K; Taniguchi, N; Sobue, G				Niwa, J; Ishigaki, S; Hishikawa, N; Yamamoto, M; Doyu, M; Murata, S; Tanaka, K; Taniguchi, N; Sobue, G			Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; UBIQUITIN-PROTEIN LIGASE; ALS-LINKED SOD1; CONJUGATING ENZYME; ALPHA-SYNUCLEIN; MUTATIONS; PARKIN; INCLUSIONS; GENE	Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disorder resulting from the degeneration of motor neurons in the cerebral cortex, brainstem, and spinal cord. The cytopathological hallmark in the remaining motor neurons of ALS is the presence of ubiquitylated inclusions consisting of insoluble protein aggregates. In this paper we report that Dorfin, a RING finger-type E3 ubiquitin ligase, is predominantly localized in the inclusion bodies of familial ALS with a copper/zinc superoxide dismutase (SOD1) mutation as well as sporadic AILS. Dorfin physically bound and ubiquitylated various SOD1 mutants derived from familial AILS patients and enhanced their degradation, but it had no effect on the stability of the wild-type SOD1. The overexpression of Dorfin protected against the toxic effects of mutant SOD1 on neural cells and reduced SOD1 inclusions. Our results indicate that Dorfin protects neurons by recognizing and then ubiquitylating mutant SOD1 proteins followed by targeting them for proteasomal degradation.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Nagoya University; Tokyo Metropolitan Institute of Medical Science; Osaka University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; ISHIGAKI, Shinsuke/I-7305-2014; Murata, Shigeo/A-1426-2010; Taniguchi, Naoyuki/I-4182-2014	Murata, Shigeo/0000-0002-3177-3503; Taniguchi, Naoyuki/0000-0001-5889-5968; Ishigaki, Shinsuke/0000-0002-9555-0659				Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bredesen DE, 1997, ANN NEUROL, V42, P135, DOI 10.1002/ana.410420202; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Emery A, 1982, HUMAN MOTOR NEURON D, P139; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hirano A, 1996, NEUROLOGY, V47, pS63, DOI 10.1212/WNL.47.4_Suppl_2.63S; Hishikawa N, 2001, NEUROPATH APPL NEURO, V27, P362, DOI 10.1046/j.1365-2990.2001.00345.x; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOWE J, 1994, J NEUROL SCI, V124, P38, DOI 10.1016/0022-510X(94)90175-9; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; MURAYAMA S, 1990, ANN NEUROL, V27, P137, DOI 10.1002/ana.410270208; Newbery HJ, 2002, TRENDS MOL MED, V8, P88, DOI 10.1016/S1471-4914(02)02283-9; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHIFFER D, 1991, J NEUROPATH EXP NEUR, V50, P463, DOI 10.1097/00005072-199107000-00007; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; TYLER HR, 1991, HDB CLIN NEUROLOGY, V59, P169; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	155	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36793	36798		10.1074/jbc.M206559200	http://dx.doi.org/10.1074/jbc.M206559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145308	hybrid			2022-12-25	WOS:000178275100130
J	Ng, HH; Xu, RM; Zhang, Y; Struhl, K				Ng, HH; Xu, RM; Zhang, Y; Struhl, K			Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; SACCHAROMYCES-CEREVISIAE; YEAST	Dot1 is a non-SET domain protein that methylates histone H3 at lysine 79, a surface-exposed residue that lies within the globular domain. In the context of a nucleosome, H3 lysine 79 is located in close proximity with lysine 123 of histone H2B, a major site for ubiquitination by Rad6. Here we show that Rad6-mediated ubiquitination of H2B lysine 123 is important for efficient methylation of lysine 79, but not lysine 36, of histone H3. in contrast, lysine 79 methylation of H3 is not required for ubiquitination of H2B. Our study provides a new example of trans-histone regulation between modifications on different histones. In addition, it suggests that Rad6 affects telonteric silencing, at least in part, by influencing methylation of histone H3.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.		xu, rui/GRX-5734-2022; Ng, Huck Hui/A-1135-2009	Zhang, Yi/0000-0002-2789-0811	NIGMS NIH HHS [GM53720, GM63067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053720, R01GM063067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	29	328	340	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34655	34657		10.1074/jbc.C200433200	http://dx.doi.org/10.1074/jbc.C200433200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167634	hybrid			2022-12-25	WOS:000178117000001
J	Fiore, E; Fusco, C; Romero, P; Stamenkovic, I				Fiore, E; Fusco, C; Romero, P; Stamenkovic, I			Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity	ONCOGENE			English	Article						ICAM-1; MMP-9; tumor; proteases; cytotoxicity	INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; RAT EMBRYO CELLS; L-SELECTIN CD62L; SERUM LEVELS; METASTATIC PHENOTYPE; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; IV COLLAGENASE	Shedding of intercellular adhesion molecule 1 (ICAM-1) is believed to play a role in tumor cell resistance to cell-mediated cytotoxicity. However, the mechanism whereby ICAM-1 is shed from the surface of tumor cells remains unclear. In this study, we have addressed the possibility that matrix metalloproteinases are implicated in ICAM-1 shedding. Our observations suggest a functional relationship between ICAM-1 and matrix metalloproteinase 9 (MMP-9) whereby ICAM-1 provides a cell surface docking mechanism for proMMP-9, which, upon activation, proteolytically cleaves the extracellular domain of ICAM-1 leading to its release from the cell surface. MMP-9-dependent shedding of ICAM-1 is found to augment tumor cell resistance to natural killer (NK) cell-mediated cytotoxicity. Taken together, our observations propose a mechanism for ICAM-1 shedding from the cell surface and provide support for MMP involvement in tumor cell evasion of immune surveillance.	Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02129 USA; Inst Univ Pathol, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Ludwig Institute for Cancer Research	Stamenkovic, I (corresponding author), Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA.		Romero, Pedro/S-6015-2017	Romero, Pedro/0000-0002-9688-2882	NCI NIH HHS [CA55735] Funding Source: Medline; NIGMS NIH HHS [GM48614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTOMONTE M, 1993, CANCER RES, V53, P3343; Aoudjit F, 1998, J IMMUNOL, V160, P2967; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Becker J C, 1995, Recent Results Cancer Res, V139, P205; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Fonsatti E, 1997, BRIT J CANCER, V76, P1255, DOI 10.1038/bjc.1997.545; GONG JH, 1994, LEUKEMIA, V8, P652; Grothey A, 1998, BRIT J CANCER, V77, P801, DOI 10.1038/bjc.1998.130; Gu B, 1998, BLOOD, V92, P946; Guo HM, 2000, CANCER RES, V60, P888; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HARNING R, 1991, CANCER RES, V51, P5003; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Huang HY, 1998, J CLIN ENDOCR METAB, V83, P1721, DOI 10.1210/jc.83.5.1721; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mitsiades N, 2000, CANCER RES, V60, P4122; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIZZOLO G, 1993, BRIT J HAEMATOL, V84, P161, DOI 10.1111/j.1365-2141.1993.tb03040.x; Sanchez-Rovira P, 1998, EUR J CANCER, V34, P394, DOI 10.1016/S0959-8049(97)10033-8; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Toth M, 1997, CANCER RES, V57, P3159; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	49	174	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5213	5223		10.1038/sj.onc.1205684	http://dx.doi.org/10.1038/sj.onc.1205684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149643				2022-12-25	WOS:000177193900003
J	Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR				Fluge, O; Bruland, O; Akslen, LA; Varhaug, JE; Lillehaug, JR			NATH, a novel gene overexpressed in papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid carcinoma; overexpression; NATH	N-TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; TETRATRICOPEPTIDE REPEAT; TPR DOMAIN; E-CADHERIN; IN-VIVO; C-MET; EXPRESSION; PROTEIN; IDENTIFICATION	In this study a replica cDNA screening (RCS) approach to identify genes differentially expressed in papillary thyroid carcinomas (PTC) was used, as compared to non-neoplastic thyroid tissues. RCS is based on hybridization of radioactively labeled cDNA probes made from the biopsies to replica membranes with 15000 clones from a PTC cDNA library. Among the genes overexpressed in PTC, and especially in clinically aggressive tumors with histologic evidence of poorly differentiated or undifferentiated areas, a novel gene named NATH was found. NATH has two mRNA species, 4.6 and 5.8 kb, both harboring the same open reading frame encoding a putative protein of 866 amino acids. The NATH protein is; homologous to yeast N-acetyltransferase (NAT)1 and to mouse NARG1 (mNAT1) and contains four tetratricopeptide repeat (TPR) domains, suggesting that NATH may be part of a multiprotein complex. Overlapping RT-PCR fragments from several PTC biopsies confirmed the NATH mRNA sequence. Northern blots, semiquantitative RT-PCR experiments, TaqMan real-time RT-PCR experiments, and in situ hybridization verified the overexpression of NATH mRNA localized to tumor cells in PTC biopsies. NATH was expressed at a low level in most human adult tissues, including the normal thyroid gland. Increased NATH expression was seen especially in a Burkitt lymphoma cell line and in adult human testis. Recombinant in vitro expression showed that NATH protein was located mainly in the cytoplasm, and was present as a single protein band of the expected 105 kDa molecular weight. Heterologous expression of NATH in the papillary carcinoma cell line (NPA) and 293 cells did not alter the cellular proliferation rate. The biological function of NATH remains to be elucidated, but the overexpression in classic PTC and especially in poorly differentiated or undifferentiated components may indicate a function in the progression of papillary thyroid carcinomas.	Univ Bergen, Dept Biol Mol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Med Genet & Mol Med, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Biol Mol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543				Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Nigris F, 1998, CANCER RES, V58, P4745; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gounalaki N, 2000, FEBS LETT, V473, P37, DOI 10.1016/S0014-5793(00)01480-0; Haugen DRF, 1996, CANCER RES, V56, P1184; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Kurozumi K, 1998, WORLD J SURG, V22, P1237, DOI 10.1007/s002689900551; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LEE FJS, 1990, J BIOL CHEM, V265, P11576; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nishida T, 2002, AM J SURG, V183, P80, DOI 10.1016/S0002-9610(01)00843-1; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Powell DJ, 1998, CANCER RES, V58, P5523; Resnick MB, 1998, MODERN PATHOL, V11, P735; Ryu S, 1997, CANCER LETT, V121, P189, DOI 10.1016/S0304-3835(97)00353-4; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Shuja S, 1999, THYROID, V9, P569, DOI 10.1089/thy.1999.9.569; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; Takano T, 1998, BRIT J CANCER, V78, P221, DOI 10.1038/bjc.1998.468; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; Trovato M, 1998, THYROID, V8, P125, DOI 10.1089/thy.1998.8.125; vonWasielewski R, 1997, CANCER RES, V57, P2501	44	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5056	5068		10.1038/sj.onc.1205687	http://dx.doi.org/10.1038/sj.onc.1205687			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140756				2022-12-25	WOS:000176975900004
J	Liu, XJ; Jana, M; Dasgupta, S; Koka, S; He, J; Wood, C; Pahan, K				Liu, XJ; Jana, M; Dasgupta, S; Koka, S; He, J; Wood, C; Pahan, K			Human immunodeficiency virus type 1 (HIV-1) Tat induces nitric-oxide synthase in human astroglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; MESSENGER-RNA EXPRESSION; RAT PRIMARY ASTROCYTES; NECROSIS-FACTOR-ALPHA; BLOOD-BRAIN-BARRIER; MICROGLIAL CELLS; PROTEIN-KINASES; GENE-EXPRESSION; GLIAL CULTURES	Human immunodeficiency virus type 1 (HIV-1) infection is known to cause neuronal injury and dementia in a significant proportion of patients. However, the mechanism by which HIV-1 mediates its deleterious effects in the brain is poorly defined. The present study was undertaken to investigate the effect of the HIV-1 tat gene on the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astroglia. Expression of the tat gene as RSV-tat but not that of the CAT gene as RSV-CAT in U373MG astroglial cells led to the induction of NO production and the expression of iNOS protein and mRNA. Induction of NO production by recombinant HIV-1 Tat protein and inhibition of RSV-tat-induced NO production by anti-Tat antibodies suggest that RSV-tat-induced production of NO is dependent on Tat and that Tat is secreted from RSV-tat-transfected astroglia. Similar to U373MG astroglial cells, RSV-tat also induced the production of NO in human primary astroglia. The induction of human iNOS promoter-derived luciferase activity by the expression of RSV-tat suggests that RSV-tat induces the transcription of iNOS. To understand the mechanism of induction of iNOS, we investigated the role of NF-kappaB and C/EBPbeta, transcription factors responsible for the induction of iNOS. Activation of NF-kappaB as well as C/EBPbeta by RSV-tat, stimulation of RSV-tat-induced production of NO by the wild type of p65 and C/EBPbeta, and inhibition of RSV-tat-induced production of NO by Deltap65, a dominant-negative mutant of p65, and DeltaC/EBPbeta, a dominant-negative mutant of C/EBPbeta, suggest that RSV-tat induces iNOS through the activation of NF-kappaB and C/EBPbeta. In addition, we show that extracellular signal-regulated kinase (ERK) but not that p38 mitogen-activated protein kinase (MAPK) is involved in RSV-tat induced production of NO. Interestingly, PD98059, an inhibitor of the ERK pathway, and DeltaERK2, a dominant-negative mutant of ERK2, inhibited RSV-tat-induced production of NO through the inhibition of C/EBPbeta but not that of NF-kappaB. This study illustrates a novel role for HIV-1 tat in inducing the expression of iNOS in human astrocytes that may participate in the pathogenesis of HIV-associated dementia.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.			Wood, Charles/0000-0002-4256-1530	NCI NIH HHS [CA76958] Funding Source: Medline; NCRR NIH HHS [P20 RR015635, P20-RR15635] Funding Source: Medline; NINDS NIH HHS [R01 NS039940, R01 NS039940-01A1, NS39940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076958] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Adamson DC, 1999, MOL MED, V5, P98, DOI 10.1007/BF03402144; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P6672, DOI 10.1073/pnas.83.18.6672; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; BERNTON EW, 1992, AIDS RES HUM RETROV, V8, P495, DOI 10.1089/aid.1992.8.495; Bhat NR, 1998, J NEUROSCI, V18, P1633; Boven LA, 1999, J IMMUNOL, V162, P4319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725, DOI 10.1002/jlb.58.6.725; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5; Glass JD, 1996, ANNU REV NEUROSCI, V19, P1; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hori K, 1999, BLOOD, V93, P1843, DOI 10.1182/blood.V93.6.1843.406k40_1843_1850; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hsu YW, 2001, J IMMUNOL, V166, P5388, DOI 10.4049/jimmunol.166.9.5388; Hu SX, 1999, J NEUROSCI, V19, P6468; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; JUNG M, 1991, VIROL LIFE SCI ADV, V10, P77; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; Kolson DL, 2000, J CLIN INVEST, V106, P11, DOI 10.1172/JCI10553; Kong LY, 1996, CELL IMMUNOL, V172, P77, DOI 10.1006/cimm.1996.0217; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY M, 1995, J NEUROVIROL, V1, P275, DOI 10.3109/13550289509114024; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muhl H, 1997, J IMMUNOL, V159, P5063; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PETITO CK, 1994, J NEUROPATH EXP NEUR, V53, P86, DOI 10.1097/00005072-199401000-00011; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; SILVA JD, 1997, J BIOL CHEM, V272, P28373; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Strelow LI, 2001, ADV VIRUS RES, V56, P355, DOI 10.1016/S0065-3527(01)56033-9; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Wiley CA, 1996, AIDS, V10, P843, DOI 10.1097/00002030-199607000-00007; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; Zhao ML, 2001, J NEUROIMMUNOL, V115, P182, DOI 10.1016/S0165-5728(00)00463-X	61	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39312	39319		10.1074/jbc.M205107200	http://dx.doi.org/10.1074/jbc.M205107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167619	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000178662500034
J	Haller, D; Russo, MP; Sartor, RB; Jobin, C				Haller, D; Russo, MP; Sartor, RB; Jobin, C			IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROINFLAMMATORY GENE-EXPRESSION; ADHESION MOLECULE-1 ICAM-1; TOLL-LIKE RECEPTOR-4; DEPENDENT TRANSCRIPTION; MUCOSAL INFLAMMATION; INVASIVE BACTERIA; P65 SUBUNIT; TNF-ALPHA; KINASE	Pathogenic and enteroinvasive bacteria have been shown to trigger the lkappaB/NF-kappaB transcriptional system and proinflammatory gene expression in epithelial cells. In this study, we investigated the molecular mechanism of the commensal Gram-negative Bacteroides vulgatus-induced NF-kappaB signal transduction in intestinal epithelial cells (IEC). We report that B. vulgatus induced interleukin-1 receptor-associated kinase-1 degradation, IkappaBalpha phosphorylation/degradation, RelA and Akt phosphorylation, as well as NF-kappaB DNA binding and NF-kappaB transcriptional activity in rat non-transformed IEC-6 cells. B. vulgatus- but not interleukin-1beta-mediated NF-kappaB transcriptional activity was inhibited by dominant negative (dn) toll-like receptor 4. Of importance, B. vulgatus induced IkappaBalpha phosphorylation/degradation and IKKalpha/beta and RelA phosphorylation in primary IEC derived from germ-free or mono-associated HLA-B27 transgenic and wild type rats, demonstrating the physiological relevance of non-pathogenic bacterial signaling in IEC. Adenoviral delivery of dn IKKbeta or treatment with wortmannin inhibited B. vulgatus-induced endogenous RelA Ser-536 and GST-p65TAD (Ser-529/Ser-536) phosphorylation as well as NF-kappaB transcriptional activity in IEC-6 cells, suggesting a critical role of IKKbeta and phosphatidylinositol 3-kinase/Akt in bacteria-induced RelA phosphorylation and NF-kappaB activation. Interestingly, B. vulgatus-induced IkappaBalpha degradation and NF-kappaB transcriptional activity in IEC transwell cultures were inhibited in the presence of lymphocytes. We propose that non-pathogenic B. vulgatus activates the NF-kappaB signaling pathway through both IkappaB degradation and RelA phosphorylation but that immune cells mediate tolerance of IEC to this commensal bacteria.	Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Div Digest Dis & Nutr, Dept Med, CB 7038,Glaxo Bldg, Chapel Hill, NC 27599 USA.	Job@med.unc.edu		Haller, Dirk/0000-0002-6977-4085	NIDDK NIH HHS [R01 DK 47700] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bhan AK, 1999, IMMUNOL REV, V169, P195, DOI 10.1111/j.1600-065X.1999.tb01316.x; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; Bocker U, 2000, J BIOL CHEM, V275, P12207, DOI 10.1074/jbc.275.16.12207; Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Cong YZ, 1998, J EXP MED, V187, P855, DOI 10.1084/jem.187.6.855; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; Elewaut D, 1999, J IMMUNOL, V163, P1457; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Erdman SE, 2001, J IMMUNOL, V166, P1443, DOI 10.4049/jimmunol.166.3.1443; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; GALANG CK, 1994, ONCOGENE, V9, P2913; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haller D, 2002, MICROBIOL IMMUNOL, V46, P195, DOI 10.1111/j.1348-0421.2002.tb02686.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; Huang GTJ, 1996, J CLIN INVEST, V98, P572, DOI 10.1172/JCI118825; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1999, J IMMUNOL, V162, P4447; Jobin C, 1999, J IMMUNOL, V163, P3474; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kim SC, 2001, GASTROENTEROLOGY, V120, pA82, DOI 10.1016/S0016-5085(01)80407-8; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; ONDERDONK AB, 1981, INFECT IMMUN, V32, P225, DOI 10.1128/IAI.32.1.225-231.1981; PANJA A, 1994, J EXP MED, V179, P943, DOI 10.1084/jem.179.3.943; Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Russo MP, 2002, AM J PHYSIOL-CELL PH, V283, pC347, DOI 10.1152/ajpcell.00166.2001; RUSSO MP, 2001, GASTROENTEROLOGY, V20, P470; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sartor RB, 1997, AM J GASTROENTEROL, V92, pS5; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	72	149	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38168	38178		10.1074/jbc.M205737200	http://dx.doi.org/10.1074/jbc.M205737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140289	Green Published, hybrid			2022-12-25	WOS:000178529600026
J	Steen, M; Dahlback, B				Steen, M; Dahlback, B			Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; ACTIVATED PROTEIN-C; BOVINE FACTOR-V; CATALYZED ACTIVATION; PROTHROMBINASE COMPLEX; FACTOR-VIII; CLEAVAGE REQUIREMENTS; ANTICOAGULANT; PLATELETS; CHAIN	To investigate the relationship between the individual thrombin cleavages in factor V (FV) and the generation of activated factor X (FXa) cofactor activity, recombinant FV mutants having the cleavage sites eliminated separately or in combination were used. After thrombin incubation, the ability of the FV variants to bind FXa and support prothrombin activation was tested. The interaction between FVa and FXa on the surface of phospholipid was investigated with a direct binding assay as well as in a functional prothrombin activation assay. FV mutated at all cleavage sites functioned poorly as FXa cofactor in prothrombin activation, the apparent K-d for FXa being similar to10 nM. Fully activated wild type FVa, yielded an apparent K, of around 0.2 nm. The Arg(709) and Arg(1018) cleavages occurred at low thrombin concentrations and decreased the Kd for FXa binding 5- and 3-fold, respectively. The Arg(1545) cleavage, being less sensitive to thrombin, decreased the Kd for FXa binding similar to20-fold. The K-m for prothrombin was the same for all FV variants, demonstrating B-domain dissociation to result in exposure of binding site for FXa but not for prothrombin. In conclusion, we demonstrate FV activation to be associated with the stepwise release of the B-domain, which results in a gradual exposure of the FXa-binding site.	Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; BRUIN T, 1987, EUR J BIOCHEM, V170, P305, DOI 10.1111/j.1432-1033.1987.tb13700.x; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; Dahlback B, 1999, J LAB CLIN MED, V133, P415, DOI 10.1016/S0022-2143(99)90018-5; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Furie B.C., 1976, Methods Enzymol, V45, P191; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JENNY RJ, 1994, HAEMOSTASIS THROMBOS, P456; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, BLOOD, V77, P2641; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; TRACY PB, 1982, BLOOD, V60, P59; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607	43	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38424	38430		10.1074/jbc.M204972200	http://dx.doi.org/10.1074/jbc.M204972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163491	hybrid			2022-12-25	WOS:000178529600056
J	Yang, WB; Kilberg, MS				Yang, WB; Kilberg, MS			Biosynthesis, intracellular targeting, and degradation of the EAAC1 glutamate/aspartate transporter in C6 glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-GLUTAMATE TRANSPORTER; HIGH-AFFINITY; RAT-BRAIN; PROTEIN; MODULATION; EXPRESSION; CULTURE	Rat C6 glioma cells were used as a model system to study the biosynthesis, intracellular targeting, and degradation of the EAAC1 transporter, a sodium-dependent glutamate/aspartate transport protein that encodes System X- (AG) activity. At steady state, nearly 70% of the EAAC1 transporter was located at the cell surface. The newly synthesized EAAC1 protein was co-translationally N-glycosylated with high mannose oligosaccharide chains that were processed into complex-type sugar chains as the protein matured. The final maturation steps for EAAC1 protein coincided with its plasma membrane arrival, which was first detected at about 45 min after the initial synthesis. The newly synthesized EAAC1 protein was protected from degradation during the maturation and targeting process, as well as during the first 5 h after plasma membrane arrival. After this initial lag period, both the newly synthesized transporter and the total cellular EAAC1 pool were degraded by first order kinetics with a half-life of 6 h. These results represent the first analysis of the synthesis and degradation of the EAAC1 amino acid transporter.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu						ALBERTS B, 1994, MOL BIOL CELL, P500; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BISSELL MG, 1974, BRAIN RES, V82, P77, DOI 10.1016/0006-8993(74)90894-4; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Davis KE, 1998, J NEUROSCI, V18, P2475; DEAS J, 1989, BRAIN RES, V483, P84, DOI 10.1016/0006-8993(89)90037-1; Dowd LA, 1996, MOL PHARMACOL, V49, P465; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; LAEMMLI UK, 1970, NATURE, V227, pC1; Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Matthews JC, 1998, AM J PHYSIOL-CELL PH, V274, pC603, DOI 10.1152/ajpcell.1998.274.3.C603; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1990, J NEUROSCI, V10, P1319; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67, DOI 10.1152/ajpcell.1996.270.1.C67	27	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38350	38357		10.1074/jbc.M202052200	http://dx.doi.org/10.1074/jbc.M202052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151387	hybrid			2022-12-25	WOS:000178529600047
J	Camire, RM				Camire, RM			Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XA; RUSSELLS VIPER VENOM; FACTOR-VA; CRYSTAL-STRUCTURE; NA+ BINDING; THERMODYNAMIC LINKAGE; ALLOSTERIC REGULATION; BOVINE TRYPSINOGEN; PROTEASE DOMAIN; CA2+ BINDING	Two loop segments (183-189 and 221-225) in the protease domain of factor Xa contribute to the formation of a Na+-binding site. Studies with factor Xa indicate that binding of a single Na+ ion to this site influences its activity by altering the S1 specificity site, and substitution of Tyr(225) with Pro diminishes sensitivity to Na+. Using full-length factor Xa(Y225P), the allosteric relationship between the Na+ site and other structural determinants in factor Xa and prothrombinase was investigated. Direct binding and kinetic measurements with probes that target the S1 specificity pocket indicate that assembly of the mutant in prothrombinase corrected the impaired binding of these probes observed with free factor Xa(Y225P). This appears to result from the apparent allosteric linkage between the factor Va, S1, and Na+-binding sites, since binding of the cofactor to membrane-bound factor Xa(Y225P) enhances binding at the S1 site and vice versa. Additional studies revealed that the internal salt bridge (Ile(16)-Asp(194)) of factor Xa(Y225P) is partially destabilized, a process that is reversible upon occupation of the S1 site. The data establish that alterations at the factor Xa Na+-binding site shift the zymogen-protease equilibrium to a more zymogen-like state, and as a consequence binding of S1-directed probes and factor Va are adversely affected. Therefore, the zymogen-like characteristics of factor Xa(Y225P) have allowed for the apparent allosteric linkage between the S1, factor Va, and Na+ sites to become evident and has provided insight into the structural transitions which accompany the conversion of factor X to factor Xa.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Div Hematol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Div Hematol, Philadelphia, PA 19104 USA.	camire@email.chop.edu			NHLBI NIH HHS [HL10343-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Bevington PR., 2002, DATA REDUCTION ERROR; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Camire RM, 2000, BLOOD, V96, p448A; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; De Cristofaro R, 1999, EUR J BIOCHEM, V260, P97, DOI 10.1046/j.1432-1327.1999.00118.x; DeCristofaro R, 1996, J MOL BIOL, V258, P190, DOI 10.1006/jmbi.1996.0242; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FURIE B, 1976, J BIOL CHEM, V251, P6807; Gomori G, 1942, J LAB CLIN MED, V27, P955; GOWDA DC, 1994, J BIOL CHEM, V269, P10644; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KIM DJ, 1994, BIOTECHNOL LETT, V16, P549, DOI 10.1007/BF00128598; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; ORTHNER CL, 1978, ARCH BIOCHEM BIOPHYS, V185, P400, DOI 10.1016/0003-9861(78)90182-0; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; PLAPP BV, 1971, J BIOL CHEM, V246, P939; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SEGAL IH, 1975, ENZYME KINETICS BEHA; STARK GR, 1960, J BIOL CHEM, V235, P3177; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUGO T, 1984, J BIOL CHEM, V259, P5705; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; Venkateswarlu D, 2002, BIOPHYS J, V82, P1190, DOI 10.1016/S0006-3495(02)75476-3; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WATZKE HH, 1995, MOL BASIS THROMBOSIS, P239; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	70	56	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37863	37870		10.1074/jbc.M203692200	http://dx.doi.org/10.1074/jbc.M203692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149252	hybrid			2022-12-25	WOS:000178447100122
J	Ehses, JA; Pelech, SL; Pederson, RA; McIntosh, CHS				Ehses, JA; Pelech, SL; Pederson, RA; McIntosh, CHS			Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GLUCAGON-LIKE PEPTIDE-1; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; GROWTH-FACTOR; B-RAF; FUNCTIONAL EXPRESSION; COUPLED RECEPTORS; LIGAND-BINDING; CELL-GROWTH	The gastrointestinal hormone, glucose-dependent insulinotropic polypeptide (GIP), is one of the most important regulators of insulin secretion following ingestion of a meal. GIP stimulates insulin secretion from the pancreatic beta-cell via its G protein-coupled receptor activation of adenylyl cyclase and other signal transduction pathways, but there is little known regarding subsequent protein kinase pathways that are activated. A screening technique was used to determine the relative abundance of 75 protein kinases in CHO-K1 cells expressing the GIP receptor and in two pancreatic beta-cell lines (PTC-3 and INS-1 (832/13) cells). This information was used to identify kinases that are potentially regulated following GIP stimulation, with a focus on GIP regulation of the ERK1/2 MAPK pathway. In CHO-K1 cells, GIP induced phosphorylation of Raf-1 (Ser-259), Mek1/2 (Ser-217/Ser-221), ERK1/2 (Thr-202 and Tyr-204), and p90 RSK (Ser-380) in a concentration-dependent manner. Activation of ERK1/2 was maximal at 4 min and was cAMP-dependent protein kinase-dependent and protein kinase C-independent. Studies using a beta-cell line (INS-1 clone 832/13) corroborated these findings, and it was also demonstrated that the ERK1/2 module could be activated by GIP in the absence of glucose. Finally, we have shown that GIP regulation of the ERK1/2 module is via Rap1 but does not involve Gbetagamma subunits nor Src tyrosine kinase, and we propose that cAMP-based regulation occurs via B-Raf in both CHO-K1 and beta-cells. These results establish the importance of GIP in the cellular regulation of the ERK1/2 module and identify a role for cAMP in coupling its G protein-coupled receptors to ERK1/2 activity in pancreatic beta-cells.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Ehses, Jan/AAK-1635-2020	Ehses, Jan/0000-0001-9066-7607				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Ehses JA, 2002, DIABETES, V51, pA339; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Hui HX, 2001, DIABETES, V50, P785, DOI 10.2337/diabetes.50.4.785; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Kubota A, 1997, BIOCHEM BIOPH RES CO, V235, P171, DOI 10.1006/bbrc.1997.6743; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PELECH SL, 2002, METHODS MOL MED SERI; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; Tourrel C, 2001, DIABETES, V50, P1562, DOI 10.2337/diabetes.50.7.1562; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	58	102	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37088	37097		10.1074/jbc.M205055200	http://dx.doi.org/10.1074/jbc.M205055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138104	hybrid			2022-12-25	WOS:000178447100025
J	Teramachi, S; Imagawa, T; Kaya, S; Taniguchi, K				Teramachi, S; Imagawa, T; Kaya, S; Taniguchi, K			Replacement of several single amino acid side chains exposed to the inside of the ATP-binding pocket induces different extents of affinity change in the high and low affinity ATP-binding sites of rat Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE; SARCOPLASMIC-RETICULUM; ION-TRANSPORT; OLIGOMERIC STRUCTURE; ALPHA-SUBUNIT; BETA-SUBUNIT; NA,K-ATPASE; NA+,K+-ATPASE; PHOSPHORYLATION; FLUORESCEIN	To investigate the relationship between the high and the low affinity ATP-binding site, which appears during the Na+/K+-ATPase reaction, four amino acids were mutated, the side chains of which are exposed to inside of the ATP-binding pocket. Six mutants, F475Y, K480A, K480E, K501A, K501E, and R544A, where the numbers correspond to the pig Na+/K+-ATPase alpha-chain, were expressed in HeLa cells. The apparent affinities were determined by high affinity ATP-dependent phosphorylation and by the low affinity activation of Na+/K+-ATPase or low affinity ATP inhibition of K+-para-nitrophenylphosphatase (pNPPase). For the mutants K480A and K501A, little affinity change was detected for either the high affinity or the low affinity effect. In contrast, the other four mutants reduced both apparent affinities. Strikingly, R544A had a 30-fold greater effect on the high affinity ATP site than the low affinity site. For the F475Y mutant, it is likely that there was a greater effect on the low affinity site than the high affinity site, but for both F475Y and K480E the affinity for the low affinity ATP effect was reduced so much that it was not possible to estimate a K-0.5. However, both the affinities for the K480E were reduced to similar to1/20. The turnover number of the Na+/K+-ATPase and the apparent affinity for Na+ and pNPP was reduced slightly or not at all for these mutants, but the turnover number of K+-pNPPase and the apparent affinity for K+ were increased. These and other data suggest the presence of only one ATP-binding site, which can change its conformation to accept ATP with a high and low affinity. The requirement of Arg-544 and possibly Lys-501 is more important in forming a high affinity ATP binding conformation, and Phe-475 and possibly Lys-480 are more important in forming the low affinity ATP binding conformation.	Hokkaido Univ, Div Chem,Dept Biol Chem, Grad Sch Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Imagawa, T (corresponding author), Hokkaido Univ, Div Chem,Dept Biol Chem, Grad Sch Sci, Kita Ku, Kita 10,Nishi 8, Sapporo, Hokkaido 0600810, Japan.	toshi@sci.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					Abe K, 2002, BIOCHEMISTRY-US, V41, P2438, DOI 10.1021/bi015622r; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Askari A, 2000, INT CONGR SER, V1207, P17; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; Ettrich R, 2001, J MOL MODEL, V7, P184; Faller LD, 2000, INT CONGR SER, V1207, P389; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; Imagawa T, 1998, JPN J PHARMACOL, V76, P415, DOI 10.1254/jjp.76.415; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nakamura J, 2002, J BIOL CHEM, V277, P24180, DOI 10.1074/jbc.M111834200; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; POST RL, 1972, J BIOL CHEM, V247, P6530; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER W, 1994, SODIUM PUMP, P332; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Tao Bernard Y., 1994, P69; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; WANG K, 1992, J BIOL CHEM, V267, P3577; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	50	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37394	37400		10.1074/jbc.M204772200	http://dx.doi.org/10.1074/jbc.M204772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138102	hybrid			2022-12-25	WOS:000178447100062
J	Yoshida, M; Kashiwagi, K; Kawai, G; Ishihama, A; Igarashi, K				Yoshida, M; Kashiwagi, K; Kawai, G; Ishihama, A; Igarashi, K			Polyamines enhance synthesis of the RNA polymerase sigma(38) subunit by suppression of an amber termination codon in the open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE-BINDING-PROTEIN; CELL-FREE SYSTEM; ESCHERICHIA-COLI; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; BOVINE LYMPHOCYTES; RIBOSOMAL-SUBUNITS; RAT-LIVER; STIMULATION; SPERMIDINE	The mechanisms by which polyamines stimulate synthesis of the RNA polymerase sigma(38) subunit in Escherichia coli were studied. Polyamine stimulation was observed only in strains in which the 33rd codon of RpoS mRNA is a UAG termination codon instead of a CAG codon for glutamine in wild-type E. coli. Readthrough of the termination codon by Gln-tRNA(supE) was stimulated by polyamines. This stimulation was found to be caused by an increase in both the level of suppressor tRNA(supE) and the binding affinity of Gln-tRNA(supE) for ribosomes. The stimulatory effect was observed with a UAG termination codon but not with UGA and UAA codons. Readthrough of the UAG termination codon at the 270th amino acid position of RpoS mRNA was also stimulated by polyamines, indicating that polyamines stimulate readthrough of a UAG codon regardless of its location within the RpoS mRNA. When cell viability of an E. coli strain having a termination codon in the 33rd position of RpoS mRNA was compared using cells cultured with or without putrescine, it was higher in cells cultured with putrescine than in cells cultured without putrescine. The level of sigma(38) subunit in the cells cultured with putrescine was higher than that in cells cultured without putrescine on days 2, 4, and 8, but the level of sigma(70) subunit was almost the same in cells cultured with or without putrescine. These results confirm that elevated expression of the rpoS gene is important for cell viability at late stationary phase.	Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Fac Engn, Dept Ind Chem, Narashino, Chiba 2758588, Japan; Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4110801, Japan	Chiba University; Chiba Institute of Technology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.			Igarashi, Kazuei/0000-0003-3751-3187				ATKINS JF, 1975, J BIOL CHEM, V250, P5688; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; Eisenstark A, 1996, FREE RADICAL BIO MED, V21, P975, DOI 10.1016/S0891-5849(96)00154-2; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HIRASHIMA A, 1979, BIOCHEM BIOPH RES CO, V88, P1046, DOI 10.1016/0006-291X(79)91514-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRYNIEWICZ MM, 1983, MOL GEN GENET, V190, P336, DOI 10.1007/BF00330661; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1978, EUR J BIOCHEM, V90, P13, DOI 10.1111/j.1432-1033.1978.tb12569.x; IGARASHI K, 1984, CANCER RES, V44, P5326; IGARASHI K, 1979, BIOCHEM BIOPH RES CO, V91, P440, DOI 10.1016/0006-291X(79)91541-9; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; ITO K, 1990, J BIOL CHEM, V265, P13036; ITO K, 1986, EUR J BIOCHEM, V156, P505, DOI 10.1111/j.1432-1033.1986.tb09609.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jishage M, 1997, J BACTERIOL, V179, P959, DOI 10.1128/jb.179.3.959-963.1997; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KAKEGAWA T, 1986, EUR J BIOCHEM, V158, P265, DOI 10.1111/j.1432-1033.1986.tb09746.x; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; Major LL, 2002, FEBS LETT, V514, P84, DOI 10.1016/S0014-5793(02)02301-3; MIYIAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63; MORCH MD, 1980, EUR J BIOCHEM, V105, P445, DOI 10.1111/j.1432-1033.1980.tb04519.x; Nagano T, 2000, BIOSCI BIOTECH BIOCH, V64, P2012, DOI 10.1271/bbb.64.2012; NAKAJIMA N, 1981, CELL, V23, P239, DOI 10.1016/0092-8674(81)90288-9; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P53; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1982, P NATL ACAD SCI-BIOL, V79, P7087, DOI 10.1073/pnas.79.23.7087; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; YANIV M, 1975, J BIOL CHEM, V250, P3243; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723	48	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37139	37146		10.1074/jbc.M206668200	http://dx.doi.org/10.1074/jbc.M206668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147703	hybrid			2022-12-25	WOS:000178447100031
J	Qian, YM; Grant, CE; Westlake, CJ; Zhang, DW; Lander, PA; Shepard, RL; Dantzig, AH; Cole, SPC; Deeley, RG				Qian, YM; Grant, CE; Westlake, CJ; Zhang, DW; Lander, PA; Shepard, RL; Dantzig, AH; Cole, SPC; Deeley, RG			Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [I-125]LY475776 and azidophenacyl-[3(5S)]glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; AMINO-ACID RESIDUE; LEUKOTRIENE C-4; DRUG-RESISTANCE; MRP GENE; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; SUBSTRATE-SPECIFICITY; CONJUGATE TRANSPORT; DEPENDENT TRANSPORT	Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-dependent transporter of structurally diverse organic anion conjugates. The protein also actively transports a number of non-conjugated chemotherapeutic drugs and certain anionic conjugates by a presently poorly understood GSH-dependent mechanism. LY475776is a newly developed I-125-labeled azido tricyclic isoxazole that binds toMRP1 with high affinity and specificity in a GSH-dependent manner. The compound has also been shown to photolabel a site in the COOH-proximal region of MRP1's third membrane spanning domain (MSD). It is presently not known where GSH interacts with the protein. Here, we demonstrate that the photactivateable GSH derivative azidophenacyl-GSH can substitute functionally for GSH in supporting the photolabeling of MRP1 by LY475776 and the transport of another GSH-dependent substrate, estrone 3-sulfate. In contrast to LY475776, azidophenacyl [S-35] photolabels both halves of the protein. Photolabeling of the COOH-proximal site can be markedly stimulated by low concentrations of estrone 3-sulfate, suggestive of cooperativity between the binding of these two compounds. We show that photolabeling of the COOH-proximal site by LY475776 and the labeling of both NH2- and COOH- proximal sites by azidophenacyl-GSH requires the cytoplasmic linker (CL3) region connecting the first and second MSDs of the protein, but not the first MSD itself. Although required for binding, CL3 is not photolabeled by azidophenacyl-GSH. Finally, we identify non-conserved amino acids in the third MSD that contribute to the high affinity with which LY475776 binds to MRP1.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Eli Lilly	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Rm A315 Botterell Hall,Stuart & George St, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Westlake, Christopher/0000-0001-7476-2014; Zhang, Dawei/0000-0001-8279-8041; Qian, Yueming/0000-0001-7340-6421				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chen ZS, 2001, INT J CANCER, V93, P107, DOI 10.1002/ijc.1290; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V222, P111, DOI 10.1006/bbrc.1996.0706; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gustafsson A, 2001, BIOCHEMISTRY-US, V40, P15835, DOI 10.1021/bi010429i; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOESCH RM, 1989, J BIOL CHEM, V264, P17712; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Keppler D, 1999, ADV ENZYME REGUL, V39, P237, DOI 10.1016/S0065-2571(98)00015-6; Kool M, 1997, CANCER RES, V57, P3537; Kool M, 1999, CANCER RES, V59, P175; KUNST M, 1989, BIOCHIM BIOPHYS ACTA, V982, P15, DOI 10.1016/0005-2736(89)90168-5; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MAO Q, 2002, IN PRESS J BIOL CHEM; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Norman BH, 2002, BIOORG MED CHEM LETT, V12, P883, DOI 10.1016/S0960-894X(02)00051-3; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; WILSON GM, 1995, PLASMID, V33, P198, DOI 10.1006/plas.1995.1021; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	54	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35225	35231		10.1074/jbc.M206058200	http://dx.doi.org/10.1074/jbc.M206058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12138119	hybrid			2022-12-25	WOS:000178117000073
J	Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S				Preobrazhenska, O; Yakymovych, M; Kanamoto, T; Yakymovych, I; Stoika, R; Heldin, CH; Souchelnytskyi, S			BRCA2 and Smad3 synergize in regulation of gene transcription	ONCOGENE			English	Article						BRCA2; Smad3; transcription	GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR; CANCER; PROMOTER; PROTEINS; ONCOPROTEIN; FAMILY; COOPERATION; INDUCTION; MUTATIONS	Smad3 is an essential component in the intracellular signaling of transforming growth factor-beta (TGFbeta), which is a potent inhibitor of tumor cell proliferation. BRCA2 is a tumor suppressor involved in early onset of breast, ovarian and prostate cancer. Both Smad3 and BRCA2 possess transcription activation domains. Here, we show that Smad3 and BRCA2 interact functionally and physically. We found that BRCA2 forms a complex with Smad3 in vitro and in vivo, and that both MH1 and MH2 domains of Smad3 contribute to the interaction. TGFbeta1 stimulates interaction of endogenous Smad3 and BRCA2 in non-transfected cells. BRCA2 co-activates Smad3-dependent transcriptional activation of luciferase reporter and expression of plasminogen activator inhibitor-1 (PAM). Smad3 increases the transcriptional activity of BRCA2 fused to the DNA-binding domain (DBD) of Gal4, and reciprocally, BRCA2 co-activates DBD-Gal4-Smad3. Thus, our results show that BRCA2 and Smad3 form a complex and synergize in regulation of transcription.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Ukrainian Acad Sci, Inst Cell Biol, UA-79005 Lvov, Ukraine; Hiroshima Univ, Sch Med, Dept Ophthalmol, Minami Ku, Hiroshima 7348551, Japan	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Cell Biology of NASU; Hiroshima University	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, SE-75124 Uppsala, Sweden.	serhiy.souchelnytskyi@licr.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Stoika, Rostyslav/0000-0001-5719-2187				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LAIHO M, 1987, J BIOL CHEM, V262, P17467; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nordling M, 1998, CANCER RES, V58, P1372; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	32	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5660	5664		10.1038/sj.onc.1205732	http://dx.doi.org/10.1038/sj.onc.1205732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165866				2022-12-25	WOS:000177442000017
J	Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL				Srivatsan, ES; Chakrabarti, R; Zainabadi, K; Pack, SD; Benyamini, P; Mendonca, MS; Yang, PK; Kang, K; Motamedi, D; Sawicki, MP; Zhuang, ZP; Jesudasan, RA; Bengtsson, U; Sun, C; Roe, BA; Stanbridge, EJ; Wilczynski, SP; Redpath, JL			Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer	ONCOGENE			English	Article						cervical cancer; tumor suppressor gene; chromosome 11q13; loss of heterozygosity; fluorescence in situ hybridization; homozygous deletion	TUMOR-SUPPRESSOR GENE; CARCINOMA CELL-LINES; HELA-CELLS; FRAGILE SITE; HOMOZYGOUS DELETIONS; ENDOCRINE TUMORS; UTERINE CERVIX; BAND 11Q13; FHIT GENE; MEN1	Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines using chromosome 11 specific probes showed deletion and translocation of 11q13 sequences in five out of eight cell lines. Fluorescence in situ hybridization (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 sequences in the HeLa cells. In order to determine whether 11q13 deletions occur in primary cervical tumors, we analysed 36 tumors using 20 different microsatellite and RFLP markers. Semi automated fluorescein based allelotyping was performed to identify loss of heterozygosity (LOH) in tumors. The results showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near MEN1, the second near D11S913, and the third near INT2 locus were observed. The smallest region of deletion overlap at the D11S913 locus was localized to a 300 Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) probes, confirmed allelic deletion in the tumors. PCR analysis further identified homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore that a putative cervical cancer tumor suppressor gene exists within the 300 kb of chromosome 11q13.	Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, Los Angeles, CA 90073 USA; Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Indiana Univ, Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA; Univ Calif Irvine, Calif Coll Med, Dept Radiat Oncol, Irvine, CA 92697 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Calif Irvine, Calif Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; City Hope Natl Med Ctr, Dept Anat Pathol, Duarte, CA 91010 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California Irvine; City of Hope	Srivatsan, ES (corresponding author), Univ Calif Los Angeles, Sch Med, VAGLAHS, Dept Surg, 10H2,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	esrivats@ucla.edu	Pack, Svetlana D./C-2020-2014; Jesudasan, Rachel/AHE-4743-2022	Pack, Svetlana D./0000-0003-3256-6626; Jesudasan, Rachel/0000-0001-9459-832X	NATIONAL CANCER INSTITUTE [R01CA019401, R55CA039312, R37CA019401, R01CA039312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER; NCI NIH HHS [CA39312, CA19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Bednarek AK, 2001, CANCER RES, V61, P8068; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Greenspan DL, 1997, CANCER RES, V57, P4692; Guo ZM, 1998, ANTICANCER RES, V18, P707; Guru SC, 1997, GENOMICS, V42, P436, DOI 10.1006/geno.1997.4783; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; Ishii H, 2001, CANCER RES, V61, P1578; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JESUDASAN RA, 1994, ANTICANCER RES, V14, P1727; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Macville M, 1999, CANCER RES, V59, P141; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; MISRA BC, 1989, AM J HUM GENET, V45, P565; MITRA AB, 1994, CANCER RES, V54, P4481; MONK BJ, 1994, DIAGN MOL PATHOL, V3, P283, DOI 10.1097/00019606-199412000-00012; Muliokandov MR, 1996, CANCER RES, V56, P197; OCADIZ R, 1987, CANCER RES, V47, P4173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Prezant TR, 1998, J CLIN ENDOCR METAB, V83, P1388, DOI 10.1210/jc.83.4.1388; Pulido HA, 2000, CANCER RES, V60, P6677; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RIOU G, 1988, ONCOGENE, V3, P329; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; SIPRASHVILI Z, 1997, CANCER RES, V57, P5207; Sozzi G, 1997, CANCER RES, V57, P5207; SREEKANTAIAH C, 1987, GYNECOL ONCOL, V28, P337, DOI 10.1016/0090-8258(87)90181-8; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; Srivatsan ES, 2000, GENE CHROMOSOME CANC, V29, P157, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1024>3.0.CO;2-P; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Tanaka C, 1998, J CLIN ENDOCR METAB, V83, P2631, DOI 10.1210/jc.83.8.2631; Venugopalan M, 1998, CANCER GENET CYTOGEN, V104, P124, DOI 10.1016/S0165-4608(97)00461-5; Wang EH, 1998, CANCER RES, V58, P4417; Wood TF, 1996, GENOMICS, V38, P166, DOI 10.1006/geno.1996.0612; Zhuang ZP, 1997, CANCER RES, V57, P4682; ZHUANG ZP, 1995, CANCER RES, V55, P467	55	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5631	5642		10.1038/sj.onc.1205698	http://dx.doi.org/10.1038/sj.onc.1205698			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165862				2022-12-25	WOS:000177442000013
J	Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY				Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY			Regulation of FGF8 expression by the androgen receptor in human prostate cancer	ONCOGENE			English	Article						FGF8; prostate cancer; androgen receptor; gene promoter	FIBROBLAST GROWTH FACTOR-8; OVER-EXPRESSION; DNA-BINDING; MAMMARY; ACTIVATION; CLONING; CELLS; FIBROBLAST-GROWTH-FACTOR-8; COACTIVATOR; INTEGRATION	Fibroblast growth factor 8 (FGF8) has been shown to play a key role in prostate carcinogenesis. It was initially cloned as an androgen induced protein in mouse mammary cancer SC3 cells. In this study, we examined if FGF8 was also regulated by the androgen receptor in human prostate cancer. FGF8b protein expression in resected clinical prostate cancer correlated closely with expression of the androgen receptor (AR). In the androgen sensitive CWR22 prostate xenograft, we observed up-regulation of FGF8b immunoreactivity in testosterone supplemented mice while castration markedly reduced its signal. Furthermore, FGF8b protein expression in AR positive LNCaP cells was similarly enhanced by androgens. The proximal promoter of the human FGF8 gene was cloned into a luciferase reporter construct (FGF8.luc). FGF8.luc activity in AR positive LNCaP and SC3 cells was increased 2.5-fold by androgens. In AR negative DU145 cells, maximal induction of FGF8.luc required both cotransfection of the AR and the presence of androgens. The anti-androgen bicalutamide completely abolished AR mediated FGF8.luc induction. Deletion constructs from FGF8.luc have further defined an active promoter region and an androgen responsive region. Nucleotide analysis of this androgen responsive region has revealed putative androgen response elements. Finally, using ChIP assays we confirmed in vivo interaction between the AR and the androgen responsive region of the FGF8 promoter. Taken together these data provide first evidence that expression of the mitogen FGF8 in prostate cancer is, at least in part, regulated by the androgen receptor at the transcriptional level.	Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.Y.Leung@ncl.ac.uk		Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Bower M, 1997, SEMIN CANCER BIOL, V8, P3, DOI 10.1006/scbi.1997.0055; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Greenwood M, 2000, HIST TODAY, V50, P3; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Koivisto PA, 1999, J PATHOL, V189, P219, DOI 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F; KOUHARA H, 1994, ONCOGENE, V9, P455; Kuriki K, 2000, CELL MOL BIOL, V46, P1147; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; Merrill RM, 1996, J NATL CANCER I, V88, P1683, DOI 10.1093/jnci/88.22.1683; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Myers RB, 1999, J UROLOGY, V161, P945, DOI 10.1016/S0022-5347(01)61826-3; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Song ZG, 2000, CANCER RES, V60, P6730; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Tanaka S, 2001, DIGEST DIS SCI, V46, P1016, DOI 10.1023/A:1010753826788; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; White RD, 1997, EUR UROL, V31, P1; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yoshiura K, 1997, AM J MED GENET, V72, P354, DOI 10.1002/(SICI)1096-8628(19971031)72:3<354::AID-AJMG21>3.3.CO;2-C	43	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5069	5080		10.1038/sj.onc.1205663	http://dx.doi.org/10.1038/sj.onc.1205663			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140757				2022-12-25	WOS:000176975900005
J	Katoh-Semba, R; Asano, T; Ueda, H; Morishita, R; Takeuchi, IK; Inaguma, Y; Kato, K				Katoh-Semba, R; Asano, T; Ueda, H; Morishita, R; Takeuchi, IK; Inaguma, Y; Kato, K			Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus	FASEB JOURNAL			English	Article						brain-derived neurotrophic factor; proliferation; granule cells; riluzole; neurogenesis	NERVE GROWTH-FACTOR; ADULT-RAT; DENTATE GYRUS; MESSENGER-RNA; NEUROGENESIS; BDNF; INCREASES; INDUCTION; RELEASE; NEURONS	The dentate gyrus of the hippocampus, generating new cells throughout life, is essential for normal recognition memory performance. Reduction of brain-derived neurotrophic factor (BDNF) in this structure impairs its functions. To elucidate the association between BDNF levels and hippocampal neurogenesis, we first conducted a search for compounds that stimulate endogenous BDNF production in hippocampal granule neurons. Among ion channel modulators tested, riluzole, a neuroprotective agent with anticonvulsant properties that is approved for treatment of amyotrophic lateral sclerosis, was highly effective as a single dose by an intraperitoneal injection, causing a rise in BDNF localized in dentate granule neurons, the hilus, and the stratum radiatum of the CA3 region. Repeated, but not single, injections resulted in prolonged elevation of hippocampal BDNF and were associated with increased numbers of newly generated cells in the granule cell layer. This appeared due to promoted proliferation rather than survival of precursor cells, many of which differentiated into neurons. Intraventricular administration of BDNF-specific antibodies blocked such riluzole effects, suggesting that BDNF increase is necessary for the promotion of precursor proliferation. Our results suggest the basis for a new strategy for treatment of memory dysfunction.	Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan		Katoh-Semba, R (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan.	katohsemba@inst-hsc.pref.aichi.jp						ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CASTREN E, 1993, NEUROREPORT, V4, P895, DOI 10.1097/00001756-199307000-00014; Conner JM, 1997, J NEUROSCI, V17, P2295; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fuchs E, 2000, EUR J NEUROSCI, V12, P2211, DOI 10.1046/j.1460-9568.2000.00130.x; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Katoh-Semba R, 1999, NEUROSCI RES, V35, P19, DOI 10.1016/S0168-0102(99)00059-0; Katoh-Semba R, 2001, J NEUROCHEM, V77, P71, DOI 10.1046/j.1471-4159.2001.00138.x; Katoh-Semba R, 1998, NEUROSCI RES, V31, P227, DOI 10.1016/S0168-0102(98)00040-6; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kinoshita S, 1999, J NEUROSCI, V19, P2122; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Li YX, 1998, J NEUROSCI, V18, P10231; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; OKADA Y, 1992, NEUROSCI LETT, V142, P233, DOI 10.1016/0304-3940(92)90380-P; Parent JM, 1997, J NEUROSCI, V17, P3727; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; WIERASZKO A, 1989, BRAIN RES, V491, P356, DOI 10.1016/0006-8993(89)90070-X; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zola SM, 2000, J NEUROSCI, V20, P451, DOI 10.1523/JNEUROSCI.20-01-00451.2000	40	136	143	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1328	+		10.1096/fj.02-0143fje	http://dx.doi.org/10.1096/fj.02-0143fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154010				2022-12-25	WOS:000176683900021
J	Dienhart, M; Pfeiffer, K; Schagger, H; Stuart, RA				Dienhart, M; Pfeiffer, K; Schagger, H; Stuart, RA			Formation of the yeast F1F0-ATP synthase dimeric complex does not require the ATPase inhibitor protein, Inh1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL F1F0-ATPASE; SACCHAROMYCES-CEREVISIAE; BOVINE F-1-ATPASE; BINDING; SUBUNIT; LACKING; GENE; IF1; PH	The yeast F1F0-ATP synthase forms dimeric complexes in the mitochondrial inner membrane and in a manner that is supported by the F-0-sector subunits, Su e and Su g. Furthermore, it has recently been demonstrated that the binding of the FFO-ATPase natural inhibitor protein to purified bovine F-1-sectors can promote their dimerization in solution (Cabezon, E., Arechaga, I., Jonathan P., Butler, G., and Walker J. E. (2000) J. Biol. Chem. 275, 28353-28355). It was unclear until now whether the binding of the inhibitor protein to the F-1 domains contributes to the process of F1F0-ATP synthase dimerization in intact mitochondria. Here we have directly addressed the involvement of the yeast inhibitor protein, Inh1, and its known accessory proteins, Stf1 and Stf2, in the formation of the yeast F1F0-ATP synthase dimer. Using mitochondria isolated from null mutants deficient in Inhl, Stf1, and Stf2, we demonstrate that formation of the F1F0-ATP synthase dimers is not adversely affected by the absence of these proteins. Furthermore, we demonstrate that the F1F0-ATPase monomers present in su e null mutant mitochondria can be as effectively inhibited by Inh1, as its dimeric counterpart in wild-type mitochondria. We conclude that dimerization of the F1F0-ATP synthase complexes involves a physical interaction of the membrane-embedded F-0 sectors from two monomeric complexes and in a manner that is independent of inhibitory activity of the Inh1 and accessory proteins.	Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA; Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany	Marquette University; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Stuart, RA (corresponding author), Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASHI A, 1988, J BIOCHEM, V104, P526, DOI 10.1093/oxfordjournals.jbchem.a122504; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1990, J BIOCHEM-TOKYO, V108, P17, DOI 10.1093/oxfordjournals.jbchem.a123154; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; ICHIKAWA N, 1990, J BIOL CHEM, V265, P6274; Iwatsuki H, 2000, J BIOCHEM-TOKYO, V128, P553, DOI 10.1093/oxfordjournals.jbchem.a022787; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lebowitz MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P342, DOI 10.1006/abbi.1996.0261; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; YOSHIDA Y, 1990, EUR J BIOCHEM, V192, P49, DOI 10.1111/j.1432-1033.1990.tb19193.x	27	52	52	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39289	39295		10.1074/jbc.M205720200	http://dx.doi.org/10.1074/jbc.M205720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167646	hybrid			2022-12-25	WOS:000178662500031
J	Weeber, EJ; Beffert, U; Jones, C; Christian, JM; Forster, E; Sweatt, JD; Herz, J				Weeber, EJ; Beffert, U; Jones, C; Christian, JM; Forster, E; Sweatt, JD; Herz, J			Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LONG-TERM POTENTIATION; APOLIPOPROTEIN-E; CONTEXTUAL FEAR; KNOCKOUT MICE; ALPHA-2-MACROGLOBULIN RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; BRAIN-DEVELOPMENT; DENDRITIC SPINE	Two apolipoprotein E (apoE) receptors, the very low density lipoprotein (VLDL) receptor and apoE receptor 2 (apoER2), are also receptors for Reelin, a signaling protein that regulates neuronal migration during brain development. In the adult brain, Reelin is expressed by GABA-ergic interneurons, suggesting a potential function as a modulator of neurotransmission. ApoE receptors have been indirectly implicated in memory and neurodegenerative disorders because their ligand, apoE, is genetically associated with Alzheimer disease. We have used knockout mice to investigate the role of Reelin and its receptors in cognition and synaptic plasticity. Mice lacking either the VLDL receptor or the apoER2 show contextual fear conditioning deficits. VLDL receptor-deficient mice also have a moderate defect in long term potentiation (LTP), and apoER2 knockouts have a pronounced one. The perfusion of mouse hippocampal slices with Reelin has no effect on baseline synaptic transmission but significantly enhances LTP in area CA1. This Reelin-dependent augmentation of LTP is abolished in VLDL receptor and apoER2 knockout mice. Our results reveal a role for Reelin in controlling synaptic plasticity in the adult brain and suggest that both of its receptors are necessary for Reelin-dependent enhancement of synaptic transmission in the hippocampus. Thus, the impairment of apoE receptor-dependent neuromodulation may contribute to cognitive impairment and synaptic loss in Alzheimer disease.	SW Texas State Univ, Dept Mol Genet, Dallas, TX 75390 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Univ Freiburg, Inst Anat, D-79001 Freiburg, Germany	Texas State University System; Texas State University San Marcos; Baylor College of Medicine; University of Freiburg	Herz, J (corresponding author), SW Texas State Univ, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Weeber, Edwin J/A-5396-2012	Beffert, Uwe/0000-0001-5877-922X; Sweatt, J. David/0000-0003-3567-485X	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762] Funding Source: Medline; NICHD NIH HHS [HD24064] Funding Source: Medline; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [NS43408, NS37444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408, P01NS037444] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYLES JK, 1986, CIRCULATION, V74, P195; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Chen C, 1996, BEHAV NEUROSCI, V110, P1177; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Drakew A, 2002, EXP NEUROL, V176, P12, DOI 10.1006/exnr.2002.7918; Flaherty DB, 2000, J NEUROSCI RES, V62, P463, DOI 10.1002/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Gu YH, 2002, J NEUROSCI, V22, P2753, DOI 10.1523/JNEUROSCI.22-07-02753.2002; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; Liu WS, 2001, P NATL ACAD SCI USA, V98, P3477, DOI 10.1073/pnas.051614698; MAHLEY RW, 1995, METABOLIC MOL BASES, V61, P1953; Morgan SL, 2001, J NEUROPHYSIOL, V86, P1289, DOI 10.1152/jn.2001.86.3.1289; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; Perez Y, 1999, NEUROSCIENCE, V90, P747, DOI 10.1016/S0306-4522(98)00531-4; Pesold C, 1999, P NATL ACAD SCI USA, V96, P3217, DOI 10.1073/pnas.96.6.3217; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1998, DEVELOPMENT, V125, P3719; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	45	473	492	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39944	39952		10.1074/jbc.M205147200	http://dx.doi.org/10.1074/jbc.M205147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167620	hybrid			2022-12-25	WOS:000178662500112
J	O'Neil, PK; Sun, GL; Yu, H; Ron, Y; Dougherty, JP; Preston, BD				O'Neil, PK; Sun, GL; Yu, H; Ron, Y; Dougherty, JP; Preston, BD			Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CONFORMATION POLYMORPHISM ANALYSIS; DNA-SYNTHESIS; STRAND TRANSFER; VECTOR REPLICATION; CELL-LINE; FIDELITY; GENE; MECHANISM; INVITRO	HIV-1 evolves rapidly, which is thought to result from one or more error-prone steps in the virus life cycle. Because HIV-1 reverse transcriptase (RT) does not possess 3'- to 5'-exonucleolytic proofreading activity and because RT has been shown to be error-prone in cell free systems, it should be an important contributor to the high rate of HIV-1 mutation. However, because RNA polymerase II (pol II) synthesizes viral RNA, it might also contribute significantly to HIV-1 mutagenesis. To assess the relative contributions of RT and RNA pol H to HIV-1 mutagenesis, a system was established to study the rate and nature of mutations in HIV-1 long terminal repeats (LTRs). Owing to the unique nature of replication at the ends of the viral genome, mutational analysis of retroviral LTRs provides an opportunity to evaluate the relative contribution of HIV-1 RT and RNA pol II to viral mutagenesis. Mutational analysis was performed on both LTRs of 215 proviruses, restricted to a single cycle of replication, employing single-stranded conformational polymorphism and DNA sequencing allowing direct identification of mutations in the absence of selection and within autologous viral sequences. A total of 21 independent mutations was identified. Ten mutations were observed in both LTRs, which could have been introduced by either RT or RNA pol II, whereas the other eleven mutations were only present in a single LTR and could only have been introduced by RT. This provides the first direct evidence that HIV-1 RT contributes significantly to HIV-1 mutagenesis and is likely to be the primary engine for HIV-1 mutagenesis. Moreover, mutations were observed at the U3-R border, but the nature of the mutations and their frequency differed from experiments performed using cell-free systems suggesting that other viral and/or cellular factors contribute to fidelity at the ends of the viral genome.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; Univ Utah, Eccles Inst Human Genet, Dept Biochem & Radiat Oncol, Salt Lake City, UT 84112 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Utah System of Higher Education; University of Utah; Rutgers State University New Brunswick	Dougherty, JP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA50777] Funding Source: Medline; NIAID NIH HHS [AI34834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050777, R29CA050777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034834, R01AI034834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Balzarini J, 2001, J VIROL, V75, P5772, DOI 10.1128/JVI.75.13.5772-5777.2001; BEBENECK K, 1993, FIDELITY RETROVIAL R, P85; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; Collins KR, 2002, J VIROL, V76, P1697, DOI 10.1128/JVI.76.4.1697-1706.2002; EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42; FITZGIBBON JE, 1993, J VIROL, V67, P7271, DOI 10.1128/JVI.67.12.7271-7275.1993; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Halvas EK, 2000, J VIROL, V74, P10349, DOI 10.1128/JVI.74.22.10349-10358.2000; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KATI WM, 1992, J BIOL CHEM, V267, P25988; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; MANSKY LM, 1994, J VIROL, V68, P494, DOI 10.1128/JVI.68.1.494-499.1994; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PARTHASARATHI S, 1995, J VIROL, V69, P7991, DOI 10.1128/JVI.69.12.7991-8000.1995; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Peeters M, 2000, AIDS, V14, pS129; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; PULSINELLI GA, 1991, J VIROL, V65, P4786, DOI 10.1128/JVI.65.9.4786-4797.1991; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Rouzine IM, 2001, MICROBIOL MOL BIOL R, V65, P151, DOI 10.1128/MMBR.65.1.151-185.2001; SEKIYA T, 1993, MUTAT RES, V288, P79, DOI 10.1016/0027-5107(93)90209-X; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Sun GL, 2001, J VIROL, V75, P11902, DOI 10.1128/JVI.75.23.11902-11906.2001; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; USHIJIMA T, 1995, MUTAT RES-ENVIR MUTA, V334, P283, DOI 10.1016/0165-1161(95)90065-9; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; WABL M, 1985, P NATL ACAD SCI USA, V82, P479, DOI 10.1073/pnas.82.2.479; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; YU H, 1992, J BIOL CHEM, V267, P10888; Yu H, 1996, J VIROL, V70, P4530, DOI 10.1128/JVI.70.7.4530-4537.1996	57	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38053	38061		10.1074/jbc.M204774200	http://dx.doi.org/10.1074/jbc.M204774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151398	hybrid			2022-12-25	WOS:000178529600012
J	Oshiro, T; Koyama, S; Sugiyama, S; Kondo, A; Onodera, Y; Asahara, T; Sabe, H; Kikuchi, A				Oshiro, T; Koyama, S; Sugiyama, S; Kondo, A; Onodera, Y; Asahara, T; Sabe, H; Kikuchi, A			Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GTPASE-ACTIVATING PROTEIN; PUTATIVE EFFECTOR PROTEIN; EH-DOMAIN; ACTIN CYTOSKELETON; REGULATE ENDOCYTOSIS; FOCAL ADHESIONS; EPSIN BINDS; MEMBRANE; EPS15	POB1 was previously identified as a RalBP1-binding protein. POB1 and RalBP1 function downstream of small G protein Ral and regulate receptor-mediated endocytosis. To look for additional functions of POB1, we screened for POB1-binding proteins using a yeast two-hybrid method and found that POB1 interacts with mouse ASAP1, which is a human PAG2 homolog. PAG2 is a paxillin-associated protein with ADP-ribosylation factor GTPase-activating protein activity. POB1 formed a complex with PAG2 in intact cells. The carboxyl-terminal region containing the proline-rich motifs of POB1 directly bound to the carboxyl-terminal region including the SH3 domain of PAG2. Substitutions of Pro(423) and Pro(426) with Ala (POB1(PA)) impaired the binding of POB1 to PAG2. Expression of PAG2 inhibited fibronectin-dependent migration and paxillin recruitment to focal contacts of CHO-IR cells. Co-expression with POB1 but not with POB1(PA) suppressed the inhibitory action of PAG2 on cell migration and paxillin localization. These results suggest that POB1 interacts with PAG2 through its proline-rich motif, thereby regulating cell migration.	Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Osaka Biosci Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan	Hiroshima University; Hiroshima University	Kikuchi, A (corresponding author), Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Onodera, Yasuhito/D-7108-2012; Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012	Onodera, Yasuhito/0000-0002-0064-9016				Andreev J, 1999, MOL CELL BIOL, V19, P2338; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Iannolo G, 1997, CANCER RES, V57, P240; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okazaki M, 1996, CANCER RES, V56, P2387; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1999, J CELL SCI, V112, P855; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Song J, 1998, J CELL SCI, V111, P2257; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	52	29	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38618	38626		10.1074/jbc.M203453200	http://dx.doi.org/10.1074/jbc.M203453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149250	hybrid			2022-12-25	WOS:000178529600079
J	Kato, U; Emoto, K; Fredriksson, C; Nakamura, H; Ohta, A; Kobayashi, T; Murakami-Murofushi, K; Kobayashi, T; Umeda, M				Kato, U; Emoto, K; Fredriksson, C; Nakamura, H; Ohta, A; Kobayashi, T; Murakami-Murofushi, K; Kobayashi, T; Umeda, M			A novel membrane protein, Ros3p, is required for phospholipid translocation across the plasma membrane in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE-LABELED PHOSPHOLIPIDS; ENDOPLASMIC-RETICULUM; TRANSBILAYER MOVEMENT; INTRACELLULAR-TRANSPORT; P-GLYCOPROTEIN; CELL-SURFACE; YEAST-CELLS; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; IDENTIFICATION	Ro09-0198 (Ro) is a tetracyclic peptide antibiotic that binds specifically to phosphatidylethanolamine (PE) and causes cytolysis. To investigate the molecular basis of transbilayer movement of PE in biological membranes, we have isolated a series of budding yeast mutants that are hypersensitive to the Ro peptide. One of the most sensitive mutants, designated ros3 (Ro-sensitive 3), showed no significant change in the cellular phospholipid composition or in the sensitivity to amphotericin B, a sterol-binding polyene macrolide antibiotic. These results suggest that the mutation of ros3 affects the PE organization on the plasma membrane, rather than PE synthesis or overall organization of the membrane structures. By functional complementation screening, we identified the gene ROS3 affected in the mutant, and we showed that the hypersensitive phenotype was caused by the defective expression of the ROS3 gene product, Ros3p, an evolutionarily conserved protein with two putative transmembrane domains. Disruption of the ROS3 gene resulted in a marked decrease in the internalization of fluorescence-labeled analogs of PE and phosphatidylcholine, whereas the uptake of fluorescence-labeled phosphatidylserine and endocytic markers was not affected. Neither expression levels nor activities of ATP-binding cassette transporters of the ros3Delta cells differed from those of wild type cells, suggesting that Ros3p is not related to the multidrug resistance activities. Immunochemical analyses of the structure and subcellular localization showed that Ros3p was a glycosylated membrane protein localized in both the plasma membrane and the endoplasmic reticulum, and that a part of Ros3p was associated with the detergentin-soluble glycolipid-enriched complexes. These results indicate that Ros3p is a membrane glycoprotein that plays an important role in the phospholipid translocation across the plasma membrane.	Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo Metropolitan Institute of Medical Science; Ochanomizu University; RIKEN; University of Tokyo	Umeda, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	umeda@rinshoken.or.jp	EMOTO, KAZUO/G-4992-2014; KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270				AOKI Y, 1994, J BIOCHEM-TOKYO, V116, P291, DOI 10.1093/oxfordjournals.jbchem.a124522; BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P183, DOI 10.1128/AAC.34.2.183; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DULIC V, 1990, J CELL SCI, V97, P517; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO S, 1984, AGR BIOL CHEM TOKYO, V48, P2181, DOI 10.1080/00021369.1984.10866492; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; Marx U, 1999, EUR J BIOCHEM, V263, P254, DOI 10.1046/j.1432-1327.1999.00497.x; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MOIR D, 1982, GENETICS, V100, P547; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nicolson T, 2000, FEBS LETT, V476, P277, DOI 10.1016/S0014-5793(00)01684-7; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SATOH O, 1990, J LIPID RES, V31, P1293; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Siegmund A, 1998, J BIOL CHEM, V273, P34399, DOI 10.1074/jbc.273.51.34399; Sitcheran R, 2000, GENETICS, V156, P963; SLEIGHT RG, 1989, J CELL SCI, V93, P363; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Umeda M, 1999, CHEM PHYS LIPIDS, V101, P81, DOI 10.1016/S0009-3084(99)00057-2; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; VANHELVOORT A, 1996, CELL, V87, P504; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WAKAMATSU K, 1990, BIOCHEMISTRY-US, V29, P113, DOI 10.1021/bi00453a013; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	53	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37855	37862		10.1074/jbc.M205564200	http://dx.doi.org/10.1074/jbc.M205564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133835	hybrid			2022-12-25	WOS:000178447100121
J	McLoughlin, P; Ehler, E; Carlile, G; Licht, JD; Schafer, BW				McLoughlin, P; Ehler, E; Carlile, G; Licht, JD; Schafer, BW			The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLZF-RAR-ALPHA; DOMAIN PROTEIN; HISTONE DEACETYLASE; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; SKELETAL-MUSCLE; FUSION PROTEINS; CELL-GROWTH; HUMAN HEART; FHL2	Members of the four-and-a-half-LIM domain (FHL) protein family, which are expressed in a tissue- and stage-specific manner, have been reported previously to function as transcriptional coactivators. One of these is the p53-inducible protein DRAL/FHL2 (where DRAL is down-regulated in rhabdomyosarcoma LIM domain protein). In this work, we identified potential binding partners for DRAL/FHL2 using an inducible yeast two-hybrid system. We present evidence of a functional interaction between the promyelocytic leukemia zinc finger protein (PLZF) and DRAL/FHL2. PLZF is a sequence-specific transcriptional repressor whose function relies on recruitment of corepressors that form part of the histone deacetylase complex involved in chromatin remodeling. DRAL/FHL2 interacts specifically with PLZF in vitro and in vivo and augments transcriptional repression mediated by PLZF. This is the first reported incidence of a bona fide FHL protein-mediated corepression and supports the notion of these proteins having a role as coregulators of tissue-specific gene expression.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; CUNY Mt Sinai Sch Med, Dept Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Schafer, BW (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland.		Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; Ehler, Elisabeth/0000-0001-5646-5964; Schafer, Beat/0000-0001-5988-2915	NCI NIH HHS [R01 CA59936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Auerbach D, 1999, MOL BIOL CELL, V10, P1297, DOI 10.1091/mbc.10.5.1297; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Kong YF, 2001, CIRCULATION, V103, P2731; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Ng EKO, 2002, J CELL BIOCHEM, V84, P556, DOI 10.1002/jcb.10041.abs; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	57	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37045	37053		10.1074/jbc.M203336200	http://dx.doi.org/10.1074/jbc.M203336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145280	hybrid			2022-12-25	WOS:000178447100020
J	Pinton, P; Tsuboi, T; Ainscow, EK; Pozzan, T; Rizzuto, R; Rutter, GA				Pinton, P; Tsuboi, T; Ainscow, EK; Pozzan, T; Rizzuto, R; Rutter, GA			Dynamics of glucose-induced membrane recruitment of protein kinase C beta II in living pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; INSULIN-SECRETION; POSSIBLE INVOLVEMENT; CA2+ OSCILLATIONS; PLASMA-MEMBRANE; TRANSLOCATION; ACTIVATION; CALCIUM; EXOCYTOSIS; EXPRESSION	The mechanisms by which glucose may affect protein kinase C (PKC) activity in the pancreatic islet beta-cell are presently unclear. By developing adenovirally expressed chimeras encoding fusion proteins between green fluorescent protein and conventional (betaII), novel (delta), or atypical (zeta) PKCs, we show that glucose selectively alters the subcellular localization of these enzymes dynamically in primary islet and MIN6 beta-cells. Examined by laser scanning confocal or total internal reflection fluorescence microscopy, elevated glucose concentrations induced oscillatory translocations of PKCbetaII to spatially confined regions of the plasma membrane. Suggesting that increases in free cytosolic Ca2+ concentrations ([Ca2+](c)) were primarily responsible, prevention of [Ca2+](c) increases with EGTA or diazoxide completely eliminated membrane recruitment, whereas elevation of cytosolic [Ca2+](c) with KCl or tolbutamide was highly effective in redistributing PKC/betaII both to the plasma membrane and to the surface of dense core secretory vesicles. By contrast, the distribution of PKCdelta.EGFP, which binds diacylglycerol but not Ca2+, was unaffected by glucose. Measurement of [Ca2+](c) immediately beneath the plasma membrane with a ratiometric "pericam," fused to synaptic vesicle-associated protein-25, revealed that depolarization induced significantly larger increases in [Ca2+](c) in this domain. These data demonstrate that nutrient stimulation of beta-cells causes spatially and temporally complex changes in the subcellular localization of PKCbetaII, possibly resulting from the generation of Ca2+ microdomains. Localized changes in PKCbetaII activity may thus have a role in the spatial control of insulin exocytosis.	Univ Bristol, Henry Wellcome Signalling Labs, Bristol BS8 1TD, Avon, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biol Membranes, I-35121 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy	University of Bristol; University of Bristol; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Ferrara; University of Ferrara	Rutter, GA (corresponding author), Univ Bristol, Henry Wellcome Signalling Labs, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk	TSUBOI, Takashi/AAD-7976-2019; Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	TSUBOI, Takashi/0000-0001-8290-2021; Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097; Rutter, Guy/0000-0001-6360-0343				Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; BOZEM M, 1987, ENDOCRINOLOGY, V121, P1025, DOI 10.1210/endo-121-3-1025; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Furukawa N, 1999, ENDOCR J, V46, P43, DOI 10.1507/endocrj.46.43; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; KHALIL RA, 1994, AM J PHYSIOL, V266, pC1544, DOI 10.1152/ajpcell.1994.266.6.C1544; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; LORD JM, 1984, BIOCHEM J, V219, P547, DOI 10.1042/bj2190547; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; ONODA K, 1990, ENDOCRINOLOGY, V126, P1235; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Quesada I, 2000, J PHYSIOL-LONDON, V525, P159, DOI 10.1111/j.1469-7793.2000.t01-1-00159.x; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SANDERSON MJ, 1995, CIBA F SYMP, V188, P175; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANIGAWA K, 1982, FEBS LETT, V138, P183, DOI 10.1016/0014-5793(82)80436-5; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2002, J BIOL CHEM, V277, P15957, DOI 10.1074/jbc.C200051200; Tsuboi T, 2001, BIOCHEM BIOPH RES CO, V282, P621, DOI 10.1006/bbrc.2001.4603; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zawalich WS, 2001, MOL CELL ENDOCRINOL, V177, P95, DOI 10.1016/S0303-7207(01)00422-1; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	65	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37702	37710		10.1074/jbc.M204478200	http://dx.doi.org/10.1074/jbc.M204478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149258	hybrid			2022-12-25	WOS:000178447100102
J	Piontek, K; Antorini, M; Choinowski, T				Piontek, K; Antorini, M; Choinowski, T			Crystal structure of a laccase from the fungus Trametes versicolor at 1.90-angstrom resolution containing a full complement of coppers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHUS-VERNICIFERA LACCASE; X-RAY-DIFFRACTION; ASCORBATE OXIDASE; ELECTRON-TRANSFER; LIGNIN; OXIDATION; SITE; PURIFICATION; ANGSTROM; STATE	Laccase is a polyphenol oxidase, which belongs to the family of blue multicopper oxidases. These enzymes catalyze the one-electron oxidation of four reducing-substrate molecules concomitant with the four-electron reduction of molecular oxygen to water. Laccases oxidize a broad range of substrates, preferably phenolic compounds. In the presence of mediators, fungal laccases exhibit an enlarged substrate range and are then able to oxidize compounds with a redox potential exceeding their own. Until now, only one crystal structure of a laccase in an inactive, type-2 copper-depleted form has been reported. We present here the first crystal structure of an active laccase containing a full complement of coppers, the complete polypeptide chain together with seven carbohydrate moieties. Despite the presence of all coppers in the new structure, the folds of the two laccases are quite similar. The coordination of the type-3 coppers, however, is distinctly different. The geometry of the trinuclear copper cluster in the Trametes versicolor laccase is similar to that found in the ascorbate oxidase and that of mammalian ceruloplasmin structures, suggesting a common reaction mechanism for the copper oxidation and the O-2 reduction. In contrast to most blue copper proteins, the type-1 copper in the T. versicolor laccase has no axial ligand and is only 3-fold coordinated. Previously, a modest elevation of the redox potential was attributed to the lack of an axial ligand. Based on the present structural data and sequence comparisons, a mechanism is presented to explain how laccases could tune their redox potential by as much as 200 MV.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Piontek, K (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, Bldg HPM,Room D 8-1-2, CH-8093 Zurich, Switzerland.	klaus.piontek@bc.biol.ethz.ch						ANDREASSON LE, 1976, BIOCHIM BIOPHYS ACTA, V438, P370, DOI 10.1016/0005-2744(76)90254-0; Antorini M, 2002, BBA-PROTEIN STRUCT M, V1594, P109, DOI 10.1016/S0167-4838(01)00289-8; ANTORINI M, 2000, THESIS ETH ZURICH SW; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; Call H-P, 1994, Patent (International), Patent No. [WO 94/29510, 9429510]; COLL PM, 1993, APPL ENVIRON MICROB, V59, P2607, DOI 10.1128/AEM.59.8.2607-2613.1993; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; EVANS CS, 1985, FEMS MICROBIOL LETT, V27, P339, DOI 10.1111/j.1574-6968.1985.tb00693.x; FAHRAEUS G, 1967, ACTA CHEM SCAND, V21, P2367, DOI 10.3891/acta.chem.scand.21-2367; FARVER O, 1993, BIOCHEMISTRY-US, V32, P7317, DOI 10.1021/bi00079a031; FEE JA, 1968, BIOCHIM BIOPHYS ACTA, V153, P299, DOI 10.1016/0005-2728(68)90175-8; GELLERSTEDT G, 1989, WOOD SCI TECHNOL, V23, P75, DOI 10.1007/BF00350609; Hough MA, 2001, ACTA CRYSTALLOGR D, V57, P355, DOI 10.1107/S0907444900010156; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li KC, 1999, APPL ENVIRON MICROB, V65, P2654; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Machonkin TE, 2001, J AM CHEM SOC, V123, P5507, DOI 10.1021/ja003975s; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 1992, EUR J BIOCHEM, V209, P597, DOI 10.1111/j.1432-1033.1992.tb17325.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Messerschmidt A., 1997, MULTICOPPER OXIDASES; NAKAMURA T, 1968, J BIOCHEM-TOKYO, V64, P267, DOI 10.1093/oxfordjournals.jbchem.a128890; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ong E, 1997, GENE, V196, P113, DOI 10.1016/S0378-1119(97)00215-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERSEN LC, 1978, BIOCHIM BIOPHYS ACTA, V526, P85, DOI 10.1016/0005-2744(78)90292-9; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAKURAI T, 1992, BIOCHEM J, V284, P681, DOI 10.1042/bj2840681; Sealey J, 1998, ENZYME MICROB TECH, V23, P422, DOI 10.1016/S0141-0229(98)00056-8; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; Xu F, 2000, APPL ENVIRON MICROB, V66, P2052, DOI 10.1128/AEM.66.5.2052-2056.2000; Xu F, 1998, BIOCHEM J, V334, P63, DOI 10.1042/bj3340063; Xu F, 1999, J BIOL CHEM, V274, P12372, DOI 10.1074/jbc.274.18.12372; Yoshida H., 1883, J AM CHEM SOC, V43, P472, DOI [10.1039/CT8834300472, DOI 10.1039/CT8834300472]; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	42	670	698	8	167	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37663	37669		10.1074/jbc.M204571200	http://dx.doi.org/10.1074/jbc.M204571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163489	hybrid			2022-12-25	WOS:000178447100097
J	del Pulgar, TG; de Ceballos, ML; Guzman, M; Velasco, G				del Pulgar, TG; de Ceballos, ML; Guzman, M; Velasco, G			Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO-SYNTHESIZED CERAMIDE; IN-VIVO; RECEPTOR; ACTIVATION; BRAIN; ANANDAMIDE; NEUROPROTECTION; IDENTIFICATION; STIMULATION; INHIBITION	Cannabinoids, the active components of marijuana and their endogenous counterparts, exert many of their actions on the central nervous system by binding to the CB, cannabinoid receptor. Different studies have shown that cannabinoids can protect neural cells from different insults. However, those studies have been performed in neurons, whereas no attention has been focused on glial cells. Here we used the pro-apoptotic lipid ceramide to induce apoptosis in astrocytes, and we studied the protective effect exerted by cannabinoids. Results show the following: (i) cannabinoids rescue primary astrocytes from C-2-ceramide-induced apoptosis in a dose- and time-dependent manner; (ii) triggering of this antiapoptotic signal depends on the phosphatidylinositol 3-kinase/protein kinase B pathway; (iii) ERK and its downstream target p90 ribosomal S6 kinase might be also involved in the protective effect of cannabinoids; and (iv) cannabinoids protect astrocytes from the cytotoxic effects of focal C-2-ceramide administration in vivo. In summary, results show that cannabinoids protect astrocytes from ceramide-induced apoptosis via stimulation of the phosphatidylinositol 3-kinase/protein kinase B pathway. These findings constitute the first evidence for an "astroprotective" role of cannabinoids.	Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; CSIC, Inst Cajal, Neurodegenerat Grp, Madrid 28002, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Velasco, G (corresponding author), Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	gvd@bbm1.ucm.es	Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020; Gomez del Pulgar, Teresa/GXV-5256-2022; de Ceballos, María L./B-4598-2008	Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; de Ceballos, María L./0000-0003-4067-9700; Guzman, Manuel/0000-0001-7475-118X				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Marsicano G, 2002, J NEUROCHEM, V80, P448, DOI 10.1046/j.0022-3042.2001.00716.x; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Pertwee RG, 2000, EXPERT OPIN INV DRUG, V9, P1553, DOI 10.1517/13543784.9.7.1553; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 2001, MOL PHARMACOL, V59, P955, DOI 10.1124/mol.59.5.955; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; van der Stelt M, 2001, J NEUROSCI, V21, P6475, DOI 10.1523/JNEUROSCI.21-17-06475.2001; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	43	129	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36527	36533		10.1074/jbc.M205797200	http://dx.doi.org/10.1074/jbc.M205797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133838	hybrid			2022-12-25	WOS:000178275100095
J	Oh, HS; Kwon, H; Sun, SK; Yang, CH				Oh, HS; Kwon, H; Sun, SK; Yang, CH			QM, a putative tumor suppressor, regulates proto-oncogene c-Yes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVEL; PROTEIN; GENE; SRC; SH3; EXPRESSION; PROLINE; BINDING; SUBUNIT; GROWTH	The QM gene encodes a 24.5 kDa ribosomal protein L10 known to be highly homologous to a Jun-binding protein (Jif-1), which inhibits the formation of Jun-Jun dimers. Here we have carried out screening with the c-Yes protein and found that a QM homologous protein showed interactions with c-Yes and other Src family members. We have found that two different regions of QM protein were associated with the SH3 domain of c-Yes. The QM protein does not contain canonical SH3 binding motifs or previously reported amino acid fragments showing interaction with SH3 domains. Several c-Yes kinase activity assays indicated that the QM protein reduced c-Yes kinase activity by 70% and that this suppression is related not only to the two SH3 binding regions but also to the C-terminal region of QM. Moreover, our autophosphorylation assays clarified that this regulation resulted from the inhibition of c-Yes autophosphorylation. Immunofluorescence studies showed that the QM proteins and c-Yes are able to interact in various tumor cell lines in vivo. The increases of the c-Yes protein and mRNA levels were detected when the QM was transfected. These results suggest that the QM protein might be a regulator for various signal transduction pathways involving SH3 domain-containing membrane proteins.	Seoul Natl Univ, Div Chem & Mol Engn, Seoul 151742, South Korea; Georgetown Univ, Inst Mol & Human Genet, Washington, DC 20057 USA	Seoul National University (SNU); Georgetown University	Yang, CH (corresponding author), Seoul Natl Univ, Div Chem & Mol Engn, Shinlim Dong San 56-1, Seoul 151742, South Korea.	chulyang@plaza.snu.ac.kr		Oh, Hyung Suk/0000-0002-1739-0389				Aghazadeh B, 1999, CHEM BIOL, V6, pR241, DOI 10.1016/S1074-5521(99)80108-2; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; BRANKA K, 1998, J BIOL CHEM, V273, P35185; BRIGGS SD, 1997, J BIOL CHEM, V172, P17699; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; EISINGER DP, 1993, BIOCHEM BIOPH RES CO, V196, P1227, DOI 10.1006/bbrc.1993.2383; Eisinger DP, 1997, MOL CELL BIOL, V17, P5136, DOI 10.1128/MCB.17.9.5136; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; FARMER AA, 1994, HUM MOL GENET, V3, P723, DOI 10.1093/hmg/3.5.723; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fujishima H, 1998, INT J CANCER, V76, P423; Green H, 2000, J BONE MINER RES, V15, P1066, DOI 10.1359/jbmr.2000.15.6.1066; Han NM, 1996, CLIN CANCER RES, V2, P1397; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; Inada H, 1997, BIOCHEM BIOPH RES CO, V230, P331, DOI 10.1006/bbrc.1996.5955; KANEKO K, 1992, HUM MOL GENET, V1, P529, DOI 10.1093/hmg/1.7.529; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Karl T, 1999, CURR GENET, V34, P419, DOI 10.1007/s002940050416; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KRUEGER J, 1991, ONCOGENE, V6, P933; Loftus TM, 1997, BIOCHEMISTRY-US, V36, P8224, DOI 10.1021/bi970288d; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Mills AA, 1999, DIFFERENTIATION, V64, P161, DOI 10.1046/j.1432-0436.1999.6430161.x; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nguyen YH, 1998, J CELL BIOCHEM, V68, P281, DOI 10.1002/(SICI)1097-4644(19980201)68:2<281::AID-JCB14>3.3.CO;2-Y; OKADA M, 1989, J BIOL CHEM, V264, P20886; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN K, 2001, J BIOL CHEM, V176, P37573; Shima T, 2001, J BIOL CHEM, V276, P42233, DOI 10.1074/jbc.M102699200; STANBRIDGE E, 1994, COLD SPRING HARB SYM, V59, P573, DOI 10.1101/SQB.1994.059.01.064; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TRON T, 1995, J BIOL CHEM, V270, P9961, DOI 10.1074/jbc.270.17.9961	40	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36489	36498		10.1074/jbc.M201859200	http://dx.doi.org/10.1074/jbc.M201859200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138090	hybrid			2022-12-25	WOS:000178275100091
J	Zhuang, SM; Wiseman, RW; Soderkvist, P				Zhuang, SM; Wiseman, RW; Soderkvist, P			Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice	ONCOGENE			English	Article						Trp53; Hras1; Catnb; 1,3-butadiene; mammary adenocarcinomas	TUMOR-SUPPRESSOR GENE; SOMATIC MUTATIONS; RAS GENES; CYCLIN D1; K-RAS; EXPRESSION; CANCER; MOUSE; ACTIVATION; P53	DNAs from 1,3-butadiene-induced mammary adenocarcinomas of B6C3F1 mice were examined for mutations in the Trp53 gene, the ras gene family and several components of the Wnt signaling pathway, including beta-catenin (Catnb), Ape and Axin. Trp53 mutations were detected in 41% (7 out of 17) of tumors. Each tumor with a Trp53 mutation also exhibited loss of the wildtype Trp53 allele, supporting the importance of Trp53 inactivation during development of these tumors. Analyses of the Hras1, Kras2 and Nras proto-oncogenes revealed Hras1 mutations in 53% (9 out of 17) of tumors. Seven of these mutations were a G-C transversion in Hras1 codon 13, consistent with a 1,3-butadiene-specific Kras2 mutation previously reported in several other tumor types. Mutation screens in Catnb exon 2, the Ape mutation cluster region and the Catnb-binding domain of the Axin gene identified Catnb missense mutations in 3 out of 17 (18%) tumors. In total, mutations of the Trp53, Hras] and/or Catnb genes were identified in 15 out of 17 1,3-butadiene-induced mammary adenocarcinomas. These results indicate that multiple genetic pathways are disrupted in chemically induced mammary tumors, and that studies in mouse models may help to understand the etiology of human breast cancers.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden; NIEHS, Lab Womens Hlth, Res Triangle Pk, NC 27709 USA	Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zhuang, SM (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.	shizh@mcb.liu.se		Zhuang, Shi-Mei/0000-0002-2512-3942				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BOS JL, 1989, CANCER RES, V49, P4682; Dashwood RH, 1998, CANCER RES, V58, P1127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; GOODROW T, 1990, CANCER RES, V50, P4818; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Melnick RL, 2001, CHEM-BIOL INTERACT, V135, P27, DOI 10.1016/S0009-2797(01)00213-7; MELNICK RL, 1990, CANCER RES, V50, P6592; Meng QX, 2000, MUTAT RES-GEN TOX EN, V464, P169, DOI 10.1016/S1383-5718(99)00157-6; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; *NAT TOX PROGR, 2000, 9 REP CARC, P14; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Osborne RJ, 2000, CANCER RES, V60, P3706; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Rubinfeld B, 1997, CANCER RES, V57, P4624; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sills RC, 2001, CHEM-BIOL INTERACT, V135, P373, DOI 10.1016/S0009-2797(01)00179-X; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOR A, 1986, LAB INVEST, V55, P603; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Zhuang SM, 1997, CANCER RES, V57, P2710	39	15	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5643	5648		10.1038/sj.onc.1205649	http://dx.doi.org/10.1038/sj.onc.1205649			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165863				2022-12-25	WOS:000177442000014
J	Linhart, B; Jahn-Schmid, B; Verdino, P; Keller, W; Ebner, C; Kraft, D; Valenta, R				Linhart, B; Jahn-Schmid, B; Verdino, P; Keller, W; Ebner, C; Kraft, D; Valenta, R			Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity	FASEB JOURNAL			English	Article						allergy; recombinant allergen; specific immunotherapy	ANTIGEN-PRESENTING CELLS; PHLEUM-PRATENSE POLLEN; FC-EPSILON-RI; HAPTEN ANTIBODY RESPONSES; HUMAN IMMUNE-RESPONSE; PERENNE RYE POLLEN; GROUP-I ALLERGENS; LOL-P-I; IGE ANTIBODIES; MAJOR ALLERGEN	Most of the 400 million grass pollen-allergic patients worldwide are co-sensitized to several unrelated grass pollen allergens. Based on frequent co-sensitization patterns determined in 200 grass pollen-allergic patients, three recombinant hybrid molecules were developed by polymerase chain reaction-based mending of cDNAs coding for the major timothy grass pollen allergens (Ph1 p 1, Ph1 p 2, Ph1 p 5, Ph1 p 6) for vaccination against grass pollen allergy. The hybrids rP2-P6, rP6-P2, and rP5-P1 contained most of the epitopes of natural grass pollen extract and induced stronger lymphoproliferative responses in cultured mononuclear cells of grass pollen-allergic patients than did equimolar mixtures of the individual allergens. Immunization of mice with the hybrids yielded higher antibody titers than did immunization with the individual allergen components or grass pollen extract, which suggests that the individual components of the hybrids can serve as molecular scaffolds for each other to enhance their immunogenicity. Antibodies induced with the hybrids in mice inhibited the binding of grass pollen-allergic patients' immunoglobulin E to each of the individual allergens and grass pollen extract and may thus represent protective antibodies. The principle of increasing the immunogenicity of antigens by engineering hybrids thereof may be applied not only for the treatment of polysensitized allergic patients but also for general vaccine development.	Univ Vienna, Sch Med, AKH,Mol Immunopathol Grp, Vienna Gen Hosp,Dept Pathophysiol, A-1090 Vienna, Austria; Karl Franzens Univ Graz, Inst Chem, Graz, Austria	University of Vienna; University of Graz	Valenta, R (corresponding author), Univ Vienna, Sch Med, AKH,Mol Immunopathol Grp, Vienna Gen Hosp,Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@akh-wien.ac.at	Keller, Walter/AAW-1501-2021	Keller, Walter/0000-0002-2261-958X; Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365				Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; BITOH S, 1993, CELL IMMUNOL, V150, P168, DOI 10.1006/cimm.1993.1188; BOAK J L, 1971, European Journal of Immunology, V1, P63, DOI 10.1002/eji.1830010202; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WW, 1975, J EXP MED, V142, P275, DOI 10.1084/jem.142.2.275; De Marino S, 1999, STRUCT FOLD DES, V7, P943; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; FERNANDEZRIVAS M, 2000, REGULATORY CONTROL S, P131; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOCKE M, 2001, FASEB J; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; FREIDHOFF LR, 1987, J ALLERGY CLIN IMMUN, V80, P646, DOI 10.1016/0091-6749(87)90283-1; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; Hoyne GF, 1999, INT ARCH ALLERGY IMM, V118, P122, DOI 10.1159/000024046; KATZ DH, 1970, J EXP MED, V132, P261, DOI 10.1084/jem.132.2.261; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; LARSEN JN, 1999, ALLERGENS ALLERGEN I, P297; LECLERC C, 1993, MOL IMMUNOL, V30, P1561, DOI 10.1016/0161-5890(93)90447-J; MITCHISON N A, 1971, European Journal of Immunology, V1, P68, DOI 10.1002/eji.1830010204; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; MYERS KR, 1995, INFECT IMMUN, V63, P168, DOI 10.1128/IAI.63.1.168-174.1995; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; PAUL WE, 1966, J EXP MED, V123, P689, DOI 10.1084/jem.123.4.689; PAUL WE, 1970, J EXP MED, V132, P283, DOI 10.1084/jem.132.2.283; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; VALENTA R, 2001, INFLAMMATORY MECH AL, P495; VANNEERVEN RJJ, 1994, IMMUNOLOGY, V82, P351; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VANREE R, 1995, ALLERGY, V50, P281; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	59	60	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1301	+		10.1096/fj.01-1012fje	http://dx.doi.org/10.1096/fj.01-1012fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154002				2022-12-25	WOS:000176683900018
J	Kojic, ZAB; Terness, P				Kojic, ZAB; Terness, P			A novel human erythrocyte glycosylphosphatidylinositol (GPI)-anchored glycoprotein ACA - Isolation, purification, primary structure determination, and molecular parameters of its lipid structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; BIOSYNTHESIS; PROTEIN; ACETYLCHOLINESTERASE; SENSITIVITY; PHOSPHATIDYLINOSITOLS; PALMITOYLATION; RESISTANCE	A method has been elaborated to isolate and purify up to homogeneity a novel membrane glycoprotein containing a glycosyl-phosphatidylinositol (GPI) anchor by means of salting out with ammonium sulfate (40-80% saturation), followed by preparative SDS-PAGE, chromatography and acetone precipitation. The preparation obtained was homogeneous upon electrophoresis in the presence of 0.1% SDS after reduction with 2-mercaptoethanol. It is protein-soluble at its isoelectrical point (pH 5.5) with molecular mass of 65,000 daltons. The isolated protein is linked to the membrane via glycosylphosphatidylinositol susceptible to cleavage by purified phospholipase C. The hydrophobic portion of the glycolipid membrane anchor of the protein was radiolabeled with the photoactivated reagent 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine and hydrolyzed with glycosyl-phosphatidylinositol-specific phospholipase C, followed by enzymatic deacetylation of the remaining lipid. Thin-layer chromatography showed that the generated radiolabeled fragment migrates with the same mobility as that of variant surface glycoprotein (VSG), obtained in the same manner. In this study we describe a novel erythrocyte membrane GPI-linked protein with the structural feature of an anchor that, in contrast to other GPI-linked erythrocyte proteins, has a non-acetylated inositol ring and diacylglycerol rather than alkylacyl glycerol as a lipid tail of the anchor.	Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kojic, ZAB (corresponding author), Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FUKOMI K, 1992, J BIOL CHEM, V264, P10988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; RATNOFF WD, 1992, CLIN EXP IMMUNOL, V87, P415; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; SAHR KE, 1990, J BIOL CHEM, V265, P4434; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; WALTER EI, 1990, J IMMUNOL, V144, P1030; WIELAND OH, 1984, METHOD ENZYMAT AN, V1, P504	25	7	10	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40472	40478		10.1074/jbc.M202416200	http://dx.doi.org/10.1074/jbc.M202416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167612	hybrid			2022-12-25	WOS:000178791400042
J	Lei, S; Liapakis, G; Xu, R; Guarnieri, F; Ballesteros, JA; Javitch, JA				Lei, S; Liapakis, G; Xu, R; Guarnieri, F; Ballesteros, JA; Javitch, JA			beta(2) adrenergic receptor activation - Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ALPHA-HELICES; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; CONFORMATIONAL-CHANGES; RHODOPSIN; SIDE; MECHANISMS; SEGMENT-6	In many rhodopsin-like G-protein-coupled receptors, agonist binding to a cluster of aromatic residues in TM6 may promote receptor activation by altering the configuration of the TM6 Pro-kink and by the subsequent movement of the cytoplasmic end of TM6 away from TM3. We hypothesized that the highly conserved Cys(6.47), in the vicinity of the conserved Pro(6.50), modulates the configuration of the aromatic cluster and the TM6 Pro-kink through specific interactions in its different rotamer configurations. In the beta2 adrenergic receptor, mutation Of Cys(6.47) to Thr, which in an alpha-helix has a different rotamer distribution from Cys and Ser, produced a constitutively active receptor, whereas the Ser mutant was similar to wild-type receptor. Use of the biased Monte Carlo technique of Conformational Memories showed that the rotamer changes among Cys/Ser/Thr(6.47), Trp(6.48), and Phe(6.52) are highly correlated, representing a rotamer "toggle switch" that may modulate the TM6 Pro-kink. Differential modulation of the accessibility Of Cys(6.47) and an engineered Cys(6.52) in wild type and a constitutively active background provides experimental support for the association of this rotamer switch with receptor activation.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Sarnoff Corp, Princeton, NJ 08543 USA; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71110, Greece	Columbia University; Columbia University; Columbia University; Sarnoff Corporation; University of Crete	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, 630 W 168th St, New York, NY 10032 USA.		Shi, Lei/AAV-1321-2020; Xu, Rui/I-8098-2012	Shi, Lei/0000-0002-4137-096X; 	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 54137, MH 57324] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BALLESTEROS JA, 1992, BIOPHYS J, V62, P107, DOI 10.1016/S0006-3495(92)81794-0; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHABRE M, 1979, PHOTOCHEM PHOTOBIOL, V30, P295, DOI 10.1111/j.1751-1097.1979.tb07150.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GUARNIERI F, 1995, J COMPUT CHEM, V16, P648, DOI 10.1002/jcc.540160512; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jayasinghe S, 2001, PROTEIN SCI, V10, P455, DOI 10.1110/ps.43501; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; RATH P, 1994, BIOPHYS J, V66, P2085, DOI 10.1016/S0006-3495(94)81003-3; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Singh J., 1992, ATLAS PROTEIN SIDE C; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; Stapley BJ, 1997, J MOL BIOL, V272, P456, DOI 10.1006/jmbi.1997.1250; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2002, METHOD ENZYMOL, V343, P329; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Zauhar RJ, 2000, BIOPOLYMERS, V53, P233, DOI 10.1002/(SICI)1097-0282(200003)53:3<233::AID-BIP3>3.3.CO;2-W	39	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40989	40996		10.1074/jbc.M206801200	http://dx.doi.org/10.1074/jbc.M206801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167654	hybrid			2022-12-25	WOS:000178791400107
J	Chelli, M; Alizon, M				Chelli, M; Alizon, M			Rescue of HIV-1 receptor function through cooperation between different forms of the CCR5 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-COUPLED RECEPTORS; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; EXTRACELLULAR DOMAINS; ENVELOPE GLYCOPROTEIN; CORECEPTOR FUNCTION; GP120; INFECTION; CXCR4	Interaction of the human immunodeficiency virus (HIV-1) envelope glycoproteins with the CCR5 chemokine receptor, a G-protein-coupled receptor, triggers a membrane fusion process and virus entry. Cooperation for HIV-1 receptor activity was observed when two forms of CCR5 were coexpressed, either the wild-type (WT) receptor and a defective mutant with deletion of the amino-terminal (NT) extracellular domain or the latter DeltaNT mutant and a human-mouse CCR5 chimera bearing the NT domain from human CCR5. Cooperation was most efficient when the two forms of CCR5 were in a 1:1 ratio. It was not observed between the CCR5 DeltaNT mutant and a chimeric receptor (5444) in which the NT domain of CCR5 was in the context of another G-protein-coupled receptor, the HIV-1 receptor CXCR4. These results suggested that physical association between two forms of CCR5 was required for their cooperation. Coimmunoprecipitation experiments in transfected cell lysates indeed showed that the DeltaNT CCR5 mutant formed oligomeric complexes with the WT CCR5 or the HMMM chimera but not with the CXCR4-derived chimera 5444. These observations suggest that the formation of CCR5 oligomers is a constitutive process independent from activation by chemokine ligands. The interaction of HIV-1 with independent subunits of CCR5 oligomers could favor the local recruitment of fusiogenic proteins and the formation of a fusion pore.	Univ Paris 05, CNRS, UMR 8404,Dept Cell Biol, INSERM,U567,Inst Cochin, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Alizon, M (corresponding author), Univ Paris 05, CNRS, UMR 8404,Dept Cell Biol, INSERM,U567,Inst Cochin, F-75014 Paris, France.		Chelli, Mario/L-7389-2015	Chelli, Mario/0000-0003-2939-6961				Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Baik SSW, 1999, VIROLOGY, V259, P267, DOI 10.1006/viro.1999.9779; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bentz J, 2000, BIOPHYS J, V78, P227, DOI 10.1016/S0006-3495(00)76587-8; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brelot A, 2001, AIDS, V15, pS3, DOI 10.1097/00002030-200100005-00002; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; Chelli M, 2001, J BIOL CHEM, V276, P46975, DOI 10.1074/jbc.M106432200; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Doms RW, 2001, AIDS, V15, pS34, DOI 10.1097/00002030-200102001-00051; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; ISSAFRAS H, 2002, IN PRESS J BIOL CHEM; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Loetscher P, 2000, Adv Immunol, V74, P127; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Milligan G, 2001, J CELL SCI, V114, P1265; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Pontow S, 2001, J VIROL, V75, P11503, DOI 10.1128/JVI.75.23.11503-11514.2001; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Trkola A, 1999, J VIROL, V73, P8966, DOI 10.1128/JVI.73.11.8966-8974.1999; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Ugolini S, 1997, J IMMUNOL, V159, P3000; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	64	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39388	39396		10.1074/jbc.M205394200	http://dx.doi.org/10.1074/jbc.M205394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154092	hybrid			2022-12-25	WOS:000178662500043
J	Constant, P; Perez, E; Malaga, W; Laneelle, MA; Saurel, O; Daffe, M; Guilhot, C				Constant, P; Perez, E; Malaga, W; Laneelle, MA; Saurel, O; Daffe, M; Guilhot, C			Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex - Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOCEROSIC ACID SYNTHASE; GRAM-NEGATIVE BACTERIA; PHENOLIC GLYCOLIPID-1; PHTHIOCEROL DIMYCOCEROSATE; SUICIDE VECTORS; BOVIS BCG; VIRULENCE; LEPRAE; SEQUENCE; MYCOSIDE	Diesters of phthiocerol and phenolphthiocerol are important virulence factors of Mycobacterium tuberculosis and Mycobacterium leprae, the two main mycobacterial pathogens in humans. They are both long-chain beta-diols, and their biosynthetic pathway is beginning to be elucidated. Although the two classes of molecules share a common lipid core, phthiocerol diesters have been found in all the strains of the M. tuberculosis complex examined although phenolphthiocerol diesters are produced by only a few groups of strains. To address the question of the origin of this diversity 8 reference strains and 10 clinical isolates of M. tuberculosis were analyzed. We report the presence of glycosylated p-hydroxybenzoic acid methyl esters, structurally related to the type-specific phenolphthiocerol glycolipids, in the culture media of all reference strains of M. tuberculosis, suggesting that the strains devoid of phenolphthiocerol derivatives are unable to elongate the putative p-hydroxybenzoic acid precursor. We also show that all the strains of M. tuberculosis examined and deficient in the production of phenolphthiocerol derivatives are natural mutants with a frameshift mutation in pks15/1 whereas a single open reading frame for pks15/1 is found in Mycobacterium bovis BCG, M. leprae, and strains of M. tuberculosis that produce phenolphthiocerol derivatives. Complementation of the H37Rv strain of M. tuberculosis, which is devoid of phenolphthiocerol derivatives, with the fused pks15/1 gene from M. bovis BCG restored phenolphthiocerol glycolipids production. Conversely, disruption of the pks15/1 gene in M. bovis BCG led to the abolition of the synthesis of type-specific phenolphthiocerol glycolipid. These data indicate that Pks15/1 is involved in the elongation of p-hydroxybenzoic acid to give p-hydroxyphenylalkanoates, which in turn are converted, presumably by the PpsA-E synthase, to phenolphthiocerol. derivatives.	CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Toulouse 3, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Daffe, M (corresponding author), CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		Olivier, Saurel/AAQ-7007-2020	Saurel, Olivier/0000-0003-1439-4103				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ancian B, 1997, J MAGN RESON, V125, P348, DOI 10.1006/jmre.1997.1112; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Belisle JT, 1998, METH MOL B, V101, P31, DOI 10.1385/0-89603-471-2:31; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; BLAKENEY AB, 1985, CARBOHYD RES, V140, P319, DOI 10.1016/0008-6215(85)85132-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHO SN, 1992, J CLIN MICROBIOL, V30, P3065, DOI 10.1128/JCM.30.12.3065-3069.1992; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1991, J INFECT DIS, V163, P161, DOI 10.1093/infdis/163.1.161; DAFFE M, 1992, J GEN MICROBIOL, V138, P131, DOI 10.1099/00221287-138-1-131; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1989, EUR J BIOCHEM, V185, P157, DOI 10.1111/j.1432-1033.1989.tb15097.x; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAFFE M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; FOURNIE JJ, 1989, INFECT IMMUN, V57, P3653, DOI 10.1128/IAI.57.11.3653-3659.1989; GAYLORD H, 1987, ANNU REV MICROBIOL, V41, P645; GOREN MB, 1974, INFECT IMMUN, V9, P150, DOI 10.1128/IAI.9.1.150-158.1974; Goren MB, 1979, TUBERCULOSIS, P62; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Le Dantec C, 2001, J BACTERIOL, V183, P2157, DOI 10.1128/JB.183.7.2157-2164.2001; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Martin Casabona N, 1989, Acta Leprol, V7 Suppl 1, P89; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; NEILL MA, 1988, J EXP MED, V167, P30, DOI 10.1084/jem.167.1.30; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; SIMONNEY N, 1995, EUR J CLIN MICROBIOL, V14, P883, DOI 10.1007/BF01691495; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THURMAN PF, 1993, EUR J BIOCHEM, V212, P705, DOI 10.1111/j.1432-1033.1993.tb17708.x; TORGALGARCIA J, 1988, ANN INST PASTEUR MIC, V139, P289, DOI 10.1016/0769-2609(88)90020-8; WATANABE M, 1994, BBA-LIPID LIPID MET, V1210, P174, DOI 10.1016/0005-2760(94)90118-X	52	192	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38148	38158		10.1074/jbc.M206538200	http://dx.doi.org/10.1074/jbc.M206538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138124	hybrid			2022-12-25	WOS:000178529600024
J	Kim, DG; You, KR; Liu, MJ; Choi, YK; Won, YS				Kim, DG; You, KR; Liu, MJ; Choi, YK; Won, YS			GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GADD153 MESSENGER-RNA; ENDOPLASMIC-RETICULUM STRESS; TRANS-RETINOIC ACID; NF-KAPPA-B; DNA-DAMAGE; GROWTH-ARREST; CARCINOMA-CELLS; GENE GADD153; CANCER-CELLS; HEPATOCELLULAR CARCINOMAS	The anticancer effects of N-(4-hydroxyphenyl)retinamide (4HPR), a potential chemopreventive or chemotherapeutic retinamide, are thought to be derived from its ability to induce apoptosis. However, the mechanism of apoptosis induced by 4HPR remains unclear. Thus, this study was designed to identify the gene(s) responsible for induction of apoptosis by 4HPR. Apoptosis was effectively induced by 4HPR in human hepatoma cells. Using the differential display-PCR method, a gene involved in the response to 4HPR was identified, and cells in which the expression of that gene was modulated were analyzed for survival, induction of apoptosis, and cell cycle. GADD153, a gene involved in growth arrest and apoptosis, was preferentially expressed in human hepatoma cells as well as in other cancer cells during 4HPR-induced apoptosis. 4HPR regulates GADD153 expression at the post-transcriptional level in Hep 3B cells and at the transcriptional and post-transcriptional levels in SK-HEP-1 cells, when assayed by in vitro transfection and mRNA stability experiments. To determine the role of the GADD153 protein overexpression that is induced by 4HPR, Hep 3B cells with ectopic overexpression. of GADD153 were found to be growth-arrested (at G,) and readily underwent apoptosis following treatment with 4HPR or even when they reached confluence. N-Acetyl-L-cysteine or GADD153 antisense significantly protected the cells from 4HPR-induced apoptosis, accompanying by the inhibition of GADD153 overexpression. Parthenolide-mediated overexpression of GADD153 resulted in enhanced 4HPR-induced apoptosis. These results suggest that GADD153 overexpression induced by 4HPR may contribute to the anticancer effects (induction of apoptosis and growth arrest) of 4HPR on cancer cells.	Chonbuk Natl Univ Med Sch & Hosp, Inst Mol Biol & Genet, Dept Internal Med, Div Gastroenterol & Hepatol, Chonju 561712, Chonbuk, South Korea; Korea Res Inst Biosci & Biotechnol, ICLAS Monitoring Subctr Korea, Taejon 305600, South Korea	Jeonbuk National University; Jeonbuk National University Hospital; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, DG (corresponding author), Chonbuk Natl Univ Med Sch & Hosp, Res Inst Clin Med, Dept Internal Med, Div Gastroenterol & Hepatol, 634-18 Keumam Dong, Chonju 561172, Chonbuk, South Korea.	daeghon@moak.chonbuk.ac.kr						BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Eastman HB, 1996, SHOCK, V6, P286, DOI 10.1097/00024382-199610000-00011; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Friedman AD, 1996, CANCER RES, V56, P3250; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Igase M, 2001, CLIN SCI, V100, P275, DOI 10.1042/CS20000220; JACKMAN J, 1994, CANCER RES, V54, P5656; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Kim MY, 2001, ONCOGENE, V20, P4568, DOI 10.1038/sj.onc.1204626; Kim R, 1999, ANTICANCER RES, V19, P1779; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; Los G, 1999, CLIN CANCER RES, V5, P1610; LUETHY JD, 1994, CANCER RES, V54, pS1902; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; OConnor PM, 1997, CANCER RES, V57, P4285; Oridate N, 1996, CLIN CANCER RES, V2, P855; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Oridate N, 1995, J CELL BIOCHEM, P80; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; PONZONI M, 1995, CANCER RES, V55, P853; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Sun SY, 1999, MOL PHARMACOL, V55, P403; Sun SY, 1999, CANCER RES, V59, P2493; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; VINCI AD, 1994, INT J CANCER, V59, P422; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; You KR, 2001, HEPATOLOGY, V34, P1119, DOI 10.1053/jhep.2001.29199; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	53	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38930	38938		10.1074/jbc.M205941200	http://dx.doi.org/10.1074/jbc.M205941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138118	hybrid			2022-12-25	WOS:000178529600116
J	Munshi, S; Kornienko, M; Hall, DL; Reid, JC; Waxman, L; Stirdivant, SM; Darke, PL; Kuo, LC				Munshi, S; Kornienko, M; Hall, DL; Reid, JC; Waxman, L; Stirdivant, SM; Darke, PL; Kuo, LC			Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase - Implication for inhibitor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; DOMAIN; TUMOR; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM; SUBSTRATE; PEPTIDE; COMPLEX; VIVO	The x-ray structure of the unactivated kinase domain of insulin-like growth factor-1 receptor (IGFRK-0P) is reported here at 2.7 Angstrom resolution. IGFRK-0P is composed of two lobes connected by a hinge region. The N-terminal lobe of the kinase is a twisted beta-sheet flanked by a single helix, and the C-terminal lobe comprises eight alpha-helices and four short beta-strands. The ATP binding pocket and the catalytic center reside at the interface of the two lobes. Despite the overall similarity to other receptor tyrosine kinases, three notable conformational modifications are observed: 1) this kinase adopts a more closed structure, with its two lobes rotated further toward each other; 2) the conformation of the proximal end of the activation loop (residues 1121-1129) is different; 3) the orientation of the nucleotide-binding loop is altered. Collectively, these alterations lead to a different ATP-binding pocket that might impact on inhibitor designs for IGFRK-0P. Two molecules of IGFRK-0P are seen in the asymmetric unit; they are associated as a dimer with their ATP binding clefts facing each other. The ordered N terminus of one monomer approaches the active site of the other, suggesting that the juxtamembrane region of one molecule could come into close proximity to the active site of the other.	Merck Res Labs, Dept Biol Struct, West Point, PA 19486 USA; Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA	Merck & Company; Merck & Company	Munshi, S (corresponding author), Merck Res Labs, Dept Biol Struct, West Point, PA 19486 USA.		ID, IMCACAT/D-5867-2014					Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; BHATAVDEKAR JM, 1994, NEOPLASMA, V41, P101; BINNS KL, 2000, SCIENCE, V275, P1640; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; DAmbrosio C, 1996, CANCER RES, V56, P4013; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; GANSLER T, 1989, AM J PATHOL, V135, P961; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 2001, MOL CELL, V8, P481, DOI 10.1016/S1097-2765(01)00350-1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MACAULAY VM, 1990, CANCER RES, V50, P2511; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; MERCOLA D, 1995, CANCER GENE THER, V2, P47; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OH Y, 1993, GROWTH REGULAT, V3, P113; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	43	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38797	38802		10.1074/jbc.M205580200	http://dx.doi.org/10.1074/jbc.M205580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138114	hybrid			2022-12-25	WOS:000178529600100
J	Pan, JL; Hinzmann, B; Yan, W; Wu, FY; Morser, J; Wu, QY				Pan, JL; Hinzmann, B; Yan, W; Wu, FY; Morser, J; Wu, QY			Genomic structures of the human and murine corin genes and functional GATA elements in their promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; HOLT-ORAM-SYNDROME; SERINE-PROTEASE; TRANSCRIPTION FACTOR; PRESSURE-OVERLOAD; CARDIAC TRANSCRIPTION; TRANSMEMBRANE DOMAIN; SEQUENCE SIMILARITY; PEPTIDE GENE; EXPRESSION	Corin is a multiple-domain type II transmembrane serine protease highly expressed in the heart. It converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regulates blood volume and pressure. Here we describe the genomic structures of the human and murine corin genes and functional analysis of their promoters. Both corin genes contain 22 exons and span >200 kb. Their intron/exon boundaries are well conserved, with most exons encoding distinct structural domains, supporting the idea that corin evolved as a result of exon duplication and rearrangement. Comparison of the 5'-flanking regions of the human and murine corin genes revealed several conserved sequences, including binding sites for TBX5, GATA, NKX2.5, and Kruppel-like transcription factors. Transfection experiments with reporter gene constructs driven by the human or murine corin 5'-flanking region indicated that the sequences from -405 to -15 in human and from -646 to -77 in mouse are sufficient to promote high levels of gene expression in murine cardiomyocytes. In contrast, these sequences produced only minimal levels of expression in HeLa cells. Within these sequences, we identified a conserved GATA element that bound to GATA-4. Mutation of the core sequence impaired both GATA-4 binding and gene expression. These data indicate that the GATA element and its binding to GATA-4 are essential for cardiac expression of the human and murine corin genes.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94806 USA; metaGen Pharmaceut, D-13347 Berlin, Germany		Pan, JL (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94806 USA.			Wu, Qingyu/0000-0003-0561-9315				APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hauschka SD, 2001, MOL CELL, V8, P1, DOI 10.1016/S1097-2765(01)00297-0; Hautala N, 2001, CIRCULATION, V103, P730; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Kawamura S, 1999, EUR J BIOCHEM, V262, P755, DOI 10.1046/j.1432-1327.1999.00431.x; Kim DR, 2001, BBA-GENE STRUCT EXPR, V1518, P204, DOI 10.1016/S0167-4781(01)00184-1; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOOP BF, 1994, NAT GENET, V7, P48, DOI 10.1038/ng0594-48; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PAN JL, 1993, J BIOL CHEM, V268, P22600; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wallrapp C, 2000, CANCER RES, V60, P2602; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; WU JP, 1989, J BIOL CHEM, V264, P6472; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	53	55	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38390	38398		10.1074/jbc.M205686200	http://dx.doi.org/10.1074/jbc.M205686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154094	hybrid			2022-12-25	WOS:000178529600052
J	Waarts, BL; Bittman, R; Wilschut, J				Waarts, BL; Bittman, R; Wilschut, J			Sphingolipid and cholesterol dependence of alphavirus membrane fusion - Lack of correlation with lipid raft formation in target liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; GPI-ANCHORED PROTEINS; CLASS-I MOLECULES; MODEL MEMBRANES; ENVELOPE GLYCOPROTEIN; LOW-PH; CELL-MEMBRANES; DOMAINS RAFTS; SINDBIS VIRUS; TRITON X-100	Semliki Forest virus (SFV) and Sindbis virus (SIN) are enveloped viruses that infect their host cells by receptor-mediated endocytosis and subsequent fusion from within acidic endosomes. Fusion of the viral envelope requires the presence of both cholesterol and sphingolipids in the target membrane. This is suggestive of a possible involvement of sphingolipid-cholesterol microdomains, or "lipid rafts," in the membrane fusion and cell entry process of the virus. In this study, large unilamellar vesicles (LUVs) were prepared from synthetic sphingolipids and sterols that vary with respect to their capacity to promote microdomain formation, as assessed by gradient flotation analysis in the presence of Triton X-100. SFV and SIN fused with LUVs irrespective of the presence or absence of Triton X-100-insoluble microdomains. These results suggest that SFV and SIN do not require the presence of lipid rafts for fusion with target membranes. Furthermore, it is not necessary for sphingolipids to reside in a detergent-insoluble complex with cholesterol to promote SFV or SIN fusion.	Univ Groningen, Dept Med Microbiol, Mol Virol Sect, NL-9713 AV Groningen, Netherlands; Acad Hosp, Dept Med Microbiol, Mol Virol Sect, NL-9713 AV Groningen, Netherlands; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Groningen; University of Groningen; City University of New York (CUNY) System; Queens College NY (CUNY)	Wilschut, J (corresponding author), Univ Groningen, Dept Med Microbiol, Mol Virol Sect, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.c.wilschut@med.rug.nl			NHLBI NIH HHS [HL-16660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016660, R37HL016660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Benting J, 1999, FEBS LETT, V462, P47, DOI 10.1016/S0014-5793(99)01501-X; Bittman R, 2000, J LIPID RES, V41, P2089; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; CHIA NC, 1993, J AM CHEM SOC, V115, P12050, DOI 10.1021/ja00078a049; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; GAROFF H, 1994, ARCH VIROL, P329; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Kielian M, 2000, Subcell Biochem, V34, P409; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; KIELIAN M, 1995, ADV VIRUS RES, V45, P113, DOI 10.1016/S0065-3527(08)60059-7; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Lu YE, 2000, J VIROL, V74, P7708, DOI 10.1128/JVI.74.17.7708-7719.2000; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; Norkin LC, 1999, IMMUNOL REV, V168, P13, DOI 10.1111/j.1600-065X.1999.tb01279.x; OMAR A, 1988, VIROLOGY, V166, P17, DOI 10.1016/0042-6822(88)90141-9; Parton RG, 1999, IMMUNOL REV, V168, P23, DOI 10.1111/j.1600-065X.1999.tb01280.x; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMABY JM, 1994, BIOCHEMISTRY-US, V33, P9135, DOI 10.1021/bi00197a016; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; Smit JM, 2001, FEBS LETT, V498, P57, DOI 10.1016/S0014-5793(01)02495-4; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WILSCHUT J, 1995, MOL MEMBR BIOL, V12, P143, DOI 10.3109/09687689509038510; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v	64	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38141	38147		10.1074/jbc.M206998200	http://dx.doi.org/10.1074/jbc.M206998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138173	hybrid			2022-12-25	WOS:000178529600023
J	Col, E; Gilquin, B; Caron, C; Khochbin, S				Col, E; Gilquin, B; Caron, C; Khochbin, S			Tat-controlled protein acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-ACETYLTRANSFERASE ACTIVITY; HIV-1 TAT; STIMULATES TRANSCRIPTION; ONCOPROTEIN E1A; P300; TRANSACTIVATOR; BINDING; INTERACTS; CBP; ACTIVATION	Human immunodeficiency virus, type 1-encoded transactivator protein Tat is known to be a substrate of and to interact with several nuclear histone acetyltransferases (HATs). Here we show that Tat is a general inhibitor of histone acetylation by cellular HATs and that for at least one of them, the CREB-binding protein (CBP), it induces a substrate selectivity. Indeed, in the presence of Tat, the acetylation of histones by CBP was severely inhibited, while that of p53 and MyoD remained unaffected. The C-terminal domain of Tat, dispensable for the activation of viral transcription, was found to be necessary and sufficient to interfere with histone acetylation. These results demonstrate that Tat is able to selectively modulate cellular protein acetylation by nuclear HATs and therefore to take over this specific signaling system in cells.	Fac Med, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, Inst Albert Bonniot, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Caron, C (corresponding author), Fac Med, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, Inst Albert Bonniot, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013; GILQUIN, Benoit/A-6234-2014	Khochbin, Saadi/0000-0002-0455-0857; GILQUIN, benoit/0000-0001-8138-7021				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakatani Y, 2002, STRUCTURE, V10, P443, DOI 10.1016/S0969-2126(02)00754-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Ren XD, 2001, J VIROL, V75, P8251, DOI 10.1128/JVI.75.17.8251-8258.2001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Weissman JD, 2001, BBA-PROTEIN STRUCT M, V1546, P156, DOI 10.1016/S0167-4838(01)00135-2	29	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37955	37960		10.1074/jbc.M206694200	http://dx.doi.org/10.1074/jbc.M206694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12154097	hybrid			2022-12-25	WOS:000178447100133
J	Ohashi, S; Koike, K; Omori, A; Ichinose, S; Ohara, S; Kobayashi, S; Sato, TA; Anzai, K				Ohashi, S; Koike, K; Omori, A; Ichinose, S; Ohara, S; Kobayashi, S; Sato, TA; Anzai, K			Identification of mRNA/protein (mRNP) complexes containing Pur alpha, mStaufen, Fragile X Protein, and myosin Va and their association with rough endoplasmic reticulum equipped with a kinesin motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; MENTAL-RETARDATION PROTEIN; SINGLE-STRANDED-DNA; CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; ACTIN-BASED TRANSPORT; MESSENGER-RNA; BC1 RNA; RIBONUCLEOPROTEIN PARTICLE; INHIBITS TRANSLATION	Puralpha, which is involved in diverse aspects of cellular functions, is strongly expressed in neuronal cytoplasm. Previously, we have reported that this protein controls BC1 RNA expression and its subsequent distribution within dendrites and that Puralpha is associated with polyribosomes. Here, we report that, following treatment with EDTA, Puralpha was released from polyribosomes in mRNA/protein complexes (mRNPs), which also contained mStaufen, Fragile X Mental Retardation Protein (FMRP), myosin Va, and other proteins with unknown functions. As the coimmunoprecipitation of these proteins by an anti-Puralpha antibody was abolished by RNase treatment, Puralpha may assist mRNP assembly in an RNA-dependent manner and be involved in targeting mRNPs to polyribosomes in cooperation with other RNA-binding proteins. The immunoprecipitation of mStaufen- and FMRP-containing mRNPs provided additional evidence that the anti-Puralpha detected structurally or functionally related mRNA subsets, which are distributed in the somatodendritic compartment. Furthermore, mRNPs appear to reside on rough endoplasmic reticulum equipped with a kinesin motor. Based on our present findings, we propose that this rough endoplasmic reticulum structure may form the molecular machinery that mediates and regulates multistep transport of polyribosomes along microtubules and actin filaments, as well as localized translation in the somatodendritic compartment.	Nihon Univ, Div Biochem, Coll Pharm, Chiba 2748555, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Kitasato Univ, Dept Biochem, Sch Med, Kanagawa 2288555, Japan; Columbia Univ, Dept Otolaryngol Pathol, New York, NY 10032 USA	Nihon University; Kitasato University; Columbia University	Anzai, K (corresponding author), Nihon Univ, Div Biochem, Coll Pharm, Chiba 2748555, Japan.							ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DESMOND NL, 1990, SYNAPSE, V5, P139, DOI 10.1002/syn.890050208; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Evans LL, 1998, J CELL SCI, V111, P2055; Feng Y, 1997, J NEUROSCI, V17, P1539; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FIFKOVA E, 1992, INT REV CYTOL, V139, P267, DOI 10.1016/S0074-7696(08)61414-X; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V277, P341, DOI 10.1006/bbrc.2000.3683; KOBAYASHI S, 1991, J BIOL CHEM, V266, P4726; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Latham VM, 2001, CURR BIOL, V11, P1010, DOI 10.1016/S0960-9822(01)00291-3; Li YM, 2001, BIOL PHARM BULL, V24, P231, DOI 10.1248/bpb.24.231; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marion RM, 1999, MOL CELL BIOL, V19, P2212; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Muramatsu T, 1998, BIOCHEM BIOPH RES CO, V247, P7, DOI 10.1006/bbrc.1998.8657; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Nadano D, 2000, JPN J CANCER RES, V91, P802, DOI 10.1111/j.1349-7006.2000.tb01017.x; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Severt WL, 1999, J CELL SCI, V112, P3691; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; STEWARD O, 1982, J NEUROSCI, V2, P284; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	54	184	194	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37804	37810		10.1074/jbc.M203608200	http://dx.doi.org/10.1074/jbc.M203608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147688	hybrid			2022-12-25	WOS:000178447100115
J	Villalonga, P; Lopez-Alcala, C; Chiloeches, A; Gil, J; Marais, R; Bachs, O; Agell, N				Villalonga, P; Lopez-Alcala, C; Chiloeches, A; Gil, J; Marais, R; Bachs, O; Agell, N			Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; CELL-CYCLE; BINDING; PHOSPHORYLATION; PATHWAYS; CLEAVAGE; CALCIUM; GAP	We have shown previously (Villalonga, P., Lopez-Alcala, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J., Marais, R., Marshall, C. J., Bachs, 0., and Agell, N. (2001) Mol. Cell. Biol. 21,7345-7354) that calmodulin negatively regulates Ras activation in fibroblasts. Hence, anti-calmodulin drugs (such as W13, trifluoroperazine, or W7) are able to induce Ras/ERK pathway activation under low levels of growth factors. We show here that cell treatment with protein kinase C (PKC) inhibitors abolishes W13-induced activation of Ras, Raf-1, and ERK. Consequently, PKC activity is essential for achieving the synergism between calmodulin inhibition and growth factors to activate Ras. Furthermore, whereas the activation of PKC by 12-O-tetradecanoylphorbol-13-acetate (TPA) does not induce Ras activation in 3T3 cells, activation is observed if calmodulin is simultaneously inhibited. This indicates that calmodulin is preventing Ras activation by PKC. Treatment of cells with epidermal growth factor receptor or platelet-derived growth factor receptor tyrosine kinase inhibitors does not abrogate the activation of Ras by calmodulin inhibition. This implies that epidermal growth factor receptor and platelet-derived growth factor receptor tyrosine kinase activities are dispensable for the activation of Ras by TPA plus W13, and, therefore, Ras activation is not a consequence of the transactivation of those receptors by the combination of the anti-calmodulin drug plus TPA. Furthermore, K-Ras, the isoform previously shown to bind to calmodulin, is the only one activated by TPA when calmodulin is inhibited. These data suggest that direct interaction between K-Ras and calmodulin may account for the inability of PKC to activate Ras in 3T3 fibroblasts. In vitro experiments showed that the phosphorylation of K-Ras by PKC was inhibited by calmodulin, suggesting that calmodulin-dependent modulation of K-Ras phosphorylation by PKC could be the mechanism underlying K-Ras activation in fibroblasts treated with TPA plus W13.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; Inst Canc Res, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Barcelona, Dept Ciencias Fisiol 2, Barcelona 08907, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Barcelona	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, C Casanova 143, Barcelona 08036, Spain.	agell@medicina.ub.es	Agell, Neus/E-9640-2016; Chiloeches, Antonio/Z-5993-2019; Villalonga, Priam/K-4350-2014	Agell, Neus/0000-0002-1205-6074; Villalonga, Priam/0000-0002-7190-6884; Marais, Richard/0000-0001-7484-4183; Antonio, Chiloeches Galvez/0000-0001-7162-330X; Gil, Joan/0000-0002-3686-3903				Agell N, 1998, CELL CALCIUM, V23, P115, DOI 10.1016/S0143-4160(98)90109-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Choudhury S, 1996, CANCER LETT, V109, P149, DOI 10.1016/S0304-3835(96)04439-4; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; Coffer PJ, 1998, BIOCHEM J, V335, P1; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; HERGET T, 1994, EUR J BIOCHEM, V225, P549, DOI 10.1111/j.1432-1033.1994.t01-1-00549.x; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001	51	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37929	37935		10.1074/jbc.M202245200	http://dx.doi.org/10.1074/jbc.M202245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151388	Green Published, hybrid			2022-12-25	WOS:000178447100130
J	Askari, B; Carroll, MA; Capparelli, M; Kramer, F; Gerrity, RG; Bornfeldt, KE				Askari, B; Carroll, MA; Capparelli, M; Kramer, F; Gerrity, RG; Bornfeldt, KE			Oleate and linoleate enhance the growth-promoting effects of insulin-like growth factor-I through a phospholipase D-dependent pathway in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIPOPROTEIN-LIPASE; OLEIC-ACID; ANGIOTENSIN-II; ATHEROSCLEROSIS; ACTIVATION; MIGRATION; METABOLISM; EXPRESSION; GLUCOSE	Diabetes causes accelerated atherosclerosis and subsequent cardiovascular disease through mechanisms that are poorly understood. We have previously shown, using a porcine model of diabetes-accelerated atherosclerosis, that diabetes leads to an increased accumulation and proliferation of arterial smooth muscle cells in atherosclerotic lesions and that this is associated with elevated levels of plasma triglycerides. We therefore used the same model to investigate the mechanism whereby diabetes may stimulate smooth muscle cell proliferation. We show that lesions from diabetic pigs fed a cholesterol-rich diet contain abundant insulin-like growth factor-I (IGF-I), in contrast to lesions from nondiabetic pigs. Furthermore, two fatty acids common in triglycerides, oleate and linoleate, enhance the growth-promoting effects of IGF-I in smooth muscle cells isolated from these animals. These fatty acids accumulate predominantly in the membrane phospholipid pool; oleate accumulates preferentially in phosphatidylcholine and phosphatidylethanolamine, whereas linoleate is found mainly in phosphatidylethanolamine. The growth-promoting effects of oleate and linoleate depend on phospholipid hydrolysis by phospholipase D and subsequent generation of diacylglycerol. Thus, concurrent increases in levels of IGF-I and triglyceride-derived oleate and linoleate in lesions may contribute to accumulation and proliferation of smooth muscle cells and lesion progression in diabetes-accelerated atherosclerosis.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	University of Washington; University of Washington Seattle; New York Medical College; University System of Georgia; Augusta University	Bornfeldt, KE (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.		Bornfeldt, Karin/AAI-2241-2019	Bornfeldt, Karin/0000-0001-9208-6523	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, R01HL062887, R01HL055789, R37HL025394, P01HL034300] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312, HL25394, HL34300, HL55789, HL62887] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen TJ, 2001, J VASC RES, V38, P276, DOI 10.1159/000051056; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Carroll MA, 1997, KIDNEY INT, V51, P1696, DOI 10.1038/ki.1997.234; Clee SM, 2000, J LIPID RES, V41, P521; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Du XN, 2001, BIOCHEM J, V357, P275, DOI 10.1042/0264-6021:3570275; Erkelens DW, 1998, EUR HEART J, V19, pH27; Esenabhalu VE, 2002, BRIT J PHARMACOL, V135, P143, DOI 10.1038/sj.bjp.0704440; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; Godessart N, 1996, J INVEST DERMATOL, V107, P726, DOI 10.1111/1523-1747.ep12365616; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; Greene EL, 2001, HYPERTENSION, V37, P308, DOI 10.1161/01.HYP.37.2.308; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; Kwok CF, 2000, METABOLISM, V49, P1386, DOI 10.1053/meta.2000.17719; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; Lu G, 1998, HYPERTENSION, V31, P978, DOI 10.1161/01.HYP.31.4.978; Lu G, 1998, HYPERTENSION, V32, P1003, DOI 10.1161/01.HYP.32.6.1003; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; RYDZEWSKA G, 1995, PANCREAS, V10, P59, DOI 10.1097/00006676-199501000-00008; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; SMITH EB, 1980, ATHEROSCLEROSIS, V37, P579, DOI 10.1016/0021-9150(80)90065-9; Suzuki LA, 2001, DIABETES, V50, P851, DOI 10.2337/diabetes.50.4.851; Van Eck M, 2000, ARTERIOSCL THROM VAS, V20, pE53, DOI 10.1161/01.ATV.20.9.e53; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	36	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36338	36344		10.1074/jbc.M205112200	http://dx.doi.org/10.1074/jbc.M205112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138107	hybrid			2022-12-25	WOS:000178275100071
J	Fuda, H; Lee, YC; Shimizu, C; Javitt, NB; Strott, CA				Fuda, H; Lee, YC; Shimizu, C; Javitt, NB; Strott, CA			Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HUMAN LIVER; SULFATE; NEUROSTEROIDS; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION; CLONING	As a result of an alternative exon 1, the gene for human hydroxysteroid sulfotransferase (SULTB1) encodes for two peptides differing only at their amino termini. The SULT2B1b isoform preferentially sulfonates cholesterol. Conversely, the SULT2B1a isoform avidly sulfonates pregnenolone but not cholesterol. The outstanding structural feature that distinguishes the SULT2B1 isoforms from the prototypical SLTLT2A1 isozyme is the presence of extended amino- and carboxyl-terminal ends in the former. Investigating the functional significance of this unique characteristic reveals that removal of 53 amino acids from the relatively long carboxyl-terminal end that is common to both SULT2B1 isoforms has no effect on the catalytic activity of either isoform. On the other hand, removal of 23 amino acids from the amino-terminal end that is unique to SULT2B1b results in loss of cholesterol sulfotransferase activity, whereas removal of 8 amino acids from the amino-terminal end that is unique to SULT2B1a has no effect on pregnenolone sulfotransferase activity. Deletion analysis along with site-directed mutagenesis of SLTLT2B1b reveal that the amino acid segment 19-23 residues from the amino terminus and particularly isoleucines at positions 21 and 23 are crucial for cholesterol catalysis. In the gene for SULT2B1, exon 1B encodes for only the unique amino-terminal region of SULT2B1b; however, exon 1A encodes for the unique amino-terminal end of SULT2B1a plus an additional 48 amino acids. Thus, if the gene for SULT2B1 employs exon 1B, cholesterol sulfotransferase is synthesized, whereas if exon 1A is used, pregnenolone sulfotransferase is produced.	NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strott, CA (corresponding author), NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	chastro@mail.nih.gov		Javitt, Norman B/0000-0001-9265-3508	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000194] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKSOY IA, 1993, DRUG METAB DISPOS, V21, P268; Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Fuda H, 2002, BIOCHEM J, V365, P497, DOI 10.1042/BJ20020044; Geese WJ, 2001, BIOCHEM BIOPH RES CO, V288, P280, DOI 10.1006/bbrc.2001.5746; Hanley K, 2001, J LIPID RES, V42, P390; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; HER C, 1995, GENOMICS, V29, P16, DOI 10.1006/geno.1995.1210; Javitt NB, 2001, ENDOCRINOLOGY, V142, P2978, DOI 10.1210/en.142.7.2978; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; Kuroki T, 2000, MUTAT RES-REV MUTAT, V462, P189, DOI 10.1016/S1383-5742(00)00036-3; Meloche CA, 2001, J STEROID BIOCHEM, V77, P261, DOI 10.1016/S0960-0760(01)00064-4; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; Sakakibara Y, 1998, BIOCHEM BIOPH RES CO, V247, P681, DOI 10.1006/bbrc.1998.8872; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Yoshinari K, 2001, J BIOCHEM MOL TOXIC, V15, P67, DOI 10.1002/jbt.1	25	72	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36161	36166		10.1074/jbc.M207165200	http://dx.doi.org/10.1074/jbc.M207165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145317	hybrid			2022-12-25	WOS:000178275100051
J	Hicks, SW; Machamer, CE				Hicks, SW; Machamer, CE			The NH2-terminal domain of golgin-160 contains both Golgi and nuclear targeting information	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL PROTEINS; MOLECULAR CHARACTERIZATION; MEMBRANE-PROTEIN; MATRIX PROTEIN; BREFELDIN-A; CYTOPLASMIC DOMAIN; COMPLEX; GM130; IDENTIFICATION; APPARATUS	Golgin-160 is a member of the golgin family of Golgilocalized membrane proteins. The COOH-terminal twothirds of golgin-160 is predicted to form a coiled-coil, with an NH2-terminal "head" domain. To identify the Golgi targeting information in golgin-160, full-length and deletion constructs tagged with green fluorescent protein were generated. The head domain alone was targeted to the Golgi complex in the absence of assembly with endogenous golgin-160. Further truncations from both ends of the head domain narrowed the Golgi targeting information to 85 amino acids between residues 172 and 257. Surprisingly, certain truncations of the head domain also specifically accumulated in the nucleus. Both a nuclear localization signal (masked in the full-length protein) and information for nuclear retention contributed to the nuclear localization of these truncations. Because the golgin-160 head is cleaved by caspases during apoptosis, we examined the localization of epitope-tagged proteins corresponding to all potential caspase cleavage fragments. Our data suggest that three of six fragments could be targeted to the nucleus, provided that they are released from Golgi membranes after cleavage. The finding that both Golgi and nuclear targeting information is present in the same region of golgin-160 suggests that this protein may have more than one function.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Machamer, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.		Hicks, Stuart/R-9815-2019		NIGMS NIH HHS [GM42522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; Beck KA, 1997, J CELL SCI, V110, P1239; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; De Matteis MA, 2000, J CELL SCI, V113, P2331; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; Infante C, 1999, J CELL BIOL, V145, P83, DOI 10.1083/jcb.145.1.83; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsukuma S, 1999, MAMM GENOME, V10, P1, DOI 10.1007/s003359900932; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; MOLLENHAUER HH, 1966, J CELL BIOL, V29, P373, DOI 10.1083/jcb.29.2.373; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045	38	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35833	35839		10.1074/jbc.M206280200	http://dx.doi.org/10.1074/jbc.M206280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130652	hybrid			2022-12-25	WOS:000178275100011
J	Hossain, S; Singh, S; Lue, NF				Hossain, S; Singh, S; Lue, NF			Functional analysis of the C-terminal extension of telomerase reverse transcriptase - A putative "Thumb" domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; TETRAHYMENA TELOMERASE; YEAST TELOMERASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; MAMMALIAN TELOMERASE; RNA-POLYMERASE; PROTEIN; PROCESSIVITY; COMPONENT	Telomerase is an RNA-protein complex responsible for the extension of one strand of telomere terminal repeats. The catalytic protein subunit of telomerase, known generically as telomerase reverse transcriptase (TERT), exhibits significant homology to reverse transcriptases (RTs) encoded by retroviruses and retroelements. The mechanisms of telomerase may therefore be similar to those of the conventional reverse transcriptases. In this report, we explore potential similarity between these two classes of proteins in a region with no evident sequence similarity. Previous analysis has implicated a C-terminal domain of retroviral RTs (known as the "thumb" domain) in template-primer binding and in processivity control. The equivalent region of TERTs, although similar to one another, does not exhibit significant sequence homology to retroviral RTs. However, we found that removal of this region of yeast TERT similarly resulted in a decrease in the stability of telomerase-DNA complex and in the processivity of telomerase-mediated nucleotide addition. Moreover, the C-terminal domain of TERT exhibits a nucleic acid binding activity when recombinantly expressed and purified. Finally, amino acid substitutions of conserved residues in this region of TERT were found to impair telomerase activity and processivity. We suggest that mechanistic similarity between telomerase and retroviral RTs may extend beyond the regions with apparent sequence similarity.	Cornell Univ, Weill Med Coll, William Randolph Hearst Microbiol Res Ctr, Dept Immunol & Microbiol, New York, NY 10021 USA	Cornell University	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, William Randolph Hearst Microbiol Res Ctr, Dept Immunol & Microbiol, New York, NY 10021 USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895; Singh, Sunitha/0000-0002-9418-9849				ARAI K, 2002, IN PRESS J BIOL CHEM; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bosoy D, 2001, J BIOL CHEM, V276, P46305, DOI 10.1074/jbc.M108168200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1495, DOI 10.1093/nar/26.6.1495; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WEINRICH SL, 1997, NAT GENET, V17, P198; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	49	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36174	36180		10.1074/JBC.m201976200	http://dx.doi.org/10.1074/JBC.m201976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151386	hybrid			2022-12-25	WOS:000178275100053
J	Guil, S; Darzynkiewicz, E; Bach-Elias, M				Guil, S; Darzynkiewicz, E; Bach-Elias, M			Study of the 2719 mutant of the c-H-ras oncogene in a bi-intronic alternative splicing system	ONCOGENE			English	Article						splicing; H-ras; 2719 H-ras mutant; CBC; mini-exon; terminal exon	SITE-DIRECTED MUTAGENESIS; SR PROTEINS; IN-VITRO; U1 SNRNP; EXPRESSION; MODULATION	C-H-ras proto-oncogene forms part of the signal transduction pathway of numerous external stimuli. This proto-oncogene is regulated by alternative splicing within its intron D due to the presence of the alternative intron D exon (IDX). The alternative splicing produces mRNA which encodes for the putative p19 protein, that lacks transforming potential. Herein, we demonstrated that SR proteins regulate the intron D splicing. Moreover, we studied the 2719 mutation of H-ras which has higher transforming potential than Ile12 and Val12 H-ras mutants and is also known to affect the 5' splice site of the IDX. However, here we show that the 2719 mutant can still be spliced when the upstream 5' splice-site is blocked. During these later studies, additionally, we generated a short 11 nucleotides 5' terminal exon that was fully defined and spliced in a bi-intronic pre-mRNA. The definition of this mini-exon was also addressed in this work.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Warsaw, Dept Biophys, Inst Expt Phys, PL-02089 Warsaw, Poland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Warsaw	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C-Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015	Guil, Sonia/0000-0002-2257-3331				Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Huang MY, 1997, ONCOL RES, V9, P611; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu L, 1996, Methods Mol Biol, V57, P13	16	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5649	5653		10.1038/sj.onc.1205722	http://dx.doi.org/10.1038/sj.onc.1205722			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165864				2022-12-25	WOS:000177442000015
J	Huang, JS; Wang, YH; Ling, TY; Chuang, SS; Johnson, FE; Huang, SS				Huang, JS; Wang, YH; Ling, TY; Chuang, SS; Johnson, FE; Huang, SS			Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring	FASEB JOURNAL			English	Article						hypertrophic scarring; tissue fibrosis; peptantagonist	MODEL; MICE	Wound healing consists of re-epithelialization, contraction and formation of granulation and scar tissue. TGF-beta is involved in these events, but its exact roles are not well understood. Here we demonstrate that topical application of a synthetic TGF-beta antagonist accelerates re-epithelialization in pig burn wounds (100% re-epithelialization in antagonist-treated wounds vs. similar to 70% re-epithelialization in control wounds on postburn day 26) and reduces wound contraction and scarring in standard pig skin burn, pig skin excision and rabbit skin excision wounds. These results support the distinct roles of TGF-beta in the complex process of wound healing and demonstrate the feasibility of manipulating wound healing by TGF-beta antagonist.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; China Med Coll, Inst Pharmaceut Chem, Taichung, Taiwan; Taiwan Pig Res Inst, Maioli, Taiwan; Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan	Saint Louis University; Saint Louis University; Academia Sinica - Taiwan; China Medical University Taiwan; Chang Gung Memorial Hospital	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu; huangss@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; KAUFMAN T, 1984, BURNS, V10, P252, DOI 10.1016/0305-4179(84)90003-2; Kitamura M, 2001, CLIN CARDIOL, V24, P325, DOI 10.1002/clc.4960240413; Knabl JS, 1999, BURNS, V25, P229, DOI 10.1016/S0305-4179(98)00172-7; Liu QJ, 2001, J BIOL CHEM, V276, P46212, DOI 10.1074/jbc.M105177200; MUTOE TA, 1991, J CLIN INVEST, V87, P694; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; WINTER GD, 1974, BURNS, V1, P191; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	16	83	90	3	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1269	+		10.1096/fj.02-0103fje	http://dx.doi.org/10.1096/fj.02-0103fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153996				2022-12-25	WOS:000176683900017
J	Schuh, JM; Power, CA; Proudfoot, AE; Kunkel, SL; Lukacs, NW; Hogaboam, CM				Schuh, JM; Power, CA; Proudfoot, AE; Kunkel, SL; Lukacs, NW; Hogaboam, CM			Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4-/- mice	FASEB JOURNAL			English	Article						Aspergillus fumigatus; asthma; allergy; airway hyperreactivity; inflammation	MACROPHAGE-DERIVED CHEMOKINE; GOBLET CELL HYPERPLASIA; CC-CHEMOKINE; PERIBRONCHIAL FIBROSIS; NEUTROPHIL ELASTASE; RECEPTOR EXPRESSION; ANTIFUNGAL ACTIVITY; ANTIGEN CHALLENGE; EPITHELIAL-CELLS; CUTTING EDGE	The role of CC chemokine receptor 4 (CCR4) during the development and maintenance of Th2-type allergic airway disease is controversial. In this study, we examined the role of CCR4 in the chronic allergic airway response to live Aspergillus fumigatus spores, or conidia, in A. fumigatus-sensitized mice. After the conidia challenge, mice lacking CCR4 (CCR4-/- mice) exhibited significantly increased numbers of airway neutrophils and macrophages, and conidia were more rapidly eliminated from these mice compared with control CCR4 wild-type (CCR4+/+) mice. Significant airway hyperresponsiveness to intravenous methacholine was observed at day 3 in CCR4-/- mice, whereas at days 7 and 30, airway hyperresponsiveness was attenuated in these mice compared with control mice. A major reduction in peribronchial and airway eosinophilia was observed in CCR4-/- mice at all times after conidia challenge in contrast to CCR4+/+ mice. Further, whole lung levels of interleukin (IL) 4 and IL-5 were significantly increased in CCR4-/- mice at day 3, whereas these Th2 cytokines and IL-13 were significantly decreased at day 30 in CCR4-/- mice compared with their wild-type counterparts. Peribronchial fibrosis and goblet cell hyperplasia were similar in both groups of mice throughout the course of this model. In summary, CCR4 modulates both innate and acquired immune responses associated with chronic fungal asthma.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Serono Pharmaceut Res Inst, Geneva, Switzerland	University of Michigan System; University of Michigan	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Room 5214,Med Sci I,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	hogaboam@med.umich.edu	hogaboam, cory/M-3578-2014	Hogaboam, Cory/0000-0003-3366-4850				Agusti C, 1998, AM J RESP CRIT CARE, V158, P1253, DOI 10.1164/ajrccm.158.4.9801041; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Blease K, 2001, J IMMUNOL, V166, P1832, DOI 10.4049/jimmunol.166.3.1832; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; Burgel PR, 2000, J ALLERGY CLIN IMMUN, V106, P705, DOI 10.1067/mai.2000.109823; Campbell E, 2000, J IMMUNOL, V164, P1096, DOI 10.4049/jimmunol.164.2.1096; Campbell EM, 1999, J IMMUNOL, V163, P2160; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Chantry D, 1999, BLOOD, V94, P1890; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Clemons KV, 2000, CLIN EXP IMMUNOL, V122, P186, DOI 10.1046/j.1365-2249.2000.01382.x; Cockrill BA, 1999, ANNU REV MED, V50, P303, DOI 10.1146/annurev.med.50.1.303; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Del Sero G, 1999, MICROBES INFECT, V1, P1169, DOI 10.1016/S1286-4579(99)00245-2; Elstad M R, 1991, Semin Respir Infect, V6, P27; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Gonzalo JA, 1999, J IMMUNOL, V163, P403; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; Hamerman JA, 2001, J IMMUNOL, V167, P2227, DOI 10.4049/jimmunol.167.4.2227; Hogaboam CM, 1999, J IMMUNOL, V162, P6071; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109, DOI 10.1164/ajrccm.151.6.7767565; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Lukacs NW, 2001, CHEST, V120, p5S, DOI 10.1378/chest.120.1_suppl.S5; Mantovani A, 2000, J LEUKOCYTE BIOL, V68, P400; Matsukawa A, 2000, J IMMUNOL, V164, P5362, DOI 10.4049/jimmunol.164.10.5362; Matsukawa A, 2000, Rev Immunogenet, V2, P339; Mehrad B, 1999, J IMMUNOL, V162, P1633; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murali PS, 1998, J LAB CLIN MED, V131, P228, DOI 10.1016/S0022-2143(98)90094-4; NADEL JA, 1991, RESPIRATION, V58, P3; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Nagase H, 2001, J ALLERGY CLIN IMMUN, V108, P563, DOI 10.1067/mai.2001.118292; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Nogami H, 2000, EUR J PHARMACOL, V390, P197, DOI 10.1016/S0014-2999(99)00921-8; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606, DOI 10.1002/jlb.63.5.606; ROILIDES E, 1994, J INFECT DIS, V170, P894, DOI 10.1093/infdis/170.4.894; Roilides E, 1997, J IMMUNOL, V158, P322; Roilides E, 1998, RES IMMUNOL, V149, P454, DOI 10.1016/S0923-2494(98)80769-4; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; Schuh JM, 2002, J IMMUNOL, V168, P1447, DOI 10.4049/jimmunol.168.3.1447; SCHUH JM, 2002, IN PRESS AM J PHYSL; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Waldorf A R, 1989, Immunol Ser, V47, P243; Warschkau H, 1999, J IMMUNOL, V163, P3409; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wu MT, 2001, J IMMUNOL, V167, P4791, DOI 10.4049/jimmunol.167.9.4791; Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	64	107	114	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1313	+		10.1096/fj.02-0193fje	http://dx.doi.org/10.1096/fj.02-0193fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154006	Green Submitted			2022-12-25	WOS:000176683900028
J	Guaita, S; Puig, I; Franci, C; Garrido, M; Dominguez, D; Batlle, E; Sancho, E; Dedhar, S; de Herreros, AG; Baulida, J				Guaita, S; Puig, I; Franci, C; Garrido, M; Dominguez, D; Batlle, E; Sancho, E; Dedhar, S; de Herreros, AG; Baulida, J			Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; ZINC-FINGER; MECHANISMS; CARCINOMA; ADHESION; REVEALS; GENES; ZFH-1	E-cadherin protein plays a key role in the establishment and maintenance of adherent junctions. Recent evidence implicates the transcription factor Snail in the blockage of E-cadherin expression in fibroblasts and some epithelial tumor cells through direct binding to three E-boxes in the E-cadherin promoter. Transfection of Snail into epithelial cells leads to a more fibroblastic phenotype. Cells expressing Snail presented a scattered flattened phenotype with low intercellular contacts. Other epithelial markers like Cytokeratin 18 or MUC1 were also repressed. The effects of Snail on MUC1 transcription were mediated by two E-boxes present in the proximal promoter. Snail also induced expression of the mesenchymal markers fibronectin and LEF1 and the transcription repressor ZEB1. ZEB1 and Snail had a similar pattern of expression in epithelial cell lines, and both were induced by overexpression of ILK1, a kinase that causes the loss of E-cadherin and the acquisition of a fibroblastic phenotype. Snail overexpression in several cell lines raised ZEB1 RNA levels and increased the activity of ZEB1 promoter. ZEB1 could also repress E-cadherin and MUC1 promoters but less strongly than Snail. However, since ZEB1 expression persisted after Snail was down-regulated, ZEB1 may regulate epithelial genes in several tumor cell lines.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada	Pompeu Fabra University; University of British Columbia	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, C Doctor Aiguader 80, E-08003 Barcelona, Spain.	agarcia@imim.es; jbaulida@imim.es	Batlle, Eduard/K-8080-2014; de Herreros, A Garcia/H-3104-2014; Sancho, Elena/ABH-4867-2020	Batlle, Eduard/0000-0003-2422-0326; de Herreros, A Garcia/0000-0001-5270-0808; Sancho, Elena/0000-0002-8182-513X; Puig Borreil, Isabel/0000-0001-5614-4298; Dedhar, Shoukat/0000-0003-4355-1657; Dominguez-Sola, David/0000-0001-9569-8402				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Casal J, 1996, P NATL ACAD SCI USA, V93, P10327, DOI 10.1073/pnas.93.19.10327; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hay ED, 1995, ACTA ANAT, V154, P8; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Takagi T, 1998, DEVELOPMENT, V125, P21; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	29	380	397	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39209	39216		10.1074/jbc.M206400200	http://dx.doi.org/10.1074/jbc.M206400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161443	hybrid			2022-12-25	WOS:000178662500021
J	Dvoretsky, A; Abusamhadneh, EM; Howarth, JW; Rosevear, PR				Dvoretsky, A; Abusamhadneh, EM; Howarth, JW; Rosevear, PR			Solution structure of calcium-saturated cardiac troponin C bound to cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; REGULATORY DOMAIN; CENTRAL HELIX; CONFORMATIONAL EXCHANGE; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; COMPLEX; NMR; PHOSPHORYLATION; RESOLUTION	Cardiac troponin C (TnC) is composed of two globular domains connected by a flexible linker. In solution, linker flexibility results in an ill defined orientation of the two globular domains relative to one another. We have previously shown a decrease in linker flexibility in response to cardiac troponin I (cTnI) binding. To investigate the relative orientation of calcium-saturated TnC domains when bound to cTnI, H-1-(15) N residual dipolar couplings were measured in two different alignment media. Similarity in alignment tensor orientation for the two TnC domains supports restriction of domain motion in the presence of cTnI. The relative spatial orientation of TnC domains bound to TnI was calculated from measured residual dipolar couplings and long-range distance restraints utilizing a rigid body molecular dynamics protocol. The relative domain orientation is such that hydrophobic pockets face each other, forming a latch to constrain separate helical segments of TnI. We have utilized this structure to successfully explain the observed functional consequences of linker region deletion mutants. Together, these studies suggest that, although linker plasticity is important, the ability of TnC to function in muscle contraction can be correlated with a preferred domain orientation and interdomain distance.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, MSB 2015, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Rosevear, PR (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, MSB 2015, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 44324] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2000, FEBS LETT, V469, P168, DOI 10.1016/S0014-5793(00)01271-0; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Abusamhadneh E, 2001, FEBS LETT, V506, P51, DOI 10.1016/S0014-5793(01)02790-9; Al-Hashimi HM, 2000, J MAGN RESON, V143, P402, DOI 10.1006/jmre.2000.2049; Andersson P, 1998, J MAGN RESON, V133, P364, DOI 10.1006/jmre.1998.1492; BABU A, 1993, J BIOL CHEM, V268, P19232; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 2000, PROTEIN SCI, V9, P280; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; Hansen MR, 2000, METHOD ENZYMOL, V317, P220; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Kranz JK, 2002, J BIOL CHEM, V277, P16351, DOI 10.1074/jbc.C200139200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; MOIR AJG, 1977, BIOCHEM J, V167, P333, DOI 10.1042/bj1670333; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; Paakkonen K, 2000, EUR J BIOCHEM, V267, P6665, DOI 10.1046/j.1432-1327.2000.01763.x; POTTER JD, 1977, J BIOL CHEM, V252, P2452; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SHENG Z, 1991, J BIOL CHEM, V266, P5711; Tung CS, 2000, PROTEIN SCI, V9, P1312; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635	37	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38565	38570		10.1074/jbc.M205306200	http://dx.doi.org/10.1074/jbc.M205306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147696	hybrid			2022-12-25	WOS:000178529600073
J	Labonte, P; Axelrod, V; Agarwal, A; Aulabaugh, A; Amin, A; Mak, P				Labonte, P; Axelrod, V; Agarwal, A; Aulabaugh, A; Amin, A; Mak, P			Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; NS5B; IDENTIFICATION; REQUIREMENTS; MECHANISM	The hepatitis C virus (HCV) encodes an RNA-dependent RNA polymerase (NS5B), which is indispensable for the viral genome replication. Although structural comparison among HCV NS5B, poliovirus 3D-pol, and human immunodeficiency virus-reverse transcriptase RNA-dependent polymerase reveals the canonical palm, fingers, and thumb domains, the crystal structure of HCV NS5B highlights the presence of a unique A1-loop, which extends from the fingers to the thumb domain (amino acids 12-46), providing many contact points for the proposed "closed" conformation of the enzyme. The polymerase also possesses a tunnel, which starts at the active site and terminates on the back surface of the enzyme. This tunnel of 19 A contains five basic amino acids, which may be engaged in NTP trafficking. In the present study, we exploited the crystal structure of the enzyme to elucidate the involvement of these two structural motifs in enzyme activity by site-directed mutagenesis. As predicted, the replacement of leucine 30 located in the Lambda1-loop is detrimental to the NS5B activity. Heparin-Sepharose column chromatography and analytical ultracentrifugation experiments strongly suggest a local alteration in the structure of the Leu-30 mutant. An analysis of amino acid substitutions in Arg-222 and Lys-151 within the putative NTP tunnel indicates that Arg-222 was critical in delivering NTPs to the active site, whereas Lys-151 was dispensable. Interestingly, the substitution of lysine 151 for a glutamic acid resulted in an enzyme that was consistently more active in de novo synthesis as well as by "copy-back" mechanism of a self-primed substrate when compared with the wild type NS5B enzyme. Burst kinetic analyses indicate that the gain in function of K151E enzyme was primarily the result of the formation of more productive preinitiation complexes that were used for the elongation reaction. In contrast to the recent observations, both the wild type and mutant enzymes were monomeric in solution, whereas molecules of higher order were apparent in the presence of RNA template.	Wyeth, Dept Infect Dis, Pearl River, NY 10965 USA; Wyeth, Dept Biol Chem, Pearl River, NY 10965 USA	Pfizer; Pfizer	Mak, P (corresponding author), Wyeth Res, 85 Bolton St,R231A, Cambridge, MA 02140 USA.	makp@wyeth.com						BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLUMENTHAL T, 1980, P NATL ACAD SCI-BIOL, V77, P2601, DOI 10.1073/pnas.77.5.2601; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Kao CC, 1996, J VIROL, V70, P6826, DOI 10.1128/JVI.70.10.6826-6830.1996; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; MURPHY FA, 1995, CLASSIFICATION NOMEN, P424; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; *WHO, 1998, LANCET, V351, P1415; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	36	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38838	38846		10.1074/jbc.M204657200	http://dx.doi.org/10.1074/jbc.M204657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145289	hybrid			2022-12-25	WOS:000178529600105
J	Okazaki, I; Suzuki, N; Nishi, N; Utani, A; Matsuura, H; Shinkai, H; Yamashita, H; Kitagawa, Y; Nomizu, M				Okazaki, I; Suzuki, N; Nishi, N; Utani, A; Matsuura, H; Shinkai, H; Yamashita, H; Kitagawa, Y; Nomizu, M			Identification of biologically active sequences in the laminin alpha 4 chain G domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL GLOBULAR DOMAIN; CELL-BINDING SEQUENCES; SYNTHETIC PEPTIDES; NEURITE OUTGROWTH; GAMMA-1 CHAIN; BETA-1 CHAIN; EXPRESSION; HEPARIN; MIGRATION; INTEGRINS	Laminins are a family of trimeric extracellular matrix proteins consisting of alpha, beta, and gamma chains. So far five different laminin alpha chains have been identified. The laminin alpha4 chain, which is present in laminin-8/9, is expressed in cells of mesenchymal origin, such as endothelial cells and adipocytes. Previously, we identified heparin-binding sites in the C-terminal globular domain (G domain) of the laminin alpha4 chain. Here we have focused on the biological functions of the laminin alpha4 chain G domain and screened active sites using a recombinant protein and synthetic peptides. The rec-alpha4G protein, comprising the entire G domain, promoted cell attachment activity. The cell attachment activity of rec-alpha4G was completely blocked by heparin and partially inhibited by EDTA. We synthesized 116 overlapping peptides covering the entire G domain and tested their cell attachment activity. Twenty peptides showed cell attachment activity, and 16 bound to heparin. We further tested the effect of the 20 active peptides in competition assays for cell attachment and heparin binding to rec-alpha4G protein. A4G6 (LAIKNDNLVYVY), A4G20 (DVISLYNFKHIY), A4G82 (TLFLAHGRLVFM), and A4G83 (LVFMFNVGHKKL), which promoted cell attachment and heparin binding, significantly inhibited both cell attachment and heparin binding to rec-alpha4G. These results suggest that the four active sites are involved in the biological functions of the laminin alpha4 chain G domain. Furthermore, rec-alpha4G, A4G6, and A4G20 were found to interact with syndecan-4. These active peptides may be useful for defining of the molecular mechanism laminin-receptor interactions and laminin-mediated cellular signaling pathways.	Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; Chiba Univ, Sch Med, Dept Dermatol, Chiba 2608670, Japan; Nagoya Univ, Grad Course Regulat Biol Signals, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Hokkaido University; Chiba University; Nagoya University	Nomizu, M (corresponding author), Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Kita 10,Nishi 5, Sapporo, Hokkaido 0600810, Japan.			Yamashita, Hironobu/0000-0003-2587-7100				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MAKINO M, 1999, CONNECT TISSUE, V31, P227; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200	39	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37070	37078		10.1074/jbc.M201672200	http://dx.doi.org/10.1074/jbc.M201672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130633	hybrid			2022-12-25	WOS:000178447100023
J	Tanji, C; Yamamoto, H; Yorioka, N; Kohno, N; Kikuchi, K; Kikuchi, A				Tanji, C; Yamamoto, H; Yorioka, N; Kohno, N; Kikuchi, K; Kikuchi, A			A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3 beta (GSK-3 beta) and mediates protein kinase A-dependent inhibition of GSK-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; SUBSTRATE-SPECIFICITY; XENOPUS EMBRYOS; GROWTH-FACTOR; PHOSPHORYLATION; INACTIVATION; INSULIN; ENCODES; YEAST	Glycogen synthase kinase-3 (GSK-3) is regulated by various extracellular ligands and phosphorylates many substrates, thereby regulating cellular functions. Using yeast two-hybrid screening, we found that GSK-3beta binds to AKAP220, which is known to act as an A-kinase anchoring protein. GSK-3beta formed a complex with AKAP220 in intact cells at the endogenous level. Cyclic AMP-dependent protein kinase (PKA) and type 1 protein phosphatase (PP1) were also detected in this complex, suggesting that AKAP220, GSK-3beta, PKA, and PP1 form a quaternary complex. It has been reported that PKA phosphorylates GSK-3beta, thereby decreasing its activity. When COS cells were treated with dibutyryl cyclic AMP to activate PKA, the activity of GSK-3beta bound to AKAP220 decreased more markedly than the total GSK-3beta activity. Calyculin A, a protein phosphatase inhibitor, also inhibited the activity of GSK-3beta bound to AKAP220 more strongly than the total GSK-3beta activity. These results suggest that PKA and PP1 regulate the activity of GSK-3beta efficiently by forming a complex with AKAP220.	Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Dept Mol & Internal Med, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hiroshima University; Hiroshima University; Hokkaido University	Kikuchi, A (corresponding author), Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				Andoh T, 2000, MOL CELL BIOL, V20, P6712, DOI 10.1128/MCB.20.18.6712-6720.2000; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dale TC, 1998, BIOCHEM J, V329, P209; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; Plyte SE, 1996, MOL CELL BIOL, V16, P179; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36955	36961		10.1074/jbc.M206210200	http://dx.doi.org/10.1074/jbc.M206210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147701	hybrid			2022-12-25	WOS:000178447100008
J	Kawate, H; Landis, DM; Loeb, LA				Kawate, H; Landis, DM; Loeb, LA			Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DNA-REPLICATION; INHIBITORS; FIDELITY; MUTANTS; POLYMERASE; COMPLEXES; THYMITAQ	Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and is the target of cancer chemotherapeutic agents (e.g. 5-fluorouracil). Here, we used error-prone PCR to mutagenize the full-length human TS cDNA and then selected mutants resistant to 5-fluorodeoxyuridine in a bacterial complementation system. We found that resistant mutants contained 1-5 amino acid substitutions and that these substitutions were located along the entire length of the polypeptide. Mutations were frequent near the active site Cys(195) and in the catalytically important Arg(50) loop; however, many mutations were also distributed throughout the remainder of the cDNA. Mutants containing a single amino acid replacement identified the following 14 residues as unreported sites of resistance: Glu(23), Thr(51), Thr(53), Val(84), Lys(93), Asp(110), Asp(116), Pro(194), Ser(206), Met(219), His(250), Asp(254), Tyr(258), and Lys(284). Many of these residues are distant from the active site and/or have no documented function in catalysis or resistance. We conclude that mutations distributed throughout the linear sequence and three-dimensional structure of human TS can confer resistance to 5-fluorodeoxyuridine. Our findings imply that long range interactions within proteins affect catalysis at the active site and that mutations at a distance can yield variant proteins with desired properties.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042570] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78885] Funding Source: Medline; NIAID NIH HHS [AI42570] Funding Source: Medline; NIEHS NIH HHS [ES007033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad SI, 1998, ANNU REV MICROBIOL, V52, P591, DOI 10.1146/annurev.micro.52.1.591; Almog R, 2001, PROTEIN SCI, V10, P988, DOI 10.1110/ps.47601; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; Danenberg PV, 1999, SEMIN ONCOL, V26, P621; Dixon M., 1964, ENZYMES, P328; Edman L, 2000, P NATL ACAD SCI USA, V97, P8266, DOI 10.1073/pnas.130589397; Kitchens ME, 1999, MOL PHARMACOL, V56, P1063, DOI 10.1124/mol.56.5.1063; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1979, J BIOL CHEM, V254, P5718; Landis DM, 1998, J BIOL CHEM, V273, P25809, DOI 10.1074/jbc.273.40.25809; Landis DM, 2001, CANCER RES, V61, P666; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Phan J, 2001, J BIOL CHEM, V276, P14170, DOI 10.1074/jbc.M009493200; Phan J, 2001, BIOCHEMISTRY-US, V40, P1897, DOI 10.1021/bi002413i; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; Rustum YM, 1997, J CLIN ONCOL, V15, P389, DOI 10.1200/JCO.1997.15.1.389; Sayre PH, 2001, J MOL BIOL, V313, P813, DOI 10.1006/jmbi.2001.5074; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; Sotelo-Mundo RR, 1999, BIOCHEMISTRY-US, V38, P1087, DOI 10.1021/bi981881d; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Tong YZ, 1998, J BIOL CHEM, V273, P31209, DOI 10.1074/jbc.273.47.31209; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11	30	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36304	36311		10.1074/jbc.M204956200	http://dx.doi.org/10.1074/jbc.M204956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147691	hybrid			2022-12-25	WOS:000178275100067
J	Prioleau, C; Visiers, I; Ebersole, BJ; Weinstein, H; Sealfon, SC				Prioleau, C; Visiers, I; Ebersole, BJ; Weinstein, H; Sealfon, SC			Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor - Identification of a novel "locked-on" phenotype and double revertant mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; SEROTONIN 5-HT2A RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; MU-OPIOID RECEPTOR; CONSTITUTIVE ACTIVATION; HORMONE RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE HELIX; ARGININE-CAGE	Studies in many rhodopsin-like G-protein-coupled receptors are providing a general scheme of the structural processes underlying receptor activation. Microdomains in several receptors have been identified that appear to function as activation switches. However, evidence is emerging that these receptor proteins exist in multiple conformational states. To study the molecular control of this switching process, we investigated the function of a microdomain involving the conserved helix 7 tyrosine in the serotonin 5HT2C receptor. This tyrosine of the NPXXY motif was substituted for all naturally occurring amino acids. Three distinct constitutively active receptor phenotypes were found: moderate, high, and "locked-on" constitutive activity. In contrast to the activity of the other receptor mutants, the high basal signaling of the locked-on Y7.53N mutant was neither increased by agonists nor decreased by inverse agonists. The Y7.53F mutant was uncoupled. Computational modeling based on the rhodopsin crystal structure suggested that Y7.53 interacts with the conserved aromatic ring at position 7.60 in the recently identified helix 8 domain. This provided a basis for seeking revertant mutations to correct the defective function of the Y7.53F receptor. When the Y7.53F receptor was mutated at position 7.60, the wild-type phenotype was restored. These results suggest that Y7.53 and Y7.60 contribute to a common functional microdomain connecting helices 7 and 8 that influences the switching of the 5HT2C receptor among multiple active and inactive conformations.	CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.sealfon@mssm.edu	WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012923] Funding Source: NIH RePORTER; NIDA NIH HHS [P01-DA12923] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Arora KK, 1996, MOL ENDOCRINOL, V10, P979, DOI 10.1210/me.10.8.979; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chen SH, 2002, BIOCHEMISTRY-US, V41, P588, DOI 10.1021/bi011868k; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; Dias JA, 2001, ARCH MED RES, V32, P510, DOI 10.1016/S0188-4409(01)00333-2; Duong TH, 1999, J COMPUT PHYS, V151, P358, DOI 10.1006/jcph.1999.6222; Ebersole BJ, 2002, METHOD ENZYMOL, V343, P123; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Fianagan CA, 1999, J BIOL CHEM, V274, P28880, DOI 10.1074/jbc.274.41.28880; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Grotewiel MS, 1999, N-S ARCH PHARMACOL, V359, P21, DOI 10.1007/PL00005318; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kitanovic S, 2001, MOL ENDOCRINOL, V15, P390, DOI 10.1210/me.15.3.390; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Miettinen HM, 1999, J BIOL CHEM, V274, P27934, DOI 10.1074/jbc.274.39.27934; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Rosendorff A, 2000, MOL BRAIN RES, V84, P90, DOI 10.1016/S0169-328X(00)00227-8; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shichida Y, 2000, METHOD ENZYMOL, V315, P347; Shinozaki H, 2001, MOL ENDOCRINOL, V15, P972, DOI 10.1210/me.15.6.972; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Tao YX, 2000, MOL ENDOCRINOL, V14, P1272, DOI 10.1210/me.14.8.1272; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Visiers I, 2002, METHOD ENZYMOL, V343, P329; Visiers I, 2002, INT J QUANTUM CHEM, V88, P65, DOI 10.1002/qua.10078; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	79	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36577	36584		10.1074/jbc.M206223200	http://dx.doi.org/10.1074/jbc.M206223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145300	hybrid			2022-12-25	WOS:000178275100101
J	Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H				Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H			Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway	ONCOGENE			English	Article						proliferation; EMT; Ras mutants; PI3K; collagen gels; breast cancer	NIH 3T3 CELLS; HORMONE-INDEPENDENT PROLIFERATION; BREAST-CANCER CELLS; MAP KINASE KINASE; CYCLIN D1; E-CADHERIN; MAMMARY TUMORIGENESIS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; CARCINOMA-CELLS	Carcinogenesis by oncogenic Ras and Her-2 involves enhanced proliferation of epithelial cells in vivo. However, hyperproliferation induced by these oncogenes, or their downstream pathways in vitro has mainly been studied in cultured, fibroblastic cell lines. Here, we demonstrate that oncogenic Ha-Ras or constitutively active Her-2 cause increased proliferation and cyclin D1 upregulation in fully polarized, mammary epithelial cells (EpH4), if cultivated as organotypic structures in three-dimensional collagen/ matrigel matrices. Under standard culture conditions, however, these oncogenes failed to induce hyperproliferation. Using both specific low molecular weight inhibitors and Ras-effector - specific mutants, we dissected signaling pathways downstream of oncogenic Ras (PI3K, Mek1/ MAPK) with respect to (i) hyperproliferation in collagen gels and tumorigenesis in mice and (ii) epithelial/ mesenchymal transition (EMT). We show that the Ras-activated PI3K pathway is required to induce rapid tumor growth and enhanced proliferation of EpH4 cells in collagen gels, but fails to cause EMT in vitro and in vivo. On the other hand, Ras-dependent activation of the Mek1/ MAPK pathway in EpH4 cells (previously shown to cause EMT and metastasis) did not induce hyperproliferation in collagen gels and caused only slow tumor growth. Our data thus indicate that Ras-dependent signaling through the PI3K- and MAPK pathways fulfil distinct, but complementary functions during carcinogenesis.	Inst Mol Pathol, A-1030 Vienna, Austria; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cancer Research UK	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Janda, Elzbieta/AFQ-7061-2022; Downward, Julian/A-3251-2012; Janda, Elzbieta/AAD-5126-2022; Gruenert, Stefan/T-7755-2019; Gruenert, Stefan/B-7598-2016	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297; Downward, Julian/0000-0002-2331-4729				Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; De Vita G, 2000, CANCER RES, V60, P3916; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FILMUS J, 1994, ONCOGENE, V9, P3627; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lenferink AEG, 2001, CANCER RES, V61, P6583; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Montesano R, 1998, IN VITRO CELL DEV-AN, V34, P468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ojakian GK, 1997, J CELL SCI, V110, P2781; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Putz E, 1999, CANCER RES, V59, P241; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Treinies I, 1999, MOL CELL BIOL, V19, P321; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	46	64	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5148	5159		10.1038/sj.onc.1205661	http://dx.doi.org/10.1038/sj.onc.1205661			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140765				2022-12-25	WOS:000176975900013
J	Barouch, R; Schwartz, M				Barouch, R; Schwartz, M			Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity	FASEB JOURNAL			English	Article						T and B lymphocytes; macrophages; CNS trauma; protective autoimmunity; neurotrophic factors	MYELIN BASIC-PROTEIN; SPINAL-CORD-INJURY; MESSENGER-RNA EXPRESSION; FACIAL MOTONEURON LOSS; GROWTH-FACTOR; IMMUNOGLOBULIN PRODUCTION; INFLAMMATORY CYTOKINES; PROMOTES RECOVERY; B-CELLS; BRAIN	Accumulating evidence suggests that activation of the immune system in the central nervous system (CNS) after trauma protects the CNS from damage propagation and facilitates regeneration. Studies by our group have shown that passive transfer of autoimmune T cells specific to myelin basic protein (TMBP) can protect injured neurons in the rat CNS from secondary degeneration. In this study, we investigated the effects of TMBP treatment on the local immune response (by B cells and macrophages) and on the expression of neurotrophic factors after crush injury of the rat optic nerve. Systemic injection of activated TMBP caused an increase in the accumulation of macrophages/microglia and B cells in the injured nerve, which was greater than that seen in the injured optic nerves of untreated animals. This accumulation was accompanied by a transient, but massive, increase in the expression of neurotrophic factors. Immunocytochemical analysis demonstrated differential expression of neurotrophins by resident astrocytes and by infiltrating B cells, T cells, and macrophages. Because postinjury neuronal survival and maintenance are known to be affected by neurotrophins, our findings point to a possible contribution of a neurotrophin-related mechanism to the protective effect conferred by T cell-mediated autoimmunity on injured neurons.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	michal.schwartz@weizmann.ac.il						ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; Aloisi F, 2000, IMMUNOL TODAY, V21, P141, DOI 10.1016/S0167-5699(99)01512-1; Aloisi F, 1999, EUR J IMMUNOL, V29, P2705, DOI 10.1002/(SICI)1521-4141(199909)29:09<2705::AID-IMMU2705>3.0.CO;2-1; Arredondo LR, 2001, EUR J IMMUNOL, V31, P625; BAHR M, 1994, NERVENARZT, V65, P355; Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7; Barouch R, 2001, J LEUKOCYTE BIOL, V69, P1019; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; Bell R B, 1991, Semin Immunol, V3, P237; BENNUN A, 1982, J IMMUNOL, V129, P303; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; Besser M, 1999, J IMMUNOL, V162, P6303; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; BRODIE C, 1994, J NEUROIMMUNOL, V52, P87, DOI 10.1016/0165-5728(94)90166-X; BRODIE C, 1992, J IMMUNOL, V148, P3492; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Elkabes S, 1998, J NEUROSCI RES, V54, P117, DOI 10.1002/(SICI)1097-4547(19981001)54:1<117::AID-JNR12>3.0.CO;2-4; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, P NATL ACAD SCI USA, V98, P15173, DOI 10.1073/pnas.011585298; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KIMATA H, 1991, CLIN IMMUNOL IMMUNOP, V60, P145, DOI 10.1016/0090-1229(91)90120-Y; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KIPNIS J, 2002, IN PRESS J NEUROIMMU; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LU X, 1991, J NEUROSCI, V11, P972; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MICERA A, 1995, ARCH ITAL BIOL, V133, P131; Miwa T, 1997, J NEUROSCI RES, V50, P1023; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Moalem G., 2000, J AUTOIMMUN, V20, P6421; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; OTTEN U, 1994, PROG BRAIN RES, V103, P293; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; Patrick CW, 1996, EXP NEUROL, V138, P277, DOI 10.1006/exnr.1996.0066; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RENNO T, 1995, J IMMUNOL, V154, P944; SCHORI H, 2002, IN PRESS J IMMUNOL; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; SCHWARTZ M, 1997, CURRENT TOPICS NEURO, V1, P123; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.0.CO;2-C; Serpe CJ, 1999, J NEUROSCI, V19; Stefan J, 1971, Cesk Patol, V7, P36; Susaki Y, 1996, BLOOD, V88, P4630, DOI 10.1182/blood.V88.12.4630.bloodjournal88124630; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; ZHOU XF, 1994, J NEUROSCI METH, V54, P95, DOI 10.1016/0165-0270(94)90163-5	71	73	78	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1304	+		10.1096/fj.01-0467fje	http://dx.doi.org/10.1096/fj.01-0467fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154003				2022-12-25	WOS:000176683900012
J	Diaz, O; Berquand, A; Dubois, M; Di Agostino, S; Sette, C; Bourgoin, S; Lagarde, M; Nemoz, G; Prigent, AF				Diaz, O; Berquand, A; Dubois, M; Di Agostino, S; Sette, C; Bourgoin, S; Lagarde, M; Nemoz, G; Prigent, AF			The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INSOLUBLE MEMBRANE DOMAINS; UNSATURATED FATTY-ACIDS; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; T-CELL RECEPTOR; PLASMA-MEMBRANES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTORS; TYROSINE KINASES	Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid that inhibits T lymphocyte activation, has been shown to stimulate phospholipase D (PLD) activity in stimulated human peripheral blood mononuclear cells (PBMC). To elucidate the mechanisms underlying the DHA-induced PLD activation, we first characterized the PLD expression pattern of PBMC. We show that these cells express PLD1 and PLD2 at the protein and mRNA level and are devoid of oleate-dependent PLD activity. DHA enrichment of PBMC increased the DHA content of cell phospholipids, which was directly correlated with the extent of PLD activation. The DHA-induced PLD activation was independent of conventional protein kinase C but inhibited by brefeldin A, which suggests ADP-ribosylation factor (ARF)-dependent mechanism. Furthermore, DHA enrichment dose-dependently stimulated ARF translocation to cell membranes. Whereas 50% of the guanosine 5'-3-O-(thio)triphosphate plus ARF-dependent PLD activity and a substantial part of PLD1 protein were located to the detergent-insoluble membranes, so-called rafts, of non-enriched PBMC, DHA treatment strongly displaced them toward detergent-soluble membranes where ARF is present. Collectively, these results suggest that the exclusion of PLD1 from lipid rafts, due to their partial disorganization by DHA, and its relocalization in the vicinity of ARF, is responsible for its activation. This PLD activation might be responsible for the immunosuppressive effect of DHA because it is known to transmit antiproliferative signals in lymphoid cells.	Inst Natl Sci Appl, INSERM, U352, Lab Biochim & Pharmacol, F-69621 Villeurbanne, France; Univ Roma Tor Vergata, Cattedra Anat Umana, Dipartimento Sanita Pubbl & Biol Cellulare, I-00173 Rome, Italy; Univ Laval, CHUL, Ctr Rech, St Foy, PQ G1V 4G2, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Rome Tor Vergata; Laval University	Prigent, AF (corresponding author), Inst Natl Sci Appl, INSERM, U352, Lab Biochim & Pharmacol, Batiment Louis Pasteur,11 Ave Jean Capelle, F-69621 Villeurbanne, France.		diaz, olivier/M-8112-2014; Sette, Claudio/S-4307-2019; Di Agostino, Silvia/S-8566-2019; Di Agostino, Silvia/H-1121-2018	diaz, olivier/0000-0002-3451-9914; Sette, Claudio/0000-0003-2864-8266; Di Agostino, Silvia/0000-0003-3730-1125; Bourgoin, Sylvain/0000-0001-9779-0368				Bacon KB, 1998, J IMMUNOL, V160, P1894; Bechoua S, 1998, J LIPID RES, V39, P873; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BOUKHCHACHE D, 1982, BIOCHIM BIOPHYS ACTA, V713, P386, DOI 10.1016/0005-2760(82)90257-0; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; CALDER PC, 1995, BIOCHEM SOC T, V23, P301; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; Czarny M, 2000, FEBS LETT, V467, P326, DOI 10.1016/S0014-5793(00)01174-1; ENDRES S, 1993, J LEUKOCYTE BIOL, V54, P599, DOI 10.1002/jlb.54.6.599; FRA AM, 1994, J BIOL CHEM, V269, P30745; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GENTRY MK, 1975, ANAL BIOCHEM, V64, P624, DOI 10.1016/0003-2697(75)90478-9; Gibbs TC, 2000, J CELL PHYSIOL, V182, P77, DOI 10.1002/(SICI)1097-4652(200001)182:1<77::AID-JCP9>3.0.CO;2-B; Gilbert JJ, 1998, J IMMUNOL, V161, P6575; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1998, BLOOD, V91, P3901; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kasai T, 1998, J IMMUNOL, V161, P6469; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MAY CL, 1993, BIOCHEM BIOPH RES CO, V195, P823, DOI 10.1006/bbrc.1993.2119; Meacci E, 2000, FEBS LETT, V473, P10, DOI 10.1016/S0014-5793(00)01486-1; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Reid PA, 1997, IMMUNOLOGY, V90, P250, DOI 10.1046/j.1365-2567.1997.00150.x; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Zakaroff-Girard A, 1999, J LEUKOCYTE BIOL, V65, P381, DOI 10.1002/jlb.65.3.381; Zurier RB, 1999, PROSTAG LEUKOTR ESS, V60, P371, DOI 10.1016/S0952-3278(99)80015-5	55	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39368	39378		10.1074/jbc.M202376200	http://dx.doi.org/10.1074/jbc.M202376200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12140281	hybrid			2022-12-25	WOS:000178662500041
J	Kim, M; Ahn, JW; Song, KW; Paek, KH; Pai, HS				Kim, M; Ahn, JW; Song, KW; Paek, KH; Pai, HS			Forkhead-associated domains of the tobacco NtFHA1 transcription activator and the yeast Fhl1 forkhead transcription factor are functionally conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; FHA DOMAIN; ZEAXANTHIN EPOXIDASE; PROTEIN PHOSPHATASE; GENE-PRODUCT; HEAD PROTEIN; KINASE; BOP1	NtFHA1 encodes a novel protein containing the forkhead-associated (FHA) domain and the acidic domain in Nicotiana tabacum. NtFHA1 functions as a transactivator and is targeted to the nucleus. The sequence of the FHA domain of NtFHA1 is significantly homologous to that of the Fhl1 forkhead transcription factor of yeast. FHL1 was previously identified as a suppressor of RNA polymerase III mutations, and the fhl1 deletion mutant exhibited severe growth defects and impaired rRNA processing. Ectopic expression of the FHA domain of NtFHA1 (but not its mutant form) resulted in severe growth retardation in yeast. Similarly, expression of Fhl1, its FHA domain, or chimeric Fhl1 containing the NtFHA1 FHA domain also inhibited yeast growth. Yeast cells overexpressing the FHA domains of NtFHA1 and Fhl1 contained lower levels of mature rRNAs and exhibited rRNA-processing defects, similar to the fhl1 null mutant. Chimeric Fhl1 (but not the mutant form with a small deletion in its FHA domain) fully complemented the growth and rRNA-processing defects of the fhl1 null mutant, demonstrating that the FHA domain of NtFHA1 can functionally substitute for the FHA domain of Fhl1. These results demonstrate that the FHA domains of NtFHA1 and Fhl1 are conserved in their structure and function and that the FHA domain of Fhl1 is critically involved in regulation of rRNA processing in yeast. NtFHA1 function in plants may be analogous to Fhl1 function in yeast.	Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University; Korea University	Pai, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, POB 115, Taejon 305600, South Korea.							Audran C, 1998, PLANT PHYSIOL, V118, P1021, DOI 10.1104/pp.118.3.1021; Burbidge A, 1997, J EXP BOT, V48, P1749, DOI 10.1093/jexbot/48.314.1749; CHEREL I, 1995, YEAST, V11, P261, DOI 10.1002/yea.320110308; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Hollenhorst PC, 2000, GENETICS, V154, P1533; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Li J, 2000, J CELL SCI, V113, P4143; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Reichheld JP, 1996, P NATL ACAD SCI USA, V93, P13819, DOI 10.1073/pnas.93.24.13819; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	30	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38781	38790		10.1074/jbc.M201559200	http://dx.doi.org/10.1074/jbc.M201559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149245	hybrid			2022-12-25	WOS:000178529600098
J	Doublet, P; Grangeasse, C; Obadia, B; Vaganay, E; Cozzone, AJ				Doublet, P; Grangeasse, C; Obadia, B; Vaganay, E; Cozzone, AJ			Structural organization of the protein-tyrosine autokinase Wzc within Escherichia coli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE BIOSYNTHESIS; BACTERIUM ACINETOBACTER-JOHNSONII; STREPTOCOCCUS-PNEUMONIAE; AUTOPHOSPHORYLATING PROTEIN; CROSS-LINKING; EXOP PROTEIN; PHOSPHORYLATION; EXPRESSION; KINASE; EXOPOLYSACCHARIDE	Protein Wzc from Escherichia coli is a member of a newly defined family of protein-tyrosine autokinases that are essential for surface polysaccharide production in both Gram-negative and Gram-positive bacteria. Although the catalytic mechanism of the autophosphorylation of Wzc was recently described, the in vivo structural organization of this protein remained unclear. Here, we have determined the membrane topology of Wzc by performing translational fusions of lacZ and phoA reporter genes to the wzc gene. It has been shown that Wzc consists of two main structural domains: an N-terminal domain, bordered by two transmembrane helices, which is located in the periplasm of cells, and a C-terminal domain, harboring all phosphorylation sites of the protein, which is located in the cytoplasm. In addition, it has been demonstrated for the first time that Wzc can oligomerize in vivo to form essentially trimers and hexamers. Cross-linking experiments performed on strains expressing various domains of Wzc have shown that the cytoplasmic C-terminal domain is sufficient to generate oligomerization of Wzc. Mutant proteins, modified in either the ATP-binding site or the different phosphorylation sites, i.e. rendered unable to undergo autophosphorylation, have appeared to oligomerize into high molecular mass species identical to those formed by the wild-type protein. It was concluded that phosphorylation of Wzc is not essential to its oligomerization. These data, connected with the phosphorylation mechanism of Wzc, may be of biological significance in the regulatory role played by this kinase in polysaccharide synthesis.	Univ Lyon, Inst Biol & Chim Prot, CNRS, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS)	Cozzone, AJ (corresponding author), Univ Lyon, Inst Biol & Chim Prot, CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.	aj.cozzone@ibcp.fr	Doublet, Patricia/L-9480-2014	Doublet, Patricia/0000-0001-5848-4317; Grangeasse, Christophe/0000-0002-5484-4589				AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; BAYER ME, 1977, J BACTERIOL, V130, P911, DOI 10.1128/JB.130.2.911-936.1977; BECKER A, 1995, MOL MICROBIOL, V16, P191, DOI 10.1111/j.1365-2958.1995.tb02292.x; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; Bender MH, 2001, J BIOL CHEM, V276, P47966, DOI 10.1074/jbc.M105448200; BINGLE WH, 1993, CAN J MICROBIOL, V39, P70, DOI 10.1139/m93-010; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Duclos B, 1996, J MOL BIOL, V259, P891, DOI 10.1006/jmbi.1996.0366; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Grangeasse C, 1999, IUBMB LIFE, V48, P339; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBlanc HN, 1996, J BACTERIOL, V178, P4801, DOI 10.1128/jb.178.16.4801-4806.1996; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller JH., 1972, EXPT MOL GENETICS; Morona JK, 1999, J BACTERIOL, V181, P5355, DOI 10.1128/JB.181.17.5355-5364.1999; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 2002, J BACTERIOL, V184, P577, DOI 10.1128/JB.184.2.577-583.2002; Niemeyer D, 2001, J BACTERIOL, V183, P5163, DOI 10.1128/JB.183.17.5163-5170.2001; Preneta R, 2002, COMP BIOCHEM PHYS B, V131, P103, DOI 10.1016/S1096-4959(01)00490-0; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37339	37348		10.1074/jbc.M204465200	http://dx.doi.org/10.1074/jbc.M204465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138098	hybrid			2022-12-25	WOS:000178447100056
J	Du, K; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Laburthe, M				Du, K; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Laburthe, M			Human VPAC1 receptor selectivity filter - Identification of a critical domain for restricting secretin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-COUPLED RECEPTORS; N-TERMINAL DOMAIN; ADENYLATE-CYCLASE; FUNCTIONAL EXPRESSION; AGONIST BINDING; VIP RECEPTOR; CLONING; MEMBERS	The human VPAC1 receptor for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) belongs to the class II family of G protein coupled receptors with seven transmembrane segments. It recognizes several VIP-related peptides and displays a very low affinity for secretin despite >70% homology between VIP and secretin. Conversely, the human secretin receptor has high affinity for secretin but low affinity for VIP. We took advantage of this reversed selectivity to identify a domain of the VPAC1 receptor responsible for selectivity toward secretin by constructing human VPAC1-secretin receptor chimeras. A first set of chimeras consisted of exchanging the entire N-terminal ectodomain or large parts of this domain. They were constructed by overlap PCR, transfected in COS-7 cells, and their ligand selectivity, expressed as the ratio of EC50 for secretin/EC50 for VIP (referred to as S/V), in stimulating cAMP production was measured. Two very informative chimeras respectively referred to as S144V and S123V were obtained by replacing the entire ectodomain or only the first 123 amino acids of the VPAC1 receptor by the corresponding sequences of the secretin receptor. Whereas S144V no longer discriminated between VIP and secretin (S/V = 1.2), S123V discriminated between the two peptides (S/V = 300) in the same manner as the wild-type VPAC1 receptor. The motif responsible for discrimination was determined by introducing small blocks or individual amino acids of secretin receptor in the 123-144 sequence of the S123V chimera. The data obtained from 14 new chimeras sustained that two nonadjacent pairs of amino acids, Gln(135) Thr(136) and Gly(140) Ser(141) in the C-terminal end of the N-terminal VPAC1 receptor ectodomain constitute a selective filter that strongly restricts access of secretin to the VPAC1 receptor.	Univ Paris 07, INSERM, Unite Neuroendocrinol & Biol Cellulaire Digest U4, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Univ Paris 07, INSERM, Unite Neuroendocrinol & Biol Cellulaire Digest U4, F-75018 Paris, France.		couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JIANG SP, 1995, BIOCHEM BIOPH RES CO, V207, P883, DOI 10.1006/bbrc.1995.1268; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LABURTHE M, 2002, IN PRESS RECEPT CHAN; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LABURTHE M, 2002, IN PRESS ENDO SERIES; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Park CG, 2000, J PHARMACOL EXP THER, V295, P682; ROBBERECHT P, 1988, PANCREAS, V3, P529, DOI 10.1097/00006676-198810000-00004; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SALOMON R, 1993, AM J PHYSIOL, V264, pE294, DOI 10.1152/ajpendo.1993.264.2.E294; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895	21	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37016	37022		10.1074/jbc.M203049200	http://dx.doi.org/10.1074/jbc.M203049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133828	hybrid			2022-12-25	WOS:000178447100016
J	Angata, K; Suzuki, M; Fukuda, M				Angata, K; Suzuki, M; Fukuda, M			ST8Sia II and ST8Sia IV polysialyltransferases exhibit marked differences in utilizing various acceptors containing oligosialic acid and short polysialic acid - The basis for cooperative polysialylation by two enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; CENTRAL-NERVOUS-SYSTEM; N-CAM; 2 POLYSIALYLTRANSFERASES; SYNAPTIC PLASTICITY; NEURITE OUTGROWTH; IN-VITRO; STX; EXPRESSION	Polysialylation of the neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development. Two polysialyltransferases, ST8Sia 11 and ST8Sia IV, play dominant roles in polysialic acid synthesis on NCAM. However, the individual roles and mechanisms by which these two enzymes form large amounts of polysialic acid on NCAM were heretofore unknown. Previous studies indicate that ST8Sia IV forms more highly polysialylated N-glycans on NCAM than ST8Sia II in vitro. In the present study, we first demonstrated that a combination of STSSia 11 and STSSia IV cooperatively polysialylated NCAM, resulting in NCAM N-glycans containing more, and thus longer, polysialic acid than when the enzymes were used individually. There was also an increase in polysialylated NCAM when we used ST8Sia 11 and ST8Sia IV sequentially, whereas there appeared to be a subtle increase when the enzymes were used in the reverse order. Furthermore, ST8Sia IV was able to add polysialic acid to oligosialylated oligosaccharides and unpolysialylated antennas in N-glycans attached to NCAM, even when polysialic acid was attached to at least one of the other antennas. By contrast, ST8Sia 11 added little polysialic acid to the same acceptors. On the other hand, neither ST8Sia 11 nor ST8Sia IV could add polysialic acid to a polysialylated antenna of NCAM N-glycans. These combined results indicate that the synergistic effect of ST8Sia 11 and ST8Sia IV is caused by: 1) the ability of ST8Sia IV to add polysialic acid to oligosialic acid formed by STSSia 11, 2) the potential of ST8Sia IV to act on more antennas of N-glycans than ST8Sia 11, and 3) the ability of ST8Sia 11 and ST8Sia IV in combination to act on the fifth and sixth N-glycosylation sites of NCAM.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NCI NIH HHS [CA 33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Bruses JL, 1998, J CELL BIOL, V140, P1177, DOI 10.1083/jcb.140.5.1177; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FINNE J, 1982, J BIOL CHEM, V257, P1966; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; Hildebrandt H, 1998, CANCER RES, V58, P779; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; IMMONS DL, 1993, CELLULAR INTERACTION, P93; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Phillips GR, 1997, DEV BRAIN RES, V102, P143, DOI 10.1016/S0165-3806(97)00069-2; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Tanaka F, 2000, CANCER RES, V60, P3072; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; von der Ohe M, 2002, GLYCOBIOLOGY, V12, P47, DOI 10.1093/glycob/12.1.47; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	52	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36808	36817		10.1074/jbc.M204632200	http://dx.doi.org/10.1074/jbc.M204632200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138100	hybrid			2022-12-25	WOS:000178275100132
J	Fjeldstad, K; Pedersen, ME; Vuong, TT; Kolsett, SO; Nordstrand, LM; Prydz, K				Fjeldstad, K; Pedersen, ME; Vuong, TT; Kolsett, SO; Nordstrand, LM; Prydz, K			Sulfation in the Golgi lumen of Madin-Darby canine kidney cells is inhibited by brefeldin A and depends on a factor present in the cytoplasm and on Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; HAMSTER OVARY CELLS; HEPARAN-SULFATE; CHONDROITIN SULFATE; MDCK CELLS; ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; SECRETORY PROTEINS; PAPS TRANSLOCASE; RAT HEPATOCYTES	Madin-Darby canine kidney cells are more resistant than most other cell types to the classical effects of brefeldin A (BFA) treatment, the induction of retrograde transport of Golgi cisternae components to the endoplasmic reticulum. Here we show that sulfation of heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), and proteins in the Golgi apparatus is dramatically reduced by low concentrations of BFA in which Golgi morphology is unaffected and secretion still takes place. BFA treatment seems to reduce sulfation by inhibition of the uptake of adenosine W-phosphate 5'-phosphosulfate (PAPS) into the Golgi lumen, and the inhibitory effect of BFA was similar for HSPGs, CSPGs, and proteins. This was different from the effect of chlorate, a well known inhibitor of PAPS synthesis in the cytoplasm. Low concentrations of chlorate (2-5 nM) inhibited sulfation of CSPGs and proteins only, whereas higher concentrations (15-30 nM) were required to inhibit sulfation of HSPGs. Golgi fractions pretreated with BFA had a reduced Capacity for the synthesis of glycosaminoglycans (GAGs), but control level capacity could be restored by the addition of cytosol from various sources. This indicates that the PAPS pathway to the Golgi lumen depends on a BFA-sensitive factor that is present both on Golgi membranes and in the cytoplasm.	Univ Oslo, Dept Biochem, N-0316 Oslo, Norway; Univ Oslo, Inst Nutr Res, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Prydz, K (corresponding author), Univ Oslo, Dept Biochem, N-0316 Oslo, Norway.							BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAUERLE PA, 1987, J CELL BIOL, V105, P2655; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CALABRO A, 1994, J BIOL CHEM, V269, P22764; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garred O, 2001, TRAFFIC, V2, P26, DOI 10.1034/j.1600-0854.2001.020105.x; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Halvorsen B, 1999, BIOCHEM J, V343, P533, DOI 10.1042/0264-6021:3430533; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Kolset SO, 2002, BIOCHEM J, V362, P359, DOI 10.1042/0264-6021:3620359; Kolset SO, 1999, J CELL SCI, V112, P1797; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Prydz K, 2000, J CELL SCI, V113, P193; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1995, J BIOL CHEM, V270, P22483, DOI 10.1074/jbc.270.38.22483; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; VOS JP, 1994, BBA-LIPID LIPID MET, V1211, P125, DOI 10.1016/0005-2760(94)90262-3	42	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36272	36279		10.1074/jbc.M206365200	http://dx.doi.org/10.1074/jbc.M206365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138122	hybrid			2022-12-25	WOS:000178275100063
J	Gogg, S; Smith, U				Gogg, S; Smith, U			Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; TRANSGENIC 3T3-L1 ADIPOCYTES; INDUCED GLUCOSE-TRANSPORT; PROTEIN-KINASE-B; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; FACTOR RECEPTORS; MOLECULAR MECHANISMS; DIABETES-MELLITUS; DOCKING PROTEIN; RAT ADIPOCYTES	The ability of the growth factors epidermal growth factor (EGF), transforming growth factor a, and platelet-derived growth factor to exert insulin-like effects on glucose transport and lipolysis were examined in human and rat fat cells. No effects were found in rat fat cells, whereas EGF (EC50 for glucose transport similar to0.02 nm) and transforming growth factor alpha (EC50 similar to0.2 nM), but not platelet-derived growth factor, mimicked the effects of insulin (EC50 similar to0.2 nM) on both pathways. EGF receptors, but not EGF, were abundantly expressed in human fat cells as well as in human skeletal muscle. EGF increased the tyrosine phosphorylation of several proteins (the EGF receptor, insulin receptor substrate (IRS)-1, IRS-2, and Grb2-associated binder 1), whereas She and Gab2 were only weakly and inconsistently phosphorylated. p85, the regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), was also found to associate with all of these docking molecules, showing that EGF activated PI 3-kinase pools that were additional to those of insulin. EGF and/or insulin increased protein kinase B/Akt serine phosphorylation to a similar extent, whereas mitogen-activated protein kinase phosphorylation was more pronounced for EGF than for insulin. The impaired insulin-stimulated downstream signaling, measured as protein kinase B/Akt serine phosphorylation, in insulin-resistant cells (Type 2 diabetes) was improved by the addition of EGF. Thus, EGF receptors, but not EGF, are abundantly expressed in human fat cells and skeletal muscle. EGF mimics the effects of insulin on both the metabolic and mitogenic pathways but utilize in part different signaling pathways. Both insulin and EGF increase the tyrosine phosphorylation and activation of IRS-1 and IRS-2, whereas EGF is also capable of activating additional PI 3-kinase pools and, thus, can augment the downstream signaling of insulin in insulin-resistant states like Type 2 diabetes.	Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, Dept Internal Med, SE-41345 Gothenburg, Sweden.		Gogg, Silvia/R-4549-2019					Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; Carvalho E, 2000, DIABETOLOGIA, V43, P1107, DOI 10.1007/s001250051501; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Fujioka T, 2001, EUR J BIOCHEM, V268, P4158, DOI 10.1046/j.1432-1327.2001.02327.x; Fujioka T, 2001, EUR J BIOCHEM, V268, P25, DOI 10.1046/j.1432-1327.2001.01831.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; OKADA T, 1994, J BIOL CHEM, V269, P3568; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SIMPSON IA, 1984, DIABETES, V33, P13, DOI 10.2337/diabetes.33.1.13; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; SMITH U, 1972, J LIPID RES, V13, P822; STAGSTED J, 1993, J BIOL CHEM, V268, P1770; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VanEppsFung M, 1996, DIABETES, V45, P1619, DOI 10.2337/diabetes.45.11.1619; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	48	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36045	36051		10.1074/jbc.M200575200	http://dx.doi.org/10.1074/jbc.M200575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138086	hybrid			2022-12-25	WOS:000178275100037
J	DeChant, AK; Dee, K; Weyman, CM				DeChant, AK; Dee, K; Weyman, CM			Raf-induced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase 3 activation	ONCOGENE			English	Article						Raf; myoblast; differentiation; apoptosis	PROTEIN-KINASE; MUSCLE DIFFERENTIATION; CELL LINEAGES; CYTOCHROME-C; INHIBITION; DEATH; TRANSFORMATION; PROLIFERATION; RECRUITMENT; MYOGENESIS	We examined the effect of a constitutively active Raf protein (Raf-CAAX) on the differentiation and the coincident apoptosis of skeletal myoblasts. We found that a low level of Raf signaling leads to accelerated differentiation when compared to parental myoblasts, while a higher level of Raf signaling induces a transformed morphology and abrogates both differentiation and the coincident apoptosis. Raf signaling abrogates apoptosis without blocking the activation of caspase 3 and the subsequent cleavage of caspase 3 substrates. Eliminating the signal from Raf through MEK does not restore the ability to differentiate or to undergo apoptosis in the myoblasts with a high level of Raf signal, nor does it abrogate the accelerated differentiation observed in myoblasts with lower levels of Raf signal. Constitutive signaling through MEK is required, however, to maintain a transformed morphology. These results indicate that the effect of Raf on the differentiation and apoptosis of skeletal myoblasts is dictated by the level of Raf signaling, and that Raf signaling sufficient to abrogate the apoptosis coincident with differentiation does so downstream of caspase 3 signaling.	Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA	Cleveland State University	Weyman, CM (corresponding author), Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA.	c.weyman@csuohio.edu			NATIONAL CANCER INSTITUTE [R01CA084212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA84212-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chinni C, 1999, J BIOL CHEM, V274, P9169, DOI 10.1074/jbc.274.14.9169; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FIDZIANSKA A, 1991, ACTA NEUROPATHOL, V81, P572, DOI 10.1007/BF00310140; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Mampuru LJ, 1996, EXP CELL RES, V226, P372, DOI 10.1006/excr.1996.0238; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sandri M, 1996, BASIC APPL MYOL, V6, P257; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5268	5279		10.1038/sj.onc.1205648	http://dx.doi.org/10.1038/sj.onc.1205648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149648				2022-12-25	WOS:000177193900008
J	Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R				Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R			Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis	ONCOGENE			English	Article						DNA repair; BADD45; JNK	DNA-DAMAGE RESPONSE; CELL-CYCLE; ACTIVATION; PROTEIN; GADD45; PHOSPHORYLATION; INDUCTION; BREAST; TRANSCRIPTION; REQUIREMENT	The breast cancer suppressor protein, BRCA1 plays an important role in mediating cell cycle arrest, apoptosis and DNA responses to DNA damage signals. In this study, we show that BRCA1 level is downregulated during UV-induced apoptosis by caspase-3 mediated cleavage. Cleavage of BRCA1 by caspase-3 produced a fragment that contained the C-terminal of the molecule. Accordingly, treatment of cells with caspase-3 inhibitor or mutation of a specific caspase-3 cleavage site (DLLD) at amino acid 1151 - 1154 of BRCA1 abolished cleavage and consequential accumulation of the BRCA1 C-terminal fragment. Whereas expression of the non-cleavable BRCA1 (D/A 1154) mutant conferred the resistance phenotype to UV-induced cell death, expression of the cleaved BRCA1 C-terminus induced cell death in the absence of UV. Examination of the mechanism of C-terminus-induced cell death revealed that the cleaved fragment triggers the apoptotic response through activation of BRCA1 downstream effectors, GADD45 and JNK. Altogether, results of our study demonstrate a functional role for caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis.	Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Pittsburgh, PA 15261 USA; Louisiana State Univ, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Louisiana State University System; Louisiana State University System	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, E1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	bask@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060945, R01GM060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93640] Funding Source: Medline; NIGMS NIH HHS [GM 60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afford S, 2000, J CLIN PATHOL-MOL PA, V53, P55, DOI 10.1136/mp.53.2.55; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2001, J CELL SCI, V114, P3771; Deng CX, 2000, BIOESSAYS, V22, P728; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Larson JS, 1997, CANCER RES, V57, P3351; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Shao NS, 1996, ONCOGENE, V13, P1; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VANDEVIJVER MJ, 1993, ADV CANCER RES, V61, P25; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang Y, 2000, GENE DEV, V14, P927; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu V, 2000, BREAST CANCER RES, V2, P82, DOI 10.1186/bcr37; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037	40	40	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5335	5345		10.1038/sj.onc.1205665	http://dx.doi.org/10.1038/sj.onc.1205665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149654				2022-12-25	WOS:000177193900014
J	Larminat, F; Germanier, M; Papouli, E; Defais, M				Larminat, F; Germanier, M; Papouli, E; Defais, M			Deficiency in BRCA2 leads to increase in non-conservative homologous recombination	ONCOGENE			English	Article						BRCA2; homologous recombination; DNA repair; DNA interstrand crosslink; Rad51; single-strand annealing	STRAND BREAK REPAIR; INTERSTRAND CROSS-LINKS; HAMSTER CELL MUTANTS; MAMMALIAN-CELLS; DNA-REPAIR; RAD51 RECOMBINATION; CHROMOSOMAL BREAKS; IONIZING-RADIATION; VERTEBRATE CELLS; PROTEIN	The BRCA2 tumor suppressor has been implicated in the maintenance of genomic integrity through a function in cellular responses to DNA damage. The BRCA2 protein directly associates with Rad51, that is essential for repair of double-strand breaks (DSBs) by homologous recombination (HR). In this report, we study the BRCA2-defective Chinese hamster cell mutant V-C8 for its ability to perform homology-directed repair (HDR) between repeated sequences. V-C8 cells were recently shown to be defective in Rad51 foci formation in response to DNA damage. Strikingly, we find that these BRCA2 mutant cells exhibit a strong stimulation of HDR activity compared to the V79 parental cells, which harbor a wild-type BRCA2. Furthermore, molecular characterization of the HDR products shows that loss of BRCA2 in V-C8 cells leads to significant reduction in Rad51-dependent gene conversion but strong enhancement of Rad51-independent single-strand annealing (SSA) events frequency. These data imply that, when HDR by conservative gene conversion is impaired, DSBs usually repaired by this pathway are instead resolved by other non-conservative HDR subpathways. Therefore, high chromosomal instability in BRCA2-deficient cells presumably results from enhancement of error-prone repair mechanisms, such as SSA.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Larminat, F (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.							Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; OVERKAMP WJI, 1993, SOMAT CELL MOLEC GEN, V19, P431, DOI 10.1007/BF01233248; Papouli E, 2000, BIOCHEM PHARMACOL, V59, P1101, DOI 10.1016/S0006-2952(00)00234-3; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; VERHAEGH GWCT, 1995, MUTAT RES-DNA REPAIR, V337, P119, DOI 10.1016/0921-8777(95)00017-E; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; ZDZIENICKA MZ, 1990, SOMAT CELL MOLEC GEN, V16, P575, DOI 10.1007/BF01233098; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	31	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5188	5192		10.1038/sj.onc.1205659	http://dx.doi.org/10.1038/sj.onc.1205659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140769				2022-12-25	WOS:000176975900017
J	Hong, CS; Cho, MC; Kwak, YG; Song, CH; Lee, YH; Lim, JS; Kwon, YK; Chae, SW; Kim, DH				Hong, CS; Cho, MC; Kwak, YG; Song, CH; Lee, YH; Lim, JS; Kwon, YK; Chae, SW; Kim, DH			Cardiac remodeling and atrial fibrillation in transgenic mice overexpressing junctin	FASEB JOURNAL			English	Article						excitation-contraction coupling; sarcoplasmic reticulum; ryanodine receptor; dihydropyridine receptor	SLOW CALCIUM CURRENT; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CA2+ RELEASE; MOLECULAR-CLONING; SKELETAL; CONTRACTION; CALSEQUESTRIN; HYPERTROPHY; MUSCLE	Junctin is a 26-kDa integral membrane protein, colocalized with the ryanodine receptor (RyR) and calsequestrin at the junctional sarcoplasmic reticulum (SR) membrane in cardiac and skeletal muscles. To elucidate the functional role of junctin in heart, transgenic (TG) mice overexpressing canine junctin (24-29 folds) under the control of mouse alpha-myosin heavy chain promoter were generated. Overexpression of the junctin in mouse heart was associated with heart enlargements, bradycardia, atrial fibrillation, and increased fibrosis. Many ultrastructural alterations were observed in TG atria. The junctional SR cisternae facing transverse-tubules contained a dense matrix of calsequestrin in TG heart. According to echocardiography, TG mice showed enlarged left ventricles, dilated right atriums, and ventricles with paradoxical septal motion and impaired left ventricular systolic function. Overexpression of junctin led to down-regulation of triadin and RyR but to up-regulation of dihydropyridine receptor. The L-type Ca2+ current density and action potential durations increased, which could be the cause for the bradycardia in TG heart. This study provides an important example of pathogenesis leading to substantial cardiac remodeling and atrial fibrillation, which was caused by overexpression of junctin in heart.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Chungbuk Natl Univ, Coll Med, Dept Cardiol, Cheongju, South Korea; Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Chonju, South Korea; Chonbuk Natl Univ, Sch Med, Inst Cardiovasc Res, Chonju, South Korea; Chonbuk Natl Univ, Sch Med, Dept Anat, Chonju, South Korea; Kyung Hee Univ, Dept Biol, Seoul, South Korea	Gwangju Institute of Science & Technology (GIST); Chungbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Kyung Hee University	Kim, DH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	dhkim@kjist.ac.kr						ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; Ausma J, 1997, CIRCULATION, V96, P3157, DOI 10.1161/01.CIR.96.9.3157; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; Engelhardt S, 2001, FASEB J, V15, P2718, DOI 10.1096/fj.01-0107fje; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hong CS, 2001, GENE, V278, P193, DOI 10.1016/S0378-1119(01)00718-1; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; INUI M, 1987, J BIOL CHEM, V262, P1740; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM DH, 1994, J MOL CELL CARDIOL, V26, P1505, DOI 10.1006/jmcc.1994.1169; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEPPE W, 1977, CIRCULATION, V56, P447, DOI 10.1161/01.CIR.56.3.447; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Milnes JT, 2001, J MOL CELL CARDIOL, V33, P473, DOI 10.1006/jmcc.2000.1320; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; POLLAK OJ, 1972, ANIMAL TISSUE TECHNI, P182; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROBBINS RJ, 1992, AM J PHYSIOL, V262, pH590, DOI 10.1152/ajpheart.1992.262.2.H590; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Thijssen VLJL, 2001, CARDIOVASC RES, V52, P14, DOI 10.1016/S0008-6363(01)00367-4; TIAN Q, 1991, BIOCHIM BIOPHYS ACTA, V1094, P27; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEYMAN AE, 1976, CIRCULATION, V54, P179, DOI 10.1161/01.CIR.54.2.179; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	50	63	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1310	+		10.1096/fj.01-0908fje	http://dx.doi.org/10.1096/fj.01-0908fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154005				2022-12-25	WOS:000176683900024
J	Zardo, G; Reale, A; Passananti, C; Pradhan, S; Buontempo, S; De Matteis, G; Adams, RLP; Caiafa, P				Zardo, G; Reale, A; Passananti, C; Pradhan, S; Buontempo, S; De Matteis, G; Adams, RLP; Caiafa, P			Inhibition of poly(ADP-ribosyl)ation induces DNA hypermethylation: a possible molecular mechanism	FASEB JOURNAL			English	Article						DNA methylation; DNMT1-PCNA complex; poly(ADP-ribosyl)ation; oncosuppressor gene hypermethylation	MESSENGER-RNA EXPRESSION; CPG ISLANDS; CELL-CYCLE; EUKARYOTIC DNA; HISTONE DEACETYLASE; METHYLATION PATTERN; METHYLTRANSFERASE; GENE; CANCER; TRANSCRIPTION	The pattern of DNA methylation established during embryonic development is necessary for the control of gene expression and is preserved during the replicative process. DNA regions of about 1-2 kb in size, termed CpG islands and located mostly in the promoter regions of housekeeping genes, are protected from methylation, despite being about 6-10 times richer in the dinucleotide CpG than the rest of DNA. Their unmethylated state guarantees the expression of the corresponding housekeeping genes. At present, the mechanism by which CpG islands remain protected from methylation is not clear. However, some results suggest that poly(ADP-ribosyl)ation, an enzymatic process that introduces a postsynthetic modification onto chromatin proteins, might be involved. Here we show in L929 mouse fibroblast cells that inhibition of poly(ADP-ribose) polymerase(s) at different cell-cycle phases increases the mRNA and protein levels of the major maintenance DNA methyltransferase (DNMT1) in G1/S border. Increase of DNMT1 results in a premature PCNA-DNMT1 complex formation, which facilitates robust maintenance, as well as de novo DNA methylation processes during the G1/S border, which leads to abnormal hypermethylation.	Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Biochim Clin, I-00161 Rome, Italy; CNR, ITBM, Rome, Italy; New England Biolabs Inc, Beverly, MA 01915 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Glasgow	Caiafa, P (corresponding author), Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Biochim Clin, Vle Regina Elena 324, I-00161 Rome, Italy.	caiafa@bce.med.uniroma1.it	De Matteis, Giovanna/ABD-1479-2020; Passananti, Claudio/K-9593-2016; Reale, Anna/J-5933-2016	Reale, Anna/0000-0001-8988-2342; De Matteis, Giovanna/0000-0003-2963-3365; PASSANANTI, CLAUDIO/0000-0002-9288-5736	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams R. L. P., 1985, MOL BIOL DNA METHYLA; ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; De Capoa A, 1999, FASEB J, V13, P89; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eads CA, 1999, CANCER RES, V59, P2302; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karymov MA, 2001, FASEB J, V15, P2631, DOI 10.1096/fj.01-0345com; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Marenzi S, 1999, MOL BIOL REP, V26, P261, DOI 10.1023/A:1007009022336; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Schmutte C, 1998, BIOL CHEM, V379, P377; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SimibulanRosenthal CMG, 1996, PROG NUCLEIC ACID RE, V55, P135; Slack A, 2001, GENE, V268, P87, DOI 10.1016/S0378-1119(01)00427-9; SZYF M, 1985, J BIOL CHEM, V260, P8653; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WOODCOCK DM, 1988, GENE, V74, P151, DOI 10.1016/0378-1119(88)90273-9; YISRAELI J, 1984, DNA METHYLATION BIOL; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	59	23	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1319	+		10.1096/fj.01-0827fje	http://dx.doi.org/10.1096/fj.01-0827fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154007				2022-12-25	WOS:000176683900013
J	Janausch, IG; Garcia-Moreno, I; Unden, G				Janausch, IG; Garcia-Moreno, I; Unden, G			Function of DcuS from Escherichia coli as a fumarate-stimulated histidine protein kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; SENSOR-KINASE; RHIZOBIUM-MELILOTI; GENE-EXPRESSION; OXYGEN SENSOR; TRANSFORMATION; TRANSPORT; PLASMIDS; DOMAIN; KDPD	The two-component regulatory system DcuSR of Escherichia coli controls the expression of genes of C-4-dicarboxylate metabolism in response to extracellular C-4-dicarboxylates such as fumarate or succinate. DcuS is a membrane-integral sensor kinase, and the sensory and kinase domains are located on opposite sides of the cytoplasmic membrane. The intact DcuS protein (HiS(6)-DcuS) was overproduced and isolated in detergent containing buffer. His(6)-DcuS was reconstituted into liposomes made from E. coli phospholipids. Reconstituted His(6)-DcuS catalyzed, in contrast to the detergent-solubilized sensor, autophosphorylation by [gamma-P-33]ATp with an approximate K-D of 0.16 mm for ATP. Up to 7% of the reconstituted DcuS was phosphorylated. Phosphorylation was stimulated up to 5.9-fold by C4-dicarboxylates, but not by other carboxylates. The phosphoryl group of DcuS was rapidly transferred to the response regulator DcuR. Upon phosphorylation, DcuR bound specifically to dcuB promoter DNA. The reconstituted DeuSR system therefore represents a defined in vitro system, which is capable of the complete transmembrane signal transduction by the DcuSR two-component system from the stimulus (fumarate) to the DNA, including signal transfer across the phospholipid membrane.	Univ Mainz, Inst Mikrobiol & Weinforsch, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Unden, G (corresponding author), Univ Mainz, Inst Mikrobiol & Weinforsch, Becherweg 15, D-55099 Mainz, Germany.							Aizawa S, 2000, J BACTERIOL, V182, P1459, DOI 10.1128/JB.182.6.1459-1471.2000; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; BOTT M, 1995, MOL MICROBIOL, V18, P533, DOI 10.1111/j.1365-2958.1995.mmi_18030533.x; CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Emmerich R, 1999, EUR J BIOCHEM, V263, P455, DOI 10.1046/j.1432-1327.1999.00517.x; ENGEL P, 1994, EUR J BIOCHEM, V222, P605, DOI 10.1111/j.1432-1033.1994.tb18903.x; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Golby P, 1999, J BACTERIOL, V181, P1238, DOI 10.1128/JB.181.4.1238-1248.1999; Golby P, 1998, J BACTERIOL, V180, P6586, DOI 10.1128/JB.180.24.6586-6596.1998; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Heermann R, 2000, J BIOL CHEM, V275, P17080, DOI 10.1074/jbc.M000093200; Himpens S, 2000, MICROBIOL-SGM, V146, P3091, DOI 10.1099/00221287-146-12-3091; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Janausch IG, 2002, BBA-BIOENERGETICS, V1553, P39, DOI 10.1016/S0005-2728(01)00233-X; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Jung K, 2001, J BACTERIOL, V183, P3800, DOI 10.1128/JB.183.12.3800-3803.2001; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kaspar S, 2002, ARCH MICROBIOL, V177, P313, DOI 10.1007/s00203-001-0393-z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIS AF, 1993, J BACTERIOL, V175, P1103, DOI 10.1128/JB.175.4.1103-1109.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NINFA AJ, 1995, 2 COMPONENT SIGNAL T, P65; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SIX S, 1994, J BACTERIOL, V176, P6470, DOI 10.1128/JB.176.21.6470-6478.1994; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Tran QH, 1998, EUR J BIOCHEM, V251, P538, DOI 10.1046/j.1432-1327.1998.2510538.x; Tuckerman JR, 2001, J MOL BIOL, V308, P449, DOI 10.1006/jmbi.2001.4591; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998; Zientz E, 1996, J BACTERIOL, V178, P7241, DOI 10.1128/jb.178.24.7241-7247.1996	40	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39809	39814		10.1074/jbc.M204482200	http://dx.doi.org/10.1074/jbc.M204482200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167640	hybrid			2022-12-25	WOS:000178662500096
J	Kahya, N; Wiersma, DA; Poolman, B; Hoekstra, D				Kahya, N; Wiersma, DA; Poolman, B; Hoekstra, D			Spatial organization of bacteriorhodopsin in model membranes - Light-induced mobility changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; FRACTURE ELECTRON-MICROSCOPY; PURPLE-MEMBRANE; HALOBACTERIUM-HALOBIUM; PROTON TRANSLOCATION; ION-TRANSPORT; PROTEIN; RESOLUTION; MECHANISM; PEPTIDE	Bacteriorhodopsin is a proton-transporting membrane protein in Halophilic archaea, and it is considered a prototype of membrane transporters and a model for G-protein-coupled receptors. Oligomerization of the protein has been reported, but it is unknown whether this feature is correlated with, for instance, light activation. Here, we have addressed this issue by reconstituting bacteriorhodopsin into giant unilamellar vesicles. The dynamics of the fully active protein was investigated using fluorescence correlation spectroscopy and freeze fracture electron microscopy. At low protein-to-lipid ratios (<1:10 w/w), a decrease in mobility was observed upon protein photoactivation. This process occurred on a second time scale and was fully reversible, i.e. when the dark-adapted state was reestablished the lateral diffusion rate of the protein was returned to that prior to activation. A similar decrease in lateral mobility as observed upon photoactivation was obtained when bacteriorhodopsin was reconstituted at high protein-to-lipid ratios (> 1:10 w/w). We interpret the shifts in mobility during light adaptation as being caused by transient photoinduced oligomerization of bacteriorhodopsin. These observations are fully supported by freeze-fracture electron microscopy, and the size of the clusters during photoactivation was estimated to consist of two or three trimers.	Univ Groningen, Ctr Mat Sci, Ultrafast Laser & Spect Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kahya, N (corresponding author), Univ Groningen, Ctr Mat Sci, Ultrafast Laser & Spect Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Wiersma, Douwe/AAU-6535-2020; Poolman, Bert/D-1882-2012					ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303; BAUER PJ, 1976, BIOPHYS STRUCT MECH, V2, P79, DOI 10.1007/BF00535654; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P358; CASADIO R, 1980, BIOCHEMISTRY-US, V19, P3374, DOI 10.1021/bi00555a043; CHERRY RJ, 1978, J MOL BIOL, V121, P283, DOI 10.1016/S0022-2836(78)80010-2; DENCHER NA, 1979, FEBS LETT, V108, P307, DOI 10.1016/0014-5793(79)80552-9; DENCHER NA, 1982, METHOD ENZYMOL, V88, P5; Dracheva S, 1996, FEBS LETT, V382, P209, DOI 10.1016/0014-5793(96)00181-0; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GULIKKRZYWICKI T, 1987, J BIOL CHEM, V262, P15580; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; HEYN MP, 1975, BIOCHEM BIOPH RES CO, V67, P897, DOI 10.1016/0006-291X(75)90761-5; HIRAKI K, 1981, PHOTOCHEM PHOTOBIOL, V33, P429, DOI 10.1111/j.1751-1097.1981.tb05442.x; Kahya N, 2001, BIOPHYS J, V81, P1464, DOI 10.1016/S0006-3495(01)75801-8; Kirkpatrick P, 2002, NAT REV DRUG DISCOV, V1, P7, DOI 10.1038/nrd711; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; KUBO R, 1985, STAT PHYSICS, V2, P10; Kuhlbrandt W, 2000, NATURE, V406, P569, DOI 10.1038/35020654; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Martin I, 1999, BIOCHEMISTRY-US, V38, P9337, DOI 10.1021/bi9829534; Mollaaghababa R, 2000, BIOCHEMISTRY-US, V39, P1120, DOI 10.1021/bi991963h; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pecheur EI, 1997, BIOCHEMISTRY-US, V36, P3773, DOI 10.1021/bi9622128; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; STERNBERG B, 1989, BIOCHIM BIOPHYS ACTA, V980, P117, DOI 10.1016/0005-2736(89)90207-1; STERNBERG B, 1993, J STRUCT BIOL, V110, P196, DOI 10.1006/jsbi.1993.1022; Subramaniam S, 1999, J STRUCT BIOL, V128, P19, DOI 10.1006/jsbi.1999.4178; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; VONDERWOUDE I, 1997, P NATL ACAD SCI USA, V94, P1160; Widengren J., 1996, Bioimaging, V4, P149, DOI 10.1002/1361-6374(199609)4:3<149::AID-BIO5>3.3.CO;2-4	45	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39304	39311		10.1074/jbc.M202635200	http://dx.doi.org/10.1074/jbc.M202635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167614	hybrid			2022-12-25	WOS:000178662500033
J	Vetcher, AA; Napierala, M; Iyer, RR; Chastain, PD; Griffith, JD; Wells, RD				Vetcher, AA; Napierala, M; Iyer, RR; Chastain, PD; Griffith, JD; Wells, RD			Sticky DNA, a long GAA center dot GAA center dot TTC triplex that is formed intramolecularly, in the sequence of intron 1 of the frataxin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICH ATAXIA GENE; REPEAT EXPANSION; SUPERCOILED PLASMIDS; MOLECULAR-GENETICS; PROTEIN COMPLEXES; B-DNA; TRANSCRIPTION; PATHOGENESIS; RECOMBINATION; VISUALIZATION	Friedreich's ataxia is caused by the massive expansion of GAA.TTC repeats in intron I of the frataxin-(X25) gene. Our prior investigations showed that long GAA.TTC repeats formed very stable triplex structures which caused two repeat tracts to adhere to each other (sticky DNA). This process was dependent on negative supercoiling and the presence of divalent metal ions. Herein, we have investigated the formation of sticky DNA from plasmid monomers and dimers; sticky DNA is formed only when two tracts of sufficiently long (GAA.TTC)(n) (n = 59-270) are present in a single plasmid DNA and are in the direct repeat orientation. If the inserts are in the indirect (inverted) repeat orientation, no sticky DNA was observed. Furthermore, kinetic studies support the intramolecular nature of sticky DNA formation. Electron microscopy investigations also provide strong data for sticky DNA as a single long triplex. Hence, these results give new insights into our understanding of the capacity of sticky DNA to inhibit transcription and thereby reduce the level of frataxin protein as related to the etiology of Friedreich's ataxia.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, Houston, TX 77030 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Texas A&M University System; University of North Carolina; University of North Carolina Chapel Hill	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Vetcher, Alexandre/0000-0002-4828-8571	NIEHS NIH HHS [ES11347] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982, R01GM031819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Filla A, 1996, AM J HUM GENET, V59, P554; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANAUER A, 1990, AM J HUM GENET, V46, P133; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; JAMES AA, 1982, J MOL BIOL, V160, P411, DOI 10.1016/0022-2836(82)90305-9; KANG S, 1992, J BIOL CHEM, V267, P20887; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LE DT, 1987, NUCLEIC ACIDS RES, V15, P7749; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Pandolfo M, 1998, NEUROMUSCULAR DISORD, V8, P409, DOI 10.1016/S0960-8966(98)00039-X; Pandolfo M, 1999, ARCH NEUROL-CHICAGO, V56, P1201, DOI 10.1001/archneur.56.10.1201; Pandolfo M, 2000, Neurologia, V15, P325; Pandolfo M, 1998, ADV GENET, V38, P31, DOI 10.1016/S0065-2660(08)60141-8; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; Shin C, 1996, BIOCHEMISTRY-US, V35, P968, DOI 10.1021/bi952163j; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; Soyfer V. N., 1995, TRIPLE HELICAL NUCL; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WANG YH, 1991, BIOCHEMISTRY-US, V30, P5443, DOI 10.1021/bi00236a017; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	52	50	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39217	39227		10.1074/jbc.M205209200	http://dx.doi.org/10.1074/jbc.M205209200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161437	hybrid, Green Published			2022-12-25	WOS:000178662500022
J	Baltzis, D; Lit, SY; Koromilas, AE				Baltzis, D; Lit, SY; Koromilas, AE			Functional characterization of pkr gene products expressed in cells from mice with a targeted deletion of the N terminus or C terminus domain of PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; DSRNA BINDING DOMAIN; KAPPA-B; INITIATION FACTOR-2-ALPHA; TRANSLATIONAL CONTROL; INTERFERON ACTION; VACCINIA VIRUS; ACTIVATION; MECHANISM	The interferon-inducible double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays an important role in messenger (m) RNA translation by phosphorylating the a subunit of eukaryotic initiation factor 2. Through this capacity PKR is thought to be a mediator of the antiviral and antiproliferative actions of interferon. In addition to translational function, PKR has been implicated in many signaling pathways to gene transcription by modulating the activities of a number of transcription factors, including NF-kappaB and STATs. However, experiments with two different PKR knockout (PKR-/-) mouse models have failed to verify many of the biological functions attributed to PKR. In addition, results with cells from the two PKR-/- mice have been contradictory and confusing. Here, we show that the first PKR-/- mouse with deletion of exons 2 and 3, corresponding to the N terminus domain of PKR (N-PYR-/-), expresses a truncated protein, resulting from the translation of the exon-skipped mouse PKR (ES-mPKR) mRNA. The ES-mPKR protein is defective in dsRNA binding but remains catalytically active both in vitro and in vivo. Furthermore, we show that the second PKR-/- mouse with a targeted deletion of exon 12, which corresponds to the C terminus of the molecule (C-PKR-/-), expresses a truncated mPKR produced by alternative splicing of exon 12. Although the spliced form of mPKR (SF-mPKR) is catalytically inactive, it retains the dsRNA-binding properties of the wild type mPKR. Reverse transcription-PCRs demonstrate that SF-mPKR mRNA is expressed in several normal mouse tissues, and appears to be under developmental control during embryogenesis. Our data demonstrate that both PKR-/- models are incomplete knockouts, and expression of the PKR variants may account, at least in part, for the significant signaling differences between cells from the two PKR-/- mice.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Koromilas, AE (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine St, Montreal, PQ H3T 1E2, Canada.	antonis.koromilas@mcgill.ca						Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; Adams A, 1997, METHODS YEAST GENETI; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Bass BL, 1997, RNA, V3, P947; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	43	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38364	38372		10.1074/jbc.M203564200	http://dx.doi.org/10.1074/jbc.M203564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161430	hybrid			2022-12-25	WOS:000178529600049
J	Kawauchi, J; Zhang, C; Nobori, K; Hashimoto, Y; Adachi, MT; Noda, A; Sunamori, M; Kitajima, S				Kawauchi, J; Zhang, C; Nobori, K; Hashimoto, Y; Adachi, MT; Noda, A; Sunamori, M; Kitajima, S			Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-JUN; AP-1 REPRESSOR; IN-VIVO; EXPRESSION; ATF3; PROMOTER; BINDING; DEATH; INDUCTION	Activating transcription factor 3 (ATF3) is a transcriptional repressor that is rapidly induced in cells exposed to a wide range of stress stimuli. To clarify the role of ATF3 in determining cell fate, we overexpressed it in human umbilical vein endothelial cells (HUVECs) by adenovirus-mediated gene transfer. ATF3 protected these cells from tumor necrosis factor (TNF)-alpha-induced apoptosis, as measured by flow cytometric analysis, trypan blue exclusion assay, and cleavage of procaspase 3 and poly(ADP-ribose) polymerase. Northern blot and nuclear run on assay showed that the transcription of tumor suppressor gene p53 was down-regulated in the ATF3-overexpressing cells. In the transient expression assay, ATF3 suppressed the p53 gene promoter activity through its specific binding to an atypical AP-1 element, PF-1 site, in the p53 gene promoter. Furthermore, the cell-protecting effect of ATF3 was remarkably reduced in p53-deficient cells. These results demonstrate that overexpression of ATF3 suppresses TNF-alpha-induced cell death of HUVECs, at least in part, through down-regulating the transcription of p53 gene. ATF3 may function as a cell survival factor of endothelial cells during vascular inflammation and atherogenesis.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Cardiothorac Surg, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Cardiovasc Regulat, Bunkyo Ku, Tokyo 1138510, Japan; Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kobe University	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp		Noda, Asao/0000-0002-9029-9813				Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GINSBERG D, 1990, ONCOGENE, V5, P1285; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hai T, 1999, GENE EXPRESSION, V7, P321; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, J Atheroscler Thromb, V3, P75; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; NAWA T, 2000, BIOCHEM BIOPH RES CO, V87, P565; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; ROBAYE B, 1991, AM J PATHOL, V138, P447; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	49	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39025	39034		10.1074/jbc.M202974200	http://dx.doi.org/10.1074/jbc.M202974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161427	hybrid			2022-12-25	WOS:000178529600127
J	Won, J; Yim, Y; Kim, TK				Won, J; Yim, Y; Kim, TK			Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTAL HUMAN-CELLS; HUMAN TUMOR-CELLS; GENE PROMOTER; REPLICATIVE SENESCENCE; MULTIPROTEIN COMPLEX; C-MYC; ACTIVATION; EXPRESSION; INHIBITOR; ELEMENTS	Activation of telomerase is crucial for cells to gain immortality. In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, human telomerase reverse transcriptase (hTERT). In most normal human somatic cells, hTERT is not expressed, and its suppression acts as an important gatekeeper against tumorigenesis. Here we describe the systematic analyses of hTERT promoter to understand the transcriptional repression mechanism of the hTERT gene in normal human somatic cells. Through the serial deletion analysis of hTERT promoter in normal human fibroblasts, we identified a critical repressive element on the hTERT promoter. The repressive element formed DNA-protein complexes with Sp1 and Sp3 in nuclear extracts. Using formaldehyde cross-linked chromatin immunoprecipitation analysis, we found that Sp1 and Sp3 were associated with the endogenously repressed hTERT promoter in human fibroblasts. Furthermore, Sp1 and Sp3 interacted with histone deacetylase (HDAC) in these cells. Overexpression of dominant-negative mutants of Sp1 and Sp3, which contained mainly the HDAC2-binding domain, relieved the HDAC-mediated repression of the hTERT promoter. Taken together, these results suggest that Sp1 and Sp3 associate with the hTERT promoter, recruiting HDAC for the localized deacetylation of nucleosomal histones and transcriptional silencing of the hTERT gene in normal human somatic cells.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Harvard University; Harvard Medical School; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST)	Yim, Y (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA.							BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gunes C, 2000, CANCER RES, V60, P2116; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Horikawa I, 1999, CANCER RES, V59, P826; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Ishii Y, 1999, MECH AGEING DEV, V110, P175, DOI 10.1016/S0047-6374(99)00054-8; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Sowa Y, 1999, CANCER RES, V59, P4266; Sridhar P, 1999, MOL CELL BIOL, V19, P4219; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Ulaner GA, 1998, CANCER RES, V58, P4168; Vines CR, 2000, ENDOCRINOLOGY, V141, P938, DOI 10.1210/en.141.3.938; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zaid A, 1999, J BIOENERG BIOMEMBR, V31, P129, DOI 10.1023/A:1005499727732; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	50	150	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38230	38238		10.1074/jbc.M206064200	http://dx.doi.org/10.1074/jbc.M206064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151407	hybrid			2022-12-25	WOS:000178529600033
J	Belli, G; Polaina, J; Tamarit, J; de la Torre, MA; Rodriguez-Manzaneque, MT; Ros, J; Herrero, E				Belli, G; Polaina, J; Tamarit, J; de la Torre, MA; Rodriguez-Manzaneque, MT; Ros, J; Herrero, E			Structure-function analysis of yeast Grx5 monothiol glutaredoxin defines essential amino acids for the function of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; SITE-DIRECTED MUTAGENESIS; NF-KAPPA-B; MIXED DISULFIDE; THIOLTRANSFERASE GLUTAREDOXIN; SACCHAROMYCES-CEREVISIAE; ENZYMATIC MECHANISM; T4 GLUTAREDOXIN	Grx5 defines a family of yeast monothiol glutaredoxins that also includes Grx3 and Grx4. All three proteins display significant sequence homology with proteins found from bacteria to humans. Grx5 is involved in iron/ sulfur cluster assembly at the mitochondria, but the function of Grx3 and Grx4 is unknown. Three-dimensional modeling based on known dithiol glutaredoxin structures predicted a thioredoxin fold structure for Grx5. Positionally conserved amino acids in this glutaredoxin family were replaced in Grx5, and the effect on the biological function of the protein has been tested. For all changes studied, there was a correlation between the effects on several different phenotypes: sensitivity to oxidants, constitutive protein oxidation, ability for respiratory growth, auxotrophy for a number of amino acids, and iron accumulation. Cys(60) and Gly(61) are essential for Grx5 function, whereas other single or double substitutions in the same region had no phenotypic effects. Gly(115) and Gly(116) could be important for the formation of a glutathione cleft on the Grx5 surface, in contrast to adjacent Cys(117). Substitution of Phe(50) alters the beta-sheet in the thioredoxin fold structure and inhibits Grx5 function. None of the substitutions tested affect the structure at a significant enough level to reduce protein, stability.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Valencia 46980, Spain	Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Rovira Roure 44, Lleida 25198, Spain.		ROS, Joaquim/ABG-7487-2020; Rodriguez-Manzaneque Martinez, Maria Teresa/C-6449-2011; Tamarit, Jordi/C-6316-2008; Herrero, Enrique/B-5592-2009; belli, gemma/A-7424-2011; Ros, Joaquim/A-7507-2010; de la Torre, M Angeles/A-7357-2010; Polaina, Julio/H-4498-2012; Bellí, Gemma/AAD-5325-2019	ROS, Joaquim/0000-0003-0901-8648; Tamarit, Jordi/0000-0003-3227-6928; Herrero, Enrique/0000-0002-6763-111X; belli, gemma/0000-0002-4161-3204; de la Torre, M Angeles/0000-0002-6111-1359; Bellí, Gemma/0000-0002-4161-3204; Polaina, Julio/0000-0001-9912-0640				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Berardi MJ, 1999, J MOL BIOL, V292, P151, DOI 10.1006/jmbi.1999.3067; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz RD., 1988, GENE, V74, P3065; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herrero E, 2002, METHOD ENZYMOL, V348, P136, DOI 10.1016/S0076-6879(02)48633-8; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; INGELMAN M, 1995, FEBS LETT, V370, P209, DOI 10.1016/0014-5793(95)00806-K; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kaiser C., 1998, METHODS YEAST GENETI, DOI DOI 10.1016/j.copbio.2011.03.007; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; SODANO P, 1991, J MOL BIOL, V221, P1311; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weiner Michael P., 1995, P613; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; XIA TH, 1992, PROTEIN SCI, V1, P310; YANG YF, 1991, J BIOL CHEM, V266, P12759	44	62	62	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37590	37596		10.1074/jbc.M201688200	http://dx.doi.org/10.1074/jbc.M201688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138088	hybrid, Green Published			2022-12-25	WOS:000178447100087
J	Jaikaran, DCJ; Collins, CH; MacMillan, AM				Jaikaran, DCJ; Collins, CH; MacMillan, AM			Adenosine to inosine editing by ADAR2 requires formation of a ternary complex on the GluR-B R/G site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; GLUTAMATE-RECEPTOR RNA; IN-VITRO; UNWINDING ACTIVITY; BINDING DOMAINS; DEAMINASE; CLONING; GENE; PURIFICATION; CONVERSION	RNA editing by members of the ADAR (adenosine deaminase that acts on RNA) enzyme family involves hydrolytic deamination of adenosine to inosine within the context of a double-stranded pre-mRNA substrate. Editing of the human GluR-B transcript is catalyzed by, the enzyme ADAR2 at the Q/R and R/G sites. We have established a minimal RNA substrate for editing based on the RIG site and have characterized the interaction of ADAR2 with this RNA by gel shift, kinetic, and cross-linking analyses. Gel shift analysis revealed that two complexes are formed on the RNA as protein concentration is increased; the ADAR monomers can be crosslinked to one another in an RNA-dependent fashion. We performed a detailed kinetic study of the editing reaction; the data from this study are consistent with a reaction scheme in which formation of an ADAR2.RNA ternary complex is required for efficient RNA editing and in which formation of this complex is rate determining. These observations suggest that RNA adenosine deaminases function as homodimers on their RNA substrates and may partially explain regulation of RNA editing in these systems.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	University of Alberta; University of Toronto	MacMillan, AM (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							BASS B, 1992, RNA WORLD, P383; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CARTER CW, 1995, BIOCHIMIE, V77, P92, DOI 10.1016/0300-9084(96)88110-7; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; Gerber A, 1997, RNA, V3, P453; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hough RF, 1997, RNA, V3, P356; Hurst SR, 1995, RNA, V1, P1051; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MALEY GF, 1990, J BIOL CHEM, V265, P47; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Ohman M, 2000, RNA, V6, P687, DOI 10.1017/S1355838200000200; Polson AG, 1996, NATURE, V380, P454; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCOTT J, 1995, PREMRNA PROCESSING, P157; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354; Yi-Brunozzi HY, 2001, J BIOL CHEM, V276, P37827	42	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37624	37629		10.1074/jbc.M204126200	http://dx.doi.org/10.1074/jbc.M204126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163487	hybrid, Green Accepted			2022-12-25	WOS:000178447100092
J	Willis, DM; Loewy, AP; Charlton-Kachigian, N; Shao, JS; Ornitz, DM; Towler, DA				Willis, DM; Loewy, AP; Charlton-Kachigian, N; Shao, JS; Ornitz, DM; Towler, DA			Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STRAND BREAK REPAIR; VITAMIN-D-RECEPTOR; DNA-BINDING; OSTEOBLAST DIFFERENTIATION; HOMEODOMAIN PROTEINS; MASS-SPECTROMETRY; PROMOTER; MSX2; ELEMENT	We previously described an osteocalcin (OC) fibroblast growth factor (FGF) response element (FRE) DNA binding activity as a target of Msx2 transcriptional regulation. We now identify Ku70, Ku80, and Tbdn100, a variant of Tubedown-1, as constituents of the purified OCFRE-binding complex. Northern and Western blot analyses demonstrate expression of Ku and Tbdn100 in MC3T3E1 osteoblasts. FGF2 treatment regulates Ku, but not Tbdn100, protein accumulation. Gel supershift studies confirm sequence-specific DNA binding of Ku in the OCFRE complex; chromatin immunoprecipitation assays confirm association of Ku and Tbdn100 with the endogenous OC promoter. In the promoter region -154 to -113, the OCFRE is juxtaposed to OSE2, an osteoblast-specific element that binds Runx2 (Osf2, Cbfa1). Expression of the Ku-Tbdn100 complex up-regulates both the basal and Runx2-dependent transcription driven by this 42-bp OC promoter element, reconstituted in CV-1 cells. Synergistic transactivation occurs in the presence of activated FGF receptor 2 signaling. Msx2 suppresses Ku- and Runx2-dependent transcription; suppression is dependent upon the Msx2 homeodomain NH2-terminal arm and extension. Pull-down assays confirm physical interactions between Ku and these coregulatory transcription factors, consistent with the functional interactions identified. Finally, cultured Ku70 -/- calvarial cells exhibit a profound, selective deficiency in OC expression as compared with wild-type calvarial cells, confirming the biochemical data showing a role for Ku in OC transcription. In toto, these data indicate that a novel Ku antigen complex assembles on the OC promoter, functioning in concert with Msx2 and Runx2 to regulate OC gene expression.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Med Ctr, Div Bone & Mineral Dis, Barnes Jewish Hosp, N Campus,216 S Kingshighway Blvd, St Louis, MO 63110 USA.	dtowler@im.wustl.edu		Ornitz, David/0000-0003-1592-7629; Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052446] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR43731] Funding Source: Medline; NIDDK NIH HHS [R01 DK52446] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Camara-Clayette V, 2001, BIOCHEM J, V356, P171, DOI 10.1042/0264-6021:3560171; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cooper MP, 2000, GENE DEV, V14, P907; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Ishikawa Y, 2000, JPN J CANCER RES, V91, P1345, DOI 10.1111/j.1349-7006.2000.tb00924.x; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Li BM, 2000, J BIOL CHEM, V275, P39800; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Nishishita T, 1998, J BIOL CHEM, V273, P10901, DOI 10.1074/jbc.273.18.10901; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Petroski MD, 1998, J VIROL, V72, P8181, DOI 10.1128/JVI.72.10.8181-8190.1998; Reddy SV, 1998, BLOOD, V91, P1793, DOI 10.1182/blood.V91.5.1793.1793_1793_1801; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rowley A, 2000, METHODS, V20, P383, DOI 10.1006/meth.2000.0951; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Sneddon WB, 1999, J CELL BIOCHEM, V73, P400, DOI 10.1002/(SICI)1097-4644(19990601)73:3<400::AID-JCB11>3.0.CO;2-O; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; WANG JS, 1994, J CELL SCI, V107, P3223; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhang PL, 1999, DNA CELL BIOL, V18, P197, DOI 10.1089/104454999315411; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhang ZM, 2001, J BIOL CHEM, V276, P38231	82	70	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37280	37291		10.1074/jbc.M206482200	http://dx.doi.org/10.1074/jbc.M206482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145306	hybrid			2022-12-25	WOS:000178447100049
J	Chen, WB; Lenschow, W; Tiede, K; Fischer, JW; Kalthoff, H; Ungefroren, H				Chen, WB; Lenschow, W; Tiede, K; Fischer, JW; Kalthoff, H; Ungefroren, H			Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ENDOTHELIAL-CELLS; SMAD PROTEINS; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; PROTEOGLYCANS BIGLYCAN; EXTRACELLULAR-MATRIX; ENHANCED EXPRESSION; MESANGIAL CELLS; CARCINOMA CELLS	Overexpression of the small leucine-rich proteoglycan biglycan (BGN) in fibrosis and desmoplasia results from enhanced activity of transforming growth factor-P (TGF-beta). In pancreatic adenocarcinoma, the tumor cells themselves may contribute to, BGN synthesis in vivo, since 8 of 18 different pancreatic carcinoma cell lines constitutively expressed BGN mRNA, as shown by reverse transcription-PCR analysis. In PANC-1 cells, TGF-beta1 dramatically stimulated BGN mRNA accumulation through a BGN transcription-independent, cycloheximide-sensitive mechanism and strongly increased the synthesis and release of the proteoglycan form of BGN. The ability of TGF-beta1 to induce BGN mRNA was critically dependent on Smad signaling, since 1) the upregulation of BGN mRNA was preceded by a marked increase in Smad2 phosphorylation in TGF-beta1-treated PANC-1 cells, 2) TGF-beta1 was unable to induce BGN mRNA in pancreatic carcinoma cell lines that carry homozygous deletions of the Smad4/DPC4 gene, 3) inhibition of the Smad pathway in PANC-1 cells by transfection with a dominant negative Smad4/DPC4 mutant significantly reduced TGF-beta1-induced BGN mRNA expression, 4) stable reintroduction of wild type Smad4/DPC4 into Smad4-null CFPAC-1 cells restored the TGF-beta1 effect, and 5) overexpression of Smad2 and Smad3 in PANC-1 cells augmented TGF-beta1 induction of BGN mRNA, whereas forced expression of Smad7, an inhibitory Smad, effectively blocked it. These results clearly show that a functional Smad pathway is crucial for TGF-beta regulation of BGN mRNA expression. Since BGN has been shown to inhibit growth of pancreatic cancer cells, the Smad4/DPC4 mediation of the TGF-beta effect may represent a novel tumor suppressor function for Smad4/DPC4: antiproliferation via expression of autoinhibitory BGN.	Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, D-24105 Kiel, Germany; Univ Dusseldorf, Inst Pharmacol & Clin Pharmacol, D-40225 Dusseldorf, Germany	University of Kiel; Heinrich Heine University Dusseldorf	Ungefroren, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, Arnold Heller Str 7, D-24105 Kiel, Germany.		Kalthoff, Holger/B-1618-2010					BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1998, CANCER RES, V58, P4592; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; Evanko SP, 1998, AM J PATHOL, V152, P533; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hakkinen L, 1996, J DENT RES, V75, P1767, DOI 10.1177/00220345960750101001; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heegaard AM, 1997, J BONE MINER RES, V12, P2050, DOI 10.1359/jbmr.1997.12.12.2050; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KALTHOFF H, 1991, ONCOGENE, V6, P1015; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; KRULL NB, 1993, HEPATOLOGY, V18, P581, DOI 10.1016/0270-9139(93)90359-U; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; NAKAO A, 1997, NATURE, V389, P549; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, CANCER RES, V58, P1741; Usui T, 1998, INVEST OPHTH VIS SCI, V39, P1981; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Voss M, 1999, INT J ONCOL, V14, P93; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	65	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36118	36128		10.1074/jbc.M203709200	http://dx.doi.org/10.1074/jbc.M203709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140283	hybrid			2022-12-25	WOS:000178275100046
J	Fam, SS; Murphey, LJ; Terry, ES; Zackert, WE; Chen, Y; Gao, L; Pandalai, S; Milne, GL; Roberts, LJ; Porter, NA; Montine, TJ; Morrow, JD				Fam, SS; Murphey, LJ; Terry, ES; Zackert, WE; Chen, Y; Gao, L; Pandalai, S; Milne, GL; Roberts, LJ; Porter, NA; Montine, TJ; Morrow, JD			Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A(4)/J(4)-neuroprostanes) in vivo from docosahexaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; ELECTROSPRAY MASS-SPECTROMETRY; IN-VIVO; ALZHEIMERS-DISEASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); FATTY-ACIDS; PROSTAGLANDIN J(2); OXYGEN-TENSION; CANCER CELLS; KAPPA-B	Free radical-initiated oxidant injury and lipid peroxidation have been implicated in a number of neural disorders. Docosahexaenoic acid is the most abundant unsaturated fatty acid in the central nervous system. We have shown previously that this 22-carbon fatty acid can yield, upon oxidation, isoprostane-like compounds termed neuroprostanes, with E/D-type prostane rings (E-4/D-4-neuroprostanes). Eicosanoids with E/D-type prostane rings are unstable and dehydrate to cyclopentenone-containing compounds possessing A-type and J-type prostane rings, respectively. We thus explored whether cyclopentenone neuroprostanes (A(4)/(4)-neuroprostanes) are formed from the dehydration of E-4/D-4-neuroprostanes. Indeed, oxidation of docosahexaenoic acid in vitro increased levels of putative A(4)/J(4)-neuroprostanes 64-fold from 88 +/- 43 to 5463 +/- 2579 ng/mg docosahexaenoic acid. Chemical approaches and liquid chromatography/electrospray ionization tandem mass spectrometry definitively identified them as A(4)/J(4)-neuroprostanes. We subsequently showed these compounds are formed in significant amounts from a biological source, rat brain synaptosomes. A(4)/J(4)-neuroprostanes increased 13-fold, from a basal level of 89 +/- 72 ng/mg protein to 1187 +/- 217 ng/mg (n = 4), upon oxidation. We also detected these compounds in very large amounts in fresh brain tissue from rats at levels of 97 +/- 25 ng/g brain tissue (n = 3) and from humans at levels of 98 +/- 26 ng/g brain tissue (n = 5), quantities that are nearly an order of magnitude higher than other classes of neuroprostanes. Because of the fact that A(4)/J(4)-neuroprostanes contain highly reactive cyclopentenone ring structures, it would be predicted that they readily undergo Michael addition with glutathione and adduct covalently to proteins. Indeed, incubation of A(4)/J(4)-neuroprostanes in vitro with excess glutathione resulted in the formation of large amounts of adducts. Thus, these studies have identified novel, highly reactive A/J-ring isoprostane-like compounds that are derived from docosahexaenoic acid in vivo.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 526 RRB, Nashville, TN 37232 USA.		Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X	NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007569, R37GM042056, P01GM015431, R01GM042056, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005144, R01AG016835] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839] Funding Source: Medline; NIA NIH HHS [AG16835, AG05144] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM07569, GM15431, GM42056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKELY RD, 1986, J NEUROCHEM, V47, P1013; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; CARLSON SE, 2001, SEMIN NEUNATOL, V5, P437; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chinery R, 1999, CANCER RES, V59, P2739; Clay CE, 2001, J INVEST MED, V49, P413, DOI 10.2310/6650.2001.33786; CONNOR WE, 1992, NUTR REV, V50, P21; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; Kerwin JL, 1996, J MASS SPECTROM, V31, P184, DOI 10.1002/(SICI)1096-9888(199602)31:2<184::AID-JMS283>3.0.CO;2-2; Kerwin JL, 1996, ANAL BIOCHEM, V237, P56, DOI 10.1006/abio.1996.0200; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHAHABI NA, 1987, EXP CELL BIOL, V55, P18; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; SIMONIAN NA, 1997, PROG LIPID RES, V36, P1; SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; ZIROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325	42	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36076	36084		10.1074/jbc.M205638200	http://dx.doi.org/10.1074/jbc.M205638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133837	hybrid			2022-12-25	WOS:000178275100041
J	Kupke, T				Kupke, T			Molecular characterization of the 4 '-phosphopantothenoylcysteine synthetase domain of bacterial Dfp flavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND PYRUVATE; COENZYME-A BIOSYNTHESIS; ESCHERICHIA-COLI K-12; PHOSPHOPANTOTHENOYLCYSTEINE DECARBOXYLASE; PANTOTHENATE SYNTHETASE; CRYSTAL-STRUCTURE; PURIFICATION; ENZYME; GENE; IDENTIFICATION	In bacteria, coenzyme A is synthesized in five steps from pantothenate. The flavoprotein Dfp catalyzes the synthesis of the coenzyme A precursor 4'-phosphopantetheine in the presence of 4'-phosphopantothenate, cysteine, CTP, and Mg2+ (Strauss, E., Kinsland, C., Ge, Y., McLafferty, F. W., and Begley, T. P. (2001) J. Biol. Chem. 276,13513-13516). It has been shown that the NH2-terminal domain of Dfp has 4'-phosphopantothenoylcysteine decarboxylase activity (Kupke, T., Uebele, M., Schmid, D., Jung, G., Blaesse, M., and Steinbacher, S. (2000) J. Biol. Chem. 275, 31838-31846). Here I demonstrate that the COOH-terminal CoaB domain of Dfp catalyzes the synthesis of 4'-phosphopantothenoylcysteine. The exchange of conserved amino acid residues within the CoaB domain revealed that the synthesis of 4'-phosphopantothenoylcysteine occurs in two half-reactions. Using the mutant protein His-CoaB N210D the putative acyl-cytidylate intermediate of 4'-phosphopantothenate was detectable. The same intermediate was detectable for the wild-type CoaB enzyme if cysteine was omitted in the reaction mixture. Exchange of the conserved Lys(289) residue, which is part of the strictly conserved (KXKK292)-K-289 motif of the CoaB domain, resulted in complete loss of activity with neither the acyl-cytidylate intermediate nor 4'-phosphopantothenoylcysteine being detectable. Gel filtration experiments indicated that CoaB forms dimers. Residues that are important for dimerization are conserved in CoaB proteins from eubacteria, Archaea, and eukaryotes.	Univ Tubingen, Lehrstuhl Mikrobiol Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobiol Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P300, DOI 10.1093/oxfordjournals.jbchem.a128548; ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; ABIKO Y, 1968, J BIOCHEM-TOKYO, V64, P115, DOI 10.1093/oxfordjournals.jbchem.a128855; ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P309, DOI 10.1093/oxfordjournals.jbchem.a128549; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; BROWN GM, 1959, J BIOL CHEM, V234, P370; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Miyatake K, 1979, Methods Enzymol, V62, P215; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Strauss E, 2001, J AM CHEM SOC, V123, P6449, DOI 10.1021/ja016020y; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; SUZUKI T, 1967, J BIOCHEM-TOKYO, V62, P642, DOI 10.1093/oxfordjournals.jbchem.a128719; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; WILLIAMSON JM, 1979, J BIOL CHEM, V254, P8074; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050; Zheng RJ, 2001, BIOCHEMISTRY-US, V40, P12904, DOI 10.1021/bi011522+	31	28	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36137	36145		10.1074/jbc.M206188200	http://dx.doi.org/10.1074/jbc.M206188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140293	hybrid			2022-12-25	WOS:000178275100048
J	Shimomura, Y; Harada, M; Goto, M; Sugo, T; Matsumoto, Y; Abe, M; Watanabe, T; Asami, T; Kitada, C; Mori, M; Onda, H; Fujino, M				Shimomura, Y; Harada, M; Goto, M; Sugo, T; Matsumoto, Y; Abe, M; Watanabe, T; Asami, T; Kitada, C; Mori, M; Onda, H; Fujino, M			Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; MAMMALIAN-CELLS; UROTENSIN-II; CUG CODONS; INITIATION; TRANSLATION; PEPTIDE; BRAIN; OBESITY; GHRELIN	The structurally related orphan G-protein-coupled receptors GPR7 and GPR8 are expressed in the central nervous system, and their ligands have not been identified. Here, we report the identification of the endogenous ligand for both of these receptors. We purified the peptide ligand from porcine hypothalamus using stable Chinese hamster ovary cell lines expressing human GPR8 and cloned the cDNA encoding its precursor protein. The cDNA encodes two forms of the peptide ligand with lengths of 23 and 30 amino acid residues as mature peptides. We designated the two ligands neuropeptide W-23 (NPW23) and neuropeptide W-30 (NPW30). The amino acid sequence of NPW23 is completely identical to that of the N-terminal 23 residues of NPW30. Synthetic NPW23 and NPW30 activated and bound to both GPR7 and GPR8 at similar effective doses. Intracerebroventricular administration of NPW23 in rats increased food intake and stimulated prolactin release. These findings indicate that neuropeptide W is the endogenous ligand for both GPR7 and GPR8 and acts as a mediator of the central control of feeding and the neuroendocrine system.	Takeda Chem Ind Ltd, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Discovery Res Labs 2, Pharmaceut Res Div, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Discovery Ctr, Yodogawa Ku, Osaka 5328686, Japan; Takeda Chem Ind Ltd, Pharmaceut Res Div, Strateg Res Planning, Yodogawa Ku, Osaka 5328686, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Shimomura, Y (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs 1, 10 Wadai, Tsukuba, Ibaraki 3004293, Japan.							Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Beck B, 2000, NUTRITION, V16, P916, DOI 10.1016/S0899-9007(00)00410-X; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee DK, 1999, MOL BRAIN RES, V71, P96, DOI 10.1016/S0169-328X(99)00171-0; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; Meiron M, 2001, BIOCHEM BIOPH RES CO, V282, P1053, DOI 10.1006/bbrc.2001.4684; Mori M, 1999, BIOCHEM BIOPH RES CO, V265, P123, DOI 10.1006/bbrc.1999.1640; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimomura Y, 1999, BIOCHEM BIOPH RES CO, V261, P622, DOI 10.1006/bbrc.1999.1104; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Takekawa S, 2002, EUR J PHARMACOL, V438, P129, DOI 10.1016/S0014-2999(02)01314-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wynick D, 1998, P NATL ACAD SCI USA, V95, P12671, DOI 10.1073/pnas.95.21.12671; Yang SP, 2000, NEUROENDOCRINOLOGY, V72, P20, DOI 10.1159/000054567	32	142	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35826	35832		10.1074/jbc.M205337200	http://dx.doi.org/10.1074/jbc.M205337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130646	hybrid			2022-12-25	WOS:000178275100010
J	Vial, S; Lu, H; Allen, S; Savory, P; Thornton, D; Sheehan, J; Tokatlidis, K				Vial, S; Lu, H; Allen, S; Savory, P; Thornton, D; Sheehan, J; Tokatlidis, K			Assembly of Tim9 and Tim10 into a functional chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; ADP-ATP CARRIER; PROTEIN IMPORT RECEPTOR; MEDIATES INSERTION; PRECURSOR PROTEINS; OUTER-MEMBRANE; TOM COMPLEX; MUC5B MUCIN; ACID CHAIN; TRANSLOCATION	The TIM10 complex is localized in the mitochondrial intermembrane space and mediates insertion of hydrophobic proteins at the inner membrane. We have characterized TIM10 assembly and analyzed the structural properties of its subunits, Tim9 and Tim10. Both proteins are a-helical with a protease-resistant central domain, and each self-associates to form mainly dimers and trimers in solution. Tim9 and Tim10 bound to one another with submicromolar affinity in equimolar amounts and assembled in a stable, significantly extended complex that was indistinguishable from the native mitochondrial TIM10 complex. Importantly, the reconstituted TIM10 complex is functional because it bound to the physiological substrate ADP/ATP carrier and displayed chaperone activity in refolding the model substrate firefly luciferase. These data demonstrate that the individual subunits can exist as independent, dynamically self-associating proteins. Assembly into the thermodynamically stable hexameric complex is necessary for the TIM10 chaperone function.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Crete, Dept Chem, Iraklion, Greece; Inst Mol Biol & Biotechnol, Iraklion, Greece	University of Manchester; University of Manchester; University of Crete			Lu, Hui/AAB-5476-2021	Tokatlidis, Kostas/0000-0001-6295-8183; Allen, Scott/0000-0003-4418-7375; Lu, Hui/0000-0002-7029-2681; Thornton, David/0000-0001-7148-1970	Medical Research Council [G0000153] Funding Source: Medline; MRC [G0000153] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rost B, 1996, METHOD ENZYMOL, V266, P525; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	54	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36100	36108		10.1074/jbc.M202310200	http://dx.doi.org/10.1074/jbc.M202310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138093	hybrid			2022-12-25	WOS:000178275100044
J	Wu, Q; Kirschmeier, P; Hockenberry, T; Yang, TY; Brassard, DL; Wang, LQ; McClanahan, T; Black, S; Rizzi, G; Musco, ML; Mirza, A; Liu, SX				Wu, Q; Kirschmeier, P; Hockenberry, T; Yang, TY; Brassard, DL; Wang, LQ; McClanahan, T; Black, S; Rizzi, G; Musco, ML; Mirza, A; Liu, SX			Transcriptional regulation during p21(WAF1/CIP1)-induced apoptosis in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CYCLE ARREST; GENE-EXPRESSION; P53-INDEPENDENT EXPRESSION; E2F-1-MEDIATED APOPTOSIS; GROWTH ARREST; ADENOVIRUS; P21; PROTEIN; INDUCTION	In this study we used adenovirus vector-mediated transduction of either the p53 gene (rAd-p53) or the p21(WAF1/CIP1) gene (rAd-p21) to mimic both p53-dependent and -independent up-regulation of p21(WAF1/CIP1) within a human ovarian cancer cell line, 2774, and the derivative cell lines, 2774qw1 and 2774qw2. We observed that rAd-p53 can induce apoptosis in both 2774 and 2774qw1 cells but not in 2774qw2 cells. Surprisingly, overexpression of p21(WAF1/CIP1) also triggered apoptosis within these two cell lines. Quantitative reverse transcription-PCR analysis revealed that the differential expression of BAX, BCL2, and caspase 3 genes, specific in rAd-p53-induced apoptotic cells, was not altered in rAd-p21-induced apoptotic cells, suggesting p21(WAF1/CIP1)-induced apoptosis through a pathway distinguishable from p53-induced apoptosis. Expression analysis of 2774qw1 cells infected with rAd-p21 on 60,000 cDNA microarrays identified 159 genes in response to p21(WAF1/CIP1) expression in at least one time point with 2.5-fold change as a cutoff. Integration of the data with the parallel microarray experiments with rAd-p53 infection allowed us to extract 66 genes downstream of both p53 and p21(WAF1/CIP1) and 93 genes in response to p21(WAF1/CIP1) expression in a p53-independent pathway. The genes in the former set may play a dual role in both p53-dependent and p53-independent pathways, and the genes in the latter set gave a mechanistic molecular explanation for p53-independent p21(WAF1/CIP1)-induced apoptosis. Furthermore, promoter sequence analysis suggested that transcription factor E2F family is partially responsible for the differential expression of genes following p21(WAF1/CIP1). This study has profound significance toward understanding the role of p21(WAF1/CIP1) in p53-independent apoptosis.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res dept, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Biotechnol Dev, Union, NJ 07083 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering-Plough Research Institute; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com	McClanahan, Tim/K-4998-2019					Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Boulaire J, 2000, PATHOL BIOL, V48, P190; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ding ZH, 2001, CLIN CANCER RES, V7, P3336; Draus JM, 2001, EXP MOL MED, V33, P209, DOI 10.1038/emm.2001.35; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elliott MJ, 2002, CANCER GENE THER, V9, P453, DOI 10.1038/sj.cgt.7700458; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grassilli E, 1999, CANCER RES, V59, P2451; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; Hatoum A, 2001, CARCINOGENESIS, V22, P1955, DOI 10.1093/carcin/22.12.1955; Hsu SL, 1999, EXP CELL RES, V248, P87, DOI 10.1006/excr.1999.4397; Hussain SP, 1998, CANCER RES, V58, P4023; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MICHIELI P, 1994, CANCER RES, V54, P3391; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakashima S, 2000, ANTICANCER RES, V20, P1933; Park JS, 2000, J BIOL CHEM, V275, P18, DOI 10.1074/jbc.275.1.18; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Ramondetta L, 2000, CLIN CANCER RES, V6, P278; SANTOSO JT, 1995, GYNECOL ONCOL, V59, P171; Sato T, 2002, INFECT IMMUN, V70, P528, DOI 10.1128/IAI.70.2.528-534.2002; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Ueta E, 2001, INT J CANCER, V94, P545, DOI 10.1002/ijc.1513; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WIGENDER E, 1996, NUCLEIC ACIDS RES, V24, P238; WIGENDER E, 2001, NUCLEIC ACIDS RES, V29, P281; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; ZHANG W, 1995, CANCER RES, V55, P668	49	93	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36329	36337		10.1074/jbc.M204962200	http://dx.doi.org/10.1074/jbc.M204962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138103	hybrid			2022-12-25	WOS:000178275100070
J	Coady, MJ; Wallendorff, B; Gagnon, DG; Lapointe, JY				Coady, MJ; Wallendorff, B; Gagnon, DG; Lapointe, JY			Identification of a novel Na+/myo-inositol cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL TRANSPORT; XENOPUS-OOCYTES; DOUBLE-BLIND; CONTROLLED TRIAL; ENZYMATIC ASSAY; GLUCOSE; NA+; CLONING; EXPRESSION; CELLS	rkST1, an orphan cDNA of the SLC5 family (43% identical in sequence to the sodium myo-inositol cotransporter SMIT), was expressed in Xenopus laevis oocytes that were subsequently voltage-clamped and exposed to likely substrates. Whereas superfusion with glucose and other sugars produced a small inward current, the largest current was observed with myo-inositol. The expressed protein, which we have named SMIT2, cotransports myo-inositol with a K-m of 120 muM and displays a current-voltage relationship similar to that seen with SMIT (now called SMIT1). The transport is Na+-dependent, with a K-m of 13 mM. SMIT2 exhibits phlorizin-inhibitable presteady-state currents and substrate-independent "Na+ leak" currents similar to those of related cotransporters. The steady-state cotransport current is also phlorizin-inhibitable with a K-i of 76 muM. SMIT2 exhibits stereospecific cotransport of both D-glucose and D-xylose but does not transport fucose. In addition, SMIT2 (but not SMIT1) transports D-chiro-inositol. Based on previous publications, the tissue distribution of SMIT2 is different from that of SMIT1, and the existence of this second cotransporter may explain much of the heterogeneity that has been reported for inositol transport.	Univ Montreal, Grp Rech Transport Membranaire, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	Coady, MJ (corresponding author), Grp Rech Transport Membranaire, POB 6128 Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.							Ashizawa N, 2000, J BIOCHEM BIOPH METH, V44, P89, DOI 10.1016/S0165-022X(00)00069-5; Barak Y, 1996, PROG NEURO-PSYCHOPH, V20, P729, DOI 10.1016/0278-5846(96)00043-7; BENJAMIN J, 1995, AM J PSYCHIAT, V152, P1084; CAMMARATA PR, 1992, INVEST OPHTH VIS SCI, V33, P3572; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; DOLHOFER R, 1987, J CLIN CHEM CLIN BIO, V25, P733; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; Eid SR, 2002, INT J DEV BIOL, V46, P177; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Fux M, 1996, AM J PSYCHIAT, V153, P1219; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HITOMI K, 1994, BBA-BIOMEMBRANES, V1190, P469, DOI 10.1016/0005-2736(94)90110-4; KALUZ S, 1992, NUCLEIC ACIDS RES, V20, P4369, DOI 10.1093/nar/20.16.4369; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEVINE J, 1995, AM J PSYCHIAT, V152, P792; MACGREGOR LC, 1984, ANAL BIOCHEM, V141, P382, DOI 10.1016/0003-2697(84)90058-7; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Nagata K, 1999, AM J PHYSIOL-GASTR L, V276, pG1251, DOI 10.1152/ajpgi.1999.276.5.G1251; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; Noh SJ, 1998, J CELL PHYSIOL, V176, P412, DOI 10.1002/(SICI)1097-4652(199808)176:2<412::AID-JCP20>3.0.CO;2-3; Novak JE, 1999, J NEUROCHEM, V72, P1431, DOI 10.1046/j.1471-4159.1999.721431.x; OSTLUND RE, 1993, P NATL ACAD SCI USA, V90, P9988, DOI 10.1073/pnas.90.21.9988; Ostlund RE, 1996, J BIOL CHEM, V271, P10073, DOI 10.1074/jbc.271.17.10073; PAJOR AM, 1994, BBA-BIOMEMBRANES, V1194, P349, DOI 10.1016/0005-2736(94)90319-0; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Porcellati F, 1999, AM J PHYSIOL-CELL PH, V276, pC1325, DOI 10.1152/ajpcell.1999.276.6.C1325; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; Roll P, 2002, GENE, V285, P141, DOI 10.1016/S0378-1119(02)00416-X; SCHMOLKE M, 1990, BIOL CHEM H-S, V371, P909, DOI 10.1515/bchm3.1990.371.2.909; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; SILBERNAGL S, 2001, IUPS 34 INT C; Sima AAF, 1997, DIABETES, V46, P301, DOI 10.2337/diabetes.46.2.301; SPECTOR R, 1975, AM J PHYSIOL, V228, P1510, DOI 10.1152/ajplegacy.1975.228.5.1510; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRACHTMAN H, 1992, PEDIATR NEPHROL, V6, P104, DOI 10.1007/BF00856852; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WARFIELD A, 1978, J NEUROCHEM, V31, P957, DOI 10.1111/j.1471-4159.1978.tb00133.x; Wiese TJ, 1996, AM J PHYSIOL-CELL PH, V270, pC990, DOI 10.1152/ajpcell.1996.270.4.C990; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Wright EM, 2001, AM J PHYSIOL-RENAL, V280, pF10, DOI 10.1152/ajprenal.2001.280.1.F10; YOREK MA, 1991, DIABETES, V40, P1016, DOI 10.2337/diabetes.40.8.1016	48	127	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35219	35224		10.1074/jbc.M204321200	http://dx.doi.org/10.1074/jbc.M204321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133831	hybrid			2022-12-25	WOS:000178117000072
J	Gautreau, A; Manent, J; Fievet, B; Louvard, D; Giovannini, M; Arpin, M				Gautreau, A; Manent, J; Fievet, B; Louvard, D; Giovannini, M; Arpin, M			Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-2; TERMINAL DOMAIN; MERLIN; MEMBRANE; PROTEIN; EXPRESSION; SCHWANNOMAS; CYTOSKELETON; ASSOCIATIONS; MENINGIOMAS	Neurofibromatosis type. 2 (NF2), a syndrome associated with multiple tumors of the nervous system, mostly schwannomas, is caused by mutations in the NF2 tumor suppressor gene that encodes schwannomin (Sch). Here we examined NF2 pathogenetic mutations that result in misfolding of the FERM domain. We found that these mutant forms of Sch were efficiently degraded by the ubiquitin-proteasome pathway. In transfected cells, SchDeltaF118 was 3-fold more efficiently degraded than the related molecule ezrin bearing the equivalent mutation. In heterozygous Nf2 knock-out mouse fibroblasts, endogenous mutant SchDelta81-121, but not wild type Sch, was also degraded by proteasomes. We further show that this degradation pathway is functional in primary Schwann cells. We analyzed SchDelta39-121 expressed in a transgenic mouse model of NF2 and found that SchDelta39-121, but not the endogenous wild type Sch, was unstable due to proteasome-mediated degradation. Altogether these results suggest that degradation of mutant Sch mediated by the ubiquitin-proteasome pathway is a physiopathological pathway contributing to the loss of Sch function in NF2 patients.	Inst Curie, UMR144 CNRS, F-75248 Paris 05, France; INSERM, U434, CEPH, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Arpin, M (corresponding author), Inst Curie, UMR144 CNRS, 26 Rue Ulm, F-75248 Paris 05, France.		Gautreau, Alexis/AAT-2751-2020	Gautreau, Alexis/0000-0002-2369-4362; Manent, Jan/0000-0001-9152-5459				Brault E, 2001, J CELL SCI, V114, P1901; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; den Bakker MA, 2001, NEUROPATHOLOGY, V21, P168; Faudoa R, 2000, HUM MUTAT, V15, P474, DOI 10.1002/(SICI)1098-1004(200005)15:5<474::AID-HUMU9>3.0.CO;2-7; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hogan B, 1994, MANIPULATING MOUSE E; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; StemmerRachamimov AO, 1997, AM J PATHOL, V151, P1649; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7	27	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31279	31282		10.1074/jbc.C200125200	http://dx.doi.org/10.1074/jbc.C200125200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12130630	hybrid			2022-12-25	WOS:000177718700001
J	Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P				Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P			Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells	ONCOGENE			English	Article						embryonic stem cell; cell cycle; cyclin D1; extracellular regulated kinase; phosphatidylinositol 3-kinase	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; AIRWAY SMOOTH-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; CANCER CELLS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; G(1) PHASE; PHOSPHORYLATION; ACTIVATION	Mouse embryonic stem (ES) cells are known to express D-type cyclins at very low levels and these levels increase dramatically during in vitro and in vivo differentiation. Here, we investigate some of the signalling pathways regulating expression of cyclin D1 and progression to S phase, the Ras/Extracellular signal-regulated protein kinase (ERK) pathway and the phosphatidylinositol 3-kinase (P13-kinase) pathway. We demonstrate that ERK phosphorylation is fully dispensable for the regulation of cyclin D1 level and for the progression from G1 to S phase in ES cells. By contrast, P13-kinase activity is required for both. Differentiation induced by retinoic acid results in the gain of ERK-dependent control of cyclin D1 expression and of S phase progression. Differentiation is also paralleled by an increase in P13-kinase activity. This leads (a) to an increase in the p70 S6 kinase-dependent regulation of the steady-state level of cyclin D1, and (b) to a concomitant decrease in the GSK3beta-dependent rate of cyclin D1 degradation. Altogether, these multiple pathways account for the dramatic increase in the level of cyclin D1 protein which parallels ES cell differentiation. Our studies suggest that P13-kinase is an important regulator of the ES cell cycle and that its activity is not regulated by mitogen stimulation.	Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, CNRS UMR 5534, F-69622 Villeurbanne, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Savatier, P (corresponding author), Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 07, France.		SAVATIER, Pierre/J-4663-2014; AFANASSIEFF, Marielle/M-6570-2014; stephanie, gobert/AAC-4061-2020	AFANASSIEFF, Marielle/0000-0002-6353-6617; Markossian, Suzy/0000-0003-3545-569X				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Badache A, 2001, CANCER RES, V61, P383; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; DEL PL, 1997, SCIENCE, V278, P687; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Grewe M, 1999, CANCER RES, V59, P3581; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HERBER B, 1994, ONCOGENE, V9, P1295; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; Ravenhall C, 2000, BRIT J PHARMACOL, V131, P17, DOI 10.1038/sj.bjp.0703454; Savatier P, 1996, ONCOGENE, V12, P309; Savatier P, 2002, Methods Mol Biol, V185, P27; SAVATIER P, 1994, ONCOGENE, V9, P809; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Treinies I, 1999, MOL CELL BIOL, V19, P321; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	57	161	167	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5515	5528		10.1038/sj.onc.1205728	http://dx.doi.org/10.1038/sj.onc.1205728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165850				2022-12-25	WOS:000177442000001
J	Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ				Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ			Elevated JNK activation contributes to the pathogenesis of human brain tumors	ONCOGENE			English	Article						apoptosis; brain tumor; glioblastoma multiforme; EGF receptor; JNK; MAP kinase	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; LUNG-CARCINOMA CELLS; C-JUN; PROTEIN-KINASE; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; SUPPRESSES GROWTH; HA-RAS; TRANSFORMATION	The ERK pathway is typically associated with activation of the EGF receptor and has been shown to play a major role in promoting several tumor phenotypes. An analogous signaling module, the JNK pathway, has not been shown to be consistently activated by the EGF receptor but is instead more uniformly stimulated by cellular stresses and cytokines. The function of the JNK pathway in primary tumors is unclear as it has been implicated in both promoting apoptosis and cell growth in vitro, which may be a reflection of the cell lines chosen. Primary human brain tumors frequently show overexpression of the EGF receptor. To clarify the role of JNK in tumorigenesis, we have investigated the role of JNK in a large panel of primary human brain tumors and tumor derived cell lines. Here we present evidence that JNK has a major role in promoting tumorigenesis both in vivo and in vitro. Western blot analysis demonstrated that 86% (18 of 21) of primary brain tumors showed evidence of JNK activation but only 38% (8 of 21) showed evidence of ERK activation. Kinase assays revealed that 77% of brain tumor cell lines activated JNK in response to EGF (7 of 13) or had high levels of basal activity (3 of 13), whereas none of six normal cell lines analysed, including astrocytes, had these properties. Of several growth factors examined, EGF produced the highest level of JNK induction in tumor cell lines and the duration of activation was greater than that seen for ERK. Expression of a dominant-negative (dn) form of JNK potently inhibited EGF mediated anchorage independent growth and protection from cell death in two glial tumor cell lines. These findings demonstrate that enhanced JNK activation is frequently found in primary brain tumors and that this activation contributes to phenotypes related to transformation.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Mayo Clin & Res Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Coriell Inst Med Res, Differenciat Cell Lab, Camden, NJ 08103 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center; Mayo Clinic; Coriell Institute for Medical Research	Wong, AJ (corresponding author), 233 S 10th St,BLSB 1002, Philadelphia, PA 19107 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X; Kenyon, Lawrence/0000-0002-3719-9565				Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moscatello DK, 1996, ONCOGENE, V13, P85; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Teng DHF, 1997, CANCER RES, V57, P4177; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WONG AJ, 1994, SEMIN ONCOL, V21, P139; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655	40	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5038	5046		10.1038/sj.onc.1205593	http://dx.doi.org/10.1038/sj.onc.1205593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140754				2022-12-25	WOS:000176975900002
J	Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M				Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M			Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells	ONCOGENE			English	Article						cathepsin-D; antisense RNA; breast cancer; growth; metastasis	HUMAN GLIOBLASTOMA CELLS; ESTROGEN-RECEPTOR; BASEMENT-MEMBRANE; PROCATHEPSIN-D; INVASIVENESS; INVASION; PROTEIN; RNA; TUMORIGENICITY; MACROPHAGES	Overexpression of cathepsin-D in primary breast cancer has been associated with rapid development of clinical metastasis. To investigate the role of this protease in breast cancer growth and progression to metastasis, we stably transfected a highly metastatic human breast cancer cell line, MDA-MB-231, with a plasmid containing either the full-length cDNA for cathepsin-D or a 535 bp antisense cathepsin-D cDNA fragment. Clones expressing antisense cathepsin-D cDNA that exhibited a 70-80% reduction in cathepsin-D protein, both intra- and extracellularly compared to controls, were selected for further experiments. These antisense-transfected cells displayed a reduced outgrowth rate when embedded in a Matrigel matrix, formed smaller colonies in soft agar and presented a significantly decreased tumor growth and experimental lung metastasis in nude mice compared with controls. However, manipulating the cathepsin-D level in the antisense cells has no effect on their in vitro invasiveness. These studies demonstrate that cathepsin-D enhances anchorage-independent cell proliferation and subsequently facilitates tumorigenesis and metastasis of breast cancer cells. Our overall results provide the first evidence on the essential role of cathepsin-D in breast cancer, and support the development of a new cathepsin-D-targeted therapy.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Garcia, M (corresponding author), Univ Montpellier 1, INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Bissell MJ, 1999, CANCER RES, V59, p1757S; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coyne CP, 2001, MOL IMMUNOL, V38, P347, DOI 10.1016/S0161-5890(01)00074-8; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; JOHNSON MD, 1993, CANCER RES, V53, P873; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Kondraganti S, 2000, CANCER RES, V60, P6851; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; STEWART AJ, 1994, INT J CANCER, V57, P715, DOI 10.1002/ijc.2910570518; Tedone T, 1997, FASEB J, V11, P785, DOI 10.1096/fasebj.11.10.9271363; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WORMINGTON WM, 1986, P NATL ACAD SCI USA, V83, P8639, DOI 10.1073/pnas.83.22.8639	42	94	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5127	5134		10.1038/sj.onc.1205657	http://dx.doi.org/10.1038/sj.onc.1205657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140763				2022-12-25	WOS:000176975900011
J	Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T				Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T			Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer	ONCOGENE			English	Article						Brca1; mouse models; SKY; genomic imbalances; centrosome	SUPPRESSOR GENE BRCA1; CHROMOSOMAL-ABERRATIONS; COPY NUMBER; CELL-CYCLE; MOUSE; TUMORIGENESIS; CARCINOMAS; CARCINOGENESIS; MORPHOGENESIS; PROGRESSION	BRCA1 mutation carriers have an increased susceptibility to breast and ovarian cancer. Excision of exon 11 of Brca1 in the mouse, using a conditional knockout (Cre-loxP) approach, results in mammary tumor formation after long latency. To characterize the genomic instability observed in these tumors, to establish a comparative map of chromosomal imbalances and to contribute to the validation of this mouse model of breast cancer, we have characterized chromosomal imbalances and aberrations using comparative genomic hybridization (CGH), and spectral karyotyping (SKY). We found that all tumors exhibit chromosome instability as evidenced by structural chromosomal aberrations and aneuploidy, yet they display a pattern of chromosomal gain and loss that is similar to the pattern in human breast carcinomas. Of note, nine of 15 tumors exhibited a gain of distal chromosome 11, a region that is orthologous to human chromosome 17q11-qter, the mapping position of Erbb2. However, our analysis suggests that genes distal to Erbb2 are the main targets of amplification. Four of the tumors also exhibited a copy number loss of proximal chromosome 11 (11A-B), a region orthologous to human 17p. In eight of the tumors we observed whole or partial gain of chromosome 15 centering on 15D2-D3 (orthologous to human chromosome 8q24), the map location of the c-Myc gene, and six of the tumors exhibited copy number loss of whole or partial chromosome 14, including 14D3, the map location of Rb1. We conclude that despite the tremendous shuffling of chromosomes during the course of mammalian evolution, the pattern of genomic imbalances is conserved between BRCA1-associated mammary gland tumors in mice and humans. Western blot analysis showed that while p53 is absent or mutated in some tumors, at least two tumors revealed wild-type protein, suggesting that other genetic events may lead to tumorigenesis. Similar to BRCA1-deficient mouse embryonic fibroblasts, the tumor cells contained supernumerary functional centrosomes with intact centrioles whose presence results in multipolar mitoses and aneuploidy.	NIH, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIAMSD, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ried, T (corresponding author), NIH, Genet Branch, Ctr Canc Res, 50 S Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	deng, chuxia/N-6713-2016; Gadina, Massimo/R-4195-2019	Weaver Ohler, Zoe/0000-0002-6287-2504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Deng CX, 2001, SEMIN CANCER BIOL, V11, P387, DOI 10.1006/scbi.2001.0394; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Phillips JL, 2001, CANCER RES, V61, P8143; Platzer P, 2002, CANCER RES, V62, P1134; Rhei E, 1998, CANCER RES, V58, P3193; RIED T, 1995, CANCER RES, V55, P5415; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Schuyer M, 1999, MOL CELL ENDOCRINOL, V155, P143, DOI 10.1016/S0303-7207(99)00117-3; Schuyer M, 1999, EUR J OBSTET GYN R B, V82, P147, DOI 10.1016/S0301-2115(98)00217-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SPECTOR DL, 1997, CELLS LAB MANUAL; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu GJ, 2000, CANCER RES, V60, P5371; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	112	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5097	5107		10.1038/sj.onc.1205636	http://dx.doi.org/10.1038/sj.onc.1205636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140760				2022-12-25	WOS:000176975900008
J	Guhan, N; Muniyappa, K				Guhan, N; Muniyappa, K			The RecA intein of Mycobacterium tuberculosis promotes cleavage of ectopic DNA sites - Implications for the dispersal of inteins in natural populations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODED HOMING ENDONUCLEASES; GROUP-II INTRON; PI-SCEI; DIRECTED MUTAGENESIS; PYROCOCCUS-FURIOSUS; PROTEIN; IDENTIFICATION; PURIFICATION; MOBILITY; BINDING	The RecA intein of Mycobacterium tuberculosis, a novel double-stranded DNA endonuclease, requires both Mn2+ and ATP for efficient cleavage of the intein-less recA allele. In this study, we show that Mg2+ alone was sufficient to stimulate PI-MtuI to cleave double-stranded DNA at ectopic sites. In the absence of Mg2+, PI-MtuI formed complexes with topologically different forms of DNA containing ectopic recognition sequences with equal affinity but failed to cleave DNA. We observed that PI-MtuI was able to inflict double-strand breaks robustly within the ectopic recognition sequence to generate either a blunt end or 1-2-nucleotide 3'-hydroxyl overhangs. Mutational analyses of the presumptive metal ion-binding ligands (Asp(121), Asp(222), and Glu(220)) together with immunoprecipitation assays provided compelling evidence to link both the Mg2+- and Mn2+ and ATP-dependent endonuclease activities to PI-MtuI. The kinetic mechanism of PI-MtuI promoted cleavage of ectopic DNA sites proceeded through a sequential mechanism with transient accumulation of nicked circular duplex DNA as an intermediate. Together, these data suggest that PI-MtuI, like group II introns, might mediate ectopic DNA transposition and hence its lateral transfer in natural populations.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						Aiyar A, 1996, Methods Mol Biol, V57, P177; Bakshi RP, 2001, J MOL ENDOCRINOL, V26, P193, DOI 10.1677/jme.0.0260193; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Chevalier BS, 2001, NAT STRUCT BIOL, V8, P312, DOI 10.1038/86181; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DALGAARD JZ, 1994, J BIOL CHEM, V269, P28885; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; Dickson L, 2001, P NATL ACAD SCI USA, V98, P13207, DOI 10.1073/pnas.231494498; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Guhan N, 2002, J BIOL CHEM, V277, P16257, DOI 10.1074/jbc.M112365200; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4175, DOI 10.1093/nar/27.21.4175; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER H, 1981, NUCLEIC ACIDS RES, V9, P4833, DOI 10.1093/nar/9.19.4833; MUELLER JE, 1993, NUCLEASES, P111; Munoz E, 2001, MOL MICROBIOL, V41, P645, DOI 10.1046/j.1365-2958.2001.02540.x; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schottler S, 2000, BIOCHEMISTRY-US, V39, P15895, DOI 10.1021/bi001775n; Wang JS, 1997, NUCLEIC ACIDS RES, V25, P3767, DOI 10.1093/nar/25.19.3767	33	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40352	40361		10.1074/jbc.M205697200	http://dx.doi.org/10.1074/jbc.M205697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167644	hybrid, Green Submitted			2022-12-25	WOS:000178791400026
J	Murakami, M; Fleischmann, B; De Felipe, C; Freichel, M; Trost, C; Ludwig, A; Wissenbach, U; Schwegler, H; Hofmann, F; Hescheler, J; Flockerzi, V; Cavalie, A				Murakami, M; Fleischmann, B; De Felipe, C; Freichel, M; Trost, C; Ludwig, A; Wissenbach, U; Schwegler, H; Hofmann, F; Hescheler, J; Flockerzi, V; Cavalie, A			Pain perception in mice lacking the beta 3 subunit of voltage-activated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; OMEGA-CONOTOXIN; ALPHA(1) SUBUNIT; CA2+ CHANNELS; SPINAL-CORD; P-TYPE; EXPRESSION; NEURONS; CURRENTS; MOUSE	The importance of voltage-activated calcium channels in pain processing has been suggested by the spinal antinociceptive action of blockers of N- and P/Q-type calcium channels as well as by gene targeting of the alpha1B subunit (N-type). The accessory beta3 subunits of calcium channels are preferentially associated with the alpha1B subunit in neurones. Here we show that deletion of the beta3 subunit by gene targeting affects strongly the pain processing of mutant mice. We pinpoint this defect in the pain-related behavior and ascending pain pathways of the spinal cord in vivo and at the level of calcium channel currents and proteins in single dorsal root ganglion neurones in vitro. The pain induced by chemical inflammation is preferentially damped by deletion of beta3 subunits, whereas responses to acute thermal and mechanical harmful stimuli are reduced moderately or not at all, respectively. The defect results in a weak wind-up of spinal cord activity during intense afferent nerve stimulation. The molecular mechanism responsible for the phenotype was traced to low expression of N-type calcium channels (alpha1B) and functional alterations of calcium channel currents in neurones projecting to the spinal cord.	Univ Saarland, D-66421 Homburg, Germany; Univ Magdeburg, Inst Anat, D-39120 Magdeburg, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Miguel Hernandez, Inst Neurosci, Alacant 03550, Spain; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan	Saarland University; Otto von Guericke University; Technical University of Munich; Universidad Miguel Hernandez de Elche; University of Cologne; Tohoku University	Cavalie, A (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	adolfo.cavalie@uniklinik-saarland.de	de Felipe, Carmen/D-3813-2012					BERROW NS, 1995, J PHYSIOL-LONDON, V482, P481, DOI 10.1113/jphysiol.1995.sp020534; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Brice NL, 1999, J PHYSIOL-LONDON, V515, P685, DOI 10.1111/j.1469-7793.1999.685ab.x; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cox B, 2000, Curr Rev Pain, V4, P488; Dascal N, 2001, TRENDS ENDOCRIN MET, V12, P391, DOI 10.1016/S1043-2760(01)00475-1; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Diaz A, 1997, PAIN, V69, P93, DOI 10.1016/S0304-3959(96)03271-X; DIOCHOT S, 1995, NEUROSCIENCE, V69, P627, DOI 10.1016/0306-4522(95)00267-M; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; Feng ZP, 2001, J BIOL CHEM, V276, P45051, DOI 10.1074/jbc.M107784200; GOHIL K, 1994, BRAIN RES, V653, P258, DOI 10.1016/0006-8993(94)90398-0; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; GRUNER W, 1994, J NEUROSCI, V14, P2800; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hatakeyama S, 2001, NEUROREPORT, V12, P2423, DOI 10.1097/00001756-200108080-00027; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Honore P, 1999, J NEUROSCI, V19, P7670, DOI 10.1523/JNEUROSCI.19-17-07670.1999; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; KERR LM, 1988, EUR J PHARMACOL, V146, P181, DOI 10.1016/0014-2999(88)90501-8; Kim C, 2001, MOL CELL NEUROSCI, V18, P235, DOI 10.1006/mcne.2001.1013; Lambert RC, 1997, J NEUROSCI, V17, P6621; Ludwig A, 1997, J NEUROSCI, V17, P1339; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; MALMBERG AB, 1994, J NEUROSCI, V14, P4882; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; Marquart A, 1997, FEBS LETT, V407, P137, DOI 10.1016/S0014-5793(97)00316-5; MIRANDA HF, 1992, EUR J PHARMACOL, V217, P137, DOI 10.1016/0014-2999(92)90833-P; Moreno H, 1997, P NATL ACAD SCI USA, V94, P14042, DOI 10.1073/pnas.94.25.14042; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Morimoto H, 1996, JPN J PHARMACOL, V71, P161, DOI 10.1254/jjp.71.161; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; Murakami M, 2000, J CARDIOVASC PHARM, V36, pS69, DOI 10.1097/00005344-200000006-00015; Murakami M, 2001, EUR J PHARMACOL, V419, P175, DOI 10.1016/S0014-2999(01)00985-2; Murakami M, 2001, BRAIN RES, V903, P231, DOI 10.1016/S0006-8993(01)02427-1; Muth JN, 2001, TRENDS PHARMACOL SCI, V22, P526, DOI 10.1016/S0165-6147(00)01797-1; Namkung Y, 1998, P NATL ACAD SCI USA, V95, P12010, DOI 10.1073/pnas.95.20.12010; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Rice ASC, 2001, PAIN, V94, P215, DOI 10.1016/S0304-3959(01)00407-9; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; SCOTT RH, 1986, NEUROSCI LETT, V69, P59, DOI 10.1016/0304-3940(86)90414-3; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639, DOI 10.1113/jphysiol.1992.sp018944; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Vanegas H, 2000, PAIN, V85, P9, DOI 10.1016/S0304-3959(99)00241-9; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Wilson SG, 2001, BEHAV BRAIN RES, V125, P65, DOI 10.1016/S0166-4328(01)00281-9; YU C, 1992, J NEUROPHYSIOL, V67, P561, DOI 10.1152/jn.1992.67.3.561; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035	64	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40342	40351		10.1074/jbc.M203425200	http://dx.doi.org/10.1074/jbc.M203425200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12161429	hybrid			2022-12-25	WOS:000178791400025
J	Furukawa, Y; Nishimura, N; Furukawa, Y; Satoh, M; Endo, H; Iwase, S; Yamada, H; Matsuda, M; Kano, Y; Nakamura, M				Furukawa, Y; Nishimura, N; Furukawa, Y; Satoh, M; Endo, H; Iwase, S; Yamada, H; Matsuda, M; Kano, Y; Nakamura, M			Apaf-1 is a mediator of E2F-1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CELL-DEATH; TRANSCRIPTIONAL TARGET; DEPENDENT APOPTOSIS; ECTOPIC EXPRESSION; PROMOTES APOPTOSIS; IN-VITRO; E2F-1; PROTEIN; RELEASE	E2F-1 is capable of promoting both cell cycle progression and apoptosis. The latter is important for suppressing untoward expansion of proliferating cells. In this study, we investigated its underlying mechanisms. E2F1-induced apoptosis was accompanied by caspase-9 activation and inhibited by a specific inhibitor of caspase-9 in K562 sublines overexpressing E2F-1. E2F-1 enhanced the expression of Apaf-1 without the cytosolic accumulation of cytochrome c. Apaf-l-deficient melanoma cell lines were resistant to E2F-1, indicating that Apaf-1 is an essential element of E2F-1-mediated apoptosis. Finally, we isolated the promoter region of the Apaf-1 gene and found a putative binding site for E2F. A chromatin immunoprecipitation assay revealed that E2F-1 bound to Apaf-1 promoter upon E2F-1 overexpression, suggesting that Apaf-1 is under transcriptional regulation of E2F-1. These data demonstrate a novel mechanism of apoptosis in which an increase in Apaf-1 levels results in direct activation of caspase-9 without mitochondrial damage, leading to the initiation of a caspase cascade.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan; Jikei Univ, Sch Med, Inst DNA Med, Tokyo 1058461, Japan; Jikei Univ, Sch Med, Dept Internal Med, Tokyo 1058461, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Jichi Medical University; Jikei University; Jikei University; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chang YC, 2000, ONCOGENE, V19, P4713, DOI 10.1038/sj.onc.1203833; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; IRVIN M, 2000, NATURE, V407, P645; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LEIST M, 1994, J IMMUNOL, V153, P1778; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mundle SD, 2000, BRIT J HAEMATOL, V109, P376, DOI 10.1046/j.1365-2141.2000.01937.x; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Perkins C, 1998, CANCER RES, V58, P4561; Perkins CL, 2000, CANCER RES, V60, P1645; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	121	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39760	39768		10.1074/jbc.M200805200	http://dx.doi.org/10.1074/jbc.M200805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149244	hybrid			2022-12-25	WOS:000178662500090
J	Jang, W; Chiem, B; Gomer, RH				Jang, W; Chiem, B; Gomer, RH			A secreted cell number counting factor represses intracellular glucose levels to regulate group size in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; S6 KINASE; DISCOIDEUM; GROWTH; CHEMOTAXIS; CAMP; ACTIVATION; MECHANISM; RECEPTOR; PROTEINS	Developing Dictyostelium cells form evenly sized groups of similar to2 x 10(4) cells. A secreted 450-kDa protein complex called counting factor (CF) regulates group size by repressing cell-cell adhesion and myosin polymerization and by increasing cAMP-stimulated cAMP production, actin polymerization, and cell motility. We find that CF regulates group size in part by repressing internal glucose levels. Transformants lacking bioactive CF and wild-type cells with extracellular CF depleted by antibodies have high glucose levels, whereas transformants oversecreting CF have low glucose levels. A component of CF, countin, affects group size in a manner similar to CF, and a 1-min exposure of cells to countin decreases glucose levels. Adding 1 mm exogenous glucose negates the effect of high levels of extracellular CF on group size and mimics the effect of depleting CF on glucose levels, cell-cell adhesion, cAMP pulse size, actin polymerization, myosin assembly, and motility. These results suggest that glucose is a downstream component in part of the CF signaling pathway and may be relevant to the observed role of the insulin pathway in tissue size regulation in higher eukaryotes.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA	Rice University; Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307; Jang, Wonhee/0000-0003-2470-8137				BAUMANN P, 1969, BIOCHEMISTRY-US, V8, P5011, DOI 10.1021/bi00840a050; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2002, DEVELOPMENT, V129, P3657; Brown JM, 2000, TRENDS GENET, V16, P191, DOI 10.1016/S0168-9525(00)01977-6; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; Gao T, 2002, J BIOL CHEM, V277, P32596, DOI 10.1074/jbc.M203075200; GARROD DR, 1972, J EMBRYOL EXP MORPH, V28, P463; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; GUSTAFSON GL, 1972, CRIT REV MICROBIOL, V1, P453; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Kawabe J, 2000, J HYPERTENS, V18, P1457, DOI 10.1097/00004872-200018100-00014; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; Kishi Y, 2000, EXP CELL RES, V261, P187, DOI 10.1006/excr.2000.5061; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LEHNINGER A, 1993, PRINCIPLES BIOCH, P759; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; MAKMAN RS, 1965, J BIOL CHEM, V240, P1309; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; NEWELL PC, 1988, J CELL SCI, V89, P123; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Patel J, 2001, BIOCHEM J, V358, P497, DOI 10.1042/0264-6021:3580497; PETERKOFSKY A, 1971, P NATL ACAD SCI USA, V68, P2794, DOI 10.1073/pnas.68.11.2794; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SHAFFER BM, 1957, Q J MICROSC SCI, V98, P393; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Tang L, 2001, J BIOL CHEM, V276, P27663, DOI 10.1074/jbc.M102205200; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; VERKERKEVANWIJK I, 1997, DICTYOSTELIUM MODEL, P145; WRIGHT BE, 1972, J BIOL CHEM, V247, P7875; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251	43	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39202	39208		10.1074/jbc.M205635200	http://dx.doi.org/10.1074/jbc.M205635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161440	hybrid			2022-12-25	WOS:000178662500020
J	Sklyarova, T; De Corte, V; Meerschaert, K; Devriendt, L; Vanloo, B; Bailey, J; Cook, LJ; Goethals, M; Van Damme, J; Puype, M; Vandekerckhove, J; Gettemans, J				Sklyarova, T; De Corte, V; Meerschaert, K; Devriendt, L; Vanloo, B; Bailey, J; Cook, LJ; Goethals, M; Van Damme, J; Puype, M; Vandekerckhove, J; Gettemans, J			Fragmin60 encodes an actin-binding protein with a C2 domain and controls actin Thr-203 phosphorylation in Physarum plasmodia and sclerotia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; PHOSPHOLIPID-BINDING; CELL-CYCLE; CAENORHABDITIS-ELEGANS; CRYSTAL-STRUCTURE; CA2+ BINDING; BARBED ENDS; GELSOLIN; CALCIUM; SYNAPTOTAGMIN	We report the isolation of a cDNA clone encoding a 60-kDa protein termed fragmin60 that cross-reacts with firagmin antibodies. Unlike other gelsolin-related proteins, fragmin60 contains a unique N-terminal domain that shows similarity with C2 domains of aczonin, protein kinase C, and synaptotagmins. The fragmin60 C2 domain binds three calcium ions, one with nanomolar affinity and two with micromolar affinity. Actin binding by fragmin60 requires higher calcium concentrations than does binding of actin by a fragmin60 mutant lacking the C2 domain, suggesting that the C2 domain secures the actin binding moiety in a conformation preventing actin binding at low calcium concentrations. The fragmin60 C2 domain does not bind phospholipids but interacts with the endogenous homologue of Saccharomyces cerevisiae S-phase kinase-associated protein (Skp1), as shown by pull-down assays and co-expression in mammalian cells. Recombinant fragmin60 promotes in vitro phosphorylation of actin Thr-203 by the actin-fragmin kinase. We further show that in vivo phosphorylation of actin in the fragmin60-actin complex occurs in sclerotia, a dormant stage of Physarum development, as well as in plasmodia. Our findings indicate that we have cloned a novel type of gelsolin-related actin-binding protein that is involved in controlling regulation of actin phosphorylation in vivo.	Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Romalaere Inst, B-9000 Ghent, Belgium; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	Ghent University; University of Leicester	Gettemans, J (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Romalaere Inst, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@rug.ac.be						AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY J, 1987, PROTOPLASMA, V141, P101, DOI 10.1007/BF01272891; Bailey J, 1999, ARCH MICROBIOL, V172, P364, DOI 10.1007/s002030050773; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BRUNDAGE RA, 1993, AM J PHYSIOL, V265, pC1527, DOI 10.1152/ajpcell.1993.265.6.C1527; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Constantin B, 1998, J CELL SCI, V111, P1695; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DeCorte V, 1996, EUR J BIOCHEM, V241, P901; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Furuhashi K, 1998, BIOCHEM BIOPH RES CO, V242, P653, DOI 10.1006/bbrc.1997.8044; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GETTEMANS J, 1992, EMBO J, V11, P3185, DOI 10.1002/j.1460-2075.1992.tb05395.x; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE S, 1988, ANAL BIOCHEM, V168, P148, DOI 10.1016/0003-2697(88)90022-X; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; Marks PW, 1998, J CELL SCI, V111, P2129; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; Steinbacher S, 1999, EMBO J, V18, P2923, DOI 10.1093/emboj/18.11.2923; Stocker S, 1999, MOL BIOL CELL, V10, P161, DOI 10.1091/mbc.10.1.161; SUN HQ, 1994, J BIOL CHEM, V269, P9473; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; T'Jampens D, 2002, FEBS LETT, V516, P20, DOI 10.1016/S0014-5793(02)02456-0; T'Jampens D, 1999, EUR J BIOCHEM, V265, P240, DOI 10.1046/j.1432-1327.1999.00721.x; TJampens D, 1997, J CELL SCI, V110, P1215; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wang JS, 1997, MOL BIOL CELL, V8, P121, DOI 10.1091/mbc.8.1.121; WATTS RG, 1995, CELL MOTIL CYTOSKEL, V30, P136, DOI 10.1002/cm.970300205; Wilson SA, 1998, NUCLEIC ACIDS RES, V26, P3460, DOI 10.1093/nar/26.15.3460; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200	74	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39840	39849		10.1074/jbc.M207052200	http://dx.doi.org/10.1074/jbc.M207052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167630	Green Published, hybrid			2022-12-25	WOS:000178662500100
J	Suzuki, C; Murakami, G; Fukuchi, M; Shimanuki, T; Shikauchi, Y; Imamura, T; Miyazono, K				Suzuki, C; Murakami, G; Fukuchi, M; Shimanuki, T; Shikauchi, Y; Imamura, T; Miyazono, K			Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; UBIQUITIN LIGASE COMPLEX; SIGNALING PATHWAYS; C2 DOMAIN; DEPENDENT DEGRADATION; TUMOR-SUPPRESSOR; I RECEPTOR; PROTEINS; ASSOCIATION; ANTAGONIST	Smad ubiquitin regulatory factor 1 (Smurf1), a HECT-type E3 ubiquitin ligase, interacts with inhibitory Smad7 and induces cytoplasmic localization of Smad7. Smurf1 then associates with transforming growth factor-beta type I receptor (TbetaR-1) and enhances the turnover of this receptor. However, the mechanisms of the nuclear export and plasma membrane localization of the Smurf1-Smad7 complex have not been elucidated. We show here that Smurf1 targets Smad7 to the plasma membrane through its N-terminal conserved 2 (C2) domain. Both wild-type Smurf1 (Smurf1(WT)) and Smurf1 lacking the C2 domain (Smurf1(DeltaC2)) bound to Smad7 and translocated nuclear Smad7 to the cytoplasm. However, unlike Smurf1(WT), Smurf1(DeltaC2) did not move to the plasma membrane and failed to recruit Smad7 to the cell surface TbetaR-II-TbetaR-I complex. Moreover, although Smurf1(DeltaC2) induced ubiquitination of Smad7, it failed to induce the ubiquitination and degradation of TbetaR-1 and did not enhance the inhibitory activity of Smad7. Thus, these results suggest that the plasma membrane localization of Smad7 by Smurf1 requires the C2 domain of Smurf1 and is essential for the inhibitory effect of Smad7 in the transforming growth factor-beta signaling pathway.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Das P, 1999, CYTOKINE GROWTH F R, V10, P179, DOI 10.1016/S1359-6101(99)00014-3; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIETL P, 1994, MOL PHARMACOL, V45, P300; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	39	143	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39919	39925		10.1074/jbc.M201901200	http://dx.doi.org/10.1074/jbc.M201901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151385	hybrid			2022-12-25	WOS:000178662500109
J	Brini, M; Manni, S; Carafoli, E				Brini, M; Manni, S; Carafoli, E			Recombinant expression of the plasma membrane Na+/Ca2+ exchanger affects local and global Ca2+ homeostasis in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM; ENDOPLASMIC-RETICULUM; CYTOSOLIC CA2+; I-CRAC; RELEASE; MYOCYTES; OVEREXPRESSION; INACTIVATION	The cardiac type Na+/Ca2+ exchanger (NCX1) has been transiently expressed in Chinese hamster ovary cells, which do not contain an endogenous exchanger, together with aequorin chimeras that are targeted to different intracellular compartments to investigate intracellular Ca2+ homeostasis. The expression of NCX decreased the endoplasmic reticulum Ca2+ concentration, [Ca2+](er), in resting cells, showing that the exchanger was operative under these conditions. It induced a greater reduction in the height of the mitochondrial and cytosolic Ca2+ transients in agonist-stimulated cells than would have been expected from the [Ca2+](er) decrease. It also had a major effect on the sub-plasma membrane Ca2+ concentration, [Ca2+](pm): after a transient [Ca2+](pm) rise induced by the activation of capacitative Ca2+ influx, [Ca2+](pm) settled to a value about 3-fold higher than in controls. The sustained [Ca2+](pm) increase after the transient was due to the operation of the exchanger, either directly by operating in the Ca2+ entry mode, or indirectly by removing the Ca2+ inhibition on the capacitative Ca2+ influx channels.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Padua, Ctr Study Biomembranes, Natl Res Council, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; University of Padua; Veneto Institute Molecular Medicine	Brini, M (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.		Brini, Marisa/K-5189-2016; Carafoli, Ernesto/K-5192-2016; Manni, Sabrina/AAE-9182-2021	Carafoli, Ernesto/0000-0002-7826-0094; Brini, Marisa/0000-0001-5141-0243; MANNI, SABRINA/0000-0001-6804-0680	Telethon [GP0193Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BERLIN JR, 1989, CIRC RES, V65, P115, DOI 10.1161/01.RES.65.1.115; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; Chernaya G, 1996, J BIOL CHEM, V271, P5378, DOI 10.1074/jbc.271.10.5378; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; DOSTAL DE, 1992, AM J PHYSIOL, V263, P851; Fang Y, 1998, AM J PHYSIOL-CELL PH, V275, pC50, DOI 10.1152/ajpcell.1998.275.1.C50; Fang Y, 1999, CELL CALCIUM, V26, P15, DOI 10.1054/ceca.1999.0046; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Iwamoto T, 1998, EUR J CELL BIOL, V76, P228, DOI 10.1016/S0171-9335(98)80038-1; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Litwin S, 1996, ANN NY ACAD SCI, V779, P451, DOI 10.1111/j.1749-6632.1996.tb44820.x; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38693	38699		10.1074/jbc.M206075200	http://dx.doi.org/10.1074/jbc.M206075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145298	hybrid			2022-12-25	WOS:000178529600087
J	Madison, DL; Yaciuk, P; Kwok, RPS; Lundblad, JR				Madison, DL; Yaciuk, P; Kwok, RPS; Lundblad, JR			Acetylation of the adenovirus-transforming protein E1A determines nuclear localization by disrupting association with importin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY EPITHELIAL-CELLS; REGION 1A PROTEINS; HISTONE ACETYLTRANSFERASE ACTIVITY; TERMINAL BINDING-PROTEIN; RNA-POLYMERASE-II; COREPRESSOR CTBP; ONCOPROTEIN E1A; CRYSTALLOGRAPHIC ANALYSIS; TRANSCRIPTION INITIATION; CELLULAR PHOSPHOPROTEIN	Posttranslational modifications may alter the biochemical functions of a protein by modifying associations with other macromolecules, allosterically altering intrinsic catalytic activities, or determining subcellular localization. The adenovirus-transforming protein E1A is acetylated by its cellular targets, the co-activators CREB-binding protein, p300, and p300/CREB-binding protein-associated factor in vitro and also in vivo at a single lysine residue (Lys(239)) within a multifunctional carboxyl-terminal domain necessary for both nuclear localization and interaction with the transcriptional corepressor carboxyl-terminal binding protein (CtBP). In contrast to a previous report, we demonstrate that acetylation of Lys(239) does not disrupt CtBP binding and that 12 S E1A-mediated repression of CREB-binding protein-dependent transcription does not require recruitment of CtBP. Instead we find that the cytoplasmic fraction of E1-transformed 293 cells is enriched for acetylated E1A with relative exclusion from the nuclear compartment. Whereas wild type 12 S E1A binds importin-alpha3, binding affinity was markedly reduced both by single amino acid substitution mutations and acetylation at Lys(239). This is the first demonstration that acetylation may alter nuclear partitioning by direct interference with nuclear import receptor recognition. The finding that the cytoplasmic fraction of E1A is acetylated indicates that E1A may exert its pleiotropic effects on cellular transformation in part by affecting cytoplasmic processes.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Oregon Health & Science University; Oregon Health & Science University; Saint Louis University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lundblad, JR (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, HRC-3,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	lundblad@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060133, R29DK051732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK060133, DK051732] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1994, CELL GROWTH DIFFER, V5, P475; Douglas JL, 1996, VIROLOGY, V220, P339, DOI 10.1006/viro.1996.0322; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; FELDMAN LT, 1983, MOL CELL BIOL, V3, P829, DOI 10.1128/MCB.3.5.829; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Goodman RH, 2000, GENE DEV, V14, P1553; Gopalakrishnan S, 1997, CELL GROWTH DIFFER, V8, P541; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; Grand RJA, 1999, ONCOGENE, V18, P449, DOI 10.1038/sj.onc.1202304; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E., 1988, ANTIBODIES LAB MANUA, P148; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kohler M, 2001, VIROLOGY, V289, P186, DOI 10.1006/viro.2001.1151; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; KRIPPL B, 1985, P NATL ACAD SCI USA, V82, P7480, DOI 10.1073/pnas.82.22.7480; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Molloy DP, 2001, BBA-PROTEIN STRUCT M, V1546, P55, DOI 10.1016/S0167-4838(00)00071-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; O'Connor MJ, 1999, J VIROL, V73, P3574; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; RICHTER JD, 1985, P NATL ACAD SCI USA, V82, P8434, DOI 10.1073/pnas.82.24.8434; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHENK T, 1991, ADV CANCER RES, V57, P47; SLAVICEK JM, 1989, J VIROL, V63, P4047, DOI 10.1128/JVI.63.9.4047-4050.1989; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	91	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38755	38763		10.1074/jbc.M207512200	http://dx.doi.org/10.1074/jbc.M207512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161448	hybrid			2022-12-25	WOS:000178529600095
J	Betson, M; Lozano, E; Zhang, JK; Braga, VMM				Betson, M; Lozano, E; Zhang, JK; Braga, VMM			Rac activation upon cell-cell contact formation is dependent on signaling from the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASES RHO; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; ADHESION; PROTEIN; EXPRESSION; LOCALIZATION; POLARITY; MATRIX	Cadherins are transmembrane receptors that mediate cell-cell adhesion. They play an essential role in embryonic development and maintenance of tissue architecture. The Rho family small GTPases regulate actin cytoskeletal dynamics in different cell types. The function of two family members, Rho and Rac, is required for the stability of cadherins at cell-cell contacts. Consistent with the published data we have found that Rac is activated upon induction of intercellular adhesion in epithelial cells. This activation is dependent on functional cadherins (Nakagawa, M., Fukata, M., Yamaga, M., Itoh, N., and Kaibuchi, K. (2001) J. Cell Sci. 114, 1829-1838; Noren, N. K., Niessen, C. M., Gumbiner, B. M., and Burridge, K. (2001) J. Biol. Chem. 276, 3305-3308). Here we show for the first time that clustering of cadherins using antibody-coated beads is sufficient to promote Rac activation. In the presence of Latrunculin B, Rac can be partially activated by antibody-clustered cadherins. These results suggest that actin polymerization is not required for initial Rac activation. Contrary to what has been described before, phosphatidylinositol 3-kinases are not involved in Rac activation following cell-cell adhesion in keratinocytes. Interestingly, inhibition of epidermal growth factor receptor signaling efficiently blocks the increased Rac-GTP levels observed after contact formation. We conclude that cadherin-dependent adhesion can activate Rac via epidermal growth factor receptor signaling.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Braga, VMM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Cell & Mol Biol Sect, Div Biomed Sci, Fac Med, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	v.braga@ic.ac.uk	Lozano, Encarnacion/C-5161-2008; Betson, Martha/D-3818-2014; Braga, Vania MM/C-7345-2008	Betson, Martha/0000-0002-4220-3290; Lozano, Encarnacion/0000-0003-0254-0935; Braga, Vania/0000-0003-0546-7163				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amsler K, 1999, AM J PHYSIOL-CELL PH, V276, pC91, DOI 10.1152/ajpcell.1999.276.1.C91; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; BUSE P, 1995, J BIOL CHEM, V270, P28223; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Ko KS, 2001, J CELL SCI, V114, P1155; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	57	103	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36962	36969		10.1074/jbc.M207358200	http://dx.doi.org/10.1074/jbc.M207358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147707	hybrid			2022-12-25	WOS:000178447100009
J	Li, XD; Meriane, M; Triki, I; Shekarabi, M; Kennedy, TE; Larose, L; Lamarche-Vane, N				Li, XD; Meriane, M; Triki, I; Shekarabi, M; Kennedy, TE; Larose, L; Lamarche-Vane, N			The adaptor protein Nck-1 couples the netrin-1 receptor DCC (deleted in colorectal cancer) to the activation of the small GTPase Rac1 through an atypical mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXON GUIDANCE; TYROSINE KINASES; UNC-5; CELL; DOMAINS; CDC42; RHO; IMMUNOGLOBULIN; MIGRATIONS; HOMOLOG	Netrins are a family of secreted proteins that guide the migration of cells and axonal growth cones during development. DCC (deleted in colorectal cancer) is a receptor for netrin-1 implicated in mediating these responses. Here, we show that DCC interacts constitutively with the SH3/SH2 adaptor Nck in commissural neurons. This interaction is direct and requires the SH3 but not SH2 domains of Nck-1. Moreover, both DCC and Nck-1 associate with the actin cytoskeleton, and this association is mediated by DCC. A dominant negative Nck-1 inhibits the ability of DCC to induce neurite outgrowth in N1E-115 cells and to activate Rac1 in fibroblasts in response to netrin-1. These studies provide evidence for an important role of mammalian Nck-1 in a novel signaling pathway from an extracellular guidance cue to changes in the actin-based cytoskeleton responsible for axonal guidance.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University; McGill University	Lamarche-Vane, N (corresponding author), Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca						Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Desai CJ, 1999, DEVELOPMENT, V126, P1527; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hummel T, 2000, GENE DEV, V14, P863; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Merz DC, 2001, GENETICS, V158, P1071; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	34	86	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37788	37797		10.1074/jbc.M205428200	http://dx.doi.org/10.1074/jbc.M205428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149262	hybrid			2022-12-25	WOS:000178447100113
J	Lu, M; Wang, T; Yan, QS; Yang, XB; Dong, K; Knepper, MA; Wang, WH; Giebisch, G; Shull, GE; Hebert, SC				Lu, M; Wang, T; Yan, QS; Yang, XB; Dong, K; Knepper, MA; Wang, WH; Giebisch, G; Shull, GE; Hebert, SC			Absence of small conductance K+ channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter's) knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; POTASSIUM CHANNEL; RAT-KIDNEY; GENETIC-HETEROGENEITY; NACL TRANSPORT; MOUSE KIDNEY; HENLES-LOOP; MUTATIONS; SECRETION; TUBULE	The ROMK (Kir1.1; Kcnj1) gene is believed to encode the apical small conductance K+ channels (SK) of the thick ascending limb (TAL) and cortical collecting duct (CCD). Loss-of-function mutations in the human ROMK gene cause Bartter's syndrome with renal Na+ wasting, consistent with the role of this channel in apical K+ recycling in the TAL that is crucial for NaCl reabsorption. However, the mechanism of renal K+ wasting and hypokalemia that develop in individuals with ROMK Bartter's syndrome is not apparent given the proposed loss of the collecting duct SK channel. Thus, we generated a colony of ROMK null mice with similar to25% survival to adulthood that provides a good model for ROMK Bartter's syndrome. The remaining 75% of null mice die in less than 14 days after birth. The surviving ROMK null mice have normal gross renal morphology with no evidence of significant hydronephrosis, whereas non-surviving null mice exhibit marked hydronephrosis. ROMK protein expression was absent in TAL and CCD from null mice but exhibited normal abundance and localization in wild-type littermates. ROMK null mice were polyuric and natriuretic with an elevated hematocrit consistent with mild extracellular volume depletion. SK channel activity in TAL and CCD was assessed by patch clamp analysis in ROMK wild-type ROMK(+/+), heterozygous ROMK(+/-), and null ROMK(-/-) mice. In 313 patches with successful seals from the three ROMK genotypes, SK channel activity in ROMK (+/+ and +/-) exhibited normal single channel kinetics. The expression frequencies are as follows: 67 (TAL) and 58% (CCD) in ROMK(+/+); about half that of the wild-type in ROMK(+/-), being 38 (TAL) and 25% (CCD); absent in both TAL or CCD in ROMK(-/-) between 2 and 5 weeks in 15 mice (61 and 66 patches, respectively). The absence of SK channel activity in ROMK null mice demonstrates that ROMK is essential for functional expression of SK channels in both TAL and CCD. Despite loss of ROMK expression, the normokalemic null mice exhibited significantly increased kaliuresis, indicating alternative mechanisms for K+ absorption/secretion in the nephron.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Yale University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); New York Medical College	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	steven.hebert@yale.edu	Knepper, Mark/AAF-8412-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054983, R37DK050594, R01DK054999, R01DK050594, R01DK054998] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline; NIDDK NIH HHS [R37 DK050594, R01 DK054983, R01 DK054998, R01 DK050594, DK54983, DK50594, R01 DK054999, DK54998, DK54999] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asteria C, 1997, EUR J ENDOCRINOL, V137, P613, DOI 10.1530/eje.0.1370613; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Derst C, 1997, BIOCHEM BIOPH RES CO, V230, P641, DOI 10.1006/bbrc.1996.6024; Derst C, 1998, J BIOL CHEM, V273, P23884, DOI 10.1074/jbc.273.37.23884; Ecelbarger CA, 2001, J AM SOC NEPHROL, V12, P10, DOI 10.1681/ASN.V12110; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; GILL JR, 1980, ANNU REV MED, V31, P405, DOI 10.1146/annurev.me.31.020180.002201; GILL JR, 1978, AM J MED, V65, P766, DOI 10.1016/0002-9343(78)90794-5; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; GORDON JA, 1994, HOSP PRACT, V29, P103, DOI 10.1080/21548331.1994.11443023; GREGER R, 1981, PFLUG ARCH EUR J PHY, V392, P92, DOI 10.1007/BF00584588; GREGER R, 1991, KIDNEY INT, V40, pS119; Guay-Woodford LM, 1998, AM J MED, V105, P151, DOI 10.1016/S0002-9343(98)00196-X; GUGGINO SE, 1987, AM J PHYSIOL, V252, pC121, DOI 10.1152/ajpcell.1987.252.2.C121; HEBERT SC, 1986, J GEN PHYSIOL, V87, P567, DOI 10.1085/jgp.87.4.567; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; Hebert TE, 1998, BIOCHEM J, V330, P287; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HROPOT M, 1985, KIDNEY INT, V28, P477, DOI 10.1038/ki.1985.154; Karolyi L, 1997, HUM MOL GENET, V6, P17; Karolyi L, 1998, J MOL MED, V76, P317, DOI 10.1007/s001090050223; Kohda Y, 1998, KIDNEY INT, V54, P1214, DOI 10.1046/j.1523-1755.1998.00120.x; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; Lu M, 2000, J GEN PHYSIOL, V116, P299, DOI 10.1085/jgp.116.2.299; Lu M, 1996, J GEN PHYSIOL, V108, P537, DOI 10.1085/jgp.108.6.537; Lu M, 2000, KIDNEY BLOOD PRESS R, V23, P75, DOI 10.1159/000025957; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Schwalbe RA, 1998, HUM MOL GENET, V7, P975, DOI 10.1093/hmg/7.6.975; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; Simon DB, 1998, CURR OPIN CELL BIOL, V10, P450, DOI 10.1016/S0955-0674(98)80057-4; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; STEIN JH, 1985, KIDNEY INT, V28, P85, DOI 10.1038/ki.1985.123; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Taniguchi J, 1998, J MEMBRANE BIOL, V164, P35, DOI 10.1007/s002329900391; TSUKAMOTO T, 1995, AM J KIDNEY DIS, V25, P637, DOI 10.1016/0272-6386(95)90137-X; VELAZQUEZ H, 1987, AM J PHYSIOL, V253, pF555, DOI 10.1152/ajprenal.1987.253.3.F555; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; Vollmer M, 1998, PEDIATR NEPHROL, V12, P69, DOI 10.1007/s004670050408; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809; Zolotnitskaya A, 1999, AM J PHYSIOL-RENAL, V276, pF825, DOI 10.1152/ajprenal.1999.276.6.F825	68	135	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37881	37887		10.1074/jbc.M206644200	http://dx.doi.org/10.1074/jbc.M206644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130653	Green Accepted, hybrid			2022-12-25	WOS:000178447100124
J	Paszty, K; Penheiter, AR; Verma, AK; Padanyi, R; Filoteo, AG; Penniston, JT; Enyedi, A				Paszty, K; Penheiter, AR; Verma, AK; Padanyi, R; Filoteo, AG; Penniston, JT; Enyedi, A			Asp(1080) upstream of the calmodulin-binding domain is critical for autoinhibition of hPMCA4b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; CA-2+ PUMP; INTERACTS; CA2+-ATPASE; ACTIVATION; CONTAINS; ENZYME; REGION; SITE	The role of the plasma membrane Ca2+ pump (PMCA) is to remove excess Ca2+ from the cytosol to maintain low intracellular Ca2+ levels. Asp(1080) lies within an acidic sequence between the C-terminal inhibitory region and the catalytic core of PMCAs and is part of the caspase-3 recognition site of isoforin 4b. Caspase-3 cuts immediately after this residue and activates the pump by removing the inhibitory region (Paszty, K., Verma, A. K., Padanyi, R., Filoteo, A. G., Penniston, J. T., and Enyedi, A. (2002) J. Biol. Chem. 277, 6822-6829). Asp(1080) had not been believed to have any other role, but here we show that it also plays a critical role in the autoinhibition and calmodulin activation of PMCA4b. Site-specific mutation of Asp(1080) to Asn, Ala, or Lys in PMCA4b resulted in a substantial increase in the basal activity in the absence of calmodulin. All Asp(1080) mutants exhibited an increased affinity for calmodulin because of an increase in the rate of activation by calmodulin. This rate was higher when the inhibition was weaker, showing that a strong inhibitory interaction slows the activation rate. In contrast, mutating the nearby Asp(1077) had no effect on basal activity or calmodulin activation. We propose that the conserved Asp(1080), even though it is neither in the regulatory domain nor in the catalytic core, plays an essential role in inhibition by stabilizing the inhibited state of the enzyme.	Natl Med Ctr, Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Membrane Res Grp, H-1051 Budapest, Hungary; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Hungarian Academy of Sciences; Mayo Clinic	Enyedi, A (corresponding author), Natl Med Ctr, Inst Haematol & Immunol, Dioszegi U 64, H-1113 Budapest, Hungary.		Pászty, Katalin/X-3785-2019; Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376; Paszty, Katalin/0000-0003-2457-8555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ba-Thein W, 2001, BIOCHEM J, V356, P241, DOI 10.1042/0264-6021:3560241; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GRAF E, 1981, J BIOL CHEM, V256, P1587; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; PENNISTON JT, 1982, BIOCHIM BIOPHYS ACTA, V688, P735, DOI 10.1016/0005-2736(82)90286-3; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	23	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36146	36151		10.1074/jbc.M205457200	http://dx.doi.org/10.1074/jbc.M205457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145294	hybrid			2022-12-25	WOS:000178275100049
J	Aarnisalo, P; Kim, CH; Lee, JW; Perlmann, T				Aarnisalo, P; Kim, CH; Lee, JW; Perlmann, T			Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; NGFI-B; ACTIVATION FUNCTION-2; ACID; GENE; RXR; IDENTIFICATION; ALPHA	Nurr1, an orphan nuclear receptor mainly expressed in the central nervous system, is essential for the development of the midbrain dopaminergic neurons. Nurr1 binds DNA as a monomer and exhibits constitutive transcriptional activity. Nurr1 can also regulate transcription as a heterodimer with the retinoid X receptor (RXR) and activate transcription in response to RXR ligands. However, the specific physiological roles of Nurr1 monomers and RXR-Nurr1 heterodimers remain to be elucidated. The aim of this study was to define structural requirements for RXR-Nurr1 heterodimerization. Several amino acid substitutions were introduced in both Nurr1 and RXR in the I-box, a region previously shown to be important for nuclear receptor dimerization. Single amino acid substitutions introduced in either Nurr1 or RXR abolished heterodimerization. Importantly, heterodimerization-deficient Nurr1 mutants exhibited normal activities as monomers. Thus, by introducing specific amino acid substitutions in Nurr1, monomeric and heterodimeric properties of Nurr1 can be distinguished. Interestingly, substitutions in the RXR I-box differentially affected heterodimerization with Nurr1, retinoic acid receptor, thyroid hormone receptor, and constitutive androstane receptor demonstrating that the dimerization interfaces in these different heterodimers are functionally unique. Furthermore, heterodimerization between RXR and Nurr1 had a profound influence on the constitutive activity of Nurr1, which was diminished as a result of RXR interaction. In conclusion, our data show unique structural and functional properties of RXR-Nurr1 heterodimers and also demonstrate that specific mutations in Nurr1 can abolish heterodimerization without affecting other essential functions.	Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Pohang University of Science & Technology (POSTECH)	Perlmann, T (corresponding author), Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se						Botling J, 1997, J BIOL CHEM, V272, P9443; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Depoix C, 2001, J BIOL CHEM, V276, P9452, DOI 10.1074/jbc.M008004200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gorla-Bajszczak A, 1999, MOL CELL ENDOCRINOL, V147, P37, DOI 10.1016/S0303-7207(98)00217-2; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee SK, 2000, J BIOL CHEM, V275, P33522, DOI 10.1074/jbc.M006418200; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35118	35123		10.1074/jbc.M201707200	http://dx.doi.org/10.1074/jbc.M201707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130634	hybrid			2022-12-25	WOS:000178117000059
J	Lavoie, C; Mercier, JF; Salahpour, A; Umapathy, D; Breit, A; Villeneuve, LR; Zhu, WZ; Xiao, RP; Lakatta, EG; Bouvier, M; Hebert, TE				Lavoie, C; Mercier, JF; Salahpour, A; Umapathy, D; Breit, A; Villeneuve, LR; Zhu, WZ; Xiao, RP; Lakatta, EG; Bouvier, M; Hebert, TE			beta(1)/beta(2)-adrenergic receptor heterodimerization regulates beta(2)-adrenergic receptor internalization and ERK signaling efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; FUNCTIONAL GABA(B) RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA-2-ADRENERGIC RECEPTORS; BETA(1)-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; VENTRICULAR CARDIOMYOCYTES; HETEROMERIC COMPLEXES; MOUSE CARDIOMYOCYTES; CARDIAC MYOCYTES	beta(1)- and beta(2)-adrenergic receptors (beta(1)AR and beta(2)AR) are co-expressed in numerous tissues where they play a central role in the responses of various organs to sympathetic stimulation. Although the two receptor subtypes share some signaling pathways, each has been shown to have specific signaling and regulatory properties. Given the recent recognition that many G protein-coupled receptors can form homo- and heterodimers, the present study was undertaken to determine whether the beta(1)AR and beta(2)AR can form dimers in cells and, if so, to investigate the potential functional consequences of such heterodimerization. Using co-immunoprecipitation and bioluminescence resonance energy transfer, we show that beta(1)AR and beta(2)AR can form heterodimers in HEK 293 cells co-expressing the two receptors. Functionally, beta-adrenergic stimulated adenylyl cyclase activity was found to be identical in cells expressing beta(1)AR, beta(2)AR, or both receptors at similar levels, indicating that heterodimerization did not affect this signaling pathway. When considering ERK1/2 MAPK activity, a significant agonist-promoted activation was detected in beta(2)AR- but not beta(1)AR-expressing cells. Similarly to what was observed in cells expressing the beta(1)AR alone, no beta-adrenergic stimulated ERK1/2 phosphorylation was observed in cells co-expressing the two receptors. A similar inhibition of agonist-promoted internalization of the beta(2)AR was observed upon co-expression of the beta(1)AR, which by itself internalized to a lesser extent. Taken together, our data suggest that heterodimerization between beta(1)AR and beta(2)AR inhibits the agonist-promoted internalization of the beta(2)AR and its ability to activate the ERK1/2 MAPK signaling pathway.	Inst Cardiol Montreal, Ctr Rech, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Auton, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Anesthesiol, Montreal, PQ H3C 3J7, Canada; NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	Universite de Montreal; Institut de Cardiologie de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hebert, TE (corresponding author), Inst Cardiol Montreal, Ctr Rech, 5000 Rue Belanger Est, Montreal, PQ H1T 1C8, Canada.	hebertt@icm.umontreal.ca	Xiao, Rui-Ping/AAE-2629-2019; Bouvier, Michel/H-2758-2014; Lakatta, Edward G/AAL-1447-2020; Yimei, Wang/AAE-4083-2019	Bouvier, Michel/0000-0003-1128-0100; Lakatta, Edward/0000-0002-4772-0035	NATIONAL INSTITUTE ON AGING [ZIAAG000287, Z01AG000287] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Billinton A, 2001, TRENDS NEUROSCI, V24, P277, DOI 10.1016/S0166-2236(00)01815-4; Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRODDE OE, 1983, CIRC RES, V53, P752, DOI 10.1161/01.RES.53.6.752; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; Dunigan CD, 2000, METH MOL B, V136, P329; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lemire I, 1998, J MOL CELL CARDIOL, V30, P1827, DOI 10.1006/jmcc.1998.0746; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Magne S, 2001, J BIOL CHEM, V276, P39539, DOI 10.1074/jbc.M100954200; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; Petrecca K, 1998, J ANAT, V192, P517, DOI 10.1046/j.1469-7580.1998.19240517.x; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANO M, 1993, LIFE SCI, V52, P1063, DOI 10.1016/0024-3205(93)90199-D; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, LIFE SCI, V68, P2251, DOI 10.1016/S0024-3205(01)01013-X; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zhang SJ, 2000, J BIOL CHEM, V275, P21773, DOI 10.1074/jbc.M909484199; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	60	182	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35402	35410		10.1074/jbc.M204163200	http://dx.doi.org/10.1074/jbc.M204163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12140284	hybrid			2022-12-25	WOS:000178117000096
J	Chen, QM; Merrett, JB; Dilley, T; Purdom, S				Chen, QM; Merrett, JB; Dilley, T; Purdom, S			Down regulation of p53 with HPV E6 delays and modifies cell death in oxidant response of human diploid fibroblasts: an apoptosis-like cell death associated with mitosis	ONCOGENE			English	Article						cell cycle; historic kinase; caspases; bcl-2; morphology	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; CYTOCHROME-C RELEASE; HYDROGEN-PEROXIDE; CASPASE ACTIVATION; EPITHELIAL-CELLS; GROWTH ARREST; BCL-2 FAMILY; GENERATION; PROTEIN	The tumor suppressor p53 protein is known to play a critical role in apoptosis. In normal human diploid fibroblasts (HDFs), expression of the human papillomaviral (HPV) E6 gene results in a reduction of p53 protein and an inhibition of oxidant induced apoptosis within 24 h. In comparison, expression of the HPV E7 gene causes down-regulation of Rb protein without inhibiting apoptosis. Here we determine whether HDFs expressing E6 undergo cell death with a delayed time course following H2O2 exposure. Appearances of caspase-3 activity, cell detachment, trypan blue uptake and aberrant nuclei were all delayed in E6 cells compared to wild type (wt) or E7 cells. A mutant E6 gene that failed to reduce p53 could not delay cell death. Morphological examination revealed nuclear condensation in dying wt or E7 cells but nuclear fragmentation in E6 cells. Flow cytometry analysis indicated an S phase distribution of dying wt or E7 cells but a G2/M phase distribution of dying E6 cells. An elevation of cyclin B was observed in dying E6 cells but not in apoptotic E7 cells. Dying E6 cells also had elevated levels of cdc-2 protein and histone kinase activity, suggesting that the cells died at mitosis. Electron microscopy studies showed that E6 cells may die at prophase or prometaphase. Overexpression of bcl-2 resulted in an inhibition of both caspase-3 and death of E7 or E6 cells. Inactivating caspases with zVAD-fmk also reduced the death rate of E7 and E6 cells. Our data indicate that expression of HPV E6 causes a delay and morphological modification of cell death induced by oxidants. E6 cells die at mitosis, which can be inhibited by bcl-2 overexpression or caspase inhibition.	Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.				NIA NIH HHS [AG17688] Funding Source: Medline; NIEHS NIH HHS [ES010826] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG017688] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2000, J CELL SCI, V113, P4087; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; EARNSHAW WC, 1994, BIOESSAYS, V16, P639, DOI 10.1002/bies.950160908; Endlich B, 2000, RADIAT RES, V153, P36, DOI 10.1667/0033-7587(2000)153[0036:CVTLMS]2.0.CO;2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Levin S, 1999, TOXICOL PATHOL, V27, P484, DOI 10.1177/019262339902700419; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAJNO G, 1995, AM J PATHOL, V146, P3; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	40	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5313	5324		10.1038/sj.onc.1205644	http://dx.doi.org/10.1038/sj.onc.1205644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149652				2022-12-25	WOS:000177193900012
J	Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK				Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK			Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4	ONCOGENE			English	Article						chromosome 4; senescence; keratinocyte; squamous cancer	REPLICATIVE LIFE-SPAN; TUMOR-SUPPRESSOR; INDEFINITE DIVISION; TELOMERASE ACTIVITY; IMMORTAL PHENOTYPE; CERVICAL-CARCINOMA; HUMAN-FIBROBLASTS; BREAST-CANCER; SENESCENCE; GROWTH	Squamous cell carcinoma (SCC) immortality is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) of other chromosomes, including chromosome 4. To test for a functional cancer mortality gene on human chromosome 4 we introduced a complete or fragmented copy of the chromosome into SCC lines by microcell-mediated chromosome transfer (MMCT). Human chromosome 4 caused a delayed crisis, specifically in SCC lines with LOH on chromosome 4, but chromosomes 3, 6, 11 and 15 were without effect. The introduction of the telomerase reverse transcriptase into the target lines extended the average telomere terminal fragment length but did not affect the frequency of mortal hybrids following MMCT of chromosome 4. Furthermore, telomerase activity was still present in hybrids displaying the mortal phenotype. The MMCT of chromosomal fragments into BICR6 mapped the mortality gene to between the centromere and 4q23. Deletion analysis of the introduced chromosome in immortal segregants narrowed the candidate interval to 2.7 Mb spanning D4S423 and D4S1557. The results suggest the existence of a gene on human chromosome 4 whose dysfunction contributes to the continuous proliferation of SCC and that this gene operates independently from telomeres, p53 and INK4A.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Brunel Univ, Dept Sci Biol, Uxbridge UB8 3PH, Middx, England	Beatson Institute; University of Cambridge; Brunel University	Parkinson, EK (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Arribas R, 1999, LAB INVEST, V79, P111; Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Bryce SD, 1999, CANCER RES, V59, P2038; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Hu W, 1998, GENOMICS, V47, P143, DOI 10.1006/geno.1997.5108; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee YA, 2000, AM J HUM GENET, V66, P326, DOI 10.1086/302718; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; McGregor F, 1997, CANCER RES, V57, P3886; MITRA AB, 1994, CANCER RES, V54, P4481; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Shah SI, 2000, ARCH OTOLARYNGOL, V126, P1073, DOI 10.1001/archotol.126.9.1073; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Snedecor GW, 1973, STAT METHODS; SOININEN R, 1992, MECH DEVELOP, V39, P111, DOI 10.1016/0925-4773(92)90030-N; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Terada Y, 2001, AM J MED GENET, V103, P176, DOI 10.1002/ajmg.1521; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Virgin JB, 1999, PROSTATE, V41, P49, DOI 10.1002/(SICI)1097-0045(19990915)41:1<49::AID-PROS7>3.0.CO;2-8; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	52	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5135	5147		10.1038/sj.onc.1205688	http://dx.doi.org/10.1038/sj.onc.1205688			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140764				2022-12-25	WOS:000176975900012
J	Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A				Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A			Human rgr: transforming activity and alteration in T-cell malignancies	ONCOGENE			English	Article						oncogene; rgr; lymphomas; gene rearrangement; Jurkat	NUCLEOTIDE DISSOCIATION STIMULATOR; ABL GENE; RAS; ONCOGENE	We have previously identified the oncogene rgr (ralGDS related) in DNA, derived from a rabbit squamous cell carcinoma. Here we describe the identification of the human orthologue of the rabbit rgr gene termed hrgr (human ralGDS related). Four alternatively spliced full-length hrgr transcripts were isolated from normal human testes and liver libraries. Truncation of hrgr confers transforming ability to its cDNA. Using a RT-PCR assay we have been able to detect the expression of an abnormally truncated transcript in several human T-cell lymphoma lines, and in fresh tissue samples of patients with T-cell malignancies. In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was detected within the hrgr gene region. We propose that these T-cell lymphomas, at least in part, owe their malignant phenotypes to genetic alterations of the hrgr gene. These findings also raise the possibility that mutations in the hrgr gene are involved in other malignancies.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Netherlands Canc Inst, Amsterdam, Netherlands	New York University; Netherlands Cancer Institute	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bouck N, 1979, Methods Enzymol, V58, P296; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; JIANG XY, 1990, BLOOD, V76, P597; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; PELLICER A, 1980, SCIENCE, V209, P1414, DOI 10.1126/science.7414320; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439	10	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5108	5116		10.1038/sj.onc.1205694	http://dx.doi.org/10.1038/sj.onc.1205694			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140761				2022-12-25	WOS:000176975900009
J	Walther, T; Siems, WE; Hauke, D; Spillmann, F; Dendorfer, A; Krause, W; Schultheiss, HP; Tschope, C				Walther, T; Siems, WE; Hauke, D; Spillmann, F; Dendorfer, A; Krause, W; Schultheiss, HP; Tschope, C			AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats	FASEB JOURNAL			English	Article						bradykinin; enzymes; hemodynamics; inhibitors; neutral endopeptidase; renin-angiotensin system	ANGIOTENSIN-CONVERTING ENZYME; KININ SYSTEM; INHIBITION; EXPRESSION; OMAPATRILAT; HEART	ACE inhibition protects the heart against ischemic injury by reducing angiotensin II and promoting bradykinin (BK) accumulation. Since neutral endopeptidase (NEP) metabolizes BK, we determined its activity after induction of myocardial infarction (MI) and examined whether it is influenced by treatment with an ACE inhibitor or AT1 receptor blocker. Rats were studied 6 days and 3 wk after coronary occlusion. Starting 48 h after MI induction, additional animals were treated with the ACE inhibitor quinapril (2 mg.kg(-1).day(-1)) or the AT1 blocker irbesartan (50 mg.kg(-1).day(-1)). Animals were hemodynamically characterized. Finally, NEP-specific activity and BK concentrations were detected in homogenates of heart compartments. Quinapril and irbesartan treatment improved left ventricular function 6 days and 3 wk after MI induction, and NEP activity was elevated only in the infarcted area of untreated compared with sham-operated rats. After 6 days, irbesartan reversed this increase by 80% and quinapril by 35%. Quinapril had no effect after 3 wk, whereas irbesartan almost completely blocked the increased NEP activity in the infarcted area and concomitantly induced a further rise in the BK concentrations. These results indicate mechanisms of NEP regulation influenced by the AT1 receptor. Our data suggest that NEP is more decisive than ACE in mediating BK degradation and may indicate BK involvement in the cardioprotective effects of AT1 antagonists.	Free Univ Berlin, Dept Cardiol & Pneumol, D-1000 Berlin, Germany; Inst Mol Pharmacol, Berlin, Germany; Med Univ Lubeck, Inst Pharmacol, Lubeck, Germany	Free University of Berlin; University of Lubeck	Walther, T (corresponding author), Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cardiol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de		Spillmann, Frank/0000-0003-0002-5745; Tschope, Carsten/0000-0001-5243-8985				Bischoff A, 1999, PFLUG ARCH EUR J PHY, V438, P797, DOI 10.1007/s004240051109; Blais C, 2001, PEPTIDES, V22, P953, DOI 10.1016/S0196-9781(01)00401-6; HASHIMOTO K, 1978, AM HEART J, V95, P619, DOI 10.1016/0002-8703(78)90304-6; Jalowy A, 1998, J AM COLL CARDIOL, V32, P1787, DOI 10.1016/S0735-1097(98)00441-0; Kokkonen JO, 1999, CIRCULATION, V99, P1984, DOI 10.1161/01.CIR.99.15.1984; Liu YH, 1997, J CLIN INVEST, V99, P1926, DOI 10.1172/JCI119360; Maeda K, 2000, J APPL PHYSIOL, V89, P458, DOI 10.1152/jappl.2000.89.2.458; Marie C, 1996, CARDIOVASC DRUG THER, V10, P593, DOI 10.1007/BF00051002; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Trippodo NC, 1999, J CARDIOVASC PHARM, V34, P782, DOI 10.1097/00005344-199912000-00003; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; Tschope C, 1997, J Card Fail, V3, P133, DOI 10.1016/S1071-9164(97)90047-6; Tschope C, 2000, BRIT J PHARMACOL, V129, P1537, DOI 10.1038/sj.bjp.0703239; Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Winkler A, 1998, ALCOHOL CLIN EXP RES, V22, P1262, DOI 10.1097/00000374-199809000-00011; Yang XP, 1997, J CARDIOVASC PHARM, V29, P250, DOI 10.1097/00005344-199702000-00014	18	21	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1237	10.1096/fj.01-0641com	http://dx.doi.org/10.1096/fj.01-0641com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153991				2022-12-25	WOS:000177814000032
J	Li, HH; Lyles, DS; Pan, W; Alexander, E; Thomas, MJ; Sorci-Thomas, MG				Li, HH; Lyles, DS; Pan, W; Alexander, E; Thomas, MJ; Sorci-Thomas, MG			ApoA-I structure on discs and spheres - Variable helix registry and conformational states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; RESONANCE ENERGY-TRANSFER; BELT MODEL; COMPLEXES; ORIENTATION	Apolipoprotein A-I (apoA-I) readily forms discoidal high density lipoprotein (HDL) particles with phospholipids serving as an ideal transporter of plasma cholesterol. In the lipid-bound conformation, apoA-I activates the enzyme lecithin:cholesterol acyltransferase stimulating the formation of cholesterol esters from free cholesterol. As esterification proceeds cholesterol esters accumulate within the hydrophobic core of the discoidal phospholipid bilayer transforming it into a spherical HDL particle. To investigate the change in apoA-I conformation as it adapts to a spherical surface, fluorescence resonance energy transfer studies were performed. Discoidal rHDL particles containing two lipid-bound apoA-I molecules were prepared with acceptor and donor fluorescent probes attached to cysteine residues located at specific positions. Fluorescence quenching was measured for probe combinations located within repeats 5 and 5 (residue 132), repeats 5 and 6 (residues 132 and 154), and repeats 6 and 6 (residue 154). Results from these experiments indicated that each of the 2 molecules of discoidal bound apoA-I exists in multiple conformations and support the concept of a "variable registry" rather than a "fixed helix-helix registry." Additionally, discoidal rHDL were transformed in vitro to core-containing particles by incubation with lecithin:cholesterol acyltransferase. Compositional analysis showed that core-containing particles contained 11% less phospholipid and 633% more cholesterol ester and a total of 3 apoA-I molecules per particle. Spherical particles showed a lowering of acceptor to donor probe quenching when compared with starting rHDL. Therefore, we conclude that as lipid-bound apoA-I adjusts from a discoidal to a spherical surface its intermolecular interactions are significantly reduced presumably to cover the increased surface area of the particle.	Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Dept Immunol & Microbiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sorci-Thomas, MG (corresponding author), Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Sorci-Thomas, Mary/0000-0002-6464-5006; Lyles, Douglas/0000-0002-8401-3073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL064963, R01HL060079, R01HL064163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI015892, R01AI015892] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64163, HL49373, HL-60079, HL64963] Funding Source: Medline; NIAID NIH HHS [AI15892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Calabresi L, 1997, BIOCHEMISTRY-US, V36, P12428, DOI 10.1021/bi970505a; Chisholm JW, 1999, J LIPID RES, V40, P1512; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Garda HA, 2002, J BIOL CHEM, V277, P19773, DOI 10.1074/jbc.M110089200; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; Klon AE, 2000, BIOPHYS J, V79, P1679, DOI 10.1016/S0006-3495(00)76417-4; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2001, J LIPID RES, V42, P2084; Libby P, 2001, AM J CARDIOL, V88, p3N; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; Navab M, 2001, CIRCULATION, V104, P2386, DOI 10.1161/circ.104.20.2386; NICHOLS AV, 1985, BIOCHIM BIOPHYS ACTA, V834, P285, DOI 10.1016/0005-2760(85)90001-3; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; RUDEL LL, 1990, J LIPID RES, V31, P1873; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; VANLOO B, 1992, BIOCHIM BIOPHYS ACTA, V1128, P258, DOI 10.1016/0005-2760(92)90316-N	25	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39093	39101		10.1074/jbc.M206770200	http://dx.doi.org/10.1074/jbc.M206770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167653	hybrid			2022-12-25	WOS:000178662500007
J	Yamao, T; Noguchi, T; Takeuchi, O; Nishiyama, U; Morita, H; Hagiwara, T; Akahori, H; Kato, T; Inagaki, K; Okazawa, H; Hayashi, Y; Matozaki, T; Takeda, K; Akira, S; Kasuga, M				Yamao, T; Noguchi, T; Takeuchi, O; Nishiyama, U; Morita, H; Hagiwara, T; Akahori, H; Kato, T; Inagaki, K; Okazawa, H; Hayashi, Y; Matozaki, T; Takeda, K; Akira, S; Kasuga, M			Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; TYROSINE-PHOSPHATASE SHP-1; COLONY-STIMULATING FACTOR; ALPHA SIRP-ALPHA; MYELOID CELLS; RECEPTOR; FAMILY; ADHESION; ASSOCIATION; KINASE	SHPS-1 is a receptor-type glycoprotein that binds and activates the protein-tyrosine phosphatases SHP-1 and SHP-2, and thereby negatively modulates intracellular signaling initiated by various cell surface receptors coupled to tyrosine kinases. SHPS-1 also regulates intercellular communication in the neural and immune systems through its association with CD47 (integrin-associated protein) on adjacent cells. Furthermore, recent studies with fibroblasts derived from mice expressing an SHPS-1 mutant that lacks most of the cytoplasmic region suggested that the intact protein contributes to cytoskeletal function. Mice homozygous for this SHPS-1 mutation have now been shown to manifest thrombocytopenia. These animals did not exhibit a defect in megakaryocytopoiesis or in platelet production. However, platelets were cleared from the bloodstream more rapidly in the mutant mice than in wild-type animals. Furthermore, peritoneal macrophages from the mutant mice phagocytosed red blood cells more effectively than did those from wild-type mice; in addition, they exhibited an increase both in the rate of cell spreading and in the formation of filopodia-like structures at the cell periphery. These results indicate that SHPS-1 both contributes to the survival of circulating platelets and down-regulates the macrophage phagocytic response.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Biomed Informat, Div Surg Pathol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan; Kirin Brewery Co Ltd, Pharmaceut Dev Labs, Takasaki, Gumma 3701295, Japan; Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	Kobe University; Kobe University; Gunma University; Kirin Brewery Company Limited; Kirin Brewery Company Limited	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp	Akira, Shizuo/C-3134-2009; Takeuchi, Osamu/D-6007-2011; Okazawa, Hideki/E-3055-2010; Takeuchi, Osamu/AAG-9359-2019; Okazawa, Hideki/C-3836-2011	Takeuchi, Osamu/0000-0002-1260-6232; 				Adams S, 1998, J IMMUNOL, V161, P1853; AULT KA, 1995, EXP HEMATOL, V23, P996; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baker GR, 1998, BLOOD, V91, P89, DOI 10.1182/blood.V91.1.89.89_89_99; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Brooke GP, 1998, EUR J IMMUNOL, V28, P1, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;1::AID-IMMU1&gt;3.0.CO;2-V; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Comu S, 1997, J NEUROSCI, V17, P8702; Francois B, 1997, AM J MED, V103, P114, DOI 10.1016/S0002-9343(97)00136-8; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Hagiwara T, 1998, EXP HEMATOL, V26, P228; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; McMillan R, 2000, SEMIN HEMATOL, V37, P239, DOI 10.1016/S0037-1963(00)90102-1; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Mi ZP, 2000, J COMP NEUROL, V416, P335; NASH RA, 1995, BLOOD, V86, P1765, DOI 10.1182/blood.V86.5.1765.bloodjournal8651765; NEIMAN JC, 1987, ARCH PATHOL LAB MED, V111, P563; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; ROSALES C, 1992, J IMMUNOL, V149, P2759; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Shibuya K, 1998, BLOOD, V91, P37, DOI 10.1182/blood.V91.1.37.37_37_45; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Turner CE, 2001, CURR BIOL, V11, pR875, DOI 10.1016/S0960-9822(01)00521-8; VANNUCCHI AM, 1990, BLOOD, V76, P1473; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047	48	104	118	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39833	39839		10.1074/jbc.M203287200	http://dx.doi.org/10.1074/jbc.M203287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167615	hybrid			2022-12-25	WOS:000178662500099
J	Zheng, QL; Van Die, I; Cummings, RD				Zheng, QL; Van Die, I; Cummings, RD			Molecular cloning and characterization of a novel alpha 1,2-fucosyltransferase (CE2FT-1) from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-L-FUCOSE; D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE; SCHISTOSOME TRICHOBILHARZIA-OCELLATA; CYSTEINE PROTEASE GENE; EPITHELIAL INVAGINATION; TRANSFERASE GENES; UDP-GALACTOSE; HUMAN-SERUM; EXPRESSION	Here we report the discovery of a unique fucosyltransferase (FT) in Caenorhabditis elegans. In studying the activities of FTs in extracts of adult C. elegans, we detected activity toward the unusual disaccharide acceptors Galbeta1-4Xyl-R and Galbeta1-6GlcNAc-R to generate products with the general structure Fucalpha1-2Galbeta1-R. We identified a gene encoding a unique alpha1,2FT (designated CE2FT-1), which contains an open reading frame encoding a predicted protein of 355 amino acids with the type 2 topology and domain structure typical of other glycosyltransferases. The predicted cDNA for CE2FT-1 has very low identity (5-10%) at the amino acid level to alpha1,2FT sequences in humans, rabbits, and mice. Recombinant CE2FT-1 expressed in human 293T cells has high alpha1,2FT activity toward the simple acceptor Galbeta-O-phenyl acceptor to generate Fucalpha1-2Galbeta-R, which in this respect resembles mammalian alpha1,2FTs. However, CE2FT-1 is otherwise completely different from known alpha1,2FTs in its acceptor specificity, since it is unable to fucosylate either Galbeta1-4GIcbeta-R or free lactose and prefers the unusual acceptors Galbetal-4XyIbeta-R and Galbeta1-6GlcNAc-R. Promoter analysis of the CE2FT-1 gene using green fluorescent protein reporter constructs demonstrates that CE2FT-1 is expressed in single cells of early stage embryos and exclusively in the 20 intestinal cells of L1-L-4 and adult worms. These and other results suggest that multiple fucosyltransferase genes in C. elegans may encode enzymes with unique activities, expression, and developmental roles.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Vrije Universiteit Amsterdam; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th ST,BRC417, Oklahoma City, OK 73104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037549] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD037549] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Apoil PA, 2000, MOL BIOL EVOL, V17, P337, DOI 10.1093/oxfordjournals.molbev.a026314; AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Britton C, 1999, MOL BIOCHEM PARASIT, V103, P171, DOI 10.1016/S0166-6851(99)00121-8; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Bureau V, 2001, EUR J BIOCHEM, V268, P1006, DOI 10.1046/j.1432-1327.2001.01962.x; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8914, DOI 10.1021/bi952193m; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; Domino SE, 1997, BIOCHEM J, V327, P105, DOI 10.1042/bj3270105; Domino SE, 2001, MOL CELL BIOL, V21, P8336, DOI 10.1128/MCB.21.24.8336-8345.2001; Domino SE, 2001, J BIOL CHEM, V276, P23748, DOI 10.1074/jbc.M100735200; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; Lin B, 2000, BBA-MOL CELL BIOL L, V1487, P275, DOI 10.1016/S1388-1981(00)00103-7; Lin B, 2001, ARCH BIOCHEM BIOPHYS, V388, P207, DOI 10.1006/abbi.2001.2303; LINDENBERG S, 1990, J REPROD FERTIL, V89, P431, DOI 10.1530/jrf.0.0890431; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; MASUTANI H, 1995, J BIOCHEM-TOKYO, V118, P541, DOI 10.1093/oxfordjournals.jbchem.a124942; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Soejima M, 1999, EUR J BIOCHEM, V266, P274, DOI 10.1046/j.1432-1327.1999.00865.x; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Warren CE, 2002, J BIOL CHEM, V277, P22829, DOI 10.1074/jbc.M201390200; Warren CE, 2001, GLYCOBIOLOGY, V11, P979, DOI 10.1093/glycob/11.11.979; WHITE S, 1994, BIOL REPROD, V50, P73, DOI 10.1095/biolreprod50.1.73; YAMAGATA T, 1991, BIOCHEM BIOPH RES CO, V181, P1004, DOI 10.1016/0006-291X(91)92036-J; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626	56	25	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39823	39832		10.1074/jbc.M207487200	http://dx.doi.org/10.1074/jbc.M207487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163507	hybrid			2022-12-25	WOS:000178662500098
J	Hattan, D; Nesti, E; Cachero, TG; Morielli, AD				Hattan, D; Nesti, E; Cachero, TG; Morielli, AD			Tyrosine phosphorylation of Kv1.2 modulates its interaction with the actin-binding protein cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; ION-CHANNEL; K+ CHANNEL; ACETYLCHOLINE-RECEPTOR; DOWN-REGULATION; CURRENT-DENSITY; SODIUM-CHANNEL; LOCALIZATION; KINASE; SRC	Tyrosine phosphorylation evokes functional changes in a variety of ion channels. Modulation of the actin cytoskeleton also affects the function of some channels. Little is known about how these avenues of ion channel regulation may interact. We report that the potassium channel Kv1.2 associates with the actin-binding protein cortactin and that the binding is modulated by tyrosine phosphorylation. Immunocytochemical and biochemical analyses show that Kv1.2 and cortactin co-localize to the cortical actin cytoskeleton at the leading edges of the cell. Binding assays using purified recombinant proteins reveal a 19-amino acid span within the carboxyl terminus of Kv1.2 that is necessary for direct cortactin binding. Phosphorylation of specific tyrosines within the C terminus of Kv1.2 attenuates that binding. In HEK293 cells, activation of the M1 muscarinic acetylcholine receptor evokes tyrosine phosphorylation-dependent suppression of Kv1.2 ionic current. We show that M1 receptor activation also reduces the interaction of cortactin with Kv1.2 and that mutant Kv1.2 channels deficient for cortactin binding exhibit strongly attenuated ionic current. These results demonstrate a dynamic, phosphorylation-dependent interaction,between Kv1.2 and the actin cytoskeleton-binding protein cortactin and suggest a role for that interaction in the regulation of Kv1.2 ionic current.	Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Morielli, AD (corresponding author), Univ Vermont, Coll Med, Dept Pharmacol, Given Bldg,Rm E-317,89 Beaumont Ave, Burlington, VT 05405 USA.	moriell@zoo.uvm.edu		Nesti, Edmund/0000-0002-1474-193X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR16435] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Chien AJ, 1998, J BIOENERG BIOMEMBR, V30, P377, DOI 10.1023/A:1021941706726; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; Kaksonen M, 2000, J CELL SCI, V113, P4421; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Maruoka ND, 2000, FEBS LETT, V473, P188, DOI 10.1016/S0014-5793(00)01521-0; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; Moody WJ, 1998, J NEUROBIOL, V37, P97, DOI 10.1002/(SICI)1097-4695(199810)37:1<97::AID-NEU8>3.0.CO;2-3; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; Petrecca K, 2000, J NEUROSCI, V20, P8736; PRAT AG, 1995, AM J PHYSIOL, V6, pC1152; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; SHEETZ MP, 1980, BILAYER SHELL MODEL; SHENG M, 1994, J NEUROSCI, V14, P2408; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spitzer NC, 1998, J NEUROBIOL, V37, P190, DOI 10.1002/(SICI)1097-4695(199810)37:1<190::AID-NEU14>3.3.CO;2-2; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Stevens CF, 1998, CURR BIOL, V8, pR151, DOI 10.1016/S0960-9822(98)70097-1; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; WANG H, 1994, J NEUROSCI, V14, P4588; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	55	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38596	38606		10.1074/jbc.M205005200	http://dx.doi.org/10.1074/jbc.M205005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151401	hybrid			2022-12-25	WOS:000178529600077
J	Rocnik, EF; van der Veer, E; Cao, H; Hegele, RA; Pickering, JG				Rocnik, EF; van der Veer, E; Cao, H; Hegele, RA; Pickering, JG			Functional linkage between the endoplasmic reticulum protein Hsp47 and procollagen expression in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-BINDING HEAT-SHOCK-PROTEIN-47; NEWLY SYNTHESIZED COLLAGEN; MOLECULAR CHAPERONE HSP47; INTRACELLULAR DEGRADATION; FIBRILLAR COLLAGEN; I PROCOLLAGEN; GENE CBP2; STRESS; HYDROXYLATION; SECRETION	Hsp47 is a heat stress protein that interacts with procollagen in the lumen of the endoplasmic reticulum, which is vital for collagen elaboration and embryonic viability. The precise actions of Hsp47 remain unclear, however. To evaluate the effects of Hsp47 on collagen production we infected human vascular smooth muscle cells (SMCs) with a retrovirus containing Hsp47 cDNA. SMCs overexpressing Hsp47 secreted type I procollagen faster than SMCs transduced with empty vector, yielding a greater accumulation of proal(l) collagen in the extracellular milieu. Interestingly, the amount of intracellular proal (I) collagen was also increased. This was associated with an unexpected increase in the rate of proalpha1 (I) collagen chain synthesis and 2.5-fold increase in proalpha1(I) collagen mRNA expression, without a change in fibronectin expression. This amplification of procollagen expression, synthesis, and secretion by Hsp47 imparted SMCs with an enhanced capacity to elaborate a fibrillar collagen network. The effects of Hsp47 were qualitatively distinct from, and independent of, those of ascorbate and the combination of both factors yielded an even more intricate fibril network. Given the in vitro impact of altered Hsp47 expression on procollagen production, we sought evidence for interindividual variability in Hsp47 expression and identified a common, single nucleotide polymorphism in the Hsp47 gene promoter among African Americans that significantly reduced promoter activity. Together, these findings indicate a novel means by which type I collagen production is regulated by the endoplasmic reticulum, constituent, Hsp47, and suggest a potential basis for inherent differences in collagen production within the population.	Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Biochem, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Biophys, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Cardiol, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011; Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020	Pickering, J. Geoffrey/0000-0001-6474-3274; Hegele, Robert/0000-0003-2861-5325				Abe K, 2000, NEPHROL DIAL TRANSPL, V15, P529, DOI 10.1093/ndt/15.4.529; BERG RA, 1983, ARCH BIOCHEM BIOPHYS, V226, P681, DOI 10.1016/0003-9861(83)90338-7; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1984, COLLAGEN REL RES, V4, P399; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Davis R, 2000, BIOTECHNOL PROGR, V16, P736, DOI 10.1021/bp000107q; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; FLEISCHMAJER R, 1990, J STRUCT BIOL, V105, P162, DOI 10.1016/1047-8477(90)90110-X; Hendershot LM, 2000, CURR BIOL, V10, pR912, DOI 10.1016/S0960-9822(00)00850-2; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; IKEGAWA S, 1995, CYTOGENET CELL GENET, V71, P182, DOI 10.1159/000134103; Ikegawa S, 1997, GENE, V194, P301, DOI 10.1016/S0378-1119(97)00209-6; Iwashita T, 2000, HUM PATHOL, V31, P1498, DOI 10.1053/hupa.2000.20378; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2000, J BIOL CHEM, V275, P27957; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Li SH, 1999, CIRC RES, V85, P338, DOI 10.1161/01.RES.85.4.338; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagai N, 1999, GENE, V227, P241, DOI 10.1016/S0378-1119(98)00592-7; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; NATSUME T, 1994, J BIOL CHEM, V269, P31224; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; RENNARD SI, 1982, J INVEST DERMATOL, V79, pS77, DOI 10.1111/1523-1747.ep12545844; Rocnik E, 2000, CIRCULATION, V101, P1229, DOI 10.1161/01.CIR.101.11.1229; Rocnik E, 2001, ARTERIOSCL THROM VAS, V21, P40, DOI 10.1161/01.ATV.21.1.40; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Sauk JJ, 1998, CONNECT TISSUE RES, V37, P105, DOI 10.3109/03008209809028904; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tomita M, 1999, J BIOCHEM, V126, P1118, DOI 10.1093/oxfordjournals.jbchem.a022557; TSCHANK G, 1991, BIOCHEM J, V275, P469, DOI 10.1042/bj2750469; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	51	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38571	38578		10.1074/jbc.M206689200	http://dx.doi.org/10.1074/jbc.M206689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163502	hybrid			2022-12-25	WOS:000178529600074
J	Tanaka, T; Mizukoshi, T; Taniyama, C; Kohda, D; Arai, K; Masai, H				Tanaka, T; Mizukoshi, T; Taniyama, C; Kohda, D; Arai, K; Masai, H			DNA binding of PriA protein requires cooperation of the N-terminal D-loop/arrested-fork binding and C-terminal helicase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DEPENDENT ATPASE ACTIVITY; REPLICATION FACTOR-Y; HOMOLOGOUS RECOMBINATION; PHI-X174-TYPE PRIMOSOME; GENETIC-ANALYSIS; STRAND SYNTHESIS; D-LOOPS; INITIATION; MUTANTS	PriA protein is essential for RecA-dependent DNA replication induced by stalled replication forks in Escherichia coli. PriA is a DEXH-type DNA helicase, ATPase activity of which depends on its binding to structured DNA including a D-loop-like structure. Here, we show that the N-terminal 181-amino acid polypeptide can form a complex with D-loop in gel shift assays and have identified a unique motif present in the N-terminal segment of PriA that plays a role in its DNA binding. We have also identified residues in the C terminus proximal helicase domain essential for D-loop binding. PriA proteins mutated in this domain do not bind to D-loop, despite the presence of the N-terminal DNA-binding motif. Those mutants that cannot bind to D-loop in vitro do not support a recombination-dependent mode of DNA replication in vivo, indicating that binding to a D-loop-like structure is essential for the ability of PriA to initiate DNA replication and repair from stalled replication forks. We propose that binding of the PriA protein to stalled replication forks requires proper configuration of the N-terminal fork-recognition and C-terminal helicase domains and that the latter may stabilize binding and increase binding specificity.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; JST, CREST, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Japan Science & Technology Agency (JST)	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; HONG XK, 1993, J BACTERIOL, V175, P6731, DOI 10.1128/jb.175.20.6731-6734.1993; IMBER R, 1983, P NATL ACAD SCI-BIOL, V80, P7132, DOI 10.1073/pnas.80.23.7132; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; MAGEE TR, 1990, J BACTERIOL, V172, P1834, DOI 10.1128/jb.172.4.1834-1839.1990; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1988, J BIOL CHEM, V263, P15016; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McCool JD, 2001, P NATL ACAD SCI USA, V98, P8203, DOI 10.1073/pnas.121007698; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; NOMURA N, 1991, GENE, V108, P15; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; OUZOUNIS CA, 1991, NUCLEIC ACIDS RES, V19, P6953, DOI 10.1093/nar/19.24.6953; Polard P, 2002, NUCLEIC ACIDS RES, V30, P1593, DOI 10.1093/nar/30.7.1593; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; TORREY TA, 1987, MOL GEN GENET, V208, P420, DOI 10.1007/BF00328133; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521; ZIPURSKY SL, 1981, P NATL ACAD SCI-BIOL, V78, P6111, DOI 10.1073/pnas.78.10.6111	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38062	38071		10.1074/jbc.M204397200	http://dx.doi.org/10.1074/jbc.M204397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151393	hybrid			2022-12-25	WOS:000178529600013
J	Hamano, Y; Kuzuyama, T; Itoh, N; Furihata, K; Seto, H; Dairi, T				Hamano, Y; Kuzuyama, T; Itoh, N; Furihata, K; Seto, H; Dairi, T			Functional analysis of eubacterial diterpene cyclases responsible for biosynthesis of a diterpene antibiotic, terpentecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUALENE-HOPENE CYCLASE; ENT-KAURENE SYNTHASE; BACTERIUM PRODUCING HOPANOIDS; HIGH-LEVEL EXPRESSION; PHAEOSPHAERIA SP L487; FIR ABIES GRANDIS; GIBBERELLIN BIOSYNTHESIS; ABIETADIENE SYNTHASE; LANOSTEROL SYNTHASE; MOLECULAR-CLONING	Eubacterial diterpene cyclase genes had previously been cloned from a diterpenoid antibiotic terpentecin producer (Dairi, T., Hamano, Y., Kuzuyama, T., Itoh, N., Furihata, K., and Seto, H. (2001) J. BacterioL 183, 60856094). Their products, open reading frame 11 (ORF11) and ORF12, were essential for the conversion of geranylgeranyl diphosphate (GGDP) into terpentetriene (TTE) that had the same basic skeleton as terpentecin. In this study, functional analyses of these two enzymes were performed by using purified recombinant enzymes. The ORF11 product converted GGDP into a cyclized intermediate, terpentedienol diphosphate (TDP), which was then transformed into TTE by the ORF12 product. Interestingly, the ORF12 product directly catalyzed the conversion of GGDP into three olefinic compounds. Moreover, the ORF12 product utilized farnesyl diphosphate as a substrate to give three olefinic compounds, which had the same structures as those formed from GGDP with the exception of the chain lengths. These results suggested that the ORF11 product with a DXDD motif converted GGDP into TDP by a protonation-initiated cyclization and that the ORF12 product with a DDXXD motif completed the transformation of TDP to the olefin, terpentetriene by an ionization-initiated reaction followed by deprotonation. The kinetics of the ORF12 product indicated that the affinity for TDP and GGDP were higher than that of farnesyl diphosphate and that the relative activity of the reaction converting TDP into TTE was highest among the reactions using TDP, GGDP, or farnesyl diphosphate as the substrate. These results suggested that an actual reaction catalyzed by the ORF12 was the conversion of TDP into TTE in vivo.	Toyama Prefectural Univ, Biotechnol Res Ctr, Toyama 9390398, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Div Agr & Agr Life Sci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Univ Agr, Fac Appl Biosci, Setagaya Ku, Tokyo 1568502, Japan	Toyama Prefectural University; University of Tokyo; University of Tokyo; Tokyo University of Agriculture	Dairi, T (corresponding author), Toyama Prefectural Univ, Biotechnol Res Ctr, Toyama 9390398, Japan.	dairi@pu-toyama.ac.jp	Dairi, Tohru/A-5448-2012	Dairi, Tohru/0000-0002-3406-7970; Kuzuyama, Tomohisa/0000-0002-7221-5858; Hamano, Yoshimitsu/0000-0001-5117-5116				ABE E, 1980, NIPPON NOGEI KAGAKU, V54, P761; ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; AitAli T, 1997, PLANT J, V11, P443, DOI 10.1046/j.1365-313X.1997.11030443.x; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; BURGER BV, 1981, Z NATURFORSCH C, V36, P340; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; Connolly J. D., 1992, DICT TERPENOIDS; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Dairi T, 2001, J BACTERIOL, V183, P6085, DOI 10.1128/JB.183.20.6085-6094.2001; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; FROST RG, 1977, PLANT PHYSIOL, V59, P22, DOI 10.1104/pp.59.1.22; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Hill AM, 1996, ARCH BIOCHEM BIOPHYS, V336, P283, DOI 10.1006/abbi.1996.0559; Hoshino T, 2002, CHEM COMMUN, P291, DOI 10.1039/b108995c; Huang KX, 1998, ARCH BIOCHEM BIOPHYS, V352, P144, DOI 10.1006/abbi.1998.0578; Kawaide H, 2000, J BIOL CHEM, V275, P2276, DOI 10.1074/jbc.275.4.2276; Kawaide H, 1997, J BIOL CHEM, V272, P21706, DOI 10.1074/jbc.272.35.21706; KLEEMANN G, 1994, BBA-LIPID LIPID MET, V1210, P317, DOI 10.1016/0005-2760(94)90235-6; KOEPP AE, 1995, J BIOL CHEM, V270, P8686, DOI 10.1074/jbc.270.15.8686; KUSANO M, 1995, BIOL PHARM BULL, V18, P195; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MACMILLAN J, 1999, COMPREHENSIVE NATURA, V2, P217; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; McCaskill D, 1997, Adv Biochem Eng Biotechnol, V55, P107; NABETA K, 1990, J NAT PROD, V53, P1241, DOI 10.1021/np50071a016; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; Perzl M, 1997, MICROBIOL-UK, V143, P1235, DOI 10.1099/00221287-143-4-1235; Peters RJ, 2002, BIOCHEMISTRY-US, V41, P1836, DOI 10.1021/bi011879d; Peters RJ, 2002, P NATL ACAD SCI USA, V99, P580, DOI 10.1073/pnas.022627099; Peters RJ, 2001, J AM CHEM SOC, V123, P8974, DOI 10.1021/ja010670k; Peters RJ, 2000, BIOCHEMISTRY-US, V39, P15592, DOI 10.1021/bi001997l; RAILTON ID, 1984, PHYTOCHEMISTRY, V23, P1261, DOI 10.1016/S0031-9422(00)80438-0; Ravn MM, 2000, ORG LETT, V2, P573, DOI 10.1021/ol991230p; REIPEN IG, 1995, MICROBIOL-SGM, V141, P155, DOI 10.1099/00221287-141-1-155; SASAOKA S, 1985, CHEM LETT, P315, DOI 10.1246/cl.1985.315; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Tippelt A, 1998, BBA-LIPID LIPID MET, V1391, P223, DOI 10.1016/S0005-2760(97)00212-9; Vogel BS, 1996, J BIOL CHEM, V271, P23262, DOI 10.1074/jbc.271.38.23262; Waterhouse JS, 1996, J CHEM ECOL, V22, P1307, DOI 10.1007/BF02266967; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201	46	75	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37098	37104		10.1074/jbc.M206382200	http://dx.doi.org/10.1074/jbc.M206382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138123	hybrid			2022-12-25	WOS:000178447100026
J	O'Brian, JJ; Ram, ML; Kiarash, A; Cala, SE				O'Brian, JJ; Ram, ML; Kiarash, A; Cala, SE			Mass spectrometry of cardiac calsequestrin characterizes microheterogeneity unique to heart and indicative of complex intracellular transit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RAT SKELETAL-MUSCLE; CASEIN KINASE-II; CLATHRIN-COATED VESICLES; AMINO-ACID SEQUENCE; RYANODINE RECEPTOR; ENDOPLASMIC-RETICULUM; PHOSPHORYLATION SITE; MOLECULAR-CLONING; RELEASE CHANNEL	Cardiac calsequestrin concentrates in junctional sarcoplasmic reticulum in heart and skeletal muscle cells by an undefined mechanism. During transit through the secretory pathway, it undergoes an as yet uncharacterized glycosylation and acquires phosphate on CK2-sensitive sites. In this study, we have shown that active calsequestrin phosphorylation occurred in nonmuscle cells as well as muscle cells, reflecting a widespread cellular process. To characterize this post-translational modification and resolve individual molecular mass species, we subjected purified calsequestrin to mass spectrometry using electrospray ionization. Mass spectra showed that calsequestrin glycan structure in nonmuscle cells was that expected for an endoplasmic reticulum-localized glycoprotein and showed that each glycoform existed as four mass peaks representing molecules that also had 0-3 phosphorylation sites occupied. In heart, mass peaks indicated carbohydrate modifications characteristic of transit through Golgi compartments. Phosphorylation did not occur on every glycoform present, suggesting a far more complex movement of calsequestrin molecules in heart cells. Significant amounts of calsequestrin contained glycan with only a single mannose residue, indicative of a novel post-endoplasmic reticulum mannosidase activity. In conclusion, glyco- and phosphoforms of calsequestrin chart a complex cellular transport in heart, with calsequestrin following trafficking pathways not present or not accessible to the same molecules in nonmuscle.	Wayne State Univ, Dept Med, Program Mol & Cellular Cardiol, Detroit, MI 48201 USA	Wayne State University	Cala, SE (corresponding author), Wayne State Univ, Dept Med, Program Mol & Cellular Cardiol, Elliman Bldg,Rm 1107,421 E Canfield Ave, Detroit, MI 48201 USA.	s.cala@wayne.edu			NHLBI NIH HHS [R01 HL062586, HL62586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; CAIN SE, 2000, BIOCHIM BIOPHYS ACTA, V1496, P296; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CALA SE, 1991, J BIOL CHEM, V266, P391; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; DAMIANI E, 1990, J MUSCLE RES CELL M, V11, P522, DOI 10.1007/BF01745219; FLIEGEL L, 1989, BIOCHEM CELL BIOL, V67, P696, DOI 10.1139/o89-104; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1980, FED PROC, V39, P2403; FRANZINIARMSTRONG C, 1975, FED PROC, V34, P1382; Gatti G, 2001, J CELL BIOL, V154, P525, DOI 10.1083/jcb.200103002; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JORGENSEN AO, 1979, J CELL BIOL, V80, P372, DOI 10.1083/jcb.80.2.372; JORGENSEN AO, 1977, J CELL BIOL, V74, P287, DOI 10.1083/jcb.74.1.287; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU YH, 1977, J BIOL CHEM, V252, P5565; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MEGGIO F, 1984, EUR J BIOCHEM, V138, P379, DOI 10.1111/j.1432-1033.1984.tb07926.x; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Nori A, 1997, AM J PHYSIOL-CELL PH, V272, pC1420, DOI 10.1152/ajpcell.1997.272.5.C1420; Nori A, 1999, AM J PHYSIOL-CELL PH, V277, pC974, DOI 10.1152/ajpcell.1999.277.5.C974; Nori A, 2000, EXP CELL RES, V260, P40, DOI 10.1006/excr.2000.4989; OTSU K, 1990, J BIOL CHEM, V265, P13472; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SEILER S, 1984, J BIOL CHEM, V259, P8550; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; THOMAS K, 1989, J BIOL CHEM, V264, P3140; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WAUGH RA, 1974, J CELL BIOL, V63, P337, DOI 10.1083/jcb.63.1.337; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZUBRZYCKA E, 1976, J BIOL CHEM, V251, P7733	50	23	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37154	37160		10.1074/jbc.M204370200	http://dx.doi.org/10.1074/jbc.M204370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147690	hybrid			2022-12-25	WOS:000178447100033
J	Wang, JH; Doyle, M; Manning, BJ; Wu, QD; Blankson, S; Redmond, HP				Wang, JH; Doyle, M; Manning, BJ; Wu, QD; Blankson, S; Redmond, HP			Induction of bacterial lipoprotein tolerance is associated with suppression of Toll-like receptor 2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BORRELIA-BURGDORFERI LIPOPROTEINS; GRAM-NEGATIVE BACTERIA; TUMOR-NECROSIS-FACTOR; LPS BINDING-PROTEIN; CUTTING EDGE; ENDOTOXIN TOLERANCE; LIPOPOLYSACCHARIDE LPS; SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION	Tolerance to bacterial cell wall components including lipopolysaccharide (LPS) may represent an essential regulatory mechanism during bacterial infection. Two members of the Toll-like receptor (TLR) family, TLR2 and TLR4, recognize the specific pattern of bacterial cell wall components. TLR4 has been found to be responsible for LPS tolerance. However, the role of TLR2 in bacterial lipoprotein (BLP) tolerance and LPS tolerance is unclear. Pretreatment of human THP-1 monocytic cells with a synthetic bacterial lipopeptide induced tolerance to a second BLP challenge with diminished tumor necrosis factor-alpha and interleukin-6 production, termed BLP tolerance. Furthermore, BLP-tolerized THP-1 cells no longer responded to LPS stimulation, indicating a cross-tolerance to LPS. Induction of BLP tolerance was CD14-independent, as THP-1 cells that lack membrane-bound CD14 developed tolerance both in serum-free conditions and in the presence of a specific CD14 blocking monoclonal antibody (MEM-18). Pre-exposure of THP-1 cells to BLP suppressed mitogen-activated protein kinase phosphorylation and nuclear factor-kappaB activation in response to subsequent BLP and LPS stimulation, which is comparable with that found in LPS-tolerized cells, indicating that BLP tolerance and LPS tolerance may share similar intracellular pathways. However, BLP strongly enhanced TLR2 expression in non-tolerized THP-1 cells, whereas LPS stimulation had no effect. Furthermore, a specific TLR2 blocking monoclonal antibody (2392) attenuated BLP-induced, but not LPS-induced, tumor necrosis factor-a and interleukin-6 production, indicating BLP rather than LPS as a ligand for TLR2 engagement and activation. More importantly, pretreatment of THP-1 cells with BLP strongly inhibited TLR2 activation in response to subsequent BLP stimulation. In contrast, LPS tolerance did not prevent BLP-induced TLR2 overexpression. These results demonstrate that BLP tolerance develops through down-regulation of TLR2 expression.	Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Acad Dept Surg, Cork, Ireland	University College Cork	Wang, JH (corresponding author), Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Acad Dept Surg, Wilton, Cork, Ireland.		Eckhardt, Erik/G-1567-2010					Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Biberstine KJ, 1996, INFECT IMMUN, V64, P3641, DOI 10.1128/IAI.64.9.3641-3645.1996; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; DeFranco AL, 1998, PROG CLIN BIOL RES, V397, P119; DIRIENZO JM, 1978, ANNU REV BIOCHEM, V47, P481, DOI 10.1146/annurev.bi.47.070178.002405; DOYLE M, 2000, SURG FORUM, V51, P191; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; HAZIOT A, 1993, J IMMUNOL, V151, P1500; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Heine H, 1999, J IMMUNOL, V162, P6971; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Kohler NG, 1997, BIOCHEM BIOPH RES CO, V232, P602, DOI 10.1006/bbrc.1997.6337; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kraatz J, 1999, J SURG RES, V83, P158, DOI 10.1006/jsre.1999.5587; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; LABETA MO, 1993, IMMUNOLOGY, V80, P415; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; MANTHEY CL, 1992, REV MED MICROBIOL, V3, P72; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Perera PY, 1997, J IMMUNOL, V158, P4422; Plotz SG, 2001, BLOOD, V97, P235, DOI 10.1182/blood.V97.1.235; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SANCHEZCANTU L, 1989, ARCH SURG-CHICAGO, V124, P1432; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; SCHADE FU, 1999, ENDOTOXIN HLTH DIS, P50; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Sessler CN, 1996, CLIN CHEST MED, V17, P213, DOI 10.1016/S0272-5231(05)70310-5; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Tominaga K, 1999, BBA-MOL CELL RES, V1450, P130, DOI 10.1016/S0167-4889(99)00037-3; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; Wooten RM, 1998, J IMMUNOL, V160, P5485; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x; Zhang HW, 1997, J IMMUNOL, V159, P4868; Zhang HW, 1998, INFECT IMMUN, V66, P5196, DOI 10.1128/IAI.66.11.5196-5201.1998	53	99	109	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36068	36075		10.1074/jbc.M205584200	http://dx.doi.org/10.1074/jbc.M205584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133836	hybrid			2022-12-25	WOS:000178275100040
J	Mayer, SM; Gormal, CA; Smith, BE; Lawson, DM				Mayer, SM; Gormal, CA; Smith, BE; Lawson, DM			Crystallographic analysis of the MoFe protein of nitrogenase from a nifV mutant of Klebsiella pneumoniae identifies citrate as a ligand to the molybdenum of iron molybdenum cofactor (FeMoco)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN EVOLUTION; CARBON-MONOXIDE; ALPHA-SUBUNIT; BINDING; HOMOCITRATE; SUBSTRATE; PURIFICATION; REFINEMENT; INVITRO; MAPS	The x-ray crystal structure of NifV(-) Klebsiella pneumoniae nitrogenase MoFe protein (NifV(-) Kp1) has been determined and refined to a resolution of 1.9 Angstrom. This is the first structure for a nitrogenase MoFe protein with an altered cofactor. Moreover, it is the first direct evidence that the organic acid citrate is not just present, but replaces homocitrate as a ligand to the molybdenum atom of the iron molybdenum cofactor (FeMoco). Subsequent refinement of the structure revealed that the citrate was present at reduced occupancy.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Lawson, DM (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.	david.lawson@bbsrc.ac.uk	Lawson, David M/D-1810-2009					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; George SJ, 1997, J AM CHEM SOC, V119, P6450, DOI 10.1021/ja971088s; Gronberg KLC, 1998, J AM CHEM SOC, V120, P10613, DOI 10.1021/ja981832o; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawson DM, 2002, MET IONS BIOL SYST, V39, P75; Lee HI, 1997, J AM CHEM SOC, V119, P10121, DOI 10.1021/ja9715096; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; MA L, 1994, J BIOL CHEM, V269, P18007; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; MCLEAN PA, 1983, BIOCHEM J, V211, P589, DOI 10.1042/bj2110589; MCLEAN PA, 1981, NATURE, V292, P655, DOI 10.1038/292655a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEWTON WE, 2002, 13 INT C NITR FIX; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; POLLOCK RC, 1995, J AM CHEM SOC, V117, P8686, DOI 10.1021/ja00138a033; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1992, J BIOL CHEM, V267, P20002; Shen J, 1997, BIOCHEMISTRY-US, V36, P4884, DOI 10.1021/bi9628578; STRASSMAN M, 1964, BIOCHEM BIOPH RES CO, V14, P262, DOI 10.1016/0006-291X(64)90446-2; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	36	63	68	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35263	35266		10.1074/jbc.M205888200	http://dx.doi.org/10.1074/jbc.M205888200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133839	hybrid			2022-12-25	WOS:000178117000078
J	Beck, MT; Peirce, SK; Chen, WY				Beck, MT; Peirce, SK; Chen, WY			Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R	ONCOGENE			English	Article						prolactin; prolactin antagonist; Bcl-2; breast cancer; apoptosis	MAMMARY-GLAND INVOLUTION; MESSENGER-RNA; CDNA MICROARRAY; APOPTOSIS; RECEPTOR; HORMONE; FAMILY; PROTEIN; BAX; IDENTIFICATION	To gain insight into the molecular basis of human prolactin (hPRL) antagonist induced apoptosis, we compared the differential gene expression profile of four human breast cancer cell lines following treatment with hPRL and its antagonist (hPRL-G129R). Among the genes identified, the bcl-2 gene was of particular interest. We found that bcl-2 mRNA was up regulated in three of the four cell lines that were treated with hPRL. To further confirm these results, real time RT-PCR and ELISA analyses were used to detect bcl-2 mRNA and Bcl-2 protein, respectively, in 11 different breast cancer cell lines after hPRL or hPRL-G129R treatment. Our data suggests that Bcl-2 is up-regulated in response to hPRL stimulation and is competitively inhibited by hPRL-G129R in the majority of the cell lines tested. Thus, we propose that the anti-apoptotic role of hPRL in breast cancer is mediated, at least in part, through regulation of Bcl-2.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Microbiol & Mol Med, Clemson, SC 29630 USA	Greenville Health System; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER; NCI NIH HHS [1R21CA87093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2001, BIOTECHNIQUES, V31, P782, DOI 10.2144/01314st04; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DeRisi J, 1996, NAT GENET, V14, P457; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Green L, 1999, IEEE CIRCUITS DEVICE, V15, P7, DOI 10.1109/101.808850; Greenberg RK, 2000, J ENDOVASC THER, V7, P1, DOI 10.1583/1545-1550(2000)007<0001:AEMOHC>2.3.CO;2; Guiliano D, 1999, BIOTECHNIQUES, V27, P146, DOI 10.2144/99271rr03; HAKVOORT TBM, 1994, NUCLEIC ACIDS RES, V22, P878, DOI 10.1093/nar/22.5.878; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Leff MA, 1996, ENDOCRINOLOGY, V137, P5456, DOI 10.1210/en.137.12.5456; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Ramamoorthy P, 2001, INT J ONCOL, V18, P25; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhan JH, 1997, BIOTECHNIQUES, V22, P500, DOI 10.2144/97223st05	45	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5047	5055		10.1038/sj.onc.1205637	http://dx.doi.org/10.1038/sj.onc.1205637			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140755				2022-12-25	WOS:000176975900003
J	Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB				Tsimbouri, P; Drotar, ME; Coy, JL; Wilson, JB			bcl-x(L) and RAG genes are induced and the response to IL-2 enhanced in E mu EBNA-1 transgenic mouse lymphocytes	ONCOGENE			English	Article						EBV; EBNA-1; IL-2; Bcl-x(L); transgenic mice; lymphoma	EPSTEIN-BARR-VIRUS; EXPRESSION; MICE; DNA; SURVIVAL; CELLS	We have described transgenic mice expressing Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) in B-cells which show a predisposition to lymphoma. To investigate the underlying oncogenic mechanisms, we have cross bred transgenic strains of mice, examined the pre-tumour B-cell phenotype and investigated the expression levels of selected cellular genes as a response to EBNA-1 expression. We have found that bcl-X-L and the recombination activating genes (RAG) 1 and 2 are induced in pre-neoplastic samples of EBNA-1 expressing mice. Induction of bcl-x(L) may explain the observed redundancy in lymphomagenesis between transgenic EBNA-1 and bcl-2. In addition, bone marrow cells derived from the EmuEBNA-1 mice show a greater capacity for cultured growth compared to controls, particularly in the presence of IL-2. Notably, bcl-x(L) expression is responsive to IL-2. These data shed new light on the potential contribution of EBNA-1 to EBV associated tumorigenicity as well as to the viral life cycle and open a potential avenue for therapeutic intervention.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Wilson, JB (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	Joanna.Wilson@bio.gla.ac.uk	Wilson, Joanna B/B-4466-2009; Tsimbouri, Penelope/F-4373-2010	Tsimbouri, Penelope/0000-0001-5124-7458				ADAMS JM, 1992, CANCER SURV, V15, P119; Berns A, 1999, CANCER RES, V59, p1773S; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; ISCOVE NN, 1974, J CELL PHYSIOL, V83, P309, DOI 10.1002/jcp.1040830218; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kapoor P, 2001, EMBO J, V20, P222, DOI 10.1093/emboj/20.1.222; Kawa K, 2000, INT J HEMATOL, V71, P108; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Meru N, 2001, INT J CANCER, V92, P75, DOI 10.1002/1097-0215(200102)9999:9999&lt;::AID-IJC1163&gt;3.0.CO;2-M; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; RICKINSON AB, 1996, FIELDS VIROLOGY, P2360; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Tsimbouri P, 2001, Methods Mol Biol, V174, P411; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson J B, 2001, Methods Mol Biol, V174, P361; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1997, EBV REPORT, V4, P63; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026	25	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5182	5187		10.1038/sj.onc.1205490	http://dx.doi.org/10.1038/sj.onc.1205490			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140768				2022-12-25	WOS:000176975900016
J	Carr, KM; Kaguni, JM				Carr, KM; Kaguni, JM			Escherichia coli DnaA protein loads a single DnaB helicase at a DnaA box hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BINDING-PROTEIN; N-TERMINAL DOMAIN; REPLICATION-FORK; CHROMOSOMAL ORIGIN; GENE-PRODUCT; PHYSICAL-PROPERTIES; NUCLEIC-ACIDS; ABC-PRIMOSOME; COMPLEX; INITIATION	The molecular engine that drives bidirectional replication fork movement from the Escherichia coli replication origin (oriC) is the replicative helicase, DnaB. At oriC, two and only two helicase molecules are loaded, one for each replication fork. DnaA participates in helicase loading; DnaC is also involved, because it must be in a complex with DnaB for delivery of the helicase. Since DnaA induces a local unwinding of oriC, one model is that the limited availability of single-stranded DNA at oriC restricts the number of DnaB molecules that can bind. In this report, we determined that one DnaB helicase or one DnaB-DnaC complex is bound to a single-stranded DNA in a biologically relevant DNA replication system. These results indicate that the availability of single-stranded DNA is not a limiting factor and support a model in which the site of entry for DnaB is altered so that it cannot be reused. We also show that 2-4 DnaA monomers are bound on the single-stranded DNA at a specific site that carries a DnaA box sequence in a hairpin structure.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.			Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Chang P, 2000, J BIOL CHEM, V275, P26187, DOI 10.1074/jbc.M001800200; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HU GX, 1993, DNA CELL BIOL, V12, P763, DOI 10.1089/dna.1993.12.763; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Kaguni JM, 1997, MOL CELLS, V7, P145; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Katayama T, 1995, MOL MICROBIOL, V18, P813, DOI 10.1111/j.1365-2958.1995.18050813.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LOHMAN TM, 1994, BIOCHEMISTRY-US, V33, P6167, DOI 10.1021/bi00186a016; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Ludlam AV, 2001, J BIOL CHEM, V276, P27345, DOI 10.1074/jbc.M101940200; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1990, J BIOL CHEM, V265, P15134; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NOMURA N, 1991, GENE, V108, P15; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SUN WL, 1993, J BIOL CHEM, V268, P8026; Sun WL, 1996, J BACTERIOL, V178, P6701, DOI 10.1128/jb.178.23.6701-6705.1996; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39815	39822		10.1074/jbc.M205031200	http://dx.doi.org/10.1074/jbc.M205031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161435	hybrid			2022-12-25	WOS:000178662500097
J	Egawa, K; Maegawa, H; Shi, K; Nakamura, T; Obata, T; Yoshizaki, T; Morino, K; Shimizu, S; Nishio, Y; Suzuki, E; Kashiwagi, A				Egawa, K; Maegawa, H; Shi, K; Nakamura, T; Obata, T; Yoshizaki, T; Morino, K; Shimizu, S; Nishio, Y; Suzuki, E; Kashiwagi, A			Membrane localization of 3-phosphoinositide-dependent protein kinase-1 stimulates activities of Akt and atypical protein kinase C but does not stimulate glucose transport and glycogen synthesis in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; IN-VIVO; INSULIN; ACTIVATION; PHOSPHORYLATION; 3-KINASE; RAF; REQUIREMENT; INHIBITION; EXPRESSION	It is reported that 3-phosphoinositide-dependent protein kinase-1 (PDK-1) is activated in a phosphatidylinositol 3,4,5-trisphosphate-dependent manner and phosphorylates Akt, p70S6 kinase, and atypical protein kinase C (PKC), but its function on insulin signaling is still unclear. We cloned a full-length pdk-1 cDNA from a human brain cDNA library, and the adenovirus to overexpress wild type PDK-1 (PDK-1WT) or membrane-targeted PDK-1 (PDK-1CAAX) was constructed. Overexpressed PDK-1WT existed mainly at cytosol, and PDK-1CAAX was located at the plasma membrane. In 3T3-L1 adipocytes, insulin induced mobility shift of PDk-1 protein, but overexpressed PDK-1WT and CAAX were shifted at the basal state. Insulin stimulated tyrosine phosphorylation of PDK-1WT, but PDK-1CAAX was already tyrosine-phosphorylated at the basal state. Overexpression of PDK-1WT led to a full activation of PKCzeta/lambda without insulin stimulation but showed only the minimum effects to stimulate phosphorylation of Akt and GSK-3. In contrast, the overexpression of PDK-1CAAX caused phosphorylation of Akt and GSK-3 more strongly without insulin stimulation. However, PDK-1CAAX did not affect 2-deoxyglucose uptake and inhibited glycogen synthesis, surprisingly. Finally, PDK-1CAAX expression inhibited insulin-induced ERK1/2 phosphorylation in a dose-dependent manner. Taken together, the translocation of PDK-1 from cytosol to the plasma membrane is critical for Akt and GSK-3 activation. On the other hand, only atypical PKC and Akt activation was insufficient for stimulation of glucose transport, and constitutive activation of Akt-GSK-3 pathway may inhibit glycogen synthesis and MAPK cascade in 3T3-L1 adipocytes.	Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan.	maegawa@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019; MORINO, KATSUTARO/I-3207-2019	MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Guan KL, 2000, J BIOL CHEM, V275, P27354; HARUTA T, 1995, J BIOL CHEM, V270, P27991; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kotani K, 2000, J BIOL CHEM, V275, P26390, DOI 10.1074/jbc.M002537200; Morino K, 2001, ENDOCRINOLOGY, V142, P2669, DOI 10.1210/en.142.6.2669; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Nakamura T, 2001, J CLIN ENDOCR METAB, V86, P1795, DOI 10.1210/jc.86.4.1795; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	32	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38863	38869		10.1074/jbc.M203132200	http://dx.doi.org/10.1074/jbc.M203132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147684	hybrid			2022-12-25	WOS:000178529600108
J	Elfering, SL; Sarkela, TM; Giulivi, C				Elfering, SL; Sarkela, TM; Giulivi, C			Biochemistry of mitochondrial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER MITOCHONDRIA; FATTY-ACID ACYLATION; CELLULAR PROTEINS; MYRISTIC ACID; PHOSPHORYLATION; PURIFICATION; MYRISTOYLATION; IDENTIFICATION; MACROPHAGES	We reported that the generation of nitric oxide by mitochondria is catalyzed by a constitutive, mitochondrial nitric-oxide synthase (mtNOS). Given that this production may establish the basis for a novel regulatory pathway of energy metabolism, oxygen consumption, and oxygen free radical production, it becomes imperative to identify unequivocally and characterize this enzyme to provide a basis for its regulation. The mitochondrial localization of mtNOS was supported by following the hepatic distribution of mtNOS, immunoblotting submitochondrial fractions, and immunohistochemistry of liver tissues. mtNOS was identified as brain NOSalpha by various methods (mass spectrometry of proteolytic fragments, amino acid analysis, molecular weight, pI, and analysis of PCR fragments), excluding the occurrence of a novel isoform. or other splice variants. Distribution of mtNOS transcript indicated its occurrence in liver, brain, heart, muscle, kidney, lung, testis, and spleen. In contrast to brain NOS, mtNOS has two post-translational modifications: acylation with myristic acid and phosphorylation at the C terminus. The former modification is a reversible and post-translational process, which may serve for subcellular targeting or membrane anchoring. The latter modification could be linked to enzymatic regulation. These results are discussed in terms of the role that nitric oxide may have in cellular bioenergetics.	Univ Minnesota, Dept Chem, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Giulivi, C (corresponding author), Univ Minnesota, Dept Chem, 10 Univ Dr, Duluth, MN 55812 USA.	cgiulivi@d.umn.edu	Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/ABB-7809-2020; Hu, Ruogu/B-2203-2008	Giulivi, Cecilia/0000-0003-1033-7435; 	NIEHS NIH HHS [ES011407-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011407] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAM M, 1984, J BIOL CHEM, V259, P5460; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHANCE B, 1963, 5 P INT C BIOCH USSR, V5, P3; CHEUNG CW, 1981, ARCH BIOCHEM BIOPHYS, V209, P643, DOI 10.1016/0003-9861(81)90324-6; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; French S, 2001, AM J PHYSIOL-HEART C, V280, pH2863, DOI 10.1152/ajpheart.2001.280.6.H2863; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; GEISOW MJ, 1989, PROTEIN SEQUENCING P, P85; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1999, FASEB J, V13, pA1554; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; JAWORSKI JG, 1974, ARCH BIOCHEM BIOPHYS, V162, P166, DOI 10.1016/0003-9861(74)90115-5; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Kotake Y, 1996, METHOD ENZYMOL, V268, P222; Kotake Y, 1996, BBA-GEN SUBJECTS, V1289, P362, DOI 10.1016/0304-4165(95)00172-7; LIU JW, 1994, J BIOL CHEM, V269, P11691; Liu RM, 1998, AM J PHYSIOL-LUNG C, V274, pL330, DOI 10.1152/ajplung.1998.274.3.L330; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; MINEGOLOMB D, 1996, NITRIC OXIDE SYNTHAS, P173; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NAKANE PK, 1996, NITRIC OXIDE SYNTHAS, P54; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SIMON SM, 1992, J BIOL CHEM, V267, P3922; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; STUEHR DJ, 1987, J IMMUNOL, V139, P518; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; WALL L, 1986, J BIOL CHEM, V261, P5981; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	64	290	306	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38079	38086		10.1074/jbc.M205256200	http://dx.doi.org/10.1074/jbc.M205256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154090	hybrid			2022-12-25	WOS:000178529600015
J	Fukuda, R; Hirota, K; Fan, F; Do Jung, Y; Ellis, LM; Semenza, GL				Fukuda, R; Hirota, K; Fan, F; Do Jung, Y; Ellis, LM; Semenza, GL			Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR 1-ALPHA HIF-1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; CAP-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVITY; TRANSLATION INITIATION; PROLYL HYDROXYLATION; UP-REGULATION; HIF-ALPHA; IN-VIVO	Stimulation of human colon cancer cells with insulin-like growth factor 1 (IGF-1) induces expression of the VEGF gene, encoding vascular endothelial growth factor. In this article we demonstrate that exposure of HCT116 human colon carcinoma cells to IGF-1 induces the expression of HIF-1alpha, the regulated subunit of hypoxia-inducible factor 1, a known transactivator of the VEGF gene. In contrast to hypoxia, which induces HIF-1alpha expression by inhibiting its ubiquitination and degradation, IGF-1 did not inhibit these processes, indicating an effect on HIF-1alpha protein synthesis. IGF-1 stimulation of HIF-1alpha protein and VEGF mRNA expression was inhibited by treating cells with inhibitors of phosphatidylinositol 3-kinase and MAP kinase signaling pathways. These inhibitors also blocked the IGF-1-induced phosphorylation of the translational regulatory proteins 4E-BP1, p70 S6 kinase, and eIF-4E, thus providing a mechanism for the modulation of HIF-1alpha protein synthesis. Forced expression of a constitutively active form of the MAP kinase kinase, MEK2, was sufficient to induce HIF-1alpha protein and VEGF mRNA expression. Involvement of the MAP kinase pathway represents a novel mechanism for the induction of HIF-1alpha protein expression in human cancer cells.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, CMSC-1004,600 N Wolfe St, Baltimore, MD 21287 USA.		高, 雨莉/HGU-8187-2022; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827	NCI NIH HHS [R01-CA74821] Funding Source: Medline; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi Y, 1998, CANCER RES, V58, P4008; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rak J, 2000, CANCER RES, V60, P490; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schramek H, 1997, J BIOL CHEM, V272, P11426; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Viloria-Petit A, 2001, CANCER RES, V61, P5090; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wu YP, 2002, CANCER RES, V62, P1030; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhong H, 1999, CANCER RES, V59, P5830; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	42	662	701	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38205	38211		10.1074/jbc.M203781200	http://dx.doi.org/10.1074/jbc.M203781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149254	hybrid			2022-12-25	WOS:000178529600030
J	Islas-Osuna, MA; Ellis, TP; Marnell, LL; Mittelmeier, TM; Dieckmann, CL				Islas-Osuna, MA; Ellis, TP; Marnell, LL; Mittelmeier, TM; Dieckmann, CL			Cbp1 is required for translation of the mitochondrial cytochrome b mRNA of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COB MESSENGER-RNA; IN-VIVO ANALYSIS; YEAST MITOCHONDRIA; 5'-UNTRANSLATED REGION; IDENTIFICATION; TRANSCRIPTS; EXPRESSION; STABILITY; GENES; ENDONUCLEASE	Expression of the yeast mitochondrial cytochrome b gene (COB) is controlled by at least 15 nuclear-encoded proteins. One of these proteins, Cbp1, is required for COB mRNA stability. Deltacbp1 null strains fail to accumulate mature COB mRNA and cannot respire. Since Deltacbp1 null strains lack mature COB transcripts, the hypothesis that Cbp1 also plays a role in translation of these mRNAs could not be tested previously. 5'-End trimming of precursor COB RNA and other mitochondrial transcripts is dependent on Pet127. pet127 mutants accumulate high levels of precursor COB mRNA and have no mature mRNA. pet127 mutants respire well; this phenotype implies that COB precursor RNA is translated efficiently. With the expectation that a Deltacbp1Deltapet127 strain might accumulate substantial levels of COB RNA, the double null strain was constructed and analyzed to test the hypothesis that Cbp1 is required for translation of COB RNA. The Deltacbp1Deltapet127 strain does accumulate levels of COB precursor mRNA that are similar to60% of the level of COB mRNA in the wild-type strain. However, cytochrome b protein is not synthesized, and thus the Deltacbp1Deltapet127 strain does not respire. These results suggest that Cbp1 is required for translation of COB RNAs.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Dieckmann, CL (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St,LSS Bldg Room 454, Tucson, AZ 85721 USA.	dieckman@u.arizona.edu	Islas-Osuna, María A./AAI-3764-2020	Islas-Osuna, María A./0000-0002-7170-3366	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEN JY, 1988, J BIOL CHEM, V263, P13677; CHEN W, 1994, J BIOL CHEM, V269, P16574; Chen W, 1999, GENETICS, V151, P1315; Chen W, 1997, MOL CELL BIOL, V17, P6203, DOI 10.1128/MCB.17.11.6203; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; DIECKMANN CL, 1982, P NATL ACAD SCI-BIOL, V79, P1805, DOI 10.1073/pnas.79.6.1805; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; Groom K R, 1996, Methods Enzymol, V264, P86, DOI 10.1016/S0076-6879(96)64011-7; LABOUESSE M, 1984, EUR J BIOCHEM, V144, P85, DOI 10.1111/j.1432-1033.1984.tb08434.x; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MITTELMEIER TM, 1990, CURR GENET, V18, P421, DOI 10.1007/BF00309911; MITTELMEIER TM, 1993, MOL CELL BIOL, V13, P4203, DOI 10.1128/MCB.13.7.4203; MITTELMEIER TM, 1995, MOL CELL BIOL, V15, P780; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; ROSE MD, 1990, METHODS YEAST GENETI, P179; STAPLES RR, 1993, GENETICS, V135, P981; WEBER ER, 1990, J BIOL CHEM, V265, P1594; Wiesenberger G, 1997, MOL CELL BIOL, V17, P2816, DOI 10.1128/MCB.17.5.2816	25	37	38	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37987	37990		10.1074/jbc.M206132200	http://dx.doi.org/10.1074/jbc.M206132200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149267	hybrid			2022-12-25	WOS:000178529600004
J	Chariot, A; Leonardi, A; Muller, J; Bonif, M; Brown, K; Siebenlist, U				Chariot, A; Leonardi, A; Muller, J; Bonif, M; Brown, K; Siebenlist, U			Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED FACTOR-2; SEVERE LIVER DEGENERATION; EMBRYONIC LETHALITY; DEFICIENT MICE; TAX PROTEIN; T-CELLS; ACTIVATION; ALPHA; PHOSPHORYLATION; SUBUNIT	Canonical activation of NF-kappaB is mediated via phosphorylation of the inhibitory IkappaB proteins by the IkappaB kinase complex (IKK). IKK is composed of a heterodimer of the catalytic IKKalpha and IKKbeta subunits and a presumed regulatory protein termed NEMO (NF-kappaB essential modulator) or IKKgamma. NEMO/IKKgamma is indispensable for activation of the IKKs in response to many signals, but its mechanism of action remains unclear. Here we identify TANK (TRAF family member-associated NF-kappaB activator) as a NEMO/IKKgamma-interacting protein via yeast two-hybrid analyses. This interaction is confirmed in mammalian cells, and the domains required are mapped. TANK was previously shown to assist NF-kappaB activation in a complex with TANK-binding kinase 1 (TBK1) or IKKepsilon, two kinases distantly related to IKKalpha/beta, but the underlying mechanisms remained unknown. Here we show that TBK1 and IKKepsilon synergize with TANK to promote interaction with the IKKs. The TANK binding domain within NEMO/IKKgamma is required for proper functioning of this IKK subunit. These results indicate that TANK can synergize with IKKepsilon or TBK1 to link them to IKK complexes, where the two kinases may modulate aspects of NF-kappaB activation.	NIAID, Lab Immunoregulat, NIH, Bethesda, MD 20892 USA; CHU Sart Tilman, Med Chem Lab, Ctr Cellular & Mol Therapy Pathol, B-4000 Liege, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Liege	Siebenlist, U (corresponding author), NIAID, Lab Immunoregulat, NIH, Bldg 10,Rm 11B16, Bethesda, MD 20892 USA.		leonardi, antonio/A-2887-2009	leonardi, antonio/0000-0001-8636-9623; Chariot, Alain/0000-0002-1691-4347				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nomura F, 2000, GENES CELLS, V5, P191; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	41	134	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37029	37036		10.1074/jbc.M205069200	http://dx.doi.org/10.1074/jbc.M205069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133833	Green Submitted, hybrid			2022-12-25	WOS:000178447100018
J	Ederth, J; Artsimovitch, I; Isaksson, LA; Landick, R				Ederth, J; Artsimovitch, I; Isaksson, LA; Landick, R			The downstream DNA jaw of bacterial RNA polymerase facilitates both transcriptional initiation and pausing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3.3 ANGSTROM RESOLUTION; PROMOTER OPEN COMPLEX; ESCHERICHIA-COLI; ELONGATION COMPLEX; STRUCTURAL BASIS; TERMINATION; MECHANISM; SITE; REGION; MUTANTS	Regulation of RNA polymerase during initiation, elongation, and termination of transcription is mediated in part by interactions with intrinsic regulatory signals encoded in the RNA and DNA that contact the enzyme. These interactions include contacts to an 8-9-bp RNA: DNA hybrid within the active-site cleft of the enzyme, contacts to the melted nontemplate DNA strand in the vicinity of the hybrid, contacts to exiting RNA upstream of the hybrid, and contacts to similar to20 bp of duplex DNA downstream of the active site. Based on characterization of an amino acid substitution (G1161R) and a deletion (Delta1149-1190) in the jaw domain of the bacterial RNA polymerase largest subunit (beta'), we report here that contacts of the jaw domain to downstream DNA at the leading edge of the transcription complex contribute to regulation during all three phases of transcription. The results provide insight into the role of the jaw domain-downstream DNA contact in transcriptional initiation and pausing and suggest possible explanations for the previously reported isolation of the jaw mutants based on reduced ColEI plasmid replication.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Stockholm, Dept Microbiol, S-10691 Stockholm, Sweden	University of Wisconsin System; University of Wisconsin Madison; Stockholm University	Landick, R (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.		Artsimovitch, Irina/L-3467-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R29GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Ederth J, 2002, MOL GENET GENOMICS, V267, P587, DOI 10.1007/s00438-002-0689-y; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Geetha V, 1997, PROTEIN SCI, V6, P2538; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; LAFLAMME SE, 1985, NUCLEIC ACIDS RES, V13, P8425, DOI 10.1093/nar/13.23.8425; Landick R, 1996, METHOD ENZYMOL, V274, P334; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Pan T, 1999, P NATL ACAD SCI USA, V96, P9545, DOI 10.1073/pnas.96.17.9545; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	52	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37456	37463		10.1074/jbc.M207038200	http://dx.doi.org/10.1074/jbc.M207038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147705	hybrid			2022-12-25	WOS:000178447100070
J	Ma, TH; Vetrivel, L; Yang, H; Pedemonte, N; Zegarra-Moran, O; Galietta, LJV; Verkman, AS				Ma, TH; Vetrivel, L; Yang, H; Pedemonte, N; Zegarra-Moran, O; Galietta, LJV; Verkman, AS			High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL; CURRENTS	Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that reduce cAMP-stimulated Cl- conductance in airway and other epithelia. The purpose of this investigation was to identify new classes of potent CFTR activators. A collection of 60,000 diverse drug-like compounds was screened at 10 pm together with a low concentration of forskolin (0.5 muM) in Fisher rat thyroid epithelial cells co-expressing human CFTR and a green fluorescent protein-based Cl- sensor. Primary screening yielded 57 strong activators (greater activity than reference compound apigenin), most of which were unrelated in chemical structure to known CFTR activators, and 284 weaker activators. Secondary analysis of the strong activators included analysis of CFTR specificity, forskolin requirement, transepithelial short-circuit current, activation kinetics, dose response, toxicity, and activation mechanism. Three compounds, the most potent being a dihydroisoquinoline, activated CFTR by elevating cellular cAMP, probably by phosphodiesterase inhibition. Fourteen compounds activated CFTR without cAMP elevation or phosphatase inhibition, suggesting direct CFTR interaction. The most potent compounds had tetrahydrocarbazol, hydroxycoumarin, and thiazolidine core structures. These compounds induced CFTR Cl- currents rapidly (<5 min) with K-d down to 200 nm and were CFTR-selective, reversible, and nontoxic. Several compounds, the most potent being a trifluoromethylphenylbenzamine, activated the CF-causing mutant G551D, but with much weaker affinity (K-d > 10 muM). When added for 10 min, none of the compounds activated DeltaPhe(508)-CFTR in transfected cells grown at 37 degreesC (with DeltaPhe(508)-CFTR trapped in the endoplasmic reticulum). However, after correction of trafficking by 48 h of growth at 27 degreesC, tetrahydrocarbazol and N-phenyltriazine derivatives strongly stimulated Cl- conductance with K-d < 1 &mu;M. The new activators identified here may be useful in defining molecular mechanisms of CFTR activation and as lead compounds in CF drug development.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Genoa; IRCCS Istituto Giannina Gaslini	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.		Pedemonte, Nicoletta/B-3607-2010; Galietta, Luis JV/HCG-8692-2022	Pedemonte, Nicoletta/0000-0002-5161-1720; Galietta, Luis/0000-0001-8686-3461	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; Telethon [E.0593] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		Bachmann A, 2000, BRIT J PHARMACOL, V131, P433, DOI 10.1038/sj.bjp.0703600; Becq F, 1999, J BIOL CHEM, V274, P27415, DOI 10.1074/jbc.274.39.27415; Chappe V, 1998, BRIT J PHARMACOL, V123, P683, DOI 10.1038/sj.bjp.0701648; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; Illek B, 2000, AM J PHYSIOL-CELL PH, V279, pC1838, DOI 10.1152/ajpcell.2000.279.6.C1838; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Schultz BD, 1999, PHYSL REV S, V79, P109; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	16	164	198	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37235	37241		10.1074/jbc.M205932200	http://dx.doi.org/10.1074/jbc.M205932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161441	hybrid			2022-12-25	WOS:000178447100044
J	Trigueros, S; Roca, J				Trigueros, S; Roca, J			Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; CLONING; TRANSFORMATION; TRANSCRIPTION; REPLICATION; MECHANISM; MUTANTS; RDNA	In the yeast Saccharomyces cerevisiae, DNA topoisomerases I and II can functionally substitute for each other in removing positive and negative DNA supercoils. Yeast Deltatop1 top2(ts) mutants grow slowly and present structural instability in the genome; over half of the rDNA repeats are excised in the form of extrachromosomal rings, and small circular minichromosomes strongly multimerize. Because these traits can be reverted by the extrachromosomal expression of either eukaryotic topoisomerase I or II, their origin is attributed to the persistence of unconstrained DNA supercoiling. Here, we examine whether the expression of the Escherichia coli topA gene, which encodes the bacterial topoisomerase I that removes only negative supercoils, compensates the phenotype of Deltatop1 top2(ts) yeast cells. We found that Deltatop1 top2(ts) mutants expressing E. coli topoisomerase I grow faster and do not manifest rDNA excision and minichromosome multimerization. Furthermore, the recombination frequency in repeated DNA sequences, which is increased by nearly two orders of magnitude in Deltatop1 top2(ts) mutants relative to the parental TOP+ cells, is restored to normal levels when the bacterial topoisomerase is expressed. These results indicate that the suppression of mitotic hyper-recombination caused by eukaryotic topoisomerases I and II is effected mainly by the relaxation of negative rather than positive supercoils; they also highlight the potential of unconstrained negative supercoiling to promote homologous recombination.	Consejo Super Invest Cientificas, Inst Biol Mol Barcelona, E-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Roca, J (corresponding author), Consejo Super Invest Cientificas, Inst Biol Mol Barcelona, Jordi Girona 18-26, E-08034 Barcelona, Spain.	jrbbmc@cid.csic.es	Roca, Joaquim/AAP-1077-2020; Trigueros, Sonia/O-7358-2014	Roca, Joaquim/0000-0003-1462-954X; Trigueros, Sonia/0000-0001-5621-7303				BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KIM RA, 1992, J BIOL CHEM, V267, P17178; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; PRADO F, 1995, GENETICS, V139, P109; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1983, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; Trigueros S, 2001, J BIOL CHEM, V276, P2243, DOI 10.1074/jbc.M008930200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	31	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37207	37211		10.1074/jbc.M206663200	http://dx.doi.org/10.1074/jbc.M206663200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151411	hybrid			2022-12-25	WOS:000178447100040
J	Wade, WN; Willingham, MC; Koumenis, C; Cramer, SD				Wade, WN; Willingham, MC; Koumenis, C; Cramer, SD			p27(Kip1) is essential for the antiproliferative action of 1,25-dihydroxyvitamin D-3 in primary, but not immortalized, mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CANCER-CELLS; IN-VITRO; VITAMIN-D-3; INDUCTION; GROWTH; P21; DIFFERENTIATION; PROLIFERATION; TRANSCRIPTION	1alpha,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) inhibits the growth of numerous cancer cell types. The intracellular proteins that mediate 1,25(OH)(2)D-3-induced growth inhibition are poorly defined, although it is speculated that p21 and p27 are involved. We tested the requirement of p21 and p27 by treating primary wild-type, p21(-/-), and p27(-/-) mouse embryonic fibroblasts (MEFs) with 100 nM 1,25(OH)(2)D-3. In response to treatment, the wild-type and p21(-/-) MEFs exhibited 54 and 60% growth inhibition (p < 0.05), respectively, whereas the growth of p27(-/-)MEFs was unaffected. Western analyses indicated that p27 expression is induced by 1,25(OH)(2)D-3 treatment in wild-type and p21(-/-) MEFs. p21 expression is also induced by 1,25(OH)(2)D-3 treatment in wild-type and p27(-/-) MEFs, although the effect is less robust than for p27. Next, we spontaneously immortalized each MEF strain, which resulted in a gain of responsiveness to 1,25(OH)(2)D-3 by the p27(-/-) MEFs, as exhibited by 87% growth inhibition (p < 0.05). Both wild-type and p21(-/-) MEFs retained responsiveness (43 and 72% growth inhibition (p < 0.05), respectively). These data from primary and immortalized MEFs demonstrate that there are both p27-dependent and -independent pathways that mediate the antiproliferative action of 1,25(OH)(2)D-3.	Wake Forest Univ, Dept Canc Biol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Pathol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Radiat Oncol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Urol, Sch Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Cramer, SD (corresponding author), Wake Forest Univ, Dept Canc Biol, Sch Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.		Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NATIONAL CANCER INSTITUTE [T32CA079448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK052623] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA79448] Funding Source: Medline; NIDDK NIH HHS [R29-DK52623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fife RS, 1997, CANCER LETT, V120, P65, DOI 10.1016/S0304-3835(97)00298-X; Geng Y, 1996, ONCOGENE, V12, P1173; Hershberger PA, 1999, CANCER RES, V59, P2644; JIANG HP, 1994, ONCOGENE, V9, P3397; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Mitchell JH, 2000, NUTR CANCER, V38, P223, DOI 10.1207/S15327914NC382_12; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WADHWA R, 1993, BIOCHEM BIOPH RES CO, V197, P202, DOI 10.1006/bbrc.1993.2461; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	22	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37301	37306		10.1074/jbc.M204162200	http://dx.doi.org/10.1074/jbc.M204162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163488	hybrid			2022-12-25	WOS:000178447100051
J	Ambrogelly, A; Ahel, I; Polycarpo, C; Bunjun-Srihari, S; Krett, B; Jacquin-Becker, C; Ruan, BF; Kohrer, C; Stathopoulos, C; RajBhandary, UL; Soll, D				Ambrogelly, A; Ahel, I; Polycarpo, C; Bunjun-Srihari, S; Krett, B; Jacquin-Becker, C; Ruan, BF; Kohrer, C; Stathopoulos, C; RajBhandary, UL; Soll, D			Methanocaldococcus jannaschii prolyl-tRNA synthetase charges tRNA(Pro) with cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; SEQUENCE; ACIDS; SITE; DISCRIMINATION; MECHANISM; DOMAIN	Methanocaldococcus jannaschii prolyl-tRNA synthetase (ProRS) was previously reported to also catalyze the synthesis of cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) to make up for the absence of the canonical cysteinyl-tRNA synthetase in this organism (Stathopoulos, C., Li, T., Longman, R., Vothknecht, U. C., Becker, H., Ibba, M., and Soll, D. (2000) Science 287, 479-482; Lipman, R. S., Sowers, K. R., and Hou, Y. M. (2000) Biochemistry 39, 7792-7798). Here we show by acid urea gel electrophoresis that pure heterologously expressed recombinant M. jannaschii ProRS misaminoacylates M. jannaschii tRNA(Pro), with cysteine. The enzyme is unable to aminoacylate purified mature M. jannaschii tRNA(Cys) with cysteine in contrast to facile aminoacylation of the same tRNA with cysteine by Methanococcus maripaludis cysteinyl-tRNA synthetase. Although M. jannaschii ProRS catalyzes the synthesis of Cys-tRNA(Pro) readily, the enzyme is unable to edit this misaminoacylated tRNA. We discuss the implications of these results on the in vivo activity of the M. jannaschii ProRS and on the nature of the enzyme involved in the synthesis of Cys-tRNA(Cys) in M. jannaschii.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Yale University; Yale University; Massachusetts Institute of Technology (MIT)	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.		Polycarpo, Carla R/G-2832-2011	Ahel, Ivan/0000-0002-9446-3756; Stathopoulos, Constantinos/0000-0002-5699-4118; Polycarpo, Carla/0000-0001-9663-3563	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022854, R56GM017151, F32GM017151, R01GM017151, R37GM017151, R37GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151, GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Bovee ML, 1999, BIOCHEMISTRY-US, V38, P13725, DOI 10.1021/bi991182g; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fabrega C, 2001, NATURE, V411, P110, DOI 10.1038/35075121; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; HECHT SM, 1976, P NATL ACAD SCI USA, V73, P405, DOI 10.1073/pnas.73.2.405; Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Lipman RSA, 2002, J MOL BIOL, V315, P943, DOI 10.1006/jmbi.2001.5297; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Newberry KJ, 2002, EMBO J, V21, P2778, DOI 10.1093/emboj/21.11.2778; RIBEIRO S, 1995, ANAL BIOCHEM, V228, P330, DOI 10.1006/abio.1995.1359; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SPRINZL M, 1975, P NATL ACAD SCI USA, V72, P3049, DOI 10.1073/pnas.72.8.3049; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, P NATL ACAD SCI USA, V98, P14292, DOI 10.1073/pnas.201540498; Stathopoulos C, 2001, BIOCHEMISTRY-US, V40, P46, DOI 10.1021/bi002108x; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712; Yarus M, 2000, SCIENCE, V287, P440, DOI 10.1126/science.287.5452.440	43	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34749	34754		10.1074/jbc.M206929200	http://dx.doi.org/10.1074/jbc.M206929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130658	hybrid			2022-12-25	WOS:000178117000014
J	Kimberly, WT; LaVoie, MJ; Ostaszewski, BL; Ye, WJ; Wolfe, MS; Selkoe, DJ				Kimberly, WT; LaVoie, MJ; Ostaszewski, BL; Ye, WJ; Wolfe, MS; Selkoe, DJ			Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; PRECURSOR PROTEIN; PRESENILIN-1; NOTCH; ENDOPROTEOLYSIS; DROSOPHILA; CLEAVAGE	The intramembranous proteolysis of Notch and the amyloid precursor protein by gamma-secretase exemplifies an unusual and newly recognized mechanism of signal transduction in multicellular organisms. Here, we show that only a form of nicastrin (NCT) containing N-linked complex oligosaccharides is present in active gamma-secretase complexes. Overexpression of NCT does not generate more of this mature protein, a phenomenon analogous to the strictly regulated formation of mature presenilin heterodimers from immature holoprotein. The absence of presenilin severely limits the maturation of NCT, yet combined overexpression of both proteins does not increase respective mature types. Taken together, our findings describe unusual regulatory features of this key signaling protease: the association of NCT with gamma-secretase is tightly regulated via glycosylation; at least one other cofactor exists; the least abundant member of the complex becomes limiting; and the cofactor that serves this role may vary by cell type.	Brigham & Womens Hosp, Ctr Neurol Dis, Harvard Inst Med 730, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Harvard Inst Med 730, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017574, R01AG012749] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12749, AG 17574] Funding Source: Medline; NINDS NIH HHS [NS 41355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	34	103	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35113	35117		10.1074/jbc.M204446200	http://dx.doi.org/10.1074/jbc.M204446200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130643	hybrid			2022-12-25	WOS:000178117000058
J	Ji, SN; Frank, SJ; Messina, JL				Ji, SN; Frank, SJ; Messina, JL			Growth hormone-induced differential desensitization of STAT5, ERK, and Akt phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; INSULIN-LIKE; GH RECEPTOR; RAT-LIVER; NEGATIVE REGULATORS; TRUNCATED ISOFORM; BINDING PROTEIN; FEMALE RATS; IM-9 CELLS	Secretion of growth hormone (GH) in adult male rats is characterized by high peak and undetectable trough levels, both of which are required for male-specific pattern of liver gene expression and GH-induced phosphorylation of STAT5. The present study suggests that regulation of GH receptor (GHR) levels in rat hepatoma cells by repeated GH stimulation determines GH responsiveness via the JAK2/STAT5 pathway. A short exposure to GH rapidly reduced GHR levels which resulted in an equal desensitization of the JAK2/STAT5 pathway. Recovery of GH-induced STAT5 phosphorylation correlated with the time-dependent recovery of GHR levels during incubation in the absence of GH. Acute GH also induced phosphorylation of ERK1/2 and Akt, and this induction was also inhibited by prior exposure to GH. However, unlike the JAK2/STAT5 pathway, the effect of GH to activate the MEK/ERK and phosphatidylinositol 3-kinase/Akt pathways did not recover following prolonged incubation in the absence of GH. Thus, GH administration desensitizes the JAK2/STAT5 pathway, possibly because of down-regulation of GHR, whereas an additional post-receptor mechanism is required for the prolonged refractoriness of the MEK/ERK and phosphatidylinositol 3-kinase/Akt pathways toward a second GH stimulation. Our study suggests that both receptor and post-receptor mechanisms are important in GH-induced homologous desensitization.	Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Messina, JL (corresponding author), Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Volker Hall,G019,1670 Univ Blvd, Birmingham, AL 35294 USA.	messina@path.uab.edu			NIDDK NIH HHS [DK40456, DK46395, DK58259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R56DK058259, R01DK046395, R29DK046395, R01DK058259, R01DK040456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amit T, 1997, J CLIN ENDOCR METAB, V82, P3813, DOI 10.1210/jc.82.11.3813; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BICK T, 1992, ENDOCRINOLOGY, V131, P423, DOI 10.1210/en.131.1.423; BIRNBAUM RS, 1979, HORM METAB RES, V11, P136, DOI 10.1055/s-0028-1092695; BJORGELL P, 1984, ENDOCRINOLOGY, V115, P1151; CHIPKIN SR, 1989, ENDOCRINOLOGY, V125, P450, DOI 10.1210/endo-125-1-450; EDEN S, 1978, ACTA ENDOCRINOL-COP, V88, P676, DOI 10.1530/acta.0.0880676; EDEN S, 1978, ACTA PHYSIOL SCAND, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; MacKenzie S, 1997, BIOCHEM J, V324, P159, DOI 10.1042/bj3240159; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; SCHWARTZ Y, 1991, P NATL ACAD SCI USA, V88, P6790, DOI 10.1073/pnas.88.15.6790; Shoba LNN, 2001, ENDOCRINOLOGY, V142, P3980, DOI 10.1210/en.142.9.3980; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; WAXMAN DJ, 1995, MOL PHARMACOL, V48, P790; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7	53	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28384	28393		10.1074/jbc.M111723200	http://dx.doi.org/10.1074/jbc.M111723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12161450	hybrid			2022-12-25	WOS:000177342600007
J	Hohaus, A; Person, V; Behlke, J; Schaper, J; Morano, I; Haase, H				Hohaus, A; Person, V; Behlke, J; Schaper, J; Morano, I; Haase, H			The carboxyl-terminal region of ahnak provides a link between cardiac L-type Ca2+ channels and the actin-based cytoskeleton	FASEB JOURNAL			English	Article						L-type calcium channel; beta subunit; protein-protein interaction; cardiomyocytes	PROTEIN-KINASE-A; CALCIUM-CHANNEL; BETA-SUBUNIT; DESMOYOKIN/AHNAK PROTEIN; GENE AHNAK; PLASMA-MEMBRANE; EXPRESSION; BINDING; IDENTIFICATION; TRANSLOCATION	Ahnak is a ubiquitously expressed giant protein of 5643 amino acids implicated in cell differentiation and signal transduction. In a recent study, we demonstrated the association of ahnak with the regulatory beta2 subunit of the cardiac L-type Ca2+ channel. Here we identify the most carboxyl-terminal ahnak region (aa 5262-5643) to interact with recombinant beta2a as well as with beta2 and beta1a isoforms of native muscle Ca2+ channels using a panel of GST fusion proteins. Equilibrium sedimentation analysis revealed K-d values of 55 +/- 11 nM and 328 +/- 24 nM for carboxyl- terminal (aa 195- 606) and amino-terminal (aa 1-200) truncates of the beta2a subunit, respectively. The same carboxyl-terminal ahnak region (aa 5262-5643) bound to G-actin and cosedimented with F-actin. Confocal microscopy of human left ventricular tissue localized the carboxyl-terminal ahnak portion to the sarcolemma including the T-tubular system and the intercalated disks of cardiomyocytes. These results suggest that ahnak provides a structural basis for the subsarcolemmal cytoarchitecture and confers the regulatory role of the actin-based cytoskeleton to the L-type Ca2+ channel.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany; Humboldt Univ, Charite, Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Franz Volhard Clin, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haase, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	haase@mdc-berlin.de						Behlke J, 1997, EUR BIOPHYS J BIOPHY, V25, P325, DOI 10.1007/s002490050046; Behlke J, 1999, PROG COLL POL SCI S, V113, P182; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Caldwell JH, 2000, MICROSC RES TECHNIQ, V49, P84, DOI 10.1002/(SICI)1097-0029(20000401)49:1<84::AID-JEMT9>3.0.CO;2-E; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gomez AM, 2000, CIRC RES, V86, P30, DOI 10.1161/01.RES.86.1.30; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; Haase H, 2000, J CELL BIOCHEM, V76, P695, DOI 10.1002/(SICI)1097-4644(20000315)76:4<695::AID-JCB17>3.0.CO;2-Q; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAASE H, 1994, RECEPTOR CHANNEL, V2, P41; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; HIEDA Y, 1989, J CELL BIOL, V109, P1511, DOI 10.1083/jcb.109.4.1511; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; Kostin S, 1998, CELL TISSUE RES, V294, P449, DOI 10.1007/s004410051196; Krafft C, 2000, FEBS LETT, V471, P128, DOI 10.1016/S0014-5793(00)01377-6; KUDOH J, 1995, CYTOGENET CELL GENET, V70, P218, DOI 10.1159/000134037; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; MASUNAGA T, 1995, J INVEST DERMATOL, V104, P941, DOI 10.1111/1523-1747.ep12606213; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; Morano I, 1997, FEBS LETT, V408, P71, DOI 10.1016/S0014-5793(97)00390-6; Nakamura M, 2000, AM J PHYSIOL-CELL PH, V279, pC480, DOI 10.1152/ajpcell.2000.279.2.C480; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Schade M, 1999, FEBS LETT, V458, P27, DOI 10.1016/S0014-5793(99)01119-9; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; Wyman J., 1990, BINDING LINKAGE; Xu H, 2000, FEBS LETT, V482, P180, DOI 10.1016/S0014-5793(00)02026-3	44	107	107	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1205	10.1096/fj.01-0855com	http://dx.doi.org/10.1096/fj.01-0855com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153988				2022-12-25	WOS:000177814000029
J	Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR				Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR			Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant	ONCOGENE			English	Article						multidrug resistance; caspases; apoptosis; proteinase-3; leukemia; doxorubicin	FLOW-CYTOMETRIC DETECTION; CYTOCHROME-C; REACTIVE OXYGEN; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; MULTIDRUG RESISTANCE; GROWTH ARREST; TUMOR-CELLS; BCR-ABL; ACTIVATION	We report here that expression or proteinase 3 (PR3), a serine protease, is down-regulated in the HL60/ADR multidrug resistant variant of the human myelogenous leukemia cell line HL-60, and that down-regulation of PR3 is associated with doxorubicin (DOX) resistance in these cells. To determine whether PR3 is involved in DOX-induced apoptosis in HL-60 cells, and whether its loss causes resistance to DOX, we inhibited PR3 expression by an anti-sense PR3 oligodeoxynucleotide and showed that inhibition of PR3 expression results in a significant reduction in DOX-induced DNA fragmentation and increased resistance to DOX-induced apoptosis. Our results revealed that PR3-mediated DOX-induced apoptosis in HL-60 cells is independent of the loss of mitochondrial membrane potential (AT) and activation of the caspase-8 and -9 pathways. Moreover, while PR3 is involved in the cleavage of caspase-3, PR3-mediated DOX-induced DNA fragmentation and apoptosis were not prevented by a specific inhibitor of caspase-3. These data suggest that activation of caspase-3 alone is not sufficient to trigger PR3-mediated DOX-induced apoptosis. Treatment with an anti-PR3 oligomer significantly decreased reactive oxygen species (ROS) generation in cells treated with low concentrations of DOX, revealing a role for PR3 in enhancing production of DOX-induced ROS. Moreover, DOX-induced apoptosis at 0.001 - 0.01 muM was only inhibited in HL-60 cells pre-treated with the antioxidant N-acetyl-cysteine in the absence of anti-PR3, revealing that DOX-induced apoptosis in these cells is PR3- and ROS-dependent. Our results show that Ill is involved in DOX-induced ROS-dependent apoptosis and that its loss is associated with resistance to DOX in HL-60 cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734, R01CA056078, R01CA090878] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56078, CA 80734, CA 90878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arrigo AP, 1998, BIOL CHEM, V379, P19; Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Bauer G, 2000, ANTICANCER RES, V20, P4115; Bauer V, 1999, GEN PHYSIOL BIOPHYS, V18, P7; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAMPOS L, 1993, BLOOD, V81, P3091; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CHEN T, 1994, BIOCHEM BIOPH RES CO, V200, P1130, DOI 10.1006/bbrc.1994.1568; Decaudin D, 1997, CANCER RES, V57, P62; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; Harper L, 2001, KIDNEY INT, V59, P1729, DOI 10.1046/j.1523-1755.2001.0590051729.x; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hirsch T, 1998, J IMMUNOL, V161, P35; Hishita T, 2001, CANCER RES, V61, P2878; HOIDAL JR, 1994, METHOD ENZYMOL, V244, P61; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Horman S, 2000, CELL PROLIFERAT, V33, P331, DOI 10.1046/j.1365-2184.2000.00188.x; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LABBAYE C, 1993, BLOOD, V81, P475; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li X, 2000, EXP CELL RES, V257, P290, DOI 10.1006/excr.2000.4901; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Mayet WJ, 1997, EUR J CLIN INVEST, V27, P893, DOI 10.1046/j.1365-2362.1997.2160771.x; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Morano KA, 1999, GENE EXPRESSION, V7, P271; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; RAO NV, 1991, J BIOL CHEM, V266, P9540; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Safa AR, 1998, METHOD ENZYMOL, V292, P289; Schwarting A, 2000, KIDNEY INT, V57, P2412, DOI 10.1046/j.1523-1755.2000.00100.x; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SLAPERCORTENBACH ICM, 1988, BLOOD, V72, P1639; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; Sun JY, 1998, J IMMUNOL METHODS, V211, P111, DOI 10.1016/S0022-1759(97)00203-2; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taekema-Roelvink MEJ, 1998, SCAND J IMMUNOL, V48, P37; Tammariello SP, 2000, J NEUROSCI, V20; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wong TWL, 2000, LIFE SCI, V67, pPL1111; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; Wu CH, 2001, ONCOGENE, V20, P7006, DOI 10.1038/sj.onc.1204893; Yang JJ, 2001, AM J PATHOL, V158, P581, DOI 10.1016/S0002-9440(10)64000-X; Yang JJ, 1996, AM J PATHOL, V149, P1617; Zimber A, 2000, CANCER RES, V60, P672	75	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5160	5174		10.1038/sj.onc.1205639	http://dx.doi.org/10.1038/sj.onc.1205639			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140766				2022-12-25	WOS:000176975900014
J	Ramsauer, M; Krause, D; Dermietzel, R				Ramsauer, M; Krause, D; Dermietzel, R			Angiogenesis of the blood-brain barrier in vitro and the function of cerebral pericytes	FASEB JOURNAL			English	Article						astrocyte; coculture; endothelial cell; TGF-beta 1	TRANSFORMING-GROWTH-FACTOR; IMMUNOREACTIVE GLUTAMYL AMINOPEPTIDASE; CAPILLARY-LIKE STRUCTURES; SMOOTH-MUSCLE-CELLS; FACTOR TYPE-BETA; ENDOTHELIAL-CELLS; RAT-BRAIN; SPROUT FORMATION; TGF-BETA; CULTURE	Cerebral pericytes constitute an essential component of the blood-brain barrier (BBB) and are involved in blood vessel assembly. Recently, we reported on the induction of a BBB-specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) in coculture with cerebral endothelial cells. We completed this in vitro BBB system by adding astrocytes to these mixed cultures of endothelial cells and pericytes. Under these triculture conditions, endothelial cells and pericytes reorganize into capillary-like structures (CLSs). Capillary formation can also be achieved by the application of transforming growth factor beta 1 (TGF-beta1) in the culture medium of endothelial-pericyte cultures lacking astrocytes. In contrast to the effect achieved by astrocytes, pericytes did not assemble with endothelial cells. In both cases (application of astrocytes or TGF-beta1), endothelial cells underwent apoptosis. However, endothelial cells that form CLSs in the presence of pericytes appeared to be resistant to induction of apoptosis. On the basis of these observations, we concluded that astrocytes have a profound influence on the morphogenetic events underlying the organization of the vessel wall; that the effect of TGF-beta1 is different from the astrocytic effect because it lacks induction of endothelial-pericyte association; and that pericytes stabilize CLSs formed by endothelial cells in coculture with astrocytes.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany	Ruhr University Bochum	Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ Str 150, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de						ABBOTT NJ, 1992, J CELL SCI, V103, P23; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AUDUS KL, 1987, ANN NY ACAD SCI, V507, P9, DOI 10.1111/j.1749-6632.1987.tb45787.x; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUSBACK HH, 1988, BIOCHEM PHARMACOL, V37, P155, DOI 10.1016/0006-2952(88)90712-5; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Crone C., 1984, HDB PHYSL CARDIOVASC, P411; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; DERMIETZEL R, 1975, CELL TISSUE RES, V164, P45; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FARRELL CR, 1987, ANAT REC, V218, P466, DOI 10.1002/ar.1092180416; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1986, CANCER RES, V46, P467; FREY A, 1991, EUR J BIOCHEM, V202, P421, DOI 10.1111/j.1432-1033.1991.tb16391.x; GEHRMANN J, 1991, J COMP NEUROL, V313, P409, DOI 10.1002/cne.903130302; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GREENWOOD J, 1991, ANN NY ACAD SCI, V633, P426; HEALY DP, 1993, BRAIN RES, V606, P295, DOI 10.1016/0006-8993(93)90997-2; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; IMAYAMA S, 1984, ANAT EMBRYOL, V169, P271, DOI 10.1007/BF00315632; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; JOO F, 1992, J NEUROCHEM, V58, P1, DOI 10.1111/j.1471-4159.1992.tb09272.x; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KRAUSE D, 1988, CELL TISSUE RES, V252, P543, DOI 10.1007/BF00216641; KUNZ J, 1995, J NEUROIMMUNOL, V59, P41, DOI 10.1016/0165-5728(95)00024-V; KUNZ J, 1994, J NEUROCHEM, V62, P2375; LATERRA J, 1990, J CELL PHYSIOL, V144, P204, DOI 10.1002/jcp.1041440205; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAXWELL K, 1989, J NEUROPATH EXP NEUR, V48, P69, DOI 10.1097/00005072-198901000-00006; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER J, 1991, J NEUROCHEM, V57, P1971, DOI 10.1111/j.1471-4159.1991.tb06411.x; MEYER J, 1990, BRAIN RES, V514, P305, DOI 10.1016/0006-8993(90)91425-G; MINAKAWA T, 1991, LAB INVEST, V65, P32; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061; NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PEPPER MS, 1991, J CELL PHYSIOL, V146, P170, DOI 10.1002/jcp.1041460122; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Ramsauer M, 1998, J CEREBR BLOOD F MET, V18, P1270, DOI 10.1097/00004647-199811000-00014; RAYCHAUDHURY A, 1991, J CELL BIOCHEM, V47, P224, DOI 10.1002/jcb.240470307; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RISAU W, 1992, J NEUROCHEM, V58, P667, DOI 10.1111/j.1471-4159.1992.tb09769.x; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SONG L, 1993, BRAIN RES, V606, P286, DOI 10.1016/0006-8993(93)90996-Z; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; VERHOEVEN D, 1988, VIRCHOWS ARCH B, V54, P263; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	63	119	120	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1274	+		10.1096/fj.01-0814fje	http://dx.doi.org/10.1096/fj.01-0814fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153997				2022-12-25	WOS:000176683900026
J	Cavarec, L; Kamphausen, T; Dubourg, B; Callebaut, I; Lemeunier, F; Metivier, D; Feunteun, J; Fischer, G; Modjtahedi, N				Cavarec, L; Kamphausen, T; Dubourg, B; Callebaut, I; Lemeunier, F; Metivier, D; Feunteun, J; Fischer, G; Modjtahedi, N			Identification and characterization of Moca-cyp - A Drosophilia melanogaster nuclear cyclophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; PRE-MESSENGER-RNA; A-INSENSITIVE CYCLOPHILIN; CYCLOSPORINE-A; BINDING-PROTEIN; HOMOLOGOUS DOMAIN; CRYSTAL-STRUCTURE; BRUGIA-MALAYI; IMMUNOPHILINS; TRANSCRIPTION	Cyclophilins are enzymes catalyzing the cis-trans isomerization of peptidyl-prolyl bonds and belong to the enzyme class of peptidyl-prolyl cis-trans isomerases (PPIases), which includes two more families (FK506 binding proteins and parvulins). We report the characterization of a novel cyclophilin (Moca-cyp) isolated from Drosophila melanogaster. The single-copy Moca-cyp gene, which is localized on chromosome 3R, was cloned and sequenced. The sequence alignment of the gene against Moca-cyp cDNA allowed us to define its intron/exon structure and to identify a variant cDNA corresponding to an alternatively spliced mRNA. By embryo in situ RNA hybridization and immunostaining, we show that the expression of Moca-cyp is regulated during embryogenesis of Drosophila. The 120-kDa nuclear Moca-cyp protein belongs to a subfamily of large cyclophilins sharing structural and enzymatic features: their highly conserved N-terminal PPIase domain is extended by a positively charged and divergent C-terminal tail. Compared with cyclophilin 18, the enzymatic activity carried by the PPIase domain of Moca-cyp is low, exhibits characteristic substrate specificity, and shows a reduced sensitivity to the drug cyclosporin A (CsA). The reduced affinity for CsA is one of the typical features linking members of this subfamily and is probably the consequence of two amino acid substitutions within their active site. Another structural feature shared by members of this subfamily is a conserved polypeptidic segment ("moca" domain) that we report for the first time. The moca domain is located within the C-terminal tail and is the exclusive hallmark of a group of large cyclophilins found in multicellular organisms of the animal kingdom.	Inst Gustave Roussy, UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France; Max Planck Forsch Stelle Enzymol Prot Faltung, D-06120 Halle An Der Saale, Germany; Univ Paris 06, CNRS, UMR7590, Lab Mineral & Cristallog Paris, F-75252 Paris 05, France; Univ Paris 07, CNRS, UMR7590, Lab Mineral & Cristallog Paris, F-75252 Paris 05, France; CNRS, Lab Populat Genet & Evolut, F-91198 Gif Sur Yvette, France	UNICANCER; Gustave Roussy; Max Planck Society; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Modjtahedi, N (corresponding author), Inst Gustave Roussy, UMR 1599, Lab Genet Oncol, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	nazanine@igr.fr	Feunteun, Jean/AAZ-1267-2020; MODJTAHEDI, Nazanine/D-4377-2017	Feunteun, Jean/0000-0003-1212-9189				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Ellis PJ, 2000, BIOCHEMISTRY-US, V39, P592, DOI 10.1021/bi991730q; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; Galat A, 1999, ARCH BIOCHEM BIOPHYS, V371, P149, DOI 10.1006/abbi.1999.1434; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Giardina SL, 1996, BLOOD, V87, P2269, DOI 10.1182/blood.V87.6.2269.bloodjournal8762269; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; Lemeunier F., 2000, P137; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Ma D, 2002, J BIOL CHEM, V277, P14925, DOI 10.1074/jbc.M112293200; Ma D, 1998, MOL BIOCHEM PARASIT, V92, P361, DOI 10.1016/S0166-6851(98)00006-1; Maniatis T., 1982, MOL CLONING LAB MANU; Mi HF, 1996, FEBS LETT, V398, P201, DOI 10.1016/S0014-5793(96)01248-3; Mikol V, 1998, PROTEIN SCI, V7, P1310, DOI 10.1002/pro.5560070606; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos AN, 2000, BIOL REPROD, V62, P1, DOI 10.1095/biolreprod62.1.1; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Taylor P, 1998, FEBS LETT, V425, P361, DOI 10.1016/S0014-5793(98)00264-6; Teigelkamp S, 1998, RNA, V4, P127; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	71	15	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41171	41182		10.1074/jbc.M203757200	http://dx.doi.org/10.1074/jbc.M203757200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154086	hybrid			2022-12-25	WOS:000178791400128
J	Moreira, LA; Ito, J; Ghosh, A; Devenport, M; Zieler, H; Abraham, EG; Crisanti, A; Nolan, T; Catteruccia, F; Jacobs-Lorena, M				Moreira, LA; Ito, J; Ghosh, A; Devenport, M; Zieler, H; Abraham, EG; Crisanti, A; Nolan, T; Catteruccia, F; Jacobs-Lorena, M			Bee venom phospholipase inhibits malaria parasite development in transgenic mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER MOSQUITO; AEDES-AEGYPTI; GERMLINE TRANSFORMATION; ANOPHELES-GAMBIAE; SALIVARY-GLANDS; GENE-EXPRESSION; BLOOD MEAL; MIDGUT; VECTOR; GUT	Malaria kills millions of people every year, and new control measures are urgently needed. The recent demonstration that (effector) genes can be introduced into the mosquito germ line to diminish their ability to transmit the malarift parasite offers new hope toward the fight of the disease (Ito, J., Ghosh, AL, Moreira, L. A., Wimmer, E. A. & Jacobs-Lorena, M. (2002) Nature, 417, 452-455). Because of the high selection pressure that an effector gene imposes on the parasite population, development of resistant strains is likely to occur. In search of additional antiparasitic effector genes, we have generated transgenic Anopheles stephensi mosquitoes that express the bee venom phospholipase A2 (PLA2) gene from the gut-specific and blood-inducible Anopheles gambiae carboxypeptidase (AgCP) promoter. Northern blot analysis indicated that the PLA2 mRNA is specifically expressed in the guts of transgenic mosquitoes with peak expression at similar to4 h after blood ingestion. Western blot and immunofluorescence analyses detected PLA2 protein in the midgut epithelia of transgenic mosquitoes from 8 to 24 h after a blood meal. Importantly, transgene expression reduced Plasmodium berghei oocyst formation by 87% on average and greatly impaired transmission of the parasite to naive mice. The results indicate that PLA2 may be used as an additional effector gene to block the development, of the malaria parasite in mosquitoes.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England	Case Western Reserve University; Imperial College London	Jacobs-Lorena, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Nolan, Tony/I-4925-2012	Nolan, Tony/0000-0002-2982-8333; Catteruccia, Flaminia/0000-0003-3295-6683; Crisanti, Andrea/0000-0002-2406-4426				BLACK IV, 1996, BIOL DIS VECTORS, P438; Capurro MD, 2000, AM J TROP MED HYG, V62, P427, DOI 10.4269/ajtmh.2000.62.427; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Horn C, 2000, DEV GENES EVOL, V210, P630, DOI 10.1007/s004270000110; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; Kokoza V, 2000, P NATL ACAD SCI USA, V97, P9144, DOI 10.1073/pnas.160258197; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moreira LA, 2000, P NATL ACAD SCI USA, V97, P10895, DOI 10.1073/pnas.97.20.10895; Nolan T, 2002, J BIOL CHEM, V277, P8759, DOI 10.1074/jbc.C100766200; Pinkerton AC, 2000, INSECT MOL BIOL, V9, P1, DOI 10.1046/j.1365-2583.2000.00133.x; Shahabuddin M, 1998, PARASITOL TODAY, V14, P493, DOI 10.1016/S0169-4758(98)01348-9; Webster D, 2001, J PUBLIC HEALTH POL, V22, P23, DOI 10.2307/3343552; Zieler H, 2001, J EXP BIOL, V204, P4157	21	141	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40839	40843		10.1074/jbc.M206647200	http://dx.doi.org/10.1074/jbc.M206647200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167627	hybrid			2022-12-25	WOS:000178791400088
J	Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y				Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y			Nek11, a new member of the NIMA family of kinases, involved in DNA replication and genotoxic stress responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; POLO-LIKE KINASE-1; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; SUBSTRATE-SPECIFICITY; MITOTIC REGULATOR; DAMAGE CHECKPOINT; TYR15 PHOSPHORYLATION; EXPRESSION PATTERN; MURINE NEK3	DNA replication and genotoxic stresses activate various checkpoint-associated protein kinases, and checkpoint dysfunction often leads to cell lethality. Here, we have identified new members of the mammalian NIMA family of kinases, termed Nek11L and Nek11S (NIMA-related kinase 11 Lone and Short isoform) as novel DNA replication/damage stresses-responsive kinases. Molecular cloning and biochemical studies showed that the catalytic domain of Nek11 is most similar to Nek4 and Nek3, and substrate specificity of Nek11L is distinguishable from those of NIMA and Nek2. The expression of nek11L mRNA increased through S to G(2)/M phase, and subcellular localization of Nek11 protein altered between interphase and prometaphase, suggesting multiple roles of Nek11. We found an activation of Nek11 kinase activity when cells were treated with various DNA-damaging agents and replication inhibitors, and this activation of Nek11 was suppressed by caffeine in HeLaS3 cells. The transient expression of wild-type Nek11L enhanced the aphidicolin-induced S-phase arrest, whereas the aphidicolin-induced S-phase arrest was reduced in the U2OS cell lines expressing kinase-negative Nek11L (K61R), and these cells were more sensitive to aphidicolin-induced cell lethality. Collectively, these results suggest that Nek11 has a role in the S-phase checkpoint downstream of the caffeine-sensitive pathway.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Uehara, Y (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.							Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kimura M, 2001, CYTOGENET CELL GENET, V94, P33, DOI 10.1159/000048779; Krien MJE, 1998, J CELL SCI, V111, P967; Krien MJE, 2002, EMBO J, V21, P1713, DOI 10.1093/emboj/21.7.1713; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; Li MZ, 1999, CYTOGENET CELL GENET, V87, P271, DOI 10.1159/000015445; Liu QH, 2000, GENE DEV, V14, P1448; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	50	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39655	39665		10.1074/jbc.M204599200	http://dx.doi.org/10.1074/jbc.M204599200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154088	hybrid			2022-12-25	WOS:000178662500078
J	Wolfert, MA; Murray, TF; Boons, GJ; Moore, JN				Wolfert, MA; Murray, TF; Boons, GJ; Moore, JN			The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; CELL WALL COMPONENTS; LIPOPOLYSACCHARIDE LPS; BACTERIAL PEPTIDOGLYCAN; STAPHYLOCOCCUS-AUREUS; CUTTING EDGE; ALPHA GENE; TNF-ALPHA; CD14	Although the basis for the high mortality rate for patients with mixed bacterial infections is likely to be multifactorial, there is evidence for a synergistic effect of muramyldipeptide (MDP) with lipopolysaccharide (LPS) on the synthesis of proinflammatory cytokines by mononuclear phagocytes. In this study, co-incubation of human Mono Mac 6 cells with MDP and either LPS or peptidoglycan (PGN) resulted in an apparent synergistic effect on tumor necrosis factor-alpha (TNF-alpha) secretion. Although incubation of cells with MDP alone produced minimal TNF-alpha, it caused significant expression of TNF-alpha mRNA. These findings suggest that the majority of TNF-alpha mRNA induced by MDP alone is not translated into protein. Furthermore, simultaneous incubation of cells with MDP and either LPS or PGN resulted in TNF-alpha mRNA expression that approximated the sum of the amounts expressed in response to MDP, LPS, and PGN individually. These findings indicate that the apparent synergistic effect of MDP on TNF-alpha production induced by either LPS or PGN is due to removal of a block in translation of the mRNA expressed in response to MDP. In subsequent studies, the effects of MDP alone and its effect on the production of TNF-alpha by LPS and PGN were determined to be independent of CD14, Toll-like receptor 2, and Toll-like receptor 4. These findings indicate that MDP acts through receptor(s) other than those primarily responsible for transducing the effects of LPS and PGN. Successful treatment of patients having mixed bacterial infections is likely to require interventions that address the mechanisms involved in responses induced by a variety of bacterial cell wall components.	Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA; Univ Georgia, Coll Vet Med, Dept Physiol & Pharmacol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Wolfert, MA (corresponding author), Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA.		Wolfert, Margreet A/J-1726-2016; Boons, Geert-Jan P H/J-3211-2016	Wolfert, Margreet A/0000-0003-4864-0026; Boons, Geert-Jan P H/0000-0003-3111-5954				BASCHANG G, 1989, TETRAHEDRON, V45, P6331, DOI 10.1016/S0040-4020(01)89512-0; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BEUTLER B, 1992, AM J MED SCI, V303, P129, DOI 10.1097/00000441-199202000-00015; BIRAGYN A, 1995, J IMMUNOL, V155, P674; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Crawford EK, 1997, J BIOL CHEM, V272, P21120, DOI 10.1074/jbc.272.34.21120; Crowe M, 1998, EUR J CLIN MICROBIOL, V17, P377, DOI 10.1007/s100960050089; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Gao JJ, 2001, J IMMUNOL, V166, P6855, DOI 10.4049/jimmunol.166.11.6855; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LICHTMAN SN, 1994, HEPATOLOGY, V19, P1013, DOI 10.1002/hep.1840190429; Mijatovic T, 2000, EUR J BIOCHEM, V267, P6004, DOI 10.1046/j.1432-1327.2000.01676.x; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; RIBI EE, 1979, CANCER RES, V39, P4756; ROBERTS FJ, 1991, REV INFECT DIS, V13, P34; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Siriwardena A, 2001, J AM CHEM SOC, V123, P8145, DOI 10.1021/ja0104655; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; van Langevelde P, 1999, ANTIMICROB AGENTS CH, V43, P2984, DOI 10.1128/AAC.43.12.2984; Wang JE, 2001, SHOCK, V16, P178, DOI 10.1097/00024382-200116030-00002; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WEIDEMANN B, 1997, INFECT IMMUN, V65, P558; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Yoshimura A, 1999, J IMMUNOL, V163, P1	37	128	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39179	39186		10.1074/jbc.M204885200	http://dx.doi.org/10.1074/jbc.M204885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151399	hybrid			2022-12-25	WOS:000178662500017
J	Kamradt, MC; Chen, F; Sam, S; Cryns, VL				Kamradt, MC; Chen, F; Sam, S; Cryns, VL			The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; SKELETAL-MUSCLE; CYTOCHROME-C; MYOCYTE DIFFERENTIATION; PROTECTIVE ACTIVITY; CELL-DEATH; EXPRESSION; HSP27; PHOSPHORYLATION; NECROSIS	Myoblasts-respond to growth factor deprivation either by differentiating into multinucleated myotubes or by undergoing apoptosis; hence, the acquisition of apoptosis resistance by myogenic precursors is essential for their development. Here we demonstrate that the expression of the small heat shock protein alphaB-crystallin is selectively induced in C2C12 myoblasts that are resistant to differentiation-induced apoptosis, and we show that this induction occurs at an early stage in their differentiation in vitro. In contrast, the expression of several known anti-apoptotic proteins (FLIP, XLAP, Bcl-x(L)) was not altered during myogenesis. We also demonstrate that ectopic expression of alphaB-crystallin, but not the closely related small heat shock protein Hsp27, renders C2C12 myoblasts resistant to differentiation-induced apoptosis. Furthermore, we show that the myopathy-causing R120G alphaB-crystallin mutant is partly impaired in its cytoprotective function, whereas a pseudophosphorylation alphaB-crystallin mutant that mimics stress-induced phosphorylation is completely devoid of anti-apoptotic activity. Finally, we demonstrate that alphaB-crystallin negatively regulates apoptosis during myogenesis by inhibiting the proteolytic activation of caspase-3, whereas the R120G and pseudophosphorylation mutants are defective in this function. Taken together, our findings indicate that alphaB-crystallin is a novel negative regulator of myogenic apoptosis that directly links the differentiation program to apoptosis resistance.	Northwestern Univ, Div Endocrinol, Feinberg Sch Med, Dept Med,Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Cryns, VL (corresponding author), Northwestern Univ, Div Endocrinol, Feinberg Sch Med, Dept Med,Ctr Endocrinol Metab & Mol Med, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA70085] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benjamin IJ, 1997, DEV DYNAM, V208, P75; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SCHAART G, 1989, DEVELOPMENT, V107, P585; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688	33	237	256	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38731	38736		10.1074/jbc.M201770200	http://dx.doi.org/10.1074/jbc.M201770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140279	hybrid			2022-12-25	WOS:000178529600092
J	Wechsler, J; Choi, YH; Krall, J; Ahmad, F; Manganiello, VC; Movsesian, MA				Wechsler, J; Choi, YH; Krall, J; Ahmad, F; Manganiello, VC; Movsesian, MA			Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SARCOPLASMIC-RETICULUM; GENE-TRANSFER; IN-VITRO; CAMP; ACTIVATION; PHOSPHORYLATION; INSULIN; PHOSPHOLAMBAN; IDENTIFICATION	PDE3A cyclic nucleotide phosphodiesterases regulate cAMP- and cGMP-mediated intracellular signaling in cardiac myocytes. We used antibodies to different regions of PDE3A to demonstrate the presence of three PDE3A isoforms in these cells. These isoforms, whose apparent molecular weights are 136,000, 118,000, and 94,000 ("PDE3A-136,"PDE3A-118," and "PDE3A-94"), are identical save for the deletion of different lengths of N-terminal sequence containing two membrane-association domains and sites for phosphorylation/activation by protein kinase B ("PK-B") and protein kinase A ("PK-A"). PDE3A-136 contains both membrane-association domains and the PK-B and PK-A sites. PDE3-118 contains only the downstream membrane-association domain and the PK-A sites. PDE3A-94 lacks both membrane localization domains and the PK-B and PK-A sites. The three isoforms are translated from two mRNAs derived from the PDE3A1 gene: PDE3A-136 is translated from PDE3A1 mRNA, whereas PDE3A-118 and PDE3A-94 are translated from PDE3A2 mRNA. Experiments involving in vitro transcription/translation indicate that PDE3A-118 and PDE3A-94 may be translated from different AUGs in PDE3A2 mRNA. These findings suggest that alternative transcriptional and post-transcriptional processing of the PDE3A gene results in the generation of two mRNAs and three protein isoforms in cardiac myocytes that differ with respect to intracellular localization and may be regulated through different signaling pathways.	Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect, Salt Lake City, UT 84148 USA; Univ Utah, Sch Med, Dept Internal Med Cardiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Pharmacol, Salt Lake City, UT 84132 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Movsesian, MA (corresponding author), Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect 111C, 500 Foothill Blvd, Salt Lake City, UT 84148 USA.	matthew.movsesian@med.va.gov	Khan, Faiyaz Ahmad/AAW-7944-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002540, Z01HL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; Choi YH, 2001, BIOCHEM J, V353, P41, DOI 10.1042/0264-6021:3530041; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HAYES JS, 1980, J BIOL CHEM, V255, P5113; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Huston E, 2000, J BIOL CHEM, V275, P28063; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KASUYA J, 1995, J BIOL CHEM, V270, P14305, DOI 10.1074/jbc.270.24.14305; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Krall J, 1999, J MOL CELL CARDIOL, V31, P971, DOI 10.1006/jmcc.1999.0926; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Movsesian MA, 1999, J AM COLL CARDIOL, V34, P318, DOI 10.1016/S0735-1097(99)00220-X; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; RASCON A, 1994, J BIOL CHEM, V269, P11962; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	40	95	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38072	38078		10.1074/jbc.M203647200	http://dx.doi.org/10.1074/jbc.M203647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154085	hybrid			2022-12-25	WOS:000178529600014
J	Karasawa, T; Yokokura, H; Kitajewski, J; Lombroso, PJ				Karasawa, T; Yokokura, H; Kitajewski, J; Lombroso, PJ			Frizzled-9 is activated by Wnt-2 and functions in Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; AXIS FORMATION; PROTEIN INTERACTIONS; NEGATIVE REGULATOR; COLON-CARCINOMA; PATHWAY; FAMILY; GENE; DROSOPHILA; RECEPTOR	Frizzled has been known to function as a Wnt receptor. Although there have been a number of mammalian Frizzled members identified, their binding specificities with Wnt and functions in mammalian cells have been poorly understood. Here, we demonstrate that rat Frizzled-9 (Rfz9) functions in Wnt/beta-catenin signaling in 293T cells. Rfz9 overexpression induces the hyperphosphorylation and relocalization of mouse Dishevelled-1 (Dvl-1) from the cytoplasm to the cell membrane and the accumulation of cytosolic beta-catenin. Transfections of Rfz9 with each of several Wnt members show that only Wnt-2 activates Rfz9 in T cell factor (TCF)-dependent transcription. Deletion mutant analysis determines that there is a difference in Rfz9 C-terminal residues required for the modifications of Dvl-1 and those required for the inductions of beta-catenin stabilization and TCF transactivation. Deletion of the Wnt-binding domain does not abolish Rfz9 activity completely, although it causes the inactivation of Wnt-2-dependent TCF transcription. Rfz9 also relocalizes Axin from the cytoplasm to the plasma membrane in the presence of Dvl-1, suggesting that one of the consequences of Dvl-1 relocalization by Rfz9 is to bring Axin to the cell membrane.	Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdept Neurosci Program, New Haven, CT 06520 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Obstet Gynecol, New York, NY 10032 USA	Yale University; Yale University; Columbia University; Columbia University	Lombroso, PJ (corresponding author), Yale Univ, Sch Med, Ctr Child Study, SHM I-270,230 S Frontage Rd, New Haven, CT 06520 USA.							Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; Tago K, 2000, GENE DEV, V14, P1741; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wang YK, 1999, GENOMICS, V57, P235, DOI 10.1006/geno.1999.5773; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	44	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37479	37486		10.1074/jbc.M205658200	http://dx.doi.org/10.1074/jbc.M205658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138115	hybrid			2022-12-25	WOS:000178447100073
J	Sekine, O; Nishio, Y; Egawa, K; Nakamura, T; Maegawa, H; Kashiwagi, A				Sekine, O; Nishio, Y; Egawa, K; Nakamura, T; Maegawa, H; Kashiwagi, A			Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; ENDOTHELIAL DYSFUNCTION; HEART-DISEASE; RABBIT MODEL; ATHEROSCLEROSIS; RESISTANCE; PHOSPHORYLATION; AKT; INFLAMMATION	Phosphatidylinositol 3-kinase (PI3K) is a key molecule mediating signals of insulin in vascular smooth muscle cells (VSMCs). To examine the effect of chronic activation of PI3K on the gene expression of VSMCs, membrane-targeted p110CAAX, a catalytic subunit of PI3K, was overexpressed in rat VSMCs by adenovirus-mediated gene transfer. Similar to insulin's effects, cells overexpressing p110CAAX exhibited a 10- to 15-fold increase in monocyte chemoattractant protein-1 (MCP-1) mRNA expression as compared with the control cells. Electrophoretic mobility shift assay analysis showed that the overexpression of p110CAAX activated neither the NF-kappaB binding nor the activator protein (AP-1) binding activities. We found that two CCAAT/enhancer binding protein (C/EBP) binding sites located between 2.6 and 3.6 kb upstream of the MCP-1 gene were responsible for the induction by p110CAAX. The overexpression of C/EBP-beta and C/EBP-delta but not C/EBP-alpha caused 6- to 8-fold induction of MCP-1 promoter activity. Consistently, the overexpression of p110CAAX as well as insulin induced mRNA expression and nuclear expression of C/EBP-beta and C/EBP-delta in VSMCs. These results clearly indicate that the activation of PI3K induced proinflammatory gene expression through activating C/EBP-beta and C/EBP-delta but not NF-kappaB, which may explain the proinflammatory effect of insulin in the insulin-resistant state.	Shiga Univ Med Sci, Div Endocrinol & Metab, Dept Med, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Nishio, Y (corresponding author), Shiga Univ Med Sci, Div Endocrinol & Metab, Dept Med, Otsu, Shiga 5202192, Japan.		Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Chen XL, 1998, CIRC RES, V83, P952; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; FONTBONNE A, 1988, INT J OBESITY, V12, P557; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; HernandezPresa M, 1997, CIRCULATION, V95, P1532; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Landry DB, 1997, AM J PATHOL, V151, P1085; Libby P, 2001, AM J CARDIOL, V88, p3J; Merola M, 1996, J INTERF CYTOK RES, V16, P783, DOI 10.1089/jir.1996.16.783; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Nakamura T, 2001, J CLIN ENDOCR METAB, V86, P1795, DOI 10.1210/jc.86.4.1795; Obata T, 1996, CIRC RES, V79, P1167, DOI 10.1161/01.RES.79.6.1167; Ozes ON, 1999, NATURE, V401, P82; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Shinozaki K, 2000, CIRC RES, V87, P566, DOI 10.1161/01.RES.87.7.566; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; TAKAGI Y, 1995, ATHEROSCLEROSIS, V113, P19, DOI 10.1016/0021-9150(94)05422-F; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tomita H, 1998, ARTERIOSCL THROM VAS, V18, P1456, DOI 10.1161/01.ATV.18.9.1456; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wang YP, 2000, KIDNEY INT, V57, P2011, DOI 10.1046/j.1523-1755.2000.00051.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu TJ, 2002, AM J EPIDEMIOL, V155, P65, DOI 10.1093/aje/155.1.65	42	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36631	36639		10.1074/jbc.M206266200	http://dx.doi.org/10.1074/jbc.M206266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145301	hybrid			2022-12-25	WOS:000178275100108
J	Morley, SJ; Naegele, S				Morley, SJ; Naegele, S			Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT TRANSLATION; MESSENGER-RNA; FACTOR 4G; KINASE; BINDING; AFFINITY; MNK1; SITE; STIMULATION; INHIBITION	Previous work has suggested that increased phosphorylation of eukaryotic initiation factor (eIF) 4E at Ser-209 in the C-terminal loop of the protein often correlates with increased translation rates. However, the functional consequences of phosphorylation have remained contentious with our understanding of the role of eIF4E phosphorylation in translational control far from complete. To investigate the role for eIF4E phosphorylation in de novo translation, we studied the recovery of human kidney cells from hypertonic stress. Results show that hypertonic shock caused a rapid inhibition of protein synthesis and the disaggregation of polysomes. These changes were associated with the dephosphorylation of eIF4G, eIF4E, 4E-binding protein 1 (4E-BP1), and ribosomal protein S6. In addition, decreased levels of the eIF4F complex and increased association of 4E-BP1 with eIF4E were observed over a similar time course. The return of cells to isotonic medium rapidly promoted the phosphorylation of these initiation factors, increased levels of eIF4F complexes, promoted polysome assembly, and increased rates of translation. However, by using a cell-permeable, specific inhibitor of eIF4E kinase, Mnk1 (CGP57380), we show that de novo initiation of translation and eIF4F complex assembly during this recovery phase did not require eIF4E phosphorylation.	Univ Sussex, Sch Biol Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England	University of Sussex	Morley, SJ (corresponding author), Univ Sussex, Sch Biol Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England.	s.j.morley@sussex.ac.uk						DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; KRUPPA J, 1984, EMBO J, V3, P95, DOI 10.1002/j.1460-2075.1984.tb01767.x; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Morley SJ, 2001, PROG MOLEC, V27, P1; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Morley SJ, 1997, RNA, V3, P1085; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; Novoa I, 1999, MOL CELL BIOL, V19, P2445; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Tomoo K, 2002, BIOCHEM J, V362, P539, DOI 10.1042/0264-6021:3620539; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	43	76	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32855	32859		10.1074/jbc.C200376200	http://dx.doi.org/10.1074/jbc.C200376200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12138083	hybrid			2022-12-25	WOS:000177859000061
J	Plat, J; Mensink, RP				Plat, J; Mensink, RP			Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption	FASEB JOURNAL			English	Article						sitostanol; intestine; LXR; cholesterol transport	BETA-SITOSTEROL; METABOLISM; STEROL; MARGARINES; PATHWAY; MICE; ACCUMULATION; MUTATIONS; EFFLUX	The hypocholesterolemic effect of plant stanols is explained by a decreased intestinal cholesterol absorption due to a competition between plant stanols and cholesterol for incorporation into mixed micelles. Earlier we had suggested that plant stanols have a so far unknown action inside the enterocytes. The recent discovery of the involvement of ATP binding cassette (ABC) transporters in cholesterol absorption was a lead to further explore the hypocholesterolemic mechanism of plant stanols. We found that mixed micelles enriched with sitostanol or with cholesterol plus sitostanol were potent inducers of ABCA1 expression in caco-2 cells, an accepted model to study human intestinal lipoprotein metabolism. Based on these findings, we now hypothesize that plant stanols- and possibly plant sterols-increase ABCA1-mediated cholesterol efflux back into the intestinal lumen. We further hypothesize that intracellular levels of plant stanols are monitored by the same sensors (SREBP-2 and LXR) as those that monitor cholesterol. Consequently, increased plant stanol levels within the enterocyte activate cholesterol efflux through ABCA1- but not SREBP-2-mediated endogenous cholesterol synthesis even if intracellular cholesterol concentrations are lowered through consumption of plant stanols. If our hypothesis is correct, then the LXR pathway may be a target for dietary regulation of intestinal lipid metabolism.	Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	Maastricht University	Plat, J (corresponding author), Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.	J.Plat@HB.UNIMAAS.NL						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Costet P, 2000, J BIOL CHEM, V275, P28240; Dean M, 2001, J LIPID RES, V42, P1007; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Field FJ, 1997, J LIPID RES, V38, P348; FIELD FJ, 1983, J LIPID RES, V24, P409; IKEDA I, 1989, J NUTR SCI VITAMINOL, V35, P361, DOI 10.3177/jnsv.35.361; IKEDA I, 1988, J LIPID RES, V29, P1573; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PETERSON DW, 1951, P SOC EXP BIOL MED, V78, P143, DOI 10.3181/00379727-78-19002; Plat J, 2000, EUR J CLIN NUTR, V54, P671, DOI 10.1038/sj.ejcn.1601071; Plat J, 2001, METABOLISM, V50, P520, DOI 10.1053/meta.2001.22509; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sierksma A, 1999, BRIT J NUTR, V82, P273, DOI 10.1017/S0007114599001476; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	29	176	187	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1248	10.1096/fj.01-0718hyp	http://dx.doi.org/10.1096/fj.01-0718hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	11772951				2022-12-25	WOS:000177814000034
